Suche

Amtliche deutsche Fassung 2014 Anatomisch-therapeutisch- chemische Klassi�kation mit Tagesdosen Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2014 Im Auftrag des Bundesministeriums für Gesundheit Erstellt vom: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO) Herausgegeben vom: Deutschen Institut für Medizinische Dokumentation und Information Anatomisch-therapeutisch-chemische-Klassifikation mit Tagesdosen Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2014 Beauftragt durch: Bundesministerium für Gesundheit Friedrichstraße 108 10117 Berlin Herausgegeben durch: Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) Waisenhausgasse 36-38a 50676 Köln Tel.: +49 221 4724-1 Fax: +49 221 4724-444 E-Mail: posteingang@dimdi.de Unter Beteiligung: Arbeitsgruppe ATC/DDD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG) Erstellt durch: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO) des AOK-Bundesverbandes GbR Rosenthaler Str. 31 10178 Berlin Tel.: +49 30 3-4646-2393 Fax: +49 30 3-4646-2144 www.wido.de E-Mail: ai@wido.bv.aok.de Wissenschaftliche Bearbeitung: Prof. Dr. rer. nat. Uwe Fricke Institut für Pharmakologie Klinikum der Universität zu Köln Gleueler Str. 24 50931 Köln Dr. rer. nat. Judith Günther Wilhelmstraße 1e 79098 Freiburg Dr. rer. nat. Anette Zawinell Wissenschaftliches Institut der AOK Rosenthaler Str. 31 10178 Berlin Rana Zeidan Wissenschaftliches Institut der AOK Rosenthaler Str. 31 10178 Berlin Pharmazeutisch-technische Assistenz: Manuela Steden Wissenschaftliches Institut der AOK Rosenthaler Str. 31 10178 Berlin Amtliche Fassung: http://www.dimdi.de/static/de/amg/atcddd.htm Aktuelle Informationen zum Thema erhalten Sie im Internet unter: http://www.wido.de/arz_atcddd-klassifi.html Die vorliegende Ausgabe beruht auf dem vom WHO Collaborating Centre for Drug Statistics Methodology herausgegebenen Werk mit dem Titel „ATC Index with DDDs and Guidelines for ATC Classification and DDD Assignment“. Das WHO Collaborating Centre for Drug Statistics Methodology hat dem Deutschen Institut für Medizinische Dokumentation und Information die Rechte zu deren Nutzung im Rahmen einer deutschsprachigen Ausgabe erteilt. Jede Änderung oder Manipulation des Materials ist untersagt. Inhalt Vorwort ........................................................................................................................... 4 1 Nutzungshinweise für den amtlichen ATC-Index mit DDD-Angaben .................................................................................................... 6 2 ATC-Index mit DDD-Angaben: Amtliche deutsche Fassung 2014 .................................................................... 7 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code ........................................... 8 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen ................................... 142 1 Nutzungshinweise für den amtlichen ATC-Index mit DDD-Angaben Vorwort Gemäß § 73 Absatz 8 des Fünften Buches Sozialgesetzbuch (SGB V) gibt das Deutsche Institut für Medizinische Dokumentation und Information (DIMDI) im Auftrag des Bundesministeriums für Gesundheit die amtliche deutsche Fassung der Anatomisch-Therapeutisch-Chemischen (ATC) Klassifikation mit definierten Tagesdosen (DDD) heraus. Die gesetzliche Regelung sieht vor, dass die ATC- Klassifikation mit definierten Tagesdosen bei Bedarf an die Besonderheiten der Versorgungssituation in Deutschland angepasst wird. Dies gilt insbesondere für die Anpassung von DDD-Angaben an die Angaben zur Dosierung in den amtli- chen Fachinformationen, wobei im Rahmen der Dosierangaben der Fachinfor- mation auch Besonderheiten der Versorgung berücksichtigt werden, soweit hierzu valide Daten vorliegen. Die jetzt vorliegende deutsche ATC-Klassifikation gilt für das Jahr 2014. Damit liegt nunmehr die elfte Version dieser amtlichen ATC-Klassifikation vor. Die gesetzlichen Anwendungszwecke dieser Klassifikation sind im Fünften Buch Sozialgesetzbuch (SGB V) geregelt. Gemäß § 92 Absatz 2 SGB V hat der Gemeinsame Bundesausschuss in seinen Richtlinien nach § 92 Absatz 1 Satz 2 Nummer 6 Hinweise zu Arznei- und Hilfsmitteln aufzunehmen, die dem Ver- tragsarzt einen Preisvergleich verschiedener Arzneimittel nach Indikationsge- biet und Wirkstoffgruppen ermöglicht. Nach § 73 Absatz 8 SGB V sind die Ko- sten der Arzneimittel je Tagesdosis nach den Angaben der Anatomisch-Thera- peutisch-Chemischen-Klassifikation anzugeben. Die DDD-Angaben der Klassifi- kation nach § 73 Absatz 8 SGB V sind eine rechtssichere Grundlage für die Be- stimmung von Tagestherapiekosten, durch welche dem Arzt der Vergleich von Arzneimittelkosten erleichtert werden soll. Die Anwendung dieser Klassifika- tion gewährleistet für alle Hersteller und Präparate einen einheitlichen Bezug für die Angabe von Tagestherapiekosten. Dabei dienen die Tagesdosenangaben als Durchschnittsgröße, die nicht notwendigerweise die im Einzelfall angewen- dete Dosierung eines Arzneimittels wiedergibt. Dies gilt entsprechend auch für die auf dieser Basis errechneten Tagestherapiekosten. Die vorliegende Fortschreibung der Klassifikation zur Anwendung im Jahre 2014 ist in einem transparenten, regelgebundenen Verfahren durchgeführt 1 Hauptkapitel worden, an dem Sachverständige auch von pharmazeutischen Unternehmen eingehend beteiligt worden sind. Die Geschäftsstelle hat den GKV-Arzneimittelindex im Wissenschaftlichen Ins- titut der AOK (WIdO) beauftragt, die Anträge zur Anpassung an den deutschen Arzneimittelmarkt inhaltlich zu bewerten und für die Arbeitsgruppe eine ent- sprechende Beratungsunterlage zu erstellen. Die daraus resultierende Beschlussvorlage enthält eine ausführliche Dokumen- tation und Bewertung aller eingegangenen Änderungsvorschläge. Diese Be- schlussvorlage wurde der zuständigen Arbeitsgruppe beim Kuratorium für Fra- gen der Klassifikation im Gesundheitswesen zugeleitet, in der die maßgeblichen Fachkreise vertreten sind. Die Arbeitsgruppe hat die Vorlage in ihrer Sitzung am 29. November 2013 eingehend beraten. Den Trägern des GKV-Arzneimittelindexes gilt besonderer Dank, dass sie um- fangreiche eigene Vorarbeiten durch das WIdO für die Fortschreibung der Klas- sifikation eingebracht haben, welche in die Beratungen eingegangen sind. Die nächste turnusmäßige Anpassung der Klassifikation erfolgt für das Jahr 2015. Vorschläge zu Änderungen der Klassifikation sind im Rahmen des jährli- chen Anhörungsverfahrens zu richten an: Geschäftsstelle der Arbeitsgruppe ATC/DDD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen DIMDI – Deutsches Institut für Medizinische Dokumentation und Information Waisenhausgasse 36-38a 50676 Köln Dr. Ulrich Orlowski Leiter der Abteilung Gesundheitsversorgung Krankenversicherung BMG Hinweis der Redaktion: Die ATC-Klassifikation mit DDD-Angaben in deutscher Sprache kann von der Internetseite des DIMDI aus dem Downloadbereich kostenfrei heruntergeladen werden. 1 Nutzungshinweise für den amtlichen ATC-Index mit DDD-Angaben 1 Nutzungshinweise für den amtlichen ATC-Index mit DDD-Angaben Für jede DDD werden Einheit und Darreichungsform angegeben. Folgende Abkürzungen werden verwendet: Einheit Darreichungsform g Gramm AT Augentropfen mg Milligramm AS Augensalben mcg Mikrogramm EDO Ein-Dosis-Ophtiolen mcm Mikrometer i.m. intramuskulär DE Dosiseinheit Inhal Inhalation E Einheit N nasal FIP E Federation Internationale Pharmaceutique Einheit O oral P parenteral TSD E Tausend Einheiten R rektal MIO E Millionen Einheiten s.c. subkutan mmol Millimol SL sublingual/bukkal ml Milliliter T topisch TD transdermal U urethral V Vaginal Die wesentlichen Grundlagen für die ATC-Klassifikation und DDD-Festlegung sind in der „Methodik der ATC-Klassifikation und DDD-Festlegung für den deutschen Arzneimittelmarkt“ (Bearbeitungsstand April 2013) beschrieben (Uwe Fricke, Judith Günther, Anette Zawinell und Rana Zeidan: Anatomisch- therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt. Methodik der ATC-Klassifikation und DDD-Festlegung. ATC-Index mit DDD-Angaben. Berlin 2013). Lesehinweis ATC-Codes mit besonderen Hinweisen werden in der ATC-Bedeutung mit Sternchen gekennzeichnet. Die Hinweise sind am Ende des Index eingefügt. 2 ATC-Index mit DDD-Angaben – sortiert nach ATC-Code 2 ATC-Index mit DDD-Angaben Amtliche deutsche Fassung 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 1 von 133 BEDEUTUNG DDD-INFO A ALIMENTÄRES SYSTEM UND STOFFWECHSEL A01 STOMATOLOGIKA A01A STOMATOLOGIKA A01AA Mittel zur Kariesprophylaxe A01AA01 Natriumfluorid 1,1 mg O 0.5 mg Fluorid A01AA02 Natriummonofluorphosphat A01AA03 Olaflur 1,1 mg O A01AA04 Zinn(II)-fluorid A01AA05 Fluorsilan A01AA30 Kombinationen A01AA51 Natriumfluorid, Kombinationen A01AB Antiinfektiva und Antiseptika zur oralen Lokalbehandlung A01AB02 Wasserstoffperoxid 60 mg O A01AB03 Chlorhexidin 30 mg O A01AB04 Amphotericin B 40 mg O A01AB05 Polynoxylin 0,18 g O A01AB06 Domiphen 3 mg O A01AB07 Oxychinolin 80 mg O A01AB08 Neomycin A01AB09 Miconazol 0,2 g O A01AB10 Natamycin 20 mg O A01AB11 Verschiedene A01AB12 Hexetidin A01AB13 Tetracyclin A01AB14 Benzoxoniumchlorid A01AB15 Tibezoniumiodid A01AB16 Mepartricin A01AB17 Metronidazol A01AB18 Clotrimazol A01AB19 Natriumperborat A01AB21 Chlortetracyclin A01AB22 Doxycyclin A01AB23 Minocyclin 1 mg O A01AB24 Thymol A01AB26 Aluminiumchlorid A01AB27 Ethacridinlactat A01AB29 Eugenol A01AB31 Natriumhypochlorit A01AB32 Natriumpercarbonat A01AB33 Nystatin 500 000 IE O A01AB36 Aluminiumchlorat A01AB37 Aluminiumsulfat A01AB39 Andere Aluminium-haltige Verbindungen A01AB50 Kombinationen A01AB53 Chlorhexidin, Kombinationen A01AB57 Oxychinolin, Kombinationen A01AB62 Hexetidin, Kombinationen A01AB75 Chlorphenol, Kombinationen A01AB76 Aluminiumchlorid, Kombinationen A01AB78 Sulfanilamid, Kombinationen A01AB84 Paraformaldehyd, Kombinationen A01AB85 Formaldehyd, Kombinationen A01AB88 Azulen, Kombinationen A01AB90 Demeclocyclin, Kombinationen A01AC Corticosteroide zur oralen Lokalbehandlung A01AC01 Triamcinolon A01AC02 Dexamethason A01AC03 Hydrocortison A01AC04 Prednisolon A01AC05 Betamethason A01AC54 Prednisolon, Kombinationen A01AD Andere Mittel zur oralen Lokalbehandlung A01AD01 Epinephrin A01AD02 Benzydamin A01AD05 Acetylsalicylsäure A01AD06 Adrenalon A01AD07 Amlexanox A01AD08 Becaplermin A01AD11 Verschiedene A01AD18 Cholinsalicylat A01AD20 Carbenoxolon A01AD22 Milchsäure A01AD50 Andere Mittel zur oralen Lokalbehandlung, Kombinationen ATC-CODE 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 1 von 133 BEDEUTUNG DDD-INFO A ALIMENTÄRES SYSTEM UND STOFFWECHSEL A01 STOMATOLOGIKA A01A STOMATOLOGIKA A01AA Mittel zur Kariesprophylaxe A01AA01 Natriumfluorid 1,1 mg O 0.5 mg Fluorid A01AA02 Natriummonofluorphosphat A01AA03 Olaflur 1,1 mg O A01AA04 Zinn(II)-fluorid A01AA05 Fluorsilan A01AA30 Kombinationen A01AA51 Natriumfluorid, Kombinationen A01AB Antiinfektiva und Antiseptika zur oralen Lokalbehandlung A01AB02 Wasserstoffperoxid 60 mg O A01AB03 Chlorhexidin 30 mg O A01AB04 Amphotericin B 40 mg O A01AB05 Polynoxylin 0,18 g O A01AB06 Domiphen 3 mg O A01AB07 Oxychinolin 80 mg O A01AB08 Neomycin A01AB09 Miconazol 0,2 g O A01AB10 Natamycin 20 mg O A01AB11 Verschiedene A01AB12 Hexetidin A01AB13 Tetracyclin A01AB14 Benzoxoniumchlorid A01AB15 Tibezoniumiodid A01AB16 Mepartricin A01AB17 Metronidazol A01AB18 Clotrimazol A01AB19 Natriumperborat A01AB21 Chlortetracyclin A01AB22 Doxycyclin A01AB23 Minocyclin 1 mg O A01AB24 Thymol A01AB26 Aluminiumchlorid A01AB27 Ethacridinlactat A01AB29 Eugenol A01AB31 Natriumhypochlorit A01AB32 Natriumpercarbonat A01AB33 Nystatin 500 000 IE O A01AB36 Aluminiumchlorat A01AB37 Aluminiumsulfat A01AB39 Andere Aluminium-haltige Verbindungen A01AB50 Kombinationen A01AB53 Chlorhexidin, Kombinationen A01AB57 Oxychinolin, Kombinationen A01AB62 Hexetidin, Kombinationen A01AB75 Chlorphenol, Kombinationen A01AB76 Aluminiumchlorid, Kombinationen A01AB78 Sulfanilamid, Kombinationen A01AB84 Paraformaldehyd, Kombinationen A01AB85 Formaldehyd, Kombinationen A01AB88 Azulen, Kombinationen A01AB90 Demeclocyclin, Kombinationen A01AC Corticosteroide zur oralen Lokalbehandlung A01AC01 Triamcinolon A01AC02 Dexamethason A01AC03 Hydrocortison A01AC04 Prednisolon A01AC05 Betamethason A01AC54 Prednisolon, Kombinationen A01AD Andere Mittel zur oralen Lokalbehandlung A01AD01 Epinephrin A01AD02 Benzydamin A01AD05 Acetylsalicylsäure A01AD06 Adrenalon A01AD07 Amlexanox A01AD08 Becaplermin A01AD11 Verschiedene A01AD18 Cholinsalicylat A01AD20 Carbenoxolon A01AD22 Milchsäure A01AD50 Andere Mittel zur oralen Lokalbehandlung, Kombinationen ATC-CODE 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 2 von 133 BEDEUTUNG DDD-INFOATC-CODE A01AD65 Dexpanthenol, Kombinationen A01AD69 Mineralsalz, Kombinationen A01AD71 Salicylate, Kombinationen A01AD72 Speichelersatzlösungen A01AE Lokalanästhetika für die orale Lokalbehandlung A01AE01 Lidocain A01AE02 Tetracain A01AE05 Polidocanol (Lauromacrogol 400) A01AE51 Lidocain, Kombinationen A01AE52 Tetracain, Kombinationen A01AE53 Benzocain, Kombinationen A01AE54 Propipocain, Kombinationen A01AE55 Polidocanol (Lauromacrogol 400), Kombinationen A01AH Homöopathische und anthroposophische Stomatologika A01AH20 Kombinationen A01AP Pflanzliche Stomatologika A01AP01 Myrrhentinktur A01AP02 Kamillenblüten A01AP03 Salbeiblätter A01AP10 Verschiedene A01AP30 Kombinationen A01AP50 Andere pflanzliche Stomatologika, Kombinationen A01AP52 Kamillenblüten, Kombinationen A02 MITTEL BEI SÄURE BEDINGTEN ERKRANKUNGEN A02A ANTACIDA A02AA Magnesium-haltige Verbindungen A02AA01 Magnesiumcarbonat A02AA02 Magnesiumoxid A02AA03 Magnesiumperoxid A02AA04 Magnesiumhydroxid 3 g O A02AA05 Magnesiumsilikat A02AA10 Kombinationen A02AB Aluminium-haltige Verbindungen A02AB01 Aluminiumhydroxid A02AB02 Algeldrat 5 g O A02AB03 Aluminiumphosphat A02AB04 Dihydroxyaluminiumnatriumcarbonat (Carbaldrat) A02AB05 Aluminiumacetoacetat A02AB06 Aloglutamol A02AB07 Aluminiumglycinat A02AB10 Kombinationen A02AC Calcium-haltige Verbindungen A02AC01 Calciumcarbonat A02AC02 Calciumsilikat 6 g O A02AC10 Kombinationen A02AD Kombinationen und Komplexe von Aluminium-, Calcium- und Magnesium-haltigen Verbindungen A02AD01 Einfache Salzkombinationen A02AD02 Magaldrat 3,2 g O A02AD03 Almagat A02AD04 Hydrotalcit 3,5 g O A02AD05 Almasilat 4 g O A02AD06 Simaldrat 5 g O A02AD10 Aluminiumoxid in Kombination mit Magnesiumhydroxid A02AF Antacida mit Karminativa A02AF01 Magaldrat und Karminativa A02AF02 Einfache Salzkombinationen und Karminativa A02AF03 Dihydroxyaluminiumnatriumcarbonat und Karminativa A02AF04 Simaldrat und Karminativa A02AF05 Aluminiumhydroxid und Karminativa A02AG Antacida mit Spasmolytika A02AG01 Antacida, Kombinationen mit Butinolin A02AG02 Antacida, Kombinationen mit Atropin A02AG20 Antacida, Kombinationen mit mehreren Spasmolytika 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 3 von 133 BEDEUTUNG DDD-INFOATC-CODE A02AH Antacida mit Natriumbicarbonat A02AH01 Natriumhydrogencarbonat A02AH20 Kombinationen A02AX Antacida, andere Kombinationen A02AX01 Antacida, Kombinationen mit Bismutsalzen A02AX02 Antacida, Kombinationen mit Lokalanästhetika A02AX04 Antacida, Kombinationen mit Schwefel A02AX50 Antacida, andere Kombinationen A02B MITTEL BEI PEPTISCHEM ULKUS UND GASTROESOPHAGEALER REFLUXKRANKHEIT A02BA Histamin-H2-Rezeptorantagonisten A02BA01 Cimetidin 0,8 g O,P A02BA02 Ranitidin 0,3 g O,P A02BA03 Famotidin 40 mg O,P A02BA04 Nizatidin 0,3 g O,P A02BA05 Niperotidin A02BA06 Roxatidin 0,15 g O A02BA07 Ranitidinbismutcitrat 0,8 g O A02BA08 Lafutidin 20 mg O A02BA51 Cimetidin, Kombinationen A02BA53 Famotidin, Kombinationen A02BB Prostaglandine A02BB01 Misoprostol 0,8 mg O A02BB02 Enprostil 70 mcg O A02BC Protonenpumpenhemmer A02BC01 Omeprazol 20 mg O,P A02BC02 Pantoprazol 20 mg O,P A02BC03 Lansoprazol 15 mg O A02BC04 Rabeprazol 10 mg O,P A02BC05 Esomeprazol 20 mg O,P A02BC06 Dexlansoprazol A02BD Kombinationen zur Eradikation von Helicobacter pylori A02BD01 Omeprazol, Amoxicillin und Metronidazol A02BD02 Lansoprazol, Tetracyclin und Metronidazol A02BD03 Lansoprazol, Amoxicillin und Metronidazol A02BD04 Pantoprazol, Amoxicillin und Clarithromycin Kombinationspackung: 6 DE O A02BD05 Omeprazol, Amoxicillin und Clarithromycin Kombinationspackung: 6 DE O A02BD06 Esomeprazol, Amoxicillin und Clarithromycin A02BD07 Lansoprazol, Amoxicillin und Clarithromycin A02BD08 Bismutsubcitrat, Tetracyclin und Metronidazol 12 Applikationsformen O A02BX Andere Mittel bei peptischem Ulkus und gastrooesophagealer Refluxkrankheit A02BX01 Carbenoxolon 0,15 g O A02BX02 Sucralfat 4 g O A02BX03 Pirenzepin 0,1 g O; 20 mg P A02BX04 Methiosulfoniumchlorid A02BX05 Bismutsubcitrat 0,48 g O A02BX06 Proglumid 1,2 g O A02BX07 Gefarnat A02BX08 Sulglicotid A02BX09 Acetoxolon A02BX10 Zolimidin A02BX11 Troxipid A02BX12 Bismutsubnitrat A02BX13 Alginsäure A02BX15 Silbereiweiß-Acetyltannat A02BX17 Bismut(III)-citrat-hydroxid-Komplex A02BX18 Dibismut-tris(tetraoxodialuminat) A02BX22 Bismutsubsalicylat A02BX50 Andere Ulkustherapeutika, Kombinationen exkl. Psycholeptika A02BX51 Carbenoxolon, Kombinationen exkl. Psycholeptika A02BX62 Bismutsubnitrat, Kombinationen exkl. Psycholeptika A02BX63 Alginsäure, Kombinationen Standarddosis: 10 Tabletten oder 50 ml Mixtur A02BX70 Andere Ulkustherapeutika, Kombinationen mit Psycholeptika A02BX71 Carbenoxolon, Kombinationen mit Psycholeptika A02BX77 Gefarnat, Kombinationen mit Psycholeptika A02X ANDERE MITTEL BEI SÄURE BEDINGTEN ERKRANKUNGEN A02XA Andere Mittel bei Säure bedingten Erkrankungen A02XA01 Kälberblutextrakt A02XA03 Guajazulen A02XA52 Benzocain, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 4 von 133 BEDEUTUNG DDD-INFOATC-CODE A02XA53 Guajazulen, Kombinationen A02XH Andere homöopathische und anthroposophische Mittel bei Säure bedingten Erkrankungen A02XH01 Nux vomica A02XH20 Kombinationen A02XH50 Kombinationen mit anderen Mitteln A02XP Andere pflanzliche Mittel bei Säure bedingten Erkrankungen A02XP30 Kombinationen A03 MITTEL BEI FUNKTIONELLEN GASTROINTESTINALEN STÖRUNGEN A03A MITTEL BEI FUNKTIONELLEN GASTROINTESTINALEN STÖRUNGEN A03AA Synthetische Anticholinergika, Ester mit tertiären Aminogruppen A03AA01 Oxyphencyclimin 20 mg O A03AA03 Camylofin 0,2 g O,R A03AA04 Mebeverin 0,4 g O A03AA05 Trimebutin 0,6 g O A03AA06 Rociverin A03AA07 Dicycloverin 80 mg O,P A03AA08 Dihexyverin A03AA09 Difemerin A03AA30 Piperidolat A03AA31 Phenamazid A03AB Synthetische Anticholinergika, quartäre Ammonium- Verbindungen A03AB01 Benzilon 70 mg O A03AB02 Glycopyrronium 3 mg O,P,R A03AB03 Oxyphenonium 25 mg O A03AB04 Penthienat 15 mg O A03AB05 Propanthelin 60 mg O,P A03AB06 Otiloniumbromid A03AB07 Methanthelinium 0,15 g O A03AB08 Tridihexethyl 0,125 g O A03AB09 Isopropamid 10 mg O A03AB10 Hexocyclium 0,15 g O A03AB11 Poldin 12 mg O A03AB12 Mepenzolat 0,1 g O A03AB13 Bevonium 0,2 g O A03AB14 Pipenzolat 20 mg O A03AB15 Diphemanil A03AB16 (2-Benzhydryloxyethyl)diethylmethylammoniumiodid 0,3 g O A03AB17 Tiemoniumiodid A03AB18 Prifiniumbromid A03AB19 Timepidiumbromid A03AB20 Trospium A03AB21 Fenpiverinium A03AB53 Oxyphenonium, Kombinationen A03AC Synthetische Spasmolytika, Amide mit tertiären Aminen A03AC02 Dimethylaminopropionylphenothiazin A03AC04 Nicofetamid A03AC05 Tiropramid A03AD Papaverin und Derivate A03AD01 Papaverin 0,1 g O,P A03AD02 Drotaverin 0,1 g O,P A03AD30 Moxaverin 50 mg O A03AE Serotonin-Rezeptor-Antagonisten A03AE01 Alosetron 1 mg O A03AE03 Cilansetron A03AH A03AH01 Carum Carvi A03AH10 Verschiedene A03AH20 Kombinationen A03AP Andere pflanzliche Mittel bei funktionellen gastrointestinalen Störungen A03AP01 Pfefferminzblätter A03AP02 Kamillenblüten A03AP03 Fenchelfrüchte Andere homöopathische und anthroposophische Mittel 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 5 von 133 BEDEUTUNG DDD-INFOATC-CODE A03AP04 Melissenblätter A03AP11 Sonstige A03AP30 Kombinationen A03AX Andere Mittel bei funktionellen gastrointestinalen Störungen A03AX01 Fenpipran A03AX02 Diisopromin A03AX03 Chlorbenzoxamin 0,15 g O A03AX04 Pinaverium 0,15 g O A03AX05 Fenoverin A03AX06 Idanpramin A03AX07 Proxazol A03AX08 Alverin A03AX09 Trepibuton A03AX10 Isomethepten A03AX11 Caroverin A03AX12 Phloroglucinol A03AX13 Silikone 0,5 g O A03AX14 Cholinsalze A03AX20 Kombinationen A03AX30 Trimethyldiphenylpropylamin 50 mg O,P A03AX31 Pramiverin A03AX32 Denaverin A03AX33 Dipiproverin A03AX50 Andere Mittel bei funktionellen Störungen des Darms, Kombinationen A03AX58 Alverin, Kombinationen A03AX63 Silikone, Kombinationen A03B BELLADONNA UND DERIVATE, REIN A03BA Belladonna-Alkaloide, tertiäre Amine A03BA01 Atropin 1,5 mg O,P A03BA03 Hyoscyamin 1,2 mg O A03BA04 Belladonna-Gesamtalkaloide 1 mg O A03BA20 Kombinationen A03BB Belladonna-Alkaloide, halbsynthetisch, quartäre Ammonium-Verbindungen A03BB01 Butylscopolamin 60 mg O,P,R A03BB02 Methylatropin 3 mg O A03BB03 Methylscopolamin 12 mg O,P A03BB04 Fentonium 60 mg O A03BB05 Cimetropiumbromid A03C SPASMOLYTIKA IN KOMBINATION MIT PSYCHOLEPTIKA A03CA Synthetische Anticholinergika in Kombination mit Psycholeptika A03CA01 Isopropamid und Psycholeptika A03CA02 Clidinium und Psycholeptika A03CA03 Oxyphencyclimin und Psycholeptika A03CA04 Otiloniumbromid und Psycholeptika A03CA05 Glycopyrronium und Psycholeptika A03CA06 Bevonium und Psycholeptika A03CA07 Ambutonium und Psycholeptika A03CA08 Diphemanil und Psycholeptika A03CA30 Emepronium und Psycholeptika A03CA34 Propanthelin und Psycholeptika A03CA39 Moxaverin und Psycholeptika A03CA41 Pipenzolat und Psycholeptika A03CA42 Tridihexethyl und Psycholeptika A03CA43 Benactyzin und Psycholeptika A03CB Belladonna und Derivate in Kombination mit Psycholeptika A03CB01 Methylscopolamin und Psycholeptika A03CB02 Belladonna-Gesamtalkaloide und Psycholeptika A03CB03 Atropin und Psycholeptika A03CB04 Methylhomatropin und Psycholeptika A03CB31 Hyoscyamin und Psycholeptika A03CB37 Xenytropiumbromid und Psycholeptika A03CB38 Butylscopolamin und Psycholeptika A03CC Andere Spasmolytika in Kombination mit Psycholeptika A03D SPASMOLYTIKA IN KOMBINATION MIT ANALGETIKA 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 6 von 133 BEDEUTUNG DDD-INFOATC-CODE A03DA Synthetische Anticholinergika in Kombination mit Analgetika A03DA01 Tropenzilon und Analgetika A03DA02 Pitofenon und Analgetika A03DA03 Bevonium und Analgetika A03DA04 Ciclonium und Analgetika A03DA05 Camylofin und Analgetika A03DA06 Trospium und Analgetika A03DA07 Tiemoniumiodid und Analgetika A03DA08 Barverin und Analgetika A03DA09 Ambucetamid und Analgetika A03DA12 Drofenin und Analgetika A03DB Belladonna und Derivate in Kombination mit Analgetika A03DB04 Butylscopolamin und Analgetika A03DC Andere Spasmolytika in Kombination mit Analgetika A03DC02 Tropinbenzilat und Analgetika A03DC04 Pramiverin und Analgetika A03DC05 Ethaverin und Analgetika A03E SPASMOLYTIKA UND ANTICHOLINERGIKA IN KOMBINATION MIT ANDEREN MITTELN A03EA Spasmolytika, Psycholeptika und Analgetika in Kombination A03EA01 Ciclonium, Kombinationen A03EA02 Butylscopolamin, Kombinationen A03EA03 Tropinbenzilat, Kombinationen A03EA04 Trospiumchlorid, Kombinationen A03EA05 Drofenin, Kombinationen A03EA06 Ethaverin, Kombinationen A03EA40 Fencarbamid, Kombinationen A03ED Spasmolytika in Kombination mit anderen Mitteln A03ED01 Benzylmandelat in Kombination mit anderen Mitteln A03ED02 Ethaverin in Kombination mit anderen Mitteln A03ED04 Butinolin in Kombination mit anderen Mitteln A03F PROKINETIKA A03FA Prokinetika A03FA01 Metoclopramid 30 mg O,P,R; 10 mg R Kinder DDD A03FA02 Cisaprid 30 mg O,R A03FA03 Domperidon 30 mg O,P; 0,12 g R A03FA04 Bromoprid 20 mg O,P A03FA05 Alizaprid 0,15 g O,P A03FA06 Cleboprid A03FA07 Dexpanthenol A03FA51 Metoclopramid, Kombinationen A03FA54 Bromoprid, Kombinationen A03FP Pflanzliche Prokinetika A03FP30 Kombinationen A03H ANDERE HOMÖOPATHISCHE UND ANTHROPOSOPHISCHE ZUBEREITUNGEN A03HH Homöopathische und anthroposophische Spasmolytika A03HH10 Verschiedene A03HH20 Kombinationen A03P ANDERE PFLANZLICHE ZUBEREITUNGEN A03PP Pflanzliche Spasmolytika A03PP01 Mohnkapsel A03PP02 Schöllkraut 3,5 g O Droge; 21 mg O Gesamtalkaloide, berechnet als Chelidonin A03PP03 Boldoblätter 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 7 von 133 BEDEUTUNG DDD-INFOATC-CODE A04 ANTIEMETIKA UND MITTEL GEGEN ÜBELKEIT A04A ANTIEMETIKA UND MITTEL GEGEN ÜBELKEIT A04AA Serotonin-5HT3-Antagonisten A04AA01 Ondansetron 16 mg O,P,R A04AA02 Granisetron 2 mg O; 3 mg P A04AA03 Tropisetron 5 mg O,P A04AA04 Dolasetron 0,2 g O; 0,1 g P A04AA05 Palonosetron 0,25 mg P; 0,5 mg O A04AB Antihistaminika A04AB02 Dimenhydrinat 0,275 g O; 0,2 g R A04AB03 Thiethylperazin A04AB04 Meclozin 37,5 mg O; 50 mg R A04AB05 Diphenhydramin A04AB52 Dimenhydrinat, Kombinationen A04AB54 Meclozin, Kombinationen 37,5 mg O bezogen auf Meclozin; 50 mg R bezogen auf Meclozin A04AB55 Diphenhydramin, Kombinationen A04AB56 Doxylamin, Kombinationen A04AB57 Chlorphenoxamin, Kombinationen A04AB58 Promethazin, Kombinationen A04AD Andere Antiemetika A04AD01 Scopolamin A04AD02 Ceriumoxalat A04AD04 Chlorbutanol A04AD05 Metopimazin 15 mg O,P A04AD06 Triflupromazin A04AD08 Chlorphenethazin A04AD10 Dronabinol A04AD11 Nabilon A04AD12 Aprepitant, Fosaprepitant 95 mg O; 95 mg P bezogen auf Fosaprepitant (115 mg); 1 DE P bezogen auf Fosaprepitant (150 mg) A04AD13 Casopitant A04AD50 Andere Antiemetika, Kombinationen A04AD51 Scopolamin, Kombinationen A04AD54 Chlorbutanol, Kombinationen A04AH Homöopathische und anthroposophische Antiemetika A04AH10 Verschiedene homöopathische und anthroposophische Antiemetika A04AH20 Kombinationen A04AP Pflanzliche Antiemetika A04AP01 Ingwerwurzelstock A05 GALLEN- UND LEBERTHERAPIE A05A GALLENTHERAPIE A05AA Gallensäure-haltige Zubereitungen A05AA01 Chenodeoxycholsäure A05AA02 Ursodeoxycholsäure 0,75 g O A05AA03 Cholsäure A05AA04 Dehydrocholsäure A05AA05 Gesamtgallensäuren (Fel tauri) A05AA20 Kombinationen A05AA54 Dehydrocholsäure, Kombinationen A05AA55 Gesamtgallensäuren, Kombinationen A05AB Zubereitungen zur Gallentherapie A05AB01 N-(Hydroxymethyl)nicotinamid A05AB20 Kombinationen A05AC Gallentherapeutika in Kombination A05AC01 Gallentherapeutika in Kombination mit Spasmolytika A05AH Homöopathische und anthroposophische Mittel zur Gallentherapie A05AH20 Kombinationen A05AP Pflanzliche Mittel zur Gallentherapie A05AP01 Schwarzrettichwurzel A05AP03 Artischockenblätter 6 g O Droge; 30 g O Frischpflanze A05AP04 Erdrauchkraut A05AP05 Pfefferminzöl 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 8 von 133 BEDEUTUNG DDD-INFOATC-CODE A05AP06 Löwenzahnwurzel mit -kraut A05AP07 Curcumawurzelstock 2 g O Javanische Gelbwurz; 2,25 g O Curcumawurzelstock A05AP08 Glockenbilsenkrautwurzelstock A05AP09 Gundelrebenkraut A05AP10 Verschiedene A05AP30 Kombinationen A05AX Andere Mittel zur Gallentherapie A05AX01 Piprozolin A05AX02 Hymecromon 1 g O A05AX03 Cyclobutyrol A05AX07 Fenipentol A05AX08 Glyceroltrinitrat A05AX09 Febuprol A05AX50 Andere Mittel zur Gallentherapie, Kombinationen A05B LEBERTHERAPIE, LIPOTROPE SUBSTANZEN A05BA Lebertherapie A05BA01 Argininglutamat A05BA04 Citiolon A05BA05 Epomediol A05BA06 Ornithinoxoglurat A05BA07 Tidiacicarginin A05BA08 Glycyrrhizinsäure A05BA09 Methionin und N-Acetylmethionin A05BA10 Cholin A05BA12 Myo-Inositol A05BA17 Ornithinaspartat A05BA18 Cianidanol A05BA50 Andere Lebertherapeutika, Kombinationen A05BA60 Cholin, Kombinationen A05BA61 Betain, Kombinationen A05BA63 Cyanocobalamin, Kombinationen A05BA66 Leucin, Kombinationen A05BA67 Ornithinaspartat, Kombinationen A05BA71 Laevulose, Kombinationen A05BH Homöopathische und anthroposophische Mittel zur Lebertherapie A05BH01 Mariendistelfrüchte A05BH10 Verschiedene A05BH20 Kombinationen A05BP Pflanzliche Mittel zur Lebertherapie A05BP01 Mariendistelfrüchte 13,5 g O Droge; 0,3 g O bezogen auf Silymarin A05BP02 Phospholipide A05BP51 Mariendistelfrüchte, Kombinationen A05C MITTEL ZUR GALLENTHERAPIE UND LIPOTROPE SUBSTANZEN IN KOMBINATION A06 MITTEL GEGEN OBSTIPATION A06A MITTEL GEGEN OBSTIPATION A06AA Gleitmittel, Emollientia A06AA01 Dickflüssiges Paraffin 15 g O A06AA02 Docusat-Natrium 0,15 g O A06AA03 Dünnflüssiges Paraffin A06AA51 Dickflüssiges Paraffin, Kombinationen A06AB Kontaktlaxanzien A06AB01 Oxyphenisatin 10 mg O A06AB02 Bisacodyl 10 mg O,R A06AB03 Dantron 50 mg O A06AB04 Phenolphthalein 0,2 g O A06AB05 Rizinusöl 20 g O A06AB06 Sennoside A06AB07 Cascara A06AB08 Natriumpicosulfat 5 mg O A06AB09 Bisoxatin 0,12 g O A06AB10 Koloquinthen 0,3 g O Droge A06AB13 Aloe A06AB20 Kontaktlaxanzien in Kombination A06AB30 Kontaktlaxanzien in Kombination mit Belladonna-Alkaloiden A06AB52 Bisacodyl, Kombinationen A06AB53 Dantron, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 9 von 133 BEDEUTUNG DDD-INFOATC-CODE A06AB56 Sennoside, Kombinationen A06AB57 Cascara, Kombinationen A06AB58 Natriumpicosulfat, Kombinationen A06AB59 Bisoxatin, Kombinationen A06AB60 Koloquinthen, Kombinationen A06AB63 Aloe, Kombinationen A06AC Quellmittel A06AC01 Ispaghula (Flohsamen) 7 g O A06AC02 Ethulose 3 g O A06AC03 Sterculia 8 g O A06AC05 Leinsamen A06AC06 Methylcellulose 2 g O A06AC07 Triticum (Weizenkleie) 10 g O A06AC08 Polycarbophil-Calcium 2,5 g O A06AC51 Ispaghula, Kombinationen A06AC53 Sterculia, Kombinationen A06AC55 Leinsamen, Kombinationen A06AC59 Bassorin, Kombinationen A06AD Osmotisch wirkende Laxanzien A06AD01 Magnesiumcarbonat 7 g O A06AD02 Magnesiumoxid 7 g O A06AD03 Magnesiumperoxid A06AD04 Magnesiumsulfat 7 g O A06AD10 Mineralsalze in Kombination A06AD11 Lactulose 12,5 g O A06AD12 Lactitol 10 g O A06AD13 Natriumsulfat A06AD14 Pentaerythrityl A06AD15 Macrogol 10 g O A06AD16 Mannitol A06AD17 Natriumphosphat 50 g O A06AD18 Sorbitol 10 g O A06AD19 Magnesiumcitrat A06AD21 Natriumtartrat A06AD61 Lactulose, Kombinationen A06AD65 Macrogol, Kombinationen Standarddosis: 2 Applikationsformen O A06AG Klysmen A06AG01 Natriumphosphat Standarddosis: 1 Klysma A06AG02 Bisacodyl Standarddosis: 1 Klysma A06AG03 Dantron, inkl. Kombinationen Standarddosis: 1 Klysma A06AG04 Glycerol Standarddosis: 1 Klysma A06AG06 Öl Standarddosis: 1 Klysma A06AG07 Sorbitol Standarddosis: 1 Klysma A06AG10 Docusat-Natrium, inkl. Kombinationen Standarddosis: 1 Klysma A06AG11 Laurylsulfat, inkl. Kombinationen Standarddosis: 1 Klysma A06AG20 Kombinationen Standarddosis: 1 Klysma A06AH Periphere Opioidrezeptor-Antagonisten A06AH01 Methylnaltrexon bromid 6 mg P A06AH02 Alvimopan A06AX Andere Mittel gegen Obstipation A06AX01 Glycerol 2 g R A06AX02 Kohlendioxid freisetzende Mittel A06AX03 Lubiproston A06AX04 Linaclotid 0,29 mg O A06AX05 Prucaloprid 2 mg O A06AX06 Tegaserod 12 mg O A07 ANTIDIARRHOIKA UND INTESTINALE ANTIPHLOGISTIKA/ANTIINFEKTIVA A07A INTESTINALE ANTIINFEKTIVA A07AA Antibiotika A07AA01 Neomycin 5 g O A07AA02 Nystatin 1,5 MIO E O A07AA03 Natamycin 0,3 g O A07AA04 Streptomycin A07AA05 Polymyxin B 3 MIO E O A07AA06 Paromomycin 3 g O A07AA07 Amphotericin B 0,4 g O A07AA08 Kanamycin A07AA09 Vancomycin 2 g O A07AA10 Colistin A07AA11 Rifaximin 0,6 g O A07AA12 Fidaxomicin 0,4 g O A07AA51 Neomycin, Kombinationen A07AA54 Streptomycin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 10 von 133 BEDEUTUNG DDD-INFOATC-CODE A07AB Sulfonamide A07AB02 Phthalylsulfathiazol 9 g O A07AB03 Sulfaguanidin 4 g O A07AB04 Succinylsulfathiazol A07AB06 Sulfaguanol A07AB50 Andere Sulfonamide, Kombinationen A07AC Imidazol-Derivate A07AC01 Miconazol 1 g O A07AX Andere intestinale Antiinfektiva A07AX01 Broxychinolin A07AX02 Acetarsol A07AX03 Nifuroxazid 0,6 g O A07AX04 Nifurzid A07AX05 Dichlorchinolinol A07AX06 Furazolidon A07AX07 Ethacridinlactat A07AX51 Broxychinolin, Kombinationen A07AX55 Dichlorchinolinol, Kombinationen A07B INTESTINALE ADSORBENZIEN A07BA Kohle-haltige Zubereitungen A07BA01 Medizinische Kohle 5 g O A07BA51 Medizinische Kohle, Kombinationen A07BB Bismut-haltige Zubereitungen A07BB51 Bismut, Kombinationen A07BC Andere intestinale Adsorbenzien A07BC01 Pektin A07BC02 Kaolin A07BC03 Crospovidon A07BC04 Attapulgit A07BC05 Diosmectit 9 g O A07BC07 Siliciumdioxid A07BC08 Huminsäuren A07BC30 Kombinationen A07BC51 Pektin, Kombinationen A07BC54 Attapulgit, Kombinationen A07BC55 Diosmectit, Kombinationen A07BP Pflanzliche Adsorbenzien A07BP51 Johannisbrotfruchtmehl, Kombinationen A07C ELEKTROLYTE MIT KOHLENHYDRATEN A07CA Elektrolyte zur oralen Rehydrierung A07CA50 Elektrolyte zur oralen Rehydrierung, Kombinationen A07D MOTILITÄTSHEMMER A07DA Motilitätshemmer A07DA01 Diphenoxylat 15 mg O A07DA02 Opium 0,1 g O A07DA03 Loperamid 10 mg O; 3,5 mg O Kinder DDD A07DA04 Difenoxin A07DA05 Loperamidoxid 5 mg O A07DA51 Diphenoxylat, Kombinationen A07DA52 Morphin, Kombinationen A07DA53 Loperamid, Kombinationen A07DA54 Difenoxin, Kombinationen A07E INTESTINALE ANTIPHLOGISTIKA A07EA Corticosteroide mit lokaler Wirkung A07EA01 Prednisolon A07EA02 Hydrocortison A07EA03 Prednison A07EA04 Betamethason Standarddosis: 1 Klysma A07EA05 Tixocortol A07EA06 Budesonid 9 mg O; Standarddosis: 1 Klysma A07EA07 Beclometason A07EA51 Prednisolon, Kombinationen Standarddosis: 1 Klysma A07EB Antiallergika, exkl. Corticosteroide 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 11 von 133 BEDEUTUNG DDD-INFOATC-CODE A07EB01 Cromoglicinsäure 0,8 g O A07EC Aminosalicylsäure und ähnliche Mittel A07EC01 Sulfasalazin 2 g O,R; Standarddosis: 1 Klysma A07EC02 Mesalazin 1,5 g O,R; Standarddosis: 1 Klysma A07EC03 Olsalazin 1 g O A07EC04 Balsalazid 6,75 g O A07ED Andere entzündungshemmende Mittel A07ED01 Aluminiumphosphat A07EF Mikrobielle Antiphlogistika A07EF01 Escherichia coli, Stamm Nissle 1917 A07F MIKROBIELLE ANTIDIARRHOIKA A07FA Mikrobielle Antidiarrhoika A07FA01 Milchsäurebildner A07FA02 Saccharomyces boulardii 1 g O A07FA05 IP-Bacillussporen A07FA06 Escherichia coli A07FA20 Kombinationen A07FA50 Mikrobielle Antidiarrhoika, Kombinationen A07FA51 Milchsäurebildner, Kombinationen A07FA52 Saccharomyces boulardii, Kombinationen A07X ANDERE ANTIDIARRHOIKA A07XA Andere Antidiarrhoika A07XA01 Albumintannat 3 g O A07XA03 Calcium-haltige Verbindungen A07XA04 Racecadotril 0,3 g O; 0,1 g O Kinder DDD A07XA50 Andere Antidiarrhoika, Kombinationen A07XA51 Albumintannat, Kombinationen A07XH Homöopathische und anthroposophische Antidiarrhoika A07XH10 Verschiedene A07XH20 Kombinationen A07XP Pflanzliche Antidiarrhoika A07XP01 Ceratonia A07XP02 Uzarawurzel A07XP03 Eichenrinde A07XP04 Karottenextrakt A07XP05 Apfelfruchtextrakt A07XP06 Tormentillwurzelstock A07XP30 Kombinationen A08 ANTIADIPOSITA, EXKL. DIÄTETIKA A08A ANTIADIPOSITA, EXKL. DIÄTETIKA A08AA Zentral wirkende Antiadiposita A08AA01 Phentermin 15 mg O A08AA02 Fenfluramin 0,12 g O A08AA03 Amfepramon 75 mg O A08AA04 Dexfenfluramin 30 mg O A08AA05 Mazindol 1 mg O A08AA06 Etilamfetamin A08AA07 Cathin A08AA08 Clobenzorex A08AA09 Mefenorex A08AA10 Sibutramin 10 mg O A08AA12 Phendimetrazin A08AA13 Phenylpropanolamin A08AA53 Amfepramon, Kombinationen A08AA56 Ephedrin, Kombinationen A08AA57 Cathin, Kombinationen A08AA63 Phenylpropanolamin, Kombinationen A08AB Peripher wirkende Antiadiposita A08AB01 Orlistat 0,36 g O A08AB11 Andere peripher wirkende Antiadiposita A08AB20 Kombinationen A08AH Homöopathische und anthroposophische Antiadiposita A08AH01 Madar A08AH02 Fucus vesiculosus 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 12 von 133 BEDEUTUNG DDD-INFOATC-CODE A08AH20 Kombinationen A08AX Andere Antiadiposita A08AX01 Rimonabant 20 mg O A09 DIGESTIVA, INKL. ENZYME A09A DIGESTIVA, INKL. ENZYME A09AA Enzym-haltige Zubereitungen A09AA01 Diastase A09AA02 Multienzyme (Lipase, Protease etc.) 240 TSD FIP E O Lipase A09AA03 Pepsin A09AA04 Tilactase A09AA07 Aspergillus oryzae A09AA50 Andere Enzyme, Kombinationen A09AA52 Multienzyme, Kombinationen A09AA57 Aspergillus oryzae, Kombinationen A09AB Säure-haltige Zubereitungen A09AB01 Glutaminsäurehydrochlorid 1,5 g O A09AB02 Betainhydrochlorid 1 g O A09AB03 Salzsäure A09AB04 Zitronensäure 2 g O A09AB50 Andere Säuren, Kombinationen A09AC Enzym- und Säure-haltige Zubereitungen, Kombinationen A09AC01 Pepsin- und Säure-haltige Zubereitungen A09AC02 Multienzyme und Säure-haltige Zubereitungen A09AC50 Andere Enzyme und Säuren, Kombinationen A09AH Homöopathische und anthroposophische Digestiva A09AH20 Kombinationen A09AP Pflanzliche Digestiva A09AP01 Harongarinde und -blätter A09AP02 Wermutkraut A09AP03 Enzianwurzel A09AX Andere Digestiva A09AX50 Andere Digestiva, Kombinationen A10 ANTIDIABETIKA A10A INSULINE UND ANALOGA A10AB Insuline und Analoga zur Injektion, schnell wirkend A10AB01 Insulin (human) 40 E P A10AB02 Insulin (Rind) 40 E P A10AB03 Insulin (Schwein) 40 E P A10AB04 Insulin lispro 40 E P A10AB05 Insulin aspart 40 E P A10AB06 Insulin glulisin 40 E P A10AB30 Kombinationen 40 E P A10AC Insuline und Analoga zur Injektion, intermediär wirkend A10AC01 Insulin (human) 40 E P A10AC02 Insulin (Rind) 40 E P A10AC03 Insulin (Schwein) 40 E P A10AC04 Insulin lispro 40 E P A10AC30 Kombinationen 40 E P A10AD Insuline und Analoga zur Injektion, intermediär wirkend kombiniert mit schnell wirkend A10AD01 Insulin (human) 40 E P A10AD02 Insulin (Rind) 40 E P A10AD03 Insulin (Schwein) 40 E P A10AD04 Insulin lispro 40 E P A10AD05 Insulin aspart 40 E P A10AD30 Kombinationen 40 E P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 13 von 133 BEDEUTUNG DDD-INFOATC-CODE A10AE Insuline und Analoga zur Injektion, lang wirkend A10AE01 Insulin (human) 40 E P A10AE02 Insulin (Rind) 40 E P A10AE03 Insulin (Schwein) 40 E P A10AE04 Insulin glargin 40 E P A10AE05 Insulin detemir 40 E P A10AE30 Kombinationen 40 E P A10AF Insuline und Analoga zur Inhalation A10AF01 Insulin (human) 15 mg Inhal A10B ANTIDIABETIKA, EXKL. INSULINE A10BA Biguanide A10BA01 Phenformin 0,1 g O A10BA02 Metformin 2 g O A10BA03 Buformin 0,2 g O A10BB Sulfonylharnstoff-Derivate A10BB01 Glibenclamid 10 mg O; 7 mg O mikrokristall. Substanz A10BB02 Chlorpropamid 0,375 g O A10BB03 Tolbutamid 1,5 g O A10BB04 Glibornurid 38 mg O A10BB05 Tolazamid 0,5 g O A10BB06 Carbutamid 0,75 g O A10BB07 Glipizid 10 mg O A10BB08 Gliquidon 60 mg O A10BB09 Gliclazid 60 mg O A10BB10 Metahexamid A10BB11 Glisoxepid A10BB12 Glimepirid 2 mg O A10BB31 Acetohexamid 0,5 g O A10BC Sulfonamide (heterozyklisch) A10BC01 Glymidin 1 g O A10BD Kombinationen mit oralen Antidiabetika A10BD01 Phenformin und Sulfonamide A10BD02 Metformin und Sulfonamide A10BD03 Metformin und Rosiglitazon Standarddosis: 2 Applikationsformen O A10BD04 Glimepirid und Rosiglitazon Standarddosis: 1 Applikationsform O A10BD05 Metformin und Pioglitazon Standarddosis: 2 Applikationsformen O A10BD06 Glimepirid und Pioglitazon Standarddosis: 1 Applikationsform O A10BD07 Metformin und Sitagliptin Standarddosis: 2 Applikationsformen O A10BD08 Metformin und Vildagliptin Standarddosis: 2 Applikationsformen O A10BD09 Pioglitazon und Alogliptin A10BD10 Metformin und Saxagliptin Standarddosis: 2 Applikationsformen O A10BD11 Metformin und Linagliptin A10BD12 Pioglitazon und Sitagliptin A10BD13 Metformin und Alogliptin A10BD15 Metformin und Glibenclamid Standarddosis: 2 Applikationsformen O A10BF Alpha-Glukosidasehemmer A10BF01 Acarbose 0,3 g O A10BF02 Miglitol 0,3 g O A10BF03 Voglibose A10BG Thiazolidindione A10BG01 Troglitazon 0,4 g O A10BG02 Rosiglitazon 6 mg O A10BG03 Pioglitazon 30 mg O A10BH Dipeptidyl-Peptidase-4-Inhibitoren A10BH01 Sitagliptin 0,1 g O A10BH02 Vildagliptin 0,1 g O A10BH03 Saxagliptin 5 mg O A10BH04 Alogliptin A10BH05 Linagliptin 5 mg O A10BH51 Sitagliptin und Simvastatin A10BX Andere Antidiabetika, exkl. Insuline A10BX02 Repaglinid 4 mg O A10BX03 Nateglinid 0,36 g O A10BX04 Exenatid 15 mcg P; 0,286 mg P Depotinjektion A10BX05 Pramlintid A10BX06 Benfluorex 0,45 g O A10BX07 Liraglutid 1,2 mg P A10BX08 Mitiglinid 30 mg O A10BX09 Dapagliflozin 10 mg O A10BX10 Lixisenatid 20 mcg P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 14 von 133 BEDEUTUNG DDD-INFOATC-CODE A10X ANDERE ANTIDIABETIKA A10XA Aldosereduktasehemmer A10XA01 Tolrestat A10XH Homöopathische und anthroposophische Antidiabetika A10XH20 Kombinationen A10XP Pflanzliche Antidiabetika A10XP01 Guar-Mehl A10XP02 Copalchirindenextrakt A10XP30 Kombinationen A11 VITAMINE A11A MULTIVITAMINE, KOMBINATIONEN A11AA Multivitamine mit Mineralstoffen A11AA01 Multivitamine und Eisen A11AA02 Multivitamine und Calcium Standarddosis: 1 Tablette oder 30 ml Mixtur A11AA03 Multivitamine und andere Mineralstoffe, inkl. Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11AA04 Multivitamine und Spurenelemente A11AB Multivitamine, andere Kombinationen A11AB50 Multivitamine, andere Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11B MULTIVITAMINE, REIN A11BA Multivitamine, rein A11BA01 Multivitamine, rein Standarddosis: 1 Tablette oder 30 ml Mixtur A11C VITAMIN A UND D, INKL. DEREN KOMBINATIONEN A11CA Vitamin A, rein A11CA01 Retinol (Vitamin A) 50 TSD E O,P A11CA02 Betacaroten A11CB Vitamin A und D in Kombination A11CB02 Retinol und Colecalciferol A11CC Vitamin D und Analoga A11CC01 Ergocalciferol A11CC02 Dihydrotachysterol 1 mg O A11CC03 Alfacalcidol 1 mcg O,P A11CC04 Calcitriol 1 mcg O,P A11CC05 Colecalciferol 500 IE O Kinder DDD prophylaktische Dosis A11CC06 Calcifediol A11CC08 Trans-Calcifediol A11CC20 Kombinationen A11CC80 Colecalciferol, Kombinationen mit Natriumfluorid 500 IE O Kinder DDD bezogen auf Colecalciferol, prophylaktische Dosis A11D VITAMIN B1, REIN UND IN KOMBINATION MIT VITAMIN B6 UND VITAMIN B12 A11DA Vitamin B1, rein A11DA01 Thiamin (Vitamin B1) 50 mg O,P A11DA02 Sulbutiamin A11DA03 Benfotiamin A11DA04 Fursultiamin A11DA06 Thiaminpyrophosphat A11DA07 Acethiamin A11DB Vitamin B1 in Kombination mit Vitamin B6 und/oder Vitamin B12 A11DB01 Thiamin (Vitamin B1) und Pyridoxin (Vitamin B6) A11DB03 Vitamin B1, Vitamin B6 und Vitamin B12 A11DB04 Thiamin, Pyridoxin und Nicotinamid 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 15 von 133 BEDEUTUNG DDD-INFOATC-CODE A11E VITAMIN-B-KOMPLEX, INKL. KOMBINATIONEN A11EA Vitamin-B-Komplex, rein A11EA01 Vitamin-B-Komplex, rein A11EB Vitamin-B-Komplex mit Vitamin C A11EB01 Vitamin-B-Komplex mit Vitamin C Standarddosis: 1 Tablette oder 30 ml Mixtur A11EC Vitamin-B-Komplex mit Mineralstoffen A11ED Vitamin-B-Komplex mit anabolen Steroiden A11EX Vitamin-B-Komplex, andere Kombinationen A11EX50 Vitamin-B-Komplex, andere Kombinationen A11G ASCORBINSÄURE (VITAMIN C), INKL. KOMBINATIONEN A11GA Ascorbinsäure (Vitamin C), rein A11GA01 Ascorbinsäure (Vitamin C) 0,2 g O,P A11GB Ascorbinsäure (Vitamin C), Kombinationen A11GB01 Ascorbinsäure (Vitamin C) und Calcium A11GB50 Ascorbinsäure (Vitamin C), andere Kombinationen A11H ANDERE VITAMINPRÄPARATE, REIN A11HA Andere Vitaminpräparate, rein A11HA01 Nicotinamid 0,15 g O A11HA02 Pyridoxin (Vitamin B6) 0,16 g O,P A11HA03 Tocopherol (Vitamin E) 0,2 g O,P A11HA04 Riboflavin (Vitamin B2) A11HA05 Biotin 5 mg O A11HA06 Pyridoxalphosphat A11HA07 Inositol A11HA08 Tocofersolan 0,2 g O bezogen auf Tocopherol; 0,425 g O Kinder DDD RRR-alpha-Tocopherol in Form v. Tocofersolan A11HA30 Dexpanthenol A11HA31 Calciumpantothenat A11HA32 Pantethin A11J ANDERE VITAMINPRÄPARATE, KOMBINATIONEN A11JA Kombinationen von Vitaminen A11JA01 Retinol, Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11JA03 Tocopherol (Vitamin E), Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11JA20 Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11JB Vitamine mit Mineralstoffen A11JB01 Vitamin E, Kombinationen mit Mineralstoffen Standarddosis: 1 Tablette oder 30 ml Mixtur A11JC Vitamine, andere Kombinationen A11JC50 Vitamine, andere Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A12 MINERALSTOFFE A12A CALCIUM A12AA Calcium A12AA01 Calciumphosphat 2 g O A12AA02 Calciumglubionat 2,75 g P A12AA03 Calciumgluconat 3 g O A12AA04 Calciumcarbonat 3 g O A12AA05 Calciumlactat 2 g O A12AA06 Calciumlactogluconat 3 g O A12AA07 Calciumchlorid 0,2 g P A12AA08 Calciumglycerylphosphat A12AA09 Calciumcitratlysin-Komplex 0,5 g O A12AA10 Calciumglucoheptonat 3 g O A12AA11 Calciumpangamat A12AA12 Calciumacetat, wasserfrei 2 g O A12AA20 Calcium (verschiedene Salze in Kombination) 0,5 g O Ca2+ 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 16 von 133 BEDEUTUNG DDD-INFOATC-CODE A12AA30 Calciumlaevulat 1 g P A12AA31 Calciumthiosulfat A12AA32 Calciumdiaspartat A12AA33 Calciumorotat A12AA34 Calciumcitrat A12AH Homöopathische und anthroposophische Calcium-haltige Zubereitungen A12AH20 Kombinationen A12AX Calcium, Kombinationen mit Vitamin D und/oder anderen Mitteln A12AX01 Calciumcarbonat und Colecalciferol A12AX02 Calciumsalze und Ergocalciferol A12AX41 Andere Calciumsalze und Colecalciferol A12AX50 Andere Calciumsalze, Kombinationen mit anderen Mitteln A12AX51 Calciumcarbonat und Colecalciferol, Kombinationen mit anderen Mitteln A12B KALIUM A12BA Kalium A12BA01 Kaliumchlorid 3 g O A12BA02 Kaliumcitrat 4 g O A12BA03 Kaliumhydrogentartrat 7,5 g O A12BA04 Kaliumhydrogencarbonat 4 g O A12BA05 Kaliumgluconat A12BA06 Kaliumadipat A12BA10 Kaliumsulfid A12BA30 Kombinationen A12BA51 Kaliumchlorid, Kombinationen A12BA52 Kaliumcitrat, Kombinationen A12BA54 Kaliumhydrogencarbonat, Kombinationen A12C ANDERE MINERALSTOFFE A12CA Natrium A12CA01 Natriumchlorid 1 g O A12CA02 Natriumsulfat A12CB Zink A12CB01 Zinksulfat 20 mg O,P A12CB02 Zinkgluconat 20 mg O,P A12CB03 Zinkprotein-Komplex 20 mg O,P A12CB05 Zinkhydrogenaspartat 20 mg O,P A12CB06 Zinkorotat 20 mg O,P A12CC Magnesium A12CC01 Magnesiumchlorid 2,5 g O; 0,8 g P A12CC02 Magnesiumsulfat 3 g O; 1 g P A12CC03 Magnesiumgluconat 5 g O A12CC04 Magnesiumcitrat 2 g O A12CC05 Magnesiumaspartat 10 mmol O Mg2+ A12CC06 Magnesiumlactat A12CC07 Magnesiumlevulinat A12CC08 Magnesiumpidolat A12CC09 Magnesiumorotat A12CC10 Magnesiumoxid 0,5 g O A12CC11 Magnesiumcarbonat A12CC12 Magnesiumascorbat A12CC14 Magnesiumhydrogenglutamat A12CC15 Magnesiumadipat A12CC30 Magnesium (verschiedene Salze in Kombination) A12CC50 Andere Magnesiumsalze, Kombinationen A12CD Fluorid A12CD01 Natriumfluorid 88 mg O bezogen auf Fluorid 40 mg A12CD02 Natriummonofluorphosphat 0,152 g O bezogen auf Fluorid 20mg A12CD51 Natriumfluorid, Kombinationen A12CD52 Natriummonofluorphosphat, Kombinationen 20 mg O bezogen auf Fluorid A12CE Selen A12CE01 Natriumselenat 0,2 mg O Se A12CE02 Natriumselenit 0,2 mg O Se; 0,2 mg P A12CH Andere homöopathische und anthroposophische Mineralstoff-haltige Zubereitungen A12CH01 Magnesium-haltige Zubereitungen A12CH02 Selen-haltige Zubereitungen A12CH10 Verschiedene 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 17 von 133 BEDEUTUNG DDD-INFOATC-CODE A12CH20 Kombinationen A12CX Andere Mineralstoff-haltige Zubereitungen A12CX01 Kieselerde A12CX02 Siliciumdioxid A12CX50 Andere Mineralstoff-haltige Zubereitungen, Kombinationen A13 TONIKA A13A TONIKA A13AA Tonika A13AA01 Glutaminsäure Standarddosis: 30 ml flüssige Zubereitung A13AA02 Lebertran Standarddosis: 30 ml flüssige Zubereitung A13AA50 Tonika Standarddosis: 30 ml flüssige Zubereitung A13AH Homöopathische und anthroposophische Tonika A13AH10 Verschiedene A13AH20 Kombinationen A13AP Pflanzliche Tonika A13AP01 Eleutherococcuswurzel A13AP02 Ginsengwurzel A13AP10 Verschiedene A13AP30 Kombinationen A14 ANABOLIKA ZUR SYSTEMISCHEN ANWENDUNG A14A ANABOLE STEROIDE A14AA Androstan-Derivate A14AA01 Androstanolon A14AA02 Stanozolol 5 mg O; 3,5 mg P A14AA03 Metandienon 5 mg O A14AA04 Metenolon 10 mg O; 7 mg P A14AA05 Oxymetholon 0,25 g O A14AA06 Quinbolon A14AA07 Prasteron A14AA08 Oxandrolon A14AA09 Norethandrolon A14AA10 Chlordehydromethyltestosteron A14AA11 Clostebol A14AA50 Andere Androstan-Derivate, Kombinationen A14AB Estren-Derivate A14AB01 Nandrolon 2 mg P A14AB02 Ethylestrenol 2 mg O A14AB03 Oxaboloncipionat A14B ANDERE ANABOLIKA A15 APPETIT STIMULIERENDE MITTEL A15A APPETIT STIMULIERENDE MITTEL A15AA Appetit stimulierende Mittel A15AA01 Cyproheptadin A15AA02 Pizotifen A15AA50 Andere Appetit stimulierende Mittel, Kombinationen A15AA51 Cyproheptadin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 18 von 133 BEDEUTUNG DDD-INFOATC-CODE A16 ANDERE MITTEL FÜR DAS ALIMENTÄRE SYSTEM UND DEN STOFFWECHSEL A16A ANDERE MITTEL FÜR DAS ALIMENTÄRE SYSTEM UND DEN STOFFWECHSEL A16AA Aminosäuren und Derivate A16AA01 Levocarnitin 2 g O,P A16AA02 Ademetionin A16AA03 Glutamin A16AA04 Mercaptamin 2 g O A16AA05 Carglumsäure 0,2 g O A16AA06 Betain 6 g O A16AA11 Tiopronin A16AA50 Andere Aminosäuren, Kombinationen A16AB Enzyme A16AB01 Alglucerase A16AB02 Imiglucerase 300 E P A16AB03 Agalsidase alfa 1 mg P A16AB04 Agalsidase beta 5 mg P A16AB05 Laronidase 1 TSD E P A16AB06 Sacrosidase 68 TSD E O A16AB07 Alglucosidase alfa 0,1 g P A16AB08 Galsulfase A16AB09 Idursulfase 5 mg P A16AB10 Velaglucerase alfa 300 E P A16AB11 Taliglucerase alfa A16AX Sonstige Mittel für das alimentäre System und den Stoffwechsel A16AX01 Alpha-Liponsäure (Thioctsäure) 0,2 g O,P A16AX02 Anetholtrithion A16AX03 Natriumphenylbutyrat 20 g O A16AX04 Nitisinon 20 mg O A16AX05 Zinkacetat 0,15 g O A16AX06 Miglustat 0,3 g O A16AX07 Sapropterin 0,7 g O A16AX08 Teduglutid A16AX09 Glycerolphenylbutyrat 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 19 von 133 BEDEUTUNG DDD-INFOATC-CODE B BLUT UND BLUTBILDENDE ORGANE B01 ANTITHROMBOTISCHE MITTEL B01A ANTITHROMBOTISCHE MITTEL B01AA Vitamin-K-Antagonisten B01AA01 Dicoumarol 0,1 g O B01AA02 Phenindion 0,1 g O B01AA03 Warfarin 7,5 mg O,P B01AA04 Phenprocoumon 3 mg O B01AA07 Acenocoumarol 5 mg O B01AA08 Ethylbiscoumacetat 0,6 g O B01AA09 Clorindion B01AA10 Diphenadion B01AA11 Tioclomarol B01AA12 Fluindion B01AB Heparingruppe B01AB01 Heparin 10 TSD E P B01AB02 Antithrombin III, Antithrombin alfa 2,1 TSD E P; 7,5 TSD E P bezogen auf Antithrombin alfa B01AB04 Dalteparin 2,5 TSD E P anti Xa B01AB05 Enoxaparin 2 TSD E P anti Xa B01AB06 Nadroparin 2,85 TSD E P anti Xa B01AB07 Parnaparin 3,2 TSD E P anti Xa B01AB08 Reviparin 1,43 TSD E P anti Xa B01AB09 Danaparoid 1,5 TSD E P anti Xa B01AB10 Tinzaparin 3,5 TSD E P anti Xa B01AB11 Sulodexid 500 LSU O,P (Lipoprotein-Lipase-Releasing-Einheiten) B01AB12 Bemiparin 2,5 TSD E P B01AB13 Certoparin 3 TSD E P anti Xa B01AB51 Heparin, Kombinationen B01AB63 Certoparin, Kombinationen B01AC Thrombozytenaggregationshemmer, exkl. Heparin B01AC01 Ditazol B01AC02 Cloricromen B01AC03 Picotamid B01AC04 Clopidogrel 75 mg O B01AC05 Ticlopidin 0,5 g O B01AC06 Acetylsalicylsäure 1 Tablette O (unabhängig von der Wirkstärke) B01AC07 Dipyridamol 0,4 g O; 0,2 g P B01AC08 Carbasalat calcium 1 Tablette O B01AC09 Epoprostenol 38 mcg P B01AC10 Indobufen B01AC11 Iloprost 0,15 mg Inhal; 50 mcg P B01AC12 Sulfinpyrazon B01AC13 Abciximab 25 mg P B01AC15 Aloxiprin B01AC16 Eptifibatid 0,2 g P B01AC17 Tirofiban 10 mg P B01AC18 Triflusal 0,6 g O B01AC19 Beraprost B01AC21 Treprostinil 4,3 mg P B01AC22 Prasugrel 10 mg O B01AC23 Cilostazol 0,2 g O B01AC24 Ticagrelor 0,18 g O B01AC30 Kombinationen B01AC34 Clopidogrel, Kombinationen 75 mg O bezogen auf Clopidogrel B01AC36 Acetylsalicylsäure und Dipyridamol 0,4 g O bezogen auf Dipyridamol B01AC56 Acetylsalicylsäure und Esomeprazol Standarddosis: 1 Applikationsform O B01AD Enzyme B01AD01 Streptokinase 1,5 MIO E P B01AD02 Alteplase 0,1 g P B01AD03 Anistreplase 30 E P B01AD04 Urokinase 3 MIO E P B01AD05 Fibrinolysin B01AD06 Brinase B01AD07 Reteplase 20 E P B01AD08 Saruplase B01AD09 Ancrod B01AD10 Drotrecogin alfa (aktiviert) 40 mg P B01AD11 Tenecteplase 40 mg P B01AD12 Protein C B01AD51 Streptokinase, Kombinationen B01AE Direkte Thrombininhibitoren B01AE01 Desirudin 30 mg P B01AE02 Lepirudin 0,25 g P B01AE03 Argatroban 0,2 g P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 20 von 133 BEDEUTUNG DDD-INFOATC-CODE B01AE04 Melagatran 6 mg P B01AE05 Ximelagatran 48 mg O B01AE06 Bivalirudin 0,25 g P B01AE07 Dabigatran etexilat 0,22 g O B01AF Direkte Faktor-Xa-Inhibitoren B01AF01 Rivaroxaban 10 mg O B01AF02 Apixaban 5 mg O B01AX Andere antithrombotische Mittel B01AX01 Defibrotid B01AX04 Chondroitinsulfat B B01AX05 Fondaparinux 2,5 mg P B01AX07 Natriumpentosanpolysulfat B01AY Enzyme zu lokalen Anwendung B01AY01 Streptokinase B01AY02 Urokinase 25 TSD E P B02 ANTIHÄMORRHAGIKA B02A ANTIFIBRINOLYTIKA B02AA Aminosäuren B02AA01 Aminocapronsäure 16 g O,P B02AA02 Tranexamsäure 2 g O,P B02AA03 Aminomethylbenzoesäure 0,25 g O B02AB Proteinasehemmer B02AB01 Aprotinin 500 TSD E P B02AB02 Alfa1-Antitrypsin 0,6 g P B02AB04 Camostat B02B VITAMIN K UND ANDERE HÄMOSTATIKA B02BA Vitamin K B02BA01 Phytomenadion 20 mg O,P B02BA02 Menadion 10 mg O; 2 mg P B02BB Fibrinogene B02BB01 Fibrinogen, human 5 g P B02BC Lokale Hämostatika B02BC01 Absorbierbarer Gelatineschwamm Standarddosis: 1 Applikationsform B02BC02 Oxidierte Zellulose Standarddosis: 1 Applikationsform B02BC03 Tetragalacturonsäurehydroxymethylester B02BC05 Adrenalon B02BC06 Thrombin B02BC07 Kollagen Standarddosis: 1 Applikationsform B02BC08 Calciumalginat B02BC09 Epinephrin B02BC10 Fibrinogen, human B02BC12 Thromboplastin B02BC13 Polyglycolsäure B02BC14 Gelatine B02BC30 Kombinationen B02BC51 Blutgerinnungsfaktoren, Kombinationen B02BC57 Kollagen, Kombinationen Standarddosis: 1 Applikationsform B02BD Blutgerinnungsfaktoren B02BD01 Gerinnungsfaktoren IX, II, VII und X in Kombination 350 E P B02BD02 Gerinnungsfaktor VIII 500 E P B02BD03 Faktor-VIII-Inhibitor-bypass-Aktivität 10 TSD E P B02BD04 Gerinnungsfaktor IX 350 E P B02BD05 Gerinnungsfaktor VII 6 TSD E P B02BD06 Von Willebrand-Faktor und Gerinnungsfaktor VIII in Kombination 7,2 TSD E P B02BD07 Gerinnungsfaktor XIII 3,5 TSD E P B02BD08 Eptacog alfa (aktiviert) 2500 TSD E P B02BD09 Nonacog alfa 450 E P B02BD10 Von Willebrand-Faktor 6 TSD E P B02BD11 Catridecacog B02BD12 Trenonacog alfa B02BD13 Octocog alfa 500 E P B02BD14 Moroctocog alfa 500 E P B02BD30 Thrombin B02BP Pflanzliche Antihämorrhagika B02BP50 Pflanzliche Antihämorrhagika, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 21 von 133 BEDEUTUNG DDD-INFOATC-CODE B02BX Andere systemische Hämostatika B02BX01 Etamsylat B02BX02 Carbazochrom B02BX03 Batroxobin B02BX04 Romiplostim 30 mcg P B02BX05 Eltrombopag 50 mg O B03 ANTIANÄMIKA B03A EISEN-HALTIGE ZUBEREITUNGEN B03AA Eisen zweiwertig, orale Zubereitungen B03AA01 Eisen(II)glycinsulfat 0,2 g O Fe2+ B03AA02 Eisen(II)fumarat 0,2 g O Fe2+ B03AA03 Eisen(II)gluconat 0,2 g O Fe2+ B03AA04 Eisen(II)carbonat 0,2 g O Fe2+ B03AA05 Eisen(II)chlorid 0,2 g O Fe2+ B03AA06 Eisen(II)succinat 0,2 g O Fe2+ B03AA07 Eisen(II)sulfat 0,2 g O Fe2+ B03AA08 Eisen(II)tartrat 0,2 g O Fe2+ B03AA09 Eisen(II)aspartat 0,2 g O Fe2+ B03AA10 Eisen(II)ascorbat 0,2 g O Fe2+ B03AA11 Eisen(II)iodat 0,2 g O Fe2+ B03AA12 Ammoniumeisen(II)sulfat 0,2 g O Fe2+ B03AA13 Eisen(II)polystyrol-sulfonat 0,2 g O Fe2+ B03AA20 Kombinationen B03AA50 Kombinationen von II-und III-wertigem Eisen B03AB Eisen dreiwertig, orale Zubereitungen B03AB01 Eisen(III)natrium-citrat 0,75 g O Fe3+ B03AB02 Eisen(III)oxid-Saccharose-Komplex 0,11 g O Fe3+ B03AB03 Natriumferedetat 0,17 g O Fe3+ B03AB04 Eisen(III)hydroxid B03AB05 Eisen(III)hydroxid-Polymaltose-Komplex 90 mg O Fe3+ B03AB06 Eisen(III)citrat B03AB07 Chondroitinsulfat-Eisen(III)-Komplex B03AB08 Eisen(III)acetyltransferrin B03AB09 Eisen(III)proteinsuccinylat B03AB11 Kalium-Eisen(III)phosphat-Citrat-Komplex B03AC Eisen dreiwertig, parenterale Zubereitungen B03AC01 Eisen(III)hydroxid-Polymaltose-Komplex 0,1 g P Fe3+ B03AC02 Eisen(III)oxid-Saccharose-Komplex 0,1 g P Fe3+ B03AC03 Eisen(III)sorbit-Zitronensäure-Komplex 0,1 g P Fe3+ B03AC05 Eisen(III)sorbit-Gluconsäure-Komplex 0,1 g P Fe3+ B03AC06 Eisen(III)hydroxid-Dextran-Komplex 0,1 g P Fe3+ B03AC07 Eisen(III)natrium-Gluconat-Komplex 0,1 g P Fe3+ B03AD Eisen in Kombination mit Folsäure B03AD01 Eisen-Aminosäure-Komplex B03AD02 Eisen(II)fumarat B03AD03 Eisen(II)sulfat 0,1 g O Fe2+ B03AD04 Eisen(III)hydroxid-Polymaltose-Komplex B03AD05 Ammoniumeisen(II)sulfat 0,1 g O Fe2+ B03AD06 Eisen(II)glycinsulfat 0,1 g O Fe2+ B03AD09 Eisen(II)gluconat B03AE Eisen in anderen Kombinationen B03AE01 Eisen, Vitamin B12 und Folsäure B03AE02 Eisen, Multivitamine und Folsäure B03AE03 Eisen und Multivitamine B03AE04 Eisen, Multivitamine und Mineralstoffe B03AE10 Verschiedene Kombinationen B03B VITAMIN B12 UND FOLSÄURE B03BA Vitamin B12 (Cyanocobalamin und Analoga) B03BA01 Cyanocobalamin 70 mcg N; 1 mg O; 20 mcg P B03BA02 Cyanocobalamin-Tannin-Komplex 20 mcg P B03BA03 Hydroxocobalamin 20 mcg P B03BA04 Cobamamid B03BA05 Mecobalamin 1,5 mg O; 0,2 mg P B03BA51 Cyanocobalamin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 22 von 133 BEDEUTUNG DDD-INFOATC-CODE B03BA53 Hydroxocobalamin, Kombinationen B03BB Folsäure und Derivate B03BB01 Folsäure 0,4 mg O prophylaktische Dosis; 10 mg P therapeutische Dosis; 10 mg O therapeutische Dosis B03BB02 Calciumfolinat B03BB51 Folsäure, Kombinationen B03X ANDERE ANTIANÄMIKA B03XA Andere Antianämika B03XA01 Erythropoietin 1 TSD E P B03XA02 Darbepoetin alfa 4,5 mcg P B03XA03 Methoxy-Polyethylenglycol-Epoetin beta 4 mcg P B03XA04 Peginesatid B03XA05 Epoetin delta 1 TSD E P B03XH Homöopathische und anthroposophische Antianämika B03XH20 Kombinationen B05 BLUTERSATZMITTEL UND PERFUSIONSLÖSUNGEN B05A BLUT UND VERWANDTE PRODUKTE B05AA Blutersatzmittel und Plasmaproteinfraktionen B05AA01 Albumin Standarddosis: 1 Applikationsform P B05AA02 Andere Plasmaproteinfraktionen Standarddosis: 1 Applikationsform P B05AA03 Fluorocarbon-Blutersatzmittel Standarddosis: 1 Applikationsform P B05AA05 Dextran Standarddosis: 1 Applikationsform P B05AA06 Gelatine-haltige Mittel Standarddosis: 1 Applikationsform P B05AA07 Hydroxyethylstärke Standarddosis: 1 Applikationsform P B05AA08 Hämoglobin crosfumaril Standarddosis: 1 Applikationsform P B05AA09 Hämoglobin raffimer Standarddosis: 1 Applikationsform P B05AA10 Hämoglobin glutamer (Rind) B05AA51 Albumin, Kombinationen Standarddosis: 1 Applikationsform P B05AA55 Dextran, Kombinationen Standarddosis: 1 Applikationsform P B05AA56 Gelatine-haltige Mittel, Kombinationen Standarddosis: 1 Applikationsform P B05AA57 Hydroxyethylstärke, Kombinationen Standarddosis: 1 Applikationsform P B05AX Andere Blutprodukte B05AX01 Erythrozyten B05AX02 Thrombozyten B05AX03 Blutplasma B05AX04 Stammzellen aus Nabelschnurblut B05AX05 Granulozyten B05AX06 Leukozyten B05AX07 Vollblut B05AX10 Sonstige Blutprodukte B05AX40 Sonstige Blutprodukte ohne Pharmazentralnummer B05AX41 Erythrozyten ohne Pharmazentralnummer B05AX42 Thrombozyten ohne Pharmazentralnummer B05AX43 Blutplasma ohne Pharmazentralnummer B05AX45 Granulozyten ohne Pharmazentralnummer B05AX46 Leukozyten ohne Pharmazentralnummer B05AX47 Vollblut ohne Pharmazentralnummer B05B I.V.-LÖSUNGEN B05BA Lösungen zur parenteralen Ernährung B05BA01 Aminosäuren Standarddosis: 1 Applikationsform P B05BA02 Fett-Emulsionen Standarddosis: 1 Applikationsform P B05BA03 Kohlenhydrate Standarddosis: 1 Applikationsform P B05BA04 Proteinhydrolysate Standarddosis: 1 Applikationsform P B05BA10 Kombinationen Standarddosis: 1 Applikationsform P B05BA11 Glucose Standarddosis: 1 Applikationsform P B05BA12 Fructose Standarddosis: 1 Applikationsform P B05BA13 Sorbitol Standarddosis: 1 Applikationsform P B05BA14 Xylitol Standarddosis: 1 Applikationsform P B05BB Lösungen mit Wirkung auf den Elektrolythaushalt B05BB01 Elektrolyte Standarddosis: 1 Applikationsform P B05BB02 Elektrolyte mit Kohlenhydraten Standarddosis: 1 Applikationsform P B05BB03 Trometamol Standarddosis: 1 Applikationsform P B05BB04 Elektrolyte in Kombination mit anderen Mitteln Standarddosis: 1 Applikationsform P B05BB10 Kombinationen Standarddosis: 1 Applikationsform P B05BB11 Physiologische Kochsalzlösung Standarddosis: 1 Applikationsform P B05BB12 Ringerlösung Standarddosis: 1 Applikationsform P B05BB13 Ringerlactatlösung Standarddosis: 1 Applikationsform P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 23 von 133 BEDEUTUNG DDD-INFOATC-CODE B05BB14 Ringeracetatlösung Standarddosis: 1 Applikationsform P B05BB53 Trometamol, Kombinationen Standarddosis: 1 Applikationsform P B05BC Osmodiuretika B05BC01 Mannitol Standarddosis: 1 Applikationsform P B05BC02 Harnstoff Standarddosis: 1 Applikationsform P B05BC03 Sorbitol Standarddosis: 1 Applikationsform P B05BC51 Mannitol, Kombinationen Standarddosis: 1 Applikationsform P B05BC53 Sorbitol, Kombinationen Standarddosis: 1 Applikationsform P B05C SPÜLLÖSUNGEN B05CA Antiinfektiva B05CA01 Cetylpyridinium B05CA02 Chlorhexidin B05CA03 Nitrofural B05CA04 Sulfamethizol B05CA05 Taurolidin B05CA06 Mandelsäure B05CA07 Noxytiolin B05CA08 Ethacridinlactat B05CA09 Neomycin B05CA10 Kombinationen B05CB Salzlösungen B05CB01 Natriumchlorid Standarddosis: 1 Applikationsform P B05CB02 Natriumcitrat Standarddosis: 1 Applikationsform P B05CB03 Magnesiumcitrat Standarddosis: 1 Applikationsform P B05CB04 Natriumbicarbonat Standarddosis: 1 Applikationsform P B05CB10 Kombinationen Standarddosis: 1 Applikationsform P B05CX Andere Spüllösungen B05CX01 Glucose Standarddosis: 1 Applikationsform P B05CX02 Sorbitol Standarddosis: 1 Applikationsform P B05CX03 Glycin Standarddosis: 1 Applikationsform P B05CX04 Mannitol Standarddosis: 1 Applikationsform P B05CX05 Heparin B05CX10 Kombinationen Standarddosis: 1 Applikationsform P B05D LÖSUNGEN ZUR PERITONEALDIALYSE B05DA Isotone Lösungen B05DB Hypertone Lösungen B05DB50 Kombinationen Standarddosis: 1 Applikationsform P B05X ADDITIVA ZU I.V.-LÖSUNGEN B05XA Elektrolytlösungen B05XA01 Kaliumchlorid Standarddosis: 1 Applikationsform P B05XA02 Natriumbicarbonat Standarddosis: 1 Applikationsform P B05XA03 Natriumchlorid Standarddosis: 1 Applikationsform P B05XA04 Ammoniumchlorid B05XA05 Magnesiumsulfat Standarddosis: 1 Applikationsform P B05XA06 Kaliumphosphat, inkl. Kombinationen mit anderen Kaliumsalzen B05XA07 Calciumchlorid Standarddosis: 1 Applikationsform P B05XA08 Natriumacetat B05XA09 Natriumphosphat B05XA10 Magnesiumphosphat B05XA11 Magnesiumchlorid B05XA12 Zinkchlorid B05XA13 Salzsäure B05XA14 Dinatrium-1-glycerinphosphat B05XA15 Kaliumlactat B05XA16 Kardioplege Lösungen B05XA17 Kaliumacetat B05XA18 Dinatrium-1(2)-glycerin-phosphat-Gemisch Standarddosis: 1 Applikationsform P B05XA19 Kalium L-malat Standarddosis: 1 Applikationsform P B05XA21 Natriumcitrat Standarddosis: 1 Applikationsform P B05XA30 Kombinationen von Elektrolyten Standarddosis: 1 Applikationsform P B05XA31 Elektrolyte in Kombination mit anderen Mitteln Standarddosis: 1 Applikationsform P B05XB Aminosäuren B05XB01 Argininhydrochlorid Standarddosis: 1 Applikationsform P B05XB02 Alanylglutamin Standarddosis: 1 Applikationsform P B05XB03 Lysin Standarddosis: 1 Applikationsform P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 24 von 133 BEDEUTUNG DDD-INFOATC-CODE B05XC Vitamine B05XC30 Kombinationen Standarddosis: 1 Applikationsform P B05XX Andere Additiva zu i.v.-Lösungen B05XX02 Trometamol Standarddosis: 1 Applikationsform P B05XX03 Blut und Organextrakte vom Kalb, inkl. Kombinationen B05XX04 Ethanol Standarddosis: 1 Applikationsform P B05Z HÄMODIALYSEKONZENTRATE UND HÄMOFILTRATE B05ZA Hämodialysekonzentrate B05ZA50 Kombinationen Standarddosis: 1 Applikationsform P B05ZB Hämofiltrate B05ZB50 Kombinationen Standarddosis: 1 Applikationsform P B06 ANDERE HÄMATOLOGIKA B06A ANDERE HÄMATOLOGIKA B06AA Enzyme B06AA02 Fibrinolysin und Desoxyribonuclease B06AA03 Hyaluronidase B06AA04 Chymotrypsin B06AA07 Trypsin B06AA10 Desoxyribonuclease B06AA11 Bromelaine 0,2 g O B06AA12 Serrapeptase B06AA55 Streptokinase, Kombinationen B06AB Andere Hämprodukte B06AB01 Hematin B06AC Mittel zur Behandlung des Hereditären Angioödems B06AC01 C1-Inhibitor, aus Plasma gewonnen 1,4 TSD E P B06AC02 Icatibant 30 mg P B06AC03 Ecallantid B06AC04 Conestat alfa 3,5 TSD E P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 25 von 133 BEDEUTUNG DDD-INFOATC-CODE C KARDIOVASKULÄRES SYSTEM C01 HERZTHERAPIE C01A HERZGLYKOSIDE C01AA Digitalisglykoside C01AA01 Acetyldigitoxin 0,2 mg O C01AA02 Acetyldigoxin 0,5 mg O C01AA03 Digitalisblätter 0,1 g O C01AA04 Digitoxin 0,1 mg O,P C01AA05 Digoxin 0,25 mg O,P C01AA06 Lanatosid C 1 mg O,R C01AA07 Deslanosid 1 mg P zur Akutbehandlung C01AA08 Metildigoxin 0,2 mg O,P C01AA09 Gitoformat C01AA10 Pengitoxin C01AA20 Kombinationen C01AA52 Acetyldigoxin, Kombinationen C01AA54 Digitoxin, Kombinationen C01AA55 Digoxin, Kombinationen C01AA56 Lanatosid C, Kombinationen C01AA58 Metildigoxin, Kombinationen C01AB Scillaglykoside C01AB01 Proscillaridin 0,75 mg O C01AB02 Meproscillarin C01AB51 Proscillaridin, Kombinationen C01AC Strophantusglykoside C01AC01 g-Strophanthin 0,25 mg P C01AC03 Cymarin 2,5 mg O C01AC04 k-Strophanthin C01AC05 Strophantustinktur/-öl C01AC51 g-Strophanthin, Kombinationen exkl. Psycholeptika C01AC54 k-Strophanthin, Kombinationen exkl. Psycholeptika C01AC55 Strophantustinktur/-öl, Kombinationen exkl. Psycholeptika C01AC71 g-Strophanthin, Kombinationen mit Psycholeptika C01AH Homöopathische und anthroposophische Zubereitungen mit Herzglykosiden C01AH01 Strophantus gratus C01AH20 Kombinationen C01AH50 Kombinationen mit anderen Mitteln C01AP Andere pflanzliche Zubereitungen mit Herzglykosiden C01AP01 Maiglöckchenkraut C01AP03 Meerzwiebel C01AP30 Kombinationen C01AP50 Andere Pflanzenglykoside, Kombinationen C01AP51 Maiglöckchenkraut, Kombinationen C01AP52 Oleanderglykoside, Kombinationen C01AP53 Meerzwiebel, Kombinationen C01AX Andere Herzglykoside C01AX02 Peruvosid C01B ANTIARRHYTHMIKA, KLASSE I UND III C01BA Antiarrhythmika, Klasse Ia C01BA01 Chinidin 1,2 g O C01BA02 Procainamid 3 g O,P C01BA03 Disopyramid 0,4 g O,P C01BA04 Spartein 0,2 g P C01BA05 Ajmalin 0,3 g O; 50 mg P C01BA08 Prajmalin 30 mg O C01BA12 Lorajmin 0,3 g O C01BA33 Detajmium C01BA50 Antiarrhythmika, Kombinationen exkl. Psycholeptika C01BA51 Chinidin, Kombinationen exkl. Psycholeptika C01BA70 Antiarrhythmika, Kombinationen mit Psycholeptika C01BA71 Chinidin, Kombinationen mit Psycholeptika C01BB Antiarrhythmika, Klasse Ib C01BB01 Lidocain Standarddosis: 1 Applikationsform P C01BB02 Mexiletin 0,8 g O,P C01BB03 Tocainid 1,2 g O,P C01BB04 Aprindin 0,1 g O,P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 26 von 133 BEDEUTUNG DDD-INFOATC-CODE C01BC Antiarrhythmika, Klasse Ic C01BC03 Propafenon 0,5 g O,P C01BC04 Flecainid 0,2 g O,P C01BC07 Lorcainid 0,2 g P C01BC08 Encainid 0,1 g O C01BD Antiarrhythmika, Klasse III C01BD01 Amiodaron 0,2 g O,P C01BD02 Bretyliumtosilat C01BD03 Bunaftin C01BD04 Dofetilid C01BD05 Ibutilid 1 mg P C01BD06 Tedisamil C01BD07 Dronedaron 0,8 g O C01BG Andere Antiarrhythmika, Klasse I und III C01BG01 Moracizin 0,75 g O C01BG03 Tiracizin C01BG07 Cibenzolin C01BG11 Vernakalant 0,2 g P bezogen auf Vernakalanthydrochlorid C01C KARDIOSTIMULANZIEN, EXKL. HERZGLYKOSIDE C01CA Adrenerge und dopaminerge Mittel C01CA01 Etilefrin 50 mg O,P C01CA02 Isoprenalin 90 mg O,P C01CA03 Norepinephrin 6 mg P C01CA04 Dopamin 0,5 g P C01CA05 Norfenefrin 25 mg O C01CA06 Phenylephrin 4 mg P C01CA07 Dobutamin 0,5 g P C01CA08 Oxedrin 0,2 g O,P C01CA09 Metaraminol 50 mg P C01CA10 Methoxamin 30 mg P C01CA11 Mephentermin 30 mg P; 30 mg O C01CA12 Dimetofrin C01CA13 Prenalterol 10 mg P C01CA14 Dopexamin 0,5 g P C01CA15 Gepefrin 30 mg O C01CA16 Ibopamin 0,3 g O C01CA17 Midodrin 30 mg O C01CA18 Octopamin C01CA19 Fenoldopam C01CA21 Cafedrin C01CA22 Arbutamin C01CA23 Theodrenalin C01CA24 Epinephrin 0,5 mg P C01CA25 Amezinium metilsulfat 30 mg O C01CA26 Ephedrin 50 mg P C01CA27 Pholedrin C01CA29 Orciprenalin C01CA30 Kombinationen C01CA50 Adrenerge und dopaminerge Mittel, Kombinationen C01CA51 Etilefrin, Kombinationen C01CA55 Norfenefrin, Kombinationen C01CA58 Oxedrin, Kombinationen C01CA68 Octopamin, Kombinationen C01CA81 Metamfepramon, Kombinationen C01CB Ephedrin-Derivate C01CB01 Ephedrin C01CB04 Oxilofrin C01CB51 Ephedrin, Kombinationen C01CB54 Oxilofrin, Kombinationen C01CE Phosphodiesterasehemmer C01CE01 Amrinon 0,5 g P C01CE02 Milrinon 50 mg P C01CE03 Enoximon 1 g P C01CE04 Bucladesin C01CH Homöopathische und anthroposophische Kardiostimulanzien C01CH20 Kombinationen C01CX Andere Kardiostimulanzien C01CX06 Angiotensinamid 5 mg P C01CX07 Xamoterol 0,4 g O C01CX08 Levosimendan 11 mg P C01CX10 Ipratropium bromid 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 27 von 133 BEDEUTUNG DDD-INFOATC-CODE C01D BEI HERZERKRANKUNGEN EINGESETZTE VASODILATATOREN C01DA Organische Nitrate C01DA02 Glyceroltrinitrat 5 mg O,TD; 2,5 mg oral Aerosol,SL; Standarddosis: 1 Applikationsform P C01DA04 Methylpropylpropanedioldinitrat C01DA05 Pentaerythrityltetranitrat 0,12 g O C01DA07 Propatylnitrat 30 mg O C01DA08 Isosorbiddinitrat 60 mg O; 20 mg oral Aerosol,SL; 0,1 g TD; Standarddosis: 1 Applikationsform P C01DA09 Trolnitrat 20 mg O C01DA13 Erythrityltetranitrat 90 mg O C01DA14 Isosorbidmononitrat 40 mg O C01DA20 Organische Nitrate in Kombination C01DA38 Tenitramin C01DA52 Glyceroltrinitrat, Kombinationen C01DA54 Methylpropylpropanedioldinitrat, Kombinationen C01DA55 Pentaerythrityltetranitrat, Kombinationen C01DA57 Propatylnitrat, Kombinationen C01DA58 Isosorbiddinitrat, Kombinationen C01DA59 Trolnitrat, Kombinationen C01DA63 Erythrityltetranitrat, Kombinationen C01DA70 Organische Nitrate in Kombination mit Psycholeptika C01DB Chinolon-Vasodilatatoren C01DB01 Flosequinan C01DX Andere bei Herzerkrankungen eingesetzte Vasodilatatoren C01DX01 Itramintosilat C01DX02 Prenylamin 0,12 g O C01DX03 Oxyfedrin 40 mg O,P C01DX04 Benziodaron 0,25 g O C01DX05 Carbocromen C01DX06 Hexobendin C01DX07 Etafenon 0,225 g O C01DX08 Heptaminol 0,45 g O,P C01DX09 Imolamin 90 mg O C01DX10 Dilazep 0,1 g O C01DX11 Trapidil C01DX12 Molsidomin 8 mg O C01DX13 Efloxat 0,2 g O C01DX14 Cinepazet 0,9 g O C01DX15 Cloridarol C01DX16 Nicorandil 40 mg O C01DX18 Linsidomin C01DX19 Nesiritid 1,5 mg P C01DX21 Dipyridamol C01DX51 Itramintosilat, Kombinationen C01DX52 Prenylamin, Kombinationen C01DX53 Oxyfedrin, Kombinationen C01DX54 Benziodaron, Kombinationen C01DX55 Carbocromen, Kombinationen C01DX71 Dipyridamol, Kombinationen C01E ANDERE HERZMITTEL C01EA Prostaglandine C01EA01 Alprostadil 0,5 mg P C01EB Andere Herzmittel C01EB02 Campher 0,15 g O C01EB03 Indometacin C01EB05 Creatinolfosfat C01EB06 Fosfocreatin C01EB07 Fructose-1,6-diphosphat C01EB09 Ubidecarenon C01EB10 Adenosin 15 mg P C01EB11 Tiracizin C01EB13 Acadesin C01EB15 Trimetazidin 40 mg O C01EB16 Ibuprofen 30 mg P C01EB17 Ivabradin 10 mg O C01EB18 Ranolazin 1,5 g O C01EB20 Fleischextrakt C01EB21 Regadenoson 0,4 mg P C01EB22 Theophyllin 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 28 von 133 BEDEUTUNG DDD-INFOATC-CODE C01EH Andere homöopathische und anthroposophische Herzmittel C01EH01 Crataegus C01EH10 Verschiedene C01EH20 Kombinationen C01EH50 Kombinationen mit anderen Mitteln C01EP Andere pflanzliche Herzmittel C01EP01 Weißdornblätter mit Blüten 0,53 g O wässrig-ethanolischer Extrakt C01EP02 Besenginsterkraut C01EP03 Galgantwurzelstock C01EP04 Ammi-visnaga-Früchte C01EP30 Kombinationen C01EP51 Weißdornblätter, Kombinationen C01EX Andere Herzmittel, Kombinationen C01EX52 Campher, Kombinationen C01EX66 Theophyllin, Kombinationen C01EX67 Proxyphyllin, Kombinationen C01EX68 Theobromin, Kombinationen C02 ANTIHYPERTONIKA C02A ANTIADRENERGE MITTEL, ZENTRAL WIRKEND C02AA Rauwolfia-Alkaloide C02AA01 Rescinnamin C02AA02 Reserpin 0,5 mg O,P C02AA03 Kombinationen von Rauwolfia-Alkaloiden C02AA05 Deserpidin C02AA06 Methoserpidin C02AA07 Bietaserpin 15 mg O C02AA52 Reserpin, Kombinationen C02AA53 Kombinationen von Rauwolfia-Alkaloiden, Kombinationen C02AA57 Bietaserpin, Kombinationen C02AB Methyldopa C02AB01 Methyldopa (linksdrehend) 1 g O,P C02AB02 Methyldopa (racemisch) 2 g O C02AC Imidazolin-Rezeptoragonisten C02AC01 Clonidin 0,45 mg O,P C02AC02 Guanfacin 3 mg O C02AC04 Tolonidin 0,75 mg O C02AC05 Moxonidin 0,3 mg O C02AC06 Rilmenidin C02AC07 Tiamenidin C02AP Pflanzliche antiadrenerge Mittel, zentral wirkend C02AP01 Rauwolfia-Alkaloide, ganze Wurzel C02AP51 Rauwolfia-Alkaloide, ganze Wurzel, Kombinationen C02B ANTIADRENERGE MITTEL, GANGLIENBLOCKER C02BA Sulfonium-Derivate C02BA01 Trimetaphan 0,25 g P C02BB Sekundäre und tertiäre Amine C02BB01 Mecamylamin C02BC Bisquartäre Ammonium-Verbindungen C02C ANTIADRENERGE MITTEL, PERIPHER WIRKEND C02CA Alpha-Adrenozeptor-Antagonisten C02CA01 Prazosin 5 mg O C02CA02 Indoramin C02CA03 Trimazosin 0,3 g O C02CA04 Doxazosin 4 mg O C02CA06 Urapidil 0,12 g O; 50 mg P C02CA07 Bunazosin 6 mg O C02CA08 Terazosin 5 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 29 von 133 BEDEUTUNG DDD-INFOATC-CODE C02CC Guanidin-Derivate C02CC01 Betanidin 0,1 g O C02CC02 Guanethidin 30 mg O C02CC03 Guanoxan 20 mg O C02CC04 Debrisoquin 20 mg O C02CC05 Guanoclor C02CC06 Guanazodin C02CC07 Guanoxabenz 25 mg O C02D MITTEL MIT WIRKUNG AUF DIE ARTERIELLE GEFÄSSMUSKULATUR C02DA Thiazid-Derivate C02DA01 Diazoxid 0,3 g P C02DB Hydrazinophthalazin-Derivate C02DB01 Dihydralazin 75 mg O; 25 mg P C02DB02 Hydralazin 0,1 g O C02DB03 Endralazin 10 mg O C02DB04 Cadralazin 15 mg O C02DC Pyrimidin-Derivate C02DC01 Minoxidil 20 mg O C02DD Nitroferrocyanid-Derivate C02DD01 Nitroprussid 50 mg P C02DG Guanidin-Derivate C02DG01 Pinacidil 50 mg O C02K ANDERE ANTIHYPERTONIKA C02KA Alkaloide, exkl. Rauwolfia C02KA01 Veratrum C02KB Tyrosinhydroxylasehemmer C02KB01 Metirosin C02KC MAO-Hemmer C02KC01 Pargylin C02KD Serotonin-Antagonisten C02KD01 Ketanserin 40 mg O,P C02KH Homöopathische und anthroposophische Antihypertonika C02KH01 Viscum album C02KH10 Verschiedene C02KH20 Kombinationen C02KP Pflanzliche Antihypertonika C02KP01 Olivenblätter C02KP02 Mistelkraut C02KP30 Kombinationen C02KP52 Mistelkraut, Kombinationen C02KX Andere Antihypertonika C02KX01 Bosentan 0,25 g O C02KX02 Ambrisentan 7,5 mg O C02KX03 Sitaxentan 0,1 g O C02KX04 Sildenafil 60 mg O C02KX05 Tadalafil 40 mg O C02L ANTIHYPERTONIKA UND DIURETIKA IN KOMBINATION C02LA Rauwolfia-Alkaloide und Diuretika in Kombination C02LA01 Reserpin und Diuretika Standarddosis: 1 Applikationsform O C02LA02 Rescinnamin und Diuretika C02LA03 Deserpidin und Diuretika C02LA04 Methoserpidin und Diuretika C02LA07 Bietaserpin und Diuretika C02LA08 Rauwolfia-Alkaloide, ganze Wurzel und Diuretika C02LA09 Syrosingopin und Diuretika C02LA50 Kombinationen von Rauwolfia-Alkaloiden und Diuretika inkl. andere Kombinationen C02LA51 Reserpin und Diuretika, Kombinationen mit anderen Mitteln Standarddosis: 1 Applikationsform O C02LA52 Rescinnamin und Diuretika, Kombinationen mit anderen Mitteln Standarddosis: 1 Applikationsform O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 30 von 133 BEDEUTUNG DDD-INFOATC-CODE C02LA58 Rauwolfia-Alkaloide, ganze Wurzel und Diuretika, Kombinationen Standarddosis: 1 Applikationsform O C02LA71 Reserpin und Diuretika, Kombinationen mit Psycholeptika C02LB Methyldopa und Diuretika in Kombination C02LB01 Methyldopa (linksdrehend) und Diuretika Standarddosis: 1 Applikationsform O C02LC Imidazolin-Rezeptoragonisten in Kombination mit Diuretika C02LC01 Clonidin und Diuretika Standarddosis: 1 Applikationsform O C02LC05 Moxonidin und Diuretika C02LC51 Clonidin und Diuretika, Kombinationen mit anderen Mitteln C02LE Alpha-Adrenozeptor-Antagonisten und Diuretika C02LE01 Prazosin und Diuretika Standarddosis: 1 Applikationsform O C02LF Guanidin-Derivate und Diuretika C02LF01 Guanethidin und Diuretika Standarddosis: 1 Applikationsform O C02LG Hydrazinophthalazin-Derivate und Diuretika C02LG01 Dihydralazin und Diuretika C02LG02 Hydralazin und Diuretika C02LG03 Picodralazin und Diuretika C02LG51 Dihydralazin und Diuretika, Kombinationen mit anderen Mitteln C02LG73 Picodralazin und Diuretika, Kombinationen mit Psycholeptika C02LK Alkaloide, exkl. Rauwolfia, in Kombination mit Diuretika C02LK01 Veratrum und Diuretika C02LL MAO-Hemmer und Diuretika C02LL01 Pargylin und Diuretika C02LN Serotonin-Antagonisten und Diuretika C02LX Andere Antihypertonika und Diuretika C02LX01 Pinacidil und Diuretika C02N KOMBINATIONEN VON ANTIHYPERTENSIVEN WIRKSTOFFEN AUS ATC-GRUPPE C02 C03 DIURETIKA C03A LOW-CEILING-DIURETIKA, THIAZIDE C03AA Thiazide, rein C03AA01 Bendroflumethiazid 2,5 mg O C03AA02 Hydroflumethiazid 25 mg O C03AA03 Hydrochlorothiazid 25 mg O C03AA04 Chlorothiazid 0,5 g O C03AA05 Polythiazid 1 mg O C03AA06 Trichlormethiazid 4 mg O C03AA07 Cyclopenthiazid 0,5 mg O C03AA08 Methylclothiazid 5 mg O C03AA09 Cyclothiazid 5 mg O C03AA13 Mebutizid C03AB Thiazide und Kalium in Kombination C03AB01 Bendroflumethiazid und Kalium 2,5 mg O bezogen auf Bendroflumethiazid C03AB02 Hydroflumethiazid und Kalium 25 mg O bezogen auf Hydroflumethiazid C03AB03 Hydrochlorothiazid und Kalium 25 mg O bezogen auf Hydrochlorothiazid C03AB04 Chlorothiazid und Kalium 0,5 g O bezogen auf Chlorothiazid C03AB05 Polythiazid und Kalium 1 mg O bezogen auf Polythiazid C03AB06 Trichlormethiazid und Kalium 4 mg O bezogen auf Trichlormethiazid C03AB07 Cyclopenthiazid und Kalium 0,5 mg O bezogen auf Cyclopenthiazid C03AB08 Methylclothiazid und Kalium 5 mg O bezogen auf Methylclothiazid C03AB09 Cyclothiazid und Kalium 5 mg O bezogen auf Cyclothiazid C03AH Thiazide, Kombinationen mit Psycholeptika und/oder Analgetika C03AH01 Chlorothiazid, Kombinationen C03AH02 Hydroflumethiazid, Kombinationen C03AX Thiazide, Kombinationen mit anderen Mitteln C03AX01 Hydrochlorothiazid, Kombinationen C03AX02 Bemetizid, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 31 von 133 BEDEUTUNG DDD-INFOATC-CODE C03B LOW-CEILING-DIURETIKA, EXKL. THIAZIDE C03BA Sulfonamide, rein C03BA02 Quinethazon 50 mg O C03BA03 Clopamid 10 mg O C03BA04 Chlortalidon 25 mg O C03BA05 Mefrusid 25 mg O C03BA07 Clofenamid C03BA08 Metolazon 5 mg O C03BA09 Meticran C03BA10 Xipamid 20 mg O C03BA11 Indapamid 2,5 mg O C03BA12 Clorexolon C03BA13 Fenquizon C03BA82 Clorexolon, Kombinationen mit Psycholeptika C03BB Sulfonamide und Kalium in Kombination C03BB02 Quinethazon und Kalium 50 mg O bezogen auf Quinethazon C03BB03 Clopamid und Kalium 10 mg O bezogen auf Clopamid C03BB04 Chlortalidon und Kalium 25 mg O bezogen auf Chlortalidon C03BB05 Mefrusid und Kalium 25 mg O bezogen auf Mefrusid C03BB07 Clofenamid und Kalium C03BC Quecksilber-haltige Diuretika C03BC01 Mersalyl C03BD Xanthin-Derivate C03BD01 Theobromin 4 g O C03BK Sulfonamide, Kombinationen mit anderen Mitteln C03BX Andere Low-ceiling-Diuretika C03BX03 Cicletanin C03C HIGH-CEILING-DIURETIKA C03CA Sulfonamide, rein C03CA01 Furosemid 40 mg O,P C03CA02 Bumetanid 1 mg O,P C03CA03 Piretanid 6 mg O C03CA04 Torasemid 15 mg O,P C03CA05 Azosemid C03CB Sulfonamide und Kalium in Kombination C03CB01 Furosemid und Kalium 40 mg O bezogen auf Furosemid C03CB02 Bumetanid und Kalium 1 mg O bezogen auf Bumetanid C03CC Aryloxyessigsäure-Derivate C03CC01 Etacrynsäure 50 mg O,P C03CC02 Tienilinsäure C03CD Pyrazolon-Derivate C03CD01 Muzolimin 20 mg O C03CX Andere High-ceiling-Diuretika C03CX01 Etozolin C03D KALIUM SPARENDE MITTEL C03DA Aldosteron-Antagonisten C03DA01 Spironolacton 75 mg O C03DA02 Kaliumcanrenoat 0,4 g P C03DA03 Canrenon C03DA04 Eplerenon 50 mg O C03DB Andere Kalium sparende Mittel C03DB01 Amilorid 10 mg O C03DB02 Triamteren 0,1 g O C03E DIURETIKA UND KALIUM SPARENDE MITTEL IN KOMBINATION C03EA Low-ceiling-Diuretika und Kalium sparende Mittel C03EA01 Hydrochlorothiazid und Kalium sparende Mittel C03EA02 Trichlormethiazid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EA03 Epitizid und Kalium sparende Mittel C03EA04 Altizid und Kalium sparende Mittel C03EA05 Mebutizid und Kalium sparende Mittel 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 32 von 133 BEDEUTUNG DDD-INFOATC-CODE C03EA06 Chlortalidon und Kalium sparende Mittel C03EA07 Cyclopenthiazid und Kalium sparende Mittel C03EA12 Metolazon und Kalium sparende Mittel C03EA13 Bendroflumethiazid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EA14 Butizid und Kalium sparende Mittel C03EA15 Xipamid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EA16 Bemetizid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EA21 Hydrochlorothiazid und Triamteren Standarddosis: 1 Applikationsform O C03EA41 Hydrochlorothiazid und Amilorid Standarddosis: 1 Applikationsform O C03EB High-ceiling-Diuretika und Kalium sparende Diuretika C03EB01 Furosemid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EB02 Bumetanid und Kalium sparende Mittel C03EB21 Furosemid und Triamteren Standarddosis: 1 Applikationsform O C03EC Aldosteron-Antagonisten und Low-ceiling-Diuretika C03EC01 Spironolacton und Low-ceiling-Diuretika Standarddosis: 1 Applikationsform O C03EC02 Kaliumcanrenoat und Low-ceiling-Diuretika C03EC21 Spironolacton und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C03EC41 Spironolacton und Bendroflumethiazid Standarddosis: 1 Applikationsform O C03ED Aldosteron-Antagonisten und High-ceiling-Diuretika C03ED01 Spironolacton und High-ceiling-Diuretika Standarddosis: 1 Applikationsform O C03ED02 Kaliumcanrenoat und High-ceiling-Diuretika C03X ANDERE DIURETIKA C03XA Vasopressin-Antagonisten C03XA01 Tolvaptan 30 mg O C03XA02 Conivaptan C03XH Andere homöopathische und anthroposophische Diuretika C03XH20 Kombinationen C03XP Pflanzliche Diuretika C03XP01 Schachtelhalmkraut C03XP02 Birkenblätter C03XP03 Wacholderbeeren C03XP30 Kombinationen C04 PERIPHERE VASODILATATOREN C04A PERIPHERE VASODILATATOREN C04AA 2-Amino-1-phenylethanol-Derivate C04AA01 Isoxsuprin 60 mg O,P C04AA02 Buphenin 30 mg O C04AA31 Bamethan 75 mg O C04AA52 Buphenin, Kombinationen C04AA81 Bamethan, Kombinationen C04AB Imidazolin-Derivate C04AB01 Phentolamin 10 mg O,P C04AB02 Tolazolin 75 mg O C04AC Nicotinsäure und Derivate C04AC01 Nicotinsäure 0,2 g O,P C04AC02 Nicotinylalkohol (Pyridylcarbinol) 0,3 g O,P C04AC03 Inositolnicotinat 1,2 g O C04AC07 Ciclonicat C04AC20 Kombinationen C04AC51 Nicotinsäure, Kombinationen C04AC52 Pyridylcarbinol, Kombinationen C04AC53 Inositolnicotinat, Kombinationen C04AC58 Benzylnicotinat, Kombinationen C04AD Purin-Derivate C04AD01 Pentifyllin C04AD02 Xantinolnicotinat 0,9 g O,P C04AD03 Pentoxifyllin 1 g O; 0,3 g P C04AD04 Etofyllinnicotinat 0,3 g O C04AD50 Andere Purin-Derivate, Kombinationen C04AD54 Etofyllin, Kombinationen C04AD56 Proxyphyllin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 33 von 133 BEDEUTUNG DDD-INFOATC-CODE C04AE Mutterkorn-Alkaloide C04AE01 Ergoloidmesylat 3 mg O,P C04AE02 Nicergolin C04AE04 Dihydroergocristin C04AE51 Ergoloidmesylat, Kombinationen C04AE54 Dihydroergocristin, Kombinationen C04AF Enzyme C04AF01 Kallidinogenase 30 E O,P C04AF51 Kallidinogenase, Kombinationen C04AG Prostaglandine C04AG01 Alprostadil 40 mcg P C04AG02 Iloprost 50 mcg Inhal.lösung C04AH Homöopathische und anthroposophische Vasodilatatoren C04AH10 Verschiedene C04AH20 Kombinationen C04AX Andere periphere Vasodilatatoren C04AX01 Cyclandelat 0,6 g O C04AX02 Phenoxybenzamin 30 mg O C04AX07 Vincamin C04AX10 Moxisylyt C04AX11 Bencyclan C04AX13 Piribedil C04AX17 Vinburnin C04AX19 Suloctidil C04AX20 Buflomedil 0,6 g O C04AX21 Naftidrofuryl 0,6 g O; 0,3 g P C04AX23 Butalamin C04AX24 Visnadin 0,6 g O C04AX26 Cetiedil C04AX27 Cinepazid C04AX28 Ifenprodil C04AX30 Azapetin 0,15 g O C04AX32 Fasudil C04AX37 Diisopropylamin C04AX38 Papaverin C04AX39 Raubasin C04AX42 Moxaverin C04B KOMBINATIONEN VON ANDEREN PERIPHEREN VASODILATATOREN C04BA Kombinationen von anderen peripheren Vasodilatatoren C04BA01 Moxaverin, Kombinationen C04BA02 Papaverin, Kombinationen C04BA03 Raubasin, Kombinationen C04BA04 Organextrakt, Kombinationen C04BA05 Diisopropylamin, Kombinationen C04BA06 Visnadin, Kombinationen C05 VASOPROTEKTOREN C05A MITTEL ZUR BEHANDLUNG VON HÄMORRHOIDEN UND ANALFISSUREN ZUR TOPISCHEN ANWENDUNG C05AA Corticosteroide C05AA01 Hydrocortison C05AA04 Prednisolon C05AA05 Betamethason C05AA06 Fluorometholon C05AA08 Fluocortolon C05AA09 Dexamethason C05AA10 Fluocinolonacetonid C05AA11 Fluocinonid C05AA12 Triamcinolon C05AA51 Hydrocortison, Kombinationen C05AA54 Prednisolon, Kombinationen C05AA55 Betamethason, Kombinationen C05AA56 Fluorometholon, Kombinationen C05AA58 Fluocortolon, Kombinationen C05AA60 Fluocinolonacetonid, Kombinationen C05AA61 Fluocinonid, Kombinationen C05AA62 Triamcinolon, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 34 von 133 BEDEUTUNG DDD-INFOATC-CODE C05AA64 Flupredniden, Kombinationen C05AA65 Clocortolon, Kombinationen C05AB Antibiotika C05AD Lokalanästhetika C05AD01 Lidocain C05AD02 Tetracain C05AD03 Benzocain C05AD04 Cinchocain C05AD05 Procain C05AD06 Oxetacain C05AD07 Pramocain C05AD10 Polidocanol (Lauromacrogol 400) C05AD11 Quinisocain C05AD20 Kombinationen C05AD51 Lidocain, Kombinationen C05AD53 Benzocain, Kombinationen C05AD54 Cinchocain, Kombinationen C05AD55 Procain, Kombinationen C05AD58 Propipocain, Kombinationen C05AD59 Fomocain, Kombinationen C05AD60 Polidocanol (Lauromacrogol 400), Kombinationen C05AD61 Quinisocain, Kombinationen C05AD62 Butoxycain, Kombinationen C05AE Muskelrelaxanzien C05AE01 Glyceroltrinitrat C05AE02 Isosorbiddinitrat C05AF Verödungsmittel C05AF01 Chinin C05AF51 Chinin, Kombinationen C05AH Homöopathische und anthroposophische Hämorrhoidenmittel zur topischen Anwendung C05AH01 Hamamelis C05AH20 Kombinationen C05AP Pflanzliche Hämorrhoidenmittel zur topischen Anwendung C05AP01 Hamamelisblätter und -rinde C05AP30 Kombinationen C05AP52 Rosskastaniensamen, Kombinationen C05AX Andere Mittel zur Behandlung von Hämorrhoiden und Analfissuren zur topischen Anwendung C05AX01 Aluminium-haltige Zubereitungen C05AX02 Bismutpräparate, Kombinationen C05AX03 Andere Hämorrhoidenmittel, Kombinationen C05AX04 Zinkpräparate C05AX05 Tribenosid C05AX06 Ruscogenin C05AX07 Lebertran C05AX08 Heparin C05AX09 Mikroorganismen C05AX13 Bituminosulfonate, inkl. Kombinationen C05AX14 Dioxopromethazin C05B ANTIVARIKOSA C05BA Heparine oder Heparinoide zur topischen Anwendung C05BA01 Heparinoide C05BA02 Natriumapolat C05BA03 Heparin Standarddosis: 2,5 g Salbe etc. C05BA04 Natriumpentosanpolysulfat C05BA05 Mucopolysaccharidschwefelsäureester C05BA51 Heparinoid, Kombinationen C05BA53 Heparin, Kombinationen C05BA54 Natriumpentosanpolysulfat, Kombinationen C05BA55 Mucopolysaccharidschwefelsäureester, Kombinationen C05BB Sklerosierende Mittel zur lokalen Injektion C05BB01 Monoethanolaminoleat C05BB02 Polidocanol (Lauromacrogol 400) C05BB03 Invertzucker C05BB04 Natriumtetradecylsulfat C05BB05 Phenol C05BB56 Glucose, Kombinationen C05BP Pflanzliche Venenmittel zur topischen Anwendung C05BP01 Rosskastaniensamen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 35 von 133 BEDEUTUNG DDD-INFOATC-CODE C05BP02 Weinlaubblätter C05BP03 Hamamelisblätter und -rinde C05BP04 Arnikablüten C05BP30 Kombinationen C05BP51 Rosskastaniensamen, Kombinationen C05BP52 Weinlaubblätter, Kombinationen C05BX Andere sklerosierende Mittel C05BX01 Calciumdobesilat C05BX51 Calciumdobesilat, Kombinationen C05BZ Andere Venenmittel zur topischen Anwendung C05BZ02 Hydroxyethylrutoside C05BZ04 Diosmin C05BZ05 Digitoxin C05BZ06 Benzaron C05BZ07 Cumarin C05BZ09 Aescin C05BZ20 Kombinationen C05BZ59 Aescin, Kombinationen C05C KAPILLARSTABILISIERENDE MITTEL C05CA Bioflavonoide C05CA01 Rutoside C05CA02 Monoxerutin C05CA03 Diosmin C05CA04 Troxerutin 0,9 g O C05CA05 Hidrosmin C05CA06 Pygnogenol C05CA07 Aescin 0,1 g O C05CA13 Hydroxyethylrutoside C05CA20 Kombinationen C05CA51 Rutosid, Kombinationen C05CA53 Diosmin, Kombinationen C05CA54 Troxerutin, Kombinationen C05CA57 Aescin, Kombinationen C05CA59 Trimethylhesperidin, Kombinationen C05CH Homöopathische und anthroposophische kapillarstabilisierende Mittel C05CH10 Verschiedene C05CH20 Kombinationen C05CH50 Kombinationen mit anderen Mitteln C05CP Pflanzliche kapillarstabilisierende Mittel C05CP01 Rosskastaniensamen 0,1 g O bezogen auf Aescin C05CP02 Weinlaubblätter C05CP04 Mäusedornwurzelstock C05CP05 Steinkleekraut C05CP30 Kombinationen C05CP50 Andere pflanzliche kapillarstabilisierende Mittel, Kombinationen C05CP51 Rosskastaniensamen, Kombinationen C05CP52 Weinlaubblätter, Kombinationen C05CP53 Goldrutenkraut, Kombinationen C05CP54 Mäusedornwurzelstock, Kombinationen C05CX Andere kapillarstabilisierende Mittel C05CX01 Tribenosid C05CX02 Naftazon C05CX05 Benzaron C05CX54 Spartein, Kombinationen C06 ANDERE HERZ- UND KREISLAUFMITTEL C06A ANTIHYPOTONIKA C06AA Ergotamin-Derivate C06AA02 Dihydroergotaminmesilat 4 mg O C06AA50 Dihydroergotaminmesilat und Etilefrin C06AH Homöopathische und anthroposophische Antihypotonika C06AH10 Verschiedene C06AH20 Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 36 von 133 BEDEUTUNG DDD-INFOATC-CODE C07 BETA-ADRENOZEPTOR-ANTAGONISTEN C07A BETA-ADRENOZEPTOR-ANTAGONISTEN C07AA Beta-Adrenozeptor-Antagonisten, nichtselektiv C07AA01 Alprenolol 0,4 g O C07AA02 Oxprenolol 0,16 g O C07AA03 Pindolol 15 mg O C07AA05 Propranolol 0,16 g O C07AA06 Timolol 20 mg O C07AA07 Sotalol 0,16 g O C07AA12 Nadolol 0,16 g O C07AA14 Mepindolol 5 mg O C07AA15 Carteolol 10 mg O C07AA16 Tertatolol 5 mg O C07AA17 Bopindolol C07AA18 Metipranolol C07AA19 Bupranolol 0,1 g O C07AA23 Penbutolol 40 mg O C07AA27 Cloranolol C07AA30 Carazolol C07AA31 Bunitrolol C07AA57 Sotalol, Kombinationspackungen C07AB Beta-Adrenozeptor-Antagonisten, selektiv C07AB01 Practolol 0,3 g O C07AB02 Metoprolol 0,15 g O C07AB03 Atenolol 75 mg O C07AB04 Acebutolol 0,4 g O C07AB05 Betaxolol 20 mg O C07AB06 Bevantolol 0,3 g O C07AB07 Bisoprolol 10 mg O bezogen auf Bisoprololhemifumarat C07AB08 Celiprolol 0,2 g O C07AB09 Esmolol C07AB10 Epanolol 0,2 g O C07AB11 S-Atenolol 50 mg O C07AB12 Nebivolol 5 mg O C07AB13 Talinolol 0,1 g O C07AB52 Metoprolol, Kombinationen C07AB57 Bisoprolol, Kombinationen C07AG Alpha- und Beta-Adrenozeptor-Antagonisten C07AG01 Labetalol 0,6 g O C07AG02 Carvedilol 37,5 mg O C07B BETA-ADRENOZEPTOR-ANTAGONISTEN UND THIAZIDE C07BA Beta-Adrenozeptor-Antagonisten, nichtselektiv, und Thiazide C07BA01 Alprenolol und Thiazide Standarddosis: 1 Applikationsform O C07BA02 Oxprenolol und Thiazide C07BA05 Propranolol und Thiazide Standarddosis: 1 Applikationsform O C07BA06 Timolol und Thiazide C07BA07 Sotalol und Thiazide Standarddosis: 1 Applikationsform O C07BA12 Nadolol und Thiazide Standarddosis: 1 Applikationsform O C07BA14 Mepindolol und Thiazide Standarddosis: 1 Applikationsform O C07BA18 Metipranolol und Thiazide Standarddosis: 1 Applikationsform O C07BA68 Metipranolol und Thiazide, Kombinationen C07BB Beta-Adrenozeptor-Antagonisten, selektiv, und Thiazide C07BB02 Metoprolol und Thiazide Standarddosis: 1 Applikationsform O C07BB03 Atenolol und Thiazide C07BB04 Acebutolol und Thiazide C07BB06 Bevantolol und Thiazide C07BB07 Bisoprolol und Thiazide Standarddosis: 1 Applikationsform O C07BB12 Nebivolol und Thiazide C07BB52 Metoprolol und Thiazide, Kombinationen C07BG Alpha- und Beta-Adrenozeptor-Antagonisten und Thiazide C07BG01 Labetalol und Thiazide C07BG02 Carvedilol und Thiazide 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 37 von 133 BEDEUTUNG DDD-INFOATC-CODE C07C BETA-ADRENOZEPTOR-ANTAGONISTEN UND ANDERE DIURETIKA C07CA Beta-Adrenozeptor-Antagonisten, nichtselektiv, und andere Diuretika C07CA02 Oxprenolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CA03 Pindolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CA05 Propranolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CA17 Bopindolol und andere Diuretika C07CA23 Penbutolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CB Beta-Adrenozeptor-Antagonisten, selektiv, und andere Diuretika C07CB02 Metoprolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CB03 Atenolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CB04 Acebutolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CB08 Celiprolol und andere Diuretika C07CB53 Atenolol und andere Diuretika, Kombinationen C07CG Alpha- und Beta-Adrenozeptor-Antagonisten und andere Diuretika C07CG01 Labetalol und andere Diuretika C07D BETA-ADRENOZEPTOR-ANTAGONISTEN, THIAZIDE UND ANDERE DIURETIKA C07DA Beta-Adrenozeptor-Antagonisten, nichtselektiv, Thiazide und andere Diuretika C07DA05 Propranolol, Thiazide und andere Diuretika Standarddosis: 1 Applikationsform O C07DA06 Timolol, Thiazide und andere Diuretika Standarddosis: 1 Applikationsform O C07DB Beta-Adrenozeptor-Antagonisten, selektiv, Thiazide und andere Diuretika C07DB01 Atenolol, Thiazide und andere Diuretika C07E BETA-ADRENOZEPTOR-ANTAGONISTEN UND VASODILATATOREN C07EA Beta-Adrenozeptor-Antagonisten, nichtselektiv, und Vasodilatatoren C07EA03 Pindolol und Vasodilatatoren Standarddosis: 1 Applikationsform O C07EA05 Propranolol und Vasodilatatoren Standarddosis: 1 Applikationsform O C07EA19 Bupranolol und Vasodilatatoren Standarddosis: 1 Applikationsform O C07EB Beta-Adrenozeptor-Antagonisten, selektiv, und Vasodilatatoren C07F BETA-ADRENOZEPTOR-ANTAGONISTEN UND ANDERE ANTIHYPERTONIKA C07FA Beta-Adrenozeptor-Antagonisten, nichtselektiv, und andere Antihypertonika C07FA02 Oxprenolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FA05 Propranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FA18 Metipranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FA19 Bupranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FB Beta-Adrenozeptor-Antagonisten, selektiv, und andere Antihypertonika C07FB02 Metoprolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FB03 Atenolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FB04 Acebutolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07FB07 Bisoprolol und andere Antihypertonika C07FB22 Metoprolol und Nifedipin Standarddosis: 1 Applikationsform O C07FB23 Atenolol und Nifedipin Standarddosis: 1 Applikationsform O C07FB24 Metoprolol und Felodipin Standarddosis: 1 Applikationsform O C07G BETA-ADRENOZEPTOR-ANTAGONISTEN UND ANDERE MITTEL C07GA Beta-Adrenozeptor-Antagonisten, nicht selektiv, und andere Mittel C07GA19 Bupranolol und andere Mittel 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 38 von 133 BEDEUTUNG DDD-INFOATC-CODE C08 CALCIUMKANALBLOCKER C08C SELEKTIVE CALCIUMKANALBLOCKER MIT VORWIEGENDER GEFÄSSWIRKUNG C08CA Dihydropyridin-Derivate C08CA01 Amlodipin 5 mg O C08CA02 Felodipin 5 mg O C08CA03 Isradipin 5 mg O,P C08CA04 Nicardipin 90 mg O,P C08CA05 Nifedipin 30 mg O,P C08CA06 Nimodipin 0,3 g O; 50 mg P C08CA07 Nisoldipin 20 mg O C08CA08 Nitrendipin 20 mg O C08CA09 Lacidipin 4 mg O C08CA10 Nilvadipin 8 mg O C08CA11 Manidipin 10 mg O C08CA12 Barnidipin 10 mg O C08CA13 Lercanidipin 10 mg O C08CA14 Cilnidipin 10 mg O C08CA15 Benidipin C08CA16 Clevidipin C08CA55 Nifedipin, Kombinationen C08CX Andere selektive Calciumkanalblocker mit vorwiegender Gefäßwirkung C08CX01 Mibefradil 75 mg O C08D SELEKTIVE CALCIUMKANALBLOCKER MIT VORWIEGENDER HERZWIRKUNG C08DA Phenylalkylamin-Derivate C08DA01 Verapamil 0,24 g O,P C08DA02 Gallopamil 0,1 g O C08DA51 Verapamil, Kombinationen C08DA81 Verapamil in Kombination mit Chinidin C08DB Benzothiazepin-Derivate C08DB01 Diltiazem 0,24 g O C08E NICHTSELEKTIVE CALCIUMKANALBLOCKER C08EA Phenylalkylamin-Derivate C08EA01 Fendilin C08EA02 Bepridil 0,3 g O C08EX Andere nichtselektive Calciumkanalblocker C08EX01 Lidoflazin 0,18 g O C08EX02 Perhexilin C08G CALCIUMKANALBLOCKER UND DIURETIKA C08GA Calciumkanalblocker und Diuretika C08GA01 Nifedipin und Diuretika Standarddosis: 1 Applikationsform O C08GA02 Verapamil und Diuretika Standarddosis: 1 Applikationsform O C09 MITTEL MIT WIRKUNG AUF DAS RENIN- ANGIOTENSIN-SYSTEM C09A ACE-HEMMER, REIN C09AA ACE-Hemmer, rein C09AA01 Captopril 50 mg O C09AA02 Enalapril 10 mg O,P C09AA03 Lisinopril 10 mg O C09AA04 Perindopril 4 mg O C09AA05 Ramipril 2,5 mg O C09AA06 Quinapril 15 mg O,P C09AA07 Benazepril 7,5 mg O C09AA08 Cilazapril 2,5 mg O C09AA09 Fosinopril 15 mg O C09AA10 Trandolapril 2 mg O C09AA11 Spirapril 6 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 39 von 133 BEDEUTUNG DDD-INFOATC-CODE C09AA12 Delapril 30 mg O C09AA13 Moexipril 15 mg O C09AA14 Temocapril 10 mg O C09AA15 Zofenopril 30 mg O C09AA16 Imidapril 10 mg O C09B ACE-HEMMER, KOMBINATIONEN C09BA ACE-Hemmer und Diuretika C09BA01 Captopril und Diuretika Standarddosis: 1 Applikationsform O C09BA02 Enalapril und Diuretika Standarddosis: 1 Applikationsform O C09BA03 Lisinopril und Diuretika Standarddosis: 1 Applikationsform O C09BA04 Perindopril und Diuretika Standarddosis: 1 Applikationsform O C09BA05 Ramipril und Diuretika Standarddosis: 1 Applikationsform O C09BA06 Quinapril und Diuretika Standarddosis: 1 Applikationsform O C09BA07 Benazepril und Diuretika Standarddosis: 1 Applikationsform O C09BA08 Cilazapril und Diuretika Standarddosis: 1 Applikationsform O C09BA09 Fosinopril und Diuretika Standarddosis: 1 Applikationsform O C09BA12 Delapril und Diuretika C09BA13 Moexipril und Diuretika Standarddosis: 1 Applikationsform O C09BA15 Zofenopril und Diuretika Standarddosis: 1 Applikationsform O C09BA23 Moexipril und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09BA25 Ramipril und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09BB ACE-Hemmer und Calciumkanalblocker C09BB02 Enalapril und Lercanidipin Standarddosis: 1 Applikationsform O C09BB03 Lisinopril und Amlodipin C09BB04 Perindopril und Amlodipin C09BB05 Ramipril und Felodipin Standarddosis: 1 Applikationsform O C09BB06 Enalapril und Nitrendipin Standarddosis: 1 Applikationsform O C09BB07 Ramipril und Amlodipin Standarddosis: 1 Applikationsform O C09BB10 Trandolapril und Verapamil Standarddosis: 1 Applikationsform O C09BB12 Delapril und Manidipin Standarddosis: 1 Applikationsform O C09C ANGIOTENSIN-II-ANTAGONISTEN, REIN C09CA Angiotensin-II-Antagonisten, rein C09CA01 Losartan 50 mg O C09CA02 Eprosartan 0,6 g O C09CA03 Valsartan 80 mg O C09CA04 Irbesartan 0,15 g O C09CA05 Tasosartan C09CA06 Candesartan 8 mg O C09CA07 Telmisartan 40 mg O C09CA08 Olmesartan medoxomil 20 mg O C09CA09 Azilsartan medoxomil 40 mg O C09D ANGIOTENSIN-II-ANTAGONISTEN, KOMBINATIONEN C09DA Angiotensin-II-Antagonisten und Diuretika C09DA01 Losartan und Diuretika Standarddosis: 1 Applikationsform O C09DA02 Eprosartan und Diuretika Standarddosis: 1 Applikationsform O C09DA03 Valsartan und Diuretika Standarddosis: 1 Applikationsform O C09DA04 Irbesartan und Diuretika Standarddosis: 1 Applikationsform O C09DA06 Candesartan und Diuretika Standarddosis: 1 Applikationsform O C09DA07 Telmisartan und Diuretika Standarddosis: 1 Applikationsform O C09DA08 Olmesartan medoxomil und Diuretika Standarddosis: 1 Applikationsform O C09DB Angiotensin-II-Antagonisten und Calciumkanalblocker C09DB01 Valsartan und Amlodipin Standarddosis: 1 Applikationsform O C09DB02 Olmesartan medoxomil und Amlodipin Standarddosis: 1 Applikationsform O C09DB04 Telmisartan und Amlodipin Standarddosis: 1 Applikationsform O C09DB05 Irbesartan und Amlodipin C09DB06 Losartan und Amlodipin C09DX Angiotensin-II-Antagonisten, andere Kombinationen C09DX01 Valsartan, Amlodipin und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09DX02 Valsartan und Aliskiren C09DX03 Olmesartan medoxomil, Amlodipin und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09X ANDERE MITTEL MIT WIRKUNG AUF DAS RENIN- ANGIOTENSIN-SYSTEM C09XA Renin-Inhibitoren C09XA01 Remikiren C09XA02 Aliskiren 0,15 g O C09XA52 Aliskiren und Hydrochlorothiazid Standarddosis: 1 Applikationsform O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 40 von 133 BEDEUTUNG DDD-INFOATC-CODE C09XA53 Aliskiren und Amlodipin C09XA54 Aliskiren, Amlodipin und Hydrochlorothiazid C10 MITTEL, DIE DEN LIPIDSTOFFWECHSEL BEEINFLUSSEN C10A MITTEL, DIE DEN LIPIDSTOFFWECHSEL BEEINFLUSSEN, REIN C10AA HMG-CoA-Reduktasehemmer C10AA01 Simvastatin 30 mg O C10AA02 Lovastatin 45 mg O C10AA03 Pravastatin 30 mg O C10AA04 Fluvastatin 60 mg O C10AA05 Atorvastatin 20 mg O C10AA06 Cerivastatin 0,2 mg O C10AA07 Rosuvastatin 10 mg O C10AA08 Pitavastatin 2 mg O C10AB Fibrate C10AB01 Clofibrat 2 g O C10AB02 Bezafibrat 0,6 g O C10AB03 Aluminiumclofibrat C10AB04 Gemfibrozil 1,2 g O C10AB05 Fenofibrat 0,2 g O mikronisiert; 0,25 g O nicht mikronisiert C10AB06 Simfibrat C10AB07 Ronifibrat C10AB08 Ciprofibrat 0,1 g O C10AB09 Etofibrat C10AB10 Clofibrid C10AB11 Cholinfenofibrat 0,135 g O bezogen auf Fenofibratsäure C10AB12 Etofyllinclofibrat C10AC Gallensäure bindende Mittel C10AC01 Colestyramin 14 g O C10AC02 Colestipol 20 g O C10AC03 Colextran C10AC04 Colesevelam 3,75 g O C10AD Nicotinsäure und Derivate C10AD01 Niceritrol 1,5 g O C10AD02 Nicotinsäure 2 g O C10AD03 Nicofuranose C10AD04 Aluminiumnicotinat C10AD05 Nicotinylalkohol (Pyridylcarbinol) 0,9 g O C10AD06 Acipimox 0,5 g O C10AD08 Xantinolnicotinat 2 g O C10AD09 alfa-Tocopherolnicotinat C10AD52 Nicotinsäure, Kombinationen 2 g O bezogen auf Nicotinsäure C10AP Pflanzliche Mittel, die den Lipidstoffwechsel C10AP03 Knoblauchzwiebel C10AX Andere Mittel, die den Lipidstoffwechsel beeinflussen C10AX01 Dextrothyroxin 4 mg O C10AX02 Probucol C10AX03 Tiadenol C10AX05 Meglutol C10AX06 Omega-3-Fettsäuren inkl. andere Ester und Säuren C10AX07 Magnesiumpyridoxal-5-phosphatglutamat C10AX08 Policosanol C10AX09 Ezetimib 10 mg O C10AX10 Alipogen tiparvovec C10AX11 Mipomersen C10AX12 Lomitapid C10AX13 Phospholipide C10AX14 Beta-Sitosterin 4,5 g O C10B MITTEL, DIE DEN LIPIDSTOFFWECHSEL BEEINFLUSSEN, KOMBINATIONEN C10BA HMG-CoA-Reduktasehemmer in Kombination mit anderen Mitteln, die den Lipidstoffwechsel beeinflussen C10BA01 Lovastatin und Nicotinsäure C10BA02 Simvastatin und Ezetimib Standarddosis: 1 Applikationsform O C10BA03 Pravastatin und Fenofibrat C10BA04 Simvastatin und Fenofibrat C10BA05 Atorvastatin und Ezetimib 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 41 von 133 BEDEUTUNG DDD-INFOATC-CODE C10BB Fibrate in Kombination mit anderen Mitteln, die den Lipidstoffwechsel beeinflussen C10BB01 Clofibrat und Nicotinsäure C10BB02 Clofibrat in Kombination mit anderen Mitteln, die den Lipidstoffwechsel beeinflussen C10BE Kombinationen von anderen Mitteln, die den Lipidstoffwechsel beeinflussen C10BE11 Phospholipide, Kombinationen C10BP Pflanzliche Mittel, die den Lipidstoffwechsel beeinflussen, Kombinationen C10BP03 Knoblauchzwiebel, Kombinationen C10BX HMG-CoA-Reduktasehemmer, andere Kombinationen C10BX01 Simvastatin und Acetylsalicylsäure 30 mg O bezogen auf Simvastatin C10BX02 Pravastatin und Acetylsalicylsäure C10BX03 Atorvastatin und Amlodipin C10BX04 Simvastatin, Acetylsalicylsäure und Ramipril 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 42 von 133 BEDEUTUNG DDD-INFOATC-CODE D DERMATIKA D01 ANTIMYKOTIKA ZUR DERMATOLOGISCHEN ANWENDUNG D01A ANTIMYKOTIKA ZUR TOPISCHEN ANWENDUNG D01AA Antibiotika D01AA01 Nystatin 250 TSD E T D01AA02 Natamycin D01AA03 Hachimycin D01AA04 Pecilocin D01AA06 Mepartricin D01AA07 Pyrrolnitrin D01AA08 Griseofulvin D01AA10 Amphotericin B D01AA20 Kombinationen D01AA51 Nystatin, Kombinationen 2,5 g T D01AA91 Nystatin und Zinkoxid 2,5 g T D01AC Imidazol- und Triazol-Derivate D01AC01 Clotrimazol 25 mg T D01AC02 Miconazol 40 mg T D01AC03 Econazol D01AC04 Chlormidazol D01AC05 Isoconazol D01AC06 Tiabendazol D01AC07 Tioconazol 20 mg T D01AC08 Ketoconazol 30 mg T (Creme) D01AC09 Sulconazol D01AC10 Bifonazol 10 mg T D01AC11 Oxiconazol 10 mg T D01AC12 Fenticonazol D01AC13 Omoconazol D01AC14 Sertaconazol D01AC15 Fluconazol D01AC16 Flutrimazol D01AC17 Eberconazol D01AC19 Croconazol D01AC20 Kombinationen D01AC51 Clotrimazol, Kombinationen D01AC52 Miconazol, Kombinationen D01AC53 Econazol, Kombinationen D01AC60 Bifonazol, Kombinationen D01AE Andere Antimykotika zur topischen Anwendung D01AE01 Bromchlorsalicylanilid D01AE02 Methylrosanilin D01AE03 Tribrommetacresol D01AE04 Undecylensäure D01AE05 Polynoxylin D01AE06 2-(4-chlorphenoxy)-ethanol D01AE07 Chlorphenesin D01AE08 Ticlaton D01AE09 Sulbentin D01AE10 Ethylhydroxybenzoat D01AE11 Haloprogin D01AE12 Salicylsäure 0,3 g T Seborrhoea capitis D01AE13 Selendisulfid D01AE14 Ciclopirox 20 mg T bezogen auf Ciclopirox olamin (Creme) D01AE15 Terbinafin 10 mg T D01AE16 Amorolfin D01AE17 Dimazol D01AE18 Tolnaftat 15 mg T D01AE19 Tolciclat D01AE20 Kombinationen D01AE21 Flucytosin D01AE22 Naftifin D01AE23 Butenafin D01AE24 Dichlorophen D01AE26 Bromsalicylisopropylamid D01AE51 Bromchlorsalicylanilid, Kombinationen D01AE54 Undecylensäure, Kombinationen D01AE62 Salicylsäure, Kombinationen D01AE68 Tolnaftat, Kombinationen D01AE74 Dichlorophen, Kombinationen D01AE75 Buclosamid, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 43 von 133 BEDEUTUNG DDD-INFOATC-CODE D01B ANTIMYKOTIKA ZUR SYSTEMISCHEN ANWENDUNG D01BA Antimykotika zur systemischen Anwendung D01BA01 Griseofulvin 0,5 g O D01BA02 Terbinafin 0,25 g O D02 EMOLLIENTIA UND HAUTSCHUTZMITTEL D02A EMOLLIENTIA UND HAUTSCHUTZMITTEL D02AA Silikon-haltige Mittel D02AA01 Dimeticon D02AA02 Phenylmethylpolysiloxan D02AA03 Polysiloxan D02AA20 Kombinationen D02AB Zink-haltige Mittel D02AB01 Zinkoxid Standarddosis: 2,5 g Salbe etc. D02AB02 Zinksulfat D02AB51 Zinkoxid, Kombinationen Standarddosis: 2,5 g Salbe etc. D02AB52 Zinksulfat, Kombinationen D02AC Vaseline und Fett-haltige Mittel D02AC01 Basistherapeutika D02AC02 Linolsäure D02AC05 Ethyllinolat D02AC52 Linolsäure, Kombinationen D02AC54 Paraffin, Kombinationen D02AD Flüssige Pflaster D02AD10 Verschiedene D02AE Harnstoff-haltige Mittel D02AE01 Harnstoff 0,2 g T D02AE02 Carbamidperoxid D02AE51 Harnstoff, Kombinationen D02AF Salicylsäure-haltige Zubereitungen D02AF01 Salicylsäure D02AP Pflanzliche Emollientia und Hautschutzmittel D02AP01 Nachtkerzensamenöl D02AP02 Olivenöl D02AP53 Sojaöl, Kombinationen D02AX Andere Emollientia und Hautschutzmittel D02AX03 Guajazulen D02AX05 Schwefel-haltige Mittel D02AX06 Glycerol D02AX07 Plazentaextrakt D02AX08 Glucose D02AX09 Thymol D02AX10 Kieselsäure D02AX20 Kombinationen D02B PROTEKTIVA GEGEN UV-STRAHLUNG D02BA Protektiva gegen UV-Strahlung zur topischen Anwendung D02BA01 Aminobenzoesäure D02BA02 Octinoxat D02BA20 Kombinationen D02BB Protektiva gegen UV-Strahlung zur systemischen Anwendung D02BB01 Betacaroten 0,1 g O D02BB51 Betacaroten, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 44 von 133 BEDEUTUNG DDD-INFOATC-CODE D03 ZUBEREITUNGEN ZUR BEHANDLUNG VON WUNDEN UND GESCHWÜREN D03A WUNDBEHANDLUNGSMITTEL D03AA Lebertransalben D03AA01 Lebertran D03AA51 Lebertran, Kombinationen D03AC Narbenbehandlungsmittel D03AC50 Narbenbehandlungsmittel, Kombinationen D03AH Homöopathische und anthroposophische Wundbehandlungsmittel D03AH01 Calendula D03AH02 Echinacea D03AH20 Kombinationen D03AP Pflanzliche Wundbehandlungsmittel D03AP01 Hamamelisblätter und -rinde D03AP02 Ringelblumenblüten D03AP03 Arnikablüten D03AP04 Kamillenblüten D03AP05 Weizenkeimextrakt D03AP06 Maiskeimöl D03AP07 Echinaceakraut D03AP30 Kombinationen D03AP51 Hamamelisblätter und -rinde, Kombinationen D03AP52 Ringelblumenblüten, Kombinationen D03AP54 Kamillenblüten, Kombinationen D03AP57 Echinaceakraut, Kombinationen D03AX Andere Wundbehandlungsmittel D03AX01 Cadexomer-Iod D03AX02 Dextranomer D03AX03 Dexpanthenol 0,125 g T D03AX04 Calciumpantothenat D03AX05 Hyaluronsäure D03AX06 Becaplermin D03AX09 Crilanomer D03AX10 Enoxolon D03AX11 Natriumchlorit D03AX14 Kälberblutextrakt D03AX16 Asiaticosid D03AX17 Sauermolkekonzentrat D03AX18 Propolis D03AX27 Mineralölraffinat D03AX31 Phloroglucin D03AX32 Fliegenlarven D03AX33 Aluminiumacetattartrat D03AX50 Andere Wundbehandlungsmittel, Kombinationen D03AX53 Dexpanthenol, Kombinationen D03AX69 Titandioxid, Kombinationen D03AX70 Siliciumdioxid, Kombinationen D03AX71 Perubalsam, Kombinationen D03AX77 Mineralölraffinat, Kombinationen D03AX79 Bakterienlysat, Kombinationen D03B ENZYME D03BA Proteolytische Enzyme D03BA01 Trypsin D03BA02 Kollagenase D03BA20 Kombinationen D03BA50 Andere proteolytische Enzyme, Kombinationen D03BA52 Kollagenase, Kombinationen D03BA53 Protease, Kombinationen D03BA54 Desoxyribonuclease, Kombinationen D03BA55 Catalase, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 45 von 133 BEDEUTUNG DDD-INFOATC-CODE D04 ANTIPRURIGINOSA, INKL. ANTIHISTAMINIKA, ANÄSTHETIKA ETC. D04A ANTIPRURIGINOSA, INKL. ANTIHISTAMINIKA, ANÄSTHETIKA ETC. D04AA Antihistaminika zur topischen Anwendung D04AA01 Thonzylamin D04AA02 Mepyramin D04AA03 Thenalidin D04AA04 Tripelennamin D04AA09 Chloropyramin D04AA10 Promethazin D04AA12 Tolpropamin D04AA13 Dimetinden D04AA14 Clemastin D04AA15 Bamipin D04AA22 Isothipendyl D04AA32 Diphenhydramin D04AA33 Diphenhydraminmethylbromid D04AA34 Chlorphenoxamin D04AA38 Pheniramin D04AA39 Diphenylpyralin D04AA40 Dioxopromethazin D04AA82 Diphenhydramin, Kombinationen D04AA91 Histapyrrodin, Kombinationen D04AB Lokalanästhetika D04AB01 Lidocain D04AB02 Cinchocain D04AB03 Oxybuprocain D04AB04 Benzocain D04AB05 Chinisocain D04AB06 Tetracain D04AB07 Pramocain D04AB11 Polidocanol (Lauromacrogol 400) D04AB51 Lidocain, Kombinationen D04AB54 Benzocain, Kombinationen D04AB61 Polidocanol (Lauromacrogol 400), Kombinationen D04AH Homöopathische und anthroposophische Antipruriginosa D04AH01 Cardiospermum D04AH20 Homöopathische und anthroposophische Antipruriginosa, Kombinationen D04AX Andere Antipruriginosa D04AX01 Gerbstoffe 15 mg T D04AX02 Crotamiton D04AX03 Bufexamac 0,1 g T D04AX04 Isoprenalin D04AX05 Campher D04AX06 Aqua calcariae D04AX51 Gerbstoff, Kombinationen D04AX54 Isoprenalin, Kombinationen D04AX55 Campher, Kombinationen D05 ANTIPSORIATIKA D05A ANTIPSORIATIKA ZUR TOPISCHEN ANWENDUNG D05AA Teere D05AA01 Bituminosulfonate D05AA02 Steinkohlenteer D05AA50 Andere Teere, Kombinationen D05AA51 Bituminosulfonate, Kombinationen D05AA52 Steinkohlenteer, Kombinationen D05AC Anthracen-Derivate D05AC01 Dithranol D05AC51 Dithranol, Kombinationen D05AD Psoralene zur topischen Anwendung D05AD01 Trioxysalen D05AD02 Methoxsalen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 46 von 133 BEDEUTUNG DDD-INFOATC-CODE D05AX Andere Antipsoriatika zur topischen Anwendung D05AX01 Fumarsäure D05AX02 Calcipotriol 75 mcg T D05AX03 Calcitriol 6 mcg T D05AX04 Tacalcitol 4 mcg T D05AX05 Tazaroten D05AX51 Fumarsäure, Kombinationen D05AX52 Calcipotriol, Kombinationen D05AX56 Salicylsäure, Kombinationen D05B ANTIPSORIATIKA ZUR SYSTEMISCHEN ANWENDUNG D05BA Psoralene zur systemischen Anwendung D05BA01 Trioxysalen 10 mg O D05BA02 Methoxsalen 10 mg O D05BA03 Bergapten D05BB Retinoide zur Behandlung der Psoriasis D05BB01 Etretinat 35 mg O D05BB02 Acitretin 35 mg O D05BH Homöopathische und anthroposophische Antipsoriatika zur systemischen Anwendung D05BH20 Kombinationen D05BX Andere Antipsoriatika zur systemischen Anwendung D05BX01 Fumarsäure D05BX20 Fumarsäurealkylester D05BX51 Fumarsäure-Derivate, Kombinationen D06 ANTIBIOTIKA UND CHEMOTHERAPEUTIKA ZUR DERMATOLOGISCHEN ANWENDUNG D06A ANTIBIOTIKA ZUR TOPISCHEN ANWENDUNG D06AA Tetracyclin und Derivate D06AA01 Demeclocyclin D06AA02 Chlortetracyclin D06AA03 Oxytetracyclin D06AA04 Tetracyclin D06AA05 Meclocyclin D06AA20 Kombinationen D06AX Andere Antibiotika zur topischen Anwendung D06AX01 Fusidinsäure 60 mg T D06AX02 Chloramphenicol D06AX04 Neomycin D06AX05 Bacitracin D06AX07 Gentamicin 2,5 mg T D06AX08 Tyrothricin D06AX09 Mupirocin 40 mg T D06AX10 Virginiamycin D06AX11 Rifaximin D06AX12 Amikacin D06AX13 Retapamulin D06AX14 Framycetin D06AX20 Kombinationen D06AX52 Chloramphenicol, Kombinationen D06AX54 Neomycin, Kombinationen D06AX58 Tyrothricin, Kombinationen D06AX64 Framycetin, Kombinationen D06B CHEMOTHERAPEUTIKA ZUR TOPISCHEN ANWENDUNG D06BA Sulfonamide D06BA01 Sulfadiazin-Silber D06BA02 Sulfathiazol D06BA03 Mafenid D06BA04 Sulfamethizol D06BA05 Sulfanilamid D06BA06 Sulfamerazin D06BA10 Sulfisomidin D06BA50 Andere Sulfonamide, Kombinationen D06BA51 Sulfadiazin-Silber, Kombinationen D06BA55 Sulfanilamid, Kombinationen D06BA62 Sulfacetamid, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 47 von 133 BEDEUTUNG DDD-INFOATC-CODE D06BA63 Sulfacarbamid, Kombinationen D06BA64 Sulfisoxazol, Kombinationen D06BB Antivirale Mittel D06BB01 Idoxuridin D06BB02 Tromantadin D06BB03 Aciclovir 25 mg T für 5%-ige Zubereitungen D06BB04 Podophyllotoxin D06BB05 Inosin D06BB06 Penciclovir D06BB07 Lysozym D06BB08 Ibacitabin D06BB09 Edoxudin D06BB10 Imiquimod D06BB11 Docosanol D06BB13 Foscarnet 12 mg T D06BB15 Vidarabin D06BB20 Kombinationen D06BB53 Aciclovir, Kombinationen D06BB65 Vidarabin, Kombinationen D06BP Pflanzliche Chemotherapeutika zur topischen Anwendung D06BP01 Melissenblätter D06BP02 Salbeiblätter D06BP03 Grüner Tee D06BX Andere Chemotherapeutika D06BX01 Metronidazol 15 mg T D06BX02 Ingenol mebutat Standarddosis: 1 Applikationsform T D06C ANTIBIOTIKA UND CHEMOTHERAPEUTIKA, KOMBINATIONEN D07 CORTICOSTEROIDE, DERMATOLOGISCHE ZUBEREITUNGEN D07A CORTICOSTEROIDE, REIN D07AA Corticosteroide, schwach wirksam (Gruppe I) D07AA01 Methylprednisolon D07AA02 Hydrocortison D07AA03 Prednisolon D07AB Corticosteroide, mittelstark wirksam (Gruppe II) D07AB01 Clobetason D07AB02 Hydrocortisonbutyrat D07AB03 Flumetason D07AB04 Fluocortin D07AB05 Fluperolon D07AB06 Fluorometholon D07AB07 Flupredniden D07AB08 Desonid D07AB09 Triamcinolon 2 mg T für 0,1%-ige Zubereitungen D07AB10 Alclometason D07AB11 Hydrocortisonbuteprat D07AB19 Dexamethason D07AB21 Clocortolon D07AB30 Kombinationen mittelstark wirksamer Corticosteroide D07AC Corticosteroide, stark wirksam (Gruppe III) D07AC01 Betamethason 2 mg T für 0,1%-ige Zubereitungen D07AC02 Fluclorolon D07AC03 Desoximetason D07AC04 Fluocinolonacetonid 0,3 mg T D07AC05 Fluocortolon D07AC06 Diflucortolon D07AC07 Fludroxycortid D07AC08 Fluocinonid D07AC09 Budesonid D07AC10 Diflorason D07AC11 Amcinonid 1,5 mg T D07AC12 Halometason D07AC13 Mometason 1 mg T D07AC14 Methylprednisolonaceponat 1 mg T D07AC15 Beclometason D07AC16 Hydrocortisonaceponat D07AC17 Fluticason D07AC18 Prednicarbat 2,5 mg T 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 48 von 133 BEDEUTUNG DDD-INFOATC-CODE D07AC19 Difluprednat D07AC21 Ulobetasol D07AD Corticosteroide, sehr stark wirksam (Gruppe IV) D07AD01 Clobetasol 0,5 mg T für 0,05%-ige Zubereitungen D07AD02 Halcinonid D07B CORTICOSTEROIDE, KOMBINATIONEN MIT ANTISEPTIKA D07BA Corticosteroide, schwach wirksam, Kombinationen mit Antiseptika D07BA01 Prednisolon und Antiseptika D07BA04 Hydrocortison und Antiseptika D07BB Corticosteroide, mittelstark wirksam, Kombinationen mit Antiseptika D07BB01 Flumetason und Antiseptika D07BB02 Desonid und Antiseptika D07BB03 Triamcinolon und Antiseptika D07BB04 Hydrocortisonbutyrat und Antiseptika D07BB05 Dexamethason und Antiseptika D07BB06 Flupredniden und Antiseptika D07BC Corticosteroide, stark wirksam, Kombinationen mit Antiseptika D07BC01 Betamethason und Antiseptika D07BC02 Fluocinolonacetonid und Antiseptika D07BC03 Fluocortolon und Antiseptika D07BC04 Diflucortolon und Antiseptika D07BC05 Halometason und Antiseptika D07BC07 Fludroxycortid und Antiseptika D07BD Corticosteroide, sehr stark wirksam, Kombinationen mit Antiseptika D07C CORTICOSTEROIDE, KOMBINATIONEN MIT ANTIBIOTIKA D07CA Corticosteroide, schwach wirksam, Kombinationen mit Antibiotika D07CA01 Hydrocortison und Antibiotika D07CA02 Methylprednisolon und Antibiotika D07CA03 Prednisolon und Antibiotika D07CB Corticosteroide, mittelstark wirksam, Kombinationen mit Antibiotika D07CB01 Triamcinolon und Antibiotika D07CB02 Flupredniden und Antibiotika D07CB03 Fluorometholon und Antibiotika D07CB04 Dexamethason und Antibiotika D07CB05 Flumetason und Antibiotika D07CB06 Hydrocortisonbutyrat und Antibiotika D07CC Corticosteroide, stark wirksam, Kombinationen mit Antibiotika D07CC01 Betamethason und Antibiotika D07CC02 Fluocinolonacetonid und Antibiotika D07CC03 Fludroxycortid und Antibiotika D07CC04 Beclometason und Antibiotika D07CC05 Fluocinonid und Antibiotika D07CC06 Fluocortolon und Antibiotika D07CD Corticosteroide, sehr stark wirksam, Kombinationen mit Antibiotika D07CD01 Clobetasol und Antibiotika D07CD02 Halcinonid und Antibiotika D07X CORTICOSTEROIDE, ANDERE KOMBINATIONEN D07XA Corticosteroide, schwach wirksam, andere Kombinationen D07XA01 Hydrocortison D07XA02 Prednisolon 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 49 von 133 BEDEUTUNG DDD-INFOATC-CODE D07XB Corticosteroide, mittelstark wirksam, andere Kombinationen D07XB01 Flumetason D07XB02 Triamcinolon D07XB03 Flupredniden D07XB04 Fluorometholon D07XB05 Dexamethason D07XB10 Clocortolon D07XB30 Kombinationen mittelstark wirksamer Corticosteroide D07XC Corticosteroide, stark wirksam, andere Kombinationen D07XC01 Betamethason D07XC02 Desoximetason D07XC03 Mometason D07XC04 Diflucortolon D07XC05 Fluocortolon D07XD Corticosteroide, sehr stark wirksam, andere Kombinationen D08 ANTISEPTIKA UND DESINFEKTIONSMITTEL D08A ANTISEPTIKA UND DESINFEKTIONSMITTEL D08AA Acridin-Derivate D08AA01 Ethacridinlactat D08AA02 Aminoacridin D08AA03 Euflavin D08AB Aluminium-haltige Mittel D08AB01 Aluminiumchloridhydroxid-Komplex D08AB10 Aluminiumpulver D08AB52 Aluminiumchlorid, Kombinationen D08AC Biguanide und Amidine D08AC01 Dibrompropamidin D08AC02 Chlorhexidin D08AC03 Propamidin D08AC04 Hexamidin D08AC05 Polihexanid D08AC52 Chlorhexidin, Kombinationen D08AC54 Hexamidin, Kombinationen D08AC55 Polihexanid, Kombinationen D08AD Borsäure-haltige Mittel D08AE Phenol und Derivate D08AE01 Hexachlorophen D08AE02 Policresulen D08AE03 Phenol D08AE04 Triclosan D08AE05 Chloroxylenol D08AE06 Biphenylol D08AE08 Xylenol D08AE50 Andere Phenole und Derivate, Kombinationen D08AE51 Hexachlorophen, Kombinationen D08AE53 Phenol, Kombinationen D08AE56 Biphenylol, Kombinationen D08AE57 Chlorocresol, Kombinationen D08AF Nitrofuran-Derivate D08AF01 Nitrofural D08AG Iod-haltige Mittel D08AG01 Iodoctylphenoxypolyglycolether D08AG02 Povidon-Iod 0,4 g T D08AG03 Iod D08AG04 Diiodhydroxypropan D08AG52 Povidon-Iod, Kombinationen D08AH Chinolin-Derivate D08AH01 Dequalinium D08AH02 Chlorquinaldol D08AH03 Oxichinolin D08AH10 Cloxiquin D08AH30 Clioquinol D08AH51 Dequalinium, Kombinationen D08AH53 Oxichinolin, Kombinationen D08AH60 Cloxiquin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 50 von 133 BEDEUTUNG DDD-INFOATC-CODE D08AJ Quartäre Ammonium-Verbindungen D08AJ01 Benzalkonium D08AJ02 Cetrimonium D08AJ03 Cetylpyridinium D08AJ04 Cetrimid D08AJ05 Benzoxoniumchlorid D08AJ06 Didecyldimethylammoniumchlorid D08AJ08 Benzethoniumchlorid D08AJ51 Benzalkonium, Kombinationen D08AJ53 Cetylpyridinium, Kombinationen D08AJ57 Octenidin, Kombinationen D08AJ58 Benzethoniumchlorid, Kombinationen D08AJ59 Dodecloniumbromid, Kombinationen D08AJ60 Methalkoniumchlorid, Kombinationen D08AK Quecksilber-haltige Mittel D08AK01 Quecksilberamidochlorid D08AK02 Phenylmercuriborat D08AK03 Quecksilberchlorid D08AK04 Merbromin D08AK05 Metallisches Quecksilber D08AK06 Thiomersal D08AK10 Phenylquecksilber(II)-acetat D08AK11 Quecksilbercyanid D08AK30 Quecksilberiodid D08AK52 Phenylmercuriborat, Kombinationen D08AK60 Phenylquecksilber(II)-acetat, Kombinationen D08AL Silber-haltige Verbindungen D08AL01 Silbernitrat D08AL02 Methenamin-Silbernitrat D08AL30 Silber D08AL50 Andere Silber-haltige Verbindungen, Kombinationen D08AX Andere Antiseptika und Desinfektionsmittel D08AX01 Wasserstoffperoxid D08AX02 Eosin D08AX03 Propanol D08AX04 Tosylchloramid-Natrium D08AX05 Isopropanol D08AX06 Kaliumpermanganat D08AX07 Natriumhypochlorit D08AX08 Ethanol D08AX09 Oxoferin-Reaktionsprodukt D08AX10 Bituminosulfonate D08AX11 Glutaral D08AX14 Basisches Bismutgallat D08AX19 Formaldehyd D08AX20 Terpentin-Derivate D08AX30 Kombinationen D08AX51 Wasserstoffperoxid, Kombinationen D08AX53 Propanol, Kombinationen D08AX55 Isopropanol, Kombinationen D08AX69 Formaldehyd, Kombinationen D09 MEDIZINISCHE VERBÄNDE D09A MEDIZINISCHE VERBÄNDE D09AA Medizinische Verbände mit Antiinfektiva D09AA01 Framycetin D09AA02 Fusidinsäure D09AA03 Nitrofural D09AA04 Phenylquecksilbernitrat D09AA05 Benzododecinium D09AA06 Triclosan D09AA07 Cetylpyridinium D09AA08 Aluminiumhydroxychlorid D09AA09 Povidon-Iod Standarddosis: 1 Applikationsform D09AA10 Clioquinol D09AA11 Benzalkonium D09AA12 Chlorhexidin Standarddosis: 1 Applikationsform D09AA13 Iodoform Standarddosis: 1 Applikationsform D09AA16 Sulfadiazin-Silber D09AA30 Kombinationen Standarddosis: 1 Applikationsform D09AA51 Framycetin, Kombinationen D09AA65 Silber, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 51 von 133 BEDEUTUNG DDD-INFOATC-CODE D09AB Zink-haltige Verbände D09AB01 Zink-haltige Verbände ohne Zusätze D09AB02 Zink-haltige Verbände mit Zusätzen D09AC Andere Verbandmittel D09AC02 Verbandmittel mit Aluminiumchloridhydroxid-Komplex D09AC03 Verbandmittel mit Perubalsam D09AC04 Verbandmittel mit Ibuprofen D09AC50 Andere Verbandmittel, Kombinationen D09AX Vaselin-haltige Verbände D09AX01 Verbandmittel mit Vaselin D10 AKNEMITTEL D10A AKNEMITTEL ZUR TOPISCHEN ANWENDUNG D10AA Corticosteroide, Kombinationen zur Behandlung der Akne D10AA01 Fluorometholon D10AA02 Methylprednisolon D10AA03 Dexamethason D10AA06 Prednisolon D10AA07 Clocortolon D10AB Schwefel-haltige Mittel D10AB01 Bithionol D10AB02 Schwefel D10AB03 Tioxolon D10AB05 Mesulfen D10AD Retinoide zur topischen Anwendung bei Akne D10AD01 Tretinoin D10AD02 Retinol D10AD03 Adapalen 1 mg T D10AD04 Isotretinoin D10AD05 Motretinid D10AD51 Tretinoin, Kombinationen D10AD52 Retinol, Kombinationen D10AD53 Adapalen, Kombinationen D10AD54 Isotretinoin, Kombinationen D10AE Peroxide D10AE01 Benzoylperoxid 0,1 g T D10AE51 Benzoylperoxid, Kombinationen D10AF Antiinfektiva zur Behandlung der Akne D10AF01 Clindamycin D10AF02 Erythromycin Standarddosis: 2,0 g Salbe etc. D10AF03 Chloramphenicol D10AF04 Meclocyclin D10AF05 Tetracyclin D10AF06 Nadifloxacin 20 mg T D10AF51 Clindamycin, Kombinationen D10AF52 Erythromycin, Kombinationen D10AX Andere Aknemittel zur topischen Anwendung D10AX01 Aluminiumchlorid D10AX02 Resorcin D10AX03 Azelainsäure D10AX04 Aluminiumoxid D10AX05 Dapson D10AX07 Polydimethylsiliconharz D10AX08 Natriumtetraborat D10AX09 Hexachlorophen D10AX10 Benzalkoniumchlorid D10AX11 Salicylsäure D10AX12 Bituminosulfonate D10AX30 Verschiedene Kombinationen D10AX52 Resorcin, Kombinationen D10AX59 Hexachlorophen, Kombinationen D10AX60 Benzalkoniumchlorid, Kombinationen D10AX61 Salicylsäure, Kombinationen D10AX62 Bituminosulfonate, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 52 von 133 BEDEUTUNG DDD-INFOATC-CODE D10B AKNEMITTEL ZUR SYSTEMISCHEN ANWENDUNG D10BA Retinoide zur Behandlung der Akne D10BA01 Isotretinoin 30 mg O D10BH Homöopathische und anthroposophische Aknemittel zur systemischen Anwendung D10BH20 Kombinationen D10BX Andere Aknemittel zur systemischen Anwendung D10BX01 Natriumbituminosulfonat D10BX02 Zinksulfat D10BX50 Andere systemische Aknemittel, Kombinationen D11 ANDERE DERMATIKA D11A ANDERE DERMATIKA D11AA Antihidrotika D11AA01 Salbeiblätter D11AA02 Aluminiumsalze D11AA03 Methenamin D11AA50 Andere Antihidrotika, Kombinationen D11AA51 Salbeiblätter, Kombinationen D11AA52 Aluminiumsalze, Kombinationen D11AA53 Methenamin, Kombinationen D11AB Dermatologische Balneotherapeutika D11AB01 Kamillenblütenextrakt D11AB02 Wacholderbeeren D11AB05 Sojabohnenöl D11AB06 Erdnussöl D11AB09 Fumarsäure D11AB11 Steinkohlenteer D11AB12 Bituminosulfonate D11AB14 Natriumhydrogencarbonat D11AB30 Kombinationen D11AB50 Andere dermatologische Balneotherapeutika, Kombinationen D11AB51 Kamillenblütenextrakt, Kombinationen D11AB55 Sojabohnenöl, Kombinationen D11AB56 Erdnussöl, Kombinationen D11AB58 Paraffin, Kombinationen D11AB61 Steinkohlenteer, Kombinationen D11AB62 Bituminosulfonate, Kombinationen D11AB63 Aluminiumsalze, Kombinationen D11AC Medizinische Haarwaschmittel D11AC01 Cetrimid D11AC02 Cadmium-haltige Verbindungen D11AC03 Selen-haltige Verbindungen D11AC06 Povidon-Iod D11AC08 Schwefel-haltige Verbindungen D11AC09 Xenysalat D11AC10 Pyrithion zink D11AC11 Bituminosulfonate D11AC13 Benzoylperoxid D11AC15 Panthenol D11AC30 Verschiedene D11AC50 Andere medizinische Haarwaschmittel, Kombinationen D11AC52 Cadmium-haltige Verbindungen, Kombinationen D11AC58 Schwefel-haltige Verbindungen, Kombinationen D11AC61 Bituminosulfonate, Kombinationen D11AE Androgene zur topischen Anwendung D11AE01 Metandienon D11AF Warzenmittel und Keratolytika D11AF01 Salicylsäure Standarddosis: 0,25 ml Lösung D11AF03 Kaliumhydroxid D11AF05 Fluorouracil D11AF06 Interferon beta, natürlich D11AF07 Chloressigsäure D11AF08 Ameisensäure D11AF51 Salicylsäure, Kombinationen Standarddosis: 0,25 ml Lösung D11AF52 Salpetersäure, Kombinationen D11AF55 Fluorouracil, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 53 von 133 BEDEUTUNG DDD-INFOATC-CODE D11AG Medizinische Seifen D11AG02 Kamillenblüten D11AG03 Hamamelisblätter und -rinde D11AG50 Waschlotionen/Seife, Kombinationen D11AH Mittel zur Behandlung der Dermatitis, exkl. Corticosteroide D11AH01 Tacrolimus D11AH02 Pimecrolimus 20 mg T D11AH03 Cromoglicinsäure D11AH04 Alitretinoin 20 mg O D11AX Andere Dermatika D11AX01 Minoxidil D11AX02 Gamolensäure 0,4 g O D11AX03 Calciumgluconat D11AX04 Lithiumsuccinat D11AX05 Magnesiumsulfat D11AX06 Mequinol D11AX08 Tiratricol D11AX09 Oxaceprol D11AX10 Finasterid 1 mg O D11AX11 Hydrochinon D11AX12 Pyrithion Zink D11AX13 Monobenzon D11AX16 Eflornithin D11AX18 Diclofenac D11AX21 Hyaluronsäure D11AX22 Kaliumaminobenzoat D11AX23 Hefe D11AX26 Estradiol D11AX28 Cellulose D11AX29 Mikroorganismen D11AX31 Bittersüssstängel D11AX50 Andere Dermatika, Kombinationen D11AX52 Gamolensäure, Kombinationen D11AX57 Kollagen, Kombinationen D11B ANDERE HOMÖOPATHISCHE UND ANTHROPOSOPHISCHE DERMATIKA D11BH Andere homöopathische und anthroposophische Dermatika D11BH10 Verschiedene D11BH20 Kombinationen D11BH51 Thuja, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 54 von 133 BEDEUTUNG DDD-INFOATC-CODE G UROGENITALSYSTEM UND SEXUALHORMONE G01 GYNÄKOLOGISCHE ANTIINFEKTIVA UND ANTISEPTIKA G01A ANTIINFEKTIVA UND ANTISEPTIKA, EXKL. KOMBINATIONEN MIT CORTICOSTEROIDEN G01AA Antibiotika G01AA01 Nystatin 0,1 MIO E V G01AA02 Natamycin 25 mg V G01AA03 Amphotericin B 0,2 g V G01AA04 Candicidin 6 mg V G01AA05 Chloramphenicol G01AA06 Hachimycin G01AA07 Oxytetracyclin G01AA08 Carfecillin G01AA09 Mepartricin G01AA10 Clindamycin 0,1 g V G01AA11 Pentamycin G01AA14 Neomycin G01AA20 Kombinationen G01AA51 Nystatin, Kombinationen G01AA64 Neomycin, Kombinationen G01AB Arsen-haltige Verbindungen G01AB01 Acetarsol 0,5 g V G01AC Chinolin-Derivate G01AC01 Diiodhydroxychinolin 0,2 g V G01AC02 Clioquinol G01AC03 Chlorquinaldol 0,2 g V G01AC05 Dequalinium 10 mg V G01AC06 Broxychinolin 0,1 g V G01AC30 Oxychinolin G01AD Organische Säuren G01AD01 Milchsäure G01AD02 Essigsäure G01AD03 Ascorbinsäure 0,25 g V G01AE Sulfonamide G01AE01 Sulfatolamid G01AE10 Kombinationen von Sulfonamiden G01AF Imidazol-Derivate G01AF01 Metronidazol 0,5 g V G01AF02 Clotrimazol 0,1 g V G01AF04 Miconazol 0,1 g V G01AF05 Econazol 0,1 g V G01AF06 Ornidazol G01AF07 Isoconazol 0,6 g V G01AF08 Tioconazol 0,3 g V Ein-Dosis-Behandlung G01AF11 Ketoconazol 0,4 g V G01AF12 Fenticonazol 0,1 g V G01AF13 Azanidazol G01AF14 Propenidazol G01AF15 Butoconazol 0,1 g V G01AF16 Omoconazol G01AF17 Oxiconazol G01AF18 Flutrimazol G01AF20 Kombinationen von Imidazol-Derivaten G01AG Triazol-Derivate G01AG02 Terconazol 80 mg V G01AX Andere Antiinfektiva und Antiseptika G01AX01 Clodantoin 0,1 g V G01AX02 Inosin G01AX03 Policresulen 90 mg V G01AX05 Nifuratel 0,6 g O,V G01AX06 Furazolidon G01AX09 Methylrosanilin G01AX11 Povidon-Iod 0,2 g V G01AX12 Ciclopirox 50 mg V bezogen auf Ciclopirox olamin (Vaginalcreme) G01AX13 Protiofat G01AX14 Lactobacillus-Ferment G01AX15 Kupferusnat 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 55 von 133 BEDEUTUNG DDD-INFOATC-CODE G01AX17 Bituminosulfonate G01AX20 Kombinationen G01AX21 Chlorphenesin G01AX22 Hexetidin G01AX26 Monalazon G01AX66 Octenidin, Kombinationen G01AX67 Bituminosulfonate, Kombinationen G01AX75 Guajazulen, Kombinationen G01AX77 Milcheiweiß, Kombinationen G01B ANTIINFEKTIVA/ANTISEPTIKA IN KOMBINATION MIT CORTICOSTEROIDEN G01BA Antibiotika und Corticosteroide G01BA01 Antibiotika und Corticosteroide G01BC Chinolin-Derivate und Corticosteroide G01BD Antiseptika und Corticosteroide G01BD01 Antiseptika und Corticosteroide G01BE Sulfonamide und Corticosteroide G01BE50 Sulfonamiden und Corticosteroide, Kombinationen mit Antibiotika G01BF Imidazol-Derivate und Corticosteroide G02 ANDERE GYNÄKOLOGIKA G02A WEHEN FÖRDERNDE MITTEL G02AB Mutterkorn-Alkaloide G02AB01 Methylergometrin 0,2 mg O,P G02AB02 Mutterkorn-Alkaloide G02AB03 Ergometrin 0,2 mg O,P G02AC Mutterkorn-Alkaloide und Oxytocin inkl. Derivate, in Kombination G02AC01 Methylergometrin und Oxytocin G02AD Prostaglandine G02AD01 Dinoprost 25 mg P G02AD02 Dinoproston 0,5 mg O,V G02AD03 Gemeprost 1 mg V Ein-Dosis-Behandlung G02AD04 Carboprost 2,5 mg P Ein-Dosis-Behandlung G02AD05 Sulproston 0,5 mg P G02AD06 Misoprostol G02AX Andere Wehen fördernde Mittel G02B KONTRAZEPTIVA ZUR LOKALEN ANWENDUNG G02BA Intrauterine Kontrazeptiva G02BA01 Plastik-IUP G02BA02 Plastik-IUP mit Kupfer G02BA03 Plastik-IUP mit Gestagen G02BB Intravaginale Kontrazeptiva G02BB01 Vaginalring mit Gestagenen und Estrogenen 0,0357 DE V G02BB02 Nonoxinol 9 Standarddosis: 1 Applikationsform V G02C ANDERE GYNÄKOLOGIKA G02CA Sympathomimetika, Wehen hemmend G02CA01 Ritodrin 40 mg O,P G02CA02 Buphenin 30 mg P G02CA03 Fenoterol G02CB Prolactinhemmer G02CB01 Bromocriptin 5 mg O,P G02CB02 Lisurid 0,6 mg O G02CB03 Cabergolin 0,5 mg O G02CB04 Quinagolid 75 mcg O G02CB05 Metergolin 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 56 von 133 BEDEUTUNG DDD-INFOATC-CODE G02CB06 Tergurid G02CC Antiphlogistika zur vaginalen Anwendung G02CC01 Ibuprofen G02CC02 Naproxen G02CC03 Benzydamin G02CC04 Flunoxaprofen G02CD Andere Vaginaltherapeutika G02CD01 Mineralöl G02CD05 Lebertran G02CD07 Dexpanthenol G02CD08 Naturmoor G02CD09 Hyaluronsäure G02CD20 Kombinationen G02CH Andere homöopathische und anthroposophische Gynäkologika G02CH01 Agnus castus G02CH02 Cimicifuga racemosa G02CH10 Verschiedene G02CH20 Homöopathische und anthroposophische Antidysmenorrhoika, Kombinationen G02CH30 Homöopathische und anthroposophische Klimakteriumstherapeutika, Kombinationen G02CP Andere pflanzliche Gynäkologika G02CP01 Keuschlammfrüchte 35 mg O Droge G02CP02 Hirtentäschelkraut G02CP03 Cimicifugawurzelstock 40 mg O Droge G02CP04 Rhapontikrhabarberwurzel G02CP05 Gänsefingerkraut G02CP06 Sojabohnen G02CP53 Cimicifugawurzelstock, Kombinationen G02CP54 Rhapontikrhabarberwurzel, Kombinationen G02CP55 Tollkirsche, Kombinationen G02CX Andere Gynäkologika G02CX01 Atosiban 165 mg P G02CX02 Flibanserin G02CX07 Milzextrakt G02CX08 Ovarialextrakt G02CX55 Abucetamid, Kombinationen G02CX56 Theobromin, Kombinationen G03 G03A HORMONELLE KONTRAZEPTIVA ZUR SYSTEMISCHEN ANWENDUNG G03AA Gestagene und Estrogene, fixe Kombinationen G03AA01 Etynodiol und Ethinylestradiol G03AA02 Quingestanol und Ethinylestradiol G03AA03 Lynestrenol und Ethinylestradiol G03AA04 Megestrol und Ethinylestradiol G03AA05 Norethisteron und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA06 Norgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA07 Levonorgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA08 Medroxyprogesteron und Ethinylestradiol G03AA09 Desogestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA10 Gestoden und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA11 Norgestimat und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA12 Drospirenon und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA13 Norelgestromin und Ethinylestradiol G03AA14 Nomegestrol und Estradiol Zykluspackung mit 28 Tabletten 1 DE O G03AA15 Chlormadinon und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA17 Dienogest und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB Gestagene und Estrogene, Sequenzialpräparate G03AB01 Megestrol und Ethinylestradiol G03AB02 Lynestrenol und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB03 Levonorgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB04 Norethisteron und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB05 Desogestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB06 Gestoden und Ethinylestradiol G03AB07 Chlormadinon und Ethinylestradiol G03AB08 Dienogest und Estradiol Zykluspackung mit 28 Tabletten 1 DE O G03AB09 Norgestimat und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AC Gestagene SEXUALHORMONE UND MODULATOREN DES GENITALSYSTEMS 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 57 von 133 BEDEUTUNG DDD-INFOATC-CODE G03AC01 Norethisteron 2,5 mg P G03AC02 Lynestrenol G03AC03 Levonorgestrel Zykluspackung mit 28 Tabletten 1 DE O G03AC04 Quingestanol G03AC05 Megestrol G03AC06 Medroxyprogesteron 1,67 mg P G03AC07 Norgestrienon G03AC08 Etonogestrel 68 mcg s.c. Implantat G03AC09 Desogestrel Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AD Notfallkontrazeptiva G03AD01 Levonorgestrel 1,5 mg O G03AD02 Ulipristal 30 mg O G03B ANDROGENE G03BA 3-Oxoandrosten-4-Derivate G03BA01 Fluoxymesteron 5 mg O G03BA02 Methyltestosteron 25 mg O G03BA03 Testosteron 0,12 g O,R; 18 mg P; 60 mg SL; 3 mg TD; 50 mg TD Gel; 12 mg P bezogen auf Testosteronundecanoat G03BB 5-Androstanon-3-Derivate G03BB01 Mesterolon 50 mg O G03BB02 Androstanolon G03C ESTROGENE G03CA Natürliche und halbsynthetische Estrogene, rein G03CA01 Ethinylestradiol 25 mcg O G03CA03 Estradiol 0,3 mg N; 2 mg O; 1 mg P Depot mit kurzer Wirkdauer; 0,3 mg P Depot mit langer Wirkdauer; 5 mg R; 1 mg TD Gel; 50 mcg TD Pflaster bezogen auf die Freisetzungsrate pro 24 Stunden; 25 mcg V; 7,5 mcg V Vaginalring bezogen auf die Freisetzungsrate pro 24 Stunden G03CA04 Estriol 2 mg O,P; 0,2 mg V G03CA06 Chlorotrianisen 24 mg O G03CA07 Estron 1 mg O G03CA09 Promestrien G03CA10 Mestranol G03CA53 Estradiol, Kombinationen G03CA57 Konjugierte Estrogene 0,625 mg O,V G03CB Synthetische Estrogene, rein G03CB01 Dienestrol 2,5 mg O; 0,2 mg V G03CB02 Diethylstilbestrol 0,2 mg O; 1 mg V G03CB03 Methallenestril 9 mg O G03CB04 Moxestrol G03CC Estrogene, Kombinationen mit anderen Mitteln G03CC02 Dienestrol G03CC03 Methallenestril G03CC04 Estron G03CC05 Diethylstilbestrol G03CC06 Estriol G03CC07 Estradiol G03CC08 Konjugierte Estrogene G03CD Estrogene, vaginale Zubereitungen G03CD01 Estriol 0,2 mg V G03CD03 Estradiol 25 mcg V G03CD51 Estriol, Kombinationen G03CD53 Estradiol, Kombinationen G03CX Andere Estrogene G03CX01 Tibolon 2,5 mg O G03D GESTAGENE G03DA Pregnen-4-Derivate G03DA01 Gestonoron 30 mg P G03DA02 Medroxyprogesteron 5 mg O; 7 mg P G03DA03 Hydroxyprogesteron 10 mg P G03DA04 Progesteron 0,3 g O; 5 mg P; 0,2 g R; 90 mg V G03DA06 Levonorgestrel 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 58 von 133 BEDEUTUNG DDD-INFOATC-CODE G03DB Pregnadien-Derivate G03DB01 Dydrogesteron 10 mg O G03DB02 Megestrol 5 mg O G03DB03 Medrogeston 5 mg O G03DB04 Nomegestrol G03DB05 Demegeston G03DB06 Chlormadinon G03DB07 Promegeston G03DB08 Dienogest 2 mg O G03DC Estren-Derivate G03DC01 Allylestrenol 10 mg O G03DC02 Norethisteron 5 mg O; 0,65 mg O niedrigdosierte Zubereitungen G03DC03 Lynestrenol 5 mg O G03DC04 Ethisteron 5 mg O G03DC06 Etynodiol G03DC31 Methylestrenolon 5 mg O G03DD Gestagene, topische Zubereitungen G03DD01 Progesteron G03E ANDROGENE UND WEIBLICHE SEXUALHORMONE IN KOMBINATION G03EA Androgene und Estrogene G03EA01 Methyltestosteron und Estrogen G03EA02 Testosteron und Estrogen G03EA03 Prasteron und Estrogen G03EB Androgen, Gestagen und Estrogen in Kombination G03EK Androgene und weibliche Sexualhormone in Kombination mit anderen Mitteln G03EK01 Methyltestosteron G03F GESTAGENE UND ESTROGENE IN KOMBINATION G03FA Gestagene und Estrogene, fixe Kombinationen G03FA01 Norethisteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA02 Hydroxyprogesteron und Estrogen G03FA03 Ethisteron und Estrogen G03FA04 Progesteron und Estrogen G03FA05 Methylnortestosteron und Estrogen G03FA06 Etynodiol und Estrogen G03FA07 Lynestrenol und Estrogen G03FA08 Megestrol und Estrogen G03FA09 Noretynodrel und Estrogen G03FA10 Norgestrel und Estrogen G03FA11 Levonorgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA12 Medroxyprogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA13 Norgestimat und Estrogen G03FA14 Dydrogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O G03FA15 Dienogest und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA16 Trimegeston und Estrogen G03FA17 Drospirenon und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA20 Chlormadinon und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB Gestagene und Estrogene, Sequenzialpräparate G03FB01 Norgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB02 Lynestrenol und Estrogen G03FB03 Chlormadinon und Estrogen G03FB04 Megestrol und Estrogen G03FB05 Norethisteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB06 Medroxyprogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB07 Medrogeston und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB08 Dydrogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O G03FB09 Levonorgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB10 Desogestrel und Estrogen G03FB11 Trimegeston und Estrogen G03FB12 Nomegestrol und Estradiol Zykluspackung mit 24 Tabletten 0,86 DE O G03FC Gestagene und Estrogene, Kombinationen mit anderen Mitteln G03FC01 Norethisteron und Estrogen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 59 von 133 BEDEUTUNG DDD-INFOATC-CODE G03G GONADOTROPINE UND ANDERE OVULATIONSAUSLÖSER G03GA Gonadotropine G03GA01 Choriongonadotrophin 7,5 TSD E P zur Ovulationsauslösung G03GA02 Humanes menopausales Gonadotrophin 75 E P G03GA03 Serumgonadotrophin 750 E P G03GA04 Urofollitropin 75 E P G03GA05 Follitropin alfa 75 E P G03GA06 Follitropin beta 75 E P G03GA07 Lutropin alfa 75 E P G03GA08 Choriongonadotropin alfa 0,25 mg P G03GA09 Corifollitropin alfa 0,15 mg P G03GA21 Lutropin alfa und Follitropin alfa G03GB Ovulationsauslöser, synthetisch G03GB01 Cyclofenil 0,14 g O G03GB02 Clomifen 9 mg O G03GB03 Epimestrol 10 mg O G03H ANTIANDROGENE G03HA Antiandrogene, rein G03HA01 Cyproteron 0,1 g O,P; 25 mg P Depot, für den Mann G03HB Antiandrogene und Estrogene G03HB01 Cyproteron und Estrogen Zykluspackung mit 21 Tabletten 0,75 DE O G03X ANDERE SEXUALHORMONE UND MODULATOREN DES GENITALSYSTEMS G03XA Antigonadotropine und ähnliche Mittel G03XA01 Danazol 0,6 g O G03XA02 Gestrinon 0,7 mg O G03XB Antigestagene G03XB01 Mifepriston 0,6 g O G03XB02 Ulipristal 5 mg O G03XC Selektive Estrogenrezeptor-Modulatoren G03XC01 Raloxifen 60 mg O G03XC02 Bazedoxifen 20 mg O G03XC03 Lasofoxifen 0,5 mg O G03XC04 Ormeloxifen G04 UROLOGIKA G04B UROLOGIKA G04BA Harn ansäuernde Mittel G04BA01 Ammoniumchlorid 8,5 g O G04BA03 Calciumchlorid G04BA04 L-Methionin 2,25 g O G04BA51 Ammoniumchlorid, Kombinationen G04BC Harnkonkrement lösende Mittel G04BC01 Kalium-Natrium-Hydrogencitrat G04BC50 Andere Harnkonkrement lösende Mittel, Kombinationen G04BD Mittel bei häufiger Blasenentleerung und G04BD01 Emepronium 0,5 g O; 75 mg P G04BD02 Flavoxat 0,8 g O G04BD03 Meladrazin 0,45 g O G04BD04 Oxybutynin 15 mg O; 3,9 mg TD G04BD05 Terodilin 50 mg O G04BD06 Propiverin 30 mg O; 20 mg O Kinder DDD G04BD07 Tolterodin 4 mg O G04BD08 Solifenacin 5 mg O G04BD09 Trospium 40 mg O G04BD10 Darifenacin 7,5 mg O G04BD11 Fesoterodin 4 mg O G04BD12 Mirabegron G04BD13 Dicycloverin G04BD15 Atropin G04BD20 Phenoxybenzamin G04BD59 Trospiumchlorid, Kombinationen G04BD63 Dicycloverin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 60 von 133 BEDEUTUNG DDD-INFOATC-CODE G04BD65 Atropin, Kombinationen G04BD66 Ethaverin, Kombinationen G04BE Mittel bei erektiler Dysfunktion G04BE01 Alprostadil 20 mcg P; 0,25 mg urethral G04BE02 Papaverin G04BE03 Sildenafil 50 mg O G04BE04 Yohimbin 15 mg O G04BE06 Moxisylyt G04BE07 Apomorphin 2 mg SL G04BE08 Tadalafil 10 mg O G04BE09 Vardenafil 10 mg O G04BE30 Kombinationen G04BE52 Papaverin, Kombinationen G04BE54 Yohimbin, Kombinationen G04BE70 Andere Mittel bei erektiler Dysfunktion, Kombinationen mit Psycholeptika G04BH Homöopathische und anthroposophische Urologika G04BH10 Verschiedene G04BH20 Homöopathische und anthroposophische Urologika, Kombinationen G04BH30 Homöopathische und anthroposophische Kombinationen bei erektiler Dysfunktion G04BP Pflanzliche Urologika G04BP01 Bärentraubenblätter 7,5 g O Droge; 0,62 g O Hydrochinon G04BP02 Birkenblätter 10 g O Droge G04BP03 Orthosiphonblätter 9 g O Droge G04BP04 Glockenbilsenkrautwurzelstock G04BP05 Lespedezakraut G04BP06 Goldrutenkraut 9 g O Droge G04BP07 Kürbissamen G04BP08 Brennnesselkraut und -blätter 10 g O Droge aus Kraut und Blättern G04BP30 Kombinationen G04BP50 Andere pflanzliche Urologika, Kombinationen G04BP51 Bärentraubenblätter, Kombinationen G04BX Andere Urologika G04BX01 Magnesiumhydroxid 0,5 g O G04BX03 Acetohydroxamsäure 0,75 g O G04BX06 Phenazopyridin 0,6 g O G04BX10 Succinimid G04BX11 Kollagen G04BX12 Phenylsalicylat 2 g O G04BX13 Dimethylsulfoxid G04BX14 Dapoxetin 30 mg O G04BX15 Natriumpentosanpolysulfat G04BX16 Hyaluronsäure G04BX17 Chondroitinsulfat G04BX18 Duloxetin 80 mg O G04BX19 Chlorhexidin G04BX20 Escherichia coli G04BX50 Andere Urologika, Kombinationen G04C MITTEL BEI BENIGNER PROSTATAHYPERPLASIE G04CA Alpha-Adrenozeptor-Antagonisten G04CA01 Alfuzosin 7,5 mg O G04CA02 Tamsulosin 0,4 mg O G04CA03 Terazosin 5 mg O G04CA04 Silodosin 8 mg O G04CA05 Doxazosin 6 mg O G04CA51 Alfuzosin und Finasterid G04CA52 Tamsulosin und Dutasterid Standarddosis: 1 Applikationsform O G04CA53 Tamsulosin und Solifenacin G04CB Testosteron-5-alpha-Reduktasehemmer G04CB01 Finasterid 5 mg O G04CB02 Dutasterid 0,5 mg O G04CH Homöopathische und anthroposophische Prostatamittel G04CH01 Sabal serrulatum G04CH20 Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 61 von 133 BEDEUTUNG DDD-INFOATC-CODE G04CP Pflanzliche Prostatamittel G04CP02 Brennnesselwurzel 5 g O G04CP03 Pollenextrakt G04CP05 Kürbissamen 10 g O Samen G04CP06 Sägepalmenfrüchte 1,5 g O Droge; 0,32 g O lipophil ausgezogener Extrakt G04CP07 Pygeum africanum G04CP30 Kombinationen G04CP50 Kombinationen mit anderen Mitteln G04CP52 Brennnesselwurzel, Kombinationen G04CP55 Kürbissamen, Kombinationen G04CP56 Sägepalmenfrüchte, Kombinationen G04CX Andere Mittel bei benigner Prostatahyperplasie G04CX03 Mepartricin G04CX04 Beta-Sitosterin 60 mg O G04CX54 Beta-Sitosterin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 62 von 133 BEDEUTUNG DDD-INFOATC-CODE H SYSTEMISCHE HORMONPRÄPARATE, EXKL. SEXUALHORMONE UND INSULINE H01 HYPOPHYSEN- UND HYPOTHALAMUSHORMONE UND ANALOGA H01A HYPOPHYSENVORDERLAPPENHORMONE UND ANALOGA H01AA ACTH H01AA01 Corticotropin 25 E P H01AA02 Tetracosactid 0,25 mg P H01AB Thyrotropin H01AB01 Thyrotropin 5 E P H01AC Somatropin und Somatropin-Agonisten H01AC01 Somatropin 2 E P Kinder-DDD H01AC02 Somatrem H01AC03 Mecasermin 2 mg P H01AC04 Sermorelin H01AC05 Mecasermin rinfabat H01AC06 Tesamorelin H01AX Andere Hypophysenvorderlappenhormone und Analoga H01AX01 Pegvisomant 10 mg P H01B HYPOPHYSENHINTERLAPPENHORMONE H01BA Vasopressin und Analoga H01BA01 Vasopressin 4 E P H01BA02 Desmopressin 25 mcg N; 0,4 mg O; 4 mcg P; 0,24 mg SL Base H01BA03 Lypressin 20 E N,P H01BA04 Terlipressin 12 mg P H01BA05 Ornipressin 5 E P H01BA06 Argipressin H01BB Oxytocin und Analoga H01BB01 Demoxytocin 100 E O H01BB02 Oxytocin 15 E N,P; 200 E O H01BB03 Carbetocin 0,1 mg P H01C HYPOTHALAMUSHORMONE H01CA Gonadotropin-Releasing-Hormone H01CA01 Gonadorelin H01CA02 Nafarelin 0,4 mg N H01CA04 Leuprorelin 0,134 mg P Depotinjektion H01CA05 Goserelin 0,129 mg Implantat H01CA06 Buserelin H01CA07 Triptorelin 0,134 mg P Depotinjektion; 0,1 mg P H01CB Somatostatin und Analoga H01CB01 Somatostatin 6 mg P H01CB02 Octreotid 0,7 mg P i.m. Monatsdepot ; 0,3 mg P s.c. H01CB03 Lanreotid 3 mg P H01CB04 Vapreotid H01CB05 Pasireotid 1,2 mg P H01CC Gonadotropin-Releasing-Hormon-Antagonisten H01CC01 Ganirelix 0,25 mg P H01CC02 Cetrorelix 0,25 mg P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 63 von 133 BEDEUTUNG DDD-INFOATC-CODE H02 CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG H02A CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG, REIN H02AA Mineralocorticoide H02AA01 Aldosteron H02AA02 Fludrocortison 0,1 mg O H02AA03 Desoxycorton 5 mg O,P H02AB Glucocorticoide H02AB01 Betamethason 1,5 mg O,P; 0,4 mg P Depot H02AB02 Dexamethason 1,5 mg O,P H02AB03 Fluocortolon 10 mg O H02AB04 Methylprednisolon 7,5 mg O; 20 mg P H02AB05 Paramethason 4 mg O,P H02AB06 Prednisolon 10 mg O,P H02AB07 Prednison 10 mg O H02AB08 Triamcinolon 7,5 mg O,P H02AB09 Hydrocortison 30 mg O,P H02AB10 Cortison 37,5 mg O,P H02AB11 Prednyliden 12 mg O H02AB12 Rimexolon 20 mg P intraartikulär H02AB13 Deflazacort 15 mg O H02AB14 Cloprednol H02AB15 Meprednison H02AB17 Cortivazol H02AB51 Betamethason-Depot 0,4 mg P Depot H02AB54 Methylprednisolon-Depot H02AB56 Prednisolon-Depot 10 mg P Depot H02AB58 Triamcinolon-Depot 1,5 mg P Depot, bezogen auf Triamcinolonacetonid H02B CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG, KOMBINATIONEN H02BX Corticosteroide zur systemischen Anwendung, Kombinationen H02BX01 Methylprednisolon, Kombinationen H02BX02 Dexamethason, Kombinationen H02BX06 Prednisolon, Kombinationen 10 mg O H02BX08 Triamcinolon, Kombinationen 7,5 mg P H02BX09 Betamethason, Kombinationen 1,5 mg O,P H02BX20 Kombinationen H02BX21 Desoxycorton, Kombinationen H02C NEBENNIERENHEMMSTOFFE H02CA Anticorticosteroide H02CA01 Trilostan 0,36 g O H03 SCHILDDRÜSENTHERAPIE H03A SCHILDDRÜSENPRÄPARATE H03AA Schilddrüsenhormone H03AA01 Levothyroxin-Natrium 0,15 mg O,P H03AA02 Liothyronin-Natrium 60 mcg O,P H03AA03 Kombinationen von Levothyroxin und Liothyronin H03AA04 Tiratricol H03AA05 Zubereitungen aus Schilddrüsengewebe H03AA51 Levothyroxin, Kombinationen 1 Applikationsform O H03AA53 Kombinationen von Levothyroxin und Liothyronin, Kombinationen H03B THYREOSTATIKA H03BA Thiouracile H03BA01 Methylthiouracil 0,1 g O H03BA02 Propylthiouracil 0,1 g O H03BA03 Benzylthiouracil 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 64 von 133 BEDEUTUNG DDD-INFOATC-CODE H03BB Schwefel-haltige Imidazol-Derivate H03BB01 Carbimazol 15 mg O H03BB02 Thiamazol 10 mg O H03BB52 Thiamazol, Kombinationen H03BC Perchlorate H03BC01 Kaliumperchlorat H03BC02 Natriumperchlorat H03BH Homöopathische und anthroposophische Thyreostatika H03BH20 Kombinationen H03BP Pflanzliche Thyreostatika H03BP01 Wolfstrappkraut H03BP51 Wolfstrappkraut, Kombinationen H03BX Andere Thyreostatika H03BX01 Diiodtyrosin H03BX02 Dibromtyrosin H03C IODTHERAPIE H03CA Iodtherapie H03CA01 Iodide 0,15 mg O H03CA51 Iodid, Kombinationen H04 PANKREASHORMONE H04A GLYKOGENOLYTISCHE HORMONE H04AA Glykogenolytische Hormone H04AA01 Glucagon 1 mg P H05 CALCIUMHOMÖOSTASE H05A NEBENSCHILDDRÜSENHORMONE UND ANALOGA H05AA Nebenschilddrüsenhormone und Analoga H05AA01 Nebenschilddrüsenextrakt H05AA02 Teriparatid 20 mcg P H05AA03 Parathyroid Hormon 0,1 mg P H05AH Homöopathische und anthroposophische Nebenschilddrüsenhormone H05AH01 Glandulae parathyreoidea H05B NEBENSCHILDDRÜSEN-ANTAGONISTEN H05BA Calcitonin-haltige Zubereitungen H05BA01 Calcitonin (Lachs, synthetisch) 200 E N; 100 E P H05BA02 Calcitonin (Schwein, natürlich) 100 E P H05BA03 Calcitonin (Mensch, synthetisch) 100 E P H05BA04 Elcatonin H05BX Andere Nebenschilddrüsen-Antagonisten H05BX01 Cinacalcet 60 mg O H05BX02 Paricalcitol 2 mcg O,P H05BX03 Doxercalciferol 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 65 von 133 BEDEUTUNG DDD-INFOATC-CODE J ANTIINFEKTIVA ZUR SYSTEMISCHEN ANWENDUNG J01 ANTIBIOTIKA ZUR SYSTEMISCHEN ANWENDUNG J01A TETRACYCLINE J01AA Tetracycline J01AA01 Demeclocyclin 0,6 g O J01AA02 Doxycyclin 0,1 g O,P J01AA03 Chlortetracyclin 1 g O J01AA04 Lymecyclin 0,6 g O,P J01AA05 Metacyclin 0,6 g O J01AA06 Oxytetracyclin 1 g O,P J01AA07 Tetracyclin 1 g O,P J01AA08 Minocyclin 0,2 g O,P J01AA09 Rolitetracyclin 0,35 g P J01AA10 Penimepicyclin J01AA11 Clomocyclin 1 g O J01AA12 Tigecyclin 0,1 g P J01AA20 Kombinationen von Tetracyclinen J01AA56 Oxytetracyclin, Kombinationen 1 g O bezogen auf Oxytetracyclin J01AA57 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin J01B AMPHENICOLE J01BA Amphenicole J01BA01 Chloramphenicol 3 g O,P J01BA02 Thiamphenicol 1,5 g O,P J01BA51 Chloramphenicol, Kombinationen 3 g O bezogen auf Chloramphenicol J01BA52 Thiamphenicol, Kombinationen J01C BETALACTAM-ANTIBIOTIKA, PENICILLINE J01CA Penicilline mit erweitertem Wirkungsspektrum J01CA01 Ampicillin 2 g O,P,R; 2,5 g O Kinder DDD J01CA02 Pivampicillin 1,05 g O J01CA03 Carbenicillin 12 g P J01CA04 Amoxicillin 1 g O,P; 1 g O Kinder DDD J01CA05 Carindacillin 4 g O J01CA06 Bacampicillin 1,2 g O J01CA07 Epicillin 2 g O,P J01CA08 Pivmecillinam 0,6 g O J01CA09 Azlocillin 12 g P J01CA10 Mezlocillin 6 g P J01CA11 Mecillinam 1,2 g P J01CA12 Piperacillin 14 g P J01CA13 Ticarcillin 15 g P J01CA14 Metampicillin 1,5 g O,P J01CA15 Talampicillin 2 g O J01CA16 Sulbenicillin 15 g P J01CA17 Temocillin 2 g P J01CA18 Hetacillin 2 g O J01CA19 Aspoxicillin 4 g P J01CA20 Kombinationen J01CA51 Ampicillin, Kombinationen J01CE Beta-Lactamase-sensitive Penicilline J01CE01 Benzylpenicillin 3,6 g P J01CE02 Phenoxymethylpenicillin 2 g O; 1,5 MIO E O Kinder DDD J01CE03 Propicillin 0,9 g O J01CE04 Azidocillin 1,5 g O J01CE05 Pheneticillin 1 g O J01CE06 Penamecillin 1,05 g O J01CE07 Clometocillin 1 g O J01CE08 Benzylpenicillin-Benzathin 3,6 g P J01CE09 Benzylpenicillin-Procain 0,6 g P J01CE10 Phenoxymethylpenicillin-Benzathin 2 g O; 1,5 MIO E O Kinder DDD J01CE11 Clemizol-Penicillin J01CE30 Kombinationen J01CE52 Phenoxymethylpenicillin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 66 von 133 BEDEUTUNG DDD-INFOATC-CODE J01CF Beta-Lactamase-resistente Penicilline J01CF01 Dicloxacillin 2 g O,P J01CF02 Cloxacillin 2 g O,P J01CF03 Meticillin 4 g P J01CF04 Oxacillin 2 g O,P J01CF05 Flucloxacillin 3 g O,P; 1 g O Kinder DDD J01CF06 Nafcillin J01CG Beta-Lactamase-Inhibitoren J01CG01 Sulbactam 1 g P J01CG02 Tazobactam J01CR Kombinationen von Penicillinen, inkl. Beta-Lactamase- Inhibitoren J01CR01 Ampicillin und Enzym-Inhibitoren 2 g P bezogen auf Ampicillin J01CR02 Amoxicillin und Enzym-Inhibitoren 1,75 g O bezogen auf Amoxicillin; 3 g P bezogen auf Amoxicillin; 1 g O Kinder DDD bezogen auf Amoxicillin J01CR03 Ticarcillin und Enzym-Inhibitoren 15 g P bezogen auf Ticarcillin J01CR04 Sultamicillin 1,5 g O J01CR05 Piperacillin und Enzym-Inhibitoren 14 g P bezogen auf Piperacillin J01CR50 Kombinationen von Penicillinen J01D ANDERE BETA-LACTAM-ANTIBIOTIKA J01DB Cephalosporine der 1. Generation J01DB01 Cefalexin 2 g O; 1 g O Kinder DDD J01DB02 Cefaloridin 3 g P J01DB03 Cefalotin 4 g P J01DB04 Cefazolin 3 g P J01DB05 Cefadroxil 2 g O; 1 g O Kinder DDD J01DB06 Cefazedon 3 g P J01DB07 Cefatrizin 1 g O J01DB08 Cefapirin 4 g P J01DB09 Cefradin 2 g O,P J01DB10 Cefacetril J01DB11 Cefroxadin J01DB12 Ceftezol 3 g P J01DC Cephalosporine der 2. Generation J01DC01 Cefoxitin 6 g P J01DC02 Cefuroxim 0,5 g O; 3 g P J01DC03 Cefamandol 6 g P J01DC04 Cefaclor 1 g O; 0,75 g O Kinder DDD J01DC05 Cefotetan 4 g P J01DC06 Cefonicid 1 g P J01DC07 Cefotiam 1,2 g O; 4 g P J01DC08 Loracarbef 0,6 g O J01DC09 Cefmetazol 4 g P J01DC10 Cefprozil 1 g O J01DC11 Ceforanid 4 g P J01DC12 Cefminox 4 g P J01DC13 Cefbuperazon 2 g P J01DC14 Flomoxef 2 g P J01DD Cephalosporine der 3. Generation J01DD01 Cefotaxim 4 g P J01DD02 Ceftazidim 4 g P J01DD03 Cefsulodin 4 g P J01DD04 Ceftriaxon 2 g P J01DD05 Cefmenoxim 2 g P J01DD06 Latamoxef 4 g P J01DD07 Ceftizoxim 4 g P J01DD08 Cefixim 0,4 g O; 0,2 g O Kinder DDD J01DD09 Cefodizim 2 g P J01DD10 Cefetamet 1 g O J01DD11 Cefpiramid 2 g P J01DD12 Cefoperazon 4 g P J01DD13 Cefpodoxim 0,4 g O; 0,2 g O Kinder DDD J01DD14 Ceftibuten 0,4 g O J01DD15 Cefdinir 0,6 g O J01DD16 Cefditoren 0,4 g O J01DD17 Cefcapen 0,45 g O J01DD54 Ceftriaxon, Kombinationen J01DD62 Cefoperazon, Kombinationen 4 g P bezogen auf Cefoperazon J01DE Cephalosporine der 4. Generation J01DE01 Cefepim 2 g P J01DE02 Cefpirom 4 g P J01DE03 Cefozopran 4 g P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 67 von 133 BEDEUTUNG DDD-INFOATC-CODE J01DF Monobactame J01DF01 Aztreonam 0,225 g Inhal.lösung; 4 g P J01DF02 Carumonam 2 g P J01DH Carbapeneme J01DH02 Meropenem 2 g P J01DH03 Ertapenem 1 g P J01DH04 Doripenem 1,5 g P J01DH05 Biapenem 1,2 g P J01DH51 Imipenem und Enzym-Inhibitoren 2 g P bezogen auf Imipenem J01DH55 Panipenem und Betamipron 2 g P bezogen auf Panipenem J01DI Andere Cephalosporine und Peneme J01DI01 Ceftobiprol medocaril 1,5 g P J01DI02 Ceftarolin fosamil 1,2 g P J01DI03 Faropenem J01E SULFONAMIDE UND TRIMETHOPRIM J01EA Trimethoprim und Derivate J01EA01 Trimethoprim 0,4 g O,P; 0,15 g O Kinder DDD J01EA02 Brodimoprim 0,2 g O J01EA03 Iclaprim J01EB Kurz wirkende Sulfonamide J01EB01 Sulfaisodimidin 4 g O,P J01EB02 Sulfamethizol 4 g O J01EB03 Sulfadimidin 4 g O J01EB04 Sulfapyridin 1 g O J01EB05 Sulfafurazol 4 g O,P J01EB06 Sulfanilamid J01EB07 Sulfathiazol J01EB08 Sulfathiourea 6 g O J01EB09 Sulfacarbamid J01EB11 Formylsulfisomidin J01EB20 Kombinationen J01EB59 Sulfacarbamid, Kombinationen J01EB70 Andere kurzwirksame Sulfonamide, Kombinationen J01EC Mittellang wirkende Sulfonamide J01EC01 Sulfamethoxazol 2 g O J01EC02 Sulfadiazin 0,6 g O J01EC03 Sulfamoxol 1 g O,P J01EC20 Kombinationen J01EC52 Sulfadiazin, Kombinationen J01ED Lang wirkende Sulfonamide J01ED01 Sulfadimethoxin 0,5 g O J01ED02 Sulfalen 0,1 g O J01ED03 Sulfametomidin J01ED04 Sulfametoxydiazin 0,5 g O J01ED05 Sulfamethoxypyridazin 0,5 g O J01ED06 Sulfaperin 0,5 g O J01ED07 Sulfamerazin 3 g O J01ED08 Sulfaphenazol 1 g O J01ED09 Sulfamazon 1,5 g O,R J01ED11 Sulfaclomid J01ED20 Kombinationen J01EE Kombinationen von Sulfonamiden und Trimethoprim, inkl. Derivate J01EE01 Sulfamethoxazol und Trimethoprim 1,6 g Sulfamethoxazol + 0,32 g Trimethoprim Erwachsenen DDD; 0,8 g Sulfamethoxazol + 0,16 g Trimethoprim Kinder DDD J01EE02 Sulfadiazin und Trimethoprim J01EE03 Sulfametrol und Trimethoprim J01EE04 Sulfamoxol und Trimethoprim J01EE05 Sulfadimidin und Trimethoprim J01EE06 Sulfadiazin und Tetroxoprim J01EE07 Sulfamerazin und Trimethoprim J01EE51 Sulfamethoxazol und Trimethoprim, Kombinationen J01F MAKROLIDE, LINCOSAMIDE UND STREPTOGRAMINE J01FA Makrolide J01FA01 Erythromycin 1 g O; 2 g O Erythromycinethylsuccinat-Tabletten; 2 g P; 1 g O Kinder DDD für Erythromycinethylsuccinat-haltige Mittel J01FA02 Spiramycin 3 g O J01FA03 Midecamycin 1 g P J01FA05 Oleandomycin 1 g O J01FA06 Roxithromycin 0,3 g O; 0,15 g O Kinder DDD 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 68 von 133 BEDEUTUNG DDD-INFOATC-CODE J01FA07 Josamycin 2 g O J01FA08 Troleandomycin 1 g O J01FA09 Clarithromycin 0,5 g O; 1 g P; 0,375 g O Kinder DDD J01FA10 Azithromycin 0,3 g O; 0,5 g P; 0,25 g O Kinder DDD J01FA11 Miocamycin 1,2 g O J01FA12 Rokitamycin 0,8 g O J01FA13 Dirithromycin 0,5 g O J01FA14 Flurithromycin 0,75 g O J01FA15 Telithromycin 0,8 g O J01FA16 Erythromycinstinoprat 1 g O,P J01FF Lincosamide J01FF01 Clindamycin 1,2 g O; 1,8 g P; 0,45 g O Kinder DDD J01FF02 Lincomycin 1,8 g O,P J01FG Streptogramine J01FG01 Pristinamycin 2 g O J01FG02 Quinupristin/Dalfopristin 1,5 g P J01G AMINOGLYKOSID-ANTIBIOTIKA J01GA Streptomycine J01GA01 Streptomycin 1 g P J01GA02 Streptoduocin 1 g P J01GB Andere Aminoglykoside J01GB01 Tobramycin 0,3 g Inhal.lösung; 0,112 g Inhal.pulver; 0,24 g P J01GB03 Gentamicin 0,24 g P J01GB04 Kanamycin 1 g P J01GB05 Neomycin 1 g O J01GB06 Amikacin 1 g P J01GB07 Netilmicin 0,35 g O,P J01GB08 Sisomicin 0,24 g P J01GB09 Dibekacin 0,14 g P J01GB10 Ribostamycin 1 g P J01GB11 Isepamicin 0,4 g P J01GB12 Arbekacin 0,2 g P J01GB13 Bekanamycin 0,6 g P J01GB53 Gentamicin, Kombinationen J01GB55 Neomycin, Kombinationen J01GB64 Framycetin, Kombinationen J01M CHINOLONE J01MA Fluorchinolone J01MA01 Ofloxacin 0,4 g O,P J01MA02 Ciprofloxacin 1 g O; 0,5 g P J01MA03 Pefloxacin 0,8 g O,P J01MA04 Enoxacin 0,8 g O J01MA05 Temafloxacin 0,8 g O J01MA06 Norfloxacin 0,8 g O J01MA07 Lomefloxacin J01MA08 Fleroxacin 0,4 g O,P J01MA09 Sparfloxacin 0,2 g O J01MA10 Rufloxacin 0,2 g O J01MA11 Grepafloxacin 0,4 g O J01MA12 Levofloxacin 0,5 g O,P J01MA13 Trovafloxacin 0,2 g O,P J01MA14 Moxifloxacin 0,4 g O,P J01MA15 Gemifloxacin J01MA16 Gatifloxacin 0,4 g O,P J01MA17 Prulifloxacin 0,6 g O J01MA18 Pazufloxacin 1 g P J01MA19 Garenoxacin J01MA21 Sitafloxacin 0,1 g O J01MB Andere Chinolone J01MB01 Rosoxacin 0,3 g O J01MB02 Nalidixinsäure 4 g O J01MB03 Piromidsäure 2 g O J01MB04 Pipemidsäure 0,8 g O J01MB05 Oxolinsäure 1 g O J01MB06 Cinoxacin 1 g O J01MB07 Flumequin 1,2 g O J01R KOMBINATIONEN VON ANTIBIOTIKA J01RA Kombinationen von Antibiotika J01RA01 Penicilline, Kombination mit anderen Antibiotika 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 69 von 133 BEDEUTUNG DDD-INFOATC-CODE J01RA02 Sulfonamide, Kombination mit anderen Antibiotika (exkl. Trimethoprim) J01RA03 Cefuroxim, Kombination mit anderen Antibiotika J01RA04 Spiramycin, Kombination mit anderen Antibiotika J01X ANDERE ANTIBIOTIKA J01XA Glycopeptid-Antibiotika J01XA01 Vancomycin 2 g P J01XA02 Teicoplanin 0,4 g P J01XA03 Telavancin J01XA04 Dalbavancin J01XA05 Oritavancin J01XB Polymyxine J01XB01 Colistin 3 MIO E Inhal.lösung,P; 3 MIO E Inhal.pulver J01XB02 Polymyxin B 0,15 g P J01XC Steroid-Antibiotika J01XC01 Fusidinsäure 1,5 g O,P J01XD Imidazol-Derivate J01XD01 Metronidazol 1,5 g P J01XD02 Tinidazol 1,5 g P J01XD03 Ornidazol 1 g P J01XE Nitrofuran-Derivate J01XE01 Nitrofurantoin 0,2 g O; 0,12 g O Kinder DDD J01XE02 Nifurtoinol 0,16 g O J01XE51 Nitrofurantoin, Kombinationen J01XX Andere Antibiotika J01XX01 Fosfomycin 3 g O; 8 g P J01XX02 Xibornol J01XX03 Clofoctol 1,5 g R J01XX04 Spectinomycin 3 g P J01XX05 Methenamin 2 g O Hippurat; 3 g O Mandelat J01XX06 Mandelsäure 12 g O J01XX07 Nitroxolin 1 g O J01XX08 Linezolid 1,2 g O,P J01XX09 Daptomycin 0,28 g P zur Therapie von Haut- und Weichteilinfektionen J01XX10 Bacitracin J01XX55 Methenamin, Kombinationen J02 ANTIMYKOTIKA ZUR SYSTEMISCHEN ANWENDUNG J02A ANTIMYKOTIKA ZUR SYSTEMISCHEN ANWENDUNG J02AA Antibiotika J02AA01 Amphotericin B 35 mg P J02AA02 Hachimycin J02AB Imidazol-Derivate J02AB01 Miconazol 1 g P J02AB02 Ketoconazol 0,2 g O J02AC Triazol-Derivate J02AC01 Fluconazol 0,2 g O,P J02AC02 Itraconazol 0,2 g O,P J02AC03 Voriconazol 0,4 g O,P J02AC04 Posaconazol 0,8 g O J02AX Andere Antimykotika zur systemischen Anwendung J02AX01 Flucytosin 10 g O,P J02AX04 Caspofungin 50 mg P J02AX05 Micafungin 0,1 g P J02AX06 Anidulafungin 0,1 g P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 70 von 133 BEDEUTUNG DDD-INFOATC-CODE J04 MITTEL GEGEN MYKOBAKTERIEN J04A MITTEL ZUR BEHANDLUNG DER TUBERKULOSE J04AA Aminosalicylsäure und Derivate J04AA01 Aminosalicylsäure 12 g O J04AA02 Natriumaminosalicylat 14 g O,P J04AA03 Calciumaminosalicylat J04AB Antibiotika J04AB01 Cycloserin 0,75 g O J04AB02 Rifampicin 0,6 g O,P; 0,3 g O Kinder DDD J04AB03 Rifamycin 0,6 g P J04AB04 Rifabutin 0,15 g O J04AB05 Rifapentin J04AB30 Capreomycin 1 g P J04AC Hydrazide J04AC01 Isoniazid 0,3 g O,P J04AC51 Isoniazid, Kombinationen 0,3 g O bezogen auf Isoniazid J04AD Thiocarbamid-Derivate J04AD01 Protionamid 0,75 g O J04AD02 Tiocarlid 7 g O J04AD03 Ethionamid 0,75 g O J04AK Andere Mittel zur Behandlung der Tuberkulose J04AK01 Pyrazinamid 1,5 g O J04AK02 Ethambutol 1,2 g O,P J04AK03 Terizidon J04AK04 Morinamid J04AM Kombinationen von Mitteln zur Behandlung der Tuberkulose J04AM01 Streptomycin und Isoniazid J04AM02 Rifampicin und Isoniazid J04AM03 Ethambutol und Isoniazid J04AM04 Thioacetazon und Isoniazid J04AM05 Rifampicin, Pyrazinamid und Isoniazid J04AM06 Rifampicin, Pyrazinamid, Ethambutol und Isoniazid J04AM07 Protionamid, Kombinationen J04B MITTEL ZUR BEHANDLUNG DER LEPRA J04BA Mittel zur Behandlung der Lepra J04BA01 Clofazimin 0,1 g O J04BA02 Dapson 50 mg O J04BA03 Aldesulfonnatrium 0,33 g O J05 ANTIVIRALE MITTEL ZUR SYSTEMISCHEN ANWENDUNG J05A DIREKT WIRKENDE ANTIVIRALE MITTEL J05AA Thiosemicarbazone J05AA01 Metisazon J05AB Nukleoside und Nukleotide, exkl. Inhibitoren der Reversen Transkriptase J05AB01 Aciclovir 4 g O,P J05AB02 Idoxuridin J05AB03 Vidarabin J05AB04 Ribavirin 6 g Inhal.lösung; 1 g O J05AB06 Ganciclovir 3 g O; 0,5 g P J05AB09 Famciclovir 1,5 g O J05AB11 Valaciclovir 3 g O J05AB12 Cidofovir 25 mg P J05AB13 Penciclovir J05AB14 Valganciclovir 0,9 g O J05AB15 Brivudin 0,125 g O J05AC Cyclische Amine J05AC02 Rimantadin J05AC03 Tromantadin J05AC04 Amantadin 0,2 g O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 71 von 133 BEDEUTUNG DDD-INFOATC-CODE J05AD Phosphonsäure-Derivate J05AD01 Foscarnet 6,5 g P J05AD02 Fosfonet J05AE Proteasehemmer J05AE01 Saquinavir 2 g O J05AE02 Indinavir 2,4 g O J05AE03 Ritonavir 1,2 g O J05AE04 Nelfinavir 2,25 g O J05AE05 Amprenavir 1,2 g O J05AE07 Fosamprenavir 1,4 g O J05AE08 Atazanavir 0,3 g O J05AE09 Tipranavir 1 g O; 0,64 g O Kinder DDD J05AE10 Darunavir 1,2 g O J05AE11 Telaprevir 2,25 g O J05AE12 Boceprevir 2,4 g O J05AF Nukleosidale und nukleotidale Inhibitoren der Reversen Transkriptase J05AF01 Zidovudin 0,6 g O,P J05AF02 Didanosin 0,4 g O J05AF03 Zalcitabin 2,25 mg O J05AF04 Stavudin 80 mg O J05AF05 Lamivudin 0,3 g O J05AF06 Abacavir 0,6 g O J05AF07 Tenofovir disoproxil 0,245 g O J05AF08 Adefovir dipivoxil 10 mg O J05AF09 Emtricitabin 0,2 g O J05AF10 Entecavir 0,5 mg O J05AF11 Telbivudin 0,6 g O J05AF12 Clevudin 30 mg O J05AG Nicht-Nukleosidale Inhibitoren der Reversen Transkriptase J05AG01 Nevirapin 0,4 g O; 0,3 g O Kinder DDD J05AG02 Delavirdin 1,2 g O J05AG03 Efavirenz 0,6 g O J05AG04 Etravirin 0,4 g O J05AG05 Rilpivirin 25 mg O J05AH Neuraminidasehemmer J05AH01 Zanamivir 20 mg Inhal.pulver zur Therapie J05AH02 Oseltamivir 0,15 g O J05AR Antivirale Mittel zur Behandlung von HIV Infektionen, Kombinationen J05AR01 Zidovudin und Lamivudin Standarddosis: 2 Applikationsformen O J05AR02 Lamivudin und Abacavir Standarddosis: 1 Applikationsform O J05AR03 Tenofovir disoproxil und Emtricitabin Standarddosis: 1 Applikationsform O J05AR04 Zidovudin, Lamivudin und Abacavir Standarddosis: 2 Applikationsformen O J05AR05 Zidovudin, Lamivudin und Nevirapin J05AR06 Emtricitabin, Tenofovir disoproxil und Efavirenz Standarddosis: 1 Applikationsform O J05AR07 Stavudin, Lamivudin und Nevirapin J05AR08 Emtricitabin, Tenofovir disoproxil und Rilpivirin Standarddosis: 1 Applikationsform O J05AR09 Emtricitabin, Tenofovir disoproxil, Elvitegravir und Cobicistat Standarddosis: 1 Applikationsform O J05AR10 Lopinavir und Ritonavir 0,8 g O bezogen auf Lopinavir J05AX Andere antivirale Mittel J05AX01 Moroxydin 0,3 g O J05AX02 Lysozym J05AX05 Inosin pranobex 3 g O J05AX06 Pleconaril J05AX07 Enfuvirtid 0,18 g P J05AX08 Raltegravir 0,8 g O J05AX09 Maraviroc 0,6 g O J05AX10 Maribavir J05AX11 Elvitegravir J05AX51 Moroxydin, Kombinationen J06 IMMUNSERA UND IMMUNGLOBULINE J06A IMMUNSERA J06AA Immunsera J06AA01 Diphtherie-Antitoxin J06AA02 Tetanus-Antitoxin J06AA03 Schlangengift-Antiserum J06AA04 Botulismus-Antitoxin J06AA05 Gasbrand-Serum J06AA06 Tollwut-Serum 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 72 von 133 BEDEUTUNG DDD-INFOATC-CODE J06B IMMUNGLOBULINE J06BA Immunglobuline, normal human J06BA01 Immunglobuline, normal human, zur extravasalen Anwendung 1,4 g P J06BA02 Immunglobuline, normal human, zur intravasalen Anwendung 1,6 g P J06BB Spezifische Immunglobuline J06BB01 Anti-D(rh)-Immunglobulin J06BB02 Tetanus-Immunglobulin J06BB03 Varicella/Zoster-Immunglobulin J06BB04 Hepatitis-B-Immunglobulin 500 IE P J06BB05 Tollwut-Immunglobulin J06BB06 Röteln-Immunglobulin J06BB07 Kuhpocken-Immunglobulin J06BB08 Staphylococcus-Immunglobulin J06BB09 Cytomegalievirus-Immunglobulin J06BB10 Diphtherie-Immunglobulin J06BB11 Hepatitis-A-Immunglobulin J06BB12 FSME-Immunglobulin J06BB13 Pertussis-Immunglobulin J06BB14 Masern-Immunglobulin J06BB15 Mumps-Immunglobulin J06BB16 Palivizumab 3,75 mg P Säuglings DDD J06BB17 Motavizumab J06BB30 Kombinationen J06BC Andere Immunglobuline J06BC01 Nebacumab 0,1 g P J06BC10 Andere Immunglobuline J07 IMPFSTOFFE J07A BAKTERIELLE IMPFSTOFFE J07AC Milzbrand-Impfstoffe J07AC01 Anthrax-Antigen J07AD Brucellose-Impfstoffe J07AD01 Brucella-Antigen J07AE Cholera-Impfstoffe J07AE01 Cholera, inaktiviert, ganze Zelle Standarddosis: 1 Einzeldosis O J07AE02 Cholera, lebend abgeschwächt J07AE51 Cholera, Kombinationen mit Typhus-Impfstoff, inaktiviert, ganze Zelle J07AF Diphtherie-Impfstoffe J07AF01 Diphtherie-Toxoid Standarddosis: 1 Einzeldosis P J07AG Haemophilus influenzae B-Impfstoffe J07AG01 Haemophilus influenzae B, gereinigtes Antigen konjugiert Standarddosis: 1 Einzeldosis P J07AG51 Haemophilus influenzae B, Kombinationen mit Toxoiden Standarddosis: 1 Einzeldosis P J07AG52 Haemophilus influenzae B, Kombinationen mit Pertussis und Toxoiden Standarddosis: 1 Einzeldosis P J07AG53 Haemophilus influenzae B, Kombinationen mit Meningokokken C, konjugiert J07AH Meningokokken-Impfstoffe J07AH01 Meningokokken A, gereinigtes Polysaccharid-Antigen J07AH02 Andere Meningokokken monovalent, gereinigtes Polysaccharid- Antigen J07AH03 Meningokokken bivalent (A, C), gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AH04 Meningokokken tetravalent (A, C, Y, W-135), gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AH05 Andere Meningokokken polyvalent, gereinigtes Polysaccharid- Antigen J07AH06 Meningokokken B-Polysaccharid-Impfstoff, monovalent J07AH07 Meningokokken C, gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P J07AH08 Meningokokken tetravalent (A, C, Y, W-135), gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P J07AH09 Meningokokken B, Multikomponenten-Impfstoff Standarddosis: 1 Einzeldosis P J07AH10 Meningokokken A, gereinigtes Polysaccharid-Antigen, konjugiert 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 73 von 133 BEDEUTUNG DDD-INFOATC-CODE J07AJ Pertussis-Impfstoffe J07AJ01 Pertussis, inaktiviert, ganze Zelle J07AJ02 Pertussis, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J07AJ51 Pertussis, inaktiviert, ganze Zelle, Kombinationen mit Toxoiden J07AJ52 Pertussis, gereinigtes Antigen, Kombinationen mit Toxoiden Standarddosis: 1 Einzeldosis P J07AK Pest-Impfstoffe J07AK01 Pest, inaktiviert, ganze Zelle J07AL Pneumokokken-Impfstoffe J07AL01 Pneumokokken, gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AL02 Pneumokokken, gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P J07AL52 Pneumokokken, gereinigtes Polysaccharid-Antigen und Haemophilus influenzae B, konjugiert Standarddosis: 1 Einzeldosis P J07AM Tetanus-Impfstoffe J07AM01 Tetanus-Toxoid Standarddosis: 1 Einzeldosis P J07AM51 Tetanus-Toxoid, Kombinationen mit Diphtherie-Toxoid Standarddosis: 1 Einzeldosis P J07AM52 Tetanus-Toxoid, Kombinationen mit Tetanus-Immunglobulin J07AN Tuberkulose-Impfstoffe J07AN01 Tuberkulose, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07AP Typhus-Impfstoffe J07AP01 Typhus, oral, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07AP02 Typhus, inaktiviert, ganze Zelle J07AP03 Typhus, gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AP10 Typhus, Kombinationen mit Paratyphustypen J07AR Typhus (exanthematicus)-Impfstoffe J07AR01 Typhus exanthematicus, inaktiviert, ganze Zelle J07AX Andere bakterielle Impfstoffe J07AX01 Lactobacillus acidophilus J07AX52 Lactobacillus Stämme, Kombinationen Standarddosis: 1 Einzeldosis P J07AX53 Enterobacteriacae Stämme, Kombinationen Standarddosis: 1 Einzeldosis P J07B VIRALE IMPFSTOFFE J07BA Encephalitis-Impfstoffe J07BA01 FSME, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BA02 Encephalitis, japanische, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BB Influenza-Impfstoffe J07BB01 Influenza, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BB02 Influenza, inaktiviert, Spaltvirus oder Oberflächenantigen Standarddosis: 1 Einzeldosis P J07BB03 Influenza, lebend abgeschwächt Standarddosis: 1 Einzeldosis N J07BC Hepatitis-Impfstoffe J07BC01 Hepatitis B, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J07BC02 Hepatitis A, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BC03 Hepatitis A, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J07BC20 Kombinationen Standarddosis: 1 Einzeldosis P J07BD Masern-Impfstoffe J07BD01 Masern, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD51 Masern, Kombinationen mit Mumps, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD52 Masern, Kombinationen mit Mumps und Röteln, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD53 Masern, Kombinationen mit Röteln, lebend abgeschwächt J07BD54 Masern, Kombinationen mit Mumps, Röteln und Varicella, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BE Mumps-Impfstoffe J07BE01 Mumps, lebend abgeschwächt J07BF Poliomyelitis-Impfstoffe J07BF01 Poliomyelitis, oral, monovalent, lebend abgeschwächt J07BF02 Poliomyelitis, oral, trivalent, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07BF03 Poliomyelitis, trivalent, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BF04 Poliomyelitis, oral, bivalent, lebend abgeschwächt J07BG Tollwut-Impfstoffe J07BG01 Tollwut, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BH Rotavirus-Diarrhoe-Impfstoffe J07BH01 Rotavirus, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07BH02 Rotavirus, pentavalent, lebend, Reassortanten Standarddosis: 1 Einzeldosis O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 74 von 133 BEDEUTUNG DDD-INFOATC-CODE J07BJ Röteln-Impfstoffe J07BJ01 Röteln, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BJ51 Röteln, Kombinationen mit Mumps, lebend abgeschwächt J07BK Varicella Zoster Impfstoffe J07BK01 Varicella, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BK02 Zoster Virus, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BL Gelbfieber-Impfstoffe J07BL01 Gelbfieber, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BM Papillomvirus-Impfstoffe J07BM01 Humaner Papillomvirus-Impfstoff (Typen 6,11,16,18) Standarddosis: 1 Einzeldosis P J07BM02 Humaner Papillomvirus-Impfstoff (Typen 16,18) Standarddosis: 1 Einzeldosis P J07BX Andere virale Impfstoffe J07BX02 Inaktiviertes Herpes-simplex-Virus Standarddosis: 1 Einzeldosis P J07C BAKTERIELLE UND VIRALE IMPFSTOFFE, KOMBINIERT J07CA Bakterielle und virale Impfstoffe, kombiniert J07CA01 Diphtherie-Poliomyelitis-Tetanus Standarddosis: 1 Einzeldosis P J07CA02 Diphtherie-Pertussis-Poliomyelitis-Tetanus Standarddosis: 1 Einzeldosis P J07CA03 Diphtherie-Röteln-Tetanus J07CA04 Haemophilus influenzae B und Poliomyelitis J07CA05 Diphtherie-Hepatitis B-Pertussis-Tetanus J07CA06 Diphtherie-Haemophilus influenzae B-Pertussis-Poliomyelitis- Tetanus Standarddosis: 1 Einzeldosis P J07CA07 Diphtherie-Hepatitis B-Tetanus J07CA08 Haemophilus influenzae B und Hepatitis B Standarddosis: 1 Einzeldosis P J07CA09 Diphtherie-Haemophilus influenzae B-Pertussis-Poliomyelitis- Tetanus-Hepatitis B Standarddosis: 1 Einzeldosis P J07CA10 Typhus-Hepatitis A Standarddosis: 1 Einzeldosis P J07CA11 Diphtherie-Haemophilus influenzae B-Pertussis-Tetanus-Hepatitis B J07CA12 Diphtherie-Pertussis-Poliomyelitis-Tetanus-Hepatitis B J07CA13 Diphtherie-Haemophilus influenzae B-Pertussis-Tetanus-Hepatitis B- Meningokokken A + C J07X ANDERE IMPFSTOFFE 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 75 von 133 BEDEUTUNG DDD-INFOATC-CODE L ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL L01 ANTINEOPLASTISCHE MITTEL L01A ALKYLIERENDE MITTEL L01AA Stickstofflost-Analoga L01AA01 Cyclophosphamid L01AA02 Chlorambucil L01AA03 Melphalan L01AA05 Chlormethin L01AA06 Ifosfamid 0,7 g P L01AA07 Trofosfamid L01AA08 Prednimustin L01AA09 Bendamustin L01AB Alkylsulfonate L01AB01 Busulfan L01AB02 Treosulfan L01AB03 Mannosulfan L01AC Ethylenimine L01AC01 Thiotepa 1,62 g P L01AC02 Triaziquon L01AC03 Carboquon L01AD Nitrosoharnstoffe L01AD01 Carmustin L01AD02 Lomustin L01AD03 Semustin L01AD04 Streptozocin L01AD05 Fotemustin L01AD06 Nimustin L01AD07 Ranimustin L01AG Epoxide L01AG01 Etoglucid L01AX Andere alkylierende Mittel L01AX01 Mitobronitol L01AX02 Pipobroman L01AX03 Temozolomid 65 mg O,P L01AX04 Dacarbazin 0,1 g P L01B ANTIMETABOLITEN L01BA Folsäure-Analoga L01BA01 Methotrexat Standarddosis: 1 Applikationsform P L01BA03 Raltitrexed L01BA04 Pemetrexed 43 mg P L01BA05 Pralatrexat L01BB Purin-Analoga L01BB02 Mercaptopurin L01BB03 Tioguanin L01BB04 Cladribin L01BB05 Fludarabin 8 mg P L01BB06 Clofarabin L01BB07 Nelarabin 0,39 g P L01BC Pyrimidin-Analoga L01BC01 Cytarabin L01BC02 Fluorouracil 0,15 g O; 0,1 g P L01BC03 Tegafur L01BC04 Carmofur L01BC05 Gemcitabin 0,2 g P L01BC06 Capecitabin 3 g O L01BC07 Azacitidin 34 mg P L01BC08 Decitabin 6,43 mg P L01BC52 Fluorouracil, Kombinationen L01BC53 Tegafur, Kombinationen L01BC63 Tegafur und Uracil 0,432 g O bezogen auf Tegafur L01BC73 Tegafur, Gimeracil und Oteracil 67,5 mg O bezogen auf Tegafur 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 76 von 133 BEDEUTUNG DDD-INFOATC-CODE L01C PFLANZLICHE ALKALOIDE UND ANDERE NATÜRLICHE MITTEL L01CA Vinka-Alkaloide und Analoga L01CA01 Vinblastin 11,61 mg P Wochendosis L01CA02 Vincristin 0,36 mg P L01CA03 Vindesin L01CA04 Vinorelbin 18 mg O; 7 mg P L01CA05 Vinflunin 27,43 mg P L01CB Podophyllotoxin-Derivate L01CB01 Etoposid 50 mg O; 25 mg P L01CB02 Teniposid L01CC Colchicin-Derivate L01CC01 Demecolcin L01CD Taxane L01CD01 Paclitaxel 15 mg P; 22 mg P Nanopartikelformulierung L01CD02 Docetaxel 6,43 mg P L01CD03 Paclitaxel poliglumex L01CD04 Cabazitaxel 2,14 mg P L01CH Andere homöopathische und anthroposophische Mittel L01CH01 Mistelkraut L01CP Andere pflanzliche Mittel L01CP01 Mistelkraut L01CP02 Venusfliegenfalle L01CP50 Andere pflanzliche Mittel, Kombinationen L01CX Andere pflanzliche Alkaloide und natürliche Mittel L01CX01 Trabectedin 0,13 mg P L01D ZYTOTOXISCHE ANTIBIOTIKA UND VERWANDTE SUBSTANZEN L01DA Actinomycine L01DA01 Dactinomycin L01DB Anthracycline und verwandte Substanzen L01DB01 Doxorubicin 5 mg P; 3 mg P pegylierte liposomale Form; Standarddosis: 1 Instillationsset U L01DB02 Daunorubicin L01DB03 Epirubicin 7 mg P L01DB04 Aclarubicin L01DB05 Zorubicin L01DB06 Idarubicin 6 mg O; 3 mg P L01DB07 Mitoxantron 10 mg P Zytostatikum; 0,24 mg P Multiple Sklerose L01DB08 Pirarubicin L01DB09 Valrubicin L01DB10 Amrubicin L01DB11 Pixantron 9,64 mg P L01DC Andere zytotoxische Antibiotika L01DC01 Bleomycin 3 mg P entsprechend einer standardisierten biologischen Aktivität von 3.000 E L01DC02 Plicamycin L01DC03 Mitomycin 4,29 mg intravesikal; 0,65 mg P L01DC04 Ixabepilon L01X ANDERE ANTINEOPLASTISCHE MITTEL L01XA Platin-haltige Verbindungen L01XA01 Cisplatin 6,75 mg P L01XA02 Carboplatin 25 mg P L01XA03 Oxaliplatin 11 mg P L01XA04 Satraplatin L01XA05 Polyplatillen L01XB Methylhydrazine L01XB01 Procarbazin L01XC Monoklonale Antikörper L01XC01 Edrecolomab L01XC02 Rituximab 32 mg P L01XC03 Trastuzumab 20 mg P L01XC04 Alemtuzumab 13 mg P L01XC05 Gemtuzumab L01XC06 Cetuximab 65 mg P L01XC07 Bevacizumab 45 mg P L01XC08 Panitumumab 30 mg P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 77 von 133 BEDEUTUNG DDD-INFOATC-CODE L01XC09 Catumaxomab 21 mcg P L01XC10 Ofatumumab 0,133 g P L01XC11 Ipilimumab 10 mg P L01XC12 Brentuximab vedotin 6 mg P L01XC13 Pertuzumab 20 mg P L01XD Sensibilisatoren für die photodynamische/Radio-Therapie L01XD01 Porfimer natrium L01XD03 Methylaminolevulinat L01XD04 Aminolevulinsäure L01XD05 Temoporfin 10,5 mg P L01XD06 Efaproxiral L01XD07 Methoxsalen L01XE Proteinkinase-Inhibitoren L01XE01 Imatinib 0,5 g O L01XE02 Gefitinib 0,25 g O L01XE03 Erlotinib 0,125 g O L01XE04 Sunitinib 35 mg O L01XE05 Sorafenib 0,8 g O L01XE06 Dasatinib 0,12 g O L01XE07 Lapatinib 1,375 g O L01XE08 Nilotinib 0,6 g O L01XE09 Temsirolimus 7,1 mg P L01XE10 Everolimus 10 mg O L01XE11 Pazopanib 0,8 g O L01XE12 Vandetanib 0,3 g O L01XE13 Afatinib L01XE14 Bosutinib 0,5 g O L01XE15 Vemurafenib 1,92 g O L01XE16 Crizotinib 0,5 g O L01XE17 Axitinib 10 mg O L01XE18 Ruxolitinib 30 mg O L01XE19 Ridaforolimus L01XE21 Regorafenib L01XE22 Masitinib L01XE24 Ponatinib 45 mg O L01XX Andere antineoplastische Mittel L01XX01 Amsacrin L01XX02 Asparaginase L01XX03 Altretamin L01XX05 Hydroxycarbamid 1,75 g O L01XX07 Lonidamin L01XX08 Pentostatin L01XX09 Miltefosin L01XX10 Masoprocol L01XX11 Estramustin 0,56 g O L01XX14 Tretinoin L01XX16 Mitoguazon L01XX17 Topotecan 1 mg O; 0,65 mg P L01XX18 Tiazofurin L01XX19 Irinotecan 30 mg P L01XX22 Alitretinoin L01XX23 Mitotan L01XX24 Pegaspargase L01XX25 Bexaroten 0,54 g O L01XX27 Arsentrioxid L01XX29 Denileukin diftitox L01XX32 Bortezomib 0,45 mg P L01XX33 Celecoxib L01XX35 Anagrelid 2 mg O L01XX36 Oblimersen L01XX37 Sitimagen ceradenovec L01XX38 Vorinostat L01XX39 Romidepsin L01XX40 Omacetaxin mepesuccinat L01XX41 Eribulin 0,21 mg P bezogen auf Eribulin L01XX42 Panobinostat L01XX43 Vismodegib 0,15 g O L01XX44 Aflibercept 20 mg P L01XY Kombinationen von antineoplastischen Mitteln 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 78 von 133 BEDEUTUNG DDD-INFOATC-CODE L02 ENDOKRINE THERAPIE L02A HORMONE UND VERWANDTE MITTEL L02AA Estrogene L02AA01 Diethylstilbestrol 3 mg O L02AA02 Polyestradiolphosphat 6 mg P L02AA03 Ethinylestradiol 1,5 mg O L02AA04 Fosfestrol 0,25 g O,P L02AA05 Chlorotrianisen L02AB Gestagene L02AB01 Megestrol 0,16 g O L02AB02 Medroxyprogesteron 1 g O,P L02AB03 Gestonoron 40 mg P L02AE Gonadotropin-Releasing-Hormon-Analoga L02AE01 Buserelin 0,11 mg Implantat; 1,2 mg N; 1,5 mg P L02AE02 Leuprorelin 1 mg P; 1 DE P pro Behandlungszeitraum für Depotarzneiformen L02AE03 Goserelin 0,129 mg Implantat L02AE04 Triptorelin 0,1 mg P; 0,134 mg P Depotinjektion L02AE05 Histrelin 0,137 mg Implantat (Freisetzungsrate 50 mcg pro Tag) L02AX Andere Hormone L02B HORMONANTAGONISTEN UND VERWANDTE MITTEL L02BA Antiestrogene L02BA01 Tamoxifen 20 mg O L02BA02 Toremifen 60 mg O L02BA03 Fulvestrant 18 mg P L02BB Antiandrogene L02BB01 Flutamid 0,75 g O L02BB02 Nilutamid 0,3 g O L02BB03 Bicalutamid 50 mg O; 0,15 g O bezogen auf die Monotherapie L02BB04 Enzalutamid 0,16 g O L02BG Aromatase-Inhibitoren L02BG01 Aminoglutethimid 1 g O L02BG02 Formestan 18 mg P L02BG03 Anastrozol 1 mg O L02BG04 Letrozol 2,5 mg O L02BG05 Vorozol L02BG06 Exemestan 25 mg O L02BG09 Testolacton L02BX Andere Hormonantagonisten und verwandte Mittel L02BX01 Abarelix 3,6 mg P L02BX02 Degarelix 2,7 mg P L02BX03 Abirateron 1 g O bezogen auf Abirateronacetat L03 IMMUNSTIMULANZIEN L03A IMMUNSTIMULANZIEN L03AA Koloniestimulierende Faktoren L03AA02 Filgrastim 0,35 mg P bezogen auf kg Körpergewicht L03AA03 Molgramostim 0,35 mg P L03AA09 Sargramostim 0,45 mg P L03AA10 Lenograstim 0,35 mg P bezogen auf kg Körpergewicht L03AA12 Ancestim 1,4 mg P L03AA13 Pegfilgrastim 0,3 mg P L03AA14 Lipegfilgrastim 0,3 mg P L03AB Interferone L03AB01 Interferon alfa, natürlich 2 MIO E P L03AB02 Interferon beta, natürlich 33,33 TSD E P L03AB03 Interferon gamma 40 mcg P L03AB04 Interferon alfa-2a 2 MIO E P L03AB05 Interferon alfa-2b 2 MIO E P L03AB06 Interferon alfa-n1 5 MIO E P L03AB07 Interferon beta-1a 4,3 mcg P i.m.; 18,86 mcg P s.c. L03AB08 Interferon beta-1b 4 MIO E P L03AB09 Interferon alfacon-1 4 mcg P L03AB10 Peginterferon alfa-2b 15 mcg P Kombinationstherapie bei Hepatitis C 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 79 von 133 BEDEUTUNG DDD-INFOATC-CODE L03AB11 Peginterferon alfa-2a 26 mcg P Kombinationstherapie bei Hepatitis C L03AB12 Albinterferon alfa-2b L03AB13 Interferon gamma 1b L03AB60 Peginterferon alfa-2b, Kombinationen L03AB61 Peginterferon alfa-2a, Kombinationen L03AC Interleukine L03AC01 Aldesleukin 0,2 mg P L03AC02 Oprelvekin 3,5 mg P L03AG Bakterielle Immunstimulanzien L03AG01 Enterococcus faecalis L03AG02 Bacillus subtilis L03AG03 Mycobacterium phlei L03AG04 Escherichia coli L03AG05 Bacillus cereus L03AG50 Andere bakterielle Immunstimulanzien, Kombinationen L03AG51 Enterococcus, Kombinationen L03AH Homöopathische und anthroposophische Immunstimulanzien L03AH01 Echinacea purpurea L03AH02 Echinacea angustifolia L03AH10 Verschiedene L03AH20 Kombinationen L03AH50 Kombinationen mit anderen Mitteln L03AP Pflanzliche Immunstimulanzien L03AP01 Echinacea-purpurea-Presssaft 0,3 g O Trockenpresssaft; 7,5 ml O Presssaft L03AP02 Echinacea-pallida-Wurzel 0,9 g O Droge L03AP03 Echinacea-angustifolia-Wurzel und -Kraut L03AP50 Andere pflanzliche Immunstimulanzien, Kombinationen L03AP51 Echinacea-purpurea-Presssaft, Kombinationen L03AP52 Echinacea-pallida-Wurzel, Kombinationen L03AP53 Echinacea-angustifolia-Wurzel und -Kraut, Kombinationen L03AX Andere Immunstimulanzien L03AX01 Lentinan 0,3 mg O,P L03AX02 Roquinimex L03AX03 BCG-Impfstoff 0,033 Darreichungsform intravesikal L03AX04 Pegademase L03AX05 Pidotimod 1,6 g O L03AX07 Poly I:C L03AX08 Poly ICLC L03AX09 Thymopentin L03AX10 Immunocyanin 3 mg intravesikulär L03AX11 Tasonermin 3,5 mg P L03AX12 Melanom-Impfstoff L03AX13 Glatirameracetat 20 mg P L03AX14 Histamin dihydrochlorid 0,5 mg P L03AX15 Mifamurtid 0,7 mg P L03AX16 Plerixafor 16,8 mg P L03AX17 Sipuleucel-T L03AX18 Milzhydrolysat L03AX19 Leukozyten L03AX20 Andere Organextrakte L03AX23 Levamisol L03AX24 Histaglobin L03AX25 Thymuspeptide L03AX50 Andere Zytokine und Immunstimulanzien, Kombinationen L03AX71 Inosin, Kombinationen L04 IMMUNSUPPRESSIVA L04A IMMUNSUPPRESSIVA L04AA Selektive Immunsuppressiva L04AA02 Muromonab-CD3 5 mg P L04AA03 Antilymphozytäres Immunglobulin (Pferd) L04AA04 Antithymozytäres Immunglobulin (Kaninchen) 0,1 g P L04AA06 Mycophenolsäure 2 g O,P bezogen auf Mycophenolatmofetil L04AA10 Sirolimus 3 mg O L04AA13 Leflunomid 20 mg O L04AA15 Alefacept L04AA18 Everolimus 1,5 mg O L04AA19 Gusperimus L04AA21 Efalizumab 10 mg P L04AA22 Abetimus L04AA23 Natalizumab 10 mg P L04AA24 Abatacept 27 mg P L04AA25 Eculizumab 64 mg P L04AA26 Belimumab 25 mg P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 80 von 133 BEDEUTUNG DDD-INFOATC-CODE L04AA27 Fingolimod 0,5 mg O L04AA28 Belatacept 12,5 mg P L04AA29 Tofacitinib L04AB Tumornekrosefaktor alpha(TNF-alpha)-Inhibitoren L04AB01 Etanercept 7 mg P; 3 mg P Kinder DDD L04AB02 Infliximab 3,75 mg P L04AB03 Afelimomab L04AB04 Adalimumab 2,9 mg P; 1,6 mg P Kinder DDD L04AB05 Certolizumab pegol 14 mg P L04AB06 Golimumab 1,66 mg P L04AC Interleukin-Inhibitoren L04AC01 Daclizumab 0,35 g P Dosis pro Behandlungszyklus L04AC02 Basiliximab 40 mg P Dosis pro Behandlungszyklus L04AC03 Anakinra 0,1 g P L04AC04 Rilonacept 23 mg P L04AC05 Ustekinumab 0,54 mg P L04AC06 Mepolizumab L04AC07 Tocilizumab 20 mg P L04AC08 Canakinumab 2,7 mg P L04AC09 Briakinumab L04AC10 Secukinumab L04AD Calcineurin-Inhibitoren L04AD01 Ciclosporin 0,25 g O,P L04AD02 Tacrolimus 5 mg O,P L04AD03 Voclosporin L04AX Andere Immunsuppressiva L04AX01 Azathioprin 0,15 g O,P L04AX02 Thalidomid 0,2 g O L04AX03 Methotrexat 2,5 mg O L04AX04 Lenalidomid 18,75 mg O L04AX05 Pirfenidon 2,4 g O L04AX06 Pomalidomid 3 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 81 von 133 BEDEUTUNG DDD-INFOATC-CODE M MUSKEL- UND SKELETTSYSTEM M01 ANTIPHLOGISTIKA UND ANTIRHEUMATIKA M01A NICHTSTEROIDALE ANTIPHLOGISTIKA UND ANTIRHEUMATIKA M01AA Butylpyrazolidine M01AA01 Phenylbutazon 0,3 g O,P,R M01AA02 Mofebutazon 0,75 g O,P M01AA03 Oxyphenbutazon 0,3 g O,R M01AA05 Clofezon 0,6 g O,R M01AA06 Kebuzon M01AA07 Pyrazinobutazon M01AA51 Phenylbutazon, Kombinationen M01AA52 Mofebutazon, Kombinationen M01AA53 Oxyphenbutazon, Kombinationen M01AB Essigsäure-Derivate und verwandte Substanzen M01AB01 Indometacin 0,1 g O,P,R M01AB02 Sulindac 0,4 g O,P,R M01AB03 Tolmetin 0,7 g O,R M01AB04 Zomepirac 0,3 g O M01AB05 Diclofenac 0,1 g O,P,R M01AB06 Alclofenac 1,25 g O,R M01AB07 Bumadizon 0,4 g O M01AB08 Etodolac 0,4 g O M01AB09 Lonazolac 0,6 g O M01AB10 Fentiazac M01AB11 Acemetacin 0,12 g O M01AB12 Difenpiramid M01AB13 Oxametacin M01AB14 Proglumetacin M01AB15 Ketorolac 30 mg O,P M01AB16 Aceclofenac 0,2 g O M01AB17 Bufexamac M01AB19 Carbamoylphenoxyessigsäure M01AB51 Indometacin, Kombinationen 0,1 g O,R bezogen auf Indometacin M01AB55 Diclofenac, Kombinationen 0,1 g O bezogen auf Diclofenac M01AB69 Carbamoylphenoxyessigsäure, Kombinationen M01AC Oxicame M01AC01 Piroxicam 20 mg O,P,R M01AC02 Tenoxicam 20 mg O,P,R M01AC03 Isoxicam M01AC04 Droxicam M01AC05 Lornoxicam 12 mg O,P,R M01AC06 Meloxicam 15 mg O,P,R M01AC56 Meloxicam, Kombinationen M01AE Propionsäure-Derivate M01AE01 Ibuprofen 1,2 g O,R; 0,4 g O Kinder DDD M01AE02 Naproxen 0,5 g O,R M01AE03 Ketoprofen 0,15 g O,P,R M01AE04 Fenoprofen 1,2 g O M01AE05 Fenbufen 0,6 g O M01AE06 Benoxaprofen M01AE07 Suprofen 0,4 g O M01AE08 Pirprofen 0,8 g O M01AE09 Flurbiprofen 0,2 g O,R M01AE10 Indoprofen M01AE11 Tiaprofensäure 0,6 g O,R M01AE12 Oxaprozin 0,9 g O M01AE13 Ibuproxam M01AE14 Dexibuprofen 0,8 g O M01AE15 Flunoxaprofen M01AE16 Alminoprofen M01AE17 Dexketoprofen 75 mg O,P M01AE18 Naproxcinod M01AE20 Carprofen M01AE51 Ibuprofen, Kombinationen M01AE52 Naproxen und Esomeprazol 0,5 g O bezogen auf Naproxen M01AE53 Ketoprofen, Kombinationen M01AE56 Naproxen und Misoprostol M01AG Fenamate M01AG01 Mefenaminsäure 1 g O M01AG02 Tolfenaminsäure 0,3 g O,R M01AG03 Flufenaminsäure 0,5 g O M01AG04 Meclofenaminsäure M01AG06 Etofenamat 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 82 von 133 BEDEUTUNG DDD-INFOATC-CODE M01AH Coxibe M01AH01 Celecoxib 0,2 g O M01AH02 Rofecoxib 25 mg O M01AH03 Valdecoxib 10 mg O M01AH04 Parecoxib 40 mg P M01AH05 Etoricoxib 60 mg O M01AH06 Lumiracoxib 0,1 g O M01AX Andere nichtsteroidale Antiphlogistika und Antirheumatika M01AX01 Nabumeton 1 g O M01AX02 Nifluminsäure 0,75 g O M01AX04 Azapropazon 0,75 g O M01AX05 Glucosamin 1,5 g O bezogen auf Glucosaminsulfat M01AX07 Benzydamin 0,15 g O,R M01AX12 Glukosaminoglycanpolysulfat 50 mg P M01AX13 Proquazon 0,9 g O,R M01AX14 Orgotein M01AX17 Nimesulid 0,2 g O M01AX18 Feprazon M01AX21 Diacerein M01AX22 Morniflumat M01AX23 Tenidap M01AX24 Oxaceprol M01AX25 Chondroitinsulfat M01AX26 Avocado und Sojabohnenöl, unverseift M01AX27 Mucopolysaccharidpolyschwefelsäureester M01AX55 Glucosamin, Kombinationen M01AX68 Feprazon, Kombinationen M01B ANTIPHLOGISTIKA/ANTIRHEUMATIKA IN KOMBINATION M01BA Antiphlogistika/Antirheumatika in Kombination mit Corticosteroiden M01BA01 Phenylbutazon und Corticosteroide M01BA02 Dipyrocetyl und Corticosteroide M01BA03 Acetylsalicylsäure und Corticosteroide M01BA04 Mofebutazon und Corticosteroide M01BA05 Oxyphenbutazon und Corticosteroide M01BA06 Salicylamid und Corticosteroide M01BA07 Metamizol und Corticosteroide M01BA08 Kebuzon und Corticosteroide M01BP Andere pflanzliche Antiphlogistika/Antirheumatika in Kombination M01BP30 Kombinationen M01BX Andere Antiphlogistika/Antirheumatika in Kombination mit anderen Mitteln M01BX01 Enzyme, Kombinationen M01BX02 Organextrakt, Kombinationen M01C SPEZIFISCHE ANTIRHEUMATIKA M01CA Chinoline M01CA03 Oxycinchophen 1,5 g O M01CB Gold-Verbindungen M01CB01 Natrium aurothiomalat 2,4 mg P M01CB02 Natrium aurothiosulfat 14 mg P M01CB03 Auranofin 6 mg O M01CB04 Aurothioglucose 2,4 mg P M01CB05 Aurotioprol M01CB06 Aurothiopolypeptid M01CC Penicillamin und ähnliche Mittel M01CC01 Penicillamin 0,5 g O M01CC02 Bucillamin M01CX Andere spezifische Antirheumatika M01CX01 Methotrexat 2,5 mg O,P M01CX02 Sulfasalazin 2 g O,R 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 83 von 133 BEDEUTUNG DDD-INFOATC-CODE M02 TOPISCHE MITTEL GEGEN GELENK- UND MUSKELSCHMERZEN M02A TOPISCHE MITTEL GEGEN GELENK- UND MUSKELSCHMERZEN M02AA Nichtsteroidale Antiphlogistika zur topischen Anwendung M02AA01 Phenylbutazon M02AA02 Mofebutazon M02AA03 Clofezon M02AA04 Oxyphenbutazon M02AA05 Benzydamin M02AA06 Etofenamat 1 g T M02AA07 Piroxicam 17,5 mg T M02AA08 Felbinac 0,15 g T M02AA09 Bufexamac M02AA10 Ketoprofen 0,275 g T M02AA11 Bendazac M02AA12 Naproxen M02AA13 Ibuprofen 0,5 g T M02AA14 Fentiazac M02AA15 Diclofenac 0,1 g T; 0,28 g TD M02AA16 Feprazon M02AA17 Nifluminsäure M02AA18 Meclofenaminsäure M02AA19 Flurbiprofen M02AA20 Kebuzon M02AA21 Tolmetin M02AA22 Suxibuzon M02AA23 Indometacin 0,04 g T M02AA24 Nifenazon M02AA25 Aceclofenac M02AA26 Nimesulid M02AA27 Flufenaminsäure M02AA54 Oxyphenbutazon, Kombinationen M02AA56 Etofenamat, Kombinationen M02AA73 Indometacin, Kombinationen M02AA77 Flufenaminsäure, Kombinationen M02AA78 Ramifenazon, Kombinationen M02AB Capsaicin und ähnliche Mittel M02AB01 Capsaicin M02AB02 Zucapsaicin M02AB03 Nonivamid M02AB51 Capsaicin, Kombinationen M02AB53 Nonivamid, Kombinationen M02AC Zubereitungen mit Salicylsäure-Derivaten M02AC01 Hydroxyethylsalicylat 0,4 g T M02AC02 Methylsalicylat M02AC50 Andere Zubereitungen mit Salicylsäure-Derivaten, Kombinationen M02AC51 Hydroxyethylsalicylat, Kombinationen M02AC52 Methylsalicylat, Kombinationen M02AC53 Hydroxypropylsalicylat, Kombinationen M02AC54 Monoethanolaminsalicylat, Kombinationen M02AC55 Diethylaminsalicylat, Kombinationen M02AC56 Bornylsalicylat, Kombinationen M02AC57 Salicylsäure, Kombinationen M02AD Zubereitungen mit Nicotinsäure-Derivaten M02AD01 Propylnicotinat M02AD02 Benzylnicotinat M02AD50 Andere Zubereitungen mit Nicotinsäure-Derivaten, Kombinationen M02AD51 Propylnicotinat, Kombinationen M02AD52 Benzylnicotinat, Kombinationen M02AD53 Methylnicotinat, Kombinationen M02AH Homöopathische und anthroposophische Zubereitungen gegen Muskel- und Gelenkschmerzen zur topischen Anwendung M02AH01 Cardiospermum M02AH02 Arnika M02AH03 Guajacum M02AH10 Verschiedene M02AH20 Kombinationen M02AH50 Kombinationen mit anderen Mitteln 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 84 von 133 BEDEUTUNG DDD-INFOATC-CODE M02AP Pflanzliche Zubereitungen gegen Muskel- und Gelenkschmerzen zur topischen Anwendung M02AP01 Arnikablüten M02AP02 Fango M02AP03 Acmella ciliata M02AP04 Torf M02AP05 Kiefernnadelöl M02AP06 Symphytumwurzel und -kraut M02AP07 Capsicumfrüchte M02AP09 Rosmarinöl M02AP30 Kombinationen M02AP51 Arnikablüten, Kombinationen M02AP52 Fango, Kombinationen M02AP56 Symphytumwurzel und -kraut, Kombinationen M02AP57 Capsicumfrüchte, Kombinationen M02AP58 Tannennadelöl, Kombinationen M02AP59 Rosmarinöl, Kombinationen M02AX Andere topische Mittel gegen Gelenk- und Muskelschmerzen M02AX02 Tolazolin M02AX03 Dimethylsulfoxid M02AX04 Campher M02AX05 Idrocilamid M02AX10 Verschiedene M02AX19 Bituminosulfonate M02AX20 Organextrakte, inkl. Kombinationen M02AX27 Cholinstearat M02AX28 Chymotrypsin M02AX29 Kalium-Eisen(III)-Phosphat-Citrat-Komplex M02AX30 Kombinationen M02AX53 Dimethylsulfoxid, Kombinationen M02AX54 Campher, Kombinationen M02AX56 Alpha-Pinen, Kombinationen M02AX69 Bituminosulfonate, Kombinationen M02AX76 Bromelaine, Kombinationen M02B BALNEOTHERAPEUTISCHE ANTIRHEUMATIKA M02BA Hyperämisierende balneotherapeutische Antirheumatika M02BA04 Benzylnicotinat M02BA54 Benzylnicotinat, Kombinationen M02BA55 Campher, Kombinationen M02BB Balneotherapeutische Antirheumatika mit Salicylsäure- Derivaten M02BB02 Methylsalicylat M02BB51 Hydroxyethylsalicylat, Kombinationen M02BB52 Methylsalicylat, Kombinationen M02BB53 Monoethanolaminsalicylat, Kombinationen M02BB56 Salicylsäure, Kombinationen M02BB59 Diethylaminsalicylat, Kombinationen M02BP Pflanzliche balneotherapeutische Antirheumatika M02BP01 Fichtennadelöl M02BP02 Eukalyptusöl M02BP03 Rosmarinöl M02BP50 Kombinationen M02BP51 Fichtennadelöl, Kombinationen M02BP52 Eukalyptusöl, Kombinationen M02BP53 Rosmarinöl, Kombinationen M02BX Andere balneotherapeutische Antirheumatika M02BX01 Moor M02BX03 Fango M02BX08 Iod M02BX51 Moor, Kombinationen M02BX55 Schwefel, Kombinationen M03 MUSKELRELAXANZIEN M03A MUSKELRELAXANZIEN, PERIPHER WIRKENDE MITTEL M03AA Curare-Alkaloide M03AA01 Alcuronium M03AA02 Tubocurarin M03AA04 Dimethyltubocurarin 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 85 von 133 BEDEUTUNG DDD-INFOATC-CODE M03AB Cholin-Derivate M03AB01 Suxamethonium M03AC Andere quartäre Ammonium-Verbindungen M03AC01 Pancuronium 6,3 mg P M03AC02 Gallamin M03AC03 Vecuronium 6,3 mg P M03AC04 Atracurium 38,5 mg P M03AC05 Hexafluronium M03AC06 Pipecuroniumbromid M03AC07 Doxacuriumchlorid M03AC08 Fazadiniumbromid M03AC09 Rocuroniumbromid 42 mg P M03AC10 Mivacuriumchlorid 14 mg P M03AC11 Cisatracurium 10,5 mg P M03AX Andere Muskelrelaxanzien, peripher wirkende Mittel M03AX21 Botulinumtoxin Typ A M03AX22 Botulinumtoxin Typ B M03B MUSKELRELAXANZIEN, ZENTRAL WIRKENDE MITTEL M03BA Carbaminsäureester M03BA01 Phenprobamat 1,6 g O M03BA02 Carisoprodol 1,4 g O M03BA03 Methocarbamol 3 g O,P M03BA04 Styramat 0,5 g O M03BA05 Febarbamat 0,3 g O M03BA51 Phenprobamat, Kombinationen exkl. Psycholeptika M03BA52 Carisoprodol, Kombinationen exkl. Psycholeptika M03BA53 Methocarbamol, Kombinationen exkl. Psycholeptika M03BA57 Meprobamat, Kombinationen exkl. Psycholeptika M03BA71 Phenprobamat, Kombinationen mit Psycholeptika M03BA72 Carisoprodol, Kombinationen mit Psycholeptika M03BA73 Methocarbamol, Kombinationen mit Psycholeptika M03BB Oxazol-, Thiazin- und Triazin-Derivate M03BB02 Chlormezanon 0,6 g O M03BB03 Chlorzoxazon 1,5 g O M03BB52 Chlormezanon, Kombinationen exkl. Psycholeptika M03BB53 Chlorzoxazon, Kombinationen exkl. Psycholeptika M03BB72 Chlormezanon, Kombinationen mit Psycholeptika M03BB73 Chlorzoxazon, Kombinationen mit Psycholeptika M03BC Ether, chemisch den Antihistaminika verwandt M03BC01 Orphenadrin(citrat) 0,12 g O,P M03BC51 Orphenadrin, Kombinationen M03BX Andere zentral wirkende Mittel M03BX01 Baclofen 50 mg O; 0,55 mg P M03BX02 Tizanidin 12 mg O M03BX03 Pridinol M03BX04 Tolperison 0,2 g O M03BX05 Thiocolchicosid M03BX06 Mephenesin M03BX07 Tetrazepam 0,125 g O M03BX08 Cyclobenzaprin M03BX09 Eperison 0,15 g O M03BX30 Fenyramidol 2 g O M03BX54 Tolperison, Kombinationen M03C MUSKELRELAXANZIEN, DIREKT WIRKENDE MITTEL M03CA Dantrolen und Derivate M03CA01 Dantrolen 0,1 g O M04 GICHTMITTEL M04A GICHTMITTEL M04AA Urikostatika M04AA01 Allopurinol 0,4 g O,P M04AA02 Tisopurin M04AA03 Febuxostat 80 mg O M04AA51 Allopurinol, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 86 von 133 BEDEUTUNG DDD-INFOATC-CODE M04AB Urikosurika M04AB01 Probenecid 1 g O M04AB02 Sulfinpyrazon 0,3 g O M04AB03 Benzbromaron 0,1 g O M04AB04 Isobromindion M04AC Gichtmittel ohne Effekt auf den Harnsäuremetabolismus M04AC01 Colchicin 1 mg O,P M04AC02 Cinchophen 1 g O M04AH Homöopathische und anthroposophische Gichtmittel M04AH01 Colchicum M04AH20 Kombinationen M04AX Andere Gichtmittel M04AX01 Uratoxidase M04AX02 Pegloticase M05 MITTEL ZUR BEHANDLUNG VON KNOCHENERKRANKUNGEN M05B MITTEL MIT EINFLUSS AUF DIE KNOCHENSTRUKTUR UND DIE MINERALISATION M05BA Bisphosphonate M05BA01 Etidronsäure 0,4 g O; 1,5 g P Dosis pro Behandlungszyklus bezogen auf das Salz der Etidronsäure M05BA02 Clodronsäure 1,6 g O; 1,5 g P Dosis pro Behandlungszyklus bezogen auf das Salz der Clodronsäure M05BA03 Pamidronsäure 60 mg P Dosis pro Behandlungszyklus bezogen auf das Salz der Pamidronsäure M05BA04 Alendronsäure 10 mg O bezogen auf die Säure der Alendronsäure M05BA05 Tiludronsäure 0,4 g O bezogen auf die Säure der Tiludronsäure M05BA06 Ibandronsäure 5 mg O Osteoporose; 6 mg P Dosis pro Behandlungszyklus bei Tumor-induzierter Hyperkalzämie; 50 mg O bei Tumor-induzierter Hyperkalzämie; 33 mcg P bei Osteoporose bezogen auf die Säure der Ibandronsäure M05BA07 Risedronsäure 5 mg O Osteoporose; 30 mg O bei Morbus Paget bezogen auf das Salz der Risedronsäure M05BA08 Zoledronsäure 4 mg P Dosis pro Behandlungszyklus bei Tumor-induzierter Hyperkalzämie; 14 mcg P Osteoporose bezogen auf die Säure der Zoledronsäure M05BB Bisphosphonate, Kombinationen M05BB01 Etidronsäure und Calcium, Sequenzialpräparate 0,4 g O bezogen auf das Salz der Etidronsäure M05BB02 Risedronsäure und Calcium, Sequenzialpräparate 5 mg O bezogen auf das Salz der Risedronsäure M05BB03 Alendronsäure und Colecalciferol 10 mg O bezogen auf die Säure der Alendronsäure M05BB04 Risedronsäure, Calcium und Colecalciferol, Sequenzialpräparate 5 mg O bezogen auf das Salz der Risedronsäure M05BB05 Alendronsäure, Calcium und Colecalciferol, Sequenzialpräparate 10 mg O bezogen auf die Säure der Alendronsäure M05BB06 Alendronsäure und Alfacalcidol, Sequenzialpräparate 10 mg O bezogen auf die Säure der Alendronsäure M05BC Knochenmorphogene Proteine M05BC01 Dibotermin alfa M05BC02 Eptotermin alfa 3,3 mg P M05BX Andere Mittel mit Einfluss auf die Knochenstruktur und die Mineralisation M05BX01 Ipriflavon M05BX02 Aluminiumhydroxychlorid M05BX03 Strontium ranelat 2 g O M05BX04 Denosumab 0,33 mg P; 4,3 mg P bei Tumor-induzierter Hyperkalzämie M09 ANDERE MITTEL GEGEN STÖRUNGEN DES MUSKEL- UND SKELETTSYSTEMS M09A ANDERE MITTEL GEGEN STÖRUNGEN DES MUSKEL- UND SKELETTSYSTEMS M09AA Chinin und Derivate M09AA01 Hydrochinin 0,2 g O M09AA02 Chinin 0,2 g O M09AA52 Chinin, Kombinationen exkl. Psycholeptika M09AA72 Chinin, Kombinationen mit Psycholeptika M09AB Enzyme M09AB01 Chymopapain M09AB02 Kollagenase aus Clostridium histolyticum 0,9 mg P M09AB52 Trypsin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 87 von 133 BEDEUTUNG DDD-INFOATC-CODE M09AH Andere homöopathische und anthroposophische Zubereitungen gegen Störungen des Muskel- und Skelettsystems M09AH01 Guajacum M09AH02 Thymus M09AH03 Arnika M09AH04 Viscum album M09AH10 Verschiedene M09AH20 Kombinationen M09AH50 Kombinationen mit anderen Mitteln M09AP Andere pflanzliche Zubereitungen gegen Störungen des Muskel- und Skelettsystems M09AP03 Teufelskrallenwurzel 4,5 g O Droge M09AP04 Brennnesselblätter 10 g O Droge aus Kraut und Blättern M09AP05 Weidenrinden 90 mg O bezogen auf Gesamtsalicin M09AP06 Mistelkraut M09AP07 Guajakholz M09AP30 Kombinationen M09AX Andere Mittel gegen Störungen des Muskel- und Skelettsystems M09AX01 Hyaluronsäure 3,6 mg P intraartikulär M09AX02 Autologe Chondrozyten Standarddosis: 1 Einzeldosis P M09AX03 Nukleotide, inkl. Kombinationen M09AX04 Beta-Sitosterin M09AX07 Ademetionin M09AX08 Schwefel M09AX09 Escherichia coli M09AX10 Ribonucleinsäuren M09AX55 Gelatine, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 88 von 133 BEDEUTUNG DDD-INFOATC-CODE N NERVENSYSTEM N01 ANÄSTHETIKA N01A ALLGEMEINANÄSTHETIKA N01AA Ether N01AA01 Diethylether N01AA02 Vinylether N01AB Halogenierte Kohlenwasserstoffe N01AB01 Halothan N01AB02 Chloroform N01AB04 Enfluran N01AB05 Trichlorethylen N01AB06 Isofluran N01AB07 Desfluran N01AB08 Sevofluran N01AF Barbiturate, rein N01AF01 Methohexital N01AF02 Hexobarbital N01AF03 Thiopental N01AG Barbiturate in Kombination mit anderen Mitteln N01AG01 Narcobarbital N01AH Opioidanästhetika N01AH01 Fentanyl 0,7 mg P; 55 mcg P Kinder DDD N01AH02 Alfentanil N01AH03 Sufentanil 30 mcg P; Standarddosis: 1 Applikationsform epidural N01AH04 Phenoperidin N01AH05 Anileridin N01AH06 Remifentanil N01AH51 Fentanyl, Kombinationen N01AX Andere Allgemeinanästhetika N01AX03 Ketamin 0,25 g P N01AX04 Propanidid N01AX05 Alfaxalon N01AX07 Etomidate N01AX10 Propofol 0,14 g P N01AX11 Natriumoxybat N01AX13 Distickstoffmonoxid N01AX14 Esketamin N01AX15 Xenon N01AX63 Distickstoffmonoxid, Kombinationen N01B LOKALANÄSTHETIKA N01BA Ester der Aminobenzoesäure N01BA01 Metabutethamin Standarddosis: 1 Applikationsform P N01BA02 Procain Standarddosis: 1 Applikationsform P N01BA03 Tetracain Standarddosis: 1 Applikationsform P N01BA04 Chloroprocain Standarddosis: 1 Applikationsform P N01BA05 Benzocain Standarddosis: 1 Applikationsform P N01BA06 Oxybuprocain Standarddosis: 1 Applikationsform P N01BA52 Procain, Kombinationen Standarddosis: 1 Applikationsform P N01BA53 Tetracain, Kombinationen N01BB Amide N01BB01 Bupivacain Standarddosis: 1 Applikationsform P N01BB02 Lidocain Standarddosis: 1 Applikationsform P N01BB03 Mepivacain Standarddosis: 1 Applikationsform P N01BB04 Prilocain Standarddosis: 1 Applikationsform P N01BB05 Butanilicain Standarddosis: 1 Applikationsform P N01BB06 Cinchocain Standarddosis: 1 Applikationsform P N01BB07 Etidocain Standarddosis: 1 Applikationsform P N01BB08 Articain Standarddosis: 1 Applikationsform P N01BB09 Ropivacain Standarddosis: 1 Applikationsform P N01BB10 Levobupivacain Standarddosis: 1 Applikationsform P N01BB20 Kombinationen Standarddosis: 1 Applikationsform P N01BB51 Bupivacain, Kombinationen Standarddosis: 1 Applikationsform P N01BB52 Lidocain, Kombinationen Standarddosis: 1 Applikationsform P N01BB53 Mepivacain, Kombinationen Standarddosis: 1 Applikationsform P N01BB54 Prilocain, Kombinationen Standarddosis: 1 Applikationsform P N01BB57 Etidocain, Kombinationen Standarddosis: 1 Applikationsform P N01BB58 Articain, Kombinationen Standarddosis: 1 Applikationsform P 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 89 von 133 BEDEUTUNG DDD-INFOATC-CODE N01BC Ester der Benzoesäure N01BC01 Cocain Standarddosis: 1 Applikationsform P N01BH Homöopathische und anthroposophische Lokalanästhetika N01BH20 Kombinationen Standarddosis: 1 Applikationsform P N01BX Andere Lokalanästhetika N01BX01 Ethylchlorid Standarddosis: 1 Applikationsform P N01BX02 Dyclonin Standarddosis: 1 Applikationsform P N01BX03 Phenol Standarddosis: 1 Applikationsform P N01BX04 Capsaicin Standarddosis: 1 Applikationsform P; Standarddosis: 1 TD Pflaster N01BX05 Propipocain Standarddosis: 1 Applikationsform P N01BX06 Diphenhydramin Standarddosis: 1 Applikationsform P N01BX50 Kombinationen N02 ANALGETIKA N02A OPIOIDE N02AA Natürliche Opium-Alkaloide N02AA01 Morphin 0,1 g O; 30 mg P,R N02AA02 Opium N02AA03 Hydromorphon 20 mg O; 4 mg P,R N02AA04 Nicomorphin 30 mg O,P,R N02AA05 Oxycodon 75 mg O; 30 mg P N02AA08 Dihydrocodein 0,15 g O N02AA10 Papaveretum N02AA51 Morphin, Kombinationen N02AA55 Oxycodon, Kombinationen 75 mg O bezogen auf Oxycodon hydrochlorid, bei Kombination mit Naloxon N02AA57 Ethylmorphin, Kombinationen N02AA58 Dihydrocodein, Kombinationen N02AA59 Codein, Kombinationen exkl. Psycholeptika N02AA64 Codein in Kombination mit Propyphenazon N02AA65 Codein in Kombination mit Diclofenac N02AA66 Codein in Kombination mit Acetylsalicylsäure N02AA69 Codein in Kombination mit Paracetamol 3 g O bezogen auf Paracetamol N02AA79 Codein, Kombinationen mit Psycholeptika N02AB Phenylpiperidin-Derivate N02AB01 Ketobemidon 50 mg O,P N02AB02 Pethidin 0,4 g O,P,R N02AB03 Fentanyl 0,6 mg N,SL; 1,2 mg TD N02AB52 Pethidin, Kombinationen exkl. Psycholeptika N02AB72 Pethidin, Kombinationen mit Psycholeptika N02AC Diphenylpropylamin-Derivate N02AC01 Dextromoramid 20 mg O,P; 40 mg R N02AC03 Piritramid 45 mg P N02AC04 Dextropropoxyphen 0,2 g O Chlorid; 0,3 g O Napsylat N02AC05 Bezitramid 15 mg O N02AC06 Levomethadon N02AC52 Methadon, Kombinationen exkl. Psycholeptika N02AC54 Dextropropoxyphen, Kombinationen exkl. Psycholeptika N02AC74 Dextropropoxyphen, Kombinationen mit Psycholeptika N02AD Benzomorphan-Derivate N02AD01 Pentazocin 0,2 g O,P N02AD02 Phenazocin 3 mg P N02AE Oripavin-Derivate N02AE01 Buprenorphin 1,2 mg P,SL,TD N02AF Morphinan-Derivate N02AF01 Butorphanol 12 mg P N02AF02 Nalbufin 80 mg P N02AG Opioide in Kombination mit Spasmolytika N02AG01 Morphin mit Spasmolytika N02AG02 Ketobemidon mit Spasmolytika N02AG03 Pethidin mit Spasmolytika N02AG04 Hydromorphon mit Spasmolytika 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 90 von 133 BEDEUTUNG DDD-INFOATC-CODE N02AX Andere Opioide N02AX01 Tilidin 0,2 g O,P N02AX02 Tramadol 0,3 g O,P,R N02AX03 Dezocin N02AX05 Meptazinol 1,2 g O,P N02AX06 Tapentadol 0,4 g O N02AX51 Tilidin, Kombinationen 0,2 g O bezogen auf Tilidinhydrochlorid N02AX52 Tramadol, Kombinationen Standarddosis: 4 Applikationsformen O N02B ANDERE ANALGETIKA UND ANTIPYRETIKA N02BA Salicylsäure und Derivate N02BA01 Acetylsalicylsäure 3 g O,R; 1 g P bezogen auf Lysinacetylsalicylat; 0,3 g O Kinder DDD N02BA02 Aloxiprin 3 g O N02BA03 Cholinsalicylat 3 g O N02BA04 Natriumsalicylat 3 g O N02BA05 Salicylamid 3 g O N02BA06 Salsalat 3 g O N02BA07 Ethenzamid 3 g O N02BA08 Morpholinsalicylat N02BA09 Dipyrocetyl 3 g O N02BA10 Benorilat 3 g O N02BA11 Diflunisal 0,75 g O N02BA12 Kaliumsalicylat 7 g O N02BA13 Lysin-Acetylsalicylat 3 g O; 1 g P N02BA14 Guacetisal N02BA15 Carbasalat calcium 3,6 g O N02BA16 Imidazolsalicylat N02BA19 Cholin-Magnesium-Tris-Salicylat N02BA20 Kombinationen N02BA51 Acetylsalicylsäure, Kombinationen exkl. Psycholeptika 3 g O bezogen auf Acetylsalicylsäure N02BA55 Salicylamid, Kombinationen exkl. Psycholeptika N02BA57 Ethenzamid, Kombinationen exkl. Psycholeptika N02BA59 Dipyrocetyl, Kombinationen exkl. Psycholeptika N02BA65 Carbasalat calcium, Kombinationen exkl. Psycholeptika N02BA71 Acetylsalicylsäure, Kombinationen mit Psycholeptika N02BA75 Salicylamid, Kombinationen mit Psycholeptika N02BA77 Ethenzamid, Kombinationen mit Psycholeptika N02BA79 Dipyrocetyl, Kombinationen mit Psycholeptika N02BB Pyrazolone N02BB01 Phenazon 3 g O; 3 g R N02BB02 Metamizol-Natrium 3 g O,P,R; 0,75 g O,R Kinder DDD N02BB03 Aminophenazon 0,5 g R N02BB04 Propyphenazon 3 g R; 3 g O N02BB05 Nifenazon N02BB06 Phenazonsalicylat N02BB51 Phenazon, Kombinationen exkl. Psycholeptika 3 g O bezogen auf Phenazon N02BB52 Metamizol-Natrium, Kombinationen exkl. Psycholeptika N02BB53 Aminophenazon, Kombinationen exkl. Psycholeptika N02BB54 Propyphenazon, Kombinationen exkl. Psycholeptika N02BB56 Phenazonsalicylat, Kombinationen exkl. Psycholeptika N02BB71 Phenazon, Kombinationen mit Psycholeptika N02BB72 Metamizol-Natrium, Kombinationen mit Psycholeptika N02BB73 Aminophenazon, Kombinationen mit Psycholeptika N02BB74 Propyphenazon, Kombinationen mit Psycholeptika N02BB76 Phenazonsalicylat, Kombinationen mit Psycholeptika N02BE Anilide N02BE01 Paracetamol 3 g O,P,R; 0,75 g O Kinder DDD; 0,375 g R Säuglings DDD; 0,75 g R Kinder DDD N02BE03 Phenacetin 1,8 g O N02BE04 Bucetin N02BE05 Propacetamol 6 g P N02BE51 Paracetamol, Kombinationen exkl. Psycholeptika N02BE53 Phenacetin, Kombinationen exkl. Psycholeptika N02BE54 Bucetin, Kombinationen exkl. Psycholeptika N02BE61 Paracetamol, Kombinationen mit Coffein N02BE71 Paracetamol, Kombinationen mit Psycholeptika N02BE73 Phenacetin, Kombinationen mit Psycholeptika N02BE74 Bucetin, Kombinationen mit Psycholeptika N02BG Andere Analgetika und Antipyretika N02BG02 Rimazolium 0,9 g O N02BG03 Glafenin 0,8 g O N02BG04 Floctafenin 1 g O N02BG05 Viminol N02BG06 Nefopam N02BG07 Flupirtin 0,4 g O; 0,525 g R N02BG08 Ziconotid 12 mcg P N02BG09 Methoxyfluran N02BG10 Nabiximols 42 mg SL 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 91 von 133 BEDEUTUNG DDD-INFOATC-CODE N02BH Homöopathische und anthroposophische Analgetika und Antipyretika N02BH01 Aconitum N02BH10 Verschiedene N02BH20 Kombinationen N02BP Pflanzliche Analgetika und Antipyretika N02BP01 Blauer Eisenhut N02BP02 Lindenblüten N02C MIGRÄNEMITTEL N02CA Mutterkorn-Alkaloide N02CA01 Dihydroergotamin 1 mg N; 4 mg O,P N02CA02 Ergotamin 4 mg Inhal.Aerosol,O,P,R,SL N02CA04 Methysergid 4 mg O N02CA07 Lisurid N02CA51 Dihydroergotamin, Kombinationen N02CA52 Ergotamin, Kombinationen exkl. Psycholeptika 4 mg O bezogen auf Ergotamin N02CA71 Dihydroergotamin, Kombinationen mit Psycholeptika N02CA72 Ergotamin, Kombinationen mit Psycholeptika 4 mg O bezogen auf Ergotamin N02CB Corticosteroid-Derivate N02CB01 Flumedroxon 20 mg O N02CC Selektive Serotonin-5HT1-Agonisten N02CC01 Sumatriptan 20 mg N; 50 mg O; 6 mg P; 25 mg R N02CC02 Naratriptan 2,5 mg O N02CC03 Zolmitriptan 2,5 mg N,O N02CC04 Rizatriptan 10 mg O N02CC05 Almotriptan 12,5 mg O N02CC06 Eletriptan 40 mg O N02CC07 Frovatriptan 2,5 mg O N02CH Homöopathische und anthroposophische Migränemittel N02CH01 Pestwurz N02CH10 Verschiedene N02CH20 Kombinationen N02CP Pflanzliche Migränemittel N02CP01 Pestwurzwurzel N02CP02 Etherische Öle N02CP52 Etherische Öle, Kombinationen N02CX Andere Migränemittel N02CX01 Pizotifen 1,5 mg O N02CX02 Clonidin 0,1 mg O N02CX03 Iprazochrom 24 mg O N02CX05 Dimetotiazin N02CX06 Oxetoron N02CX11 Natriumpangamat N02CX12 Topiramat 0,1 g O N02CX57 Paracetamol, Kombinationen N02CX58 Codein, Kombinationen N02CX59 Metoclopramid, Kombinationen N03 ANTIEPILEPTIKA N03A ANTIEPILEPTIKA N03AA Barbiturate und Derivate N03AA01 Methylphenobarbital 0,5 g O N03AA02 Phenobarbital 0,1 g O,P N03AA03 Primidon 1,25 g O N03AA04 Barbexaclon N03AA05 Cathin-Phenobarbital N03AA30 Metharbital 0,2 g O N03AB Hydantoin-Derivate N03AB01 Ethotoin 2,5 g O N03AB02 Phenytoin 0,3 g O,P N03AB03 Amino(diphenylhydantoin)valeriansäure 0,3 g O N03AB04 Mephenytoin 0,4 g O N03AB05 Fosphenytoin 0,45 g P N03AB52 Phenytoin, Kombinationen N03AB54 Mephenytoin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 92 von 133 BEDEUTUNG DDD-INFOATC-CODE N03AC Oxazolidin-Derivate N03AC01 Paramethadion 0,9 g O N03AC02 Trimethadion 1,5 g O N03AC03 Ethadion N03AD Succinimid-Derivate N03AD01 Ethosuximid 1,25 g O N03AD02 Phensuximid 2 g O N03AD03 Mesuximid 0,9 g O N03AD51 Ethosuximid, Kombinationen N03AE Benzodiazepin-Derivate N03AE01 Clonazepam 8 mg O,P; 3 mg O Kinder DDD N03AE02 Midazolam 7,5 mg SL Kinder DDD N03AF Carboxamid-Derivate N03AF01 Carbamazepin 1 g O,R N03AF02 Oxcarbazepin 1 g O N03AF03 Rufinamid 1,4 g O N03AF04 Eslicarbazepin 0,8 g O N03AG Fettsäure-Derivate N03AG01 Valproinsäure 1,5 g O,P,R N03AG02 Valpromid 1,5 g O N03AG03 Aminobuttersäure 1 g O,P N03AG04 Vigabatrin 2 g O N03AG05 Progabid N03AG06 Tiagabin 30 mg O N03AX Andere Antiepileptika N03AX03 Sultiam 0,4 g O N03AX07 Phenacemid 1,5 g O N03AX09 Lamotrigin 0,3 g O N03AX10 Felbamat 2,4 g O N03AX11 Topiramat 0,3 g O N03AX12 Gabapentin 1,8 g O N03AX13 Pheneturid N03AX14 Levetiracetam 1,5 g O,P N03AX15 Zonisamid 0,4 g O N03AX16 Pregabalin 0,3 g O N03AX17 Stiripentol 1 g O N03AX18 Lacosamid 0,3 g O,P N03AX19 Carisbamat N03AX21 Retigabin 0,9 g O N03AX22 Perampanel 8 mg O N03AX23 Kaliumbromid N03AX30 Beclamid N04 ANTIPARKINSONMITTEL N04A ANTICHOLINERGIKA N04AA Tertiäre Amine N04AA01 Trihexyphenidyl 10 mg O N04AA02 Biperiden 10 mg O,P N04AA03 Metixen 40 mg O N04AA04 Procyclidin 25 mg O,P N04AA05 Profenamin N04AA08 Dexetimid 0,5 mg O; 0,125 mg P N04AA09 Phenglutarimid N04AA10 Mazaticol N04AA11 Bornaprin N04AA12 Tropatepin N04AA13 Triperiden N04AA14 Pridinol N04AB Ether, chemisch den Antihistaminika verwandt N04AB01 Etanautin N04AB02 Orphenadrin(chlorid) 0,2 g O,P N04AC Tropinether oder Tropin-Derivate N04AC01 Benzatropin 2 mg O,P N04AC30 Etybenzatropin 9 mg O N04AH Homöopathische und anthroposophische Antiparkinsonmittel N04AH20 Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 93 von 133 BEDEUTUNG DDD-INFOATC-CODE N04B DOPAMINERGE MITTEL N04BA Dopa und Dopa-Derivate N04BA01 Levodopa 3,5 g O N04BA03 Levodopa, Decarboxylasehemmer und COMT-Hemmer 0,45 g O bezogen auf Levodopa N04BA04 Melevodopa N04BA05 Melevodopa und Decarboxylasehemmer N04BA06 Etilevodopa und Decarboxylasehemmer N04BA10 Levodopa in Kombination mit Carbidopa 0,6 g O bezogen auf Levodopa N04BA11 Levodopa in Kombination mit Benserazid 0,6 g O bezogen auf Levodopa N04BB Adamantan-Derivate N04BB01 Amantadin 0,2 g O; 0,2 g P N04BC Dopamin-Agonisten N04BC01 Bromocriptin 40 mg O N04BC02 Pergolid 3 mg O N04BC03 Dihydroergocryptinmesilat N04BC04 Ropinirol 6 mg O N04BC05 Pramipexol 2,5 mg O Hydrochlorid N04BC06 Cabergolin 3 mg O N04BC07 Apomorphin 20 mg P N04BC08 Piribedil 0,2 g O N04BC09 Rotigotin 6 mg TD Pflaster N04BC10 Lisurid 1,3 mg O N04BD Monoaminoxidase-B-Hemmer N04BD01 Selegilin 5 mg O N04BD02 Rasagilin 1 mg O N04BX Andere dopaminerge Mittel N04BX01 Tolcapon 0,45 g O N04BX02 Entacapon 1 g O N04BX03 Budipin N04BX06 Ethylbenzhydramin N05 PSYCHOLEPTIKA N05A ANTIPSYCHOTIKA N05AA Phenothiazine mit aliphatischer Seitenkette N05AA01 Chlorpromazin 0,3 g O,R; 0,1 g P N05AA02 Levomepromazin 0,3 g O; 0,1 g P N05AA03 Promazin 0,3 g O; 0,1 g P N05AA04 Acepromazin 0,1 g O; 50 mg P N05AA05 Triflupromazin 0,1 g O,P N05AA06 Cyamemazin N05AA07 Chlorproethazin N05AB Phenothiazine mit Piperazinstruktur N05AB01 Dixyrazin 50 mg O; 30 mg P N05AB02 Fluphenazin 10 mg O; 1 mg P Depot N05AB03 Perphenazin 30 mg O; 10 mg P; 7 mg P Depot; 16 mg R N05AB04 Prochlorperazin 0,1 g O,R; 50 mg P N05AB05 Thiopropazat 60 mg O N05AB06 Trifluoperazin 20 mg O,R; 8 mg P N05AB07 Acetophenazin 50 mg O N05AB08 Thioproperazin 75 mg O; 20 mg P N05AB09 Butaperazin 10 mg O N05AB10 Perazin 0,1 g O,P N05AB13 Metofenazat N05AC Phenothiazine mit Piperidinstruktur N05AC01 Periciazin 50 mg O; 20 mg P N05AC02 Thioridazin 0,3 g O N05AC03 Mesoridazin 0,2 g O,P N05AC04 Pipotiazin 10 mg O; 5 mg P Depot N05AD Butyrophenon-Derivate N05AD01 Haloperidol 8 mg O,P; 3,3 mg P Depot N05AD02 Trifluperidol 2 mg O N05AD03 Melperon 0,3 g O,P N05AD04 Moperon 20 mg O,P N05AD05 Pipamperon 0,2 g O N05AD06 Bromperidol 10 mg O,P; 3,3 mg P Depot N05AD07 Benperidol 1,5 mg O; 1,5 mg P N05AD08 Droperidol 2,5 mg P N05AD09 Fluanison 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 94 von 133 BEDEUTUNG DDD-INFOATC-CODE N05AE Indol-Derivate N05AE01 Oxypertin 0,12 g O N05AE02 Molindon 50 mg O N05AE03 Sertindol 16 mg O N05AE04 Ziprasidon 80 mg O; 40 mg P N05AE05 Lurasidon N05AF Thioxanthen-Derivate N05AF01 Flupentixol 6 mg O; 4 mg P Depot N05AF02 Clopenthixol 0,1 g O,P N05AF03 Chlorprothixen 0,3 g O; 50 mg P N05AF04 Tiotixen 30 mg O N05AF05 Zuclopenthixol 30 mg O,P; 15 mg P Depot N05AG Diphenylbutylpiperidin-Derivate N05AG01 Fluspirilen 0,7 mg P Depot N05AG02 Pimozid 4 mg O N05AG03 Penfluridol 6 mg O N05AH Diazepine, Oxazepine, Thiazepine und Oxepine N05AH01 Loxapin 0,1 g O N05AH02 Clozapin 0,3 g O,P N05AH03 Olanzapin 10 mg O,P; 10 mg P Depot N05AH04 Quetiapin 0,4 g O N05AH05 Asenapin 20 mg O N05AH06 Clotiapin 80 mg O,P N05AL Benzamide N05AL01 Sulpirid 0,8 g O,P N05AL02 Sultoprid 1,2 g O N05AL03 Tiaprid 0,4 g O,P N05AL04 Remoxiprid 0,3 g O,P N05AL05 Amisulprid 0,4 g O N05AL06 Veraliprid N05AL07 Levosulpirid 0,4 g O N05AN Lithium N05AN01 Lithium 24 mmol O N05AX Andere Antipsychotika N05AX07 Prothipendyl 0,24 g O,P N05AX08 Risperidon 5 mg O; 2,7 mg P Depot N05AX10 Mosapramin N05AX11 Zotepin 0,2 g O N05AX12 Aripiprazol 15 mg O,P N05AX13 Paliperidon 6 mg O; 2,5 mg P Depot, bezogen auf Paliperidon N05AX14 Iloperidon N05AX15 Reserpin N05B ANXIOLYTIKA N05BA Benzodiazepin-Derivate N05BA01 Diazepam 10 mg O,P,R N05BA02 Chlordiazepoxid 30 mg O; 50 mg P N05BA03 Medazepam 20 mg O N05BA04 Oxazepam 50 mg O; 50 mg R N05BA05 Dikaliumclorazepat 20 mg O N05BA06 Lorazepam 2,5 mg O,P,SL N05BA07 Adinazolam N05BA08 Bromazepam 10 mg O N05BA09 Clobazam 20 mg O N05BA10 Ketazolam N05BA11 Prazepam 30 mg O N05BA12 Alprazolam 1 mg O N05BA13 Halazepam 0,1 g O N05BA14 Pinazepam N05BA15 Camazepam 30 mg O N05BA16 Nordazepam 15 mg O N05BA17 Fludiazepam 0,75 mg O N05BA18 Ethylloflazepat 2 mg O N05BA19 Etizolam N05BA21 Clotiazepam N05BA22 Cloxazolam N05BA23 Tofisopam N05BA24 Metaclazepam N05BA26 Oxazolam N05BA56 Lorazepam, Kombinationen N05BB Diphenylmethan-Derivate N05BB01 Hydroxyzin 75 mg O,P N05BB02 Captodiam 0,2 g O N05BB51 Hydroxyzin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 95 von 133 BEDEUTUNG DDD-INFOATC-CODE N05BC Carbamate N05BC01 Meprobamat 1,2 g O N05BC03 Emylcamat 0,9 g O N05BC04 Mebutamat N05BC51 Meprobamat, Kombinationen N05BD Dibenzo-bicyclo-octadien-Derivate N05BD01 Benzoctamin 30 mg O,P N05BE Azaspirodecandion-Derivate N05BE01 Buspiron 30 mg O N05BP Pflanzliche Anxiolytika N05BP02 Kava-Kava-Wurzelstock 90 mg O Kavapyrone N05BX Andere Anxiolytika N05BX01 Mephenoxalon 1,2 g O N05BX02 Gedocarnil N05BX03 Etifoxin N05BX05 Kavain N05C HYPNOTIKA UND SEDATIVA N05CA Barbiturate, rein N05CA01 Pentobarbital 0,1 g O,P,R N05CA02 Amobarbital 0,1 g O,P N05CA03 Butobarbital 0,15 g O N05CA04 Barbital 0,5 g O N05CA05 Aprobarbital 0,1 g O,P N05CA06 Secobarbital 0,1 g O N05CA07 Talbutal 0,1 g O N05CA08 Vinylbital 0,15 g O N05CA09 Vinbarbital 0,1 g O N05CA10 Cyclobarbital 0,2 g O N05CA11 Heptabarbital 0,2 g O N05CA12 Reposal 0,2 g O N05CA15 Methohexital N05CA16 Hexobarbital 0,25 g O N05CA19 Thiopental N05CA20 Etallobarbital N05CA21 Allobarbital N05CA22 Proxibarbal N05CA23 Crotylbarbital N05CA24 Phenobarbital N05CA25 Propallylonal N05CA26 Bromallylmethylbutylbarbitursäure N05CB Barbiturate, Kombinationen N05CB01 Kombinationen von Barbituraten N05CB02 Barbiturate in Kombination mit anderen Mitteln N05CC Aldehyde und Derivate N05CC01 Chloralhydrat 1 g O,R N05CC02 Chloralodol 1,6 g O N05CC03 Acetylglycinamidchloralhydrat 1,7 g O N05CC04 Dichloralphenazon 1,3 g O N05CC05 Paraldehyd 5 g O,P,R N05CD Benzodiazepin-Derivate N05CD01 Flurazepam 30 mg O N05CD02 Nitrazepam 5 mg O N05CD03 Flunitrazepam 1 mg O,P N05CD04 Estazolam 3 mg O N05CD05 Triazolam 0,25 mg O; 0,2 mg SL N05CD06 Lormetazepam 1 mg O; 1 mg P N05CD07 Temazepam 20 mg O N05CD08 Midazolam 15 mg O,P N05CD09 Brotizolam 0,25 mg O N05CD10 Quazepam 15 mg O N05CD11 Loprazolam 1 mg O N05CD12 Doxefazepam N05CD13 Cinolazepam N05CE Piperidindion-Derivate N05CE01 Glutethimid 0,25 g O N05CE02 Methyprylon 0,2 g O N05CE03 Pyrithyldion 0,2 g O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 96 von 133 BEDEUTUNG DDD-INFOATC-CODE N05CF Benzodiazepin-verwandte Mittel N05CF01 Zopiclon 7,5 mg O N05CF02 Zolpidem 10 mg O; 10 mg SL N05CF03 Zaleplon 10 mg O N05CF04 Eszopiclon N05CH Melatonin-Rezeptor-Agonisten N05CH01 Melatonin 2 mg O N05CH02 Ramelteon N05CM Andere Hypnotika und Sedativa N05CM01 Methaqualon 0,2 g O N05CM02 Clomethiazol 1,5 g O,P N05CM03 Bromisoval 0,6 g O N05CM04 Carbromal 1 g O N05CM05 Scopolamin 0,9 mg O,P N05CM06 Propiomazin 25 mg O N05CM07 Triclofos 1 g O N05CM08 Ethchlorvynol 0,5 g O N05CM10 Hexapropymate 0,4 g O N05CM11 Bromide N05CM12 Apronal 0,25 g O N05CM13 Valnoctamid 0,6 g O N05CM15 Methylpentynol N05CM16 Niaprazin N05CM18 Dexmedetomidin 1 mg P N05CM20 Diphenhydramin 50 mg O N05CM21 Doxylamin 37,5 mg O N05CM22 Promethazin 75 mg O,P N05CM25 Magnesiumaspartathydrobromid N05CM26 Magnesiumglutamathydrobromid N05CP Pflanzliche Hypnotika und Sedativa N05CP01 Baldrianwurzel 7 g O Droge; 6,5 ml O Tinktur N05CP02 Kava-Kava-Wurzelstock 90 mg O Kavapyrone N05CP03 Johanniskraut N05CP04 Melissenkraut N05CP05 Passionsblumenkraut N05CP06 Baldrianöl N05CP07 Hopfen N05CP08 Lavendel N05CP30 Kombinationen N05CP50 Andere pflanzliche Hypnotika und Sedativa, Kombinationen N05CP51 Baldrianwurzel, Kombinationen N05CP52 Kava-Kava-Wurzelstock, Kombinationen N05CX Hypnotika und Sedativa in Kombination, exkl. Barbiturate N05CX01 Meprobamat, Kombinationen N05CX02 Methaqualon, Kombinationen N05CX03 Methylpentynol, Kombinationen N05CX04 Clomethiazol, Kombinationen N05CX05 Emepronium, Kombinationen N05CX06 Dipiperonylaminoethanol, Kombinationen N05CX07 Diphenhydramin, Kombinationen N05CX08 Carbromal, Kombinationen N05CX09 Bromisoval, Kombinationen N05CX11 Chloralhydrat, Kombinationen N05CX13 Promethazin, Kombinationen N05H HOMÖOPATHISCHE UND ANTHROPOSOPHISCHE PSYCHOLEPTIKA N05HH Homöopathische und anthroposophische Hypnotika und Sedativa N05HH10 Verschiedene N05HH20 Kombinationen N05HH50 Kombinationen mit anderen Mitteln N06 PSYCHOANALEPTIKA N06A ANTIDEPRESSIVA N06AA Nichtselektive Monoamin-Wiederaufnahmehemmer N06AA01 Desipramin 0,1 g O N06AA02 Imipramin 0,1 g O,P N06AA03 Imipraminoxid 0,1 g O N06AA04 Clomipramin 0,1 g O,P N06AA05 Opipramol 0,15 g O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 97 von 133 BEDEUTUNG DDD-INFOATC-CODE N06AA06 Trimipramin 0,15 g O,P N06AA07 Lofepramin 0,105 g O N06AA08 Dibenzepin 0,3 g O N06AA09 Amitriptylin 75 mg O,P N06AA10 Nortriptylin 75 mg O; 30 mg P N06AA11 Protriptylin 30 mg O N06AA12 Doxepin 0,1 g O,P N06AA13 Iprindol 90 mg O N06AA14 Melitracen 75 mg O,P N06AA15 Butriptylin 75 mg O N06AA16 Dosulepin 0,15 g O N06AA17 Amoxapin 0,15 g O N06AA18 Dimetacrin 0,15 g O N06AA19 Amineptin N06AA20 Noxiptilin N06AA21 Maprotilin 0,1 g O,P N06AA23 Quinupramin N06AA25 Amitriptylinoxid 75 mg O,P N06AB Selektive Serotonin-Wiederaufnahmehemmer N06AB02 Zimeldin 0,2 g O N06AB03 Fluoxetin 20 mg O N06AB04 Citalopram 20 mg O,P N06AB05 Paroxetin 20 mg O N06AB06 Sertralin 50 mg O N06AB07 Alaproclat N06AB08 Fluvoxamin 0,1 g O N06AB09 Etoperidon N06AB10 Escitalopram 10 mg O N06AF Monoaminoxidasehemmer, nichtselektiv N06AF01 Isocarboxazid 15 mg O N06AF02 Nialamid 0,1 g O N06AF03 Phenelzin 60 mg O N06AF04 Tranylcypromin 10 mg O N06AF05 Iproniazid N06AF06 Iproclozid N06AG Monoaminoxidase-A-Hemmer N06AG02 Moclobemid 0,3 g O N06AG03 Toloxaton N06AH Homöopathische und anthroposophische Antidepressiva N06AH01 Hypericum N06AH10 Verschiedene N06AP Pflanzliche Antidepressiva N06AP01 Johanniskraut 3 g O Droge N06AP51 Johanniskraut, Kombinationen N06AX Andere Antidepressiva N06AX01 Oxitriptan N06AX02 Tryptophan 1 g O Schlafstörungen N06AX03 Mianserin 60 mg O N06AX04 Nomifensin 0,15 g O N06AX05 Trazodon 0,3 g O N06AX06 Nefazodon 0,4 g O N06AX07 Minaprin 0,1 g O N06AX08 Bifemelan N06AX09 Viloxazin 0,2 g O N06AX10 Oxaflozan N06AX11 Mirtazapin 30 mg O N06AX12 Bupropion 0,15 g O N06AX13 Medifoxamin N06AX14 Tianeptin 37,5 mg O N06AX15 Pivagabin N06AX16 Venlafaxin 0,1 g O N06AX17 Milnacipran 0,1 g O N06AX18 Reboxetin 8 mg O N06AX19 Gepiron N06AX21 Duloxetin 60 mg O N06AX22 Agomelatin 25 mg O N06AX23 Desvenlafaxin 50 mg O N06AX24 Vilazodon N06AX26 Pipofezin N06B PSYCHOSTIMULANZIEN, MITTEL FÜR DIE ADHD UND NOOTROPIKA N06BA Zentral wirkende Sympathomimetika N06BA01 Amfetamin 15 mg O,P N06BA02 Dexamfetamin 15 mg O N06BA03 Metamfetamin 15 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 98 von 133 BEDEUTUNG DDD-INFOATC-CODE N06BA04 Methylphenidat 30 mg O Kinder DDD; 40 mg O N06BA05 Pemolin 40 mg O N06BA06 Fencamfamin N06BA07 Modafinil 0,3 g O N06BA08 Fenozolon N06BA09 Atomoxetin 80 mg O N06BA10 Fenetyllin N06BA11 Dexmethylphenidat N06BA12 Lisdexamfetamin 30 mg O N06BA13 Amfetaminil N06BA14 Mesocarb N06BC Xanthin-Derivate N06BC01 Coffein 0,4 g O,P; 6 mg O,P Säuglings DDD bezogen auf Coffeincitrat N06BC02 Propentofyllin N06BX Andere Psychostimulanzien und Nootropika N06BX01 Meclofenoxat 1 g O,P N06BX02 Pyritinol 0,6 g O N06BX03 Piracetam 2,4 g O; 6 g P N06BX04 Deanol N06BX05 Fipexid N06BX06 Citicolin N06BX07 Oxiracetam N06BX08 Pirisudanol N06BX09 Linopirdin N06BX10 Nizofenon N06BX11 Aniracetam N06BX12 Acetylcarnitin N06BX13 Idebenon N06BX14 Prolintan N06BX15 Pipradrol 30 mg O N06BX16 Pramiracetam N06BX17 Adrafinil N06BX18 Vinpocetin 15 mg O N06BX54 Deanol, Kombinationen N06BX64 Prolintan, Kombinationen N06C PSYCHOLEPTIKA UND PSYCHOANALEPTIKA IN KOMBINATION N06CA Antidepressiva in Kombination mit Psycholeptika N06CA01 Amitriptylin und Psycholeptika N06CA02 Melitracen und Psycholeptika N06CA03 Fluoxetin und Psycholeptika N06CA04 Oxitriptan und Psycholeptika N06CA05 Nomifensin und Psycholeptika N06CA06 Nortriptylin und Psycholeptika N06CA07 Tranylcypromin und Psycholeptika N06CA10 Dosulepin und Psycholeptika N06CB Psychostimulanzien in Kombination mit Psycholeptika N06D ANTIDEMENTIVA N06DA Cholinesterasehemmer N06DA01 Tacrin 0,12 g O N06DA02 Donepezil 7,5 mg O N06DA03 Rivastigmin 9 mg O; 9,5 mg TD Freisetzungsrate N06DA04 Galantamin 16 mg O N06DA52 Donepezil und Memantin N06DP Pflanzliche Antidementiva N06DP01 Ginkgo-biloba-Blätter-Trockenextrakt 0,18 g O N06DX Andere Antidementiva N06DX01 Memantin 20 mg O N06DX07 Dihydroergotoxin 3 mg O,P N06DX08 Viquidil N06DX09 Vincamin 60 mg O N06DX10 Kälberblutextrakt, inkl. Kombinationen N06DX11 Bencyclan N06DX12 Cinnarizin 0,15 g O N06DX13 Nicergolin 30 mg O N06DX14 Cyclandelat 0,6 g O N06DX15 Xantinolnicotinat 0,9 g O,P N06DX16 Pentifyllin N06DX17 Nicotinylalkohol (Pyridylcarbinol) 0,3 g O,P N06DX18 Nimodipin 0,3 g O; 50 mg P N06DX19 Dihydroergocristin 3 mg O,P N06DX20 Organextrakte 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 99 von 133 BEDEUTUNG DDD-INFOATC-CODE N06DX57 Dihydroergotoxin, Kombinationen N06DX66 Pentifyllin, Kombinationen N07 ANDERE MITTEL FÜR DAS NERVENSYSTEM N07A PARASYMPATHOMIMETIKA N07AA Cholinesterasehemmer N07AA01 Neostigmin 60 mg O; 2 mg P N07AA02 Pyridostigmin 0,18 g O; 10 mg P N07AA03 Distigmin 5 mg O; 0,25 mg P N07AA30 Ambenonium 60 mg O N07AA51 Neostigmin, Kombinationen N07AB Cholinester N07AB01 Carbachol 6 mg O; 0,5 mg P N07AB02 Bethanechol 45 mg O N07AB03 Acetylcholin N07AX Andere Parasympathomimetika N07AX01 Pilocarpin 15 mg O; 10 mg P N07AX02 Cholinalfoscerat N07AX03 Cevimelin 90 mg O N07B MITTEL ZUR BEHANDLUNG VON SUCHTERKRANKUNGEN N07BA Mittel zur Behandlung der Nikotinabhängigkeit N07BA01 Nicotin 60 mg Inhalation; 30 mg Kaugummi,N,SL; 14 mg TD; 30 mg Lutschtabletten N07BA02 Bupropion 0,3 g O N07BA03 Vareniclin 2 mg O N07BA04 Cytisin N07BB Mittel zur Behandlung der Alkoholabhängigkeit N07BB01 Disulfiram 0,2 g O N07BB02 Calcium carbimid N07BB03 Acamprosat 2 g O N07BB04 Naltrexon 50 mg O N07BB05 Nitrefazol N07BB06 Clonidin N07BC Mittel zur Behandlung der Opiatabhängigkeit N07BC01 Buprenorphin 8 mg SL N07BC02 Methadon 25 mg O,P N07BC03 Levacetylmethadol N07BC04 Lofexidin 1,4 mg O N07BC05 Levomethadon N07BC06 Diamorphin N07BC51 Buprenorphin, Kombinationen 8 mg SL bezogen auf Buprenorphin N07C ANTIVERTIGINOSA N07CA Antivertiginosa N07CA01 Betahistin 24 mg O N07CA02 Cinnarizin 90 mg O N07CA03 Flunarizin 10 mg O N07CA04 Acetylleucin N07CA05 Sulpirid 0,225 g O; 0,2 g P N07CA52 Cinnarizin, Kombinationen 90 mg O bezogen auf Cinnarizin N07CH Homöopathische und anthroposophische Antivertigonosa N07CH20 Kombinationen N07X ANDERE MITTEL FÜR DAS NERVENSYSTEM N07XA Ganglioside und Gangliosid-Derivate N07XA01 Gangliosidgemisch N07XB Neuropathiepräparate N07XB01 Alpha-Liponsäure (Thioctsäure) 0,5 g O,P N07XB52 Thiamin, Kombinationen N07XB54 Uridinphosphat, Kombinationen N07XB56 Benfotiamin, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 100 von 133 BEDEUTUNG DDD-INFOATC-CODE N07XH Andere homöopathische und anthroposophische Mittel für das Nervensystem N07XH20 Kombinationen N07XX Andere Mittel für das Nervensystem N07XX01 Tirilazad 0,42 g P N07XX02 Riluzol 0,1 g O N07XX03 Xaliproden N07XX04 Natriumoxybat 7,5 g O N07XX05 Amifampridin 40 mg O N07XX06 Tetrabenazin 0,1 g O N07XX07 Fampridin 20 mg O N07XX08 Tafamidis 20 mg O N07XX09 Dimethyl fumarat N07XX59 Dextromethorphan, Kombinationen 40 mg O bezogen auf Dextromethorphan 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 101 von 133 BEDEUTUNG DDD-INFOATC-CODE P ANTIPARASITÄRE MITTEL, INSEKTIZIDE UND REPELLENZIEN P01 MITTEL GEGEN PROTOZOEN- ERKRANKUNGEN P01A MITTEL GEGEN AMÖBEN UND ANDERE PROTOZOEN-ERKRANKUNGEN P01AA Hydroxychinolin-Derivate P01AA01 Broxychinolin P01AA02 Clioquinol P01AA04 Chlorquinaldol P01AA05 Tilbroquinol P01AA52 Clioquinol, Kombinationen P01AB Nitroimidazol-Derivate P01AB01 Metronidazol 2 g O,R P01AB02 Tinidazol 2 g O,R P01AB03 Ornidazol 1,5 g O P01AB04 Azanidazol P01AB05 Propenidazol P01AB06 Nimorazol 2 g O P01AB07 Secnidazol P01AC Dichloracetamid-Derivate P01AC01 Diloxanid 1,5 g O P01AC02 Clefamid P01AC03 Etofamid P01AC04 Teclosan P01AR Arsen-haltige Verbindungen P01AR01 Arsthinol P01AR02 Difetarson P01AR03 Glycobiarsol P01AR53 Glycobiarsol, Kombinationen P01AX Andere Mittel gegen Amöbiasis und andere Protozoen- Erkrankungen P01AX01 Chiniofon P01AX02 Emetin 60 mg P P01AX04 Phanquinon P01AX05 Mepacrin 0,3 g O P01AX06 Atovaquon 2,25 g O P01AX07 Trimetrexat 85 mg P P01AX08 Tenonitrozol P01AX09 Dehydroemetin 60 mg P P01AX10 Fumagillin P01AX11 Nitazoxanid 1 g O P01AX52 Emetin, Kombinationen P01B MALARIAMITTEL P01BA Aminochinoline P01BA01 Chloroquin 0,5 g O,P Base P01BA02 Hydroxychloroquin 0,516 g O Base P01BA03 Primaquin 15 mg O Base P01BA06 Amodiaquin 0,5 g O P01BB Biguanide P01BB01 Proguanil 0,2 g O Hydrochlorid, (prophylaktische Tagesdosis) P01BB02 Cycloguanilembonat P01BB51 Proguanil, Kombinationen 0,4 g Proguanilhydrochlorid und 1 g Atovaquon zur Therapie; 0,1 g Proguanilhydrochlorid und 0,25 g Atovaquon zur Prophylaxe; 0,05 g Proguanilhydrochlorid und 0,125 g Atovaquon Kinder DDD zur Prophylaxe P01BC Methanolchinoline P01BC01 Chinin 1,5 g O,P Base P01BC02 Mefloquin 1 g O Base P01BD Diaminopyrimidine P01BD01 Pyrimethamin 75 mg O P01BD51 Pyrimethamin, Kombinationen 75 mg O bezogen auf Pyrimethamin 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 102 von 133 BEDEUTUNG DDD-INFOATC-CODE P01BE Artemisinin und Derivate, rein P01BE01 Artemisinin 1 g O P01BE02 Artemether 0,28 g O; 0,12 g P P01BE03 Artesunat 0,28 g O P01BE04 Artemotil P01BE05 Artenimol (Dihydroartemisinin) 0,28 g O P01BF Artemisinin und Derivate, Kombinationen P01BF01 Artemether und Lumefantrin P01BF02 Artesunat und Mefloquin P01BF03 Artesunat und Amodiaquin P01BF04 Artesunat, Sulfamethopyrazin und Pyrimethamin P01BF05 Artenimol (Dihydroartemisinin) und Piperaquin P01BF06 Artesunat und Pyronaridin P01BX Andere Malariamittel P01BX01 Halofantrin 1,5 g O P01C MITTEL GEGEN LEISHMANIASIS UND TRYPANOSOMIASIS P01CA Nitroimidazol-Derivate P01CA02 Benznidazol 0,4 g O P01CB Antimon-haltige Verbindungen P01CB01 Megluminantimonat 0,85 g P Sb5+ P01CB02 Natriumstibogluconat 0,85 g P Sb5+ P01CC Nitrofuran-Derivate P01CC01 Nifurtimox 0,7 g O P01CC02 Nitrofural P01CD Arsen-haltige Verbindungen P01CD01 Melarsoprol 60 mg P P01CD02 Acetarsol P01CX Andere Mittel gegen Leishmaniasis und Trypanosomiasis P01CX01 Pentamidindiisetionat 0,28 g P je Injektion P01CX02 Suramin natrium 0,27 g P P01CX03 Eflornithin P01CX04 Miltefosin P02 ANTHELMINTIKA P02B TREMATODENMITTEL P02BA Chinolin-Derivate und verwandte Substanzen P02BA01 Praziquantel 3 g O P02BA02 Oxamniquin 1 g O P02BB Organophosphat-Verbindungen P02BB01 Metrifonat 40 mg O P02BX Andere Trematodenmittel P02BX01 Bithionol P02BX02 Niridazol P02BX03 Stibophen P02BX04 Triclabendazol P02C NEMATODENMITTEL P02CA Benzimidazol-Derivate P02CA01 Mebendazol 0,2 g O P02CA02 Tiabendazol 3 g O P02CA03 Albendazol 0,8 g O P02CA04 Ciclobendazol P02CA05 Flubendazol 0,2 g O P02CA06 Fenbendazol P02CA51 Mebendazol, Kombinationen P02CB Piperazin und Derivate P02CB01 Piperazin 3,5 g O als Hydrat P02CB02 Diethylcarbamazin 0,4 g O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 103 von 133 BEDEUTUNG DDD-INFOATC-CODE P02CC Tetrahydropyrimidin-Derivate P02CC01 Pyrantel 0,75 g O P02CC02 Oxantel P02CE Imidazothiazol-Derivate P02CE01 Levamisol 0,15 g O P02CF Avermektine P02CF01 Ivermectin 12 mg O P02CX Andere Nematodenmittel P02CX01 Pyrvinium 0,35 g O bezogen auf die Base P02CX02 Bephenium P02CX50 Andere Nematodenmittel, Kombinationen P02D BANDWURMMITTEL P02DA Salicylsäure-Derivate P02DA01 Niclosamid 2 g O P02DX Andere Bandwurmmittel P02DX01 Desaspidin P02DX02 Dichlorophen P03 MITTEL GEGEN EKTOPARASITEN, INKL. ANTISCABIOSA, INSEKTIZIDE UND REPELLENZIEN P03A MITTEL GEGEN EKTOPARASITEN, INKL. ANTISCABIOSA P03AA Schwefel-haltige Mittel P03AA01 Dixanthogen P03AA02 Kaliumpolysulfid P03AA03 Mesulfen P03AA04 Disulfiram P03AA05 Thiram P03AA54 Disulfiram, Kombinationen P03AB Chlor-haltige Mittel P03AB01 Clofenotan P03AB02 Lindan P03AB51 Clofenotan, Kombinationen P03AC Pyrethrine, inkl. synthetische Verbindungen P03AC02 Bioallethrin P03AC03 Phenothrin P03AC04 Permethrin P03AC52 Bioallethrin, Kombinationen P03AC53 Phenothrin, Kombinationen P03AC54 Permethrin, Kombinationen P03AP Pflanzliche Mittel gegen Ektoparasiten P03AP01 Pyrethrum P03AP02 Quassia P03AP10 Verschiedene P03AP51 Pyrethrum, Kombinationen P03AX Andere Mittel gegen Ektoparasiten, inkl. Antiscabiosa P03AX01 Benzylbenzoat P03AX02 Kupferoleat P03AX03 Malathion P03AX05 Dimeticon P03AX10 Verschiedene P03B INSEKTIZIDE UND REPELLENZIEN P03BA Pyrethrine P03BA01 Cyfluthrin P03BA02 Cypermethrin P03BA03 Decamethrin P03BA04 Tetramethrin 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 104 von 133 BEDEUTUNG DDD-INFOATC-CODE P03BX Andere Insektizide und Repellenzien P03BX01 Diethyltoluamid P03BX02 Dimethylphthalat P03BX03 Dibutylphthalat P03BX04 Dibutylsuccinat P03BX05 Dimethylcarbat P03BX06 Etohexadiol 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 105 von 133 BEDEUTUNG DDD-INFOATC-CODE R RESPIRATIONSTRAKT R01 RHINOLOGIKA R01A DEKONGESTIVA UND ANDERE RHINOLOGIKA ZUR TOPISCHEN ANWENDUNG R01AA Sympathomimetika, rein R01AA02 Cyclopentamin R01AA03 Ephedrin 8 mg N R01AA04 Phenylephrin 4 mg N R01AA05 Oxymetazolin 0,4 mg N R01AA06 Tetryzolin 0,8 mg N R01AA07 Xylometazolin 0,8 mg N; 0,175 mg N Kinder DDD R01AA08 Naphazolin 0,4 mg N R01AA09 Tramazolin R01AA10 Metizolin R01AA11 Tuaminoheptan R01AA12 Fenoxazolin R01AA13 Tymazolin R01AA14 Epinephrin R01AA15 Amidefrin R01AA18 Indanazolin R01AB Sympathomimetika, Kombinationen exkl. Corticosteroide R01AB01 Phenylephrin 0,8 ml N R01AB02 Naphazolin 0,8 ml N R01AB03 Tetryzolin R01AB05 Ephedrin R01AB06 Xylometazolin R01AB07 Oxymetazolin R01AB08 Tuaminoheptan R01AB12 Epinephrin R01AC Antiallergika, exkl. Corticosteroide R01AC01 Cromoglicinsäure 40 mg N R01AC02 Levocabastin 0,6 mg N R01AC03 Azelastin 0,56 mg N R01AC04 Antazolin R01AC05 Spagluminsäure R01AC06 Thonzylamin R01AC07 Nedocromil 10,4 mg N R01AC08 Olopatadin R01AC09 Dimetinden R01AC51 Cromoglicinsäure, Kombinationen R01AD Corticosteroide R01AD01 Beclometason 0,4 mg N R01AD02 Prednisolon R01AD03 Dexamethason R01AD04 Flunisolid 0,15 mg N R01AD05 Budesonid 0,2 mg N R01AD06 Betamethason 0,4 mg N R01AD07 Tixocortol 8 mg N R01AD08 Fluticason 0,2 mg N R01AD09 Mometason 0,2 mg N R01AD11 Triamcinolon 0,22 mg N R01AD12 Fluticason furoat 0,11 mg N R01AD13 Ciclesonid 0,2 mg N R01AD21 Fluocortin R01AD52 Prednisolon, Kombinationen R01AD53 Dexamethason, Kombinationen R01AD57 Tixocortol, Kombinationen R01AD58 Fluticason, Kombinationen R01AD60 Hydrocortison, Kombinationen R01AD61 Triamcinolon, Kombinationen R01AD64 Fludrocortison, Kombinationen R01AH Homöopathische und anthroposophische Rhinologika zur topischen Anwendung R01AH01 Luffa operculata R01AH20 Kombinationen R01AH50 Kombinationen mit anderen Mitteln R01AP Pflanzliche Rhinologika zur topischen Anwendung R01AP01 Kamillenblüten R01AP02 Echinacea-purpurea-Presssaft R01AP03 Niauliöl R01AP06 Etherische Öle 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 106 von 133 BEDEUTUNG DDD-INFOATC-CODE R01AP10 Verschiedene R01AP56 Etherische Öle, Kombinationen R01AX Andere Rhinologika R01AX01 Calciumhexaminthiocyanat R01AX02 Retinol 800 E N R01AX03 Ipratropium bromid 0,24 mg N R01AX05 Ritiometan R01AX06 Mupirocin 3 mg N R01AX07 Hexamidin R01AX08 Framycetin R01AX09 Hyaluronsäure R01AX10 Verschiedene R01AX11 Diphenylpyralin R01AX14 Meerwasser R01AX15 Silbereiweiß-Acetyltannat R01AX16 Natriumchlorid R01AX17 Mesna R01AX18 Hypromellose R01AX21 Mineralsalz R01AX23 Menthol R01AX26 Dexpanthenol 35 mg N flüssige Zubereitungen R01AX28 Emser Salz R01AX30 Kombinationen R01B NASALE DEKONGESTIVA ZUR SYSTEMISCHEN ANWENDUNG R01BA Sympathomimetika R01BA01 Phenylpropanolamin 0,1 g O R01BA02 Pseudoephedrin 0,24 g O R01BA03 Phenylephrin 40 mg O R01BA51 Phenylpropanolamin, Kombinationen 0,1 g O bezogen auf Phenylpropanolamin R01BA52 Pseudoephedrin, Kombinationen 0,24 g O bezogen auf Pseudoephedrin R01BA53 Phenylephrin, Kombinationen R01BA54 Buphenin, Kombinationen R01BA56 Etilefrin, Kombinationen R01BH Homöopathische und anthroposophische Rhinologika zur systemischen Anwendung R01BH01 Luffa operculata R01BH09 Cinnabaris R01BH10 Verschiedene R01BH20 Kombinationen R01BP Pflanzliche Rhinologika zur systemischen Anwendung R01BP01 Pollen R01BP30 Kombinationen R01BX Andere systemische Rhinologika R01BX02 Cafaminol R02 HALS- UND RACHENTHERAPEUTIKA R02A HALS- UND RACHENTHERAPEUTIKA R02AA Antiseptika R02AA01 Ambazon 40 mg O R02AA02 Dequalinium 1,5 mg O R02AA03 Dichlorbenzylalkohol R02AA05 Chlorhexidin 30 mg O R02AA06 Cetylpyridinium R02AA09 Benzethonium R02AA10 Myristylbenzalkonium R02AA11 Chlorquinaldol R02AA12 Hexylresorcinol R02AA13 Acriflaviniumchlorid R02AA14 Oxychinolin R02AA15 Povidon-Iod R02AA16 Benzalkonium R02AA17 Cetrimonium R02AA18 Hexamidin R02AA19 Phenol R02AA20 Verschiedene R02AA21 Silber-haltige Verbindungen R02AA25 Phenylmercuriborat R02AA28 Hexetidin 30 mg O R02AA32 Aluminium-haltige Verbindungen R02AA33 Acetylaminonitropropoxybenzol R02AA50 Andere Antiseptika, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 107 von 133 BEDEUTUNG DDD-INFOATC-CODE R02AA51 Ambazon, Kombinationen R02AA52 Dequalinium, Kombinationen R02AA55 Chlorhexidin, Kombinationen R02AA56 Cetylpyridinium, Kombinationen R02AA59 Benzethonium, Kombinationen R02AA71 Silber-haltige Verbindungen, Kombinationen R02AA72 Paraformaldehyd, Kombinationen R02AA73 Methenamin, Kombinationen R02AA74 Formaldehyd, Kombinationen R02AA82 Aluminium-haltige Verbindungen, Kombinationen R02AA84 Benzoxonium, Kombinationen R02AB Antibiotika R02AB01 Neomycin R02AB02 Tyrothricin R02AB03 Fusafungin R02AB04 Bacitracin R02AB20 Kombinationen R02AB30 Gramicidin R02AB52 Tyrothricin, Kombinationen R02AB54 Bacitracin, Kombinationen R02AB80 Gramicidin, Kombinationen R02AD Lokalanästhetika R02AD01 Benzocain R02AD02 Lidocain R02AD03 Cocain R02AD04 Dyclonin R02AD05 Ambroxol R02AD50 Andere Lokalanästhetika, Kombinationen R02AD51 Benzocain, Kombinationen R02AD52 Lidocain, Kombinationen R02AH Homöopathische und anthroposophische Hals- und Rachentherapeutika R02AH10 Verschiedene R02AH20 Kombinationen R02AP Pflanzliche Hals- und Rachentherapeutika R02AP30 Kombinationen R02AP52 Etherische Öle, Kombinationen R02AX Andere Hals- und Rachentherapeutika R02AX01 Flurbiprofen 44 mg O R02AX02 Emser Salz R02AX50 Andere Hals- und Rachentherapeutika, Kombinationen R02AX52 Emser Salz, Kombinationen R03 MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN R03A INHALATIVE SYMPATHOMIMETIKA R03AA Alpha- und Beta-Adrenozeptor-Agonisten R03AA01 Epinephrin 2,24 mg Inhal.Aerosol; 20 mg Inhal.lösung R03AA51 Epinephrin, Kombinationen R03AA52 DL-Ephedrin, Kombinationen R03AB Nichtselektive Beta-Adrenozeptor-Agonisten R03AB02 Isoprenalin 0,64 mg Inhal.Aerosol; 10 mg Inhal.lösung R03AB03 Orciprenalin 6 mg Inhal.Aerosol R03AB52 Isoprenalin, Kombinationen R03AB53 Orciprenalin, Kombinationen R03AC Selektive Beta2-Adrenozeptor-Agonisten R03AC02 Salbutamol 0,8 mg Inhal.Aerosol/pulver; 10 mg Inhal.lösung R03AC03 Terbutalin 2 mg Inhal.Aerosol/pulver; 20 mg Inhal.lösung R03AC04 Fenoterol 0,6 mg Inhal.Aerosol/pulver; 4 mg Inhal.lösung R03AC05 Rimiterol 1,6 mg Inhal.Aerosol R03AC06 Hexoprenalin 1,5 mg Inhal.Aerosol R03AC07 Isoetarin R03AC08 Pirbuterol 1,2 mg Inhal.Aerosol R03AC09 Tretoquinol R03AC10 Carbuterol R03AC11 Tulobuterol 1,6 mg Inhal.Aerosol R03AC12 Salmeterol 0,1 mg Inhal.Aerosol/pulver R03AC13 Formoterol 24 mcg Inhal.Aerosol/pulver R03AC14 Clenbuterol R03AC15 Reproterol R03AC16 Procaterol 60 mcg Inhal.Aerosol R03AC17 Bitolterol 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 108 von 133 BEDEUTUNG DDD-INFOATC-CODE R03AC18 Indacaterol 0,15 mg Inhal.pulver R03AH Kombinationen von Sympathomimetika R03AK Sympathomimetika in Kombination mit Corticosteroiden oder anderen Mitteln, exkl. Anticholinergika R03AK01 Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen R03AK02 Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen R03AK03 Fenoterol und Cromoglicinsäure, Dinatriumsalz R03AK04 Salbutamol und Cromoglicinsäure, Dinatriumsalz R03AK05 Reproterol und Cromoglicinsäure, Dinatriumsalz R03AK06 Salmeterol und Fluticason 0,1 mg Inhal.Aerosol/pulver bezogen auf Salmeterol R03AK07 Formoterol und Budesonid 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AK08 Formoterol und Beclometason 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AK09 Formoterol und Mometason R03AK10 Vilanterol und Fluticason furoat R03AK11 Formoterol und Fluticason 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AL Sympathomimetika in Kombination mit Anticholinergika R03AL01 Fenoterol und Ipratropium bromid R03AL02 Salbutamol und Ipratropium bromid R03AL03 Vilanterol und Umeclidinium bromid R03AL04 Indacaterol und Glycopyrronium bromid R03B ANDERE INHALATIVE MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN R03BA Glucocorticoide R03BA01 Beclometason 0,8 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung; 0,4 mg Inhal.Aerosol Partikelgröße < 3,3 mcm R03BA02 Budesonid 0,8 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung R03BA03 Flunisolid 1 mg Inhal.Aerosol R03BA04 Betamethason R03BA05 Fluticason 0,6 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung R03BA06 Triamcinolon R03BA07 Mometason 0,4 mg Inhal.pulver R03BA08 Ciclesonid 0,16 mg Inhal.Aerosol R03BA09 Dexamethason R03BB Anticholinergika R03BB01 Ipratropium bromid 0,12 mg Inhal.Aerosol; 1,5 mg Inhal.lösung; 0,6 mg Inhal.pulver R03BB02 Oxitropium bromid 0,6 mg Inhal.Aerosol; 4 mg Inhal.lösung R03BB03 Stechapfel-haltige Zubereitungen R03BB04 Tiotropium bromid 5 mcg Inhal.lösung bezogen auf die Base; 18 mcg Inhal.pulver bezogen auf die Base R03BB05 Aclidinium bromid 0,644 mg Inhal.pulver bezogen auf die Base R03BB06 Glycopyrronium bromid 63 mcg Inhal.pulver R03BC Antiallergika, exkl. Corticosteroide R03BC01 Cromoglicinsäure 40 mg Inhal.Aerosol; 80 mg Inhal.lösung,Inhal.pulver R03BC03 Nedocromil 8 mg Inhal.Aerosol R03BX Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen R03BX01 Fenspirid R03C SYMPATHOMIMETIKA ZUR SYSTEMISCHEN ANWENDUNG R03CA Alpha- und Beta-Adrenozeptor-Agonisten R03CA02 Ephedrin 50 mg O R03CA51 Epinephrin, Kombinationen R03CA52 Ephedrin, Kombinationen R03CA53 Methylephedrin, Kombinationen R03CB Nichtselektive Beta-Adrenozeptor-Agonisten R03CB01 Isoprenalin 40 mg O R03CB02 Methoxyphenamin 0,4 g O R03CB03 Orciprenalin 60 mg O R03CB51 Isoprenalin, Kombinationen R03CB53 Orciprenalin, Kombinationen R03CC Selektive Beta2-Adrenozeptor-Agonisten R03CC02 Salbutamol 12 mg O,P R03CC03 Terbutalin 15 mg O; 0,25 mg P R03CC04 Fenoterol 10 mg O,R R03CC05 Hexoprenalin 1,5 mg O,P R03CC06 Isoetarin 40 mg O R03CC07 Pirbuterol 30 mg O R03CC08 Procaterol 0,1 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 109 von 133 BEDEUTUNG DDD-INFOATC-CODE R03CC09 Tretoquinol 9 mg O; 0,2 mg P R03CC10 Carbuterol 6 mg O R03CC11 Tulobuterol 4 mg O R03CC12 Bambuterol 20 mg O R03CC13 Clenbuterol 40 mcg O R03CC14 Reproterol R03CC53 Terbutalin, Kombinationen R03CC54 Fenoterol, Kombinationen R03CC63 Clenbuterol, Kombinationen R03CK Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen R03D ANDERE MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN ZUR SYSTEMISCHEN ANWENDUNG R03DA Xanthine R03DA01 Diprophyllin 1 g O,P,R R03DA02 Cholintheophyllinat 0,6 g O,R R03DA03 Proxyphyllin 1,2 g O,P,R R03DA04 Theophyllin 0,4 g O,P,R R03DA05 Aminophyllin 0,6 g O,P,R R03DA06 Etamiphyllin R03DA07 Theobromin R03DA08 Bamifyllin R03DA09 Acefyllinpiperazin R03DA10 Bufyllin R03DA11 Doxofyllin R03DA20 Kombinationen von Xanthinen R03DA50 Andere Xanthine, Kombinationen excl. Psycholeptika R03DA51 Diprophyllin, Kombinationen R03DA52 Cholintheophyllinat, Kombinationen R03DA53 Proxyphyllin, Kombinationen exkl. Psycholeptika R03DA54 Theophyllin, Kombinationen exkl. Psycholeptika R03DA55 Aminophyllin, Kombinationen R03DA57 Theobromin, Kombinationen R03DA63 Coffein, Kombinationen exkl. Psycholeptika R03DA73 Proxyphyllin, Kombinationen mit Psycholeptika R03DA74 Theophyllin, Kombinationen mit Psycholeptika R03DA82 Etofyllin, Kombinationen mit Psycholeptika R03DA90 Andere Xanthine, Kombinationen mit Psycholeptika R03DB Xanthine und Sympathomimetika R03DB01 Diprophyllin und Sympathomimetika R03DB02 Cholintheophyllinat und Sympathomimetika R03DB03 Proxyphyllin und Sympathomimetika R03DB04 Theophyllin und Sympathomimetika R03DB05 Aminophyllin und Sympathomimetika R03DB06 Etamiphyllin und Sympathomimetika R03DB12 Etofyllin und Sympathomimetika R03DB13 Coffein und Sympathomimetika R03DB20 Verschiedene Xanthine und Sympathomimetika R03DC Leukotrienrezeptor-Antagonisten R03DC01 Zafirlukast 40 mg O R03DC02 Pranlukast R03DC03 Montelukast 10 mg O; 5 mg O Kinder DDD R03DC04 Ibudilast R03DH Homöopathische und anthroposophische Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung R03DH20 Kombinationen R03DX Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung R03DX01 Amlexanox R03DX02 Eprozinol R03DX03 Fenspirid R03DX05 Omalizumab 16 mg P s.c. R03DX06 Seratrodast R03DX07 Roflumilast 0,5 mg O R03DX50 Andere systemische Antiasthmatika, Kombinationen R04 BRUSTEINREIBUNGEN UND ANDERE INHALATE 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 110 von 133 BEDEUTUNG DDD-INFOATC-CODE R04A BRUSTEINREIBUNGEN UND ANDERE INHALATE R04AH Homöopathische und anthroposophische Brusteinreibungen R04AH20 Kombinationen R04AH50 Kombinationen mit anderen Mitteln R04AP Pflanzliche Brusteinreibungen und Inhalate, inkl. Bäder R04AP02 Thymianöl R04AP03 Eukalyptusöl R04AP06 Pfefferminzöl R04AP07 Niauliöl R04AP30 Kombinationen R04AP50 Andere etherische Öle, Kombinationen R04AX Andere Inhalate R04AX01 Emser Salz R04AX02 Sole R04AX03 Natriumchlorid R04AX04 Cineol R04AX53 Natriumchlorid, Kombinationen R05 HUSTEN- UND ERKÄLTUNGSMITTEL R05C EXPEKTORANZIEN, EXKL. KOMBINATIONEN MIT ANTITUSSIVA R05CA Expektoranzien R05CA01 Tyloxapol 5 mg Inhal.lösung R05CA02 Kaliumiodid 1,2 g O R05CA03 Guaifenesin 0,9 g O,P R05CA07 Antimonpentasulfid 0,2 g O R05CA08 Kreosot R05CA09 Guajacolsulfonat R05CA10 Kombinationen R05CA11 Levoverbenon R05CA13 Caseinhydrolysat R05CA22 Emser Salz R05CA25 Cineol R05CA50 Andere Expektoranzien, Kombinationen R05CA51 Tyloxapol, Kombinationen R05CB Mukolytika R05CB01 Acetylcystein 0,5 g O, P R05CB02 Bromhexin 24 mg O,P; 24 mg Inhal.lösung R05CB03 Carbocistein 1,5 g O R05CB04 Eprazinon 0,2 g O R05CB05 Mesna 1,2 g Inhal R05CB06 Ambroxol 75 mg Inhal.lösung,O,P,R; 40 mg O,R Kinder DDD R05CB07 Sobrerol R05CB08 Domiodol R05CB09 Letostein R05CB10 Kombinationen R05CB11 Stepronin R05CB12 Tiopronin R05CB13 Dornase alfa (Desoxyribonuclease) 2,5 mg Inhal.lösung R05CB14 Neltenexin R05CB15 Erdostein 0,6 g O R05CB16 Mannitol 0,8 g Inhal.pulver R05CB50 Andere Mukolytika, Kombinationen R05CB52 Bromhexin, Kombinationen R05CH Homöopathische und anthroposophische Expektoranzien R05CH01 Cuprum aceticum R05CH20 Kombinationen R05CH50 Kombinationen mit anderen Mitteln R05CP Pflanzliche Expektoranzien R05CP01 Thymiankraut 6 g O Droge; 3,5 g O Fluidextrakt R05CP02 Efeublätter 0,3 g O Droge R05CP03 Primelwurzel R05CP04 Asarumwurzelstock R05CP05 Pelargoniumwurzel R05CP08 Spiköl R05CP09 Eukalyptusöl R05CP10 Niauliöl R05CP11 Ipecacuanha R05CP13 Senegawurzel 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 111 von 133 BEDEUTUNG DDD-INFOATC-CODE R05CP15 Wollblumen R05CP16 Andornkraut R05CP17 Süßholzwurzel R05CP30 Kombinationen R05CP51 Thymiankraut, Kombinationen R05CP59 Eukalyptusöl, Kombinationen R05D ANTITUSSIVA, EXKL. KOMBINATIONEN MIT EXPEKTORANZIEN R05DA Opium-Alkaloide und Derivate R05DA01 Ethylmorphin 50 mg O R05DA03 Hydrocodon 15 mg O; 15 mg P R05DA04 Codein 0,1 g O R05DA05 Opium-Alkaloide mit Morphin R05DA06 Normethadon R05DA07 Noscapin 0,125 g O R05DA08 Pholcodin 50 mg O R05DA09 Dextromethorphan 90 mg O R05DA10 Thebacon 15 mg O R05DA11 Dimemorfan R05DA12 Acetyldihydrocodein 30 mg O R05DA13 Nicocodin R05DA14 Dihydrocodein 40 mg O R05DA20 Kombinationen R05DA50 Andere Opium-Alkaloide und Derivate, Kombinationen R05DA54 Codein, Kombinationen R05DA56 Normethadon, Kombinationen R05DA59 Dextromethorphan, Kombinationen R05DA64 Dihydrocodein, Kombinationen R05DB Andere Antitussiva R05DB01 Benzonatat 0,6 g O R05DB02 Benproperin 75 mg O R05DB03 Clobutinol 0,12 g O,P R05DB04 Isoaminil 0,11 g O R05DB05 Pentoxyverin 0,1 g O,R R05DB07 Oxolamin 0,6 g O R05DB09 Oxeladin 80 mg O R05DB10 Clofedanol 60 mg O R05DB11 Pipazetat 80 mg O R05DB12 Bibenzoniumbromid 90 mg O R05DB13 Butamirat 25 mg O R05DB14 Fedrilat 0,2 g O R05DB15 Zipeprol R05DB16 Dibunat R05DB17 Droxypropin R05DB18 Prenoxdiazin R05DB19 Dropropizin R05DB20 Kombinationen R05DB21 Cloperastin 60 mg O (bezogen auf Cloperastin hydrochlorid) R05DB22 Meprotixol R05DB23 Piperidion R05DB24 Tipepidin R05DB25 Morclofon R05DB26 Nepinalon R05DB27 Levodropropizin 0,12 g O R05DB28 Dimethoxanat R05DB29 Fominoben R05DB30 Butetamat R05DB31 Menadiol R05DB53 Clobutinol, Kombinationen R05DB54 Isoaminil, Kombinationen R05DB55 Pentoxyverin, Kombinationen R05DB68 Prenoxdiazin, Kombinationen R05DB80 Butetamat, Kombinationen R05DP Pflanzliche Antitussiva R05DP01 Sonnentaukraut R05DP02 Isländisches Moos R05DP04 Spitzwegerich R05DP05 Eibischwurzel und -blätter R05DP07 Huflattichblätter 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 112 von 133 BEDEUTUNG DDD-INFOATC-CODE R05F ANTITUSSIVA UND EXPEKTORANZIEN, KOMBINATIONEN R05FA Opium-Derivate und Expektoranzien R05FA01 Opium-Derivate und Mukolytika R05FA02 Opium-Derivate und Expektoranzien R05FB Andere Antitussiva und Expektoranzien R05FB01 Antitussiva und Mukolytika R05FB02 Antitussiva und Expektoranzien R05FH Homöopathische und anthroposophische Antitussiva und Expektoranzien R05FH10 Verschiedene R05FH20 Kombinationen R05FP Pflanzliche Antitussiva und Expektoranzien R05FP30 Pflanzliche Antitussiva und Expektoranzien, Kombinationen R05G ANTITUSSIVA UND EXPEKTORANZIEN, KOMBINATIONEN MIT ANTIBIOTIKA R05GA Antitussiva und Antibiotika R05GA01 Doxycyclin, Kombinationen 0,1 g O,P bezogen auf Doxycyclin R05GA02 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin R05GB Expektoranzien und Antibiotika R05GB01 Doxycyclin mit Ambroxol 0,1 g O,P bezogen auf Doxycyclin R05GB02 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin R05GB03 Oxytetracyclin, Kombinationen 1 g O,P bezogen auf Oxytetracyclin R05GB04 Thiamphenicol, Kombinationen 1,5 g O,P bezogen auf Thiamphenicol R05GB05 Ampicillin, Kombinationen 2 g O,P bezogen auf Ampicillin; 2,5 g O Kinder DDD bezogen auf Ampicillin R05GB06 Cefaclor, Kombinationen 1 g O,P bezogen auf Cefaclor; 0,75 g O Kinder DDD bezogen auf Cefaclor R05GB07 Erythromycin, Kombinationen 2 g O für Erythromycinethylsuccinat-haltige Zubereitungen; 1 g O Kinder DDD für Erythromycinethylsuccinat-haltige Zubereitungen R05GB08 Metacyclin, Kombinationen 0,6 g O bezogen auf Metacyclin R05GB51 Doxycyclin, Kombinationen 0,1 g O,P bezogen auf Doxycyclin R05GC Expektoranzien und Sulfonamide R05GC01 Sulfadiazin, Kombinationen 0,6 g O bezogen auf Sulfadiazin R05GC02 Sulfamethoxazol und Trimethoprim 1,6 g Sulfamethoxazol+0,32 g Trimethoprim Erwachsenen DDD R05GC03 Sulfanilamid, Kombinationen R05X ANDERE ZUBEREITUNGEN GEGEN ERKÄLTUNGSKRANKHEITEN R05XA Analgetika-haltige Mittel gegen Erkältungskrankheiten R05XA01 Paracetamol, Kombinationen R05XA02 Acetylsalicylsäure, Kombinationen R05XA03 Propyphenazon, Kombinationen R05XA04 Ethenzamid, Kombinationen R05XA05 Aminophenazon, Kombinationen R05XA06 Natriumsalicylat, Kombinationen R05XA07 Metamizol, Kombinationen R05XA08 Phenazon, Kombinationen R05XA09 Salicylamid, Kombinationen R05XA10 Phenylbutazon, Kombinationen R05XA12 Phenacetin, Kombinationen R05XC Andere Mittel gegen Erkältungskrankheiten R05XC01 Enzym-haltige Kombinationen R05XC02 Pflanzliche Kombinationen mit anderen Mitteln R05XH Homöopathische und anthroposophische Mittel gegen Erkältungskrankheiten R05XH02 Ferrum phosphoricum R05XH04 Cinnabaris R05XH20 Kombinationen R05XH51 Echinacea angustifolia, Kombinationen R05XH52 Ferrum phosphoricum, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 113 von 133 BEDEUTUNG DDD-INFOATC-CODE R06 ANTIHISTAMINIKA ZUR SYSTEMISCHEN ANWENDUNG R06A ANTIHISTAMINIKA ZUR SYSTEMISCHEN ANWENDUNG R06AA Aminoalkylether R06AA01 Bromazin R06AA02 Diphenhydramin 0,2 g O,R chlorid; 0,3 g O,R Teoclat R06AA04 Clemastin 2 mg O,P R06AA06 Chlorphenoxamin 80 mg O,P R06AA07 Diphenylpyralin 10 mg O R06AA08 Carbinoxamin 16 mg O R06AA09 Doxylamin R06AA10 Piprinhydrinat R06AA52 Diphenhydramin, Kombinationen R06AA54 Clemastin, Kombinationen R06AA56 Chlorphenoxamin, Kombinationen R06AA57 Diphenylpyralin, Kombinationen R06AA59 Doxylamin, Kombinationen R06AB Substituierte Alkylamine R06AB01 Brompheniramin 24 mg O R06AB02 Dexchlorpheniramin 6 mg O,P R06AB03 Dimetinden 4 mg O; 4 mg P R06AB04 Chlorphenamin 12 mg O,P R06AB05 Pheniramin 75 mg O R06AB06 Dexbrompheniramin R06AB07 Talastin R06AB51 Brompheniramin, Kombinationen R06AB52 Dexchlorpheniramin, Kombinationen R06AB54 Chlorphenamin, Kombinationen R06AB56 Dexbrompheniramin, Kombinationen R06AC Substituierte Ethylendiamine R06AC01 Mepyramin 0,2 g O,P R06AC02 Histapyrrodin 80 mg O R06AC03 Chloropyramin 0,15 g O; 20 mg P R06AC04 Tripelennamin 0,15 g O R06AC05 Methapyrilen R06AC06 Thonzylamin R06AC52 Histapyrrodin, Kombinationen R06AC53 Chloropyramin, Kombinationen R06AD Phenothiazin-Derivate R06AD01 Alimemazin 30 mg O,P R06AD02 Promethazin 25 mg O,P,R R06AD03 Thiethylperazin 13 mg O,P,R R06AD04 Methdilazin 16 mg O R06AD05 Hydroxyethylpromethazin 75 mg O R06AD06 Thiazinam 0,9 g O; 0,3 g R R06AD07 Mequitazin 10 mg O R06AD08 Oxomemazin 30 mg O R06AD09 Isothipendyl R06AD10 Dioxopromethazin R06AD52 Promethazin, Kombinationen R06AD55 Hydroxyethylpromethazin, Kombinationen R06AE Piperazin-Derivate R06AE01 Buclizin 50 mg O R06AE03 Cyclizin 0,1 g O; 0,3 g R R06AE04 Chlorcyclizin 0,1 g O R06AE05 Meclozin 50 mg O,R R06AE06 Oxatomid 60 mg O R06AE07 Cetirizin 10 mg O R06AE09 Levocetirizin 5 mg O R06AE51 Buclizin, Kombinationen R06AE53 Cyclizin, Kombinationen R06AE55 Meclozin, Kombinationen R06AE57 Cetirizin, Kombinationen R06AK Kombinationen von Antihistaminika R06AX Andere Antihistaminika zur systemischen Anwendung R06AX01 Bamipin 0,1 g O R06AX02 Cyproheptadin 12 mg O R06AX03 Thenalidin R06AX04 Phenindamin R06AX05 Antazolin 0,3 g O,P R06AX07 Triprolidin 7,5 mg O R06AX08 Pyrrobutamin R06AX09 Azatadin 2 mg O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 114 von 133 BEDEUTUNG DDD-INFOATC-CODE R06AX11 Astemizol 10 mg O R06AX12 Terfenadin 0,12 g O R06AX13 Loratadin 10 mg O R06AX15 Mebhydrolin 0,2 g O R06AX16 Deptropin 2 mg O R06AX17 Ketotifen 2 mg O R06AX18 Acrivastin 24 mg O R06AX19 Azelastin 4 mg O R06AX21 Tritoqualin R06AX22 Ebastin 10 mg O R06AX23 Pimethixen R06AX24 Epinastin R06AX25 Mizolastin 10 mg O R06AX26 Fexofenadin 0,12 g O R06AX27 Desloratadin 5 mg O R06AX28 Rupatadin 10 mg O R06AX29 Bilastin 20 mg O R06AX30 Etoloxamin R06AX31 Quifenadin R06AX32 Hydroxyzin R06AX51 Bamipin, Kombinationen R06AX53 Thenalidin, Kombinationen R06AX57 Triprolidin, Kombinationen R06AX58 Pyrrobutamin, Kombinationen R06AX80 Etoloxamin, Kombinationen R07 ANDERE MITTEL FÜR DEN RESPIRATIONSTRAKT R07A ANDERE MITTEL FÜR DEN RESPIRATIONSTRAKT R07AA Surfactant-Präparate R07AA01 Colfoscerilpalmitat 0,108 g Inhal.pulver R07AA03 Ambroxol R07AA04 Natürliche Phospholipide aus Schweinelunge 0,16 g Instill.lösung R07AA05 Natürliche Phospholipide aus Rinderlunge 0,16 g Instill.lösung R07AA30 Kombinationen R07AB Atemstimulanzien R07AB01 Doxapram 0,4 g P R07AB02 Nikethamid 0,5 g O,P R07AB03 Pentetrazol 0,1 g O R07AB04 Etamivan R07AB05 Bemegrid R07AB06 Prethcamid 0,4 g O,P R07AB07 Almitrin 0,1 g O R07AB08 Dimeflin R07AB09 Mepixanox R07AB50 Andere Atemstimulanzien, Kombinationen R07AB52 Nikethamid, Kombinationen R07AB53 Pentetrazol, Kombinationen R07AH Andere homöopathische und anthroposophische Mittel für den Respirationstrakt R07AH10 Verschiedene R07AH20 Kombinationen R07AX Andere Mittel für den Respirationstrakt R07AX01 Stickoxid R07AX02 Ivacaftor 0,3 g O 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 115 von 133 BEDEUTUNG DDD-INFOATC-CODE S SINNESORGANE S01 OPHTHALMIKA* S01A ANTIINFEKTIVA S01AA Antibiotika S01AA01 Chloramphenicol S01AA02 Chlortetracyclin S01AA03 Neomycin S01AA04 Oxytetracyclin S01AA05 Tyrothricin S01AA07 Framycetin S01AA09 Tetracyclin S01AA10 Natamycin S01AA11 Gentamicin 1,25 mg AT,AS S01AA12 Tobramycin S01AA13 Fusidinsäure S01AA14 Benzylpenicillin S01AA15 Dihydrostreptomycin S01AA16 Rifamycin S01AA17 Erythromycin S01AA18 Polymyxin B S01AA19 Ampicillin S01AA20 Antibiotika in Kombination mit anderen Mitteln S01AA21 Amikacin S01AA22 Micronomicin S01AA23 Netilmicin S01AA24 Kanamycin 1,5 mg AT,AS S01AA25 Azidamfenicol S01AA26 Azithromycin S01AA27 Cefuroxim S01AA30 Kombinationen von Antibiotika S01AB Sulfonamide S01AB01 Sulfamethizol S01AB02 Sulfafurazol S01AB03 Sulfadicramid S01AB04 Sulfacetamid S01AB05 Sulfaphenazol S01AB06 Sulfisoxazol S01AB07 Sulfisomidin S01AB20 Kombinationen S01AD Antivirale Mittel S01AD01 Idoxuridin S01AD02 Trifluridin S01AD03 Aciclovir S01AD05 Interferon S01AD06 Vidarabin S01AD07 Famciclovir S01AD08 Fomivirsen S01AD09 Ganciclovir S01AD13 Tromantadin S01AE Fluorchinolone S01AE01 Ofloxacin 0,4 mg AT,AS S01AE02 Norfloxacin S01AE03 Ciprofloxacin 0,6 mg AT S01AE04 Lomefloxacin S01AE05 Levofloxacin S01AE06 Gatifloxacin S01AE07 Moxifloxacin 0,75 mg AT S01AE08 Besifloxacin S01AX Andere Antiinfektiva S01AX01 Quecksilber-haltige Verbindungen S01AX02 Silber-haltige Verbindungen S01AX03 Zink-haltige Verbindungen S01AX04 Nitrofural S01AX05 Bibrocathol S01AX06 Resorcin S01AX07 Natriumborat S01AX08 Hexamidin S01AX09 Chlorhexidin S01AX10 Natriumpropionat S01AX14 Dibrompropamidin S01AX15 Propamidin S01AX16 Picloxydin S01AX18 Povidon-Iod S01AX20 Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 116 von 133 BEDEUTUNG DDD-INFOATC-CODE S01AX24 Benzalkoniumchlorid S01AX25 Hydroxymethylchinolinium-methylsalicylat S01B ANTIPHLOGISTIKA S01BA Corticosteroide, rein S01BA01 Dexamethason 0,2 mg AT,AS S01BA02 Hydrocortison S01BA03 Cortison S01BA04 Prednisolon S01BA05 Triamcinolon S01BA06 Betamethason S01BA07 Fluorometholon S01BA08 Medryson S01BA09 Clobetason S01BA10 Alclometason S01BA11 Desonid S01BA12 Formocortal S01BA13 Rimexolon S01BA14 Loteprednol S01BA15 Fluocinolon acetonid Standarddosis: 1 Implantat S01BA16 Mazipredon S01BB Corticosteroide und Mydriatika in Kombination S01BB01 Hydrocortison und Mydriatika S01BB02 Prednisolon und Mydriatika S01BB03 Fluorometholon und Mydriatika S01BB04 Betamethason und Mydriatika S01BB05 Dexamethason und Mydriatika S01BC Nichtsteroidale Antiphlogistika S01BC01 Indometacin S01BC02 Oxyphenbutazon S01BC03 Diclofenac S01BC04 Flurbiprofen S01BC05 Ketorolac S01BC06 Piroxicam S01BC07 Bendazac S01BC08 Salicylsäure S01BC09 Pranoprofen S01BC10 Nepafenac 0,15 mg AT S01BC11 Bromfenac 66 mcg AT S01BX Corticosteroide, Kombinationen mit anderen Mitteln S01BX01 Hydrocortison, Kombinationen S01C ANTIPHLOGISTIKA UND ANTIINFEKTIVA IN KOMBINATION S01CA Corticosteroide und Antiinfektiva in Kombination S01CA01 Dexamethason und Antiinfektiva S01CA02 Prednisolon und Antiinfektiva S01CA03 Hydrocortison und Antiinfektiva S01CA04 Fluocortolon und Antiinfektiva S01CA05 Betamethason und Antiinfektiva S01CA06 Fludrocortison und Antiinfektiva S01CA07 Fluorometholon und Antiinfektiva S01CA08 Methylprednisolon und Antiinfektiva S01CA09 Chlorprednison und Antiinfektiva S01CA10 Fluocinolonacetonid und Antiinfektiva S01CA11 Clobetason und Antiinfektiva S01CA12 Prednison und Antiinfektiva S01CA13 Triamcinolon und Antiinfektiva S01CB Corticosteroide/Antiinfektiva/Mydriatika in Kombination S01CB01 Dexamethason S01CB02 Prednisolon S01CB03 Hydrocortison S01CB04 Betamethason S01CB05 Fluorometholon S01CC Nichtsteroidale Antiphlogistika und Antiinfektiva in Kombination S01CC01 Diclofenac und Antiinfektiva 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 BEDEUTUNG DDD-INFOATC-CODE S01E GLAUKOMMITTEL UND MIOTIKA S01EA Sympathomimetika in der Glaukomtherapie S01EA01 Epinephrin 0,2 ml AT S01EA02 Dipivefrin 0,2 ml AT S01EA03 Apraclonidin 0,3 ml AT S01EA04 Clonidin 0,25 ml AT S01EA05 Brimonidin 0,2 ml AT S01EA51 Epinephrin, Kombinationen S01EA52 Dipivefrin, Kombinationen S01EB Parasympathomimetika S01EB01 Pilocarpin 0,285 Lamelle; 0,4 ml; 0,4 g AS S01EB02 Carbachol 0,4 ml S01EB03 Ecothiopat 0,2 ml S01EB04 Demecarium 0,1 ml S01EB05 Physostigmin 0,4 ml S01EB06 Neostigmin 40 mg Salbe; 0,4 ml S01EB07 Fluostigmin S01EB08 Aceclidin S01EB09 Acetylcholin S01EB10 Paraoxon S01EB51 Pilocarpin, Kombinationen S01EB58 Aceclidin, Kombinationen S01EC Carboanhydrasehemmer S01EC01 Acetazolamid 0,75 g O,P S01EC02 Diclofenamid 0,1 g O S01EC03 Dorzolamid 0,3 ml S01EC04 Brinzolamid 0,2 ml S01EC05 Methazolamid 0,2 g O S01ED Beta-Adrenozeptor-Antagonisten S01ED01 Timolol 0,2 g AS; 0,2 ml AT S01ED02 Betaxolol 0,2 ml AT S01ED03 Levobunolol 0,2 ml AT S01ED04 Metipranolol 0,2 ml AT S01ED05 Carteolol 0,2 ml AT S01ED06 Befunolol 0,2 ml AT S01ED07 Pindolol 0,2 ml AT S01ED08 Bupranolol 0,2 ml AT S01ED51 Timolol, Kombinationen S01ED52 Betaxolol, Kombinationen S01ED54 Metipranolol, Kombinationen S01ED55 Carteolol, Kombinationen S01ED61 Timolol und Latanoprost 0,1 ml AT S01ED62 Timolol und Bimatoprost 0,1 ml AT S01ED63 Timolol und Travoprost 0,1 ml AT S01ED66 Timolol und Dorzolamid 0,2 ml AT S01ED67 Timolol und Brinzolamid 0,2 ml AT S01ED68 Timolol und Pilocarpin 0,2 ml AT S01ED69 Timolol und Brimonidin 0,2 ml AT S01EE Prostaglandin-Analoga S01EE01 Latanoprost 0,1 ml AT S01EE02 Unoproston 0,2 ml AT S01EE03 Bimatoprost 0,1 ml AT S01EE04 Travoprost 0,1 ml AT S01EE05 Tafluprost 0,1 ml AT S01EX Andere Glaukommittel S01EX01 Guanethidin S01EX02 Dapiprazol S01F MYDRIATIKA UND ZYKLOPLEGIKA S01FA Anticholinergika S01FA01 Atropin 1 mg AT S01FA02 Scopolamin S01FA03 Methylscopolamin S01FA04 Cyclopentolat S01FA05 Homatropin S01FA06 Tropicamid S01FA51 Atropin, Kombinationen S01FA56 Tropicamid, Kombinationen Seite 117 von 133 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 118 von 133 BEDEUTUNG DDD-INFOATC-CODE S01FB Sympathomimetika, exkl. Glaukommittel S01FB01 Phenylephrin S01FB02 Ephedrin S01FB03 Ibopamin S01FB07 Cyclodrin S01FB08 Tyramin S01G DEKONGESTIVA UND ANTIALLERGIKA S01GA Sympathomimetika als Dekongestiva S01GA01 Naphazolin S01GA02 Tetryzolin 62,5 mcg AT S01GA03 Xylometazolin S01GA04 Oxymetazolin S01GA05 Phenylephrin S01GA06 Oxedrin S01GA10 Tramazolin S01GA11 Pholedrin S01GA50 Andere Sympathomimetika, Kombinationen S01GA51 Naphazolin, Kombinationen S01GA52 Tetryzolin, Kombinationen S01GA53 Xylometazolin, Kombinationen S01GA55 Phenylephrin, Kombinationen S01GA56 Oxedrin, Kombinationen S01GX Andere Antiallergika S01GX01 Cromoglicinsäure 8 mg AT S01GX02 Levocabastin S01GX03 Spagluminsäure S01GX04 Nedocromil S01GX05 Lodoxamid S01GX06 Emedastin S01GX07 Azelastin S01GX08 Ketotifen S01GX09 Olopatadin S01GX10 Epinastin S01GX11 Alcaftadin S01GX15 Antazolin S01GX16 Diphenhydramin S01GX51 Cromoglicinsäure, Kombinationen S01H LOKALANÄSTHETIKA S01HA Lokalanästhetika S01HA01 Cocain S01HA02 Oxybuprocain S01HA03 Tetracain S01HA04 Proxymetacain S01HA05 Procain S01HA06 Cinchocain S01HA07 Lidocain S01HA30 Kombinationen S01J DIAGNOSTIKA S01JA Farbstoffe S01JA01 Fluorescein S01JA02 Bengalrosa-Natrium S01JA51 Fluorescein, Kombinationen S01JX Andere ophthalmologische Diagnostika S01K CHIRURGISCHE HILFSMITTEL S01KA Viskoelastische Substanzen S01KA01 Hyaluronsäure Standarddosis: 1 Applikationsform S01KA02 Hypromellose Standarddosis: 1 Applikationsform S01KA51 Hyaluronsäure, Kombinationen Standarddosis: 1 Applikationsform S01KX Andere chirurgische Hilfsmittel S01KX01 Chymotrypsin S01KX02 Spüllösungen Standarddosis: 1 Applikationsform S01KX10 Verschiedene 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 119 von 133 BEDEUTUNG DDD-INFOATC-CODE S01L MITTEL GEGEN VASKULÄRE AUGENERKRANKUNGEN S01LA Antineovaskuläre Mittel S01LA01 Verteporfin S01LA02 Anecortav S01LA03 Pegaptanib 0,024 DE P S01LA04 Ranibizumab 0,036 DE P S01LA05 Aflibercept 0,018 DE P S01X ANDERE OPHTHALMIKA S01XA Andere Ophthalmika S01XA01 Guajazulen S01XA02 Retinol S01XA03 Natriumchlorid, hyperton S01XA04 Kaliumiodid S01XA05 Natriumedetat S01XA06 Ethylmorphin S01XA07 Alaun S01XA08 Acetylcystein S01XA09 Iodoheparinat S01XA10 Inosin S01XA11 Nandrolon S01XA12 Dexpanthenol S01XA13 Alteplase S01XA14 Heparin S01XA15 Ascorbinsäure S01XA18 Ciclosporin S01XA19 Limbale Stammzellen, autolog S01XA20 Künstliche Tränen und andere indifferente Mittel Standarddosis: 0,4 ml AT; 0,4 g AS S01XA21 Lebertran S01XA22 Ocriplasmin Standarddosis: 1 Applikationsform S01XA23 Kälberblutextrakt S01XA24 Calciumdobesilat 0,5 g O S01XA25 Pilocarpin S01XA26 Troxerutin S01XA28 Hyaluronsäure 0,4 ml AT S01XA30 Organpräparate, inkl. Kombinationen S01XA34 Pantothensäure S01XA35 Anthocyane S01XA36 Digitalisglykoside S01XA38 Pufferlösungen S01XA39 Vincamin S01XA40 Cytidin S01XA41 Cyanocobalamin S01XA50 Andere Ophthalmika, Kombinationen S01XA52 Retinol, Kombinationen S01XA76 Troxerutin, Kombinationen S01XA85 Anthocyane, Kombinationen S01XA86 Digitalisglykoside, Kombinationen S01XA87 Pentifyllin, Kombinationen S01XA89 Vincamin, Kombinationen S01XB Antikataraktika S01XB02 Uridin-5-monophosphat S01XB03 Inosin-5-monophosphat S01XB05 Pirenoxin S01XB50 Andere Antikataraktika, Kombinationen S01XB52 Uridin-5-monophosphat, Kombinationen S01XB53 Inosin-5-monophosphat, Kombinationen S01XB54 Iodid, Kombinationen S01XC Filmbildner S01XC01 Polyvinylalkohol Standarddosis: 0,4 ml AT; 0,4 g AS S01XC02 Povidon Standarddosis: 0,4 ml AT; 0,4 g AS S01XC05 Hypromellose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC06 Hydroxyethylcellulose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC07 Carbomer Standarddosis: 0,4 ml AT; 0,4 g AS S01XC08 Carmellose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC10 Verschiedene Standarddosis: 0,4 ml AT; 0,4 g AS S01XC20 Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XC51 Polyvinylalkohol, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XC55 Hypromellose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XC56 Hydroxyethylcellulose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XC57 Carbomer, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XC58 Carmellose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XH Homöopathische und anthroposophische Ophthalmika S01XH01 Euphrasia S01XH02 Calendula officinalis S01XH10 Verschiedene S01XH20 Kombinationen S01XH51 Euphrasia, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 120 von 133 BEDEUTUNG DDD-INFOATC-CODE S02 OTOLOGIKA S02A ANTIINFEKTIVA S02AA Antiinfektiva S02AA01 Chloramphenicol S02AA02 Nitrofural S02AA03 Borsäure S02AA04 Aluminiumacetattartrat S02AA05 Clioquinol S02AA06 Hydrogenperoxid S02AA07 Neomycin S02AA08 Tetracyclin S02AA09 Chlorhexidin S02AA10 Essigsäure S02AA11 Polymyxin B S02AA12 Rifamycin S02AA13 Miconazol S02AA14 Gentamicin S02AA15 Ciprofloxacin S02AA16 Ofloxacin S02AA30 Antiinfektiva, Kombinationen S02B CORTICOSTEROIDE S02BA Corticosteroide S02BA01 Hydrocortison S02BA03 Prednisolon S02BA06 Dexamethason S02BA07 Betamethason S02BA08 Fluocinolon acetonid S02BA56 Dexamethason, Kombinationen S02C CORTICOSTEROIDE UND ANTIINFEKTIVA IN KOMBINATION S02CA Corticosteroide und Antiinfektiva in Kombination S02CA01 Prednisolon und Antiinfektiva S02CA02 Flumetason und Antiinfektiva S02CA03 Hydrocortison und Antiinfektiva S02CA04 Triamcinolon und Antiinfektiva S02CA05 Fluocinolonacetonid und Antiinfektiva S02CA06 Dexamethason und Antiinfektiva S02CA07 Fludrocortison und Antiinfektiva S02D ANDERE OTOLOGIKA S02DA Analgetika und Anästhetika S02DA01 Lidocain S02DA02 Cocain S02DA03 Phenazon S02DA04 Cinchocain S02DA06 Salicylate S02DA30 Kombinationen S02DA51 Lidocain, Kombinationen S02DA55 Procain, Kombinationen S02DA57 Tetracain, Kombinationen S02DC Indifferente Zubereitungen S02DC01 Ölsäure-Derivate S02DC02 Docusat-Natrium S02DC03 Glycerol S02DC04 Meerwasser S02DC30 Kombinationen S02DH Homöopathische und anthroposophische Otologika S02DH01 Levisticum officinale S02DH20 Kombinationen S02DH50 Kombinationen mit anderen Mitteln 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 121 von 133 BEDEUTUNG DDD-INFOATC-CODE S03 OPHTHALMOLOGISCHE UND OTOLOGISCHE ZUBEREITUNGEN S03A ANTIINFEKTIVA S03AA Antiinfektiva S03AA01 Neomycin S03AA02 Tetracyclin S03AA03 Polymyxin B S03AA04 Chlorhexidin S03AA05 Hexamidin S03AA06 Gentamicin S03AA07 Ciprofloxacin S03AA08 Chloramphenicol S03AA30 Antiinfektiva, Kombinationen S03B CORTICOSTEROIDE S03BA Corticosteroide S03BA01 Dexamethason S03BA02 Prednisolon S03BA03 Betamethason S03C CORTICOSTEROIDE UND ANTIINFEKTIVA IN KOMBINATION S03CA Corticosteroide und Antiinfektiva in Kombination S03CA01 Dexamethason und Antiinfektiva S03CA02 Prednisolon und Antiinfektiva S03CA04 Hydrocortison und Antiinfektiva S03CA05 Fludrocortison und Antiinfektiva S03CA06 Betamethason und Antiinfektiva S03D ANDERE OPHTHALMOLOGISCHE UND OTOLOGISCHE ZUBEREITUNGEN 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 122 von 133 BEDEUTUNG DDD-INFOATC-CODE V VARIA V01 ALLERGENE V01A ALLERGENE V01AA Allergen-Extrakte V01AA01 Federn V01AA02 Gräserpollen V01AA03 Hausstaubmilben V01AA04 Schimmel- und Hefepilze V01AA05 Baumpollen V01AA07 Insekten V01AA08 Nahrungsmittel V01AA09 Textilien V01AA10 Blüten V01AA11 Tiere V01AA20 Verschiedene V03 ALLE ÜBRIGEN THERAPEUTISCHEN MITTEL V03A ALLE ÜBRIGEN THERAPEUTISCHEN MITTEL V03AB Antidote V03AB01 Ipecacuanha V03AB02 Nalorphin V03AB03 Edetate V03AB04 Pralidoxim V03AB05 Prednisolon und Promethazin V03AB06 Thiosulfat V03AB08 Natriumnitrit V03AB09 Dimercaprol V03AB13 Obidoxim V03AB14 Protamin Standarddosis: 1 Applikationsform P V03AB15 Naloxon Standarddosis: 1 Applikationsform P V03AB16 Ethanol V03AB17 Methylthioniniumchlorid V03AB18 Kaliumpermanganat V03AB19 Physostigmin V03AB20 Kupfersulfat V03AB21 Kaliumiodid V03AB22 Amylnitrit V03AB23 Acetylcystein V03AB24 Digitalis-Antitoxin V03AB25 Flumazenil V03AB26 Methionin V03AB27 4-Dimethylaminophenol Standarddosis: 1 Applikationsform P V03AB29 Cholinesterase V03AB31 Eisen(III)hexacyanoferrat(II) V03AB32 Glutathion V03AB33 Hydroxocobalamin V03AB34 Fomepizol V03AB35 Sugammadex 0,28 g P V03AB36 Phentolamin Standarddosis: 1 Applikationsform P V03AB43 DMPS V03AB44 Atropin V03AB45 Apomorphin V03AB46 Toloniumchlorid V03AB47 Pentetsäure V03AB48 Silymarin V03AC Eisen-Chelatbildner V03AC01 Deferoxamin V03AC02 Deferipron V03AC03 Deferasirox V03AE Mittel zur Behandlung der Hyperkaliämie und Hyperphosphatämie V03AE01 Polystyrolsulfonat 45 g O V03AE02 Sevelamer 6,4 g O V03AE03 Lanthan(III)-carbonat 2,25 g O bezogen auf Lanthanum V03AE04 Calciumacetat und Magnesiumcarbonat V03AE05 Aluminiumhydroxid V03AE06 Colestilan 7,5 g O V03AE07 Calciumacetat, wasserfrei 6 g O V03AE08 Calciumcarbonat V03AE09 Aluminiumchloridhydroxid V03AE11 Calciumketoglutarat 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 123 von 133 BEDEUTUNG DDD-INFOATC-CODE V03AF Entgiftungsmittel für die Behandlung mit Zytostatika V03AF01 Mesna V03AF02 Dexrazoxan 1,5 g P V03AF03 Calciumfolinat 60 mg O,P bezogen auf Folinsäure V03AF04 Calciumlevofolinat 30 mg O,P bezogen auf Levofolinsäure V03AF05 Amifostin 1,7 g P V03AF06 Natriumfolinat 60 mg P bezogen auf Folinsäure; 60 mg O V03AF07 Rasburicase 14 mg P V03AF08 Palifermin 4,2 mg P V03AF09 Glucarpidase V03AF10 Natriumlevofolinat 30 mg P bezogen auf Levofolinsäure V03AG Mittel zur Behandlung der Hyperkalzämie V03AG01 Natriumcellulosephosphat V03AH Mittel zur Behandlung der Hypoglykämie V03AH01 Diazoxid V03AK Gewebekleber V03AK01 Cyanacrylsäurealkylester V03AK50 Andere Gewebekleber, Kombinationen V03AM Mittel zur Embolisation V03AM01 Amilomer V03AN Medizinische Gase V03AN01 Sauerstoff V03AN02 Kohlendioxid V03AN03 Helium V03AN04 Stickstoff V03AN05 Medizinische Luft V03AX Andere therapeutische Mittel V03AX02 Nalfurafin V03AX03 Cobicistat V03AX04 Hydroxylapatit-Keramik V03AX10 Placebo Standarddosis: 1 Applikationsform V03AX50 Andere therapeutische Mittel, Kombinationen V03AZ Nerven dämpfende Mittel V03AZ01 Ethanol V04 DIAGNOSTIKA V04B URIN-TESTS V04BA Urin-Tests V04BA01 Protein-Testzone Standarddosis: 1 Test V04BA03 Blut-Testzone Standarddosis: 1 Test V04BA05 pH-Testzone Standarddosis: 1 Test V04BA06 Ascorbinsäure-Testzone Standarddosis: 1 Test V04BA07 Schwangerschaftstest Standarddosis: 1 Test V04BA08 Bilirubin-Testzone Standarddosis: 1 Test V04BA09 Urobilinogen-Testzone Standarddosis: 1 Test V04BA10 Dichte-Testzone Standarddosis: 1 Test V04BA11 Nitrit-Testzone Standarddosis: 1 Test V04BA12 Leukozyten-Testzone Standarddosis: 1 Test V04BA13 CTX-Testzone Standarddosis: 1 Test V04BA14 Bakterien-Testzone Standarddosis: 1 Test V04BA15 Kreatin-Kinase-Testzone Standarddosis: 1 Test V04BA20 Kombinationen Standarddosis: 1 Test V04C ANDERE DIAGNOSTIKA V04CA Diabetes-Tests V04CA01 Tolbutamid V04CA02 Glucose V04CA03 Glucose-Testzone, Blut Standarddosis: 1 Test V04CA04 Glucose-Testzone, Urin Standarddosis: 1 Test V04CA05 Keton-Testzone, Blut Standarddosis: 1 Test V04CA06 Keton-Testzone, Urin Standarddosis: 1 Test V04CA07 Glucose-Keton-Testzone, Urin Standarddosis: 1 Test V04CA08 Glycohämoglobin-Testzone Standarddosis: 1 Test V04CB Fettabsorptions-Tests V04CB01 Vitamin-A-Konzentrate V04CC Gallenfluss-Tests 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 124 von 133 BEDEUTUNG DDD-INFOATC-CODE V04CC01 Sorbitol V04CC02 Magnesiumsulfat V04CC03 Sincalid V04CC04 Ceruletid V04CD Hypophysenfunktions-Tests V04CD01 Metyrapon V04CD03 Sermorelin V04CD04 Corticoliberin V04CD05 Somatorelin V04CE Leberfunktions-Tests V04CE01 Galactose V04CE02 Bromsulfalein V04CF Tuberkulose-Diagnostika V04CF01 Tuberkulin Standarddosis: 1 Test V04CG Magensäuresekretions-Tests V04CG01 Kationenaustauscherharze V04CG02 Betazol V04CG03 Histaminphosphat V04CG04 Pentagastrin V04CG05 Methylthioniniumchlorid V04CG30 Coffein und Natriumbenzoat V04CH Nierenfunktionstests und Tests auf Harnleiterverletzungen V04CH01 Inulin und andere Polyfructosane V04CH02 Indigokarmin V04CH03 Phenolsulfonphthalein V04CH04 Alsactid V04CH30 Aminohippursäure V04CJ Schilddrüsenfunktions-Tests V04CJ01 Thyrotropin V04CJ02 Protirelin V04CJ03 Levothyroxin V04CK Pankreasfunktions-Tests V04CK01 Sekretin V04CK02 Pankreozymin (Cholecystokinin) V04CK03 Bentiromid V04CL Allergie-Tests V04CL01 Methacholin V04CL02 Nickel-Testzone Standarddosis: 1 Test V04CL10 Verschiedene V04CM Fertilitäts-Tests V04CM01 Gonadorelin V04CM02 Fertilitäts-Teststreifen Standarddosis: 1 Test V04CM03 Lutropin-Testzone Standarddosis: 1 Test V04CM04 FSH-Testzone Standarddosis: 1 Test V04CM05 Spermientest Standarddosis: 1 Test V04CM20 Kombinationen Standarddosis: 1 Test V04CN Tests auf missbräuchlich angewendete Wirkstoffe V04CN01 Amfetamin-Testzone Standarddosis: 1 Test V04CN02 Barbiturat-Testzone Standarddosis: 1 Test V04CN03 Benzodiazepin-Testzone Standarddosis: 1 Test V04CN04 Kokain-Testzone Standarddosis: 1 Test V04CN05 Methadon-Testzone Standarddosis: 1 Test V04CN06 Metamfetamin-Testzone Standarddosis: 1 Test V04CN07 Opiat-Testzone Standarddosis: 1 Test V04CN08 Tricyclische Antidepressiva-Testzone Standarddosis: 1 Test V04CN09 Tetrahydrocannabinol-Testzone Standarddosis: 1 Test V04CN10 Phenylcyclohexylpiperidin-Testzone Standarddosis: 1 Test V04CN11 Alkohol-Testzone Standarddosis: 1 Test V04CN12 Methylendioxy-methamphetamin Testzone Standarddosis: 1 Test V04CN13 Buprenorphin-Testzone Standarddosis: 1 Test V04CN14 Nicotin/Cotinin-Testzone Standarddosis: 1 Test V04CN15 Tenamfetamin-Testzone (MDA) Standarddosis: 1 Test V04CN20 Kombinationen Standarddosis: 1 Test V04CO Myokardinfarkt-Tests V04CO01 kardiales Fettsäure-Bindungsprotein (h-FABP) Standarddosis: 1 Test V04CO02 N-terminal-pro BNP-Testzone Standarddosis: 1 Test V04CO03 pro BNP-Testzone Standarddosis: 1 Test V04CO04 CK-MB-Testzone Standarddosis: 1 Test V04CO20 Kombinationen Standarddosis: 1 Test V04CX Andere Diagnostika 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 125 von 133 BEDEUTUNG DDD-INFOATC-CODE V04CX03 Fluorescein Standarddosis: 1 Test V04CX04 Harnsäure-Testzone Standarddosis: 1 Test V04CX05 Tumor-Antigen-Testzone Standarddosis: 1 Test V04CX06 Imciromab V04CX07 MAB.B72.3 V04CX08 Cholesterin-Testzone Standarddosis: 1 Test V04CX09 HDL-Cholesterin-Testzone Standarddosis: 1 Test V04CX10 Verschiedene V04CX12 Troponin-Testzone Standarddosis: 1 Test V04CX13 Helicobacter-pylori-Test Standarddosis: 1 Test V04CX14 Chlamydien-Testzone Standarddosis: 1 Test V04CX15 Streptokokken-Testzone Standarddosis: 1 Test V04CX16 Gonorrhoeae-neisseria-Testzone Standarddosis: 1 Test V04CX17 Blut-Testzone (Stuhl) Standarddosis: 1 Test V04CX18 Mononucleose-Testzone Standarddosis: 1 Test V04CX21 Myoglobin-Testzone Standarddosis: 1 Test V04CX22 Prostata spezifische Antigen-Testzone Standarddosis: 1 Test V04CX23 Gerinnungsparameter Standarddosis: 1 Test V04CX24 Influenza-Testzone Standarddosis: 1 Test V04CX25 Protein-C-Testzone Standarddosis: 1 Test V04CX26 Vaterschaftstest mit DNA-Testzone Standarddosis: 1 Test V04CX27 Plaque-Testzone V04CX28 Treponema pallidum-Testzone Standarddosis: 1 Test V04CX29 Lactat-Testzone Standarddosis: 1 Test V04CX31 Triglycerid-Testzone Standarddosis: 1 Test V04CX32 Aminolevulinsäure 1,4 g O V04CX50 Andere Diagnostika, Kombinationen Standarddosis: 1 Test V04CX51 Troponin, Kombinationen Standarddosis: 1 Test V04CZ Mittel zur Diagnosevorbereitung V04CZ01 Sennesfrüchteextrakt V04CZ02 Mineralsalze, Kombinationen V04CZ04 Bisacodyl, Kombinationen V04CZ05 Faulbaumrinde, Kombinationen V04CZ08 Sorbitol V04CZ09 Silikone V04CZ10 Macrogol, Kombinationen V06 ALLGEMEINE DIÄTETIKA V06A DIÄTETIKA ZUR BEHANDLUNG DER ADIPOSITAS V06AA Niedrigkalorische Diäten V06B PROTEINZUSATZNAHRUNG V06BA Proteinzusatznahrung V06BA50 Proteinzusatznahrung, Kombinationen V06C SÄUGLINGSNAHRUNG V06CA Diätetika ohne Phenylalanin V06CA50 Diätetika ohne Phenylalanin, Kombinationen V06CX Andere Diätetika als Säuglingsnahrung V06CX50 Andere Diätetika als Säuglingsnahrung, Kombinationen V06D ANDERE DIÄTETIKA V06DA Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen V06DA50 Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen V06DB Fette/Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen V06DB50 Fette/Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen V06DB51 Fette in Kombination mit Vitaminen V06DB52 Fette, Kombinationen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 126 von 133 BEDEUTUNG DDD-INFOATC-CODE V06DC Kohlenhydrate V06DC01 Glucose V06DC02 Fructose V06DC20 Kombinationen V06DC51 Glucose, Kombinationen V06DD Aminosäuren, inkl. Kombinationen mit Polypeptiden V06DD01 Aminosäuren, Kombinationen mit Kohlenhydraten V06DD20 Kombinationen V06DE Aminosäuren/Kohlenhydrate/Mineralstoffe/Vitamine, Kombinationen V06DF Milchersatzstoffe V06DX Andere Diätetika-Kombinationen V06DX50 Andere Diätetika-Kombinationen V07 ALLE ÜBRIGEN NICHTTHERAPEUTISCHEN MITTEL V07A ALLE ÜBRIGEN NICHTTHERAPEUTISCHEN MITTEL V07AA Pflaster V07AB Lösungs- und Verdünnungsmittel, inkl. Spüllösungen V07AB01 Wasser Standarddosis: 1 Applikationsform V07AB02 Physiologische Kochsalzlösung Standarddosis: 1 Applikationsform V07AB03 Ethanol V07AC Bluttransfusionen, Hilfsstoffe V07AD Blut-Tests, Hilfsmittel V07AD01 Kontroll-Lösungen V07AG Verbandmittel V07AI Andere Hilfsmittel ohne Pharmazentralnummer V07AI01 Andere Hilfsmittel ohne Pharmazentralnummer V07AI02 Andere Hilfsmittel ohne Pharmazentralnummer, die im Zusammenhang mit einer individuell hergestellten parenteralen Lösung abgegeben werden V07AK Abrechnung von Mietgebühren für Hilfsmittel V07AN Inkontinenz-Artikel V07AN50 Katheter, Kombinationen Standarddosis: 1 Applikationsform V07AQ Sonstige apothekenübliche Ware V07AR Sensitivitäts-Tests, Plättchen und Tabletten V07AS Stoma-Artikel V07AT Kosmetika V07AV Technische Desinfektionsmittel V07AW Verbandmittel/Pflaster ohne Pharmazentralnummer V07AX Waschsubstanzen etc. V07AY Andere nichttherapeutische Hilfsmittel V07AY02 Kältepackungen (Kompressen) V07AZ Chemikalien und Reagenzien zur Analyse 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 127 von 133 BEDEUTUNG DDD-INFOATC-CODE V08 KONTRASTMITTEL V08A RÖNTGENKONTRASTMITTEL, IOD-HALTIG V08AA Wasserlösliche nephrotrope hochosmolare Röntgenkontrastmittel V08AA01 Amidotrizoesäure Standarddosis: 1 Applikationsform V08AA02 Metrizoesäure Standarddosis: 1 Applikationsform V08AA03 Iodamid Standarddosis: 1 Applikationsform V08AA04 Iotalaminsäure Standarddosis: 1 Applikationsform V08AA05 Ioxitalaminsäure Standarddosis: 1 Applikationsform V08AA06 Ioglicinsäure Standarddosis: 1 Applikationsform V08AA07 Acetrizoinsäure Standarddosis: 1 Applikationsform V08AA08 Iocarminsäure Standarddosis: 1 Applikationsform V08AA09 Methiodal Standarddosis: 1 Applikationsform V08AA10 Diodon Standarddosis: 1 Applikationsform V08AA13 Iomeglaminsäure Standarddosis: 1 Applikationsform V08AA20 Kombinationen Standarddosis: 1 Applikationsform V08AB Wasserlösliche nephrotrope niederosmolare Röntgenkontrastmittel V08AB01 Metrizamid Standarddosis: 1 Applikationsform V08AB02 Iohexol Standarddosis: 1 Applikationsform V08AB03 Ioxaglinsäure Standarddosis: 1 Applikationsform V08AB04 Iopamidol Standarddosis: 1 Applikationsform V08AB05 Iopromid Standarddosis: 1 Applikationsform V08AB06 Iotrolan Standarddosis: 1 Applikationsform V08AB07 Ioversol Standarddosis: 1 Applikationsform V08AB08 Iopentol Standarddosis: 1 Applikationsform V08AB09 Iodixanol Standarddosis: 1 Applikationsform V08AB10 Iomeprol Standarddosis: 1 Applikationsform V08AB11 Iobitridol Standarddosis: 1 Applikationsform V08AB12 Ioxilan Standarddosis: 1 Applikationsform V08AB13 Iosarcol Standarddosis: 1 Applikationsform V08AC Wasserlösliche hepatotrope Röntgenkontrastmittel V08AC01 Iodoxaminsäure Standarddosis: 1 Applikationsform V08AC02 Iotroxinsäure Standarddosis: 1 Applikationsform V08AC03 Ioglycaminsäure Standarddosis: 1 Applikationsform V08AC04 Adipiodon Standarddosis: 1 Applikationsform V08AC05 Iobenzaminsäure Standarddosis: 1 Applikationsform V08AC06 Iopansäure Standarddosis: 1 Applikationsform V08AC07 Iocetaminsäure Standarddosis: 1 Applikationsform V08AC08 Natriumiopodat Standarddosis: 1 Applikationsform V08AC09 Tyropansäure Standarddosis: 1 Applikationsform V08AC10 Calciumiopodat Standarddosis: 1 Applikationsform V08AD Wasserunlösliche Röntgenkontrastmittel V08AD01 Ethylester iodierter Fettsäuren Standarddosis: 1 Applikationsform V08AD02 Iopydol Standarddosis: 1 Applikationsform V08AD03 Propyliodon Standarddosis: 1 Applikationsform V08AD04 Iofendylat Standarddosis: 1 Applikationsform V08B RÖNTGENKONTRASTMITTEL, NICHT IOD-HALTIG V08BA Bariumsulfat-haltige Röntgenkontrastmittel V08BA01 Bariumsulfat mit Suspensionsmittel Standarddosis: 1 Applikationsform V08BA02 Bariumsulfat ohne Suspensionsmittel Standarddosis: 1 Applikationsform V08C KONTRASTMITTEL FÜR DIE MAGNETRESONANZTOMOGRAPHIE V08CA Paramagnetische Kontrastmittel V08CA01 Gadopentetsäure Standarddosis: 1 Applikationsform V08CA02 Gadotersäure Standarddosis: 1 Applikationsform V08CA03 Gadodiamid Standarddosis: 1 Applikationsform V08CA04 Gadoteridol Standarddosis: 1 Applikationsform V08CA05 Mangafodipir Standarddosis: 1 Applikationsform V08CA06 Gadoversetamid Standarddosis: 1 Applikationsform V08CA07 Ammoniumeisen(III)citrat Standarddosis: 1 Applikationsform V08CA08 Gadobensäure Standarddosis: 1 Applikationsform V08CA09 Gadobutrol Standarddosis: 1 Applikationsform V08CA10 Gadoxetsäure V08CA11 Gadofosveset 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 128 von 133 BEDEUTUNG DDD-INFOATC-CODE V08CB Superparamagnetische Kontrastmittel V08CB01 Ferumoxsil Standarddosis: 1 Applikationsform V08CB02 Ferristen Standarddosis: 1 Applikationsform V08CB03 Eisenoxid, Nanopartikel Standarddosis: 1 Applikationsform V08CX Andere Kontrastmittel für die Magnetresonanztomographie V08CX01 Perflubron Standarddosis: 1 Applikationsform V08D ULTRASCHALL-KONTRASTMITTEL V08DA Ultraschall-Kontrastmittel V08DA01 Humanalbumin-Mikrosphären Standarddosis: 1 Applikationsform V08DA02 Galactose-Mikropartikel Standarddosis: 1 Applikationsform V08DA03 Perflenapent Standarddosis: 1 Applikationsform V08DA04 Phospholipid-Mikrosphären Standarddosis: 1 Applikationsform V08DA05 Schwefelhexafluorid V08E FLUORESZENZ-KONTRASTMITTEL V08EA Fluoreszenz-Kontrastmittel V08EA01 Hexaminolevulinat V09 RADIODIAGNOSTIKA V09A ZENTRALES NERVENSYSTEM V09AA [99mTc]Technetium-Verbindungen V09AA01 [99mTc]Technetium-Exametazim V09AA02 [99mTc]Technetiumbicisat V09AB [123I]Iod-Verbindungen V09AB01 [123I]Iod-Iofetamin V09AB02 [123I]Iod-Ioloprid V09AB03 [123I]Iod-Ioflupan V09AX Andere Radiodiagnostika für das zentrale Nervensystem V09AX01 [111In]Indiumpentetat V09AX03 [124I]Iod-2 beta-carboxymethyl-3 beta-(4-iodphenyl)-tropan V09AX04 [18F]Flutemetamol V09AX05 [18F]Florbetapir V09B SKELETT V09BA [99mTc]Technetium-Verbindungen V09BA01 [99mTc]Technetiumoxidronat V09BA02 [99mTc]Technetiummedronat V09BA03 [99mTc]Technetiumpyrophosphat V09BA04 [99mTc]Technetiumbutedronat V09C NIERENSYSTEM V09CA [99mTc]Technetium-Verbindungen V09CA01 [99mTc]Technetiumpentetat V09CA02 [99mTc]Technetium-Succimer V09CA03 [99mTc]Technetiummertiatid V09CA04 [99mTc]Technetiumglucoheptonat V09CA05 [99mTc]Technetiumgluconat V09CA06 [99mTc]Technetium-Ethylendicystein V09CX Andere Radiodiagnostika für das Nierensystem V09CX01 [123I]Natrium-Iodhippurat V09CX02 [131I]Natrium-Iodhippurat V09CX03 [125I]Natrium-Iodthalamat V09CX04 [51Cr]Chromedetat 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 129 von 133 BEDEUTUNG DDD-INFOATC-CODE V09D LEBER- UND RETIKULOENDOTHELIALSYSTEM V09DA [99mTc]Technetium-Verbindungen V09DA01 [99mTc]Technetium-Disofenin V09DA02 [99mTc]Technetium-Etifenin V09DA03 [99mTc]Technetium-Lidofenin V09DA04 [99mTc]Technetium-Mebrofenin V09DA05 [99mTc]Technetium-Galtifenin V09DB [99mTc]Technetium, Partikel und Kolloide V09DB01 [99mTc]Technetium-Nanokolloid V09DB02 [99mTc]Technetium-Mikrokolloid V09DB03 [99mTc]Technetium-Millimikrosphären V09DB04 [99mTc]Technetium-Zinn-Kolloid V09DB05 [99mTc]Technetium-Schwefel-Kolloid V09DB06 [99mTc]Technetium-Rheniumsulfid-Kolloid V09DB07 [99mTc]Technetiumphytat V09DX Andere Radiodiagnostika für das Leber- und Retikuloendothelialsystem V09DX01 [75Se]Selenium-tauroselcholinat V09E RESPIRATIONSTRAKT V09EA [99mTc]Technetium, Inhalate V09EA01 [99mTc]Technetiumpentetat V09EA02 [99mTc]Technetium, Technegas V09EA03 [99mTc]Technetium-Nanokolloid V09EB [99mTc]Technetium, Partikel zur Injektion V09EB01 [99mTc]Technetium-Macrosalb V09EB02 [99mTc]Technetium-Mikrosphären V09EX Andere Radiodiagnostika für den Respirationstrakt V09EX01 [81mKr]Kryptongas V09EX02 [127Xe]Xenongas V09EX03 [133Xe]Xenongas V09F SCHILDDRÜSE V09FX Verschiedene Radiodiagnostika für die Schilddrüse V09FX01 [99mTc]Technetiumpertechnetat V09FX02 [123I]Natriumiodid V09FX03 [131I]Natriumiodid V09FX04 [124I]Natriumiodid V09G KARDIOVASKULÄRES SYSTEM V09GA [99mTc]Technetium-Verbindungen V09GA01 [99mTc]Technetiumsestamibi V09GA02 [99mTc]Technetiumtetrofosmin V09GA03 [99mTc]Technetiumteboroxim V09GA04 [99mTc]Technetium-Humanalbumin V09GA05 [99mTc]Technetiumfurifosmin V09GA06 [99mTc]Technetium-Zinn-markierte Zellen V09GA07 [99mTc]Technetiumapcitid V09GB [125I]Iod-Verbindungen V09GB01 [125I]Fibrinogen V09GB02 [125I]Iod-Humanalbumin V09GX Andere Radiodiagnostika für das kardiovaskuläre System V09GX01 [201Tl]Thalliumchlorid V09GX02 [111In]Indiumimciromab V09GX03 [51Cr]Chromchromat-markierte Zellen V09GX04 [82Rb]Rubidiumchlorid 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 130 von 133 BEDEUTUNG DDD-INFOATC-CODE V09H ENTZÜNDUNGS- UND INFEKTIONSERKENNUNG V09HA [99mTc]Technetium-Verbindungen V09HA01 [99mTc]Technetium-Humanimmunglobulin V09HA02 [99mTc]Technetium-Exametazim-markierte Zellen V09HA03 [99mTc]Technetium-Antigranulozyten-Antikörper V09HA04 [99mTc]Technetium-Sulesomab V09HB [111In]Indium-Verbindungen V09HB01 [111In]Indiumoxinat-markierte Zellen V09HB02 [111In]Indiumtropolonat-markierte Zellen V09HX Andere Radiodiagnostika zur Erkennung von Entzündungen und Infektionen V09HX01 [67Ga]Galliumcitrat V09I TUMORERKENNUNG V09IA [99mTc]Technetium-Verbindungen V09IA01 [99mTc]Technetium-Anticarcinoembryoantigen-Antikörper V09IA02 [99mTc]Technetium-Antimelanom-Antikörper V09IA03 [99mTc]Technetiumsuccimer, pentavalent V09IA04 [99mTc]Technetiumvotumumab V09IA05 [99mTc]Technetiumdepreotid V09IA06 [99mTc]Technetiumarcitumomab V09IA07 [99mTc]Technetium-hynic-octreotid V09IB [111In]Indium-Verbindungen V09IB01 [111In]Indiumpentetreotid V09IB02 [111In]Indium-Satumomab-pendetid V09IB03 [111In]Indium-Antiovariumkarzinom-Antikörper V09IB04 [111In]Indium-Capromab-Pendetid V09IX Andere Radiodiagnostika zur Tumorerkennung V09IX01 [123I]Iobenguan V09IX02 [131I]Iobenguan V09IX03 [125I]Iod-CC49-Monoklonaler Antikörper V09IX04 [18F]Fludeoxyglucose V09IX05 [18F]Fluorodopa V09IX06 [18F]Natriumfluorid V09IX07 [18F]Fluoromethylcholin V09IX08 [18F]Fluoroethylcholin V09X ANDERE RADIODIAGNOSTIKA V09XA [131I]Iod-Verbindungen V09XA01 [131I]Iodnorcholesterol V09XA02 [131I]Iodcholesterol V09XA03 [131I]Iod-Humanalbumin V09XX Verschiedene Radiodiagnostika V09XX01 [57Co]Cobaltcyanocobalamin V09XX02 [58Co]Cobaltcyanocobalamin V09XX03 [75Se]Selennorcholesterol V09XX04 [59Fe]Eisen(III)citrat V10 RADIOTHERAPEUTIKA V10A ENTZÜNDUNGSHEMMENDE MITTEL V10AA [90Y]Yttrium-Verbindungen V10AA01 [90Y]Yttriumcitrat-Kolloid V10AA02 [90Y]Yttrium-Eisen(III)hydroxid-Kolloid V10AA03 [90Y]Yttriumsilicat-Kolloid V10AX Andere entzündungshemmende Radiotherapeutika 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 131 von 133 BEDEUTUNG DDD-INFOATC-CODE V10AX01 [32P]Chrom(III)phosphat-Kolloid V10AX02 [153Sm]Samariumhydroxyapatit-Kolloid V10AX03 [165Dy]Dysprosium-Kolloid V10AX04 [169Er]Erbiumcitrat-Kolloid V10AX05 [186Re]Rheniumsulfid-Kolloid V10AX06 [198Au]Gold-Kolloid V10B SCHMERZLINDERUNG (KNOCHENMETASTASEN) V10BX Verschiedene Radiopharmaka zur Schmerzlinderung V10BX01 [89Sr]Strontiumchlorid V10BX02 [153Sm]Samariumlexidronam V10BX03 [186Re]Rheniumetidronat V10X ANDERE RADIOTHERAPEUTIKA V10XA [131I]Iod-Verbindungen V10XA01 [131I]Natriumiodid V10XA02 [131I]Iobenguan V10XA53 Tositumomab/[131I]Iod-Tositumomab V10XX Verschiedene Radiotherapeutika V10XX01 [32P]Natriumphosphat V10XX02 [90Y]Ibritumomab tiuxetan V20 WUNDVERBÄNDE V60 HOMÖOPATHIKA UND ANTHROPOSOPHIKA V60A HOMÖOPATHIKA V60AA Homöopathika mit Pharmazentralnummer V60AB Homöopathika ohne Pharmazentralnummer V60B ANTHROPOSOPHIKA V70 REZEPTUREN V70A REZEPTUREN ZUR BEHANDLUNG VON SUCHTERKRANKUNGEN V70AA Rezepturen zur Behandlung der Opiatabhängigkeit V70AA01 Methadon-Zubereitungen V70AA02 Diamorphin V70B REZEPTUREN ZUR ANTINEOPLASTISCHEN UND IMMUNMODULIERENDEN BEHANDLUNG V70BA Zytostatika-Zubereitungen V70C INDIVIDUELL HERGESTELLTE PARENTERALE LÖSUNGEN V70CA Individuell hergestellte parenterale Ernährungslösungen V70CB Individuell hergestellte parenterale antibiotikahaltige Infusionslösungen V70CC Individuell hergestellte parenterale virustatikahaltige Infusionslösungen 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 132 von 133 BEDEUTUNG DDD-INFOATC-CODE V70CD Individuell hergestellte parenterale Schmerzlösungen V70CE Individuell hergestellte parenterale Lösungen mit Monoklonalen Antikörpern V70CF Individuell hergestellte parenterale Lösungen mit Folinaten, die keine weiteren Wirkstoffe enthalten V70CX Sonstige individuell hergestellte parenterale Lösungen V70D ABRECHNUNG VON VERORDNUNGEN V70DA Abrechnung von Verordnungen im Rahmen der künstlichen Befruchtung V70X ANDERE REZEPTUREN V70XA Rezepturen (auch Rezeptursubstanzen ungemischt) V90 SONDERGRUPPEN V90A EINZELN IMPORTIERTE AM (§ 73 ABSATZ 3 AMG) V90B ARZNEIMITTEL OHNE PHARMAZENTRALNUMMER V90C STÜCKELUNG NACH ZIFFER 3, TECHNISCHE ANLAGE GEM. § 300 SGB V V90D ARZNEIMITTELDOSSIER NACH HAUSAPOTHEKERVERTRAG V90E TIERARZNEIMITTEL V90F BTM-GEBÜHR V90G NOCTU-GEBÜHR V90H ABRECHNUNGSFÄHIGE BESCHAFFUNGSKOSTEN V90I NICHTVERFÜGBARKEIT VON RABATTBEGÜNSTIGTEN ODER VON IMPORTIERTEN ARZNEIMITTELN V90K WIEDERABGABE VON ARZNEIMITTELN V90L AUSEINZELUNG V90M AUS FERTIGARZNEIMITTELN ENTNOMMENE, PATIENTENINDIVIDUELLE TEILMENGEN IM RAHMEN EINER DAUERMEDIKATION (Z.B. BLISTER) 2.1 ATC-Index mit DDD-Angaben, sortiert nach ATC-Code - Amtliche deutsche Fassung 2014 Seite 133 von 133 BEDEUTUNG DDD-INFOATC-CODE V90N ABRECHNUNG VON L-POLAMIDON- EINZELDOSEN V90O ABRECHNUNG VON SUBUTEX-EINZELDOSEN V90P ABRECHNUNG VON SUBOXONE-EINZELDOSEN V90Q ABRECHNUNG DES ZUSCHLAGES BEI ABGABE VON OSELTAMIVIR-ZUBEREITUNGEN V90S REGIONALE UND KASSENSPEZIFISCHE SONDER- PZN * S01: Die DDD für Augentropfen, die nach Einheiten dosiert werden, basieren auf dem Volumen des Eindosisbehältnisses. Eine DDD entspricht im allgemeinen der Standarddosis 1 EDO. Abweichend hiervon basiert in der Gruppe S01E Glaukommittel und Miotika die DDD von Eindosisbehältnissen auf einer Einzeldosis (oder Eindosisbehältnis) und der Applikationsfrequenz. Eine DDD entspricht in dieser Gruppe einer Einzeldosis multipliziert mit der Applikationshäufigkeit pro Tag. 2 ATC-Index mit DDD-Angaben – sortiert nach Wirkstoffen 2 ATC-Index mit DDD-Angaben Amtliche deutsche Fassung 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 1 von 92 ATC-CODE BEDEUTUNG DDD-INFO A J05AF06 Abacavir 0,6 g O L02BX01 Abarelix 3,6 mg P L04AA24 Abatacept 27 mg P B01AC13 Abciximab 25 mg P L04AA22 Abetimus L02BX03 Abirateron 1 g O bezogen auf Abirateronacetat B02BC01 Absorbierbarer Gelatineschwamm Standarddosis: 1 Applikationsform G02CX55 Abucetamid, Kombinationen C01EB13 Acadesin N07BB03 Acamprosat 2 g O A10BF01 Acarbose 0,3 g O C07AB04 Acebutolol 0,4 g O C07FB04 Acebutolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07CB04 Acebutolol und andere Diuretika Standarddosis: 1 Applikationsform O C07BB04 Acebutolol und Thiazide S01EB08 Aceclidin S01EB58 Aceclidin, Kombinationen M01AB16 Aceclofenac 0,2 g O M02AA25 Aceclofenac R03DA09 Acefyllinpiperazin M01AB11 Acemetacin 0,12 g O B01AA07 Acenocoumarol 5 mg O N05AA04 Acepromazin 0,1 g O; 50 mg P A07AX02 Acetarsol G01AB01 Acetarsol 0,5 g V P01CD02 Acetarsol S01EC01 Acetazolamid 0,75 g O,P A11DA07 Acethiamin A10BB31 Acetohexamid 0,5 g O G04BX03 Acetohydroxamsäure 0,75 g O N05AB07 Acetophenazin 50 mg O A02BX09 Acetoxolon V08AA07 Acetrizoinsäure Standarddosis: 1 Applikationsform R02AA33 Acetylaminonitropropoxybenzol N06BX12 Acetylcarnitin N07AB03 Acetylcholin S01EB09 Acetylcholin R05CB01 Acetylcystein 0,5 g O, P S01XA08 Acetylcystein V03AB23 Acetylcystein C01AA01 Acetyldigitoxin 0,2 mg O C01AA02 Acetyldigoxin 0,5 mg O C01AA52 Acetyldigoxin, Kombinationen R05DA12 Acetyldihydrocodein 30 mg O N05CC03 Acetylglycinamidchloralhydrat 1,7 g O N07CA04 Acetylleucin A01AD05 Acetylsalicylsäure B01AC06 Acetylsalicylsäure 1 Tablette O (unabhängig von der Wirkstärke) N02BA01 Acetylsalicylsäure 3 g O,R; 1 g P bezogen auf Lysinacetylsalicylat; 0,3 g O Kinder DDD R05XA02 Acetylsalicylsäure, Kombinationen N02BA51 Acetylsalicylsäure, Kombinationen exkl. Psycholeptika 3 g O bezogen auf Acetylsalicylsäure N02BA71 Acetylsalicylsäure, Kombinationen mit Psycholeptika M01BA03 Acetylsalicylsäure und Corticosteroide B01AC36 Acetylsalicylsäure und Dipyridamol 0,4 g O bezogen auf Dipyridamol B01AC56 Acetylsalicylsäure und Esomeprazol Standarddosis: 1 Applikationsform O D06BB03 Aciclovir 25 mg T für 5%-ige Zubereitungen J05AB01 Aciclovir 4 g O,P S01AD03 Aciclovir D06BB53 Aciclovir, Kombinationen C10AD06 Acipimox 0,5 g O D05BB02 Acitretin 35 mg O L01DB04 Aclarubicin R03BB05 Aclidinium bromid 0,644 mg Inhal.pulver bezogen auf die Base M02AP03 Acmella ciliata N02BH01 Aconitum R02AA13 Acriflaviniumchlorid R06AX18 Acrivastin 24 mg O L04AB04 Adalimumab 2,9 mg P; 1,6 mg P Kinder DDD D10AD03 Adapalen 1 mg T D10AD53 Adapalen, Kombinationen J05AF08 Adefovir dipivoxil 10 mg O A16AA02 Ademetionin M09AX07 Ademetionin C01EB10 Adenosin 15 mg P N05BA07 Adinazolam V08AC04 Adipiodon Standarddosis: 1 Applikationsform N06BX17 Adrafinil A01AD06 Adrenalon B02BC05 Adrenalon C01CA50 Adrenerge und dopaminerge Mittel, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 2 von 92 ATC-CODE BEDEUTUNG DDD-INFO C05BZ09 Aescin C05CA07 Aescin 0,1 g O C05BZ59 Aescin, Kombinationen C05CA57 Aescin, Kombinationen L01XE13 Afatinib L04AB03 Afelimomab L01XX44 Aflibercept 20 mg P S01LA05 Aflibercept 0,018 DE P A16AB03 Agalsidase alfa 1 mg P A16AB04 Agalsidase beta 5 mg P G02CH01 Agnus castus N06AX22 Agomelatin 25 mg O C01BA05 Ajmalin 0,3 g O; 50 mg P B05XB02 Alanylglutamin Standarddosis: 1 Applikationsform P N06AB07 Alaproclat S01XA07 Alaun P02CA03 Albendazol 0,8 g O L03AB12 Albinterferon alfa-2b B05AA01 Albumin Standarddosis: 1 Applikationsform P B05AA51 Albumin, Kombinationen Standarddosis: 1 Applikationsform P A07XA01 Albumintannat 3 g O A07XA51 Albumintannat, Kombinationen S01GX11 Alcaftadin M01AB06 Alclofenac 1,25 g O,R D07AB10 Alclometason S01BA10 Alclometason M03AA01 Alcuronium L03AC01 Aldesleukin 0,2 mg P J04BA03 Aldesulfonnatrium 0,33 g O H02AA01 Aldosteron L04AA15 Alefacept L01XC04 Alemtuzumab 13 mg P M05BA04 Alendronsäure 10 mg O bezogen auf die Säure der Alendronsäure M05BB05 Alendronsäure, Calcium und Colecalciferol, Sequenzialpräparate 10 mg O bezogen auf die Säure der Alendronsäure M05BB06 Alendronsäure und Alfacalcidol, Sequenzialpräparate 10 mg O bezogen auf die Säure der Alendronsäure M05BB03 Alendronsäure und Colecalciferol 10 mg O bezogen auf die Säure der Alendronsäure A11CC03 Alfacalcidol 1 mcg O,P C10AD09 alfa-Tocopherolnicotinat N01AX05 Alfaxalon B02AB02 Alfa1-Antitrypsin 0,6 g P N01AH02 Alfentanil G04CA01 Alfuzosin 7,5 mg O G04CA51 Alfuzosin und Finasterid A02AB02 Algeldrat 5 g O A02BX13 Alginsäure A02BX63 Alginsäure, Kombinationen Standarddosis: 10 Tabletten oder 50 ml Mixtur A16AB01 Alglucerase A16AB07 Alglucosidase alfa 0,1 g P R06AD01 Alimemazin 30 mg O,P C10AX10 Alipogen tiparvovec C09XA02 Aliskiren 0,15 g O C09XA54 Aliskiren, Amlodipin und Hydrochlorothiazid C09XA53 Aliskiren und Amlodipin C09XA52 Aliskiren und Hydrochlorothiazid Standarddosis: 1 Applikationsform O D11AH04 Alitretinoin 20 mg O L01XX22 Alitretinoin A03FA05 Alizaprid 0,15 g O,P V04CN11 Alkohol-Testzone Standarddosis: 1 Test N05CA21 Allobarbital M04AA01 Allopurinol 0,4 g O,P M04AA51 Allopurinol, Kombinationen G03DC01 Allylestrenol 10 mg O A02AD03 Almagat A02AD05 Almasilat 4 g O M01AE16 Alminoprofen R07AB07 Almitrin 0,1 g O N02CC05 Almotriptan 12,5 mg O A06AB13 Aloe A06AB63 Aloe, Kombinationen A10BH04 Alogliptin A02AB06 Aloglutamol A03AE01 Alosetron 1 mg O B01AC15 Aloxiprin N02BA02 Aloxiprin 3 g O A16AX01 Alpha-Liponsäure (Thioctsäure) 0,2 g O,P N07XB01 Alpha-Liponsäure (Thioctsäure) 0,5 g O,P M02AX56 Alpha-Pinen, Kombinationen N05BA12 Alprazolam 1 mg O C07AA01 Alprenolol 0,4 g O C07BA01 Alprenolol und Thiazide Standarddosis: 1 Applikationsform O C01EA01 Alprostadil 0,5 mg P C04AG01 Alprostadil 40 mcg P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 3 von 92 ATC-CODE BEDEUTUNG DDD-INFO G04BE01 Alprostadil 20 mcg P; 0,25 mg urethral V04CH04 Alsactid B01AD02 Alteplase 0,1 g P S01XA13 Alteplase C03EA04 Altizid und Kalium sparende Mittel L01XX03 Altretamin D03AX33 Aluminiumacetattartrat S02AA04 Aluminiumacetattartrat A02AB05 Aluminiumacetoacetat A01AB36 Aluminiumchlorat A01AB26 Aluminiumchlorid D10AX01 Aluminiumchlorid A01AB76 Aluminiumchlorid, Kombinationen D08AB52 Aluminiumchlorid, Kombinationen V03AE09 Aluminiumchloridhydroxid D08AB01 Aluminiumchloridhydroxid-Komplex C10AB03 Aluminiumclofibrat A02AB07 Aluminiumglycinat R02AA32 Aluminium-haltige Verbindungen R02AA82 Aluminium-haltige Verbindungen, Kombinationen C05AX01 Aluminium-haltige Zubereitungen A02AB01 Aluminiumhydroxid V03AE05 Aluminiumhydroxid A02AF05 Aluminiumhydroxid und Karminativa D09AA08 Aluminiumhydroxychlorid M05BX02 Aluminiumhydroxychlorid C10AD04 Aluminiumnicotinat D10AX04 Aluminiumoxid A02AD10 Aluminiumoxid in Kombination mit Magnesiumhydroxid A02AB03 Aluminiumphosphat A07ED01 Aluminiumphosphat D08AB10 Aluminiumpulver D11AA02 Aluminiumsalze D11AA52 Aluminiumsalze, Kombinationen D11AB63 Aluminiumsalze, Kombinationen A01AB37 Aluminiumsulfat A03AX08 Alverin A03AX58 Alverin, Kombinationen A06AH02 Alvimopan J05AC04 Amantadin 0,2 g O N04BB01 Amantadin 0,2 g O; 0,2 g P R02AA01 Ambazon 40 mg O R02AA51 Ambazon, Kombinationen N07AA30 Ambenonium 60 mg O C02KX02 Ambrisentan 7,5 mg O R02AD05 Ambroxol R05CB06 Ambroxol 75 mg Inhal.lösung,O,P,R; 40 mg O,R Kinder DDD R07AA03 Ambroxol A03DA09 Ambucetamid und Analgetika A03CA07 Ambutonium und Psycholeptika D07AC11 Amcinonid 1,5 mg T D11AF08 Ameisensäure C01CA25 Amezinium metilsulfat 30 mg O A08AA03 Amfepramon 75 mg O A08AA53 Amfepramon, Kombinationen N06BA01 Amfetamin 15 mg O,P N06BA13 Amfetaminil V04CN01 Amfetamin-Testzone Standarddosis: 1 Test R01AA15 Amidefrin V08AA01 Amidotrizoesäure Standarddosis: 1 Applikationsform N07XX05 Amifampridin 40 mg O V03AF05 Amifostin 1,7 g P D06AX12 Amikacin J01GB06 Amikacin 1 g P S01AA21 Amikacin V03AM01 Amilomer C03DB01 Amilorid 10 mg O N06AA19 Amineptin D08AA02 Aminoacridin D02BA01 Aminobenzoesäure N03AG03 Aminobuttersäure 1 g O,P B02AA01 Aminocapronsäure 16 g O,P N03AB03 Amino(diphenylhydantoin)valeriansäure 0,3 g O L02BG01 Aminoglutethimid 1 g O V04CH30 Aminohippursäure L01XD04 Aminolevulinsäure V04CX32 Aminolevulinsäure 1,4 g O B02AA03 Aminomethylbenzoesäure 0,25 g O N02BB03 Aminophenazon 0,5 g R R05XA05 Aminophenazon, Kombinationen N02BB53 Aminophenazon, Kombinationen exkl. Psycholeptika N02BB73 Aminophenazon, Kombinationen mit Psycholeptika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 4 von 92 ATC-CODE BEDEUTUNG DDD-INFO R03DA05 Aminophyllin 0,6 g O,P,R R03DA55 Aminophyllin, Kombinationen R03DB05 Aminophyllin und Sympathomimetika J04AA01 Aminosalicylsäure 12 g O B05BA01 Aminosäuren Standarddosis: 1 Applikationsform P V06DD01 Aminosäuren, Kombinationen mit Kohlenhydraten C01BD01 Amiodaron 0,2 g O,P N05AL05 Amisulprid 0,4 g O N06AA09 Amitriptylin 75 mg O,P N06CA01 Amitriptylin und Psycholeptika N06AA25 Amitriptylinoxid 75 mg O,P A01AD07 Amlexanox R03DX01 Amlexanox C08CA01 Amlodipin 5 mg O C01EP04 Ammi-visnaga-Früchte B05XA04 Ammoniumchlorid G04BA01 Ammoniumchlorid 8,5 g O G04BA51 Ammoniumchlorid, Kombinationen V08CA07 Ammoniumeisen(III)citrat Standarddosis: 1 Applikationsform B03AA12 Ammoniumeisen(II)sulfat 0,2 g O Fe2+ B03AD05 Ammoniumeisen(II)sulfat 0,1 g O Fe2+ N05CA02 Amobarbital 0,1 g O,P P01BA06 Amodiaquin 0,5 g O D01AE16 Amorolfin N06AA17 Amoxapin 0,15 g O J01CA04 Amoxicillin 1 g O,P; 1 g O Kinder DDD J01CR02 Amoxicillin und Enzym-Inhibitoren 1,75 g O bezogen auf Amoxicillin; 3 g P bezogen auf Amoxicillin; 1 g O Kinder DDD bezogen auf Amoxicillin A01AB04 Amphotericin B 40 mg O A07AA07 Amphotericin B 0,4 g O D01AA10 Amphotericin B G01AA03 Amphotericin B 0,2 g V J02AA01 Amphotericin B 35 mg P J01CA01 Ampicillin 2 g O,P,R; 2,5 g O Kinder DDD S01AA19 Ampicillin J01CA51 Ampicillin, Kombinationen R05GB05 Ampicillin, Kombinationen 2 g O,P bezogen auf Ampicillin; 2,5 g O Kinder DDD bezogen auf Ampicillin J01CR01 Ampicillin und Enzym-Inhibitoren 2 g P bezogen auf Ampicillin J05AE05 Amprenavir 1,2 g O C01CE01 Amrinon 0,5 g P L01DB10 Amrubicin L01XX01 Amsacrin V03AB22 Amylnitrit L01XX35 Anagrelid 2 mg O L04AC03 Anakinra 0,1 g P L02BG03 Anastrozol 1 mg O L03AA12 Ancestim 1,4 mg P B01AD09 Ancrod A01AB39 Andere Aluminium-haltige Verbindungen A16AA50 Andere Aminosäuren, Kombinationen A14AA50 Andere Androstan-Derivate, Kombinationen A07XA50 Andere Antidiarrhoika, Kombinationen A04AD50 Andere Antiemetika, Kombinationen D11AA50 Andere Antihidrotika, Kombinationen S01XB50 Andere Antikataraktika, Kombinationen R02AA50 Andere Antiseptika, Kombinationen A15AA50 Andere Appetit stimulierende Mittel, Kombinationen R07AB50 Andere Atemstimulanzien, Kombinationen L03AG50 Andere bakterielle Immunstimulanzien, Kombinationen A12AX50 Andere Calciumsalze, Kombinationen mit anderen Mitteln A12AX41 Andere Calciumsalze und Colecalciferol D11AX50 Andere Dermatika, Kombinationen D11AB50 Andere dermatologische Balneotherapeutika, Kombinationen V04CX50 Andere Diagnostika, Kombinationen Standarddosis: 1 Test V06CX50 Andere Diätetika als Säuglingsnahrung, Kombinationen V06DX50 Andere Diätetika-Kombinationen A09AX50 Andere Digestiva, Kombinationen A09AA50 Andere Enzyme, Kombinationen A09AC50 Andere Enzyme und Säuren, Kombinationen R04AP50 Andere etherische Öle, Kombinationen R05CA50 Andere Expektoranzien, Kombinationen V03AK50 Andere Gewebekleber, Kombinationen R02AX50 Andere Hals- und Rachentherapeutika, Kombinationen C05AX03 Andere Hämorrhoidenmittel, Kombinationen G04BC50 Andere Harnkonkrement lösende Mittel, Kombinationen V07AI01 Andere Hilfsmittel ohne Pharmazentralnummer V07AI02 Andere Hilfsmittel ohne Pharmazentralnummer, die im Zusammenhang mit einer individuell hergestellten parenteralen Lösung abgegeben werden J06BC10 Andere Immunglobuline J01EB70 Andere kurzwirksame Sulfonamide, Kombinationen A05BA50 Andere Lebertherapeutika, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 5 von 92 ATC-CODE BEDEUTUNG DDD-INFO R02AD50 Andere Lokalanästhetika, Kombinationen A12CC50 Andere Magnesiumsalze, Kombinationen D11AC50 Andere medizinische Haarwaschmittel, Kombinationen J07AH02 Andere Meningokokken monovalent, gereinigtes Polysaccharid- Antigen J07AH05 Andere Meningokokken polyvalent, gereinigtes Polysaccharid- Antigen A12CX50 Andere Mineralstoff-haltige Zubereitungen, Kombinationen G04BE70 Andere Mittel bei erektiler Dysfunktion, Kombinationen mit Psycholeptika A03AX50 Andere Mittel bei funktionellen Störungen des Darms, Kombinationen A05AX50 Andere Mittel zur Gallentherapie, Kombinationen A01AD50 Andere Mittel zur oralen Lokalbehandlung, Kombinationen R05CB50 Andere Mukolytika, Kombinationen P02CX50 Andere Nematodenmittel, Kombinationen S01XA50 Andere Ophthalmika, Kombinationen R05DA50 Andere Opium-Alkaloide und Derivate, Kombinationen L03AX20 Andere Organextrakte A08AB11 Andere peripher wirkende Antiadiposita C01AP50 Andere Pflanzenglykoside, Kombinationen N05CP50 Andere pflanzliche Hypnotika und Sedativa, Kombinationen L03AP50 Andere pflanzliche Immunstimulanzien, Kombinationen C05CP50 Andere pflanzliche kapillarstabilisierende Mittel, Kombinationen L01CP50 Andere pflanzliche Mittel, Kombinationen A01AP50 Andere pflanzliche Stomatologika, Kombinationen G04BP50 Andere pflanzliche Urologika, Kombinationen D08AE50 Andere Phenole und Derivate, Kombinationen B05AA02 Andere Plasmaproteinfraktionen Standarddosis: 1 Applikationsform P D03BA50 Andere proteolytische Enzyme, Kombinationen C04AD50 Andere Purin-Derivate, Kombinationen A09AB50 Andere Säuren, Kombinationen D08AL50 Andere Silber-haltige Verbindungen, Kombinationen A07AB50 Andere Sulfonamide, Kombinationen D06BA50 Andere Sulfonamide, Kombinationen S01GA50 Andere Sympathomimetika, Kombinationen D10BX50 Andere systemische Aknemittel, Kombinationen R03DX50 Andere systemische Antiasthmatika, Kombinationen D05AA50 Andere Teere, Kombinationen V03AX50 Andere therapeutische Mittel, Kombinationen A02BX50 Andere Ulkustherapeutika, Kombinationen exkl. Psycholeptika A02BX70 Andere Ulkustherapeutika, Kombinationen mit Psycholeptika G04BX50 Andere Urologika, Kombinationen D09AC50 Andere Verbandmittel, Kombinationen D03AX50 Andere Wundbehandlungsmittel, Kombinationen R03DA50 Andere Xanthine, Kombinationen excl. Psycholeptika R03DA90 Andere Xanthine, Kombinationen mit Psycholeptika M02AD50 Andere Zubereitungen mit Nicotinsäure-Derivaten, Kombinationen M02AC50 Andere Zubereitungen mit Salicylsäure-Derivaten, Kombinationen L03AX50 Andere Zytokine und Immunstimulanzien, Kombinationen R05CP16 Andornkraut A14AA01 Androstanolon G03BB02 Androstanolon S01LA02 Anecortav A16AX02 Anetholtrithion C01CX06 Angiotensinamid 5 mg P J02AX06 Anidulafungin 0,1 g P N01AH05 Anileridin N06BX11 Aniracetam B01AD03 Anistreplase 30 E P A02AX50 Antacida, andere Kombinationen A02AG02 Antacida, Kombinationen mit Atropin A02AX01 Antacida, Kombinationen mit Bismutsalzen A02AG01 Antacida, Kombinationen mit Butinolin A02AX02 Antacida, Kombinationen mit Lokalanästhetika A02AG20 Antacida, Kombinationen mit mehreren Spasmolytika A02AX04 Antacida, Kombinationen mit Schwefel R01AC04 Antazolin R06AX05 Antazolin 0,3 g O,P S01GX15 Antazolin S01XA35 Anthocyane S01XA85 Anthocyane, Kombinationen J07AC01 Anthrax-Antigen C01BA50 Antiarrhythmika, Kombinationen exkl. Psycholeptika C01BA70 Antiarrhythmika, Kombinationen mit Psycholeptika S01AA20 Antibiotika in Kombination mit anderen Mitteln G01BA01 Antibiotika und Corticosteroide J06BB01 Anti-D(rh)-Immunglobulin S02AA30 Antiinfektiva, Kombinationen S03AA30 Antiinfektiva, Kombinationen L04AA03 Antilymphozytäres Immunglobulin (Pferd) R05CA07 Antimonpentasulfid 0,2 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 6 von 92 ATC-CODE BEDEUTUNG DDD-INFO G01BD01 Antiseptika und Corticosteroide B01AB02 Antithrombin III, Antithrombin alfa 2,1 TSD E P; 7,5 TSD E P bezogen auf Antithrombin alfa L04AA04 Antithymozytäres Immunglobulin (Kaninchen) 0,1 g P R05FB02 Antitussiva und Expektoranzien R05FB01 Antitussiva und Mukolytika A07XP05 Apfelfruchtextrakt B01AF02 Apixaban 5 mg O G04BE07 Apomorphin 2 mg SL N04BC07 Apomorphin 20 mg P V03AB45 Apomorphin S01EA03 Apraclonidin 0,3 ml AT A04AD12 Aprepitant, Fosaprepitant 95 mg O; 95 mg P bezogen auf Fosaprepitant (115 mg); 1 DE P bezogen auf Fosaprepitant (150 mg) C01BB04 Aprindin 0,1 g O,P N05CA05 Aprobarbital 0,1 g O,P N05CM12 Apronal 0,25 g O B02AB01 Aprotinin 500 TSD E P D04AX06 Aqua calcariae J01GB12 Arbekacin 0,2 g P C01CA22 Arbutamin B01AE03 Argatroban 0,2 g P A05BA01 Argininglutamat B05XB01 Argininhydrochlorid Standarddosis: 1 Applikationsform P H01BA06 Argipressin N05AX12 Aripiprazol 15 mg O,P M02AH02 Arnika M09AH03 Arnika C05BP04 Arnikablüten D03AP03 Arnikablüten M02AP01 Arnikablüten M02AP51 Arnikablüten, Kombinationen L01XX27 Arsentrioxid P01AR01 Arsthinol P01BE02 Artemether 0,28 g O; 0,12 g P P01BF01 Artemether und Lumefantrin P01BE01 Artemisinin 1 g O P01BE04 Artemotil P01BE05 Artenimol (Dihydroartemisinin) 0,28 g O P01BF05 Artenimol (Dihydroartemisinin) und Piperaquin P01BE03 Artesunat 0,28 g O P01BF04 Artesunat, Sulfamethopyrazin und Pyrimethamin P01BF03 Artesunat und Amodiaquin P01BF02 Artesunat und Mefloquin P01BF06 Artesunat und Pyronaridin N01BB08 Articain Standarddosis: 1 Applikationsform P N01BB58 Articain, Kombinationen Standarddosis: 1 Applikationsform P A05AP03 Artischockenblätter 6 g O Droge; 30 g O Frischpflanze R05CP04 Asarumwurzelstock G01AD03 Ascorbinsäure 0,25 g V S01XA15 Ascorbinsäure A11GA01 Ascorbinsäure (Vitamin C) 0,2 g O,P A11GB50 Ascorbinsäure (Vitamin C), andere Kombinationen A11GB01 Ascorbinsäure (Vitamin C) und Calcium V04BA06 Ascorbinsäure-Testzone Standarddosis: 1 Test N05AH05 Asenapin 20 mg O D03AX16 Asiaticosid L01XX02 Asparaginase A09AA07 Aspergillus oryzae A09AA57 Aspergillus oryzae, Kombinationen J01CA19 Aspoxicillin 4 g P R06AX11 Astemizol 10 mg O J05AE08 Atazanavir 0,3 g O C07AB03 Atenolol 75 mg O C07DB01 Atenolol, Thiazide und andere Diuretika C07FB03 Atenolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07CB03 Atenolol und andere Diuretika Standarddosis: 1 Applikationsform O C07CB53 Atenolol und andere Diuretika, Kombinationen C07FB23 Atenolol und Nifedipin Standarddosis: 1 Applikationsform O C07BB03 Atenolol und Thiazide N06BA09 Atomoxetin 80 mg O C10AA05 Atorvastatin 20 mg O C10BX03 Atorvastatin und Amlodipin C10BA05 Atorvastatin und Ezetimib G02CX01 Atosiban 165 mg P P01AX06 Atovaquon 2,25 g O M03AC04 Atracurium 38,5 mg P A03BA01 Atropin 1,5 mg O,P G04BD15 Atropin S01FA01 Atropin 1 mg AT V03AB44 Atropin G04BD65 Atropin, Kombinationen S01FA51 Atropin, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 7 von 92 ATC-CODE BEDEUTUNG DDD-INFO A03CB03 Atropin und Psycholeptika A07BC04 Attapulgit A07BC54 Attapulgit, Kombinationen M01CB03 Auranofin 6 mg O M01CB04 Aurothioglucose 2,4 mg P M01CB06 Aurothiopolypeptid M01CB05 Aurotioprol M09AX02 Autologe Chondrozyten Standarddosis: 1 Einzeldosis P M01AX26 Avocado und Sojabohnenöl, unverseift L01XE17 Axitinib 10 mg O L01BC07 Azacitidin 34 mg P G01AF13 Azanidazol P01AB04 Azanidazol C04AX30 Azapetin 0,15 g O M01AX04 Azapropazon 0,75 g O R06AX09 Azatadin 2 mg O L04AX01 Azathioprin 0,15 g O,P D10AX03 Azelainsäure R01AC03 Azelastin 0,56 mg N R06AX19 Azelastin 4 mg O S01GX07 Azelastin S01AA25 Azidamfenicol J01CE04 Azidocillin 1,5 g O C09CA09 Azilsartan medoxomil 40 mg O J01FA10 Azithromycin 0,3 g O; 0,5 g P; 0,25 g O Kinder DDD S01AA26 Azithromycin J01CA09 Azlocillin 12 g P C03CA05 Azosemid J01DF01 Aztreonam 0,225 g Inhal.lösung; 4 g P A01AB88 Azulen, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 8 von 92 ATC-CODE BEDEUTUNG DDD-INFO B J01CA06 Bacampicillin 1,2 g O L03AG05 Bacillus cereus L03AG02 Bacillus subtilis D06AX05 Bacitracin J01XX10 Bacitracin R02AB04 Bacitracin R02AB54 Bacitracin, Kombinationen M03BX01 Baclofen 50 mg O; 0,55 mg P D03AX79 Bakterienlysat, Kombinationen V04BA14 Bakterien-Testzone Standarddosis: 1 Test N05CP06 Baldrianöl N05CP01 Baldrianwurzel 7 g O Droge; 6,5 ml O Tinktur N05CP51 Baldrianwurzel, Kombinationen A07EC04 Balsalazid 6,75 g O R03CC12 Bambuterol 20 mg O C04AA31 Bamethan 75 mg O C04AA81 Bamethan, Kombinationen R03DA08 Bamifyllin D04AA15 Bamipin R06AX01 Bamipin 0,1 g O R06AX51 Bamipin, Kombinationen N03AA04 Barbexaclon N05CA04 Barbital 0,5 g O N05CB02 Barbiturate in Kombination mit anderen Mitteln V04CN02 Barbiturat-Testzone Standarddosis: 1 Test G04BP01 Bärentraubenblätter 7,5 g O Droge; 0,62 g O Hydrochinon G04BP51 Bärentraubenblätter, Kombinationen V08BA01 Bariumsulfat mit Suspensionsmittel Standarddosis: 1 Applikationsform V08BA02 Bariumsulfat ohne Suspensionsmittel Standarddosis: 1 Applikationsform C08CA12 Barnidipin 10 mg O A03DA08 Barverin und Analgetika L04AC02 Basiliximab 40 mg P Dosis pro Behandlungszyklus D08AX14 Basisches Bismutgallat D02AC01 Basistherapeutika A06AC59 Bassorin, Kombinationen B02BX03 Batroxobin V01AA05 Baumpollen G03XC02 Bazedoxifen 20 mg O L03AX03 BCG-Impfstoff 0,033 Darreichungsform intravesikal A01AD08 Becaplermin D03AX06 Becaplermin N03AX30 Beclamid A07EA07 Beclometason D07AC15 Beclometason R01AD01 Beclometason 0,4 mg N R03BA01 Beclometason 0,8 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung; 0,4 mg Inhal.Aerosol Partikelgröße < 3,3 mcm D07CC04 Beclometason und Antibiotika S01ED06 Befunolol 0,2 ml AT J01GB13 Bekanamycin 0,6 g P L04AA28 Belatacept 12,5 mg P L04AA26 Belimumab 25 mg P A03BA04 Belladonna-Gesamtalkaloide 1 mg O A03CB02 Belladonna-Gesamtalkaloide und Psycholeptika R07AB05 Bemegrid C03AX02 Bemetizid, Kombinationen C03EA16 Bemetizid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O B01AB12 Bemiparin 2,5 TSD E P A03CA43 Benactyzin und Psycholeptika C09AA07 Benazepril 7,5 mg O C09BA07 Benazepril und Diuretika Standarddosis: 1 Applikationsform O C04AX11 Bencyclan N06DX11 Bencyclan L01AA09 Bendamustin M02AA11 Bendazac S01BC07 Bendazac C03AA01 Bendroflumethiazid 2,5 mg O C03AB01 Bendroflumethiazid und Kalium 2,5 mg O bezogen auf Bendroflumethiazid C03EA13 Bendroflumethiazid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O A10BX06 Benfluorex 0,45 g O A11DA03 Benfotiamin N07XB56 Benfotiamin, Kombinationen S01JA02 Bengalrosa-Natrium C08CA15 Benidipin N02BA10 Benorilat 3 g O M01AE06 Benoxaprofen N05AD07 Benperidol 1,5 mg O; 1,5 mg P R05DB02 Benproperin 75 mg O V04CK03 Bentiromid D08AJ01 Benzalkonium 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 9 von 92 ATC-CODE BEDEUTUNG DDD-INFO D09AA11 Benzalkonium R02AA16 Benzalkonium D08AJ51 Benzalkonium, Kombinationen D10AX10 Benzalkoniumchlorid S01AX24 Benzalkoniumchlorid D10AX60 Benzalkoniumchlorid, Kombinationen C05BZ06 Benzaron C05CX05 Benzaron N04AC01 Benzatropin 2 mg O,P M04AB03 Benzbromaron 0,1 g O R02AA09 Benzethonium R02AA59 Benzethonium, Kombinationen D08AJ08 Benzethoniumchlorid D08AJ58 Benzethoniumchlorid, Kombinationen A03AB16 (2-Benzhydryloxyethyl)diethylmethylammoniumiodid 0,3 g O A03AB01 Benzilon 70 mg O C01DX04 Benziodaron 0,25 g O C01DX54 Benziodaron, Kombinationen P01CA02 Benznidazol 0,4 g O C05AD03 Benzocain D04AB04 Benzocain N01BA05 Benzocain Standarddosis: 1 Applikationsform P R02AD01 Benzocain A01AE53 Benzocain, Kombinationen A02XA52 Benzocain, Kombinationen C05AD53 Benzocain, Kombinationen D04AB54 Benzocain, Kombinationen R02AD51 Benzocain, Kombinationen N05BD01 Benzoctamin 30 mg O,P V04CN03 Benzodiazepin-Testzone Standarddosis: 1 Test D09AA05 Benzododecinium R05DB01 Benzonatat 0,6 g O R02AA84 Benzoxonium, Kombinationen A01AB14 Benzoxoniumchlorid D08AJ05 Benzoxoniumchlorid D10AE01 Benzoylperoxid 0,1 g T D11AC13 Benzoylperoxid D10AE51 Benzoylperoxid, Kombinationen A01AD02 Benzydamin G02CC03 Benzydamin M01AX07 Benzydamin 0,15 g O,R M02AA05 Benzydamin P03AX01 Benzylbenzoat A03ED01 Benzylmandelat in Kombination mit anderen Mitteln M02AD02 Benzylnicotinat M02BA04 Benzylnicotinat C04AC58 Benzylnicotinat, Kombinationen M02AD52 Benzylnicotinat, Kombinationen M02BA54 Benzylnicotinat, Kombinationen J01CE01 Benzylpenicillin 3,6 g P S01AA14 Benzylpenicillin J01CE08 Benzylpenicillin-Benzathin 3,6 g P J01CE09 Benzylpenicillin-Procain 0,6 g P H03BA03 Benzylthiouracil P02CX02 Bephenium C08EA02 Bepridil 0,3 g O B01AC19 Beraprost D05BA03 Bergapten C01EP02 Besenginsterkraut S01AE08 Besifloxacin A11CA02 Betacaroten D02BB01 Betacaroten 0,1 g O D02BB51 Betacaroten, Kombinationen N07CA01 Betahistin 24 mg O A16AA06 Betain 6 g O A05BA61 Betain, Kombinationen A09AB02 Betainhydrochlorid 1 g O A01AC05 Betamethason A07EA04 Betamethason Standarddosis: 1 Klysma C05AA05 Betamethason D07AC01 Betamethason 2 mg T für 0,1%-ige Zubereitungen D07XC01 Betamethason H02AB01 Betamethason 1,5 mg O,P; 0,4 mg P Depot R01AD06 Betamethason 0,4 mg N R03BA04 Betamethason S01BA06 Betamethason S01CB04 Betamethason S02BA07 Betamethason S03BA03 Betamethason C05AA55 Betamethason, Kombinationen H02BX09 Betamethason, Kombinationen 1,5 mg O,P D07CC01 Betamethason und Antibiotika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 10 von 92 ATC-CODE BEDEUTUNG DDD-INFO S01CA05 Betamethason und Antiinfektiva S03CA06 Betamethason und Antiinfektiva D07BC01 Betamethason und Antiseptika S01BB04 Betamethason und Mydriatika H02AB51 Betamethason-Depot 0,4 mg P Depot C02CC01 Betanidin 0,1 g O C10AX14 Beta-Sitosterin 4,5 g O G04CX04 Beta-Sitosterin 60 mg O M09AX04 Beta-Sitosterin G04CX54 Beta-Sitosterin, Kombinationen C07AB05 Betaxolol 20 mg O S01ED02 Betaxolol 0,2 ml AT S01ED52 Betaxolol, Kombinationen V04CG02 Betazol N07AB02 Bethanechol 45 mg O L01XC07 Bevacizumab 45 mg P C07AB06 Bevantolol 0,3 g O C07BB06 Bevantolol und Thiazide A03AB13 Bevonium 0,2 g O A03DA03 Bevonium und Analgetika A03CA06 Bevonium und Psycholeptika L01XX25 Bexaroten 0,54 g O C10AB02 Bezafibrat 0,6 g O N02AC05 Bezitramid 15 mg O J01DH05 Biapenem 1,2 g P R05DB12 Bibenzoniumbromid 90 mg O S01AX05 Bibrocathol L02BB03 Bicalutamid 50 mg O; 0,15 g O bezogen auf die Monotherapie C02AA07 Bietaserpin 15 mg O C02AA57 Bietaserpin, Kombinationen C02LA07 Bietaserpin und Diuretika N06AX08 Bifemelan D01AC10 Bifonazol 10 mg T D01AC60 Bifonazol, Kombinationen R06AX29 Bilastin 20 mg O V04BA08 Bilirubin-Testzone Standarddosis: 1 Test S01EE03 Bimatoprost 0,1 ml AT P03AC02 Bioallethrin P03AC52 Bioallethrin, Kombinationen A11HA05 Biotin 5 mg O N04AA02 Biperiden 10 mg O,P D08AE06 Biphenylol D08AE56 Biphenylol, Kombinationen C03XP02 Birkenblätter G04BP02 Birkenblätter 10 g O Droge A06AB02 Bisacodyl 10 mg O,R A06AG02 Bisacodyl Standarddosis: 1 Klysma A06AB52 Bisacodyl, Kombinationen V04CZ04 Bisacodyl, Kombinationen A07BB51 Bismut, Kombinationen A02BX17 Bismut(III)-citrat-hydroxid-Komplex C05AX02 Bismutpräparate, Kombinationen A02BX05 Bismutsubcitrat 0,48 g O A02BD08 Bismutsubcitrat, Tetracyclin und Metronidazol 12 Applikationsformen O A02BX12 Bismutsubnitrat A02BX62 Bismutsubnitrat, Kombinationen exkl. Psycholeptika A02BX22 Bismutsubsalicylat C07AB07 Bisoprolol 10 mg O bezogen auf Bisoprololhemifumarat C07AB57 Bisoprolol, Kombinationen C07FB07 Bisoprolol und andere Antihypertonika C07BB07 Bisoprolol und Thiazide Standarddosis: 1 Applikationsform O A06AB09 Bisoxatin 0,12 g O A06AB59 Bisoxatin, Kombinationen D10AB01 Bithionol P02BX01 Bithionol R03AC17 Bitolterol D11AX31 Bittersüssstängel D05AA01 Bituminosulfonate D08AX10 Bituminosulfonate D10AX12 Bituminosulfonate D11AB12 Bituminosulfonate D11AC11 Bituminosulfonate G01AX17 Bituminosulfonate M02AX19 Bituminosulfonate C05AX13 Bituminosulfonate, inkl. Kombinationen D05AA51 Bituminosulfonate, Kombinationen D10AX62 Bituminosulfonate, Kombinationen D11AB62 Bituminosulfonate, Kombinationen D11AC61 Bituminosulfonate, Kombinationen G01AX67 Bituminosulfonate, Kombinationen M02AX69 Bituminosulfonate, Kombinationen B01AE06 Bivalirudin 0,25 g P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 11 von 92 ATC-CODE BEDEUTUNG DDD-INFO N02BP01 Blauer Eisenhut L01DC01 Bleomycin 3 mg P entsprechend einer standardisierten biologischen Aktivität von 3.000 E B05XX03 Blut und Organextrakte vom Kalb, inkl. Kombinationen V01AA10 Blüten B02BC51 Blutgerinnungsfaktoren, Kombinationen B05AX03 Blutplasma B05AX43 Blutplasma ohne Pharmazentralnummer V04BA03 Blut-Testzone Standarddosis: 1 Test V04CX17 Blut-Testzone (Stuhl) Standarddosis: 1 Test J05AE12 Boceprevir 2,4 g O A03PP03 Boldoblätter C07AA17 Bopindolol C07CA17 Bopindolol und andere Diuretika N04AA11 Bornaprin M02AC56 Bornylsalicylat, Kombinationen S02AA03 Borsäure L01XX32 Bortezomib 0,45 mg P C02KX01 Bosentan 0,25 g O L01XE14 Bosutinib 0,5 g O M03AX21 Botulinumtoxin Typ A M03AX22 Botulinumtoxin Typ B J06AA04 Botulismus-Antitoxin M09AP04 Brennnesselblätter 10 g O Droge aus Kraut und Blättern G04BP08 Brennnesselkraut und -blätter 10 g O Droge aus Kraut und Blättern G04CP02 Brennnesselwurzel 5 g O G04CP52 Brennnesselwurzel, Kombinationen L01XC12 Brentuximab vedotin 6 mg P C01BD02 Bretyliumtosilat L04AC09 Briakinumab S01EA05 Brimonidin 0,2 ml AT B01AD06 Brinase S01EC04 Brinzolamid 0,2 ml J05AB15 Brivudin 0,125 g O J01EA02 Brodimoprim 0,2 g O N05CA26 Bromallylmethylbutylbarbitursäure N05BA08 Bromazepam 10 mg O R06AA01 Bromazin D01AE01 Bromchlorsalicylanilid D01AE51 Bromchlorsalicylanilid, Kombinationen B06AA11 Bromelaine 0,2 g O M02AX76 Bromelaine, Kombinationen S01BC11 Bromfenac 66 mcg AT R05CB02 Bromhexin 24 mg O,P; 24 mg Inhal.lösung R05CB52 Bromhexin, Kombinationen N05CM11 Bromide N05CM03 Bromisoval 0,6 g O N05CX09 Bromisoval, Kombinationen G02CB01 Bromocriptin 5 mg O,P N04BC01 Bromocriptin 40 mg O A03FA04 Bromoprid 20 mg O,P A03FA54 Bromoprid, Kombinationen N05AD06 Bromperidol 10 mg O,P; 3,3 mg P Depot R06AB01 Brompheniramin 24 mg O R06AB51 Brompheniramin, Kombinationen D01AE26 Bromsalicylisopropylamid V04CE02 Bromsulfalein N05CD09 Brotizolam 0,25 mg O A07AX01 Broxychinolin G01AC06 Broxychinolin 0,1 g V P01AA01 Broxychinolin A07AX51 Broxychinolin, Kombinationen J07AD01 Brucella-Antigen N02BE04 Bucetin N02BE54 Bucetin, Kombinationen exkl. Psycholeptika N02BE74 Bucetin, Kombinationen mit Psycholeptika M01CC02 Bucillamin C01CE04 Bucladesin R06AE01 Buclizin 50 mg O R06AE51 Buclizin, Kombinationen D01AE75 Buclosamid, Kombinationen A07EA06 Budesonid 9 mg O; Standarddosis: 1 Klysma D07AC09 Budesonid R01AD05 Budesonid 0,2 mg N R03BA02 Budesonid 0,8 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung N04BX03 Budipin D04AX03 Bufexamac 0,1 g T M01AB17 Bufexamac M02AA09 Bufexamac C04AX20 Buflomedil 0,6 g O A10BA03 Buformin 0,2 g O R03DA10 Bufyllin M01AB07 Bumadizon 0,4 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 12 von 92 ATC-CODE BEDEUTUNG DDD-INFO C03CA02 Bumetanid 1 mg O,P C03CB02 Bumetanid und Kalium 1 mg O bezogen auf Bumetanid C03EB02 Bumetanid und Kalium sparende Mittel C01BD03 Bunaftin C02CA07 Bunazosin 6 mg O C07AA31 Bunitrolol C04AA02 Buphenin 30 mg O G02CA02 Buphenin 30 mg P C04AA52 Buphenin, Kombinationen R01BA54 Buphenin, Kombinationen N01BB01 Bupivacain Standarddosis: 1 Applikationsform P N01BB51 Bupivacain, Kombinationen Standarddosis: 1 Applikationsform P C07AA19 Bupranolol 0,1 g O S01ED08 Bupranolol 0,2 ml AT C07FA19 Bupranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07GA19 Bupranolol und andere Mittel C07EA19 Bupranolol und Vasodilatatoren Standarddosis: 1 Applikationsform O N02AE01 Buprenorphin 1,2 mg P,SL,TD N07BC01 Buprenorphin 8 mg SL N07BC51 Buprenorphin, Kombinationen 8 mg SL bezogen auf Buprenorphin V04CN13 Buprenorphin-Testzone Standarddosis: 1 Test N06AX12 Bupropion 0,15 g O N07BA02 Bupropion 0,3 g O H01CA06 Buserelin L02AE01 Buserelin 0,11 mg Implantat; 1,2 mg N; 1,5 mg P N05BE01 Buspiron 30 mg O L01AB01 Busulfan C04AX23 Butalamin R05DB13 Butamirat 25 mg O N01BB05 Butanilicain Standarddosis: 1 Applikationsform P N05AB09 Butaperazin 10 mg O D01AE23 Butenafin R05DB30 Butetamat R05DB80 Butetamat, Kombinationen A03ED04 Butinolin in Kombination mit anderen Mitteln C03EA14 Butizid und Kalium sparende Mittel N05CA03 Butobarbital 0,15 g O G01AF15 Butoconazol 0,1 g V N02AF01 Butorphanol 12 mg P C05AD62 Butoxycain, Kombinationen N06AA15 Butriptylin 75 mg O A03BB01 Butylscopolamin 60 mg O,P,R A03EA02 Butylscopolamin, Kombinationen A03DB04 Butylscopolamin und Analgetika A03CB38 Butylscopolamin und Psycholeptika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 13 von 92 ATC-CODE BEDEUTUNG DDD-INFO C L01CD04 Cabazitaxel 2,14 mg P G02CB03 Cabergolin 0,5 mg O N04BC06 Cabergolin 3 mg O D03AX01 Cadexomer-Iod D11AC02 Cadmium-haltige Verbindungen D11AC52 Cadmium-haltige Verbindungen, Kombinationen C02DB04 Cadralazin 15 mg O R01BX02 Cafaminol C01CA21 Cafedrin A11CC06 Calcifediol D05AX02 Calcipotriol 75 mcg T D05AX52 Calcipotriol, Kombinationen H05BA01 Calcitonin (Lachs, synthetisch) 200 E N; 100 E P H05BA03 Calcitonin (Mensch, synthetisch) 100 E P H05BA02 Calcitonin (Schwein, natürlich) 100 E P A11CC04 Calcitriol 1 mcg O,P D05AX03 Calcitriol 6 mcg T N07BB02 Calcium carbimid A12AA20 Calcium (verschiedene Salze in Kombination) 0,5 g O Ca2+ V03AE04 Calciumacetat und Magnesiumcarbonat A12AA12 Calciumacetat, wasserfrei 2 g O V03AE07 Calciumacetat, wasserfrei 6 g O B02BC08 Calciumalginat J04AA03 Calciumaminosalicylat A02AC01 Calciumcarbonat A12AA04 Calciumcarbonat 3 g O V03AE08 Calciumcarbonat A12AX01 Calciumcarbonat und Colecalciferol A12AX51 Calciumcarbonat und Colecalciferol, Kombinationen mit anderen Mitteln A12AA07 Calciumchlorid 0,2 g P B05XA07 Calciumchlorid Standarddosis: 1 Applikationsform P G04BA03 Calciumchlorid A12AA34 Calciumcitrat A12AA09 Calciumcitratlysin-Komplex 0,5 g O A12AA32 Calciumdiaspartat C05BX01 Calciumdobesilat S01XA24 Calciumdobesilat 0,5 g O C05BX51 Calciumdobesilat, Kombinationen B03BB02 Calciumfolinat V03AF03 Calciumfolinat 60 mg O,P bezogen auf Folinsäure A12AA02 Calciumglubionat 2,75 g P A12AA10 Calciumglucoheptonat 3 g O A12AA03 Calciumgluconat 3 g O D11AX03 Calciumgluconat A12AA08 Calciumglycerylphosphat A07XA03 Calcium-haltige Verbindungen R01AX01 Calciumhexaminthiocyanat V08AC10 Calciumiopodat Standarddosis: 1 Applikationsform V03AE11 Calciumketoglutarat A12AA05 Calciumlactat 2 g O A12AA06 Calciumlactogluconat 3 g O A12AA30 Calciumlaevulat 1 g P V03AF04 Calciumlevofolinat 30 mg O,P bezogen auf Levofolinsäure A12AA33 Calciumorotat A12AA11 Calciumpangamat A11HA31 Calciumpantothenat D03AX04 Calciumpantothenat A12AA01 Calciumphosphat 2 g O A12AX02 Calciumsalze und Ergocalciferol A02AC02 Calciumsilikat 6 g O A12AA31 Calciumthiosulfat D03AH01 Calendula S01XH02 Calendula officinalis N05BA15 Camazepam 30 mg O B02AB04 Camostat C01EB02 Campher 0,15 g O D04AX05 Campher M02AX04 Campher C01EX52 Campher, Kombinationen D04AX55 Campher, Kombinationen M02AX54 Campher, Kombinationen M02BA55 Campher, Kombinationen A03AA03 Camylofin 0,2 g O,R A03DA05 Camylofin und Analgetika L04AC08 Canakinumab 2,7 mg P C09CA06 Candesartan 8 mg O C09DA06 Candesartan und Diuretika Standarddosis: 1 Applikationsform O G01AA04 Candicidin 6 mg V C03DA03 Canrenon 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 14 von 92 ATC-CODE BEDEUTUNG DDD-INFO L01BC06 Capecitabin 3 g O J04AB30 Capreomycin 1 g P M02AB01 Capsaicin N01BX04 Capsaicin Standarddosis: 1 Applikationsform P; Standarddosis: 1 TD Pflaster M02AB51 Capsaicin, Kombinationen M02AP07 Capsicumfrüchte M02AP57 Capsicumfrüchte, Kombinationen N05BB02 Captodiam 0,2 g O C09AA01 Captopril 50 mg O C09BA01 Captopril und Diuretika Standarddosis: 1 Applikationsform O C07AA30 Carazolol N07AB01 Carbachol 6 mg O; 0,5 mg P S01EB02 Carbachol 0,4 ml N03AF01 Carbamazepin 1 g O,R D02AE02 Carbamidperoxid M01AB19 Carbamoylphenoxyessigsäure M01AB69 Carbamoylphenoxyessigsäure, Kombinationen B01AC08 Carbasalat calcium 1 Tablette O N02BA15 Carbasalat calcium 3,6 g O N02BA65 Carbasalat calcium, Kombinationen exkl. Psycholeptika B02BX02 Carbazochrom J01CA03 Carbenicillin 12 g P A01AD20 Carbenoxolon A02BX01 Carbenoxolon 0,15 g O A02BX51 Carbenoxolon, Kombinationen exkl. Psycholeptika A02BX71 Carbenoxolon, Kombinationen mit Psycholeptika H01BB03 Carbetocin 0,1 mg P H03BB01 Carbimazol 15 mg O R06AA08 Carbinoxamin 16 mg O R05CB03 Carbocistein 1,5 g O C01DX05 Carbocromen C01DX55 Carbocromen, Kombinationen S01XC07 Carbomer Standarddosis: 0,4 ml AT; 0,4 g AS S01XC57 Carbomer, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS L01XA02 Carboplatin 25 mg P G02AD04 Carboprost 2,5 mg P Ein-Dosis-Behandlung L01AC03 Carboquon N05CM04 Carbromal 1 g O N05CX08 Carbromal, Kombinationen A10BB06 Carbutamid 0,75 g O R03AC10 Carbuterol R03CC10 Carbuterol 6 mg O D04AH01 Cardiospermum M02AH01 Cardiospermum G01AA08 Carfecillin A16AA05 Carglumsäure 0,2 g O J01CA05 Carindacillin 4 g O N03AX19 Carisbamat M03BA02 Carisoprodol 1,4 g O M03BA52 Carisoprodol, Kombinationen exkl. Psycholeptika M03BA72 Carisoprodol, Kombinationen mit Psycholeptika S01XC08 Carmellose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC58 Carmellose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS L01BC04 Carmofur L01AD01 Carmustin A03AX11 Caroverin M01AE20 Carprofen C07AA15 Carteolol 10 mg O S01ED05 Carteolol 0,2 ml AT S01ED55 Carteolol, Kombinationen A03AH01 Carum Carvi J01DF02 Carumonam 2 g P C07AG02 Carvedilol 37,5 mg O C07BG02 Carvedilol und Thiazide A06AB07 Cascara A06AB57 Cascara, Kombinationen R05CA13 Caseinhydrolysat A04AD13 Casopitant J02AX04 Caspofungin 50 mg P D03BA55 Catalase, Kombinationen A08AA07 Cathin A08AA57 Cathin, Kombinationen N03AA05 Cathin-Phenobarbital B02BD11 Catridecacog L01XC09 Catumaxomab 21 mcg P J01DB10 Cefacetril J01DC04 Cefaclor 1 g O; 0,75 g O Kinder DDD R05GB06 Cefaclor, Kombinationen 1 g O,P bezogen auf Cefaclor; 0,75 g O Kinder DDD bezogen auf Cefaclor J01DB05 Cefadroxil 2 g O; 1 g O Kinder DDD J01DB01 Cefalexin 2 g O; 1 g O Kinder DDD J01DB02 Cefaloridin 3 g P J01DB03 Cefalotin 4 g P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 15 von 92 ATC-CODE BEDEUTUNG DDD-INFO J01DC03 Cefamandol 6 g P J01DB08 Cefapirin 4 g P J01DB07 Cefatrizin 1 g O J01DB06 Cefazedon 3 g P J01DB04 Cefazolin 3 g P J01DC13 Cefbuperazon 2 g P J01DD17 Cefcapen 0,45 g O J01DD15 Cefdinir 0,6 g O J01DD16 Cefditoren 0,4 g O J01DE01 Cefepim 2 g P J01DD10 Cefetamet 1 g O J01DD08 Cefixim 0,4 g O; 0,2 g O Kinder DDD J01DD05 Cefmenoxim 2 g P J01DC09 Cefmetazol 4 g P J01DC12 Cefminox 4 g P J01DD09 Cefodizim 2 g P J01DC06 Cefonicid 1 g P J01DD12 Cefoperazon 4 g P J01DD62 Cefoperazon, Kombinationen 4 g P bezogen auf Cefoperazon J01DC11 Ceforanid 4 g P J01DD01 Cefotaxim 4 g P J01DC05 Cefotetan 4 g P J01DC07 Cefotiam 1,2 g O; 4 g P J01DC01 Cefoxitin 6 g P J01DE03 Cefozopran 4 g P J01DD11 Cefpiramid 2 g P J01DE02 Cefpirom 4 g P J01DD13 Cefpodoxim 0,4 g O; 0,2 g O Kinder DDD J01DC10 Cefprozil 1 g O J01DB09 Cefradin 2 g O,P J01DB11 Cefroxadin J01DD03 Cefsulodin 4 g P J01DI02 Ceftarolin fosamil 1,2 g P J01DD02 Ceftazidim 4 g P J01DB12 Ceftezol 3 g P J01DD14 Ceftibuten 0,4 g O J01DD07 Ceftizoxim 4 g P J01DI01 Ceftobiprol medocaril 1,5 g P J01DD04 Ceftriaxon 2 g P J01DD54 Ceftriaxon, Kombinationen J01DC02 Cefuroxim 0,5 g O; 3 g P S01AA27 Cefuroxim J01RA03 Cefuroxim, Kombination mit anderen Antibiotika L01XX33 Celecoxib M01AH01 Celecoxib 0,2 g O C07AB08 Celiprolol 0,2 g O C07CB08 Celiprolol und andere Diuretika D11AX28 Cellulose A07XP01 Ceratonia A04AD02 Ceriumoxalat C10AA06 Cerivastatin 0,2 mg O L04AB05 Certolizumab pegol 14 mg P B01AB13 Certoparin 3 TSD E P anti Xa B01AB63 Certoparin, Kombinationen V04CC04 Ceruletid C04AX26 Cetiedil R06AE07 Cetirizin 10 mg O R06AE57 Cetirizin, Kombinationen D08AJ04 Cetrimid D11AC01 Cetrimid D08AJ02 Cetrimonium R02AA17 Cetrimonium H01CC02 Cetrorelix 0,25 mg P L01XC06 Cetuximab 65 mg P B05CA01 Cetylpyridinium D08AJ03 Cetylpyridinium D09AA07 Cetylpyridinium R02AA06 Cetylpyridinium D08AJ53 Cetylpyridinium, Kombinationen R02AA56 Cetylpyridinium, Kombinationen N07AX03 Cevimelin 90 mg O A05AA01 Chenodeoxycholsäure C01BA01 Chinidin 1,2 g O C01BA51 Chinidin, Kombinationen exkl. Psycholeptika C01BA71 Chinidin, Kombinationen mit Psycholeptika C05AF01 Chinin M09AA02 Chinin 0,2 g O P01BC01 Chinin 1,5 g O,P Base C05AF51 Chinin, Kombinationen M09AA52 Chinin, Kombinationen exkl. Psycholeptika M09AA72 Chinin, Kombinationen mit Psycholeptika P01AX01 Chiniofon 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 16 von 92 ATC-CODE BEDEUTUNG DDD-INFO D04AB05 Chinisocain V04CX14 Chlamydien-Testzone Standarddosis: 1 Test N05CC01 Chloralhydrat 1 g O,R N05CX11 Chloralhydrat, Kombinationen N05CC02 Chloralodol 1,6 g O L01AA02 Chlorambucil D06AX02 Chloramphenicol D10AF03 Chloramphenicol G01AA05 Chloramphenicol J01BA01 Chloramphenicol 3 g O,P S01AA01 Chloramphenicol S02AA01 Chloramphenicol S03AA08 Chloramphenicol D06AX52 Chloramphenicol, Kombinationen J01BA51 Chloramphenicol, Kombinationen 3 g O bezogen auf Chloramphenicol A03AX03 Chlorbenzoxamin 0,15 g O A04AD04 Chlorbutanol A04AD54 Chlorbutanol, Kombinationen R06AE04 Chlorcyclizin 0,1 g O A14AA10 Chlordehydromethyltestosteron N05BA02 Chlordiazepoxid 30 mg O; 50 mg P D11AF07 Chloressigsäure A01AB03 Chlorhexidin 30 mg O B05CA02 Chlorhexidin D08AC02 Chlorhexidin D09AA12 Chlorhexidin Standarddosis: 1 Applikationsform G04BX19 Chlorhexidin R02AA05 Chlorhexidin 30 mg O S01AX09 Chlorhexidin S02AA09 Chlorhexidin S03AA04 Chlorhexidin A01AB53 Chlorhexidin, Kombinationen D08AC52 Chlorhexidin, Kombinationen R02AA55 Chlorhexidin, Kombinationen G03DB06 Chlormadinon G03FA20 Chlormadinon und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB03 Chlormadinon und Estrogen G03AA15 Chlormadinon und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB07 Chlormadinon und Ethinylestradiol L01AA05 Chlormethin M03BB02 Chlormezanon 0,6 g O M03BB52 Chlormezanon, Kombinationen exkl. Psycholeptika M03BB72 Chlormezanon, Kombinationen mit Psycholeptika D01AC04 Chlormidazol D08AE57 Chlorocresol, Kombinationen N01AB02 Chloroform N01BA04 Chloroprocain Standarddosis: 1 Applikationsform P D04AA09 Chloropyramin R06AC03 Chloropyramin 0,15 g O; 20 mg P R06AC53 Chloropyramin, Kombinationen P01BA01 Chloroquin 0,5 g O,P Base C03AA04 Chlorothiazid 0,5 g O C03AH01 Chlorothiazid, Kombinationen C03AB04 Chlorothiazid und Kalium 0,5 g O bezogen auf Chlorothiazid G03CA06 Chlorotrianisen 24 mg O L02AA05 Chlorotrianisen D08AE05 Chloroxylenol R06AB04 Chlorphenamin 12 mg O,P R06AB54 Chlorphenamin, Kombinationen D01AE07 Chlorphenesin G01AX21 Chlorphenesin A04AD08 Chlorphenethazin A01AB75 Chlorphenol, Kombinationen D04AA34 Chlorphenoxamin R06AA06 Chlorphenoxamin 80 mg O,P A04AB57 Chlorphenoxamin, Kombinationen R06AA56 Chlorphenoxamin, Kombinationen D01AE06 2-(4-chlorphenoxy)-ethanol S01CA09 Chlorprednison und Antiinfektiva N05AA07 Chlorproethazin N05AA01 Chlorpromazin 0,3 g O,R; 0,1 g P A10BB02 Chlorpropamid 0,375 g O N05AF03 Chlorprothixen 0,3 g O; 50 mg P D08AH02 Chlorquinaldol G01AC03 Chlorquinaldol 0,2 g V P01AA04 Chlorquinaldol R02AA11 Chlorquinaldol C03BA04 Chlortalidon 25 mg O C03BB04 Chlortalidon und Kalium 25 mg O bezogen auf Chlortalidon C03EA06 Chlortalidon und Kalium sparende Mittel A01AB21 Chlortetracyclin D06AA02 Chlortetracyclin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 17 von 92 ATC-CODE BEDEUTUNG DDD-INFO J01AA03 Chlortetracyclin 1 g O S01AA02 Chlortetracyclin M03BB03 Chlorzoxazon 1,5 g O M03BB53 Chlorzoxazon, Kombinationen exkl. Psycholeptika M03BB73 Chlorzoxazon, Kombinationen mit Psycholeptika J07AE01 Cholera, inaktiviert, ganze Zelle Standarddosis: 1 Einzeldosis O J07AE51 Cholera, Kombinationen mit Typhus-Impfstoff, inaktiviert, ganze Zelle J07AE02 Cholera, lebend abgeschwächt V04CX08 Cholesterin-Testzone Standarddosis: 1 Test A05BA10 Cholin A05BA60 Cholin, Kombinationen N07AX02 Cholinalfoscerat V03AB29 Cholinesterase C10AB11 Cholinfenofibrat 0,135 g O bezogen auf Fenofibratsäure N02BA19 Cholin-Magnesium-Tris-Salicylat A01AD18 Cholinsalicylat N02BA03 Cholinsalicylat 3 g O A03AX14 Cholinsalze M02AX27 Cholinstearat R03DA02 Cholintheophyllinat 0,6 g O,R R03DA52 Cholintheophyllinat, Kombinationen R03DB02 Cholintheophyllinat und Sympathomimetika A05AA03 Cholsäure G04BX17 Chondroitinsulfat M01AX25 Chondroitinsulfat B01AX04 Chondroitinsulfat B B03AB07 Chondroitinsulfat-Eisen(III)-Komplex G03GA01 Choriongonadotrophin 7,5 TSD E P zur Ovulationsauslösung G03GA08 Choriongonadotropin alfa 0,25 mg P V09GX03 [51Cr]Chromchromat-markierte Zellen V09CX04 [51Cr]Chromedetat V10AX01 [32P]Chrom(III)phosphat-Kolloid M09AB01 Chymopapain B06AA04 Chymotrypsin M02AX28 Chymotrypsin S01KX01 Chymotrypsin A05BA18 Cianidanol C01BG07 Cibenzolin R01AD13 Ciclesonid 0,2 mg N R03BA08 Ciclesonid 0,16 mg Inhal.Aerosol C03BX03 Cicletanin P02CA04 Ciclobendazol C04AC07 Ciclonicat A03EA01 Ciclonium, Kombinationen A03DA04 Ciclonium und Analgetika D01AE14 Ciclopirox 20 mg T bezogen auf Ciclopirox olamin (Creme) G01AX12 Ciclopirox 50 mg V bezogen auf Ciclopirox olamin (Vaginalcreme) L04AD01 Ciclosporin 0,25 g O,P S01XA18 Ciclosporin J05AB12 Cidofovir 25 mg P A03AE03 Cilansetron C09AA08 Cilazapril 2,5 mg O C09BA08 Cilazapril und Diuretika Standarddosis: 1 Applikationsform O C08CA14 Cilnidipin 10 mg O B01AC23 Cilostazol 0,2 g O A02BA01 Cimetidin 0,8 g O,P A02BA51 Cimetidin, Kombinationen A03BB05 Cimetropiumbromid G02CH02 Cimicifuga racemosa G02CP03 Cimicifugawurzelstock 40 mg O Droge G02CP53 Cimicifugawurzelstock, Kombinationen H05BX01 Cinacalcet 60 mg O C05AD04 Cinchocain D04AB02 Cinchocain N01BB06 Cinchocain Standarddosis: 1 Applikationsform P S01HA06 Cinchocain S02DA04 Cinchocain C05AD54 Cinchocain, Kombinationen M04AC02 Cinchophen 1 g O R04AX04 Cineol R05CA25 Cineol C01DX14 Cinepazet 0,9 g O C04AX27 Cinepazid R01BH09 Cinnabaris R05XH04 Cinnabaris N06DX12 Cinnarizin 0,15 g O N07CA02 Cinnarizin 90 mg O N07CA52 Cinnarizin, Kombinationen 90 mg O bezogen auf Cinnarizin N05CD13 Cinolazepam J01MB06 Cinoxacin 1 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 18 von 92 ATC-CODE BEDEUTUNG DDD-INFO C10AB08 Ciprofibrat 0,1 g O J01MA02 Ciprofloxacin 1 g O; 0,5 g P S01AE03 Ciprofloxacin 0,6 mg AT S02AA15 Ciprofloxacin S03AA07 Ciprofloxacin A03FA02 Cisaprid 30 mg O,R M03AC11 Cisatracurium 10,5 mg P L01XA01 Cisplatin 6,75 mg P N06AB04 Citalopram 20 mg O,P N06BX06 Citicolin A05BA04 Citiolon V04CO04 CK-MB-Testzone Standarddosis: 1 Test L01BB04 Cladribin J01FA09 Clarithromycin 0,5 g O; 1 g P; 0,375 g O Kinder DDD A03FA06 Cleboprid P01AC02 Clefamid D04AA14 Clemastin R06AA04 Clemastin 2 mg O,P R06AA54 Clemastin, Kombinationen J01CE11 Clemizol-Penicillin R03AC14 Clenbuterol R03CC13 Clenbuterol 40 mcg O R03CC63 Clenbuterol, Kombinationen C08CA16 Clevidipin J05AF12 Clevudin 30 mg O A03CA02 Clidinium und Psycholeptika D10AF01 Clindamycin G01AA10 Clindamycin 0,1 g V J01FF01 Clindamycin 1,2 g O; 1,8 g P; 0,45 g O Kinder DDD D10AF51 Clindamycin, Kombinationen D08AH30 Clioquinol D09AA10 Clioquinol G01AC02 Clioquinol P01AA02 Clioquinol S02AA05 Clioquinol P01AA52 Clioquinol, Kombinationen N05BA09 Clobazam 20 mg O A08AA08 Clobenzorex D07AD01 Clobetasol 0,5 mg T für 0,05%-ige Zubereitungen D07CD01 Clobetasol und Antibiotika D07AB01 Clobetason S01BA09 Clobetason S01CA11 Clobetason und Antiinfektiva R05DB03 Clobutinol 0,12 g O,P R05DB53 Clobutinol, Kombinationen D07AB21 Clocortolon D07XB10 Clocortolon D10AA07 Clocortolon C05AA65 Clocortolon, Kombinationen G01AX01 Clodantoin 0,1 g V M05BA02 Clodronsäure 1,6 g O; 1,5 g P Dosis pro Behandlungszyklus bezogen auf das Salz der Clodronsäure L01BB06 Clofarabin J04BA01 Clofazimin 0,1 g O R05DB10 Clofedanol 60 mg O C03BA07 Clofenamid C03BB07 Clofenamid und Kalium P03AB01 Clofenotan P03AB51 Clofenotan, Kombinationen M01AA05 Clofezon 0,6 g O,R M02AA03 Clofezon C10AB01 Clofibrat 2 g O C10BB02 Clofibrat in Kombination mit anderen Mitteln, die den Lipidstoffwechsel beeinflussen C10BB01 Clofibrat und Nicotinsäure C10AB10 Clofibrid J01XX03 Clofoctol 1,5 g R N05CM02 Clomethiazol 1,5 g O,P N05CX04 Clomethiazol, Kombinationen J01CE07 Clometocillin 1 g O G03GB02 Clomifen 9 mg O N06AA04 Clomipramin 0,1 g O,P J01AA11 Clomocyclin 1 g O N03AE01 Clonazepam 8 mg O,P; 3 mg O Kinder DDD C02AC01 Clonidin 0,45 mg O,P N02CX02 Clonidin 0,1 mg O N07BB06 Clonidin S01EA04 Clonidin 0,25 ml AT C02LC01 Clonidin und Diuretika Standarddosis: 1 Applikationsform O C02LC51 Clonidin und Diuretika, Kombinationen mit anderen Mitteln C03BA03 Clopamid 10 mg O C03BB03 Clopamid und Kalium 10 mg O bezogen auf Clopamid N05AF02 Clopenthixol 0,1 g O,P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 19 von 92 ATC-CODE BEDEUTUNG DDD-INFO R05DB21 Cloperastin 60 mg O (bezogen auf Cloperastin hydrochlorid) B01AC04 Clopidogrel 75 mg O B01AC34 Clopidogrel, Kombinationen 75 mg O bezogen auf Clopidogrel H02AB14 Cloprednol C07AA27 Cloranolol C03BA12 Clorexolon C03BA82 Clorexolon, Kombinationen mit Psycholeptika B01AC02 Cloricromen C01DX15 Cloridarol B01AA09 Clorindion A14AA11 Clostebol N05AH06 Clotiapin 80 mg O,P N05BA21 Clotiazepam A01AB18 Clotrimazol D01AC01 Clotrimazol 25 mg T G01AF02 Clotrimazol 0,1 g V D01AC51 Clotrimazol, Kombinationen J01CF02 Cloxacillin 2 g O,P N05BA22 Cloxazolam D08AH10 Cloxiquin D08AH60 Cloxiquin, Kombinationen N05AH02 Clozapin 0,3 g O,P V09XX01 [57Co]Cobaltcyanocobalamin V09XX02 [58Co]Cobaltcyanocobalamin B03BA04 Cobamamid V03AX03 Cobicistat N01BC01 Cocain Standarddosis: 1 Applikationsform P R02AD03 Cocain S01HA01 Cocain S02DA02 Cocain R05DA04 Codein 0,1 g O N02AA66 Codein in Kombination mit Acetylsalicylsäure N02AA65 Codein in Kombination mit Diclofenac N02AA69 Codein in Kombination mit Paracetamol 3 g O bezogen auf Paracetamol N02AA64 Codein in Kombination mit Propyphenazon N02CX58 Codein, Kombinationen R05DA54 Codein, Kombinationen N02AA59 Codein, Kombinationen exkl. Psycholeptika N02AA79 Codein, Kombinationen mit Psycholeptika N06BC01 Coffein 0,4 g O,P; 6 mg O,P Säuglings DDD bezogen auf Coffeincitrat R03DA63 Coffein, Kombinationen exkl. Psycholeptika V04CG30 Coffein und Natriumbenzoat R03DB13 Coffein und Sympathomimetika M04AC01 Colchicin 1 mg O,P M04AH01 Colchicum A11CC05 Colecalciferol 500 IE O Kinder DDD prophylaktische Dosis A11CC80 Colecalciferol, Kombinationen mit Natriumfluorid 500 IE O Kinder DDD bezogen auf Colecalciferol, prophylaktische Dosis C10AC04 Colesevelam 3,75 g O V03AE06 Colestilan 7,5 g O C10AC02 Colestipol 20 g O C10AC01 Colestyramin 14 g O C10AC03 Colextran R07AA01 Colfoscerilpalmitat 0,108 g Inhal.pulver A07AA10 Colistin J01XB01 Colistin 3 MIO E Inhal.lösung,P; 3 MIO E Inhal.pulver B06AC04 Conestat alfa 3,5 TSD E P C03XA02 Conivaptan A10XP02 Copalchirindenextrakt G03GA09 Corifollitropin alfa 0,15 mg P V04CD04 Corticoliberin H01AA01 Corticotropin 25 E P H02AB10 Cortison 37,5 mg O,P S01BA03 Cortison H02AB17 Cortivazol C01EH01 Crataegus C01EB05 Creatinolfosfat D03AX09 Crilanomer L01XE16 Crizotinib 0,5 g O D01AC19 Croconazol A07EB01 Cromoglicinsäure 0,8 g O D11AH03 Cromoglicinsäure R01AC01 Cromoglicinsäure 40 mg N R03BC01 Cromoglicinsäure 40 mg Inhal.Aerosol; 80 mg Inhal.lösung,Inhal.pulver S01GX01 Cromoglicinsäure 8 mg AT R01AC51 Cromoglicinsäure, Kombinationen S01GX51 Cromoglicinsäure, Kombinationen A07BC03 Crospovidon D04AX02 Crotamiton N05CA23 Crotylbarbital V04BA13 CTX-Testzone Standarddosis: 1 Test C05BZ07 Cumarin R05CH01 Cuprum aceticum 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 20 von 92 ATC-CODE BEDEUTUNG DDD-INFO A05AP07 Curcumawurzelstock 2 g O Javanische Gelbwurz; 2,25 g O Curcumawurzelstock N05AA06 Cyamemazin V03AK01 Cyanacrylsäurealkylester B03BA01 Cyanocobalamin 70 mcg N; 1 mg O; 20 mcg P S01XA41 Cyanocobalamin A05BA63 Cyanocobalamin, Kombinationen B03BA51 Cyanocobalamin, Kombinationen B03BA02 Cyanocobalamin-Tannin-Komplex 20 mcg P C04AX01 Cyclandelat 0,6 g O N06DX14 Cyclandelat 0,6 g O R06AE03 Cyclizin 0,1 g O; 0,3 g R R06AE53 Cyclizin, Kombinationen N05CA10 Cyclobarbital 0,2 g O M03BX08 Cyclobenzaprin A05AX03 Cyclobutyrol S01FB07 Cyclodrin G03GB01 Cyclofenil 0,14 g O P01BB02 Cycloguanilembonat R01AA02 Cyclopentamin C03AA07 Cyclopenthiazid 0,5 mg O C03AB07 Cyclopenthiazid und Kalium 0,5 mg O bezogen auf Cyclopenthiazid C03EA07 Cyclopenthiazid und Kalium sparende Mittel S01FA04 Cyclopentolat L01AA01 Cyclophosphamid J04AB01 Cycloserin 0,75 g O C03AA09 Cyclothiazid 5 mg O C03AB09 Cyclothiazid und Kalium 5 mg O bezogen auf Cyclothiazid P03BA01 Cyfluthrin C01AC03 Cymarin 2,5 mg O P03BA02 Cypermethrin A15AA01 Cyproheptadin R06AX02 Cyproheptadin 12 mg O A15AA51 Cyproheptadin, Kombinationen G03HA01 Cyproteron 0,1 g O,P; 25 mg P Depot, für den Mann G03HB01 Cyproteron und Estrogen Zykluspackung mit 21 Tabletten 0,75 DE O L01BC01 Cytarabin S01XA40 Cytidin N07BA04 Cytisin J06BB09 Cytomegalievirus-Immunglobulin B06AC01 C1-Inhibitor, aus Plasma gewonnen 1,4 TSD E P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 21 von 92 ATC-CODE BEDEUTUNG DDD-INFO D B01AE07 Dabigatran etexilat 0,22 g O L01AX04 Dacarbazin 0,1 g P L04AC01 Daclizumab 0,35 g P Dosis pro Behandlungszyklus L01DA01 Dactinomycin J01XA04 Dalbavancin B01AB04 Dalteparin 2,5 TSD E P anti Xa B01AB09 Danaparoid 1,5 TSD E P anti Xa G03XA01 Danazol 0,6 g O M03CA01 Dantrolen 0,1 g O A06AB03 Dantron 50 mg O A06AG03 Dantron, inkl. Kombinationen Standarddosis: 1 Klysma A06AB53 Dantron, Kombinationen A10BX09 Dapagliflozin 10 mg O S01EX02 Dapiprazol G04BX14 Dapoxetin 30 mg O D10AX05 Dapson J04BA02 Dapson 50 mg O J01XX09 Daptomycin 0,28 g P zur Therapie von Haut- und Weichteilinfektionen B03XA02 Darbepoetin alfa 4,5 mcg P G04BD10 Darifenacin 7,5 mg O J05AE10 Darunavir 1,2 g O L01XE06 Dasatinib 0,12 g O L01DB02 Daunorubicin N06BX04 Deanol N06BX54 Deanol, Kombinationen C02CC04 Debrisoquin 20 mg O P03BA03 Decamethrin L01BC08 Decitabin 6,43 mg P V03AC03 Deferasirox V03AC02 Deferipron V03AC01 Deferoxamin B01AX01 Defibrotid H02AB13 Deflazacort 15 mg O L02BX02 Degarelix 2,7 mg P A05AA04 Dehydrocholsäure A05AA54 Dehydrocholsäure, Kombinationen P01AX09 Dehydroemetin 60 mg P C09AA12 Delapril 30 mg O C09BA12 Delapril und Diuretika C09BB12 Delapril und Manidipin Standarddosis: 1 Applikationsform O J05AG02 Delavirdin 1,2 g O S01EB04 Demecarium 0,1 ml D06AA01 Demeclocyclin J01AA01 Demeclocyclin 0,6 g O A01AB90 Demeclocyclin, Kombinationen L01CC01 Demecolcin G03DB05 Demegeston H01BB01 Demoxytocin 100 E O A03AX32 Denaverin L01XX29 Denileukin diftitox M05BX04 Denosumab 0,33 mg P; 4,3 mg P bei Tumor-induzierter Hyperkalzämie R06AX16 Deptropin 2 mg O D08AH01 Dequalinium G01AC05 Dequalinium 10 mg V R02AA02 Dequalinium 1,5 mg O D08AH51 Dequalinium, Kombinationen R02AA52 Dequalinium, Kombinationen P02DX01 Desaspidin C02AA05 Deserpidin C02LA03 Deserpidin und Diuretika N01AB07 Desfluran N06AA01 Desipramin 0,1 g O B01AE01 Desirudin 30 mg P C01AA07 Deslanosid 1 mg P zur Akutbehandlung R06AX27 Desloratadin 5 mg O H01BA02 Desmopressin 25 mcg N; 0,4 mg O; 4 mcg P; 0,24 mg SL Base G03AC09 Desogestrel Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB10 Desogestrel und Estrogen G03AA09 Desogestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB05 Desogestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O D07AB08 Desonid S01BA11 Desonid D07BB02 Desonid und Antiseptika D07AC03 Desoximetason D07XC02 Desoximetason H02AA03 Desoxycorton 5 mg O,P H02BX21 Desoxycorton, Kombinationen B06AA10 Desoxyribonuclease D03BA54 Desoxyribonuclease, Kombinationen N06AX23 Desvenlafaxin 50 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 22 von 92 ATC-CODE BEDEUTUNG DDD-INFO C01BA33 Detajmium A01AC02 Dexamethason C05AA09 Dexamethason D07AB19 Dexamethason D07XB05 Dexamethason D10AA03 Dexamethason H02AB02 Dexamethason 1,5 mg O,P R01AD03 Dexamethason R03BA09 Dexamethason S01BA01 Dexamethason 0,2 mg AT,AS S01CB01 Dexamethason S02BA06 Dexamethason S03BA01 Dexamethason H02BX02 Dexamethason, Kombinationen R01AD53 Dexamethason, Kombinationen S02BA56 Dexamethason, Kombinationen D07CB04 Dexamethason und Antibiotika S01CA01 Dexamethason und Antiinfektiva S02CA06 Dexamethason und Antiinfektiva S03CA01 Dexamethason und Antiinfektiva D07BB05 Dexamethason und Antiseptika S01BB05 Dexamethason und Mydriatika N06BA02 Dexamfetamin 15 mg O R06AB06 Dexbrompheniramin R06AB56 Dexbrompheniramin, Kombinationen R06AB02 Dexchlorpheniramin 6 mg O,P R06AB52 Dexchlorpheniramin, Kombinationen N04AA08 Dexetimid 0,5 mg O; 0,125 mg P A08AA04 Dexfenfluramin 30 mg O M01AE14 Dexibuprofen 0,8 g O M01AE17 Dexketoprofen 75 mg O,P A02BC06 Dexlansoprazol N05CM18 Dexmedetomidin 1 mg P N06BA11 Dexmethylphenidat A03FA07 Dexpanthenol A11HA30 Dexpanthenol D03AX03 Dexpanthenol 0,125 g T G02CD07 Dexpanthenol R01AX26 Dexpanthenol 35 mg N flüssige Zubereitungen S01XA12 Dexpanthenol A01AD65 Dexpanthenol, Kombinationen D03AX53 Dexpanthenol, Kombinationen V03AF02 Dexrazoxan 1,5 g P B05AA05 Dextran Standarddosis: 1 Applikationsform P B05AA55 Dextran, Kombinationen Standarddosis: 1 Applikationsform P D03AX02 Dextranomer R05DA09 Dextromethorphan 90 mg O N07XX59 Dextromethorphan, Kombinationen 40 mg O bezogen auf Dextromethorphan R05DA59 Dextromethorphan, Kombinationen N02AC01 Dextromoramid 20 mg O,P; 40 mg R N02AC04 Dextropropoxyphen 0,2 g O Chlorid; 0,3 g O Napsylat N02AC54 Dextropropoxyphen, Kombinationen exkl. Psycholeptika N02AC74 Dextropropoxyphen, Kombinationen mit Psycholeptika C10AX01 Dextrothyroxin 4 mg O N02AX03 Dezocin M01AX21 Diacerein N07BC06 Diamorphin V70AA02 Diamorphin A09AA01 Diastase V06CA50 Diätetika ohne Phenylalanin, Kombinationen N05BA01 Diazepam 10 mg O,P,R C02DA01 Diazoxid 0,3 g P V03AH01 Diazoxid J01GB09 Dibekacin 0,14 g P N06AA08 Dibenzepin 0,3 g O A02BX18 Dibismut-tris(tetraoxodialuminat) M05BC01 Dibotermin alfa D08AC01 Dibrompropamidin S01AX14 Dibrompropamidin H03BX02 Dibromtyrosin R05DB16 Dibunat P03BX03 Dibutylphthalat P03BX04 Dibutylsuccinat N05CC04 Dichloralphenazon 1,3 g O R02AA03 Dichlorbenzylalkohol A07AX05 Dichlorchinolinol A07AX55 Dichlorchinolinol, Kombinationen D01AE24 Dichlorophen P02DX02 Dichlorophen D01AE74 Dichlorophen, Kombinationen V04BA10 Dichte-Testzone Standarddosis: 1 Test A06AA01 Dickflüssiges Paraffin 15 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 23 von 92 ATC-CODE BEDEUTUNG DDD-INFO A06AA51 Dickflüssiges Paraffin, Kombinationen D11AX18 Diclofenac M01AB05 Diclofenac 0,1 g O,P,R M02AA15 Diclofenac 0,1 g T; 0,28 g TD S01BC03 Diclofenac M01AB55 Diclofenac, Kombinationen 0,1 g O bezogen auf Diclofenac S01CC01 Diclofenac und Antiinfektiva S01EC02 Diclofenamid 0,1 g O J01CF01 Dicloxacillin 2 g O,P B01AA01 Dicoumarol 0,1 g O A03AA07 Dicycloverin 80 mg O,P G04BD13 Dicycloverin G04BD63 Dicycloverin, Kombinationen J05AF02 Didanosin 0,4 g O D08AJ06 Didecyldimethylammoniumchlorid G03CB01 Dienestrol 2,5 mg O; 0,2 mg V G03CC02 Dienestrol G03DB08 Dienogest 2 mg O G03AB08 Dienogest und Estradiol Zykluspackung mit 28 Tabletten 1 DE O G03FA15 Dienogest und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA17 Dienogest und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O M02AC55 Diethylaminsalicylat, Kombinationen M02BB59 Diethylaminsalicylat, Kombinationen P02CB02 Diethylcarbamazin 0,4 g O N01AA01 Diethylether G03CB02 Diethylstilbestrol 0,2 mg O; 1 mg V G03CC05 Diethylstilbestrol L02AA01 Diethylstilbestrol 3 mg O P03BX01 Diethyltoluamid A03AA09 Difemerin A07DA04 Difenoxin A07DA54 Difenoxin, Kombinationen M01AB12 Difenpiramid P01AR02 Difetarson D07AC10 Diflorason D07AC06 Diflucortolon D07XC04 Diflucortolon D07BC04 Diflucortolon und Antiseptika N02BA11 Diflunisal 0,75 g O D07AC19 Difluprednat V03AB24 Digitalis-Antitoxin C01AA03 Digitalisblätter 0,1 g O S01XA36 Digitalisglykoside S01XA86 Digitalisglykoside, Kombinationen C01AA04 Digitoxin 0,1 mg O,P C05BZ05 Digitoxin C01AA54 Digitoxin, Kombinationen C01AA05 Digoxin 0,25 mg O,P C01AA55 Digoxin, Kombinationen A03AA08 Dihexyverin C02DB01 Dihydralazin 75 mg O; 25 mg P C02LG01 Dihydralazin und Diuretika C02LG51 Dihydralazin und Diuretika, Kombinationen mit anderen Mitteln N02AA08 Dihydrocodein 0,15 g O R05DA14 Dihydrocodein 40 mg O N02AA58 Dihydrocodein, Kombinationen R05DA64 Dihydrocodein, Kombinationen C04AE04 Dihydroergocristin N06DX19 Dihydroergocristin 3 mg O,P C04AE54 Dihydroergocristin, Kombinationen N04BC03 Dihydroergocryptinmesilat N02CA01 Dihydroergotamin 1 mg N; 4 mg O,P N02CA51 Dihydroergotamin, Kombinationen N02CA71 Dihydroergotamin, Kombinationen mit Psycholeptika C06AA02 Dihydroergotaminmesilat 4 mg O C06AA50 Dihydroergotaminmesilat und Etilefrin N06DX07 Dihydroergotoxin 3 mg O,P N06DX57 Dihydroergotoxin, Kombinationen S01AA15 Dihydrostreptomycin A11CC02 Dihydrotachysterol 1 mg O A02AB04 Dihydroxyaluminiumnatriumcarbonat (Carbaldrat) A02AF03 Dihydroxyaluminiumnatriumcarbonat und Karminativa G01AC01 Diiodhydroxychinolin 0,2 g V D08AG04 Diiodhydroxypropan H03BX01 Diiodtyrosin A03AX02 Diisopromin C04AX37 Diisopropylamin C04BA05 Diisopropylamin, Kombinationen N05BA05 Dikaliumclorazepat 20 mg O C01DX10 Dilazep 0,1 g O P01AC01 Diloxanid 1,5 g O C08DB01 Diltiazem 0,24 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 24 von 92 ATC-CODE BEDEUTUNG DDD-INFO D01AE17 Dimazol R07AB08 Dimeflin R05DA11 Dimemorfan A04AB02 Dimenhydrinat 0,275 g O; 0,2 g R A04AB52 Dimenhydrinat, Kombinationen V03AB09 Dimercaprol N06AA18 Dimetacrin 0,15 g O R05DB28 Dimethoxanat V03AB27 4-Dimethylaminophenol Standarddosis: 1 Applikationsform P A03AC02 Dimethylaminopropionylphenothiazin P03BX05 Dimethylcarbat N07XX09 Dimethyl fumarat P03BX02 Dimethylphthalat G04BX13 Dimethylsulfoxid M02AX03 Dimethylsulfoxid M02AX53 Dimethylsulfoxid, Kombinationen M03AA04 Dimethyltubocurarin D02AA01 Dimeticon P03AX05 Dimeticon D04AA13 Dimetinden R01AC09 Dimetinden R06AB03 Dimetinden 4 mg O; 4 mg P C01CA12 Dimetofrin N02CX05 Dimetotiazin B05XA14 Dinatrium-1-glycerinphosphat B05XA18 Dinatrium-1(2)-glycerin-phosphat-Gemisch Standarddosis: 1 Applikationsform P G02AD01 Dinoprost 25 mg P G02AD02 Dinoproston 0,5 mg O,V V08AA10 Diodon Standarddosis: 1 Applikationsform A07BC05 Diosmectit 9 g O A07BC55 Diosmectit, Kombinationen C05BZ04 Diosmin C05CA03 Diosmin C05CA53 Diosmin, Kombinationen C05AX14 Dioxopromethazin D04AA40 Dioxopromethazin R06AD10 Dioxopromethazin A03AB15 Diphemanil A03CA08 Diphemanil und Psycholeptika B01AA10 Diphenadion A04AB05 Diphenhydramin D04AA32 Diphenhydramin N01BX06 Diphenhydramin Standarddosis: 1 Applikationsform P N05CM20 Diphenhydramin 50 mg O R06AA02 Diphenhydramin 0,2 g O,R chlorid; 0,3 g O,R Teoclat S01GX16 Diphenhydramin A04AB55 Diphenhydramin, Kombinationen D04AA82 Diphenhydramin, Kombinationen N05CX07 Diphenhydramin, Kombinationen R06AA52 Diphenhydramin, Kombinationen D04AA33 Diphenhydraminmethylbromid A07DA01 Diphenoxylat 15 mg O A07DA51 Diphenoxylat, Kombinationen D04AA39 Diphenylpyralin R01AX11 Diphenylpyralin R06AA07 Diphenylpyralin 10 mg O R06AA57 Diphenylpyralin, Kombinationen J06AA01 Diphtherie-Antitoxin J07CA06 Diphtherie-Haemophilus influenzae B-Pertussis-Poliomyelitis- Tetanus Standarddosis: 1 Einzeldosis P J07CA09 Diphtherie-Haemophilus influenzae B-Pertussis-Poliomyelitis- Tetanus-Hepatitis B Standarddosis: 1 Einzeldosis P J07CA11 Diphtherie-Haemophilus influenzae B-Pertussis-Tetanus-Hepatitis B J07CA13 Diphtherie-Haemophilus influenzae B-Pertussis-Tetanus-Hepatitis B- Meningokokken A + C J07CA05 Diphtherie-Hepatitis B-Pertussis-Tetanus J07CA07 Diphtherie-Hepatitis B-Tetanus J06BB10 Diphtherie-Immunglobulin J07CA02 Diphtherie-Pertussis-Poliomyelitis-Tetanus Standarddosis: 1 Einzeldosis P J07CA12 Diphtherie-Pertussis-Poliomyelitis-Tetanus-Hepatitis B J07CA01 Diphtherie-Poliomyelitis-Tetanus Standarddosis: 1 Einzeldosis P J07CA03 Diphtherie-Röteln-Tetanus J07AF01 Diphtherie-Toxoid Standarddosis: 1 Einzeldosis P N05CX06 Dipiperonylaminoethanol, Kombinationen A03AX33 Dipiproverin S01EA02 Dipivefrin 0,2 ml AT S01EA52 Dipivefrin, Kombinationen R03DA01 Diprophyllin 1 g O,P,R R03DA51 Diprophyllin, Kombinationen R03DB01 Diprophyllin und Sympathomimetika B01AC07 Dipyridamol 0,4 g O; 0,2 g P C01DX21 Dipyridamol 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 25 von 92 ATC-CODE BEDEUTUNG DDD-INFO C01DX71 Dipyridamol, Kombinationen N02BA09 Dipyrocetyl 3 g O N02BA59 Dipyrocetyl, Kombinationen exkl. Psycholeptika N02BA79 Dipyrocetyl, Kombinationen mit Psycholeptika M01BA02 Dipyrocetyl und Corticosteroide J01FA13 Dirithromycin 0,5 g O C01BA03 Disopyramid 0,4 g O,P N01AX13 Distickstoffmonoxid N01AX63 Distickstoffmonoxid, Kombinationen N07AA03 Distigmin 5 mg O; 0,25 mg P N07BB01 Disulfiram 0,2 g O P03AA04 Disulfiram P03AA54 Disulfiram, Kombinationen B01AC01 Ditazol D05AC01 Dithranol D05AC51 Dithranol, Kombinationen P03AA01 Dixanthogen N05AB01 Dixyrazin 50 mg O; 30 mg P R03AA52 DL-Ephedrin, Kombinationen V03AB43 DMPS C01CA07 Dobutamin 0,5 g P L01CD02 Docetaxel 6,43 mg P D06BB11 Docosanol A06AA02 Docusat-Natrium 0,15 g O S02DC02 Docusat-Natrium A06AG10 Docusat-Natrium, inkl. Kombinationen Standarddosis: 1 Klysma D08AJ59 Dodecloniumbromid, Kombinationen C01BD04 Dofetilid A04AA04 Dolasetron 0,2 g O; 0,1 g P R05CB08 Domiodol A01AB06 Domiphen 3 mg O A03FA03 Domperidon 30 mg O,P; 0,12 g R N06DA02 Donepezil 7,5 mg O N06DA52 Donepezil und Memantin C01CA04 Dopamin 0,5 g P C01CA14 Dopexamin 0,5 g P J01DH04 Doripenem 1,5 g P R05CB13 Dornase alfa (Desoxyribonuclease) 2,5 mg Inhal.lösung S01EC03 Dorzolamid 0,3 ml N06AA16 Dosulepin 0,15 g O N06CA10 Dosulepin und Psycholeptika M03AC07 Doxacuriumchlorid R07AB01 Doxapram 0,4 g P C02CA04 Doxazosin 4 mg O G04CA05 Doxazosin 6 mg O N05CD12 Doxefazepam N06AA12 Doxepin 0,1 g O,P H05BX03 Doxercalciferol R03DA11 Doxofyllin L01DB01 Doxorubicin 5 mg P; 3 mg P pegylierte liposomale Form; Standarddosis: 1 Instillationsset U A01AB22 Doxycyclin J01AA02 Doxycyclin 0,1 g O,P R05GA01 Doxycyclin, Kombinationen 0,1 g O,P bezogen auf Doxycyclin R05GB51 Doxycyclin, Kombinationen 0,1 g O,P bezogen auf Doxycyclin R05GB01 Doxycyclin mit Ambroxol 0,1 g O,P bezogen auf Doxycyclin N05CM21 Doxylamin 37,5 mg O R06AA09 Doxylamin A04AB56 Doxylamin, Kombinationen R06AA59 Doxylamin, Kombinationen A03EA05 Drofenin, Kombinationen A03DA12 Drofenin und Analgetika A04AD10 Dronabinol C01BD07 Dronedaron 0,8 g O N05AD08 Droperidol 2,5 mg P R05DB19 Dropropizin G03FA17 Drospirenon und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA12 Drospirenon und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O A03AD02 Drotaverin 0,1 g O,P B01AD10 Drotrecogin alfa (aktiviert) 40 mg P M01AC04 Droxicam R05DB17 Droxypropin G04BX18 Duloxetin 80 mg O N06AX21 Duloxetin 60 mg O A06AA03 Dünnflüssiges Paraffin G04CB02 Dutasterid 0,5 mg O N01BX02 Dyclonin Standarddosis: 1 Applikationsform P R02AD04 Dyclonin G03DB01 Dydrogesteron 10 mg O G03FA14 Dydrogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O G03FB08 Dydrogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O V10AX03 [165Dy]Dysprosium-Kolloid 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 26 von 92 ATC-CODE BEDEUTUNG DDD-INFO E R06AX22 Ebastin 10 mg O D01AC17 Eberconazol B06AC03 Ecallantid D03AH02 Echinacea L03AH02 Echinacea angustifolia R05XH51 Echinacea angustifolia, Kombinationen L03AH01 Echinacea purpurea L03AP03 Echinacea-angustifolia-Wurzel und -Kraut L03AP53 Echinacea-angustifolia-Wurzel und -Kraut, Kombinationen D03AP07 Echinaceakraut D03AP57 Echinaceakraut, Kombinationen L03AP02 Echinacea-pallida-Wurzel 0,9 g O Droge L03AP52 Echinacea-pallida-Wurzel, Kombinationen L03AP01 Echinacea-purpurea-Presssaft 0,3 g O Trockenpresssaft; 7,5 ml O Presssaft R01AP02 Echinacea-purpurea-Presssaft L03AP51 Echinacea-purpurea-Presssaft, Kombinationen D01AC03 Econazol G01AF05 Econazol 0,1 g V D01AC53 Econazol, Kombinationen S01EB03 Ecothiopat 0,2 ml L04AA25 Eculizumab 64 mg P V03AB03 Edetate D06BB09 Edoxudin L01XC01 Edrecolomab L04AA21 Efalizumab 10 mg P L01XD06 Efaproxiral J05AG03 Efavirenz 0,6 g O R05CP02 Efeublätter 0,3 g O Droge D11AX16 Eflornithin P01CX03 Eflornithin C01DX13 Efloxat 0,2 g O R05DP05 Eibischwurzel und -blätter A07XP03 Eichenrinde A02AD01 Einfache Salzkombinationen A02AF02 Einfache Salzkombinationen und Karminativa B03AE02 Eisen, Multivitamine und Folsäure B03AE04 Eisen, Multivitamine und Mineralstoffe B03AE03 Eisen und Multivitamine B03AE01 Eisen, Vitamin B12 und Folsäure B03AD01 Eisen-Aminosäure-Komplex B03AA10 Eisen(II)ascorbat 0,2 g O Fe2+ B03AA09 Eisen(II)aspartat 0,2 g O Fe2+ B03AA04 Eisen(II)carbonat 0,2 g O Fe2+ B03AA05 Eisen(II)chlorid 0,2 g O Fe2+ B03AA02 Eisen(II)fumarat 0,2 g O Fe2+ B03AD02 Eisen(II)fumarat B03AA03 Eisen(II)gluconat 0,2 g O Fe2+ B03AD09 Eisen(II)gluconat B03AA01 Eisen(II)glycinsulfat 0,2 g O Fe2+ B03AD06 Eisen(II)glycinsulfat 0,1 g O Fe2+ B03AB08 Eisen(III)acetyltransferrin B03AB06 Eisen(III)citrat V09XX04 [59Fe]Eisen(III)citrat V03AB31 Eisen(III)hexacyanoferrat(II) B03AB04 Eisen(III)hydroxid B03AC06 Eisen(III)hydroxid-Dextran-Komplex 0,1 g P Fe3+ B03AB05 Eisen(III)hydroxid-Polymaltose-Komplex 90 mg O Fe3+ B03AC01 Eisen(III)hydroxid-Polymaltose-Komplex 0,1 g P Fe3+ B03AD04 Eisen(III)hydroxid-Polymaltose-Komplex B03AB01 Eisen(III)natrium-citrat 0,75 g O Fe3+ B03AC07 Eisen(III)natrium-Gluconat-Komplex 0,1 g P Fe3+ B03AA11 Eisen(II)iodat 0,2 g O Fe2+ B03AB02 Eisen(III)oxid-Saccharose-Komplex 0,11 g O Fe3+ B03AC02 Eisen(III)oxid-Saccharose-Komplex 0,1 g P Fe3+ B03AB09 Eisen(III)proteinsuccinylat B03AC05 Eisen(III)sorbit-Gluconsäure-Komplex 0,1 g P Fe3+ B03AC03 Eisen(III)sorbit-Zitronensäure-Komplex 0,1 g P Fe3+ B03AA13 Eisen(II)polystyrol-sulfonat 0,2 g O Fe2+ B03AA06 Eisen(II)succinat 0,2 g O Fe2+ B03AA07 Eisen(II)sulfat 0,2 g O Fe2+ B03AD03 Eisen(II)sulfat 0,1 g O Fe2+ B03AA08 Eisen(II)tartrat 0,2 g O Fe2+ V08CB03 Eisenoxid, Nanopartikel Standarddosis: 1 Applikationsform H05BA04 Elcatonin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 27 von 92 ATC-CODE BEDEUTUNG DDD-INFO B05BB01 Elektrolyte Standarddosis: 1 Applikationsform P B05BB04 Elektrolyte in Kombination mit anderen Mitteln Standarddosis: 1 Applikationsform P B05XA31 Elektrolyte in Kombination mit anderen Mitteln Standarddosis: 1 Applikationsform P B05BB02 Elektrolyte mit Kohlenhydraten Standarddosis: 1 Applikationsform P A07CA50 Elektrolyte zur oralen Rehydrierung, Kombinationen N02CC06 Eletriptan 40 mg O A13AP01 Eleutherococcuswurzel B02BX05 Eltrombopag 50 mg O J05AX11 Elvitegravir S01GX06 Emedastin G04BD01 Emepronium 0,5 g O; 75 mg P N05CX05 Emepronium, Kombinationen A03CA30 Emepronium und Psycholeptika P01AX02 Emetin 60 mg P P01AX52 Emetin, Kombinationen R01AX28 Emser Salz R02AX02 Emser Salz R04AX01 Emser Salz R05CA22 Emser Salz R02AX52 Emser Salz, Kombinationen J05AF09 Emtricitabin 0,2 g O J05AR09 Emtricitabin, Tenofovir disoproxil, Elvitegravir und Cobicistat Standarddosis: 1 Applikationsform O J05AR06 Emtricitabin, Tenofovir disoproxil und Efavirenz Standarddosis: 1 Applikationsform O J05AR08 Emtricitabin, Tenofovir disoproxil und Rilpivirin Standarddosis: 1 Applikationsform O N05BC03 Emylcamat 0,9 g O C09AA02 Enalapril 10 mg O,P C09BA02 Enalapril und Diuretika Standarddosis: 1 Applikationsform O C09BB02 Enalapril und Lercanidipin Standarddosis: 1 Applikationsform O C09BB06 Enalapril und Nitrendipin Standarddosis: 1 Applikationsform O C01BC08 Encainid 0,1 g O J07BA02 Encephalitis, japanische, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P C02DB03 Endralazin 10 mg O N01AB04 Enfluran J05AX07 Enfuvirtid 0,18 g P J01MA04 Enoxacin 0,8 g O B01AB05 Enoxaparin 2 TSD E P anti Xa C01CE03 Enoximon 1 g P D03AX10 Enoxolon A02BB02 Enprostil 70 mcg O N04BX02 Entacapon 1 g O J05AF10 Entecavir 0,5 mg O J07AX53 Enterobacteriacae Stämme, Kombinationen Standarddosis: 1 Einzeldosis P L03AG01 Enterococcus faecalis L03AG51 Enterococcus, Kombinationen L02BB04 Enzalutamid 0,16 g O A09AP03 Enzianwurzel M01BX01 Enzyme, Kombinationen R05XC01 Enzym-haltige Kombinationen D08AX02 Eosin C07AB10 Epanolol 0,2 g O M03BX09 Eperison 0,15 g O C01CA26 Ephedrin 50 mg P C01CB01 Ephedrin R01AA03 Ephedrin 8 mg N R01AB05 Ephedrin R03CA02 Ephedrin 50 mg O S01FB02 Ephedrin A08AA56 Ephedrin, Kombinationen C01CB51 Ephedrin, Kombinationen R03CA52 Ephedrin, Kombinationen J01CA07 Epicillin 2 g O,P G03GB03 Epimestrol 10 mg O R06AX24 Epinastin S01GX10 Epinastin A01AD01 Epinephrin B02BC09 Epinephrin C01CA24 Epinephrin 0,5 mg P R01AA14 Epinephrin R01AB12 Epinephrin R03AA01 Epinephrin 2,24 mg Inhal.Aerosol; 20 mg Inhal.lösung S01EA01 Epinephrin 0,2 ml AT R03AA51 Epinephrin, Kombinationen R03CA51 Epinephrin, Kombinationen S01EA51 Epinephrin, Kombinationen R03AK01 Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen L01DB03 Epirubicin 7 mg P C03EA03 Epitizid und Kalium sparende Mittel C03DA04 Eplerenon 50 mg O B03XA05 Epoetin delta 1 TSD E P A05BA05 Epomediol B01AC09 Epoprostenol 38 mcg P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 28 von 92 ATC-CODE BEDEUTUNG DDD-INFO R05CB04 Eprazinon 0,2 g O C09CA02 Eprosartan 0,6 g O C09DA02 Eprosartan und Diuretika Standarddosis: 1 Applikationsform O R03DX02 Eprozinol B02BD08 Eptacog alfa (aktiviert) 2500 TSD E P B01AC16 Eptifibatid 0,2 g P M05BC02 Eptotermin alfa 3,3 mg P V10AX04 [169Er]Erbiumcitrat-Kolloid D11AB06 Erdnussöl D11AB56 Erdnussöl, Kombinationen R05CB15 Erdostein 0,6 g O A05AP04 Erdrauchkraut A11CC01 Ergocalciferol C04AE01 Ergoloidmesylat 3 mg O,P C04AE51 Ergoloidmesylat, Kombinationen G02AB03 Ergometrin 0,2 mg O,P N02CA02 Ergotamin 4 mg Inhal.Aerosol,O,P,R,SL N02CA52 Ergotamin, Kombinationen exkl. Psycholeptika 4 mg O bezogen auf Ergotamin N02CA72 Ergotamin, Kombinationen mit Psycholeptika 4 mg O bezogen auf Ergotamin L01XX41 Eribulin 0,21 mg P bezogen auf Eribulin L01XE03 Erlotinib 0,125 g O J01DH03 Ertapenem 1 g P C01DA13 Erythrityltetranitrat 90 mg O C01DA63 Erythrityltetranitrat, Kombinationen D10AF02 Erythromycin Standarddosis: 2,0 g Salbe etc. J01FA01 Erythromycin 1 g O; 2 g O Erythromycinethylsuccinat-Tabletten; 2 g P; 1 g O Kinder DDD für Erythromycinethylsuccinat-haltige Mittel S01AA17 Erythromycin D10AF52 Erythromycin, Kombinationen R05GB07 Erythromycin, Kombinationen 2 g O für Erythromycinethylsuccinat-haltige Zubereitungen; 1 g O Kinder DDD für Erythromycinethylsuccinat-haltige Zubereitungen J01FA16 Erythromycinstinoprat 1 g O,P B03XA01 Erythropoietin 1 TSD E P B05AX01 Erythrozyten B05AX41 Erythrozyten ohne Pharmazentralnummer A07FA06 Escherichia coli G04BX20 Escherichia coli L03AG04 Escherichia coli M09AX09 Escherichia coli A07EF01 Escherichia coli, Stamm Nissle 1917 N06AB10 Escitalopram 10 mg O N01AX14 Esketamin N03AF04 Eslicarbazepin 0,8 g O C07AB09 Esmolol A02BC05 Esomeprazol 20 mg O,P A02BD06 Esomeprazol, Amoxicillin und Clarithromycin G01AD02 Essigsäure S02AA10 Essigsäure N05CD04 Estazolam 3 mg O D11AX26 Estradiol G03CA03 Estradiol 0,3 mg N; 2 mg O; 1 mg P Depot mit kurzer Wirkdauer; 0,3 mg P Depot mit langer Wirkdauer; 5 mg R; 1 mg TD Gel; 50 mcg TD Pflaster bezogen auf die Freisetzungsrate pro 24 Stunden; 25 mcg V; 7,5 mcg V Vaginalring bezogen auf die Freisetzungsrate pro 24 Stunden G03CC07 Estradiol G03CD03 Estradiol 25 mcg V G03CA53 Estradiol, Kombinationen G03CD53 Estradiol, Kombinationen L01XX11 Estramustin 0,56 g O G03CA04 Estriol 2 mg O,P; 0,2 mg V G03CC06 Estriol G03CD01 Estriol 0,2 mg V G03CD51 Estriol, Kombinationen G03CA07 Estron 1 mg O G03CC04 Estron N05CF04 Eszopiclon C03CC01 Etacrynsäure 50 mg O,P C01DX07 Etafenon 0,225 g O N05CA20 Etallobarbital R03DA06 Etamiphyllin R03DB06 Etamiphyllin und Sympathomimetika R07AB04 Etamivan B02BX01 Etamsylat N04AB01 Etanautin L04AB01 Etanercept 7 mg P; 3 mg P Kinder DDD A01AB27 Ethacridinlactat A07AX07 Ethacridinlactat B05CA08 Ethacridinlactat D08AA01 Ethacridinlactat N03AC03 Ethadion J04AK02 Ethambutol 1,2 g O,P J04AM03 Ethambutol und Isoniazid 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 29 von 92 ATC-CODE BEDEUTUNG DDD-INFO B05XX04 Ethanol Standarddosis: 1 Applikationsform P D08AX08 Ethanol V03AB16 Ethanol V03AZ01 Ethanol V07AB03 Ethanol A03ED02 Ethaverin in Kombination mit anderen Mitteln A03EA06 Ethaverin, Kombinationen G04BD66 Ethaverin, Kombinationen A03DC05 Ethaverin und Analgetika N05CM08 Ethchlorvynol 0,5 g O N02BA07 Ethenzamid 3 g O R05XA04 Ethenzamid, Kombinationen N02BA57 Ethenzamid, Kombinationen exkl. Psycholeptika N02BA77 Ethenzamid, Kombinationen mit Psycholeptika N02CP02 Etherische Öle R01AP06 Etherische Öle N02CP52 Etherische Öle, Kombinationen R01AP56 Etherische Öle, Kombinationen R02AP52 Etherische Öle, Kombinationen G03CA01 Ethinylestradiol 25 mcg O L02AA03 Ethinylestradiol 1,5 mg O J04AD03 Ethionamid 0,75 g O G03DC04 Ethisteron 5 mg O G03FA03 Ethisteron und Estrogen N03AD01 Ethosuximid 1,25 g O N03AD51 Ethosuximid, Kombinationen N03AB01 Ethotoin 2,5 g O A06AC02 Ethulose 3 g O N04BX06 Ethylbenzhydramin B01AA08 Ethylbiscoumacetat 0,6 g O N01BX01 Ethylchlorid Standarddosis: 1 Applikationsform P V08AD01 Ethylester iodierter Fettsäuren Standarddosis: 1 Applikationsform A14AB02 Ethylestrenol 2 mg O D01AE10 Ethylhydroxybenzoat D02AC05 Ethyllinolat N05BA18 Ethylloflazepat 2 mg O R05DA01 Ethylmorphin 50 mg O S01XA06 Ethylmorphin N02AA57 Ethylmorphin, Kombinationen N01BB07 Etidocain Standarddosis: 1 Applikationsform P N01BB57 Etidocain, Kombinationen Standarddosis: 1 Applikationsform P M05BA01 Etidronsäure 0,4 g O; 1,5 g P Dosis pro Behandlungszyklus bezogen auf das Salz der Etidronsäure M05BB01 Etidronsäure und Calcium, Sequenzialpräparate 0,4 g O bezogen auf das Salz der Etidronsäure N05BX03 Etifoxin A08AA06 Etilamfetamin C01CA01 Etilefrin 50 mg O,P C01CA51 Etilefrin, Kombinationen R01BA56 Etilefrin, Kombinationen N04BA06 Etilevodopa und Decarboxylasehemmer N05BA19 Etizolam M01AB08 Etodolac 0,4 g O P01AC03 Etofamid M01AG06 Etofenamat M02AA06 Etofenamat 1 g T M02AA56 Etofenamat, Kombinationen C10AB09 Etofibrat C04AD54 Etofyllin, Kombinationen R03DA82 Etofyllin, Kombinationen mit Psycholeptika R03DB12 Etofyllin und Sympathomimetika C10AB12 Etofyllinclofibrat C04AD04 Etofyllinnicotinat 0,3 g O L01AG01 Etoglucid P03BX06 Etohexadiol R06AX30 Etoloxamin R06AX80 Etoloxamin, Kombinationen N01AX07 Etomidate G03AC08 Etonogestrel 68 mcg s.c. Implantat N06AB09 Etoperidon L01CB01 Etoposid 50 mg O; 25 mg P M01AH05 Etoricoxib 60 mg O C03CX01 Etozolin J05AG04 Etravirin 0,4 g O D05BB01 Etretinat 35 mg O N04AC30 Etybenzatropin 9 mg O G03DC06 Etynodiol G03FA06 Etynodiol und Estrogen G03AA01 Etynodiol und Ethinylestradiol D08AA03 Euflavin A01AB29 Eugenol M02BP02 Eukalyptusöl R04AP03 Eukalyptusöl R05CP09 Eukalyptusöl 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 30 von 92 ATC-CODE BEDEUTUNG DDD-INFO R05CP59 Eukalyptusöl, Kombinationen M02BP52 Eukalyptusöl, Kombinationen S01XH01 Euphrasia S01XH51 Euphrasia, Kombinationen L01XE10 Everolimus 10 mg O L04AA18 Everolimus 1,5 mg O L02BG06 Exemestan 25 mg O A10BX04 Exenatid 15 mcg P; 0,286 mg P Depotinjektion C10AX09 Ezetimib 10 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 31 von 92 ATC-CODE BEDEUTUNG DDD-INFO F B02BD03 Faktor-VIII-Inhibitor-bypass-Aktivität 10 TSD E P J05AB09 Famciclovir 1,5 g O S01AD07 Famciclovir A02BA03 Famotidin 40 mg O,P A02BA53 Famotidin, Kombinationen N07XX07 Fampridin 20 mg O M02AP02 Fango M02BX03 Fango M02AP52 Fango, Kombinationen J01DI03 Faropenem C04AX32 Fasudil V04CZ05 Faulbaumrinde, Kombinationen M03AC08 Fazadiniumbromid M03BA05 Febarbamat 0,3 g O A05AX09 Febuprol M04AA03 Febuxostat 80 mg O V01AA01 Federn R05DB14 Fedrilat 0,2 g O N03AX10 Felbamat 2,4 g O M02AA08 Felbinac 0,15 g T C08CA02 Felodipin 5 mg O P02CA06 Fenbendazol M01AE05 Fenbufen 0,6 g O N06BA06 Fencamfamin A03EA40 Fencarbamid, Kombinationen A03AP03 Fenchelfrüchte C08EA01 Fendilin N06BA10 Fenetyllin A08AA02 Fenfluramin 0,12 g O A05AX07 Fenipentol C10AB05 Fenofibrat 0,2 g O mikronisiert; 0,25 g O nicht mikronisiert C01CA19 Fenoldopam M01AE04 Fenoprofen 1,2 g O G02CA03 Fenoterol R03AC04 Fenoterol 0,6 mg Inhal.Aerosol/pulver; 4 mg Inhal.lösung R03CC04 Fenoterol 10 mg O,R R03CC54 Fenoterol, Kombinationen R03AK03 Fenoterol und Cromoglicinsäure, Dinatriumsalz R03AL01 Fenoterol und Ipratropium bromid A03AX05 Fenoverin R01AA12 Fenoxazolin N06BA08 Fenozolon A03AX01 Fenpipran A03AB21 Fenpiverinium C03BA13 Fenquizon R03BX01 Fenspirid R03DX03 Fenspirid N01AH01 Fentanyl 0,7 mg P; 55 mcg P Kinder DDD N02AB03 Fentanyl 0,6 mg N,SL; 1,2 mg TD N01AH51 Fentanyl, Kombinationen M01AB10 Fentiazac M02AA14 Fentiazac D01AC12 Fenticonazol G01AF12 Fenticonazol 0,1 g V A03BB04 Fentonium 60 mg O M03BX30 Fenyramidol 2 g O M01AX18 Feprazon M02AA16 Feprazon M01AX68 Feprazon, Kombinationen V08CB02 Ferristen Standarddosis: 1 Applikationsform R05XH02 Ferrum phosphoricum R05XH52 Ferrum phosphoricum, Kombinationen V04CM02 Fertilitäts-Teststreifen Standarddosis: 1 Test V08CB01 Ferumoxsil Standarddosis: 1 Applikationsform G04BD11 Fesoterodin 4 mg O V06DB51 Fette in Kombination mit Vitaminen V06DB52 Fette, Kombinationen V06DB50 Fette/Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen B05BA02 Fett-Emulsionen Standarddosis: 1 Applikationsform P R06AX26 Fexofenadin 0,12 g O V09GB01 [125I]Fibrinogen B02BB01 Fibrinogen, human 5 g P B02BC10 Fibrinogen, human B01AD05 Fibrinolysin B06AA02 Fibrinolysin und Desoxyribonuclease M02BP01 Fichtennadelöl M02BP51 Fichtennadelöl, Kombinationen A07AA12 Fidaxomicin 0,4 g O L03AA02 Filgrastim 0,35 mg P bezogen auf kg Körpergewicht 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 32 von 92 ATC-CODE BEDEUTUNG DDD-INFO D11AX10 Finasterid 1 mg O G04CB01 Finasterid 5 mg O L04AA27 Fingolimod 0,5 mg O N06BX05 Fipexid G04BD02 Flavoxat 0,8 g O C01BC04 Flecainid 0,2 g O,P C01EB20 Fleischextrakt J01MA08 Fleroxacin 0,4 g O,P G02CX02 Flibanserin D03AX32 Fliegenlarven N02BG04 Floctafenin 1 g O J01DC14 Flomoxef 2 g P V09AX05 [18F]Florbetapir C01DB01 Flosequinan N05AD09 Fluanison P02CA05 Flubendazol 0,2 g O D07AC02 Fluclorolon J01CF05 Flucloxacillin 3 g O,P; 1 g O Kinder DDD D01AC15 Fluconazol J02AC01 Fluconazol 0,2 g O,P D01AE21 Flucytosin J02AX01 Flucytosin 10 g O,P L01BB05 Fludarabin 8 mg P V09IX04 [18F]Fludeoxyglucose N05BA17 Fludiazepam 0,75 mg O H02AA02 Fludrocortison 0,1 mg O R01AD64 Fludrocortison, Kombinationen S01CA06 Fludrocortison und Antiinfektiva S02CA07 Fludrocortison und Antiinfektiva S03CA05 Fludrocortison und Antiinfektiva D07AC07 Fludroxycortid D07CC03 Fludroxycortid und Antibiotika D07BC07 Fludroxycortid und Antiseptika M01AG03 Flufenaminsäure 0,5 g O M02AA27 Flufenaminsäure M02AA77 Flufenaminsäure, Kombinationen B01AA12 Fluindion V03AB25 Flumazenil N02CB01 Flumedroxon 20 mg O J01MB07 Flumequin 1,2 g O D07AB03 Flumetason D07XB01 Flumetason D07CB05 Flumetason und Antibiotika S02CA02 Flumetason und Antiinfektiva D07BB01 Flumetason und Antiseptika N07CA03 Flunarizin 10 mg O R01AD04 Flunisolid 0,15 mg N R03BA03 Flunisolid 1 mg Inhal.Aerosol N05CD03 Flunitrazepam 1 mg O,P G02CC04 Flunoxaprofen M01AE15 Flunoxaprofen S01BA15 Fluocinolon acetonid 'Standarddosis: 1 Implantat S02BA08 Fluocinolon acetonid C05AA10 Fluocinolonacetonid D07AC04 Fluocinolonacetonid 0,3 mg T C05AA60 Fluocinolonacetonid, Kombinationen D07CC02 Fluocinolonacetonid und Antibiotika S01CA10 Fluocinolonacetonid und Antiinfektiva S02CA05 Fluocinolonacetonid und Antiinfektiva D07BC02 Fluocinolonacetonid und Antiseptika C05AA11 Fluocinonid D07AC08 Fluocinonid C05AA61 Fluocinonid, Kombinationen D07CC05 Fluocinonid und Antibiotika D07AB04 Fluocortin R01AD21 Fluocortin C05AA08 Fluocortolon D07AC05 Fluocortolon D07XC05 Fluocortolon H02AB03 Fluocortolon 10 mg O C05AA58 Fluocortolon, Kombinationen D07CC06 Fluocortolon und Antibiotika S01CA04 Fluocortolon und Antiinfektiva D07BC03 Fluocortolon und Antiseptika S01JA01 Fluorescein V04CX03 Fluorescein Standarddosis: 1 Test S01JA51 Fluorescein, Kombinationen B05AA03 Fluorocarbon-Blutersatzmittel Standarddosis: 1 Applikationsform P V09IX05 [18F]Fluorodopa V09IX08 [18F]Fluoroethylcholin C05AA06 Fluorometholon 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 33 von 92 ATC-CODE BEDEUTUNG DDD-INFO D07AB06 Fluorometholon D07XB04 Fluorometholon D10AA01 Fluorometholon S01BA07 Fluorometholon S01CB05 Fluorometholon C05AA56 Fluorometholon, Kombinationen D07CB03 Fluorometholon und Antibiotika S01CA07 Fluorometholon und Antiinfektiva S01BB03 Fluorometholon und Mydriatika V09IX07 [18F]Fluoromethylcholin D11AF05 Fluorouracil L01BC02 Fluorouracil 0,15 g O; 0,1 g P D11AF55 Fluorouracil, Kombinationen L01BC52 Fluorouracil, Kombinationen A01AA05 Fluorsilan S01EB07 Fluostigmin N06AB03 Fluoxetin 20 mg O N06CA03 Fluoxetin und Psycholeptika G03BA01 Fluoxymesteron 5 mg O N05AF01 Flupentixol 6 mg O; 4 mg P Depot D07AB05 Fluperolon N05AB02 Fluphenazin 10 mg O; 1 mg P Depot N02BG07 Flupirtin 0,4 g O; 0,525 g R D07AB07 Flupredniden D07XB03 Flupredniden C05AA64 Flupredniden, Kombinationen D07CB02 Flupredniden und Antibiotika D07BB06 Flupredniden und Antiseptika N05CD01 Flurazepam 30 mg O M01AE09 Flurbiprofen 0,2 g O,R M02AA19 Flurbiprofen R02AX01 Flurbiprofen 44 mg O S01BC04 Flurbiprofen J01FA14 Flurithromycin 0,75 g O N05AG01 Fluspirilen 0,7 mg P Depot L02BB01 Flutamid 0,75 g O V09AX04 [18F]Flutemetamol D07AC17 Fluticason R01AD08 Fluticason 0,2 mg N R03BA05 Fluticason 0,6 mg Inhal.Aerosol/pulver; 1,5 mg Inhal.lösung R01AD12 Fluticason furoat 0,11 mg N R01AD58 Fluticason, Kombinationen D01AC16 Flutrimazol G01AF18 Flutrimazol C10AA04 Fluvastatin 60 mg O N06AB08 Fluvoxamin 0,1 g O G03GA05 Follitropin alfa 75 E P G03GA06 Follitropin beta 75 E P B03BB01 Folsäure 0,4 mg O prophylaktische Dosis; 10 mg P therapeutische Dosis; 10 mg O therapeutische Dosis B03BB51 Folsäure, Kombinationen V03AB34 Fomepizol R05DB29 Fominoben S01AD08 Fomivirsen C05AD59 Fomocain, Kombinationen B01AX05 Fondaparinux 2,5 mg P D08AX19 Formaldehyd A01AB85 Formaldehyd, Kombinationen D08AX69 Formaldehyd, Kombinationen R02AA74 Formaldehyd, Kombinationen L02BG02 Formestan 18 mg P S01BA12 Formocortal R03AC13 Formoterol 24 mcg Inhal.Aerosol/pulver R03AK07 Formoterol und Budesonid 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AK08 Formoterol und Beclometason 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AK11 Formoterol und Fluticason 24 mcg Inhal.Aerosol/pulver bezogen auf das Formoterolfumaratdihydrat R03AK09 Formoterol und Mometason J01EB11 Formylsulfisomidin J05AE07 Fosamprenavir 1,4 g O D06BB13 Foscarnet 12 mg T J05AD01 Foscarnet 6,5 g P L02AA04 Fosfestrol 0,25 g O,P C01EB06 Fosfocreatin J01XX01 Fosfomycin 3 g O; 8 g P J05AD02 Fosfonet C09AA09 Fosinopril 15 mg O C09BA09 Fosinopril und Diuretika Standarddosis: 1 Applikationsform O N03AB05 Fosphenytoin 0,45 g P L01AD05 Fotemustin D06AX14 Framycetin D09AA01 Framycetin R01AX08 Framycetin S01AA07 Framycetin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 34 von 92 ATC-CODE BEDEUTUNG DDD-INFO D06AX64 Framycetin, Kombinationen D09AA51 Framycetin, Kombinationen J01GB64 Framycetin, Kombinationen N02CC07 Frovatriptan 2,5 mg O B05BA12 Fructose Standarddosis: 1 Applikationsform P V06DC02 Fructose C01EB07 Fructose-1,6-diphosphat V04CM04 FSH-Testzone Standarddosis: 1 Test J07BA01 FSME, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J06BB12 FSME-Immunglobulin A08AH02 Fucus vesiculosus L02BA03 Fulvestrant 18 mg P P01AX10 Fumagillin D05AX01 Fumarsäure D05BX01 Fumarsäure D11AB09 Fumarsäure D05AX51 Fumarsäure, Kombinationen D05BX20 Fumarsäurealkylester D05BX51 Fumarsäure-Derivate, Kombinationen A07AX06 Furazolidon G01AX06 Furazolidon C03CA01 Furosemid 40 mg O,P C03CB01 Furosemid und Kalium 40 mg O bezogen auf Furosemid C03EB01 Furosemid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O C03EB21 Furosemid und Triamteren Standarddosis: 1 Applikationsform O A11DA04 Fursultiamin R02AB03 Fusafungin D06AX01 Fusidinsäure 60 mg T D09AA02 Fusidinsäure J01XC01 Fusidinsäure 1,5 g O,P S01AA13 Fusidinsäure 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 35 von 92 ATC-CODE BEDEUTUNG DDD-INFO G N03AX12 Gabapentin 1,8 g O V08CA08 Gadobensäure Standarddosis: 1 Applikationsform V08CA09 Gadobutrol Standarddosis: 1 Applikationsform V08CA03 Gadodiamid Standarddosis: 1 Applikationsform V08CA11 Gadofosveset V08CA01 Gadopentetsäure Standarddosis: 1 Applikationsform V08CA04 Gadoteridol Standarddosis: 1 Applikationsform V08CA02 Gadotersäure Standarddosis: 1 Applikationsform V08CA06 Gadoversetamid Standarddosis: 1 Applikationsform V08CA10 Gadoxetsäure V04CE01 Galactose V08DA02 Galactose-Mikropartikel Standarddosis: 1 Applikationsform N06DA04 Galantamin 16 mg O C01EP03 Galgantwurzelstock M03AC02 Gallamin A05AC01 Gallentherapeutika in Kombination mit Spasmolytika V09HX01 [67Ga]Galliumcitrat C08DA02 Gallopamil 0,1 g O A16AB08 Galsulfase D11AX02 Gamolensäure 0,4 g O D11AX52 Gamolensäure, Kombinationen J05AB06 Ganciclovir 3 g O; 0,5 g P S01AD09 Ganciclovir N07XA01 Gangliosidgemisch H01CC01 Ganirelix 0,25 mg P G02CP05 Gänsefingerkraut J01MA19 Garenoxacin J06AA05 Gasbrand-Serum J01MA16 Gatifloxacin 0,4 g O,P S01AE06 Gatifloxacin N05BX02 Gedocarnil A02BX07 Gefarnat A02BX77 Gefarnat, Kombinationen mit Psycholeptika L01XE02 Gefitinib 0,25 g O B02BC14 Gelatine M09AX55 Gelatine, Kombinationen B05AA06 Gelatine-haltige Mittel Standarddosis: 1 Applikationsform P B05AA56 Gelatine-haltige Mittel, Kombinationen Standarddosis: 1 Applikationsform P J07BL01 Gelbfieber, lebend abgeschwächt Standarddosis: 1 Einzeldosis P L01BC05 Gemcitabin 0,2 g P G02AD03 Gemeprost 1 mg V Ein-Dosis-Behandlung C10AB04 Gemfibrozil 1,2 g O J01MA15 Gemifloxacin L01XC05 Gemtuzumab D06AX07 Gentamicin 2,5 mg T J01GB03 Gentamicin 0,24 g P S01AA11 Gentamicin 1,25 mg AT,AS S02AA14 Gentamicin S03AA06 Gentamicin J01GB53 Gentamicin, Kombinationen C01CA15 Gepefrin 30 mg O N06AX19 Gepiron D04AX51 Gerbstoff, Kombinationen D04AX01 Gerbstoffe 15 mg T B02BD04 Gerinnungsfaktor IX 350 E P B02BD05 Gerinnungsfaktor VII 6 TSD E P B02BD02 Gerinnungsfaktor VIII 500 E P B02BD07 Gerinnungsfaktor XIII 3,5 TSD E P B02BD01 Gerinnungsfaktoren IX, II, VII und X in Kombination 350 E P V04CX23 Gerinnungsparameter Standarddosis: 1 Test A05AA05 Gesamtgallensäuren (Fel tauri) A05AA55 Gesamtgallensäuren, Kombinationen G03AA10 Gestoden und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB06 Gestoden und Ethinylestradiol G03DA01 Gestonoron 30 mg P L02AB03 Gestonoron 40 mg P G03XA02 Gestrinon 0,7 mg O N06DP01 Ginkgo-biloba-Blätter-Trockenextrakt 0,18 g O A13AP02 Ginsengwurzel C01AA09 Gitoformat N02BG03 Glafenin 0,8 g O H05AH01 Glandulae parathyreoidea L03AX13 Glatirameracetat 20 mg P A10BB01 Glibenclamid 10 mg O; 7 mg O mikrokristall. Substanz A10BB04 Glibornurid 38 mg O A10BB09 Gliclazid 60 mg O A10BB12 Glimepirid 2 mg O A10BD06 Glimepirid und Pioglitazon Standarddosis: 1 Applikationsform O A10BD04 Glimepirid und Rosiglitazon Standarddosis: 1 Applikationsform O A10BB07 Glipizid 10 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 36 von 92 ATC-CODE BEDEUTUNG DDD-INFO A10BB08 Gliquidon 60 mg O A10BB11 Glisoxepid A05AP08 Glockenbilsenkrautwurzelstock G04BP04 Glockenbilsenkrautwurzelstock H04AA01 Glucagon 1 mg P V03AF09 Glucarpidase M01AX05 Glucosamin 1,5 g O bezogen auf Glucosaminsulfat M01AX55 Glucosamin, Kombinationen B05BA11 Glucose Standarddosis: 1 Applikationsform P B05CX01 Glucose Standarddosis: 1 Applikationsform P D02AX08 Glucose V04CA02 Glucose V06DC01 Glucose C05BB56 Glucose, Kombinationen V06DC51 Glucose, Kombinationen V04CA07 Glucose-Keton-Testzone, Urin Standarddosis: 1 Test V04CA03 Glucose-Testzone, Blut Standarddosis: 1 Test V04CA04 Glucose-Testzone, Urin Standarddosis: 1 Test M01AX12 Glukosaminoglycanpolysulfat 50 mg P A16AA03 Glutamin A13AA01 Glutaminsäure Standarddosis: 30 ml flüssige Zubereitung A09AB01 Glutaminsäurehydrochlorid 1,5 g O D08AX11 Glutaral V03AB32 Glutathion N05CE01 Glutethimid 0,25 g O A06AG04 Glycerol Standarddosis: 1 Klysma A06AX01 Glycerol 2 g R D02AX06 Glycerol S02DC03 Glycerol A16AX09 Glycerolphenylbutyrat A05AX08 Glyceroltrinitrat C01DA02 Glyceroltrinitrat 5 mg O,TD; 2,5 mg oral Aerosol,SL; Standarddosis: 1 Applikationsform P C05AE01 Glyceroltrinitrat C01DA52 Glyceroltrinitrat, Kombinationen B05CX03 Glycin Standarddosis: 1 Applikationsform P P01AR03 Glycobiarsol P01AR53 Glycobiarsol, Kombinationen V04CA08 Glycohämoglobin-Testzone Standarddosis: 1 Test A03AB02 Glycopyrronium 3 mg O,P,R A03CA05 Glycopyrronium und Psycholeptika R03BB06 Glycopyrronium bromid 63 mcg Inhal.pulver A05BA08 Glycyrrhizinsäure A10BC01 Glymidin 1 g O V10AX06 [198Au]Gold-Kolloid G04BP06 Goldrutenkraut 9 g O Droge C05CP53 Goldrutenkraut, Kombinationen L04AB06 Golimumab 1,66 mg P H01CA01 Gonadorelin V04CM01 Gonadorelin V04CX16 Gonorrhoeae-neisseria-Testzone Standarddosis: 1 Test H01CA05 Goserelin 0,129 mg Implantat L02AE03 Goserelin 0,129 mg Implantat R02AB30 Gramicidin R02AB80 Gramicidin, Kombinationen A04AA02 Granisetron 2 mg O; 3 mg P B05AX05 Granulozyten B05AX45 Granulozyten ohne Pharmazentralnummer V01AA02 Gräserpollen J01MA11 Grepafloxacin 0,4 g O D01AA08 Griseofulvin D01BA01 Griseofulvin 0,5 g O D06BP03 Grüner Tee C01AC01 g-Strophanthin 0,25 mg P C01AC51 g-Strophanthin, Kombinationen exkl. Psycholeptika C01AC71 g-Strophanthin, Kombinationen mit Psycholeptika N02BA14 Guacetisal R05CA03 Guaifenesin 0,9 g O,P R05CA09 Guajacolsulfonat M02AH03 Guajacum M09AH01 Guajacum M09AP07 Guajakholz A02XA03 Guajazulen D02AX03 Guajazulen S01XA01 Guajazulen A02XA53 Guajazulen, Kombinationen G01AX75 Guajazulen, Kombinationen C02CC06 Guanazodin C02CC02 Guanethidin 30 mg O S01EX01 Guanethidin C02LF01 Guanethidin und Diuretika Standarddosis: 1 Applikationsform O C02AC02 Guanfacin 3 mg O C02CC05 Guanoclor 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 37 von 92 ATC-CODE BEDEUTUNG DDD-INFO C02CC07 Guanoxabenz 25 mg O C02CC03 Guanoxan 20 mg O A10XP01 Guar-Mehl A05AP09 Gundelrebenkraut L04AA19 Gusperimus 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 38 von 92 ATC-CODE BEDEUTUNG DDD-INFO H D01AA03 Hachimycin G01AA06 Hachimycin J02AA02 Hachimycin J07AG01 Haemophilus influenzae B, gereinigtes Antigen konjugiert Standarddosis: 1 Einzeldosis P J07AG53 Haemophilus influenzae B, Kombinationen mit Meningokokken C, konjugiert J07AG52 Haemophilus influenzae B, Kombinationen mit Pertussis und Toxoiden Standarddosis: 1 Einzeldosis P J07AG51 Haemophilus influenzae B, Kombinationen mit Toxoiden Standarddosis: 1 Einzeldosis P J07CA08 Haemophilus influenzae B und Hepatitis B Standarddosis: 1 Einzeldosis P J07CA04 Haemophilus influenzae B und Poliomyelitis N05BA13 Halazepam 0,1 g O D07AD02 Halcinonid D07CD02 Halcinonid und Antibiotika P01BX01 Halofantrin 1,5 g O D07AC12 Halometason D07BC05 Halometason und Antiseptika N05AD01 Haloperidol 8 mg O,P; 3,3 mg P Depot D01AE11 Haloprogin N01AB01 Halothan C05AH01 Hamamelis C05AP01 Hamamelisblätter und -rinde C05BP03 Hamamelisblätter und -rinde D03AP01 Hamamelisblätter und -rinde D11AG03 Hamamelisblätter und -rinde D03AP51 Hamamelisblätter und -rinde, Kombinationen B05AA08 Hämoglobin crosfumaril Standarddosis: 1 Applikationsform P B05AA10 Hämoglobin glutamer (Rind) B05AA09 Hämoglobin raffimer Standarddosis: 1 Applikationsform P V04CX04 Harnsäure-Testzone Standarddosis: 1 Test B05BC02 Harnstoff Standarddosis: 1 Applikationsform P D02AE01 Harnstoff 0,2 g T D02AE51 Harnstoff, Kombinationen A09AP01 Harongarinde und -blätter V01AA03 Hausstaubmilben V04CX09 HDL-Cholesterin-Testzone Standarddosis: 1 Test D11AX23 Hefe V04CX13 Helicobacter-pylori-Test Standarddosis: 1 Test V03AN03 Helium B06AB01 Hematin B01AB01 Heparin 10 TSD E P B05CX05 Heparin C05AX08 Heparin C05BA03 Heparin Standarddosis: 2,5 g Salbe etc. S01XA14 Heparin B01AB51 Heparin, Kombinationen C05BA53 Heparin, Kombinationen C05BA51 Heparinoid, Kombinationen C05BA01 Heparinoide J07BC03 Hepatitis A, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J07BC02 Hepatitis A, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BC01 Hepatitis B, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J06BB11 Hepatitis-A-Immunglobulin J06BB04 Hepatitis-B-Immunglobulin 500 IE P N05CA11 Heptabarbital 0,2 g O C01DX08 Heptaminol 0,45 g O,P J01CA18 Hetacillin 2 g O D08AE01 Hexachlorophen D10AX09 Hexachlorophen D08AE51 Hexachlorophen, Kombinationen D10AX59 Hexachlorophen, Kombinationen M03AC05 Hexafluronium D08AC04 Hexamidin R01AX07 Hexamidin R02AA18 Hexamidin S01AX08 Hexamidin S03AA05 Hexamidin D08AC54 Hexamidin, Kombinationen V08EA01 Hexaminolevulinat N05CM10 Hexapropymate 0,4 g O A01AB12 Hexetidin G01AX22 Hexetidin R02AA28 Hexetidin 30 mg O A01AB62 Hexetidin, Kombinationen N01AF02 Hexobarbital N05CA16 Hexobarbital 0,25 g O C01DX06 Hexobendin A03AB10 Hexocyclium 0,15 g O R03AC06 Hexoprenalin 1,5 mg Inhal.Aerosol R03CC05 Hexoprenalin 1,5 mg O,P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 39 von 92 ATC-CODE BEDEUTUNG DDD-INFO R02AA12 Hexylresorcinol C05CA05 Hidrosmin G02CP02 Hirtentäschelkraut L03AX24 Histaglobin L03AX14 Histamin dihydrochlorid 0,5 mg P V04CG03 Histaminphosphat R06AC02 Histapyrrodin 80 mg O D04AA91 Histapyrrodin, Kombinationen R06AC52 Histapyrrodin, Kombinationen L02AE05 Histrelin 0,137 mg Implantat (Freisetzungsrate 50 mcg pro Tag) S01FA05 Homatropin D04AH20 Homöopathische und anthroposophische Antipruriginosa, Kombinationen G02CH20 Homöopathische und anthroposophische Antidysmenorrhoika, Kombinationen G04BH30 Homöopathische und anthroposophische Kombinationen bei erektiler Dysfunktion G02CH30 Homöopathische und anthroposophische Klimakteriumstherapeutika, Kombinationen G04BH20 Homöopathische und anthroposophische Urologika, Kombinationen N05CP07 Hopfen R05DP07 Huflattichblätter V08DA01 Humanalbumin-Mikrosphären Standarddosis: 1 Applikationsform J07BM02 Humaner Papillomvirus-Impfstoff (Typen 16,18) Standarddosis: 1 Einzeldosis P J07BM01 Humaner Papillomvirus-Impfstoff (Typen 6,11,16,18) Standarddosis: 1 Einzeldosis P G03GA02 Humanes menopausales Gonadotrophin 75 E P A07BC08 Huminsäuren B06AA03 Hyaluronidase D03AX05 Hyaluronsäure D11AX21 Hyaluronsäure G02CD09 Hyaluronsäure G04BX16 Hyaluronsäure M09AX01 Hyaluronsäure 3,6 mg P intraartikulär R01AX09 Hyaluronsäure S01KA01 Hyaluronsäure Standarddosis: 1 Applikationsform S01XA28 Hyaluronsäure 0,4 ml AT S01KA51 Hyaluronsäure, Kombinationen Standarddosis: 1 Applikationsform C02DB02 Hydralazin 0,1 g O C02LG02 Hydralazin und Diuretika M09AA01 Hydrochinin 0,2 g O D11AX11 Hydrochinon C03AA03 Hydrochlorothiazid 25 mg O C03AX01 Hydrochlorothiazid, Kombinationen C03EA41 Hydrochlorothiazid und Amilorid Standarddosis: 1 Applikationsform O C03AB03 Hydrochlorothiazid und Kalium 25 mg O bezogen auf Hydrochlorothiazid C03EA01 Hydrochlorothiazid und Kalium sparende Mittel C03EA21 Hydrochlorothiazid und Triamteren Standarddosis: 1 Applikationsform O R05DA03 Hydrocodon 15 mg O; 15 mg P A01AC03 Hydrocortison A07EA02 Hydrocortison C05AA01 Hydrocortison D07AA02 Hydrocortison D07XA01 Hydrocortison H02AB09 Hydrocortison 30 mg O,P S01BA02 Hydrocortison S01CB03 Hydrocortison S02BA01 Hydrocortison C05AA51 Hydrocortison, Kombinationen R01AD60 Hydrocortison, Kombinationen S01BX01 Hydrocortison, Kombinationen D07CA01 Hydrocortison und Antibiotika S01CA03 Hydrocortison und Antiinfektiva S02CA03 Hydrocortison und Antiinfektiva S03CA04 Hydrocortison und Antiinfektiva D07BA04 Hydrocortison und Antiseptika S01BB01 Hydrocortison und Mydriatika D07AC16 Hydrocortisonaceponat D07AB11 Hydrocortisonbuteprat D07AB02 Hydrocortisonbutyrat D07CB06 Hydrocortisonbutyrat und Antibiotika D07BB04 Hydrocortisonbutyrat und Antiseptika C03AA02 Hydroflumethiazid 25 mg O C03AH02 Hydroflumethiazid, Kombinationen C03AB02 Hydroflumethiazid und Kalium 25 mg O bezogen auf Hydroflumethiazid S02AA06 Hydrogenperoxid N02AA03 Hydromorphon 20 mg O; 4 mg P,R N02AG04 Hydromorphon mit Spasmolytika A02AD04 Hydrotalcit 3,5 g O B03BA03 Hydroxocobalamin 20 mcg P V03AB33 Hydroxocobalamin B03BA53 Hydroxocobalamin, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 40 von 92 ATC-CODE BEDEUTUNG DDD-INFO L01XX05 Hydroxycarbamid 1,75 g O P01BA02 Hydroxychloroquin 0,516 g O Base S01XC06 Hydroxyethylcellulose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC56 Hydroxyethylcellulose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS R06AD05 Hydroxyethylpromethazin 75 mg O R06AD55 Hydroxyethylpromethazin, Kombinationen C05BZ02 Hydroxyethylrutoside C05CA13 Hydroxyethylrutoside M02AC01 Hydroxyethylsalicylat 0,4 g T M02AC51 Hydroxyethylsalicylat, Kombinationen M02BB51 Hydroxyethylsalicylat, Kombinationen B05AA07 Hydroxyethylstärke Standarddosis: 1 Applikationsform P B05AA57 Hydroxyethylstärke, Kombinationen Standarddosis: 1 Applikationsform P V03AX04 Hydroxylapatit-Keramik S01AX25 Hydroxymethylchinolinium-methylsalicylat G03DA03 Hydroxyprogesteron 10 mg P G03FA02 Hydroxyprogesteron und Estrogen M02AC53 Hydroxypropylsalicylat, Kombinationen N05BB01 Hydroxyzin 75 mg O,P R06AX32 Hydroxyzin N05BB51 Hydroxyzin, Kombinationen A05AX02 Hymecromon 1 g O A03BA03 Hyoscyamin 1,2 mg O A03CB31 Hyoscyamin und Psycholeptika N06AH01 Hypericum R01AX18 Hypromellose S01KA02 Hypromellose Standarddosis: 1 Applikationsform S01XC05 Hypromellose Standarddosis: 0,4 ml AT; 0,4 g AS S01XC55 Hypromellose, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 41 von 92 ATC-CODE BEDEUTUNG DDD-INFO I D06BB08 Ibacitabin M05BA06 Ibandronsäure 5 mg O Osteoporose; 6 mg P Dosis pro Behandlungszyklus bei Tumor-induzierter Hyperkalzämie; 50 mg O bei Tumor-induzierter Hyperkalzämie; 33 mcg P bei Osteoporose bezogen auf die Säure der Ibandronsäure C01CA16 Ibopamin 0,3 g O S01FB03 Ibopamin V10XX02 [90Y]Ibritumomab tiuxetan R03DC04 Ibudilast C01EB16 Ibuprofen 30 mg P G02CC01 Ibuprofen M01AE01 Ibuprofen 1,2 g O,R; 0,4 g O Kinder DDD M02AA13 Ibuprofen 0,5 g T M01AE51 Ibuprofen, Kombinationen M01AE13 Ibuproxam C01BD05 Ibutilid 1 mg P B06AC02 Icatibant 30 mg P J01EA03 Iclaprim A03AX06 Idanpramin L01DB06 Idarubicin 6 mg O; 3 mg P N06BX13 Idebenon D06BB01 Idoxuridin J05AB02 Idoxuridin S01AD01 Idoxuridin M02AX05 Idrocilamid A16AB09 Idursulfase 5 mg P C04AX28 Ifenprodil L01AA06 Ifosfamid 0,7 g P N05AX14 Iloperidon B01AC11 Iloprost 0,15 mg Inhal; 50 mcg P C04AG02 Iloprost 50 mcg Inhal.lösung L01XE01 Imatinib 0,5 g O V04CX06 Imciromab C09AA16 Imidapril 10 mg O N02BA16 Imidazolsalicylat A16AB02 Imiglucerase 300 E P J01DH51 Imipenem und Enzym-Inhibitoren 2 g P bezogen auf Imipenem N06AA02 Imipramin 0,1 g O,P N06AA03 Imipraminoxid 0,1 g O D06BB10 Imiquimod J06BA01 Immunglobuline, normal human, zur extravasalen Anwendung 1,4 g P J06BA02 Immunglobuline, normal human, zur intravasalen Anwendung 1,6 g P L03AX10 Immunocyanin 3 mg intravesikulär C01DX09 Imolamin 90 mg O J07BX02 Inaktiviertes Herpes-simplex-Virus Standarddosis: 1 Einzeldosis P R03AC18 Indacaterol 0,15 mg Inhal.pulver R03AL04 Indacaterol und Gycopyrronium bromid R01AA18 Indanazolin C03BA11 Indapamid 2,5 mg O V04CH02 Indigokarmin J05AE02 Indinavir 2,4 g O V09IB03 [111In]Indium-Antiovariumkarzinom-Antikörper V09IB04 [111In]Indium-Capromab-Pendetid V09GX02 [111In]Indiumimciromab V09HB01 [111In]Indiumoxinat-markierte Zellen V09AX01 [111In]Indiumpentetat V09IB01 [111In]Indiumpentetreotid V09IB02 [111In]Indium-Satumomab-pendetid V09HB02 [111In]Indiumtropolonat-markierte Zellen B01AC10 Indobufen C01EB03 Indometacin M01AB01 Indometacin 0,1 g O,P,R M02AA23 Indometacin 0,04 g T S01BC01 Indometacin M01AB51 Indometacin, Kombinationen 0,1 g O,R bezogen auf Indometacin M02AA73 Indometacin, Kombinationen M01AE10 Indoprofen C02CA02 Indoramin L04AB02 Infliximab 3,75 mg P J07BB01 Influenza, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J07BB02 Influenza, inaktiviert, Spaltvirus oder Oberflächenantigen Standarddosis: 1 Einzeldosis P J07BB03 Influenza, lebend abgeschwächt Standarddosis: 1 Einzeldosis N V04CX24 Influenza-Testzone Standarddosis: 1 Test D06BX02 Ingenol mebutat Standarddosis: 1 Applikationsform T A04AP01 Ingwerwurzelstock D06BB05 Inosin G01AX02 Inosin S01XA10 Inosin L03AX71 Inosin, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 42 von 92 ATC-CODE BEDEUTUNG DDD-INFO J05AX05 Inosin pranobex 3 g O S01XB03 Inosin-5-monophosphat S01XB53 Inosin-5-monophosphat, Kombinationen A11HA07 Inositol C04AC03 Inositolnicotinat 1,2 g O C04AC53 Inositolnicotinat, Kombinationen V01AA07 Insekten A10AB05 Insulin aspart 40 E P A10AD05 Insulin aspart 40 E P A10AE05 Insulin detemir 40 E P A10AE04 Insulin glargin 40 E P A10AB06 Insulin glulisin 40 E P A10AB01 Insulin (human) 40 E P A10AC01 Insulin (human) 40 E P A10AD01 Insulin (human) 40 E P A10AE01 Insulin (human) 40 E P A10AF01 Insulin (human) 15 mg Inhal A10AB04 Insulin lispro 40 E P A10AC04 Insulin lispro 40 E P A10AD04 Insulin lispro 40 E P A10AB02 Insulin (Rind) 40 E P A10AC02 Insulin (Rind) 40 E P A10AD02 Insulin (Rind) 40 E P A10AE02 Insulin (Rind) 40 E P A10AB03 Insulin (Schwein) 40 E P A10AC03 Insulin (Schwein) 40 E P A10AD03 Insulin (Schwein) 40 E P A10AE03 Insulin (Schwein) 40 E P S01AD05 Interferon L03AB01 Interferon alfa, natürlich 2 MIO E P L03AB09 Interferon alfacon-1 4 mcg P L03AB06 Interferon alfa-n1 5 MIO E P L03AB04 Interferon alfa-2a 2 MIO E P L03AB05 Interferon alfa-2b 2 MIO E P D11AF06 Interferon beta, natürlich L03AB02 Interferon beta, natürlich 33,33 TSD E P L03AB07 Interferon beta-1a 4,3 mcg P i.m.; 18,86 mcg P s.c. L03AB08 Interferon beta-1b 4 MIO E P L03AB03 Interferon gamma 40 mcg P L03AB13 Interferon gamma 1b V04CH01 Inulin und andere Polyfructosane C05BB03 Invertzucker V09IX01 [123I]Iobenguan V09IX02 [131I]Iobenguan V10XA02 [131I]Iobenguan V08AC05 Iobenzaminsäure Standarddosis: 1 Applikationsform V08AB11 Iobitridol Standarddosis: 1 Applikationsform V08AA08 Iocarminsäure Standarddosis: 1 Applikationsform V08AC07 Iocetaminsäure Standarddosis: 1 Applikationsform D08AG03 Iod M02BX08 Iod V08AA03 Iodamid Standarddosis: 1 Applikationsform V09IX03 [125I]Iod-CC49-Monoklonaler Antikörper V09XA02 [131I]Iodcholesterol V09GB02 [125I]Iod-Humanalbumin V09XA03 [131I]Iod-Humanalbumin H03CA51 Iodid, Kombinationen S01XB54 Iodid, Kombinationen H03CA01 Iodide 0,15 mg O V09AB01 [123I]Iod-Iofetamin V09AB03 [123I]Iod-Ioflupan V09AB02 [123I]Iod-Ioloprid V08AB09 Iodixanol Standarddosis: 1 Applikationsform V09XA01 [131I]Iodnorcholesterol D08AG01 Iodoctylphenoxypolyglycolether D09AA13 Iodoform Standarddosis: 1 Applikationsform S01XA09 Iodoheparinat V08AC01 Iodoxaminsäure Standarddosis: 1 Applikationsform V09AX03 [124I]Iod-2 beta-carboxymethyl-3 beta-(4-iodphenyl)-tropan V08AD04 Iofendylat Standarddosis: 1 Applikationsform V08AA06 Ioglicinsäure Standarddosis: 1 Applikationsform V08AC03 Ioglycaminsäure Standarddosis: 1 Applikationsform V08AB02 Iohexol Standarddosis: 1 Applikationsform V08AA13 Iomeglaminsäure Standarddosis: 1 Applikationsform V08AB10 Iomeprol Standarddosis: 1 Applikationsform V08AB04 Iopamidol Standarddosis: 1 Applikationsform V08AC06 Iopansäure Standarddosis: 1 Applikationsform V08AB08 Iopentol Standarddosis: 1 Applikationsform V08AB05 Iopromid Standarddosis: 1 Applikationsform 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 43 von 92 ATC-CODE BEDEUTUNG DDD-INFO V08AD02 Iopydol Standarddosis: 1 Applikationsform V08AB13 Iosarcol Standarddosis: 1 Applikationsform V08AA04 Iotalaminsäure Standarddosis: 1 Applikationsform V08AB06 Iotrolan Standarddosis: 1 Applikationsform V08AC02 Iotroxinsäure Standarddosis: 1 Applikationsform V08AB07 Ioversol Standarddosis: 1 Applikationsform V08AB03 Ioxaglinsäure Standarddosis: 1 Applikationsform V08AB12 Ioxilan Standarddosis: 1 Applikationsform V08AA05 Ioxitalaminsäure Standarddosis: 1 Applikationsform A07FA05 IP-Bacillussporen R05CP11 Ipecacuanha V03AB01 Ipecacuanha L01XC11 Ipilimumab 10 mg P C01CX10 Ipratropium bromid R01AX03 Ipratropium bromid 0,24 mg N R03BB01 Ipratropium bromid 0,12 mg Inhal.Aerosol; 1,5 mg Inhal.lösung; 0,6 mg Inhal.pulver N02CX03 Iprazochrom 24 mg O M05BX01 Ipriflavon N06AA13 Iprindol 90 mg O N06AF06 Iproclozid N06AF05 Iproniazid C09CA04 Irbesartan 0,15 g O C09DB05 Irbesartan und Amlodipin C09DA04 Irbesartan und Diuretika Standarddosis: 1 Applikationsform O L01XX19 Irinotecan 30 mg P J01GB11 Isepamicin 0,4 g P R05DP02 Isländisches Moos R05DB04 Isoaminil 0,11 g O R05DB54 Isoaminil, Kombinationen M04AB04 Isobromindion N06AF01 Isocarboxazid 15 mg O D01AC05 Isoconazol G01AF07 Isoconazol 0,6 g V R03AC07 Isoetarin R03CC06 Isoetarin 40 mg O N01AB06 Isofluran A03AX10 Isomethepten J04AC01 Isoniazid 0,3 g O,P J04AC51 Isoniazid, Kombinationen 0,3 g O bezogen auf Isoniazid C01CA02 Isoprenalin 90 mg O,P D04AX04 Isoprenalin R03AB02 Isoprenalin 0,64 mg Inhal.Aerosol; 10 mg Inhal.lösung R03CB01 Isoprenalin 40 mg O D04AX54 Isoprenalin, Kombinationen R03AB52 Isoprenalin, Kombinationen R03CB51 Isoprenalin, Kombinationen R03AK02 Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen A03AB09 Isopropamid 10 mg O A03CA01 Isopropamid und Psycholeptika D08AX05 Isopropanol D08AX55 Isopropanol, Kombinationen C01DA08 Isosorbiddinitrat 60 mg O; 20 mg oral Aerosol,SL; 0,1 g TD; Standarddosis: 1 Applikationsform P C05AE02 Isosorbiddinitrat C01DA58 Isosorbiddinitrat, Kombinationen C01DA14 Isosorbidmononitrat 40 mg O D04AA22 Isothipendyl R06AD09 Isothipendyl D10AD04 Isotretinoin D10BA01 Isotretinoin 30 mg O D10AD54 Isotretinoin, Kombinationen M01AC03 Isoxicam C04AA01 Isoxsuprin 60 mg O,P A06AC01 Ispaghula (Flohsamen) 7 g O A06AC51 Ispaghula, Kombinationen C08CA03 Isradipin 5 mg O,P J02AC02 Itraconazol 0,2 g O,P C01DX01 Itramintosilat C01DX51 Itramintosilat, Kombinationen C01EB17 Ivabradin 10 mg O R07AX02 Ivacaftor 0,3 g O P02CF01 Ivermectin 12 mg O L01DC04 Ixabepilon 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 44 von 92 ATC-CODE BEDEUTUNG DDD-INFO J A07BP51 Johannisbrotfruchtmehl, Kombinationen N05CP03 Johanniskraut N06AP01 Johanniskraut 3 g O Droge N06AP51 Johanniskraut, Kombinationen J01FA07 Josamycin 2 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 45 von 92 ATC-CODE BEDEUTUNG DDD-INFO K A02XA01 Kälberblutextrakt D03AX14 Kälberblutextrakt S01XA23 Kälberblutextrakt N06DX10 Kälberblutextrakt, inkl. Kombinationen B05XA19 Kalium L-malat Standarddosis: 1 Applikationsform P B05XA17 Kaliumacetat A12BA06 Kaliumadipat D11AX22 Kaliumaminobenzoat N03AX23 Kaliumbromid C03DA02 Kaliumcanrenoat 0,4 g P C03ED02 Kaliumcanrenoat und High-ceiling-Diuretika C03EC02 Kaliumcanrenoat und Low-ceiling-Diuretika A12BA01 Kaliumchlorid 3 g O B05XA01 Kaliumchlorid Standarddosis: 1 Applikationsform P A12BA51 Kaliumchlorid, Kombinationen A12BA02 Kaliumcitrat 4 g O A12BA52 Kaliumcitrat, Kombinationen M02AX29 Kalium-Eisen(III)-Phosphat-Citrat-Komplex B03AB11 Kalium-Eisen(III)phosphat-Citrat-Komplex A12BA05 Kaliumgluconat A12BA04 Kaliumhydrogencarbonat 4 g O A12BA54 Kaliumhydrogencarbonat, Kombinationen A12BA03 Kaliumhydrogentartrat 7,5 g O D11AF03 Kaliumhydroxid R05CA02 Kaliumiodid 1,2 g O S01XA04 Kaliumiodid V03AB21 Kaliumiodid B05XA15 Kaliumlactat G04BC01 Kalium-Natrium-Hydrogencitrat H03BC01 Kaliumperchlorat D08AX06 Kaliumpermanganat V03AB18 Kaliumpermanganat B05XA06 Kaliumphosphat, inkl. Kombinationen mit anderen Kaliumsalzen P03AA02 Kaliumpolysulfid N02BA12 Kaliumsalicylat 7 g O A12BA10 Kaliumsulfid C04AF01 Kallidinogenase 30 E O,P C04AF51 Kallidinogenase, Kombinationen V07AY02 Kältepackungen (Kompressen) A01AP02 Kamillenblüten A03AP02 Kamillenblüten D03AP04 Kamillenblüten D11AG02 Kamillenblüten R01AP01 Kamillenblüten A01AP52 Kamillenblüten, Kombinationen D03AP54 Kamillenblüten, Kombinationen D11AB01 Kamillenblütenextrakt D11AB51 Kamillenblütenextrakt, Kombinationen A07AA08 Kanamycin J01GB04 Kanamycin 1 g P S01AA24 Kanamycin 1,5 mg AT,AS A07BC02 Kaolin V04CO01 kardiales Fettsäure-Bindungsprotein (h-FABP) Standarddosis: 1 Test B05XA16 Kardioplege Lösungen A07XP04 Karottenextrakt V07AN50 Katheter, Kombinationen Standarddosis: 1 Applikationsform V04CG01 Kationenaustauscherharze N05BX05 Kavain N05BP02 Kava-Kava-Wurzelstock 90 mg O Kavapyrone N05CP02 Kava-Kava-Wurzelstock 90 mg O Kavapyrone N05CP52 Kava-Kava-Wurzelstock, Kombinationen M01AA06 Kebuzon M02AA20 Kebuzon M01BA08 Kebuzon und Corticosteroide N01AX03 Ketamin 0,25 g P C02KD01 Ketanserin 40 mg O,P N05BA10 Ketazolam N02AB01 Ketobemidon 50 mg O,P N02AG02 Ketobemidon mit Spasmolytika D01AC08 Ketoconazol 30 mg T (Creme) G01AF11 Ketoconazol 0,4 g V J02AB02 Ketoconazol 0,2 g O V04CA05 Keton-Testzone, Blut Standarddosis: 1 Test V04CA06 Keton-Testzone, Urin Standarddosis: 1 Test M01AE03 Ketoprofen 0,15 g O,P,R M02AA10 Ketoprofen 0,275 g T M01AE53 Ketoprofen, Kombinationen M01AB15 Ketorolac 30 mg O,P S01BC05 Ketorolac R06AX17 Ketotifen 2 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 46 von 92 ATC-CODE BEDEUTUNG DDD-INFO S01GX08 Ketotifen G02CP01 Keuschlammfrüchte 35 mg O Droge M02AP05 Kiefernnadelöl A12CX01 Kieselerde D02AX10 Kieselsäure C10AP03 Knoblauchzwiebel C10BP03 Knoblauchzwiebel, Kombinationen V03AN02 Kohlendioxid A06AX02 Kohlendioxid freisetzende Mittel B05BA03 Kohlenhydrate Standarddosis: 1 Applikationsform P V06DA50 Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen V04CN04 Kokain-Testzone Standarddosis: 1 Test B02BC07 Kollagen Standarddosis: 1 Applikationsform G04BX11 Kollagen B02BC57 Kollagen, Kombinationen Standarddosis: 1 Applikationsform D11AX57 Kollagen, Kombinationen D03BA02 Kollagenase M09AB02 Kollagenase aus Clostridium histolyticum 0,9 mg P D03BA52 Kollagenase, Kombinationen A06AB10 Koloquinthen 0,3 g O Droge A06AB60 Koloquinthen, Kombinationen A01AA30 Kombinationen A01AB50 Kombinationen A01AH20 Kombinationen A01AP30 Kombinationen A02AA10 Kombinationen A02AB10 Kombinationen A02AC10 Kombinationen A02AH20 Kombinationen A02XH20 Kombinationen A02XP30 Kombinationen A03AH20 Kombinationen A03AP30 Kombinationen A03AX20 Kombinationen A03BA20 Kombinationen A03FP30 Kombinationen A03HH20 Kombinationen A04AH20 Kombinationen A05AA20 Kombinationen A05AB20 Kombinationen A05AH20 Kombinationen A05AP30 Kombinationen A05BH20 Kombinationen A06AG20 Kombinationen Standarddosis: 1 Klysma A07BC30 Kombinationen A07FA20 Kombinationen A07XH20 Kombinationen A07XP30 Kombinationen A08AB20 Kombinationen A08AH20 Kombinationen A09AH20 Kombinationen A10AB30 Kombinationen 40 E P A10AC30 Kombinationen 40 E P A10AD30 Kombinationen 40 E P A10AE30 Kombinationen 40 E P A10XH20 Kombinationen A10XP30 Kombinationen A11CC20 Kombinationen A11JA20 Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A12AH20 Kombinationen A12BA30 Kombinationen A12CH20 Kombinationen A13AH20 Kombinationen A13AP30 Kombinationen B01AC30 Kombinationen B02BC30 Kombinationen B03AA20 Kombinationen B03XH20 Kombinationen B05BA10 Kombinationen Standarddosis: 1 Applikationsform P B05BB10 Kombinationen Standarddosis: 1 Applikationsform P B05CA10 Kombinationen B05CB10 Kombinationen Standarddosis: 1 Applikationsform P B05CX10 Kombinationen Standarddosis: 1 Applikationsform P B05DB50 Kombinationen Standarddosis: 1 Applikationsform P B05XC30 Kombinationen Standarddosis: 1 Applikationsform P B05ZA50 Kombinationen Standarddosis: 1 Applikationsform P B05ZB50 Kombinationen Standarddosis: 1 Applikationsform P C01AA20 Kombinationen C01AH20 Kombinationen C01AP30 Kombinationen C01CA30 Kombinationen C01CH20 Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 47 von 92 ATC-CODE BEDEUTUNG DDD-INFO C01EH20 Kombinationen C01EP30 Kombinationen C02KH20 Kombinationen C02KP30 Kombinationen C03XH20 Kombinationen C03XP30 Kombinationen C04AC20 Kombinationen C04AH20 Kombinationen C05AD20 Kombinationen C05AH20 Kombinationen C05AP30 Kombinationen C05BP30 Kombinationen C05BZ20 Kombinationen C05CA20 Kombinationen C05CH20 Kombinationen C05CP30 Kombinationen C06AH20 Kombinationen D01AA20 Kombinationen D01AC20 Kombinationen D01AE20 Kombinationen D02AA20 Kombinationen D02AX20 Kombinationen D02BA20 Kombinationen D03AH20 Kombinationen D03AP30 Kombinationen D03BA20 Kombinationen D05BH20 Kombinationen D06AA20 Kombinationen D06AX20 Kombinationen D06BB20 Kombinationen D08AX30 Kombinationen D09AA30 Kombinationen Standarddosis: 1 Applikationsform D10BH20 Kombinationen D11AB30 Kombinationen D11BH20 Kombinationen G01AA20 Kombinationen G01AX20 Kombinationen G02CD20 Kombinationen G04BE30 Kombinationen G04BP30 Kombinationen G04CH20 Kombinationen G04CP30 Kombinationen H02BX20 Kombinationen H03BH20 Kombinationen J01CA20 Kombinationen J01CE30 Kombinationen J01EB20 Kombinationen J01EC20 Kombinationen J01ED20 Kombinationen J06BB30 Kombinationen J07BC20 Kombinationen Standarddosis: 1 Einzeldosis P L03AH20 Kombinationen M01BP30 Kombinationen M02AH20 Kombinationen M02AP30 Kombinationen M02AX30 Kombinationen M02BP50 Kombinationen M04AH20 Kombinationen M09AH20 Kombinationen M09AP30 Kombinationen N01BB20 Kombinationen Standarddosis: 1 Applikationsform P N01BH20 Kombinationen Standarddosis: 1 Applikationsform P N01BX50 Kombinationen N02BA20 Kombinationen N02BH20 Kombinationen N02CH20 Kombinationen N04AH20 Kombinationen N05CP30 Kombinationen N05HH20 Kombinationen N07CH20 Kombinationen N07XH20 Kombinationen R01AH20 Kombinationen R01AX30 Kombinationen R01BH20 Kombinationen R01BP30 Kombinationen R02AB20 Kombinationen R02AH20 Kombinationen R02AP30 Kombinationen R03DH20 Kombinationen R04AH20 Kombinationen R04AP30 Kombinationen R05CA10 Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 48 von 92 ATC-CODE BEDEUTUNG DDD-INFO R05CB10 Kombinationen R05CH20 Kombinationen R05CP30 Kombinationen R05DA20 Kombinationen R05DB20 Kombinationen R05FH20 Kombinationen R05XH20 Kombinationen R07AA30 Kombinationen R07AH20 Kombinationen S01AB20 Kombinationen S01AX20 Kombinationen S01HA30 Kombinationen S01XC20 Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS S01XH20 Kombinationen S02DA30 Kombinationen S02DC30 Kombinationen S02DH20 Kombinationen V04BA20 Kombinationen Standarddosis: 1 Test V04CM20 Kombinationen Standarddosis: 1 Test V04CN20 Kombinationen Standarddosis: 1 Test V04CO20 Kombinationen Standarddosis: 1 Test V06DC20 Kombinationen V06DD20 Kombinationen V08AA20 Kombinationen Standarddosis: 1 Applikationsform A02XH50 Kombinationen mit anderen Mitteln C01AH50 Kombinationen mit anderen Mitteln C01EH50 Kombinationen mit anderen Mitteln C05CH50 Kombinationen mit anderen Mitteln G04CP50 Kombinationen mit anderen Mitteln L03AH50 Kombinationen mit anderen Mitteln M02AH50 Kombinationen mit anderen Mitteln M09AH50 Kombinationen mit anderen Mitteln N05HH50 Kombinationen mit anderen Mitteln R01AH50 Kombinationen mit anderen Mitteln R04AH50 Kombinationen mit anderen Mitteln R05CH50 Kombinationen mit anderen Mitteln S02DH50 Kombinationen mit anderen Mitteln D07AB30 Kombinationen mittelstark wirksamer Corticosteroide D07XB30 Kombinationen mittelstark wirksamer Corticosteroide S01AA30 Kombinationen von Antibiotika N05CB01 Kombinationen von Barbituraten B05XA30 Kombinationen von Elektrolyten Standarddosis: 1 Applikationsform P B03AA50 Kombinationen von II-und III-wertigem Eisen G01AF20 Kombinationen von Imidazol-Derivaten H03AA03 Kombinationen von Levothyroxin und Liothyronin H03AA53 Kombinationen von Levothyroxin und Liothyronin, Kombinationen J01CR50 Kombinationen von Penicillinen C02AA03 Kombinationen von Rauwolfia-Alkaloiden C02AA53 Kombinationen von Rauwolfia-Alkaloiden, Kombinationen C02LA50 Kombinationen von Rauwolfia-Alkaloiden und Diuretika inkl. andere Kombinationen G01AE10 Kombinationen von Sulfonamiden J01AA20 Kombinationen von Tetracyclinen R03DA20 Kombinationen von Xanthinen G03CA57 Konjugierte Estrogene 0,625 mg O,V G03CC08 Konjugierte Estrogene A06AB20 Kontaktlaxanzien in Kombination A06AB30 Kontaktlaxanzien in Kombination mit Belladonna-Alkaloiden V07AD01 Kontroll-Lösungen V04BA15 Kreatin-Kinase-Testzone Standarddosis: 1 Test R05CA08 Kreosot V09EX01 [81mKr]Kryptongas C01AC04 k-Strophanthin C01AC54 k-Strophanthin, Kombinationen exkl. Psycholeptika J06BB07 Kuhpocken-Immunglobulin S01XA20 Künstliche Tränen und andere indifferente Mittel Standarddosis: 0,4 ml AT; 0,4 g AS P03AX02 Kupferoleat V03AB20 Kupfersulfat G01AX15 Kupferusnat G04BP07 Kürbissamen G04CP05 Kürbissamen 10 g O Samen G04CP55 Kürbissamen, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 49 von 92 ATC-CODE BEDEUTUNG DDD-INFO L C07AG01 Labetalol 0,6 g O C07CG01 Labetalol und andere Diuretika C07BG01 Labetalol und Thiazide C08CA09 Lacidipin 4 mg O N03AX18 Lacosamid 0,3 g O,P V04CX29 Lactat-Testzone Standarddosis: 1 Test A06AD12 Lactitol 10 g O J07AX01 Lactobacillus acidophilus J07AX52 Lactobacillus Stämme, Kombinationen Standarddosis: 1 Einzeldosis P G01AX14 Lactobacillus-Ferment A06AD11 Lactulose 12,5 g O A06AD61 Lactulose, Kombinationen A05BA71 Laevulose, Kombinationen A02BA08 Lafutidin 20 mg O J05AF05 Lamivudin 0,3 g O J05AR02 Lamivudin und Abacavir Standarddosis: 1 Applikationsform O N03AX09 Lamotrigin 0,3 g O C01AA06 Lanatosid C 1 mg O,R C01AA56 Lanatosid C, Kombinationen H01CB03 Lanreotid 3 mg P A02BC03 Lansoprazol 15 mg O A02BD07 Lansoprazol, Amoxicillin und Clarithromycin A02BD03 Lansoprazol, Amoxicillin und Metronidazol A02BD02 Lansoprazol, Tetracyclin und Metronidazol V03AE03 Lanthan(III)-carbonat 2,25 g O bezogen auf Lanthanum L01XE07 Lapatinib 1,375 g O A16AB05 Laronidase 1 TSD E P G03XC03 Lasofoxifen 0,5 mg O J01DD06 Latamoxef 4 g P S01EE01 Latanoprost 0,1 ml AT A06AG11 Laurylsulfat, inkl. Kombinationen Standarddosis: 1 Klysma N05CP08 Lavendel A13AA02 Lebertran Standarddosis: 30 ml flüssige Zubereitung C05AX07 Lebertran D03AA01 Lebertran G02CD05 Lebertran S01XA21 Lebertran D03AA51 Lebertran, Kombinationen L04AA13 Leflunomid 20 mg O A06AC05 Leinsamen A06AC55 Leinsamen, Kombinationen L04AX04 Lenalidomid 18,75 mg O L03AA10 Lenograstim 0,35 mg P bezogen auf kg Körpergewicht L03AX01 Lentinan 0,3 mg O,P B01AE02 Lepirudin 0,25 g P C08CA13 Lercanidipin 10 mg O G04BP05 Lespedezakraut R05CB09 Letostein L02BG04 Letrozol 2,5 mg O A05BA66 Leucin, Kombinationen B05AX06 Leukozyten L03AX19 Leukozyten B05AX46 Leukozyten ohne Pharmazentralnummer V04BA12 Leukozyten-Testzone Standarddosis: 1 Test H01CA04 Leuprorelin 0,134 mg P Depotinjektion L02AE02 Leuprorelin 1 mg P; 1 DE P pro Behandlungszeitraum für Depotarzneiformen N07BC03 Levacetylmethadol L03AX23 Levamisol P02CE01 Levamisol 0,15 g O N03AX14 Levetiracetam 1,5 g O,P S02DH01 Levisticum officinale S01ED03 Levobunolol 0,2 ml AT N01BB10 Levobupivacain Standarddosis: 1 Applikationsform P R01AC02 Levocabastin 0,6 mg N S01GX02 Levocabastin A16AA01 Levocarnitin 2 g O,P R06AE09 Levocetirizin 5 mg O N04BA01 Levodopa 3,5 g O N04BA03 Levodopa, Decarboxylasehemmer und COMT-Hemmer 0,45 g O bezogen auf Levodopa N04BA11 Levodopa in Kombination mit Benserazid 0,6 g O bezogen auf Levodopa N04BA10 Levodopa in Kombination mit Carbidopa 0,6 g O bezogen auf Levodopa R05DB27 Levodropropizin 0,12 g O J01MA12 Levofloxacin 0,5 g O,P S01AE05 Levofloxacin N05AA02 Levomepromazin 0,3 g O; 0,1 g P N02AC06 Levomethadon N07BC05 Levomethadon G03AC03 Levonorgestrel Zykluspackung mit 28 Tabletten 1 DE O G03AD01 Levonorgestrel 1,5 mg O G03DA06 Levonorgestrel 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 50 von 92 ATC-CODE BEDEUTUNG DDD-INFO G03FA11 Levonorgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB09 Levonorgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA07 Levonorgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB03 Levonorgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O C01CX08 Levosimendan 11 mg P N05AL07 Levosulpirid 0,4 g O V04CJ03 Levothyroxin H03AA51 Levothyroxin, Kombinationen 1 Applikationsform O H03AA01 Levothyroxin-Natrium 0,15 mg O,P R05CA11 Levoverbenon A01AE01 Lidocain C01BB01 Lidocain Standarddosis: 1 Applikationsform P C05AD01 Lidocain D04AB01 Lidocain N01BB02 Lidocain Standarddosis: 1 Applikationsform P R02AD02 Lidocain S01HA07 Lidocain S02DA01 Lidocain A01AE51 Lidocain, Kombinationen C05AD51 Lidocain, Kombinationen D04AB51 Lidocain, Kombinationen N01BB52 Lidocain, Kombinationen Standarddosis: 1 Applikationsform P R02AD52 Lidocain, Kombinationen S02DA51 Lidocain, Kombinationen C08EX01 Lidoflazin 0,18 g O S01XA19 Limbale Stammzellen, autolog A06AX04 Linaclotid 0,29 mg O A10BH05 Linagliptin 5 mg O J01FF02 Lincomycin 1,8 g O,P P03AB02 Lindan N02BP02 Lindenblüten J01XX08 Linezolid 1,2 g O,P D02AC02 Linolsäure D02AC52 Linolsäure, Kombinationen N06BX09 Linopirdin C01DX18 Linsidomin H03AA02 Liothyronin-Natrium 60 mcg O,P L03AA14 Lipegfilgrastim 0,3 mg P A10BX07 Liraglutid 1,2 mg P N06BA12 Lisdexamfetamin 30 mg O C09AA03 Lisinopril 10 mg O C09BB03 Lisinopril und Amlodipin C09BA03 Lisinopril und Diuretika Standarddosis: 1 Applikationsform O G02CB02 Lisurid 0,6 mg O N02CA07 Lisurid N04BC10 Lisurid 1,3 mg O N05AN01 Lithium 24 mmol O D11AX04 Lithiumsuccinat A10BX10 Lixisenatid 20 mcg P G04BA04 L-Methionin 2,25 g O S01GX05 Lodoxamid N06AA07 Lofepramin 0,105 g O N07BC04 Lofexidin 1,4 mg O J01MA07 Lomefloxacin S01AE04 Lomefloxacin C10AX12 Lomitapid L01AD02 Lomustin M01AB09 Lonazolac 0,6 g O L01XX07 Lonidamin A07DA03 Loperamid 10 mg O; 3,5 mg O Kinder DDD A07DA53 Loperamid, Kombinationen A07DA05 Loperamidoxid 5 mg O J05AR10 Lopinavir und Ritonavir 0,8 g O bezogen auf Lopinavir N05CD11 Loprazolam 1 mg O J01DC08 Loracarbef 0,6 g O C01BA12 Lorajmin 0,3 g O R06AX13 Loratadin 10 mg O N05BA06 Lorazepam 2,5 mg O,P,SL N05BA56 Lorazepam, Kombinationen C01BC07 Lorcainid 0,2 g P N05CD06 Lormetazepam 1 mg O; 1 mg P M01AC05 Lornoxicam 12 mg O,P,R C09CA01 Losartan 50 mg O C09DB06 Losartan und Amlodipin C09DA01 Losartan und Diuretika Standarddosis: 1 Applikationsform O S01BA14 Loteprednol C10AA02 Lovastatin 45 mg O C10BA01 Lovastatin und Nicotinsäure A05AP06 Löwenzahnwurzel mit -kraut N05AH01 Loxapin 0,1 g O A06AX03 Lubiproston R01AH01 Luffa operculata 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 51 von 92 ATC-CODE BEDEUTUNG DDD-INFO R01BH01 Luffa operculata M01AH06 Lumiracoxib 0,1 g O N05AE05 Lurasidon G03GA07 Lutropin alfa 75 E P G03GA21 Lutropin alfa und Follitropin alfa V04CM03 Lutropin-Testzone Standarddosis: 1 Test J01AA04 Lymecyclin 0,6 g O,P G03AC02 Lynestrenol G03DC03 Lynestrenol 5 mg O G03FA07 Lynestrenol und Estrogen G03FB02 Lynestrenol und Estrogen G03AA03 Lynestrenol und Ethinylestradiol G03AB02 Lynestrenol und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O H01BA03 Lypressin 20 E N,P B05XB03 Lysin Standarddosis: 1 Applikationsform P N02BA13 Lysin-Acetylsalicylat 3 g O; 1 g P D06BB07 Lysozym J05AX02 Lysozym 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 52 von 92 ATC-CODE BEDEUTUNG DDD-INFO M V04CX07 MAB.B72.3 A06AD15 Macrogol 10 g O A06AD65 Macrogol, Kombinationen Standarddosis: 2 Applikationsformen O V04CZ10 Macrogol, Kombinationen A08AH01 Madar D06BA03 Mafenid A02AD02 Magaldrat 3,2 g O A02AF01 Magaldrat und Karminativa A12CC30 Magnesium (verschiedene Salze in Kombination) A12CC15 Magnesiumadipat A12CC12 Magnesiumascorbat A12CC05 Magnesiumaspartat 10 mmol O Mg2+ N05CM25 Magnesiumaspartathydrobromid A02AA01 Magnesiumcarbonat A06AD01 Magnesiumcarbonat 7 g O A12CC11 Magnesiumcarbonat A12CC01 Magnesiumchlorid 2,5 g O; 0,8 g P B05XA11 Magnesiumchlorid A06AD19 Magnesiumcitrat A12CC04 Magnesiumcitrat 2 g O B05CB03 Magnesiumcitrat Standarddosis: 1 Applikationsform P A12CC03 Magnesiumgluconat 5 g O N05CM26 Magnesiumglutamathydrobromid A12CH01 Magnesium-haltige Zubereitungen A12CC14 Magnesiumhydrogenglutamat A02AA04 Magnesiumhydroxid 3 g O G04BX01 Magnesiumhydroxid 0,5 g O A12CC06 Magnesiumlactat A12CC07 Magnesiumlevulinat A12CC09 Magnesiumorotat A02AA02 Magnesiumoxid A06AD02 Magnesiumoxid 7 g O A12CC10 Magnesiumoxid 0,5 g O A02AA03 Magnesiumperoxid A06AD03 Magnesiumperoxid B05XA10 Magnesiumphosphat A12CC08 Magnesiumpidolat C10AX07 Magnesiumpyridoxal-5-phosphatglutamat A02AA05 Magnesiumsilikat A06AD04 Magnesiumsulfat 7 g O A12CC02 Magnesiumsulfat 3 g O; 1 g P B05XA05 Magnesiumsulfat Standarddosis: 1 Applikationsform P D11AX05 Magnesiumsulfat V04CC02 Magnesiumsulfat C01AP01 Maiglöckchenkraut C01AP51 Maiglöckchenkraut, Kombinationen D03AP06 Maiskeimöl P03AX03 Malathion B05CA06 Mandelsäure J01XX06 Mandelsäure 12 g O V08CA05 Mangafodipir Standarddosis: 1 Applikationsform C08CA11 Manidipin 10 mg O A06AD16 Mannitol B05BC01 Mannitol Standarddosis: 1 Applikationsform P B05CX04 Mannitol Standarddosis: 1 Applikationsform P R05CB16 Mannitol 0,8 g Inhal.pulver B05BC51 Mannitol, Kombinationen Standarddosis: 1 Applikationsform P L01AB03 Mannosulfan N06AA21 Maprotilin 0,1 g O,P J05AX09 Maraviroc 0,6 g O J05AX10 Maribavir A05BH01 Mariendistelfrüchte A05BP01 Mariendistelfrüchte 13,5 g O Droge; 0,3 g O bezogen auf Silymarin A05BP51 Mariendistelfrüchte, Kombinationen J07BD51 Masern, Kombinationen mit Mumps, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD54 Masern, Kombinationen mit Mumps, Röteln und Varicella, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD52 Masern, Kombinationen mit Mumps und Röteln, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J07BD53 Masern, Kombinationen mit Röteln, lebend abgeschwächt J07BD01 Masern, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J06BB14 Masern-Immunglobulin L01XE22 Masitinib L01XX10 Masoprocol C05CP04 Mäusedornwurzelstock C05CP54 Mäusedornwurzelstock, Kombinationen N04AA10 Mazaticol A08AA05 Mazindol 1 mg O S01BA16 Mazipredon P02CA01 Mebendazol 0,2 g O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 53 von 92 ATC-CODE BEDEUTUNG DDD-INFO P02CA51 Mebendazol, Kombinationen A03AA04 Mebeverin 0,4 g O R06AX15 Mebhydrolin 0,2 g O N05BC04 Mebutamat C03AA13 Mebutizid C03EA05 Mebutizid und Kalium sparende Mittel C02BB01 Mecamylamin H01AC03 Mecasermin 2 mg P H01AC05 Mecasermin rinfabat J01CA11 Mecillinam 1,2 g P D06AA05 Meclocyclin D10AF04 Meclocyclin M01AG04 Meclofenaminsäure M02AA18 Meclofenaminsäure N06BX01 Meclofenoxat 1 g O,P A04AB04 Meclozin 37,5 mg O; 50 mg R R06AE05 Meclozin 50 mg O,R A04AB54 Meclozin, Kombinationen 37,5 mg O bezogen auf Meclozin; 50 mg R bezogen auf Meclozin R06AE55 Meclozin, Kombinationen B03BA05 Mecobalamin 1,5 mg O; 0,2 mg P N05BA03 Medazepam 20 mg O N06AX13 Medifoxamin A07BA01 Medizinische Kohle 5 g O A07BA51 Medizinische Kohle, Kombinationen V03AN05 Medizinische Luft G03DB03 Medrogeston 5 mg O G03FB07 Medrogeston und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AC06 Medroxyprogesteron 1,67 mg P G03DA02 Medroxyprogesteron 5 mg O; 7 mg P L02AB02 Medroxyprogesteron 1 g O,P G03FA12 Medroxyprogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB06 Medroxyprogesteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA08 Medroxyprogesteron und Ethinylestradiol S01BA08 Medryson R01AX14 Meerwasser S02DC04 Meerwasser C01AP03 Meerzwiebel C01AP53 Meerzwiebel, Kombinationen M01AG01 Mefenaminsäure 1 g O A08AA09 Mefenorex P01BC02 Mefloquin 1 g O Base C03BA05 Mefrusid 25 mg O C03BB05 Mefrusid und Kalium 25 mg O bezogen auf Mefrusid G03AC05 Megestrol G03DB02 Megestrol 5 mg O L02AB01 Megestrol 0,16 g O G03FA08 Megestrol und Estrogen G03FB04 Megestrol und Estrogen G03AA04 Megestrol und Ethinylestradiol G03AB01 Megestrol und Ethinylestradiol P01CB01 Megluminantimonat 0,85 g P Sb5+ C10AX05 Meglutol G04BD03 Meladrazin 0,45 g O B01AE04 Melagatran 6 mg P L03AX12 Melanom-Impfstoff P01CD01 Melarsoprol 60 mg P N05CH01 Melatonin 2 mg O N04BA04 Melevodopa N04BA05 Melevodopa und Decarboxylasehemmer A03AP04 Melissenblätter D06BP01 Melissenblätter N05CP04 Melissenkraut N06AA14 Melitracen 75 mg O,P N06CA02 Melitracen und Psycholeptika M01AC06 Meloxicam 15 mg O,P,R M01AC56 Meloxicam, Kombinationen N05AD03 Melperon 0,3 g O,P L01AA03 Melphalan N06DX01 Memantin 20 mg O R05DB31 Menadiol B02BA02 Menadion 10 mg O; 2 mg P J07AH01 Meningokokken A, gereinigtes Polysaccharid-Antigen J07AH10 Meningokokken A, gereinigtes Polysaccharid-Antigen, konjugiert J07AH09 Meningokokken B, Multikomponenten-Impfstoff Standarddosis: 1 Einzeldosis P J07AH03 Meningokokken bivalent (A, C), gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AH06 Meningokokken B-Polysaccharid-Impfstoff, monovalent J07AH07 Meningokokken C, gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P J07AH04 Meningokokken tetravalent (A, C, Y, W-135), gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 54 von 92 ATC-CODE BEDEUTUNG DDD-INFO J07AH08 Meningokokken tetravalent (A, C, Y, W-135), gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P R01AX23 Menthol P01AX05 Mepacrin 0,3 g O A01AB16 Mepartricin D01AA06 Mepartricin G01AA09 Mepartricin G04CX03 Mepartricin A03AB12 Mepenzolat 0,1 g O M03BX06 Mephenesin N05BX01 Mephenoxalon 1,2 g O C01CA11 Mephentermin 30 mg P; 30 mg O N03AB04 Mephenytoin 0,4 g O N03AB54 Mephenytoin, Kombinationen C07AA14 Mepindolol 5 mg O C07BA14 Mepindolol und Thiazide Standarddosis: 1 Applikationsform O N01BB03 Mepivacain Standarddosis: 1 Applikationsform P N01BB53 Mepivacain, Kombinationen Standarddosis: 1 Applikationsform P R07AB09 Mepixanox L04AC06 Mepolizumab H02AB15 Meprednison N05BC01 Meprobamat 1,2 g O N05BC51 Meprobamat, Kombinationen N05CX01 Meprobamat, Kombinationen M03BA57 Meprobamat, Kombinationen exkl. Psycholeptika C01AB02 Meproscillarin R05DB22 Meprotixol N02AX05 Meptazinol 1,2 g O,P D04AA02 Mepyramin R06AC01 Mepyramin 0,2 g O,P D11AX06 Mequinol R06AD07 Mequitazin 10 mg O D08AK04 Merbromin A16AA04 Mercaptamin 2 g O L01BB02 Mercaptopurin J01DH02 Meropenem 2 g P C03BC01 Mersalyl A07EC02 Mesalazin 1,5 g O,R; Standarddosis: 1 Klysma R01AX17 Mesna R05CB05 Mesna 1,2 g Inhal V03AF01 Mesna N06BA14 Mesocarb N05AC03 Mesoridazin 0,2 g O,P G03BB01 Mesterolon 50 mg O G03CA10 Mestranol D10AB05 Mesulfen P03AA03 Mesulfen N03AD03 Mesuximid 0,9 g O N01BA01 Metabutethamin Standarddosis: 1 Applikationsform P N05BA24 Metaclazepam J01AA05 Metacyclin 0,6 g O R05GB08 Metacyclin, Kombinationen 0,6 g O bezogen auf Metacyclin A10BB10 Metahexamid D08AK05 Metallisches Quecksilber C01CA81 Metamfepramon, Kombinationen N06BA03 Metamfetamin 15 mg O V04CN06 Metamfetamin-Testzone Standarddosis: 1 Test R05XA07 Metamizol, Kombinationen M01BA07 Metamizol und Corticosteroide N02BB02 Metamizol-Natrium 3 g O,P,R; 0,75 g O,R Kinder DDD N02BB52 Metamizol-Natrium, Kombinationen exkl. Psycholeptika N02BB72 Metamizol-Natrium, Kombinationen mit Psycholeptika J01CA14 Metampicillin 1,5 g O,P A14AA03 Metandienon 5 mg O D11AE01 Metandienon C01CA09 Metaraminol 50 mg P A14AA04 Metenolon 10 mg O; 7 mg P G02CB05 Metergolin A10BA02 Metformin 2 g O A10BD13 Metformin und Alogliptin A10BD15 Metformin und Glibenclamid Standarddosis: 2 Applikationsformen O A10BD11 Metformin und Linagliptin A10BD05 Metformin und Pioglitazon Standarddosis: 2 Applikationsformen O A10BD03 Metformin und Rosiglitazon Standarddosis: 2 Applikationsformen O A10BD10 Metformin und Saxagliptin Standarddosis: 2 Applikationsformen O A10BD07 Metformin und Sitagliptin Standarddosis: 2 Applikationsformen O A10BD02 Metformin und Sulfonamide A10BD08 Metformin und Vildagliptin Standarddosis: 2 Applikationsformen O V04CL01 Methacholin N07BC02 Methadon 25 mg O,P N02AC52 Methadon, Kombinationen exkl. Psycholeptika V04CN05 Methadon-Testzone Standarddosis: 1 Test 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 55 von 92 ATC-CODE BEDEUTUNG DDD-INFO V70AA01 Methadon-Zubereitungen D08AJ60 Methalkoniumchlorid, Kombinationen G03CB03 Methallenestril 9 mg O G03CC03 Methallenestril A03AB07 Methanthelinium 0,15 g O R06AC05 Methapyrilen N05CM01 Methaqualon 0,2 g O N05CX02 Methaqualon, Kombinationen N03AA30 Metharbital 0,2 g O S01EC05 Methazolamid 0,2 g O R06AD04 Methdilazin 16 mg O D11AA03 Methenamin J01XX05 Methenamin 2 g O Hippurat; 3 g O Mandelat D11AA53 Methenamin, Kombinationen J01XX55 Methenamin, Kombinationen R02AA73 Methenamin, Kombinationen D08AL02 Methenamin-Silbernitrat V08AA09 Methiodal Standarddosis: 1 Applikationsform V03AB26 Methionin A05BA09 Methionin und N-Acetylmethionin A02BX04 Methiosulfoniumchlorid M03BA03 Methocarbamol 3 g O,P M03BA53 Methocarbamol, Kombinationen exkl. Psycholeptika M03BA73 Methocarbamol, Kombinationen mit Psycholeptika N01AF01 Methohexital N05CA15 Methohexital C02AA06 Methoserpidin C02LA04 Methoserpidin und Diuretika L01BA01 Methotrexat Standarddosis: 1 Applikationsform P L04AX03 Methotrexat 2,5 mg O M01CX01 Methotrexat 2,5 mg O,P C01CA10 Methoxamin 30 mg P D05AD02 Methoxsalen D05BA02 Methoxsalen 10 mg O L01XD07 Methoxsalen N02BG09 Methoxyfluran R03CB02 Methoxyphenamin 0,4 g O B03XA03 Methoxy-Polyethylenglycol-Epoetin beta 4 mcg P L01XD03 Methylaminolevulinat A03BB02 Methylatropin 3 mg O A06AC06 Methylcellulose 2 g O C03AA08 Methylclothiazid 5 mg O C03AB08 Methylclothiazid und Kalium 5 mg O bezogen auf Methylclothiazid C02AB01 Methyldopa (linksdrehend) 1 g O,P C02LB01 Methyldopa (linksdrehend) und Diuretika Standarddosis: 1 Applikationsform O C02AB02 Methyldopa (racemisch) 2 g O V04CN12 Methylendioxy-methamphetamin Testzone Standarddosis: 1 Test R03CA53 Methylephedrin, Kombinationen G02AB01 Methylergometrin 0,2 mg O,P G02AC01 Methylergometrin und Oxytocin G03DC31 Methylestrenolon 5 mg O A03CB04 Methylhomatropin und Psycholeptika A06AH01 Methylnaltrexon bromid 6 mg P M02AD53 Methylnicotinat, Kombinationen G03FA05 Methylnortestosteron und Estrogen N05CM15 Methylpentynol N05CX03 Methylpentynol, Kombinationen N06BA04 Methylphenidat 30 mg O Kinder DDD; 40 mg O N03AA01 Methylphenobarbital 0,5 g O D07AA01 Methylprednisolon D10AA02 Methylprednisolon H02AB04 Methylprednisolon 7,5 mg O; 20 mg P H02BX01 Methylprednisolon, Kombinationen D07CA02 Methylprednisolon und Antibiotika S01CA08 Methylprednisolon und Antiinfektiva D07AC14 Methylprednisolonaceponat 1 mg T H02AB54 Methylprednisolon-Depot C01DA04 Methylpropylpropanedioldinitrat C01DA54 Methylpropylpropanedioldinitrat, Kombinationen D01AE02 Methylrosanilin G01AX09 Methylrosanilin M02AC02 Methylsalicylat M02BB02 Methylsalicylat M02AC52 Methylsalicylat, Kombinationen M02BB52 Methylsalicylat, Kombinationen A03BB03 Methylscopolamin 12 mg O,P S01FA03 Methylscopolamin A03CB01 Methylscopolamin und Psycholeptika G03BA02 Methyltestosteron 25 mg O G03EK01 Methyltestosteron G03EA01 Methyltestosteron und Estrogen V03AB17 Methylthioniniumchlorid 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 56 von 92 ATC-CODE BEDEUTUNG DDD-INFO V04CG05 Methylthioniniumchlorid H03BA01 Methylthiouracil 0,1 g O N05CE02 Methyprylon 0,2 g O N02CA04 Methysergid 4 mg O J01CF03 Meticillin 4 g P C03BA09 Meticran C01AA08 Metildigoxin 0,2 mg O,P C01AA58 Metildigoxin, Kombinationen C07AA18 Metipranolol S01ED04 Metipranolol 0,2 ml AT S01ED54 Metipranolol, Kombinationen C07FA18 Metipranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07BA18 Metipranolol und Thiazide Standarddosis: 1 Applikationsform O C07BA68 Metipranolol und Thiazide, Kombinationen C02KB01 Metirosin J05AA01 Metisazon N04AA03 Metixen 40 mg O R01AA10 Metizolin A03FA01 Metoclopramid 30 mg O,P,R; 10 mg R Kinder DDD A03FA51 Metoclopramid, Kombinationen N02CX59 Metoclopramid, Kombinationen N05AB13 Metofenazat C03BA08 Metolazon 5 mg O C03EA12 Metolazon und Kalium sparende Mittel A04AD05 Metopimazin 15 mg O,P C07AB02 Metoprolol 0,15 g O C07AB52 Metoprolol, Kombinationen C07FB02 Metoprolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07CB02 Metoprolol und andere Diuretika Standarddosis: 1 Applikationsform O C07FB24 Metoprolol und Felodipin Standarddosis: 1 Applikationsform O C07FB22 Metoprolol und Nifedipin Standarddosis: 1 Applikationsform O C07BB02 Metoprolol und Thiazide Standarddosis: 1 Applikationsform O C07BB52 Metoprolol und Thiazide, Kombinationen P02BB01 Metrifonat 40 mg O V08AB01 Metrizamid Standarddosis: 1 Applikationsform V08AA02 Metrizoesäure Standarddosis: 1 Applikationsform A01AB17 Metronidazol D06BX01 Metronidazol 15 mg T G01AF01 Metronidazol 0,5 g V J01XD01 Metronidazol 1,5 g P P01AB01 Metronidazol 2 g O,R V04CD01 Metyrapon C01BB02 Mexiletin 0,8 g O,P J01CA10 Mezlocillin 6 g P N06AX03 Mianserin 60 mg O C08CX01 Mibefradil 75 mg O J02AX05 Micafungin 0,1 g P A01AB09 Miconazol 0,2 g O A07AC01 Miconazol 1 g O D01AC02 Miconazol 40 mg T G01AF04 Miconazol 0,1 g V J02AB01 Miconazol 1 g P S02AA13 Miconazol D01AC52 Miconazol, Kombinationen S01AA22 Micronomicin N03AE02 Midazolam 7,5 mg SL Kinder DDD N05CD08 Midazolam 15 mg O,P J01FA03 Midecamycin 1 g P C01CA17 Midodrin 30 mg O L03AX15 Mifamurtid 0,7 mg P G03XB01 Mifepriston 0,6 g O A10BF02 Miglitol 0,3 g O A16AX06 Miglustat 0,3 g O A07FA50 Mikrobielle Antidiarrhoika, Kombinationen C05AX09 Mikroorganismen D11AX29 Mikroorganismen G01AX77 Milcheiweiß, Kombinationen A01AD22 Milchsäure G01AD01 Milchsäure A07FA01 Milchsäurebildner A07FA51 Milchsäurebildner, Kombinationen N06AX17 Milnacipran 0,1 g O C01CE02 Milrinon 50 mg P L01XX09 Miltefosin P01CX04 Miltefosin G02CX07 Milzextrakt L03AX18 Milzhydrolysat N06AX07 Minaprin 0,1 g O G02CD01 Mineralöl D03AX27 Mineralölraffinat D03AX77 Mineralölraffinat, Kombinationen R01AX21 Mineralsalz 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 57 von 92 ATC-CODE BEDEUTUNG DDD-INFO A01AD69 Mineralsalz, Kombinationen A06AD10 Mineralsalze in Kombination V04CZ02 Mineralsalze, Kombinationen A01AB23 Minocyclin 1 mg O J01AA08 Minocyclin 0,2 g O,P C02DC01 Minoxidil 20 mg O D11AX01 Minoxidil J01FA11 Miocamycin 1,2 g O C10AX11 Mipomersen G04BD12 Mirabegron N06AX11 Mirtazapin 30 mg O A02BB01 Misoprostol 0,8 mg O G02AD06 Misoprostol C02KP02 Mistelkraut L01CH01 Mistelkraut L01CP01 Mistelkraut M09AP06 Mistelkraut C02KP52 Mistelkraut, Kombinationen A10BX08 Mitiglinid 30 mg O L01AX01 Mitobronitol L01XX16 Mitoguazon L01DC03 Mitomycin 4,29 mg intravesikal; 0,65 mg P L01XX23 Mitotan L01DB07 Mitoxantron 10 mg P Zytostatikum; 0,24 mg P Multiple Sklerose M03AC10 Mivacuriumchlorid 14 mg P R06AX25 Mizolastin 10 mg O N06AG02 Moclobemid 0,3 g O N06BA07 Modafinil 0,3 g O C09AA13 Moexipril 15 mg O C09BA13 Moexipril und Diuretika Standarddosis: 1 Applikationsform O C09BA23 Moexipril und Hydrochlorothiazid Standarddosis: 1 Applikationsform O M01AA02 Mofebutazon 0,75 g O,P M02AA02 Mofebutazon M01AA52 Mofebutazon, Kombinationen M01BA04 Mofebutazon und Corticosteroide A03PP01 Mohnkapsel L03AA03 Molgramostim 0,35 mg P N05AE02 Molindon 50 mg O C01DX12 Molsidomin 8 mg O D07AC13 Mometason 1 mg T D07XC03 Mometason R01AD09 Mometason 0,2 mg N R03BA07 Mometason 0,4 mg Inhal.pulver G01AX26 Monalazon D11AX13 Monobenzon C05BB01 Monoethanolaminoleat M02AC54 Monoethanolaminsalicylat, Kombinationen M02BB53 Monoethanolaminsalicylat, Kombinationen V04CX18 Mononucleose-Testzone Standarddosis: 1 Test C05CA02 Monoxerutin R03DC03 Montelukast 10 mg O; 5 mg O Kinder DDD M02BX01 Moor M02BX51 Moor, Kombinationen N05AD04 Moperon 20 mg O,P C01BG01 Moracizin 0,75 g O R05DB25 Morclofon J04AK04 Morinamid M01AX22 Morniflumat B02BD14 Moroctocog alfa 500 E P J05AX01 Moroxydin 0,3 g O J05AX51 Moroxydin, Kombinationen N02AA01 Morphin 0,1 g O; 30 mg P,R A07DA52 Morphin, Kombinationen N02AA51 Morphin, Kombinationen N02AG01 Morphin mit Spasmolytika N02BA08 Morpholinsalicylat N05AX10 Mosapramin J06BB17 Motavizumab D10AD05 Motretinid A03AD30 Moxaverin 50 mg O C04AX42 Moxaverin C04BA01 Moxaverin, Kombinationen A03CA39 Moxaverin und Psycholeptika G03CB04 Moxestrol J01MA14 Moxifloxacin 0,4 g O,P S01AE07 Moxifloxacin 0,75 mg AT C04AX10 Moxisylyt G04BE06 Moxisylyt C02AC05 Moxonidin 0,3 mg O C02LC05 Moxonidin und Diuretika M01AX27 Mucopolysaccharidpolyschwefelsäureester C05BA05 Mucopolysaccharidschwefelsäureester 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 58 von 92 ATC-CODE BEDEUTUNG DDD-INFO C05BA55 Mucopolysaccharidschwefelsäureester, Kombinationen A09AA52 Multienzyme, Kombinationen A09AA02 Multienzyme (Lipase, Protease etc.) 240 TSD FIP E O Lipase A09AC02 Multienzyme und Säure-haltige Zubereitungen A11AB50 Multivitamine, andere Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11BA01 Multivitamine, rein Standarddosis: 1 Tablette oder 30 ml Mixtur A11AA03 Multivitamine und andere Mineralstoffe, inkl. Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur A11AA02 Multivitamine und Calcium Standarddosis: 1 Tablette oder 30 ml Mixtur A11AA01 Multivitamine und Eisen A11AA04 Multivitamine und Spurenelemente J07BE01 Mumps, lebend abgeschwächt J06BB15 Mumps-Immunglobulin D06AX09 Mupirocin 40 mg T R01AX06 Mupirocin 3 mg N L04AA02 Muromonab-CD3 5 mg P G02AB02 Mutterkorn-Alkaloide C03CD01 Muzolimin 20 mg O L03AG03 Mycobacterium phlei L04AA06 Mycophenolsäure 2 g O,P bezogen auf Mycophenolatmofetil V04CX21 Myoglobin-Testzone Standarddosis: 1 Test A05BA12 Myo-Inositol R02AA10 Myristylbenzalkonium A01AP01 Myrrhentinktur 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 59 von 92 ATC-CODE BEDEUTUNG DDD-INFO N A04AD11 Nabilon N02BG10 Nabiximols 42 mg SL M01AX01 Nabumeton 1 g O D02AP01 Nachtkerzensamenöl D10AF06 Nadifloxacin 20 mg T C07AA12 Nadolol 0,16 g O C07BA12 Nadolol und Thiazide Standarddosis: 1 Applikationsform O B01AB06 Nadroparin 2,85 TSD E P anti Xa H01CA02 Nafarelin 0,4 mg N J01CF06 Nafcillin C05CX02 Naftazon C04AX21 Naftidrofuryl 0,6 g O; 0,3 g P D01AE22 Naftifin V01AA08 Nahrungsmittel N02AF02 Nalbufin 80 mg P V03AX02 Nalfurafin J01MB02 Nalidixinsäure 4 g O V03AB02 Nalorphin V03AB15 Naloxon Standarddosis: 1 Applikationsform P N07BB04 Naltrexon 50 mg O A14AB01 Nandrolon 2 mg P S01XA11 Nandrolon R01AA08 Naphazolin 0,4 mg N R01AB02 Naphazolin 0,8 ml N S01GA01 Naphazolin S01GA51 Naphazolin, Kombinationen M01AE18 Naproxcinod G02CC02 Naproxen M01AE02 Naproxen 0,5 g O,R M02AA12 Naproxen M01AE52 Naproxen und Esomeprazol 0,5 g O bezogen auf Naproxen M01AE56 Naproxen und Misoprostol N02CC02 Naratriptan 2,5 mg O D03AC50 Narbenbehandlungsmittel, Kombinationen N01AG01 Narcobarbital L04AA23 Natalizumab 10 mg P A01AB10 Natamycin 20 mg O A07AA03 Natamycin 0,3 g O D01AA02 Natamycin G01AA02 Natamycin 25 mg V S01AA10 Natamycin A10BX03 Nateglinid 0,36 g O M01CB01 Natrium aurothiomalat 2,4 mg P M01CB02 Natrium aurothiosulfat 14 mg P B05XA08 Natriumacetat J04AA02 Natriumaminosalicylat 14 g O,P C05BA02 Natriumapolat B05CB04 Natriumbicarbonat Standarddosis: 1 Applikationsform P B05XA02 Natriumbicarbonat Standarddosis: 1 Applikationsform P D10BX01 Natriumbituminosulfonat S01AX07 Natriumborat V03AG01 Natriumcellulosephosphat A12CA01 Natriumchlorid 1 g O B05CB01 Natriumchlorid Standarddosis: 1 Applikationsform P B05XA03 Natriumchlorid Standarddosis: 1 Applikationsform P R01AX16 Natriumchlorid R04AX03 Natriumchlorid S01XA03 Natriumchlorid, hyperton R04AX53 Natriumchlorid, Kombinationen D03AX11 Natriumchlorit B05CB02 Natriumcitrat Standarddosis: 1 Applikationsform P B05XA21 Natriumcitrat Standarddosis: 1 Applikationsform P S01XA05 Natriumedetat B03AB03 Natriumferedetat 0,17 g O Fe3+ A01AA01 Natriumfluorid 1,1 mg O 0.5 mg Fluorid A12CD01 Natriumfluorid 88 mg O bezogen auf Fluorid 40 mg V09IX06 [18F]Natriumfluorid A01AA51 Natriumfluorid, Kombinationen A12CD51 Natriumfluorid, Kombinationen V03AF06 Natriumfolinat 60 mg P bezogen auf Folinsäure; 60 mg O A02AH01 Natriumhydrogencarbonat D11AB14 Natriumhydrogencarbonat A01AB31 Natriumhypochlorit D08AX07 Natriumhypochlorit V09CX01 [123I]Natrium-Iodhippurat V09CX02 [131I]Natrium-Iodhippurat V09FX02 [123I]Natriumiodid V09FX03 [131I]Natriumiodid 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 60 von 92 ATC-CODE BEDEUTUNG DDD-INFO V09FX04 [124I]Natriumiodid V10XA01 [131I]Natriumiodid V09CX03 [125I]Natrium-Iodthalamat V08AC08 Natriumiopodat Standarddosis: 1 Applikationsform V03AF10 Natriumlevofolinat 30 mg P bezogen auf Levofolinsäure A01AA02 Natriummonofluorphosphat A12CD02 Natriummonofluorphosphat 0,152 g O bezogen auf Fluorid 20mg A12CD52 Natriummonofluorphosphat, Kombinationen 20 mg O bezogen auf Fluorid V03AB08 Natriumnitrit N01AX11 Natriumoxybat N07XX04 Natriumoxybat 7,5 g O N02CX11 Natriumpangamat B01AX07 Natriumpentosanpolysulfat C05BA04 Natriumpentosanpolysulfat G04BX15 Natriumpentosanpolysulfat C05BA54 Natriumpentosanpolysulfat, Kombinationen A01AB19 Natriumperborat A01AB32 Natriumpercarbonat H03BC02 Natriumperchlorat A16AX03 Natriumphenylbutyrat 20 g O A06AD17 Natriumphosphat 50 g O A06AG01 Natriumphosphat Standarddosis: 1 Klysma B05XA09 Natriumphosphat V10XX01 [32P]Natriumphosphat A06AB08 Natriumpicosulfat 5 mg O A06AB58 Natriumpicosulfat, Kombinationen S01AX10 Natriumpropionat N02BA04 Natriumsalicylat 3 g O R05XA06 Natriumsalicylat, Kombinationen A12CE01 Natriumselenat 0,2 mg O Se A12CE02 Natriumselenit 0,2 mg O Se; 0,2 mg P P01CB02 Natriumstibogluconat 0,85 g P Sb5+ A06AD13 Natriumsulfat A12CA02 Natriumsulfat A06AD21 Natriumtartrat D10AX08 Natriumtetraborat C05BB04 Natriumtetradecylsulfat R07AA05 Natürliche Phospholipide aus Rinderlunge 0,16 g Instill.lösung R07AA04 Natürliche Phospholipide aus Schweinelunge 0,16 g Instill.lösung G02CD08 Naturmoor J06BC01 Nebacumab 0,1 g P H05AA01 Nebenschilddrüsenextrakt C07AB12 Nebivolol 5 mg O C07BB12 Nebivolol und Thiazide R01AC07 Nedocromil 10,4 mg N R03BC03 Nedocromil 8 mg Inhal.Aerosol S01GX04 Nedocromil N06AX06 Nefazodon 0,4 g O N02BG06 Nefopam L01BB07 Nelarabin 0,39 g P J05AE04 Nelfinavir 2,25 g O R05CB14 Neltenexin A01AB08 Neomycin A07AA01 Neomycin 5 g O B05CA09 Neomycin D06AX04 Neomycin G01AA14 Neomycin J01GB05 Neomycin 1 g O R02AB01 Neomycin S01AA03 Neomycin S02AA07 Neomycin S03AA01 Neomycin A07AA51 Neomycin, Kombinationen D06AX54 Neomycin, Kombinationen G01AA64 Neomycin, Kombinationen J01GB55 Neomycin, Kombinationen N07AA01 Neostigmin 60 mg O; 2 mg P S01EB06 Neostigmin 40 mg Salbe; 0,4 ml N07AA51 Neostigmin, Kombinationen S01BC10 Nepafenac 0,15 mg AT R05DB26 Nepinalon C01DX19 Nesiritid 1,5 mg P J01GB07 Netilmicin 0,35 g O,P S01AA23 Netilmicin J05AG01 Nevirapin 0,4 g O; 0,3 g O Kinder DDD A05AB01 N-(Hydroxymethyl)nicotinamid N06AF02 Nialamid 0,1 g O N05CM16 Niaprazin R01AP03 Niauliöl R04AP07 Niauliöl R05CP10 Niauliöl 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 61 von 92 ATC-CODE BEDEUTUNG DDD-INFO C08CA04 Nicardipin 90 mg O,P C04AE02 Nicergolin N06DX13 Nicergolin 30 mg O C10AD01 Niceritrol 1,5 g O V04CL02 Nickel-Testzone Standarddosis: 1 Test P02DA01 Niclosamid 2 g O R05DA13 Nicocodin A03AC04 Nicofetamid C10AD03 Nicofuranose N02AA04 Nicomorphin 30 mg O,P,R C01DX16 Nicorandil 40 mg O N07BA01 Nicotin 60 mg Inhalation; 30 mg Kaugummi,N,SL; 14 mg TD; 30 mg Lutschtabletten A11HA01 Nicotinamid 0,15 g O V04CN14 Nicotin/Cotinin-Testzone Standarddosis: 1 Test C04AC01 Nicotinsäure 0,2 g O,P C10AD02 Nicotinsäure 2 g O C04AC51 Nicotinsäure, Kombinationen C10AD52 Nicotinsäure, Kombinationen 2 g O bezogen auf Nicotinsäure C04AC02 Nicotinylalkohol (Pyridylcarbinol) 0,3 g O,P C10AD05 Nicotinylalkohol (Pyridylcarbinol) 0,9 g O N06DX17 Nicotinylalkohol (Pyridylcarbinol) 0,3 g O,P C08CA05 Nifedipin 30 mg O,P C08CA55 Nifedipin, Kombinationen C08GA01 Nifedipin und Diuretika Standarddosis: 1 Applikationsform O M02AA24 Nifenazon N02BB05 Nifenazon M01AX02 Nifluminsäure 0,75 g O M02AA17 Nifluminsäure G01AX05 Nifuratel 0,6 g O,V A07AX03 Nifuroxazid 0,6 g O P01CC01 Nifurtimox 0,7 g O J01XE02 Nifurtoinol 0,16 g O A07AX04 Nifurzid R07AB02 Nikethamid 0,5 g O,P R07AB52 Nikethamid, Kombinationen L01XE08 Nilotinib 0,6 g O L02BB02 Nilutamid 0,3 g O C08CA10 Nilvadipin 8 mg O M01AX17 Nimesulid 0,2 g O M02AA26 Nimesulid C08CA06 Nimodipin 0,3 g O; 50 mg P N06DX18 Nimodipin 0,3 g O; 50 mg P P01AB06 Nimorazol 2 g O L01AD06 Nimustin A02BA05 Niperotidin P02BX02 Niridazol C08CA07 Nisoldipin 20 mg O P01AX11 Nitazoxanid 1 g O A16AX04 Nitisinon 20 mg O N05CD02 Nitrazepam 5 mg O N07BB05 Nitrefazol C08CA08 Nitrendipin 20 mg O V04BA11 Nitrit-Testzone Standarddosis: 1 Test B05CA03 Nitrofural D08AF01 Nitrofural D09AA03 Nitrofural P01CC02 Nitrofural S01AX04 Nitrofural S02AA02 Nitrofural J01XE01 Nitrofurantoin 0,2 g O; 0,12 g O Kinder DDD J01XE51 Nitrofurantoin, Kombinationen C02DD01 Nitroprussid 50 mg P J01XX07 Nitroxolin 1 g O A02BA04 Nizatidin 0,3 g O,P N06BX10 Nizofenon G03DB04 Nomegestrol G03AA14 Nomegestrol und Estradiol Zykluspackung mit 28 Tabletten 1 DE O G03FB12 Nomegestrol und Estradiol Zykluspackung mit 24 Tabletten 0,86 DE O N06AX04 Nomifensin 0,15 g O N06CA05 Nomifensin und Psycholeptika B02BD09 Nonacog alfa 450 E P M02AB03 Nonivamid M02AB53 Nonivamid, Kombinationen G02BB02 Nonoxinol 9 Standarddosis: 1 Applikationsform V N05BA16 Nordazepam 15 mg O G03AA13 Norelgestromin und Ethinylestradiol C01CA03 Norepinephrin 6 mg P A14AA09 Norethandrolon G03AC01 Norethisteron 2,5 mg P G03DC02 Norethisteron 5 mg O; 0,65 mg O niedrigdosierte Zubereitungen G03FA01 Norethisteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FB05 Norethisteron und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 62 von 92 ATC-CODE BEDEUTUNG DDD-INFO G03FC01 Norethisteron und Estrogen G03AA05 Norethisteron und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB04 Norethisteron und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA09 Noretynodrel und Estrogen C01CA05 Norfenefrin 25 mg O C01CA55 Norfenefrin, Kombinationen J01MA06 Norfloxacin 0,8 g O S01AE02 Norfloxacin G03FA13 Norgestimat und Estrogen G03AA11 Norgestimat und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AB09 Norgestimat und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03FA10 Norgestrel und Estrogen G03FB01 Norgestrel und Estrogen Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AA06 Norgestrel und Ethinylestradiol Zykluspackung mit 28 Tabletten 1 DE O; Zykluspackung mit 21 Tabletten 0,75 DE O G03AC07 Norgestrienon R05DA06 Normethadon R05DA56 Normethadon, Kombinationen N06AA10 Nortriptylin 75 mg O; 30 mg P N06CA06 Nortriptylin und Psycholeptika R05DA07 Noscapin 0,125 g O N06AA20 Noxiptilin B05CA07 Noxytiolin V04CO02 N-terminal-pro BNP-Testzone Standarddosis: 1 Test M09AX03 Nukleotide, inkl. Kombinationen A02XH01 Nux vomica A01AB33 Nystatin 500 000 IE O A07AA02 Nystatin 1,5 MIO E O D01AA01 Nystatin 250 TSD E T G01AA01 Nystatin 0,1 MIO E V D01AA51 Nystatin, Kombinationen 2,5 g T G01AA51 Nystatin, Kombinationen D01AA91 Nystatin und Zinkoxid 2,5 g T 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 63 von 92 ATC-CODE BEDEUTUNG DDD-INFO O V03AB13 Obidoxim L01XX36 Oblimersen S01XA22 Ocriplasmin Standarddosis: 1 Applikationsform D08AJ57 Octenidin, Kombinationen G01AX66 Octenidin, Kombinationen D02BA02 Octinoxat B02BD13 Octocog alfa 500 E P C01CA18 Octopamin C01CA68 Octopamin, Kombinationen H01CB02 Octreotid 0,7 mg P i.m. Monatsdepot ; 0,3 mg P s.c. L01XC10 Ofatumumab 0,133 g P J01MA01 Ofloxacin 0,4 g O,P S01AE01 Ofloxacin 0,4 mg AT,AS S02AA16 Ofloxacin A06AG06 Öl Standarddosis: 1 Klysma A01AA03 Olaflur 1,1 mg O N05AH03 Olanzapin 10 mg O,P; 10 mg P Depot C01AP52 Oleanderglykoside, Kombinationen J01FA05 Oleandomycin 1 g O C02KP01 Olivenblätter D02AP02 Olivenöl C09CA08 Olmesartan medoxomil 20 mg O C09DX03 Olmesartan medoxomil, Amlodipin und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09DB02 Olmesartan medoxomil und Amlodipin Standarddosis: 1 Applikationsform O C09DA08 Olmesartan medoxomil und Diuretika Standarddosis: 1 Applikationsform O R01AC08 Olopatadin S01GX09 Olopatadin A07EC03 Olsalazin 1 g O S02DC01 Ölsäure-Derivate L01XX40 Omacetaxin mepesuccinat R03DX05 Omalizumab 16 mg P s.c. C10AX06 Omega-3-Fettsäuren inkl. andere Ester und Säuren A02BC01 Omeprazol 20 mg O,P A02BD05 Omeprazol, Amoxicillin und Clarithromycin Kombinationspackung: 6 DE O A02BD01 Omeprazol, Amoxicillin und Metronidazol D01AC13 Omoconazol G01AF16 Omoconazol A04AA01 Ondansetron 16 mg O,P,R V04CN07 Opiat-Testzone Standarddosis: 1 Test N06AA05 Opipramol 0,15 g O A07DA02 Opium 0,1 g O N02AA02 Opium R05DA05 Opium-Alkaloide mit Morphin R05FA02 Opium-Derivate und Expektoranzien R05FA01 Opium-Derivate und Mukolytika L03AC02 Oprelvekin 3,5 mg P C01CA29 Orciprenalin R03AB03 Orciprenalin 6 mg Inhal.Aerosol R03CB03 Orciprenalin 60 mg O R03AB53 Orciprenalin, Kombinationen R03CB53 Orciprenalin, Kombinationen C04BA04 Organextrakt, Kombinationen M01BX02 Organextrakt, Kombinationen N06DX20 Organextrakte M02AX20 Organextrakte, inkl. Kombinationen C01DA20 Organische Nitrate in Kombination C01DA70 Organische Nitrate in Kombination mit Psycholeptika S01XA30 Organpräparate, inkl. Kombinationen M01AX14 Orgotein J01XA05 Oritavancin A08AB01 Orlistat 0,36 g O G03XC04 Ormeloxifen G01AF06 Ornidazol J01XD03 Ornidazol 1 g P P01AB03 Ornidazol 1,5 g O H01BA05 Ornipressin 5 E P A05BA17 Ornithinaspartat A05BA67 Ornithinaspartat, Kombinationen A05BA06 Ornithinoxoglurat M03BC51 Orphenadrin, Kombinationen N04AB02 Orphenadrin(chlorid) 0,2 g O,P M03BC01 Orphenadrin(citrat) 0,12 g O,P G04BP03 Orthosiphonblätter 9 g O Droge J05AH02 Oseltamivir 0,15 g O A03AB06 Otiloniumbromid A03CA04 Otiloniumbromid und Psycholeptika G02CX08 Ovarialextrakt A14AB03 Oxaboloncipionat D11AX09 Oxaceprol M01AX24 Oxaceprol 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 64 von 92 ATC-CODE BEDEUTUNG DDD-INFO J01CF04 Oxacillin 2 g O,P N06AX10 Oxaflozan L01XA03 Oxaliplatin 11 mg P M01AB13 Oxametacin P02BA02 Oxamniquin 1 g O A14AA08 Oxandrolon P02CC02 Oxantel M01AE12 Oxaprozin 0,9 g O R06AE06 Oxatomid 60 mg O N05BA04 Oxazepam 50 mg O; 50 mg R N05BA26 Oxazolam N03AF02 Oxcarbazepin 1 g O C01CA08 Oxedrin 0,2 g O,P S01GA06 Oxedrin C01CA58 Oxedrin, Kombinationen S01GA56 Oxedrin, Kombinationen R05DB09 Oxeladin 80 mg O C05AD06 Oxetacain N02CX06 Oxetoron D08AH03 Oxichinolin D08AH53 Oxichinolin, Kombinationen D01AC11 Oxiconazol 10 mg T G01AF17 Oxiconazol B02BC02 Oxidierte Zellulose Standarddosis: 1 Applikationsform C01CB04 Oxilofrin C01CB54 Oxilofrin, Kombinationen N06BX07 Oxiracetam N06AX01 Oxitriptan N06CA04 Oxitriptan und Psycholeptika R03BB02 Oxitropium bromid 0,6 mg Inhal.Aerosol; 4 mg Inhal.lösung D08AX09 Oxoferin-Reaktionsprodukt R05DB07 Oxolamin 0,6 g O J01MB05 Oxolinsäure 1 g O R06AD08 Oxomemazin 30 mg O C07AA02 Oxprenolol 0,16 g O C07FA02 Oxprenolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07CA02 Oxprenolol und andere Diuretika Standarddosis: 1 Applikationsform O C07BA02 Oxprenolol und Thiazide D04AB03 Oxybuprocain N01BA06 Oxybuprocain Standarddosis: 1 Applikationsform P S01HA02 Oxybuprocain G04BD04 Oxybutynin 15 mg O; 3,9 mg TD A01AB07 Oxychinolin 80 mg O G01AC30 Oxychinolin R02AA14 Oxychinolin A01AB57 Oxychinolin, Kombinationen M01CA03 Oxycinchophen 1,5 g O N02AA05 Oxycodon 75 mg O; 30 mg P N02AA55 Oxycodon, Kombinationen 75 mg O bezogen auf Oxycodon hydrochlorid, bei Kombination mit Naloxon C01DX03 Oxyfedrin 40 mg O,P C01DX53 Oxyfedrin, Kombinationen R01AA05 Oxymetazolin 0,4 mg N R01AB07 Oxymetazolin S01GA04 Oxymetazolin A14AA05 Oxymetholon 0,25 g O N05AE01 Oxypertin 0,12 g O M01AA03 Oxyphenbutazon 0,3 g O,R M02AA04 Oxyphenbutazon S01BC02 Oxyphenbutazon M01AA53 Oxyphenbutazon, Kombinationen M02AA54 Oxyphenbutazon, Kombinationen M01BA05 Oxyphenbutazon und Corticosteroide A03AA01 Oxyphencyclimin 20 mg O A03CA03 Oxyphencyclimin und Psycholeptika A06AB01 Oxyphenisatin 10 mg O A03AB03 Oxyphenonium 25 mg O A03AB53 Oxyphenonium, Kombinationen D06AA03 Oxytetracyclin G01AA07 Oxytetracyclin J01AA06 Oxytetracyclin 1 g O,P S01AA04 Oxytetracyclin J01AA56 Oxytetracyclin, Kombinationen 1 g O bezogen auf Oxytetracyclin R05GB03 Oxytetracyclin, Kombinationen 1 g O,P bezogen auf Oxytetracyclin H01BB02 Oxytocin 15 E N,P; 200 E O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 65 von 92 ATC-CODE BEDEUTUNG DDD-INFO P L01CD01 Paclitaxel 15 mg P; 22 mg P Nanopartikelformulierung L01CD03 Paclitaxel poliglumex V03AF08 Palifermin 4,2 mg P N05AX13 Paliperidon 6 mg O; 2,5 mg P Depot, bezogen auf Paliperidon J06BB16 Palivizumab 3,75 mg P Säuglings DDD A04AA05 Palonosetron 0,25 mg P; 0,5 mg O M05BA03 Pamidronsäure 60 mg P Dosis pro Behandlungszyklus bezogen auf das Salz der Pamidronsäure M03AC01 Pancuronium 6,3 mg P J01DH55 Panipenem und Betamipron 2 g P bezogen auf Panipenem L01XC08 Panitumumab 30 mg P V04CK02 Pankreozymin (Cholecystokinin) L01XX42 Panobinostat A11HA32 Pantethin D11AC15 Panthenol A02BC02 Pantoprazol 20 mg O,P A02BD04 Pantoprazol, Amoxicillin und Clarithromycin Kombinationspackung: 6 DE O S01XA34 Pantothensäure N02AA10 Papaveretum A03AD01 Papaverin 0,1 g O,P C04AX38 Papaverin G04BE02 Papaverin C04BA02 Papaverin, Kombinationen G04BE52 Papaverin, Kombinationen N02BE01 Paracetamol 3 g O,P,R; 0,75 g O Kinder DDD; 0,375 g R Säuglings DDD; 0,75 g R Kinder DDD N02CX57 Paracetamol, Kombinationen R05XA01 Paracetamol, Kombinationen N02BE51 Paracetamol, Kombinationen exkl. Psycholeptika N02BE61 Paracetamol, Kombinationen mit Coffein N02BE71 Paracetamol, Kombinationen mit Psycholeptika D02AC54 Paraffin, Kombinationen D11AB58 Paraffin, Kombinationen A01AB84 Paraformaldehyd, Kombinationen R02AA72 Paraformaldehyd, Kombinationen N05CC05 Paraldehyd 5 g O,P,R N03AC01 Paramethadion 0,9 g O H02AB05 Paramethason 4 mg O,P S01EB10 Paraoxon H05AA03 Parathyroid Hormon 0,1 mg P M01AH04 Parecoxib 40 mg P C02KC01 Pargylin C02LL01 Pargylin und Diuretika H05BX02 Paricalcitol 2 mcg O,P B01AB07 Parnaparin 3,2 TSD E P anti Xa A07AA06 Paromomycin 3 g O N06AB05 Paroxetin 20 mg O H01CB05 Pasireotid 1,2 mg P N05CP05 Passionsblumenkraut L01XE11 Pazopanib 0,8 g O J01MA18 Pazufloxacin 1 g P D01AA04 Pecilocin J01MA03 Pefloxacin 0,8 g O,P L03AX04 Pegademase S01LA03 Pegaptanib 0,024 DE P L01XX24 Pegaspargase L03AA13 Pegfilgrastim 0,3 mg P B03XA04 Peginesatid L03AB11 Peginterferon alfa-2a 26 mcg P Kombinationstherapie bei Hepatitis C L03AB61 Peginterferon alfa-2a, Kombinationen L03AB10 Peginterferon alfa-2b 15 mcg P Kombinationstherapie bei Hepatitis C L03AB60 Peginterferon alfa-2b, Kombinationen M04AX02 Pegloticase H01AX01 Pegvisomant 10 mg P A07BC01 Pektin A07BC51 Pektin, Kombinationen R05CP05 Pelargoniumwurzel L01BA04 Pemetrexed 43 mg P N06BA05 Pemolin 40 mg O J01CE06 Penamecillin 1,05 g O C07AA23 Penbutolol 40 mg O C07CA23 Penbutolol und andere Diuretika Standarddosis: 1 Applikationsform O D06BB06 Penciclovir J05AB13 Penciclovir N05AG03 Penfluridol 6 mg O C01AA10 Pengitoxin M01CC01 Penicillamin 0,5 g O J01RA01 Penicilline, Kombination mit anderen Antibiotika J01AA10 Penimepicyclin A06AD14 Pentaerythrityl C01DA05 Pentaerythrityltetranitrat 0,12 g O C01DA55 Pentaerythrityltetranitrat, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 66 von 92 ATC-CODE BEDEUTUNG DDD-INFO V04CG04 Pentagastrin P01CX01 Pentamidindiisetionat 0,28 g P je Injektion G01AA11 Pentamycin N02AD01 Pentazocin 0,2 g O,P R07AB03 Pentetrazol 0,1 g O R07AB53 Pentetrazol, Kombinationen V03AB47 Pentetsäure A03AB04 Penthienat 15 mg O C04AD01 Pentifyllin N06DX16 Pentifyllin N06DX66 Pentifyllin, Kombinationen S01XA87 Pentifyllin, Kombinationen N05CA01 Pentobarbital 0,1 g O,P,R L01XX08 Pentostatin C04AD03 Pentoxifyllin 1 g O; 0,3 g P R05DB05 Pentoxyverin 0,1 g O,R R05DB55 Pentoxyverin, Kombinationen A09AA03 Pepsin A09AC01 Pepsin- und Säure-haltige Zubereitungen N03AX22 Perampanel 8 mg O N05AB10 Perazin 0,1 g O,P V08DA03 Perflenapent Standarddosis: 1 Applikationsform V08CX01 Perflubron Standarddosis: 1 Applikationsform N04BC02 Pergolid 3 mg O C08EX02 Perhexilin N05AC01 Periciazin 50 mg O; 20 mg P C09AA04 Perindopril 4 mg O C09BB04 Perindopril und Amlodipin C09BA04 Perindopril und Diuretika Standarddosis: 1 Applikationsform O P03AC04 Permethrin P03AC54 Permethrin, Kombinationen N05AB03 Perphenazin 30 mg O; 10 mg P; 7 mg P Depot; 16 mg R J07AJ02 Pertussis, gereinigtes Antigen Standarddosis: 1 Einzeldosis P J07AJ52 Pertussis, gereinigtes Antigen, Kombinationen mit Toxoiden Standarddosis: 1 Einzeldosis P J07AJ01 Pertussis, inaktiviert, ganze Zelle J07AJ51 Pertussis, inaktiviert, ganze Zelle, Kombinationen mit Toxoiden J06BB13 Pertussis-Immunglobulin L01XC13 Pertuzumab '20 mg P D03AX71 Perubalsam, Kombinationen C01AX02 Peruvosid J07AK01 Pest, inaktiviert, ganze Zelle N02CH01 Pestwurz N02CP01 Pestwurzwurzel N02AB02 Pethidin 0,4 g O,P,R N02AB52 Pethidin, Kombinationen exkl. Psycholeptika N02AB72 Pethidin, Kombinationen mit Psycholeptika N02AG03 Pethidin mit Spasmolytika A03AP01 Pfefferminzblätter A05AP05 Pfefferminzöl R04AP06 Pfefferminzöl B02BP50 Pflanzliche Antihämorrhagika, Kombinationen R05FP30 Pflanzliche Antitussiva und Expektoranzien, Kombinationen R05XC02 Pflanzliche Kombinationen mit anderen Mitteln P01AX04 Phanquinon N03AX07 Phenacemid 1,5 g O N02BE03 Phenacetin 1,8 g O R05XA12 Phenacetin, Kombinationen N02BE53 Phenacetin, Kombinationen exkl. Psycholeptika N02BE73 Phenacetin, Kombinationen mit Psycholeptika A03AA31 Phenamazid N02AD02 Phenazocin 3 mg P N02BB01 Phenazon 3 g O; 3 g R S02DA03 Phenazon R05XA08 Phenazon, Kombinationen N02BB51 Phenazon, Kombinationen exkl. Psycholeptika 3 g O bezogen auf Phenazon N02BB71 Phenazon, Kombinationen mit Psycholeptika N02BB06 Phenazonsalicylat N02BB56 Phenazonsalicylat, Kombinationen exkl. Psycholeptika N02BB76 Phenazonsalicylat, Kombinationen mit Psycholeptika G04BX06 Phenazopyridin 0,6 g O A08AA12 Phendimetrazin N06AF03 Phenelzin 60 mg O J01CE05 Pheneticillin 1 g O N03AX13 Pheneturid A10BA01 Phenformin 0,1 g O A10BD01 Phenformin und Sulfonamide N04AA09 Phenglutarimid R06AX04 Phenindamin B01AA02 Phenindion 0,1 g O D04AA38 Pheniramin R06AB05 Pheniramin 75 mg O N03AA02 Phenobarbital 0,1 g O,P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 67 von 92 ATC-CODE BEDEUTUNG DDD-INFO N05CA24 Phenobarbital C05BB05 Phenol D08AE03 Phenol N01BX03 Phenol Standarddosis: 1 Applikationsform P R02AA19 Phenol D08AE53 Phenol, Kombinationen A06AB04 Phenolphthalein 0,2 g O V04CH03 Phenolsulfonphthalein N01AH04 Phenoperidin P03AC03 Phenothrin P03AC53 Phenothrin, Kombinationen C04AX02 Phenoxybenzamin 30 mg O G04BD20 Phenoxybenzamin J01CE02 Phenoxymethylpenicillin 2 g O; 1,5 MIO E O Kinder DDD J01CE52 Phenoxymethylpenicillin, Kombinationen J01CE10 Phenoxymethylpenicillin-Benzathin 2 g O; 1,5 MIO E O Kinder DDD M03BA01 Phenprobamat 1,6 g O M03BA51 Phenprobamat, Kombinationen exkl. Psycholeptika M03BA71 Phenprobamat, Kombinationen mit Psycholeptika B01AA04 Phenprocoumon 3 mg O N03AD02 Phensuximid 2 g O A08AA01 Phentermin 15 mg O C04AB01 Phentolamin 10 mg O,P V03AB36 Phentolamin Standarddosis: 1 Applikationsform P M01AA01 Phenylbutazon 0,3 g O,P,R M02AA01 Phenylbutazon M01AA51 Phenylbutazon, Kombinationen R05XA10 Phenylbutazon, Kombinationen M01BA01 Phenylbutazon und Corticosteroide V04CN10 Phenylcyclohexylpiperidin-Testzone Standarddosis: 1 Test C01CA06 Phenylephrin 4 mg P R01AA04 Phenylephrin 4 mg N R01AB01 Phenylephrin 0,8 ml N R01BA03 Phenylephrin 40 mg O S01FB01 Phenylephrin S01GA05 Phenylephrin R01BA53 Phenylephrin, Kombinationen S01GA55 Phenylephrin, Kombinationen D08AK02 Phenylmercuriborat R02AA25 Phenylmercuriborat D08AK52 Phenylmercuriborat, Kombinationen D02AA02 Phenylmethylpolysiloxan A08AA13 Phenylpropanolamin R01BA01 Phenylpropanolamin 0,1 g O A08AA63 Phenylpropanolamin, Kombinationen R01BA51 Phenylpropanolamin, Kombinationen 0,1 g O bezogen auf Phenylpropanolamin D08AK10 Phenylquecksilber(II)-acetat D08AK60 Phenylquecksilber(II)-acetat, Kombinationen D09AA04 Phenylquecksilbernitrat G04BX12 Phenylsalicylat 2 g O N03AB02 Phenytoin 0,3 g O,P N03AB52 Phenytoin, Kombinationen D03AX31 Phloroglucin A03AX12 Phloroglucinol R05DA08 Pholcodin 50 mg O C01CA27 Pholedrin S01GA11 Pholedrin A05BP02 Phospholipide C10AX13 Phospholipide C10BE11 Phospholipide, Kombinationen V08DA04 Phospholipid-Mikrosphären Standarddosis: 1 Applikationsform V04BA05 pH-Testzone Standarddosis: 1 Test A07AB02 Phthalylsulfathiazol 9 g O B05BB11 Physiologische Kochsalzlösung Standarddosis: 1 Applikationsform P V07AB02 Physiologische Kochsalzlösung Standarddosis: 1 Applikationsform S01EB05 Physostigmin 0,4 ml V03AB19 Physostigmin B02BA01 Phytomenadion 20 mg O,P S01AX16 Picloxydin C02LG03 Picodralazin und Diuretika C02LG73 Picodralazin und Diuretika, Kombinationen mit Psycholeptika B01AC03 Picotamid L03AX05 Pidotimod 1,6 g O N07AX01 Pilocarpin 15 mg O; 10 mg P S01EB01 Pilocarpin 0,285 Lamelle; 0,4 ml; 0,4 g AS S01XA25 Pilocarpin S01EB51 Pilocarpin, Kombinationen D11AH02 Pimecrolimus 20 mg T R06AX23 Pimethixen N05AG02 Pimozid 4 mg O C02DG01 Pinacidil 50 mg O C02LX01 Pinacidil und Diuretika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 68 von 92 ATC-CODE BEDEUTUNG DDD-INFO A03AX04 Pinaverium 0,15 g O N05BA14 Pinazepam C07AA03 Pindolol 15 mg O S01ED07 Pindolol 0,2 ml AT C07CA03 Pindolol und andere Diuretika Standarddosis: 1 Applikationsform O C07EA03 Pindolol und Vasodilatatoren Standarddosis: 1 Applikationsform O A10BG03 Pioglitazon 30 mg O A10BD09 Pioglitazon und Alogliptin A10BD12 Pioglitazon und Sitagliptin N05AD05 Pipamperon 0,2 g O R05DB11 Pipazetat 80 mg O M03AC06 Pipecuroniumbromid J01MB04 Pipemidsäure 0,8 g O A03AB14 Pipenzolat 20 mg O A03CA41 Pipenzolat und Psycholeptika J01CA12 Piperacillin 14 g P J01CR05 Piperacillin und Enzym-Inhibitoren 14 g P bezogen auf Piperacillin P02CB01 Piperazin 3,5 g O als Hydrat R05DB23 Piperidion A03AA30 Piperidolat L01AX02 Pipobroman N06AX26 Pipofezin N05AC04 Pipotiazin 10 mg O; 5 mg P Depot N06BX15 Pipradrol 30 mg O R06AA10 Piprinhydrinat A05AX01 Piprozolin N06BX03 Piracetam 2,4 g O; 6 g P L01DB08 Pirarubicin R03AC08 Pirbuterol 1,2 mg Inhal.Aerosol R03CC07 Pirbuterol 30 mg O S01XB05 Pirenoxin A02BX03 Pirenzepin 0,1 g O; 20 mg P C03CA03 Piretanid 6 mg O L04AX05 Pirfenidon 2,4 g O C04AX13 Piribedil N04BC08 Piribedil 0,2 g O N06BX08 Pirisudanol N02AC03 Piritramid 45 mg P J01MB03 Piromidsäure 2 g O M01AC01 Piroxicam 20 mg O,P,R M02AA07 Piroxicam 17,5 mg T S01BC06 Piroxicam M01AE08 Pirprofen 0,8 g O C10AA08 Pitavastatin 2 mg O A03DA02 Pitofenon und Analgetika N06AX15 Pivagabin J01CA02 Pivampicillin 1,05 g O J01CA08 Pivmecillinam 0,6 g O L01DB11 Pixantron 9,64 mg P A15AA02 Pizotifen N02CX01 Pizotifen 1,5 mg O V03AX10 Placebo Standarddosis: 1 Applikationsform V04CX27 Plaque-Testzone G02BA01 Plastik-IUP G02BA03 Plastik-IUP mit Gestagen G02BA02 Plastik-IUP mit Kupfer D02AX07 Plazentaextrakt J05AX06 Pleconaril L03AX16 Plerixafor 16,8 mg P L01DC02 Plicamycin J07AL01 Pneumokokken, gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AL02 Pneumokokken, gereinigtes Polysaccharid-Antigen, konjugiert Standarddosis: 1 Einzeldosis P J07AL52 Pneumokokken, gereinigtes Polysaccharid-Antigen und Haemophilus influenzae B, konjugiert Standarddosis: 1 Einzeldosis P D06BB04 Podophyllotoxin A03AB11 Poldin 12 mg O C10AX08 Policosanol D08AE02 Policresulen G01AX03 Policresulen 90 mg V A01AE05 Polidocanol (Lauromacrogol 400) C05AD10 Polidocanol (Lauromacrogol 400) C05BB02 Polidocanol (Lauromacrogol 400) D04AB11 Polidocanol (Lauromacrogol 400) A01AE55 Polidocanol (Lauromacrogol 400), Kombinationen C05AD60 Polidocanol (Lauromacrogol 400), Kombinationen D04AB61 Polidocanol (Lauromacrogol 400), Kombinationen D08AC05 Polihexanid D08AC55 Polihexanid, Kombinationen J07BF04 Poliomyelitis, oral, bivalent, lebend abgeschwächt J07BF01 Poliomyelitis, oral, monovalent, lebend abgeschwächt J07BF02 Poliomyelitis, oral, trivalent, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07BF03 Poliomyelitis, trivalent, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 69 von 92 ATC-CODE BEDEUTUNG DDD-INFO R01BP01 Pollen G04CP03 Pollenextrakt L03AX07 Poly I:C L03AX08 Poly ICLC A06AC08 Polycarbophil-Calcium 2,5 g O D10AX07 Polydimethylsiliconharz L02AA02 Polyestradiolphosphat 6 mg P B02BC13 Polyglycolsäure A07AA05 Polymyxin B 3 MIO E O J01XB02 Polymyxin B 0,15 g P S01AA18 Polymyxin B S02AA11 Polymyxin B S03AA03 Polymyxin B A01AB05 Polynoxylin 0,18 g O D01AE05 Polynoxylin L01XA05 Polyplatillen D02AA03 Polysiloxan V03AE01 Polystyrolsulfonat 45 g O C03AA05 Polythiazid 1 mg O C03AB05 Polythiazid und Kalium 1 mg O bezogen auf Polythiazid S01XC01 Polyvinylalkohol Standarddosis: 0,4 ml AT; 0,4 g AS S01XC51 Polyvinylalkohol, Kombinationen Standarddosis: 0,4 ml AT; 0,4 g AS L04AX06 Pomalidomid 3 mg O L01XE24 Ponatinib 45 mg O L01XD01 Porfimer natrium J02AC04 Posaconazol 0,8 g O S01XC02 Povidon Standarddosis: 0,4 ml AT; 0,4 g AS D08AG02 Povidon-Iod 0,4 g T D09AA09 Povidon-Iod Standarddosis: 1 Applikationsform D11AC06 Povidon-Iod G01AX11 Povidon-Iod 0,2 g V R02AA15 Povidon-Iod S01AX18 Povidon-Iod D08AG52 Povidon-Iod, Kombinationen C07AB01 Practolol 0,3 g O C01BA08 Prajmalin 30 mg O L01BA05 Pralatrexat V03AB04 Pralidoxim N04BC05 Pramipexol 2,5 mg O Hydrochlorid N06BX16 Pramiracetam A03AX31 Pramiverin A03DC04 Pramiverin und Analgetika A10BX05 Pramlintid C05AD07 Pramocain D04AB07 Pramocain R03DC02 Pranlukast S01BC09 Pranoprofen A14AA07 Prasteron G03EA03 Prasteron und Estrogen B01AC22 Prasugrel 10 mg O C10AA03 Pravastatin 30 mg O C10BX02 Pravastatin und Acetylsalicylsäure C10BA03 Pravastatin und Fenofibrat N05BA11 Prazepam 30 mg O P02BA01 Praziquantel 3 g O C02CA01 Prazosin 5 mg O C02LE01 Prazosin und Diuretika Standarddosis: 1 Applikationsform O D07AC18 Prednicarbat 2,5 mg T L01AA08 Prednimustin A01AC04 Prednisolon A07EA01 Prednisolon C05AA04 Prednisolon D07AA03 Prednisolon D07XA02 Prednisolon D10AA06 Prednisolon H02AB06 Prednisolon 10 mg O,P R01AD02 Prednisolon S01BA04 Prednisolon S01CB02 Prednisolon S02BA03 Prednisolon S03BA02 Prednisolon A01AC54 Prednisolon, Kombinationen A07EA51 Prednisolon, Kombinationen Standarddosis: 1 Klysma C05AA54 Prednisolon, Kombinationen H02BX06 Prednisolon, Kombinationen 10 mg O R01AD52 Prednisolon, Kombinationen D07CA03 Prednisolon und Antibiotika S01CA02 Prednisolon und Antiinfektiva S02CA01 Prednisolon und Antiinfektiva S03CA02 Prednisolon und Antiinfektiva D07BA01 Prednisolon und Antiseptika S01BB02 Prednisolon und Mydriatika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 70 von 92 ATC-CODE BEDEUTUNG DDD-INFO V03AB05 Prednisolon und Promethazin H02AB56 Prednisolon-Depot 10 mg P Depot A07EA03 Prednison H02AB07 Prednison 10 mg O S01CA12 Prednison und Antiinfektiva H02AB11 Prednyliden 12 mg O N03AX16 Pregabalin 0,3 g O C01CA13 Prenalterol 10 mg P R05DB18 Prenoxdiazin R05DB68 Prenoxdiazin, Kombinationen C01DX02 Prenylamin 0,12 g O C01DX52 Prenylamin, Kombinationen R07AB06 Prethcamid 0,4 g O,P M03BX03 Pridinol N04AA14 Pridinol A03AB18 Prifiniumbromid N01BB04 Prilocain Standarddosis: 1 Applikationsform P N01BB54 Prilocain, Kombinationen Standarddosis: 1 Applikationsform P P01BA03 Primaquin 15 mg O Base R05CP03 Primelwurzel N03AA03 Primidon 1,25 g O J01FG01 Pristinamycin 2 g O V04CO03 pro BNP-Testzone Standarddosis: 1 Test M04AB01 Probenecid 1 g O C10AX02 Probucol C05AD05 Procain N01BA02 Procain Standarddosis: 1 Applikationsform P S01HA05 Procain C05AD55 Procain, Kombinationen N01BA52 Procain, Kombinationen Standarddosis: 1 Applikationsform P S02DA55 Procain, Kombinationen C01BA02 Procainamid 3 g O,P L01XB01 Procarbazin R03AC16 Procaterol 60 mcg Inhal.Aerosol R03CC08 Procaterol 0,1 mg O N05AB04 Prochlorperazin 0,1 g O,R; 50 mg P N04AA04 Procyclidin 25 mg O,P N04AA05 Profenamin N03AG05 Progabid G03DA04 Progesteron 0,3 g O; 5 mg P; 0,2 g R; 90 mg V G03DD01 Progesteron G03FA04 Progesteron und Estrogen M01AB14 Proglumetacin A02BX06 Proglumid 1,2 g O P01BB01 Proguanil 0,2 g O Hydrochlorid, (prophylaktische Tagesdosis) P01BB51 Proguanil, Kombinationen 0,4 g Proguanilhydrochlorid und 1 g Atovaquon zur Therapie; 0,1 g Proguanilhydrochlorid und 0,25 g Atovaquon zur Prophylaxe; 0,05 g Proguanilhydrochlorid und 0,125 g Atovaquon Kinder DDD zur Prophylaxe N06BX14 Prolintan N06BX64 Prolintan, Kombinationen N05AA03 Promazin 0,3 g O; 0,1 g P G03DB07 Promegeston G03CA09 Promestrien D04AA10 Promethazin N05CM22 Promethazin 75 mg O,P R06AD02 Promethazin 25 mg O,P,R A04AB58 Promethazin, Kombinationen N05CX13 Promethazin, Kombinationen R06AD52 Promethazin, Kombinationen N02BE05 Propacetamol 6 g P C01BC03 Propafenon 0,5 g O,P N05CA25 Propallylonal D08AC03 Propamidin S01AX15 Propamidin N01AX04 Propanidid D08AX03 Propanol D08AX53 Propanol, Kombinationen A03AB05 Propanthelin 60 mg O,P A03CA34 Propanthelin und Psycholeptika C01DA07 Propatylnitrat 30 mg O C01DA57 Propatylnitrat, Kombinationen G01AF14 Propenidazol P01AB05 Propenidazol N06BC02 Propentofyllin J01CE03 Propicillin 0,9 g O N05CM06 Propiomazin 25 mg O N01BX05 Propipocain Standarddosis: 1 Applikationsform P A01AE54 Propipocain, Kombinationen C05AD58 Propipocain, Kombinationen G04BD06 Propiverin 30 mg O; 20 mg O Kinder DDD N01AX10 Propofol 0,14 g P D03AX18 Propolis 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 71 von 92 ATC-CODE BEDEUTUNG DDD-INFO C07AA05 Propranolol 0,16 g O C07DA05 Propranolol, Thiazide und andere Diuretika Standarddosis: 1 Applikationsform O C07FA05 Propranolol und andere Antihypertonika Standarddosis: 1 Applikationsform O C07CA05 Propranolol und andere Diuretika Standarddosis: 1 Applikationsform O C07BA05 Propranolol und Thiazide Standarddosis: 1 Applikationsform O C07EA05 Propranolol und Vasodilatatoren Standarddosis: 1 Applikationsform O V08AD03 Propyliodon Standarddosis: 1 Applikationsform M02AD01 Propylnicotinat M02AD51 Propylnicotinat, Kombinationen H03BA02 Propylthiouracil 0,1 g O N02BB04 Propyphenazon 3 g R; 3 g O R05XA03 Propyphenazon, Kombinationen N02BB54 Propyphenazon, Kombinationen exkl. Psycholeptika N02BB74 Propyphenazon, Kombinationen mit Psycholeptika M01AX13 Proquazon 0,9 g O,R C01AB01 Proscillaridin 0,75 mg O C01AB51 Proscillaridin, Kombinationen V04CX22 Prostata spezifische Antigen-Testzone Standarddosis: 1 Test V03AB14 Protamin Standarddosis: 1 Applikationsform P D03BA53 Protease, Kombinationen B01AD12 Protein C V04CX25 Protein-C-Testzone Standarddosis: 1 Test B05BA04 Proteinhydrolysate Standarddosis: 1 Applikationsform P V04BA01 Protein-Testzone Standarddosis: 1 Test V06BA50 Proteinzusatznahrung, Kombinationen N05AX07 Prothipendyl 0,24 g O,P G01AX13 Protiofat J04AD01 Protionamid 0,75 g O J04AM07 Protionamid, Kombinationen V04CJ02 Protirelin N06AA11 Protriptylin 30 mg O A03AX07 Proxazol N05CA22 Proxibarbal S01HA04 Proxymetacain R03DA03 Proxyphyllin 1,2 g O,P,R C01EX67 Proxyphyllin, Kombinationen C04AD56 Proxyphyllin, Kombinationen R03DA53 Proxyphyllin, Kombinationen exkl. Psycholeptika R03DA73 Proxyphyllin, Kombinationen mit Psycholeptika R03DB03 Proxyphyllin und Sympathomimetika A06AX05 Prucaloprid 2 mg O J01MA17 Prulifloxacin 0,6 g O R01BA02 Pseudoephedrin 0,24 g O R01BA52 Pseudoephedrin, Kombinationen 0,24 g O bezogen auf Pseudoephedrin S01XA38 Pufferlösungen G04CP07 Pygeum africanum C05CA06 Pygnogenol P02CC01 Pyrantel 0,75 g O J04AK01 Pyrazinamid 1,5 g O M01AA07 Pyrazinobutazon P03AP01 Pyrethrum P03AP51 Pyrethrum, Kombinationen N07AA02 Pyridostigmin 0,18 g O; 10 mg P A11HA06 Pyridoxalphosphat A11HA02 Pyridoxin (Vitamin B6) 0,16 g O,P C04AC52 Pyridylcarbinol, Kombinationen P01BD01 Pyrimethamin 75 mg O P01BD51 Pyrimethamin, Kombinationen 75 mg O bezogen auf Pyrimethamin D11AC10 Pyrithion zink D11AX12 Pyrithion Zink N05CE03 Pyrithyldion 0,2 g O N06BX02 Pyritinol 0,6 g O R06AX08 Pyrrobutamin R06AX58 Pyrrobutamin, Kombinationen D01AA07 Pyrrolnitrin P02CX01 Pyrvinium 0,35 g O bezogen auf die Base 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 72 von 92 ATC-CODE BEDEUTUNG DDD-INFO Q P03AP02 Quassia N05CD10 Quazepam 15 mg O D08AK01 Quecksilberamidochlorid D08AK03 Quecksilberchlorid D08AK11 Quecksilbercyanid S01AX01 Quecksilber-haltige Verbindungen D08AK30 Quecksilberiodid N05AH04 Quetiapin 0,4 g O R06AX31 Quifenadin G02CB04 Quinagolid 75 mcg O C09AA06 Quinapril 15 mg O,P C09BA06 Quinapril und Diuretika Standarddosis: 1 Applikationsform O A14AA06 Quinbolon C03BA02 Quinethazon 50 mg O C03BB02 Quinethazon und Kalium 50 mg O bezogen auf Quinethazon G03AC04 Quingestanol G03AA02 Quingestanol und Ethinylestradiol C05AD11 Quinisocain C05AD61 Quinisocain, Kombinationen N06AA23 Quinupramin J01FG02 Quinupristin/Dalfopristin 1,5 g P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 73 von 92 ATC-CODE BEDEUTUNG DDD-INFO R A02BC04 Rabeprazol 10 mg O,P A07XA04 Racecadotril 0,3 g O; 0,1 g O Kinder DDD G03XC01 Raloxifen 60 mg O J05AX08 Raltegravir 0,8 g O L01BA03 Raltitrexed N05CH02 Ramelteon M02AA78 Ramifenazon, Kombinationen C09AA05 Ramipril 2,5 mg O C09BB07 Ramipril und Amlodipin Standarddosis: 1 Applikationsform O C09BA05 Ramipril und Diuretika Standarddosis: 1 Applikationsform O C09BB05 Ramipril und Felodipin Standarddosis: 1 Applikationsform O C09BA25 Ramipril und Hydrochlorothiazid Standarddosis: 1 Applikationsform O S01LA04 Ranibizumab 0,036 DE P L01AD07 Ranimustin A02BA02 Ranitidin 0,3 g O,P A02BA07 Ranitidinbismutcitrat 0,8 g O C01EB18 Ranolazin 1,5 g O N04BD02 Rasagilin 1 mg O V03AF07 Rasburicase 14 mg P C04AX39 Raubasin C04BA03 Raubasin, Kombinationen C02AP01 Rauwolfia-Alkaloide, ganze Wurzel C02AP51 Rauwolfia-Alkaloide, ganze Wurzel, Kombinationen C02LA08 Rauwolfia-Alkaloide, ganze Wurzel und Diuretika C02LA58 Rauwolfia-Alkaloide, ganze Wurzel und Diuretika, Kombinationen Standarddosis: 1 Applikationsform O N06AX18 Reboxetin 8 mg O C01EB21 Regadenoson 0,4 mg P L01XE21 Regorafenib N01AH06 Remifentanil C09XA01 Remikiren N05AL04 Remoxiprid 0,3 g O,P A10BX02 Repaglinid 4 mg O N05CA12 Reposal 0,2 g O R03AC15 Reproterol R03CC14 Reproterol R03AK05 Reproterol und Cromoglicinsäure, Dinatriumsalz C02AA01 Rescinnamin C02LA02 Rescinnamin und Diuretika C02LA52 Rescinnamin und Diuretika, Kombinationen mit anderen Mitteln Standarddosis: 1 Applikationsform O C02AA02 Reserpin 0,5 mg O,P N05AX15 Reserpin C02AA52 Reserpin, Kombinationen C02LA01 Reserpin und Diuretika Standarddosis: 1 Applikationsform O C02LA51 Reserpin und Diuretika, Kombinationen mit anderen Mitteln Standarddosis: 1 Applikationsform O C02LA71 Reserpin und Diuretika, Kombinationen mit Psycholeptika D10AX02 Resorcin S01AX06 Resorcin D10AX52 Resorcin, Kombinationen D06AX13 Retapamulin B01AD07 Reteplase 20 E P N03AX21 Retigabin 0,9 g O D10AD02 Retinol R01AX02 Retinol 800 E N S01XA02 Retinol A11JA01 Retinol, Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur D10AD52 Retinol, Kombinationen S01XA52 Retinol, Kombinationen A11CB02 Retinol und Colecalciferol A11CA01 Retinol (Vitamin A) 50 TSD E O,P B01AB08 Reviparin 1,43 TSD E P anti Xa G02CP04 Rhapontikrhabarberwurzel G02CP54 Rhapontikrhabarberwurzel, Kombinationen V10BX03 [186Re]Rheniumetidronat V10AX05 [186Re]Rheniumsulfid-Kolloid J05AB04 Ribavirin 6 g Inhal.lösung; 1 g O A11HA04 Riboflavin (Vitamin B2) M09AX10 Ribonucleinsäuren J01GB10 Ribostamycin 1 g P L01XE19 Ridaforolimus J04AB04 Rifabutin 0,15 g O J04AB02 Rifampicin 0,6 g O,P; 0,3 g O Kinder DDD J04AM06 Rifampicin, Pyrazinamid, Ethambutol und Isoniazid J04AM05 Rifampicin, Pyrazinamid und Isoniazid J04AM02 Rifampicin und Isoniazid J04AB03 Rifamycin 0,6 g P S01AA16 Rifamycin S02AA12 Rifamycin J04AB05 Rifapentin A07AA11 Rifaximin 0,6 g O D06AX11 Rifaximin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 74 von 92 ATC-CODE BEDEUTUNG DDD-INFO C02AC06 Rilmenidin L04AC04 Rilonacept 23 mg P J05AG05 Rilpivirin 25 mg O N07XX02 Riluzol 0,1 g O J05AC02 Rimantadin N02BG02 Rimazolium 0,9 g O H02AB12 Rimexolon 20 mg P intraartikulär S01BA13 Rimexolon R03AC05 Rimiterol 1,6 mg Inhal.Aerosol A08AX01 Rimonabant 20 mg O D03AP02 Ringelblumenblüten D03AP52 Ringelblumenblüten, Kombinationen B05BB14 Ringeracetatlösung Standarddosis: 1 Applikationsform P B05BB13 Ringerlactatlösung Standarddosis: 1 Applikationsform P B05BB12 Ringerlösung Standarddosis: 1 Applikationsform P M05BA07 Risedronsäure 5 mg O Osteoporose; 30 mg O bei Morbus Paget bezogen auf das Salz der Risedronsäure M05BB04 Risedronsäure, Calcium und Colecalciferol, Sequenzialpräparate 5 mg O bezogen auf das Salz der Risedronsäure M05BB02 Risedronsäure und Calcium, Sequenzialpräparate 5 mg O bezogen auf das Salz der Risedronsäure N05AX08 Risperidon 5 mg O; 2,7 mg P Depot R01AX05 Ritiometan G02CA01 Ritodrin 40 mg O,P J05AE03 Ritonavir 1,2 g O L01XC02 Rituximab 32 mg P B01AF01 Rivaroxaban 10 mg O N06DA03 Rivastigmin 9 mg O; 9,5 mg TD Freisetzungsrate N02CC04 Rizatriptan 10 mg O A06AB05 Rizinusöl 20 g O A03AA06 Rociverin M03AC09 Rocuroniumbromid 42 mg P M01AH02 Rofecoxib 25 mg O R03DX07 Roflumilast 0,5 mg O J01FA12 Rokitamycin 0,8 g O J01AA09 Rolitetracyclin 0,35 g P L01XX39 Romidepsin B02BX04 Romiplostim 30 mcg P C10AB07 Ronifibrat N04BC04 Ropinirol 6 mg O N01BB09 Ropivacain Standarddosis: 1 Applikationsform P L03AX02 Roquinimex A10BG02 Rosiglitazon 6 mg O M02AP09 Rosmarinöl M02BP03 Rosmarinöl M02AP59 Rosmarinöl, Kombinationen M02BP53 Rosmarinöl, Kombinationen J01MB01 Rosoxacin 0,3 g O C05BP01 Rosskastaniensamen C05CP01 Rosskastaniensamen 0,1 g O bezogen auf Aescin C05AP52 Rosskastaniensamen, Kombinationen C05BP51 Rosskastaniensamen, Kombinationen C05CP51 Rosskastaniensamen, Kombinationen C10AA07 Rosuvastatin 10 mg O J07BH01 Rotavirus, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07BH02 Rotavirus, pentavalent, lebend, Reassortanten Standarddosis: 1 Einzeldosis O J07BJ51 Röteln, Kombinationen mit Mumps, lebend abgeschwächt J07BJ01 Röteln, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J06BB06 Röteln-Immunglobulin N04BC09 Rotigotin 6 mg TD Pflaster A02BA06 Roxatidin 0,15 g O J01FA06 Roxithromycin 0,3 g O; 0,15 g O Kinder DDD V09GX04 [82Rb]Rubidiumchlorid N03AF03 Rufinamid 1,4 g O J01MA10 Rufloxacin 0,2 g O R06AX28 Rupatadin 10 mg O C05AX06 Ruscogenin C05CA51 Rutosid, Kombinationen C05CA01 Rutoside L01XE18 Ruxolitinib 30 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 75 von 92 ATC-CODE BEDEUTUNG DDD-INFO S G04CH01 Sabal serrulatum A07FA02 Saccharomyces boulardii 1 g O A07FA52 Saccharomyces boulardii, Kombinationen A16AB06 Sacrosidase 68 TSD E O G04CP06 Sägepalmenfrüchte 1,5 g O Droge; 0,32 g O lipophil ausgezogener Extrakt G04CP56 Sägepalmenfrüchte, Kombinationen A01AP03 Salbeiblätter D06BP02 Salbeiblätter D11AA01 Salbeiblätter D11AA51 Salbeiblätter, Kombinationen R03AC02 Salbutamol 0,8 mg Inhal.Aerosol/pulver; 10 mg Inhal.lösung R03CC02 Salbutamol 12 mg O,P R03AK04 Salbutamol und Cromoglicinsäure, Dinatriumsalz R03AL02 Salbutamol und Ipratropium bromid N02BA05 Salicylamid 3 g O R05XA09 Salicylamid, Kombinationen N02BA55 Salicylamid, Kombinationen exkl. Psycholeptika N02BA75 Salicylamid, Kombinationen mit Psycholeptika M01BA06 Salicylamid und Corticosteroide S02DA06 Salicylate A01AD71 Salicylate, Kombinationen D01AE12 Salicylsäure 0,3 g T Seborrhoea capitis D02AF01 Salicylsäure D10AX11 Salicylsäure D11AF01 Salicylsäure Standarddosis: 0,25 ml Lösung S01BC08 Salicylsäure D01AE62 Salicylsäure, Kombinationen D05AX56 Salicylsäure, Kombinationen D10AX61 Salicylsäure, Kombinationen D11AF51 Salicylsäure, Kombinationen Standarddosis: 0,25 ml Lösung M02AC57 Salicylsäure, Kombinationen M02BB56 Salicylsäure, Kombinationen R03AC12 Salmeterol 0,1 mg Inhal.Aerosol/pulver R03AK06 Salmeterol und Fluticason 0,1 mg Inhal.Aerosol/pulver bezogen auf Salmeterol D11AF52 Salpetersäure, Kombinationen N02BA06 Salsalat 3 g O A09AB03 Salzsäure B05XA13 Salzsäure V10AX02 [153Sm]Samariumhydroxyapatit-Kolloid V10BX02 [153Sm]Samariumlexidronam A16AX07 Sapropterin 0,7 g O J05AE01 Saquinavir 2 g O L03AA09 Sargramostim 0,45 mg P B01AD08 Saruplase C07AB11 S-Atenolol 50 mg O L01XA04 Satraplatin D03AX17 Sauermolkekonzentrat V03AN01 Sauerstoff A10BH03 Saxagliptin 5 mg O C03XP01 Schachtelhalmkraut V01AA04 Schimmel- und Hefepilze J06AA03 Schlangengift-Antiserum A03PP02 Schöllkraut 3,5 g O Droge; 21 mg O Gesamtalkaloide, berechnet als Chelidonin V04BA07 Schwangerschaftstest Standarddosis: 1 Test A05AP01 Schwarzrettichwurzel D10AB02 Schwefel M09AX08 Schwefel M02BX55 Schwefel, Kombinationen D02AX05 Schwefel-haltige Mittel D11AC08 Schwefel-haltige Verbindungen D11AC58 Schwefel-haltige Verbindungen, Kombinationen V08DA05 Schwefelhexafluorid A04AD01 Scopolamin N05CM05 Scopolamin 0,9 mg O,P S01FA02 Scopolamin A04AD51 Scopolamin, Kombinationen P01AB07 Secnidazol N05CA06 Secobarbital 0,1 g O L04AC10 Secukinumab V04CK01 Sekretin N04BD01 Selegilin 5 mg O D01AE13 Selendisulfid D11AC03 Selen-haltige Verbindungen A12CH02 Selen-haltige Zubereitungen V09DX01 [75Se]Selenium-tauroselcholinat V09XX03 [75Se]Selennorcholesterol L01AD03 Semustin R05CP13 Senegawurzel V04CZ01 Sennesfrüchteextrakt 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 76 von 92 ATC-CODE BEDEUTUNG DDD-INFO A06AB06 Sennoside A06AB56 Sennoside, Kombinationen R03DX06 Seratrodast H01AC04 Sermorelin V04CD03 Sermorelin B06AA12 Serrapeptase D01AC14 Sertaconazol N05AE03 Sertindol 16 mg O N06AB06 Sertralin 50 mg O G03GA03 Serumgonadotrophin 750 E P V03AE02 Sevelamer 6,4 g O N01AB08 Sevofluran A08AA10 Sibutramin 10 mg O D08AL30 Silber D09AA65 Silber, Kombinationen A02BX15 Silbereiweiß-Acetyltannat R01AX15 Silbereiweiß-Acetyltannat R02AA21 Silber-haltige Verbindungen S01AX02 Silber-haltige Verbindungen R02AA71 Silber-haltige Verbindungen, Kombinationen D08AL01 Silbernitrat C02KX04 Sildenafil 60 mg O G04BE03 Sildenafil 50 mg O A07BC07 Siliciumdioxid A12CX02 Siliciumdioxid D03AX70 Siliciumdioxid, Kombinationen A03AX13 Silikone 0,5 g O V04CZ09 Silikone A03AX63 Silikone, Kombinationen G04CA04 Silodosin 8 mg O V03AB48 Silymarin A02AD06 Simaldrat 5 g O A02AF04 Simaldrat und Karminativa C10AB06 Simfibrat C10AA01 Simvastatin 30 mg O C10BX04 Simvastatin, Acetylsalicylsäure und Ramipril C10BX01 Simvastatin und Acetylsalicylsäure 30 mg O bezogen auf Simvastatin C10BA02 Simvastatin und Ezetimib Standarddosis: 1 Applikationsform O C10BA04 Simvastatin und Fenofibrat V04CC03 Sincalid L03AX17 Sipuleucel-T L04AA10 Sirolimus 3 mg O J01GB08 Sisomicin 0,24 g P J01MA21 Sitafloxacin 0,1 g O A10BH01 Sitagliptin 0,1 g O A10BH51 Sitagliptin und Simvastatin C02KX03 Sitaxentan 0,1 g O L01XX37 Sitimagen ceradenovec R05CB07 Sobrerol G02CP06 Sojabohnen D11AB05 Sojabohnenöl D11AB55 Sojabohnenöl, Kombinationen D02AP53 Sojaöl, Kombinationen R04AX02 Sole G04BD08 Solifenacin 5 mg O V04CD05 Somatorelin H01CB01 Somatostatin 6 mg P H01AC02 Somatrem H01AC01 Somatropin 2 E P Kinder-DDD R05DP01 Sonnentaukraut A03AP11 Sonstige B05AX10 Sonstige Blutprodukte B05AX40 Sonstige Blutprodukte ohne Pharmazentralnummer L01XE05 Sorafenib 0,8 g O A06AD18 Sorbitol 10 g O A06AG07 Sorbitol Standarddosis: 1 Klysma B05BA13 Sorbitol Standarddosis: 1 Applikationsform P B05BC03 Sorbitol Standarddosis: 1 Applikationsform P B05CX02 Sorbitol Standarddosis: 1 Applikationsform P V04CC01 Sorbitol V04CZ08 Sorbitol B05BC53 Sorbitol, Kombinationen Standarddosis: 1 Applikationsform P C07AA07 Sotalol 0,16 g O C07AA57 Sotalol, Kombinationspackungen C07BA07 Sotalol und Thiazide Standarddosis: 1 Applikationsform O R01AC05 Spagluminsäure S01GX03 Spagluminsäure J01MA09 Sparfloxacin 0,2 g O C01BA04 Spartein 0,2 g P C05CX54 Spartein, Kombinationen J01XX04 Spectinomycin 3 g P A01AD72 Speichelersatzlösungen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 77 von 92 ATC-CODE BEDEUTUNG DDD-INFO V04CM05 Spermientest Standarddosis: 1 Test R05CP08 Spiköl J01FA02 Spiramycin 3 g O J01RA04 Spiramycin, Kombination mit anderen Antibiotika C09AA11 Spirapril 6 mg O C03DA01 Spironolacton 75 mg O C03EC41 Spironolacton und Bendroflumethiazid Standarddosis: 1 Applikationsform O C03ED01 Spironolacton und High-ceiling-Diuretika Standarddosis: 1 Applikationsform O C03EC21 Spironolacton und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C03EC01 Spironolacton und Low-ceiling-Diuretika Standarddosis: 1 Applikationsform O R05DP04 Spitzwegerich S01KX02 Spüllösungen Standarddosis: 1 Applikationsform B05AX04 Stammzellen aus Nabelschnurblut A14AA02 Stanozolol 5 mg O; 3,5 mg P J06BB08 Staphylococcus-Immunglobulin J05AF04 Stavudin 80 mg O J05AR07 Stavudin, Lamivudin und Nevirapin R03BB03 Stechapfel-haltige Zubereitungen C05CP05 Steinkleekraut D05AA02 Steinkohlenteer D11AB11 Steinkohlenteer D05AA52 Steinkohlenteer, Kombinationen D11AB61 Steinkohlenteer, Kombinationen R05CB11 Stepronin A06AC03 Sterculia 8 g O A06AC53 Sterculia, Kombinationen P02BX03 Stibophen R07AX01 Stickoxid V03AN04 Stickstoff N03AX17 Stiripentol 1 g O J01GA02 Streptoduocin 1 g P B01AD01 Streptokinase 1,5 MIO E P B01AY01 Streptokinase B01AD51 Streptokinase, Kombinationen B06AA55 Streptokinase, Kombinationen V04CX15 Streptokokken-Testzone Standarddosis: 1 Test A07AA04 Streptomycin J01GA01 Streptomycin 1 g P A07AA54 Streptomycin, Kombinationen J04AM01 Streptomycin und Isoniazid L01AD04 Streptozocin M05BX03 Strontium ranelat 2 g O V10BX01 [89Sr]Strontiumchlorid C01AH01 Strophantus gratus C01AC05 Strophantustinktur/-öl C01AC55 Strophantustinktur/-öl, Kombinationen exkl. Psycholeptika M03BA04 Styramat 0,5 g O G04BX10 Succinimid A07AB04 Succinylsulfathiazol A02BX02 Sucralfat 4 g O N01AH03 Sufentanil 30 mcg P; Standarddosis: 1 Applikationsform epidural V03AB35 Sugammadex 0,28 g P J01CG01 Sulbactam 1 g P J01CA16 Sulbenicillin 15 g P D01AE09 Sulbentin A11DA02 Sulbutiamin D01AC09 Sulconazol J01EB09 Sulfacarbamid D06BA63 Sulfacarbamid, Kombinationen J01EB59 Sulfacarbamid, Kombinationen S01AB04 Sulfacetamid D06BA62 Sulfacetamid, Kombinationen J01ED11 Sulfaclomid J01EC02 Sulfadiazin 0,6 g O J01EC52 Sulfadiazin, Kombinationen R05GC01 Sulfadiazin, Kombinationen 0,6 g O bezogen auf Sulfadiazin J01EE06 Sulfadiazin und Tetroxoprim J01EE02 Sulfadiazin und Trimethoprim D06BA01 Sulfadiazin-Silber D09AA16 Sulfadiazin-Silber D06BA51 Sulfadiazin-Silber, Kombinationen S01AB03 Sulfadicramid J01ED01 Sulfadimethoxin 0,5 g O J01EB03 Sulfadimidin 4 g O J01EE05 Sulfadimidin und Trimethoprim J01EB05 Sulfafurazol 4 g O,P S01AB02 Sulfafurazol A07AB03 Sulfaguanidin 4 g O A07AB06 Sulfaguanol J01EB01 Sulfaisodimidin 4 g O,P J01ED02 Sulfalen 0,1 g O J01ED09 Sulfamazon 1,5 g O,R 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 78 von 92 ATC-CODE BEDEUTUNG DDD-INFO D06BA06 Sulfamerazin J01ED07 Sulfamerazin 3 g O J01EE07 Sulfamerazin und Trimethoprim B05CA04 Sulfamethizol D06BA04 Sulfamethizol J01EB02 Sulfamethizol 4 g O S01AB01 Sulfamethizol J01EC01 Sulfamethoxazol 2 g O J01EE01 Sulfamethoxazol und Trimethoprim 1,6 g Sulfamethoxazol + 0,32 g Trimethoprim Erwachsenen DDD; 0,8 g Sulfamethoxazol + 0,16 g Trimethoprim Kinder DDD R05GC02 Sulfamethoxazol und Trimethoprim 1,6 g Sulfamethoxazol+0,32 g Trimethoprim Erwachsenen DDD J01EE51 Sulfamethoxazol und Trimethoprim, Kombinationen J01ED05 Sulfamethoxypyridazin 0,5 g O J01ED03 Sulfametomidin J01ED04 Sulfametoxydiazin 0,5 g O J01EE03 Sulfametrol und Trimethoprim J01EC03 Sulfamoxol 1 g O,P J01EE04 Sulfamoxol und Trimethoprim D06BA05 Sulfanilamid J01EB06 Sulfanilamid A01AB78 Sulfanilamid, Kombinationen D06BA55 Sulfanilamid, Kombinationen R05GC03 Sulfanilamid, Kombinationen J01ED06 Sulfaperin 0,5 g O J01ED08 Sulfaphenazol 1 g O S01AB05 Sulfaphenazol J01EB04 Sulfapyridin 1 g O A07EC01 Sulfasalazin 2 g O,R; Standarddosis: 1 Klysma M01CX02 Sulfasalazin 2 g O,R D06BA02 Sulfathiazol J01EB07 Sulfathiazol J01EB08 Sulfathiourea 6 g O G01AE01 Sulfatolamid B01AC12 Sulfinpyrazon M04AB02 Sulfinpyrazon 0,3 g O D06BA10 Sulfisomidin S01AB07 Sulfisomidin S01AB06 Sulfisoxazol D06BA64 Sulfisoxazol, Kombinationen J01RA02 Sulfonamide, Kombination mit anderen Antibiotika (exkl. Trimethoprim) G01BE50 Sulfonamiden und Corticosteroide, Kombinationen mit Antibiotika A02BX08 Sulglicotid M01AB02 Sulindac 0,4 g O,P,R C04AX19 Suloctidil B01AB11 Sulodexid 500 LSU O,P (Lipoprotein-Lipase-Releasing-Einheiten) N05AL01 Sulpirid 0,8 g O,P N07CA05 Sulpirid 0,225 g O; 0,2 g P G02AD05 Sulproston 0,5 mg P J01CR04 Sultamicillin 1,5 g O N03AX03 Sultiam 0,4 g O N05AL02 Sultoprid 1,2 g O N02CC01 Sumatriptan 20 mg N; 50 mg O; 6 mg P; 25 mg R L01XE04 Sunitinib 35 mg O M01AE07 Suprofen 0,4 g O P01CX02 Suramin natrium 0,27 g P R05CP17 Süßholzwurzel M03AB01 Suxamethonium M02AA22 Suxibuzon M02AP06 Symphytumwurzel und -kraut M02AP56 Symphytumwurzel und -kraut, Kombinationen C02LA09 Syrosingopin und Diuretika 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 79 von 92 ATC-CODE BEDEUTUNG DDD-INFO T D05AX04 Tacalcitol 4 mcg T N06DA01 Tacrin 0,12 g O D11AH01 Tacrolimus L04AD02 Tacrolimus 5 mg O,P C02KX05 Tadalafil 40 mg O G04BE08 Tadalafil 10 mg O N07XX08 Tafamidis 20 mg O S01EE05 Tafluprost 0,1 ml AT J01CA15 Talampicillin 2 g O R06AB07 Talastin N05CA07 Talbutal 0,1 g O A16AB11 Taliglucerase alfa C07AB13 Talinolol 0,1 g O L02BA01 Tamoxifen 20 mg O G04CA02 Tamsulosin 0,4 mg O G04CA52 Tamsulosin und Dutasterid Standarddosis: 1 Applikationsform O G04CA53 Tamsulosin und Solifenacin M02AP58 Tannennadelöl, Kombinationen N02AX06 Tapentadol 0,4 g O L03AX11 Tasonermin 3,5 mg P C09CA05 Tasosartan B05CA05 Taurolidin D05AX05 Tazaroten J01CG02 Tazobactam V09EA02 [99mTc]Technetium, Technegas V09IA01 [99mTc]Technetium-Anticarcinoembryoantigen-Antikörper V09HA03 [99mTc]Technetium-Antigranulozyten-Antikörper V09IA02 [99mTc]Technetium-Antimelanom-Antikörper V09GA07 [99mTc]Technetiumapcitid V09IA06 [99mTc]Technetiumarcitumomab V09AA02 [99mTc]Technetiumbicisat V09BA04 [99mTc]Technetiumbutedronat V09IA05 [99mTc]Technetiumdepreotid V09DA01 [99mTc]Technetium-Disofenin V09CA06 [99mTc]Technetium-Ethylendicystein V09DA02 [99mTc]Technetium-Etifenin V09AA01 [99mTc]Technetium-Exametazim V09HA02 [99mTc]Technetium-Exametazim-markierte Zellen V09GA05 [99mTc]Technetiumfurifosmin V09DA05 [99mTc]Technetium-Galtifenin V09CA04 [99mTc]Technetiumglucoheptonat V09CA05 [99mTc]Technetiumgluconat V09GA04 [99mTc]Technetium-Humanalbumin V09HA01 [99mTc]Technetium-Humanimmunglobulin V09IA07 [99mTc]Technetium-hynic-octreotid V09DA03 [99mTc]Technetium-Lidofenin V09EB01 [99mTc]Technetium-Macrosalb V09DA04 [99mTc]Technetium-Mebrofenin V09BA02 [99mTc]Technetiummedronat V09CA03 [99mTc]Technetiummertiatid V09DB02 [99mTc]Technetium-Mikrokolloid V09EB02 [99mTc]Technetium-Mikrosphären V09DB03 [99mTc]Technetium-Millimikrosphären V09DB01 [99mTc]Technetium-Nanokolloid V09EA03 [99mTc]Technetium-Nanokolloid V09BA01 [99mTc]Technetiumoxidronat V09CA01 [99mTc]Technetiumpentetat V09EA01 [99mTc]Technetiumpentetat V09FX01 [99mTc]Technetiumpertechnetat V09DB07 [99mTc]Technetiumphytat V09BA03 [99mTc]Technetiumpyrophosphat V09DB06 [99mTc]Technetium-Rheniumsulfid-Kolloid V09DB05 [99mTc]Technetium-Schwefel-Kolloid V09GA01 [99mTc]Technetiumsestamibi V09CA02 [99mTc]Technetium-Succimer V09IA03 [99mTc]Technetiumsuccimer, pentavalent V09HA04 [99mTc]Technetium-Sulesomab V09GA03 [99mTc]Technetiumteboroxim V09GA02 [99mTc]Technetiumtetrofosmin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 80 von 92 ATC-CODE BEDEUTUNG DDD-INFO V09IA04 [99mTc]Technetiumvotumumab V09DB04 [99mTc]Technetium-Zinn-Kolloid V09GA06 [99mTc]Technetium-Zinn-markierte Zellen P01AC04 Teclosan C01BD06 Tedisamil A16AX08 Teduglutid L01BC03 Tegafur L01BC73 Tegafur, Gimeracil und Oteracil 67,5 mg O bezogen auf Tegafur L01BC53 Tegafur, Kombinationen L01BC63 Tegafur und Uracil 0,432 g O bezogen auf Tegafur A06AX06 Tegaserod 12 mg O J01XA02 Teicoplanin 0,4 g P J05AE11 Telaprevir 2,25 g O J01XA03 Telavancin J05AF11 Telbivudin 0,6 g O J01FA15 Telithromycin 0,8 g O C09CA07 Telmisartan 40 mg O C09DB04 Telmisartan und Amlodipin Standarddosis: 1 Applikationsform O C09DA07 Telmisartan und Diuretika Standarddosis: 1 Applikationsform O J01MA05 Temafloxacin 0,8 g O N05CD07 Temazepam 20 mg O C09AA14 Temocapril 10 mg O J01CA17 Temocillin 2 g P L01XD05 Temoporfin 10,5 mg P L01AX03 Temozolomid 65 mg O,P L01XE09 Temsirolimus 7,1 mg P V04CN15 Tenamfetamin-Testzone (MDA) Standarddosis: 1 Test B01AD11 Tenecteplase 40 mg P M01AX23 Tenidap L01CB02 Teniposid C01DA38 Tenitramin J05AF07 Tenofovir disoproxil 0,245 g O J05AR03 Tenofovir disoproxil und Emtricitabin Standarddosis: 1 Applikationsform O P01AX08 Tenonitrozol M01AC02 Tenoxicam 20 mg O,P,R C02CA08 Terazosin 5 mg O G04CA03 Terazosin 5 mg O D01AE15 Terbinafin 10 mg T D01BA02 Terbinafin 0,25 g O R03AC03 Terbutalin 2 mg Inhal.Aerosol/pulver; 20 mg Inhal.lösung R03CC03 Terbutalin 15 mg O; 0,25 mg P R03CC53 Terbutalin, Kombinationen G01AG02 Terconazol 80 mg V R06AX12 Terfenadin 0,12 g O G02CB06 Tergurid H05AA02 Teriparatid 20 mcg P J04AK03 Terizidon H01BA04 Terlipressin 12 mg P G04BD05 Terodilin 50 mg O D08AX20 Terpentin-Derivate C07AA16 Tertatolol 5 mg O H01AC06 Tesamorelin L02BG09 Testolacton G03BA03 Testosteron 0,12 g O,R; 18 mg P; 60 mg SL; 3 mg TD; 50 mg TD Gel; 12 mg P bezogen auf Testosteronundecanoat G03EA02 Testosteron und Estrogen J06AA02 Tetanus-Antitoxin J06BB02 Tetanus-Immunglobulin J07AM01 Tetanus-Toxoid Standarddosis: 1 Einzeldosis P J07AM51 Tetanus-Toxoid, Kombinationen mit Diphtherie-Toxoid Standarddosis: 1 Einzeldosis P J07AM52 Tetanus-Toxoid, Kombinationen mit Tetanus-Immunglobulin N07XX06 Tetrabenazin 0,1 g O A01AE02 Tetracain C05AD02 Tetracain D04AB06 Tetracain N01BA03 Tetracain Standarddosis: 1 Applikationsform P S01HA03 Tetracain A01AE52 Tetracain, Kombinationen N01BA53 Tetracain, Kombinationen S02DA57 Tetracain, Kombinationen H01AA02 Tetracosactid 0,25 mg P A01AB13 Tetracyclin D06AA04 Tetracyclin D10AF05 Tetracyclin J01AA07 Tetracyclin 1 g O,P S01AA09 Tetracyclin S02AA08 Tetracyclin S03AA02 Tetracyclin J01AA57 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin R05GA02 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin R05GB02 Tetracyclin, Kombinationen 1 g O,P bezogen auf Tetracyclin 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 81 von 92 ATC-CODE BEDEUTUNG DDD-INFO B02BC03 Tetragalacturonsäurehydroxymethylester V04CN09 Tetrahydrocannabinol-Testzone Standarddosis: 1 Test P03BA04 Tetramethrin M03BX07 Tetrazepam 0,125 g O R01AA06 Tetryzolin 0,8 mg N R01AB03 Tetryzolin S01GA02 Tetryzolin 62,5 mcg AT S01GA52 Tetryzolin, Kombinationen M09AP03 Teufelskrallenwurzel 4,5 g O Droge V01AA09 Textilien L04AX02 Thalidomid 0,2 g O V09GX01 [201Tl]Thalliumchlorid R05DA10 Thebacon 15 mg O D04AA03 Thenalidin R06AX03 Thenalidin R06AX53 Thenalidin, Kombinationen C03BD01 Theobromin 4 g O R03DA07 Theobromin C01EX68 Theobromin, Kombinationen G02CX56 Theobromin, Kombinationen R03DA57 Theobromin, Kombinationen C01CA23 Theodrenalin C01EB22 Theophyllin R03DA04 Theophyllin 0,4 g O,P,R C01EX66 Theophyllin, Kombinationen R03DA54 Theophyllin, Kombinationen exkl. Psycholeptika R03DA74 Theophyllin, Kombinationen mit Psycholeptika R03DB04 Theophyllin und Sympathomimetika H03BB02 Thiamazol 10 mg O H03BB52 Thiamazol, Kombinationen N07XB52 Thiamin, Kombinationen A11DB04 Thiamin, Pyridoxin und Nicotinamid A11DA01 Thiamin (Vitamin B1) 50 mg O,P A11DB01 Thiamin (Vitamin B1) und Pyridoxin (Vitamin B6) A11DA06 Thiaminpyrophosphat J01BA02 Thiamphenicol 1,5 g O,P J01BA52 Thiamphenicol, Kombinationen R05GB04 Thiamphenicol, Kombinationen 1,5 g O,P bezogen auf Thiamphenicol R06AD06 Thiazinam 0,9 g O; 0,3 g R A04AB03 Thiethylperazin R06AD03 Thiethylperazin 13 mg O,P,R J04AM04 Thioacetazon und Isoniazid M03BX05 Thiocolchicosid D08AK06 Thiomersal N01AF03 Thiopental N05CA19 Thiopental N05AB05 Thiopropazat 60 mg O N05AB08 Thioproperazin 75 mg O; 20 mg P N05AC02 Thioridazin 0,3 g O V03AB06 Thiosulfat L01AC01 Thiotepa 1,62 g P P03AA05 Thiram D04AA01 Thonzylamin R01AC06 Thonzylamin R06AC06 Thonzylamin B02BC06 Thrombin B02BD30 Thrombin B02BC12 Thromboplastin B05AX02 Thrombozyten B05AX42 Thrombozyten ohne Pharmazentralnummer D11BH51 Thuja, Kombinationen R05CP01 Thymiankraut 6 g O Droge; 3,5 g O Fluidextrakt R05CP51 Thymiankraut, Kombinationen R04AP02 Thymianöl A01AB24 Thymol D02AX09 Thymol L03AX09 Thymopentin M09AH02 Thymus L03AX25 Thymuspeptide H01AB01 Thyrotropin 5 E P V04CJ01 Thyrotropin D01AC06 Tiabendazol P02CA02 Tiabendazol 3 g O C10AX03 Tiadenol N03AG06 Tiagabin 30 mg O C02AC07 Tiamenidin N06AX14 Tianeptin 37,5 mg O N05AL03 Tiaprid 0,4 g O,P M01AE11 Tiaprofensäure 0,6 g O,R L01XX18 Tiazofurin A01AB15 Tibezoniumiodid G03CX01 Tibolon 2,5 mg O 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 82 von 92 ATC-CODE BEDEUTUNG DDD-INFO B01AC24 Ticagrelor 0,18 g O J01CA13 Ticarcillin 15 g P J01CR03 Ticarcillin und Enzym-Inhibitoren 15 g P bezogen auf Ticarcillin D01AE08 Ticlaton B01AC05 Ticlopidin 0,5 g O A05BA07 Tidiacicarginin A03AB17 Tiemoniumiodid A03DA07 Tiemoniumiodid und Analgetika C03CC02 Tienilinsäure V01AA11 Tiere J01AA12 Tigecyclin 0,1 g P A09AA04 Tilactase P01AA05 Tilbroquinol N02AX01 Tilidin 0,2 g O,P N02AX51 Tilidin, Kombinationen 0,2 g O bezogen auf Tilidinhydrochlorid M05BA05 Tiludronsäure 0,4 g O bezogen auf die Säure der Tiludronsäure A03AB19 Timepidiumbromid C07AA06 Timolol 20 mg O S01ED01 Timolol 0,2 g AS; 0,2 ml AT S01ED51 Timolol, Kombinationen C07DA06 Timolol, Thiazide und andere Diuretika Standarddosis: 1 Applikationsform O S01ED62 Timolol und Bimatoprost 0,1 ml AT S01ED69 Timolol und Brimonidin 0,2 ml AT S01ED67 Timolol und Brinzolamid 0,2 ml AT S01ED66 Timolol und Dorzolamid 0,2 ml AT S01ED61 Timolol und Latanoprost 0,1 ml AT S01ED68 Timolol und Pilocarpin 0,2 ml AT C07BA06 Timolol und Thiazide S01ED63 Timolol und Travoprost 0,1 ml AT J01XD02 Tinidazol 1,5 g P P01AB02 Tinidazol 2 g O,R B01AB10 Tinzaparin 3,5 TSD E P anti Xa J04AD02 Tiocarlid 7 g O B01AA11 Tioclomarol D01AC07 Tioconazol 20 mg T G01AF08 Tioconazol 0,3 g V Ein-Dosis-Behandlung L01BB03 Tioguanin A16AA11 Tiopronin R05CB12 Tiopronin N05AF04 Tiotixen 30 mg O R03BB04 Tiotropium bromid 5 mcg Inhal.lösung bezogen auf die Base; 18 mcg Inhal.pulver bezogen auf die Base D10AB03 Tioxolon R05DB24 Tipepidin J05AE09 Tipranavir 1 g O; 0,64 g O Kinder DDD C01BG03 Tiracizin C01EB11 Tiracizin D11AX08 Tiratricol H03AA04 Tiratricol N07XX01 Tirilazad 0,42 g P B01AC17 Tirofiban 10 mg P A03AC05 Tiropramid M04AA02 Tisopurin D03AX69 Titandioxid, Kombinationen A07EA05 Tixocortol R01AD07 Tixocortol 8 mg N R01AD57 Tixocortol, Kombinationen M03BX02 Tizanidin 12 mg O J01GB01 Tobramycin 0,3 g Inhal.lösung; 0,112 g Inhal.pulver; 0,24 g P S01AA12 Tobramycin C01BB03 Tocainid 1,2 g O,P L04AC07 Tocilizumab 20 mg P A11HA08 Tocofersolan 0,2 g O bezogen auf Tocopherol; 0,425 g O Kinder DDD RRR-alpha-Tocopherol in Form v. Tocofersolan A11HA03 Tocopherol (Vitamin E) 0,2 g O,P A11JA03 Tocopherol (Vitamin E), Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur L04AA29 Tofacitinib N05BA23 Tofisopam A10BB05 Tolazamid 0,5 g O C04AB02 Tolazolin 75 mg O M02AX02 Tolazolin A10BB03 Tolbutamid 1,5 g O V04CA01 Tolbutamid N04BX01 Tolcapon 0,45 g O D01AE19 Tolciclat M01AG02 Tolfenaminsäure 0,3 g O,R G02CP55 Tollkirsche, Kombinationen J07BG01 Tollwut, inaktiviert, ganzes Virus Standarddosis: 1 Einzeldosis P J06BB05 Tollwut-Immunglobulin J06AA06 Tollwut-Serum M01AB03 Tolmetin 0,7 g O,R M02AA21 Tolmetin D01AE18 Tolnaftat 15 mg T 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 83 von 92 ATC-CODE BEDEUTUNG DDD-INFO D01AE68 Tolnaftat, Kombinationen C02AC04 Tolonidin 0,75 mg O V03AB46 Toloniumchlorid N06AG03 Toloxaton M03BX04 Tolperison 0,2 g O M03BX54 Tolperison, Kombinationen D04AA12 Tolpropamin A10XA01 Tolrestat G04BD07 Tolterodin 4 mg O C03XA01 Tolvaptan 30 mg O A13AA50 Tonika Standarddosis: 30 ml flüssige Zubereitung N02CX12 Topiramat 0,1 g O N03AX11 Topiramat 0,3 g O L01XX17 Topotecan 1 mg O; 0,65 mg P C03CA04 Torasemid 15 mg O,P L02BA02 Toremifen 60 mg O M02AP04 Torf A07XP06 Tormentillwurzelstock V10XA53 Tositumomab/[131I]Iod-Tositumomab D08AX04 Tosylchloramid-Natrium L01CX01 Trabectedin 0,13 mg P N02AX02 Tramadol 0,3 g O,P,R N02AX52 Tramadol, Kombinationen Standarddosis: 4 Applikationsformen O R01AA09 Tramazolin S01GA10 Tramazolin C09AA10 Trandolapril 2 mg O C09BB10 Trandolapril und Verapamil Standarddosis: 1 Applikationsform O B02AA02 Tranexamsäure 2 g O,P A11CC08 Trans-Calcifediol N06AF04 Tranylcypromin 10 mg O N06CA07 Tranylcypromin und Psycholeptika C01DX11 Trapidil L01XC03 Trastuzumab 20 mg P S01EE04 Travoprost 0,1 ml AT N06AX05 Trazodon 0,3 g O B02BD12 Trenonacog alfa L01AB02 Treosulfan A03AX09 Trepibuton V04CX28 Treponema pallidum-Testzone Standarddosis: 1 Test B01AC21 Treprostinil 4,3 mg P D10AD01 Tretinoin L01XX14 Tretinoin D10AD51 Tretinoin, Kombinationen R03AC09 Tretoquinol R03CC09 Tretoquinol 9 mg O; 0,2 mg P A01AC01 Triamcinolon C05AA12 Triamcinolon D07AB09 Triamcinolon 2 mg T für 0,1%-ige Zubereitungen D07XB02 Triamcinolon H02AB08 Triamcinolon 7,5 mg O,P R01AD11 Triamcinolon 0,22 mg N R03BA06 Triamcinolon S01BA05 Triamcinolon C05AA62 Triamcinolon, Kombinationen H02BX08 Triamcinolon, Kombinationen 7,5 mg P R01AD61 Triamcinolon, Kombinationen D07CB01 Triamcinolon und Antibiotika S01CA13 Triamcinolon und Antiinfektiva S02CA04 Triamcinolon und Antiinfektiva D07BB03 Triamcinolon und Antiseptika H02AB58 Triamcinolon-Depot 1,5 mg P Depot, bezogen auf Triamcinolonacetonid C03DB02 Triamteren 0,1 g O L01AC02 Triaziquon N05CD05 Triazolam 0,25 mg O; 0,2 mg SL C05AX05 Tribenosid C05CX01 Tribenosid D01AE03 Tribrommetacresol N01AB05 Trichlorethylen C03AA06 Trichlormethiazid 4 mg O C03AB06 Trichlormethiazid und Kalium 4 mg O bezogen auf Trichlormethiazid C03EA02 Trichlormethiazid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O P02BX04 Triclabendazol N05CM07 Triclofos 1 g O D08AE04 Triclosan D09AA06 Triclosan V04CN08 Tricyclische Antidepressiva-Testzone Standarddosis: 1 Test A03AB08 Tridihexethyl 0,125 g O A03CA42 Tridihexethyl und Psycholeptika N05AB06 Trifluoperazin 20 mg O,R; 8 mg P N05AD02 Trifluperidol 2 mg O A04AD06 Triflupromazin N05AA05 Triflupromazin 0,1 g O,P 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 84 von 92 ATC-CODE BEDEUTUNG DDD-INFO S01AD02 Trifluridin B01AC18 Triflusal 0,6 g O V04CX31 Triglycerid-Testzone Standarddosis: 1 Test N04AA01 Trihexyphenidyl 10 mg O H02CA01 Trilostan 0,36 g O C02CA03 Trimazosin 0,3 g O A03AA05 Trimebutin 0,6 g O G03FA16 Trimegeston und Estrogen G03FB11 Trimegeston und Estrogen C02BA01 Trimetaphan 0,25 g P C01EB15 Trimetazidin 40 mg O N03AC02 Trimethadion 1,5 g O J01EA01 Trimethoprim 0,4 g O,P; 0,15 g O Kinder DDD A03AX30 Trimethyldiphenylpropylamin 50 mg O,P C05CA59 Trimethylhesperidin, Kombinationen P01AX07 Trimetrexat 85 mg P N06AA06 Trimipramin 0,15 g O,P D05AD01 Trioxysalen D05BA01 Trioxysalen 10 mg O D04AA04 Tripelennamin R06AC04 Tripelennamin 0,15 g O N04AA13 Triperiden R06AX07 Triprolidin 7,5 mg O R06AX57 Triprolidin, Kombinationen H01CA07 Triptorelin 0,134 mg P Depotinjektion; 0,1 mg P L02AE04 Triptorelin 0,1 mg P; 0,134 mg P Depotinjektion A06AC07 Triticum (Weizenkleie) 10 g O R06AX21 Tritoqualin L01AA07 Trofosfamid A10BG01 Troglitazon 0,4 g O J01FA08 Troleandomycin 1 g O C01DA09 Trolnitrat 20 mg O C01DA59 Trolnitrat, Kombinationen D06BB02 Tromantadin J05AC03 Tromantadin S01AD13 Tromantadin B05BB03 Trometamol Standarddosis: 1 Applikationsform P B05XX02 Trometamol Standarddosis: 1 Applikationsform P B05BB53 Trometamol, Kombinationen Standarddosis: 1 Applikationsform P N04AA12 Tropatepin A03DA01 Tropenzilon und Analgetika S01FA06 Tropicamid S01FA56 Tropicamid, Kombinationen A03EA03 Tropinbenzilat, Kombinationen A03DC02 Tropinbenzilat und Analgetika A04AA03 Tropisetron 5 mg O,P V04CX51 Troponin, Kombinationen Standarddosis: 1 Test V04CX12 Troponin-Testzone Standarddosis: 1 Test A03AB20 Trospium G04BD09 Trospium 40 mg O A03DA06 Trospium und Analgetika A03EA04 Trospiumchlorid, Kombinationen G04BD59 Trospiumchlorid, Kombinationen J01MA13 Trovafloxacin 0,2 g O,P C05CA04 Troxerutin 0,9 g O S01XA26 Troxerutin C05CA54 Troxerutin, Kombinationen S01XA76 Troxerutin, Kombinationen A02BX11 Troxipid B06AA07 Trypsin D03BA01 Trypsin M09AB52 Trypsin, Kombinationen N06AX02 Tryptophan 1 g O Schlafstörungen R01AA11 Tuaminoheptan R01AB08 Tuaminoheptan V04CF01 Tuberkulin Standarddosis: 1 Test J07AN01 Tuberkulose, lebend abgeschwächt Standarddosis: 1 Einzeldosis P M03AA02 Tubocurarin R03AC11 Tulobuterol 1,6 mg Inhal.Aerosol R03CC11 Tulobuterol 4 mg O V04CX05 Tumor-Antigen-Testzone Standarddosis: 1 Test R05CA01 Tyloxapol 5 mg Inhal.lösung R05CA51 Tyloxapol, Kombinationen R01AA13 Tymazolin J07AR01 Typhus exanthematicus, inaktiviert, ganze Zelle J07AP03 Typhus, gereinigtes Polysaccharid-Antigen Standarddosis: 1 Einzeldosis P J07AP02 Typhus, inaktiviert, ganze Zelle J07AP10 Typhus, Kombinationen mit Paratyphustypen J07AP01 Typhus, oral, lebend abgeschwächt Standarddosis: 1 Einzeldosis O J07CA10 Typhus-Hepatitis A Standarddosis: 1 Einzeldosis P S01FB08 Tyramin V08AC09 Tyropansäure Standarddosis: 1 Applikationsform 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 85 von 92 ATC-CODE BEDEUTUNG DDD-INFO D06AX08 Tyrothricin R02AB02 Tyrothricin S01AA05 Tyrothricin D06AX58 Tyrothricin, Kombinationen R02AB52 Tyrothricin, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 86 von 92 ATC-CODE BEDEUTUNG DDD-INFO U C01EB09 Ubidecarenon G03AD02 Ulipristal 30 mg O G03XB02 Ulipristal 5 mg O D07AC21 Ulobetasol D01AE04 Undecylensäure D01AE54 Undecylensäure, Kombinationen S01EE02 Unoproston 0,2 ml AT C02CA06 Urapidil 0,12 g O; 50 mg P M04AX01 Uratoxidase N07XB54 Uridinphosphat, Kombinationen S01XB02 Uridin-5-monophosphat S01XB52 Uridin-5-monophosphat, Kombinationen V04BA09 Urobilinogen-Testzone Standarddosis: 1 Test G03GA04 Urofollitropin 75 E P B01AD04 Urokinase 3 MIO E P B01AY02 Urokinase 25 TSD E P A05AA02 Ursodeoxycholsäure 0,75 g O L04AC05 Ustekinumab 0,54 mg P A07XP02 Uzarawurzel 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 87 von 92 ATC-CODE BEDEUTUNG DDD-INFO V G02BB01 Vaginalring mit Gestagenen und Estrogenen 0,0357 DE V J05AB11 Valaciclovir 3 g O M01AH03 Valdecoxib 10 mg O J05AB14 Valganciclovir 0,9 g O N05CM13 Valnoctamid 0,6 g O N03AG01 Valproinsäure 1,5 g O,P,R N03AG02 Valpromid 1,5 g O L01DB09 Valrubicin C09CA03 Valsartan 80 mg O C09DX01 Valsartan, Amlodipin und Hydrochlorothiazid Standarddosis: 1 Applikationsform O C09DX02 Valsartan und Aliskiren C09DB01 Valsartan und Amlodipin Standarddosis: 1 Applikationsform O C09DA03 Valsartan und Diuretika Standarddosis: 1 Applikationsform O A07AA09 Vancomycin 2 g O J01XA01 Vancomycin 2 g P L01XE12 Vandetanib 0,3 g O H01CB04 Vapreotid G04BE09 Vardenafil 10 mg O N07BA03 Vareniclin 2 mg O J07BK01 Varicella, lebend abgeschwächt Standarddosis: 1 Einzeldosis P J06BB03 Varicella/Zoster-Immunglobulin H01BA01 Vasopressin 4 E P V04CX26 Vaterschaftstest mit DNA-Testzone Standarddosis: 1 Test M03AC03 Vecuronium 6,3 mg P A16AB10 Velaglucerase alfa 300 E P L01XE15 Vemurafenib 1,92 g O N06AX16 Venlafaxin 0,1 g O L01CP02 Venusfliegenfalle N05AL06 Veraliprid C08DA01 Verapamil 0,24 g O,P C08DA81 Verapamil in Kombination mit Chinidin C08DA51 Verapamil, Kombinationen C08GA02 Verapamil und Diuretika Standarddosis: 1 Applikationsform O C02KA01 Veratrum C02LK01 Veratrum und Diuretika D09AC02 Verbandmittel mit Aluminiumchloridhydroxid-Komplex D09AC04 Verbandmittel mit Ibuprofen D09AC03 Verbandmittel mit Perubalsam D09AX01 Verbandmittel mit Vaselin C01BG11 Vernakalant 0,2 g P bezogen auf Vernakalanthydrochlorid A01AB11 Verschiedene A01AD11 Verschiedene A01AP10 Verschiedene A03AH10 Verschiedene A03HH10 Verschiedene A05AP10 Verschiedene A05BH10 Verschiedene A07XH10 Verschiedene A12CH10 Verschiedene A13AH10 Verschiedene A13AP10 Verschiedene C01EH10 Verschiedene C02KH10 Verschiedene C04AH10 Verschiedene C05CH10 Verschiedene C06AH10 Verschiedene D02AD10 Verschiedene D11AC30 Verschiedene D11BH10 Verschiedene G02CH10 Verschiedene G04BH10 Verschiedene L03AH10 Verschiedene M02AH10 Verschiedene M02AX10 Verschiedene M09AH10 Verschiedene N02BH10 Verschiedene N02CH10 Verschiedene N05HH10 Verschiedene N06AH10 Verschiedene P03AP10 Verschiedene P03AX10 Verschiedene R01AP10 Verschiedene R01AX10 Verschiedene R01BH10 Verschiedene R02AA20 Verschiedene R02AH10 Verschiedene R05FH10 Verschiedene R07AH10 Verschiedene S01KX10 Verschiedene S01XC10 Verschiedene Standarddosis: 0,4 ml AT; 0,4 g AS 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 88 von 92 ATC-CODE BEDEUTUNG DDD-INFO S01XH10 Verschiedene V01AA20 Verschiedene V04CL10 Verschiedene V04CX10 Verschiedene A04AH10 Verschiedene homöopathische und anthroposophische Antiemetika B03AE10 Verschiedene Kombinationen D10AX30 Verschiedene Kombinationen R03DB20 Verschiedene Xanthine und Sympathomimetika S01LA01 Verteporfin D06BB15 Vidarabin J05AB03 Vidarabin S01AD06 Vidarabin D06BB65 Vidarabin, Kombinationen N03AG04 Vigabatrin 2 g O R03AK10 Vilanterol und Fluticason furoat R03AL03 Vilanterol und Umeclidinium bromid N06AX24 Vilazodon A10BH02 Vildagliptin 0,1 g O N06AX09 Viloxazin 0,2 g O N02BG05 Viminol N05CA09 Vinbarbital 0,1 g O L01CA01 Vinblastin 11,61 mg P Wochendosis C04AX17 Vinburnin C04AX07 Vincamin N06DX09 Vincamin 60 mg O S01XA39 Vincamin S01XA89 Vincamin, Kombinationen L01CA02 Vincristin 0,36 mg P L01CA03 Vindesin L01CA05 Vinflunin 27,43 mg P L01CA04 Vinorelbin 18 mg O; 7 mg P N06BX18 Vinpocetin 15 mg O N05CA08 Vinylbital 0,15 g O N01AA02 Vinylether N06DX08 Viquidil D06AX10 Virginiamycin C02KH01 Viscum album M09AH04 Viscum album L01XX43 Vismodegib 0,15 g O C04AX24 Visnadin 0,6 g O C04BA06 Visnadin, Kombinationen A11DB03 Vitamin B1, Vitamin B6 und Vitamin B12 A11JB01 Vitamin E, Kombinationen mit Mineralstoffen Standarddosis: 1 Tablette oder 30 ml Mixtur V04CB01 Vitamin-A-Konzentrate A11EX50 Vitamin-B-Komplex, andere Kombinationen A11EB01 Vitamin-B-Komplex mit Vitamin C Standarddosis: 1 Tablette oder 30 ml Mixtur A11EA01 Vitamin-B-Komplex, rein A11JC50 Vitamine, andere Kombinationen Standarddosis: 1 Tablette oder 30 ml Mixtur L04AD03 Voclosporin A10BF03 Voglibose B05AX07 Vollblut B05AX47 Vollblut ohne Pharmazentralnummer B02BD10 Von Willebrand-Faktor 6 TSD E P B02BD06 Von Willebrand-Faktor und Gerinnungsfaktor VIII in Kombination 7,2 TSD E P J02AC03 Voriconazol 0,4 g O,P L01XX38 Vorinostat L02BG05 Vorozol 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 89 von 92 ATC-CODE BEDEUTUNG DDD-INFO W C03XP03 Wacholderbeeren D11AB02 Wacholderbeeren B01AA03 Warfarin 7,5 mg O,P D11AG50 Waschlotionen/Seife, Kombinationen V07AB01 Wasser Standarddosis: 1 Applikationsform A01AB02 Wasserstoffperoxid 60 mg O D08AX01 Wasserstoffperoxid D08AX51 Wasserstoffperoxid, Kombinationen M09AP05 Weidenrinden 90 mg O bezogen auf Gesamtsalicin C05BP02 Weinlaubblätter C05CP02 Weinlaubblätter C05BP52 Weinlaubblätter, Kombinationen C05CP52 Weinlaubblätter, Kombinationen C01EP51 Weißdornblätter, Kombinationen C01EP01 Weißdornblätter mit Blüten 0,53 g O wässrig-ethanolischer Extrakt D03AP05 Weizenkeimextrakt A09AP02 Wermutkraut H03BP01 Wolfstrappkraut H03BP51 Wolfstrappkraut, Kombinationen R05CP15 Wollblumen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 90 von 92 ATC-CODE BEDEUTUNG DDD-INFO X N07XX03 Xaliproden C01CX07 Xamoterol 0,4 g O C04AD02 Xantinolnicotinat 0,9 g O,P C10AD08 Xantinolnicotinat 2 g O N06DX15 Xantinolnicotinat 0,9 g O,P N01AX15 Xenon V09EX02 [127Xe]Xenongas V09EX03 [133Xe]Xenongas D11AC09 Xenysalat A03CB37 Xenytropiumbromid und Psycholeptika J01XX02 Xibornol B01AE05 Ximelagatran 48 mg O C03BA10 Xipamid 20 mg O C03EA15 Xipamid und Kalium sparende Mittel Standarddosis: 1 Applikationsform O D08AE08 Xylenol B05BA14 Xylitol Standarddosis: 1 Applikationsform P R01AA07 Xylometazolin 0,8 mg N; 0,175 mg N Kinder DDD R01AB06 Xylometazolin S01GA03 Xylometazolin S01GA53 Xylometazolin, Kombinationen 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 91 von 92 ATC-CODE BEDEUTUNG DDD-INFO Y G04BE04 Yohimbin 15 mg O G04BE54 Yohimbin, Kombinationen V10AA01 [90Y]Yttriumcitrat-Kolloid V10AA02 [90Y]Yttrium-Eisen(III)hydroxid-Kolloid V10AA03 [90Y]Yttriumsilicat-Kolloid 2.2 ATC-Index mit DDD-Angaben, sortiert nach Wirkstoffen – Amtliche deutsche Fassung 2014 Seite 92 von 92 ATC-CODE BEDEUTUNG DDD-INFO Z R03DC01 Zafirlukast 40 mg O J05AF03 Zalcitabin 2,25 mg O N05CF03 Zaleplon 10 mg O J05AH01 Zanamivir 20 mg Inhal.pulver zur Therapie N02BG08 Ziconotid 12 mcg P J05AF01 Zidovudin 0,6 g O,P J05AR04 Zidovudin, Lamivudin und Abacavir Standarddosis: 2 Applikationsformen O J05AR05 Zidovudin, Lamivudin und Nevirapin J05AR01 Zidovudin und Lamivudin Standarddosis: 2 Applikationsformen O N06AB02 Zimeldin 0,2 g O A16AX05 Zinkacetat 0,15 g O B05XA12 Zinkchlorid A12CB02 Zinkgluconat 20 mg O,P D09AB02 Zink-haltige Verbände mit Zusätzen D09AB01 Zink-haltige Verbände ohne Zusätze S01AX03 Zink-haltige Verbindungen A12CB05 Zinkhydrogenaspartat 20 mg O,P A12CB06 Zinkorotat 20 mg O,P D02AB01 Zinkoxid Standarddosis: 2,5 g Salbe etc. D02AB51 Zinkoxid, Kombinationen Standarddosis: 2,5 g Salbe etc. C05AX04 Zinkpräparate A12CB03 Zinkprotein-Komplex 20 mg O,P A12CB01 Zinksulfat 20 mg O,P D02AB02 Zinksulfat D10BX02 Zinksulfat D02AB52 Zinksulfat, Kombinationen A01AA04 Zinn(II)-fluorid R05DB15 Zipeprol N05AE04 Ziprasidon 80 mg O; 40 mg P A09AB04 Zitronensäure 2 g O C09AA15 Zofenopril 30 mg O C09BA15 Zofenopril und Diuretika Standarddosis: 1 Applikationsform O M05BA08 Zoledronsäure 4 mg P Dosis pro Behandlungszyklus bei Tumor-induzierter Hyperkalzämie ; 14 mcg P Osteoporose bezogen auf die Säure der Zoledronsäure A02BX10 Zolimidin N02CC03 Zolmitriptan 2,5 mg N,O N05CF02 Zolpidem 10 mg O; 10 mg SL M01AB04 Zomepirac 0,3 g O N03AX15 Zonisamid 0,4 g O N05CF01 Zopiclon 7,5 mg O L01DB05 Zorubicin J07BK02 Zoster Virus, lebend abgeschwächt Standarddosis: 1 Einzeldosis P N05AX11 Zotepin 0,2 g O H03AA05 Zubereitungen aus Schilddrüsengewebe M02AB02 Zucapsaicin N05AF05 Zuclopenthixol 30 mg O,P; 15 mg P Depot * S01: Die DDD für Augentropfen, die nach Einheiten dosiert werden, basieren auf dem Volumen des Eindosisbehältnisses. Eine DDD entspricht im allgemeinen der Standarddosis 1 EDO. Abweichend hiervon basiert in der Gruppe S01E Glaukommittel und Miotika die DDD von Eindosisbehältnissen auf einer Einzeldosis (oder Eindosisbehältnis) und der Applikationsfrequenz. Eine DDD entspricht in dieser Gruppe einer Einzeldosis multipliziert mit der Applikationshäufigkeit pro Tag. Impressum Inhalt Vorwort 1 Nutzungshinweise für den amtlichen ATC-Index mit DDD-Angaben 2 ATC-Index mit DDD-Angaben Amtliche deutsche Fassung 2.1 sortiert nach ATC-Code A ALIMENTÄRES SYSTEM UNDSTOFFWECHSEL B BLUT UND BLUTBILDENDE ORGANE C KARDIOVASKULÄRES SYSTEM D DERMATIKA G UROGENITALSYSTEM UND SEXUALHORMONE H SYSTEMISCHE HORMONPRÄPARATE, EXKL. SEXUALHORMONE UND INSULINE J ANTIINFEKTIVA ZUR SYSTEMISCHENANWENDUNG L ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL M MUSKEL- UND SKELETTSYSTEM N NERVENSYSTEM P ANTIPARASITÄRE MITTEL, INSEKTIZIDE UND REPELLENZIEN R RESPIRATIONSTRAKT S SINNESORGANE V VARIA 2 ATC-Index mit DDD-Angaben Amtliche deutsche Fassung 2.2 sortiert nach Wirkstoffen A B C D E F G H I J K L M N O P Q R S T U V W X Y Z << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Dot Gain 20%) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Warning /CompatibilityLevel 1.4 /CompressObjects /Off /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages true /CreateJDFFile false /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /DetectCurves 0.0000 /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams false /MaxSubsetPct 100 /Optimize false /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveDICMYKValues true /PreserveEPSInfo true /PreserveFlatness true /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Preserve /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true /AgfaRotisSansSerif /AgfaRotisSansSerif-Bold /AgfaRotisSansSerifExtraBold /AgfaRotisSansSerif-Italic /AgfaRotisSansSerifLight /AgfaRotisSansSerifLight-Italic /AgfaRotisSemiSerif /AgfaRotisSemiSerif-Bold /AgfaRotisSerif /AgfaRotisSerif-Bold /AgfaRotisSerif-Italic ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages true /ColorImageMinResolution 300 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages true /ColorImageDownsampleType /Bicubic /ColorImageResolution 300 /ColorImageDepth -1 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.50000 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages true /GrayImageMinResolution 300 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Bicubic /GrayImageResolution 300 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50000 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages true /MonoImageMinResolution 1200 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Bicubic /MonoImageResolution 1200 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox true /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (None) /PDFXOutputConditionIdentifier () /PDFXOutputCondition () /PDFXRegistryName () /PDFXTrapped /False /Description << /CHS <FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000500044004600206587686353ef901a8fc7684c976262535370673a548c002000700072006f006f00660065007200208fdb884c9ad88d2891cf62535370300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002> /CHT <FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef653ef5728684c9762537088686a5f548c002000700072006f006f00660065007200204e0a73725f979ad854c18cea7684521753706548679c300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002> /DAN <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> /ESP <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> /FRA <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> /ITA <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> /JPN <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> /KOR <FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020b370c2a4d06cd0d10020d504b9b0d1300020bc0f0020ad50c815ae30c5d0c11c0020ace0d488c9c8b85c0020c778c1c4d560002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e> /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken voor kwaliteitsafdrukken op desktopprinters en proofers. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.) /NOR <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> /PTB <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> /SUO <FEFF004b00e40079007400e40020006e00e40069007400e4002000610073006500740075006b007300690061002c0020006b0075006e0020006c0075006f0074002000410064006f0062006500200050004400460020002d0064006f006b0075006d0065006e007400740065006a00610020006c0061006100640075006b006100730074006100200074007900f6007000f60079007400e400740075006c006f0073007400750073007400610020006a00610020007600650064006f007300740075007300740061002000760061007200740065006e002e00200020004c0075006f0064007500740020005000440046002d0064006f006b0075006d0065006e00740069007400200076006f0069006400610061006e0020006100760061007400610020004100630072006f0062006100740069006c006c00610020006a0061002000410064006f00620065002000520065006100640065007200200035002e0030003a006c006c00610020006a006100200075007500640065006d006d0069006c006c0061002e> /SVE <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> /ENU (Use these settings to create Adobe PDF documents for quality printing on desktop printers and proofers. Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.) /DEU <FEFF0044006900650073002000730069006e00640020006400690065002000450069006e007300740065006c006c0075006e00670020006600fc007200200064006900650020006e0065007500650020005000750062006c0069006b006100740069006f006e00730072006500690068006500200064006500730020005700490064004f002e0020005300740061006e0064003a00200032003000300036002d00300035002d00320033002e> >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /ConvertColors /NoConversion /DestinationProfileName () /DestinationProfileSelector /NA /Downsample16BitImages true /FlattenerPreset << /PresetSelector /MediumResolution >> /FormElements false /GenerateStructure true /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles true /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /NA /PreserveEditing true /UntaggedCMYKHandling /LeaveUntagged /UntaggedRGBHandling /LeaveUntagged /UseDocumentBleed false >> ] >> setdistillerparams << /HWResolution [2400 2400] /PageSize [612.000 792.000] >> setpagedevice

Pharmaceutical Forum First Progress Report, 29th of September 2006 Introduction This is the first progress report for the Pharmaceutical Forum. The Pharmaceutical Forum was established by Vice President Verheugen and Commissioner Kyprianou in June 2005 to examine the competitiveness of the European-based pharmaceutical industry and related public health issues. The Pharmaceutical Forum will take forward some of the most crucial issues outstanding from the G10 Medicines process, in particular Information to Patients, Relative Effectiveness and Pricing/Reimbursement. This report sets out the key areas where progress is being made and the directions for future work in the form of Conclusions for the Forum to adopt. Background The European pharmaceutical industry is making a major contribution to achieving the renewed Lisbon objectives and in fulfilling the growing needs in public health. It is a major contributor to Europe’s science base and employment. However, it is facing a number of serious challenges and is losing ground vis-à-vis its global competitors. In parallel, the ageing of the European population, the increasing health demands of the European patients and the high level of expenditure for innovative products are putting significant pressure on the social systems and public health budgets of Member States. Pharmaceuticals are subject to European as well as to national regulations. Fully in line with the responsibilities of Member States and the Community, the Pharmaceutical Forum will provide a platform to discuss and examine major concerns in relation to EU pharmaceutical policy. The importance of this sector for economic growth and public health and the need for action was stressed by the conclusions of the Competitiveness and Health Councils on 22nd September and 3rd December 2003 respectively in which ministers responded and welcomed the recommendations of the G10 Medicines Group. Some of the most crucial and outstanding issues of the G10 process, namely Information to Patients, Relative Effectiveness and Pricing/Reimbursement, have been selected as topics to be addressed in the Forum. Three technical Working Groups, supported by a Steering Committee, have been established on each of these three subjects in order to prepare the ground for the Forum discussions, share experiences and explore possible concrete and practical ways forward. Pharmaceutical Forum members are asked to consider and adopt the first draft conclusions of each of the three working groups. Collectively these conclusions will provide the mandate for the future work programme. 29/9/2006 First Pharmaceutical Forum 1/8 Information to patients Mission Statement The aim of the working group is to advise the Commission on ways to improve the quality of information on authorised medicines available to European patients. This will supplement the key role of health professionals in providing information to patients on medicines and health issues more generally. Patients are increasingly loaded with different information, provided by multiple parties with differing objectives and sent through multiple channels (E.g., the internet). This initiative will cover different topics that could help improve electronic and non-electronic information for patients and, in particular, develop a model for a Public Private Partnership that could implement the recommendations in an effective and sustainable way. It will also explore the feasibility of establishing a database of comprehensive and easily accessible information. Progress The Forum’s Working Group on Information to Patients was established in January 2006. It has developed the following three work streams to: a) develop a model package of information on diseases (using diabetes as a first example); b) consider areas for more harmonised action on information on medicines at an EU level; and c) improve patient access to good quality health information in healthcare environments (pharmacies and hospitals and ways to enhance access more generally). Underpinning the work is a questionnaire that has been issued to all participants (Member States and stakeholders) seeking details of the main mechanisms for distributing information on medicines and related health issues in each Member State. Conclusions 1. The Pharmaceutical Forum welcomes the proposal for developing guidance in Europe on the production of high quality and easily understandable and accessible information on diseases and medicines (including prevention where appropriate) for people in Europe. Such information should also take into account other relevant treatment options. New patient information guidance a. According to a set of core principles/criteria and appropriate assessment and validation procedures to be agreed, on the production of high quality health- related information for patients and citizens as a framework for information on diseases and medicines; b. In liaison with authorised databases on diseases and/or medicines, such as the planned European EudraPharm database; 29/9/2006 First Pharmaceutical Forum 2/8 c. Information creation and exchange based on partnerships to be defined according to different situations (e.g. differences between national health systems) – possible partners include Member States, patient/consumer organisations, physicians, pharmacists, other health care professionals, industry, social insurers and the wider stakeholder community including learned societies and academia; d. Develop an example on diabetes, based on the above mentioned criteria and principles, to demonstrate what might be possible; and e. Given the importance of the availability of information to patients in their language it must be capable of translation into all the official EU languages, and take into account different capabilities/competencies of patients and citizens to understand and use such information. Improving access to information 2. The Pharmaceutical Forum also welcomes the work being carried out to examine ways of improving patient access to high quality information on diseases and medicines (including prevention, where appropriate). Such information should also take into account other relevant treatment options. a. Through all healthcare environments, with work initially focusing on hospitals and pharmacies. b. By identifying tools that can help people in Europe to access and distinguish between good/objective and poor quality information on diseases and medicines and through all modern communication formats (including electronic and non- electronic means). c. By identifying valid national sources of information. d. By exploring methods to support National Competent Authorities to disseminate and manage information on diseases and medicines. 3. The Pharmaceutical Forum notes the contribution of the European Medicines Agency’s Working Group with Patient Organisations with regard to provision of statutory information (approved information for health care professionals and patients) to the work of the Information to Patients Working Group and the forthcoming launch of the EudraPharm Database. 4. The Pharmaceutical Forum also notes that the Commission will take account of the output of the Information to Patients Working Group in the context of the Commission’s report to the European Parliament and Council following the entry into force of Directive 2004/27/EC (amending Directive 2001/83/EC). 5. The Pharmaceutical Forum requests the Information to Patients Working Group to further develop its proposals, in particular in relation to implementation plans (including the important issues of user-testing and appropriate validation), and to report back to its next meeting in 2007. 29/9/2006 First Pharmaceutical Forum 3/8 Pricing and Reimbursement Mission Statement To examine alternative pricing and reimbursement mechanisms to support Member States in fulfilling their commitment towards the G10 recommendations, as well as towards the public health objectives of offering an equal access to medicines at an affordable overall cost. Several factors have generated significant changes in the pricing and reimbursement mechanisms of most Member States during the last years: raising expenditure on medicines, inequity of access to medicines in Europe, the call for early access to innovative medicines. This Workgroup aims to identify, explore and exchange alternative mechanisms that can help Member States answer these different challenges. It will be up to each Member State to see how to apply these mechanisms. Progress This Working Group was established in February 2006. To start, participants have raised a variety of concerns and problems, related to pricing and reimbursement, to be addressed within this group. Most of these were structured within four work streams which allow a more focused approach: • Control of expenditure, including use of price control and the variety and impact of national cost-containment strategies in line with Member State responsibilities for pricing & reimbursement decisions and ensuring the sustainability of their health systems. • Access to medicines, for all patients within Europe, including availability and affordability issues. • Market and trade, including organisation of distribution and cross-border trade of medicines. • Transparency of pricing and reimbursement data, exchanged between Member States. The participants within this Working Group started examining different national practices relating to the first three work streams, with the help of independent academic experts. The fourth work stream is more technical and will be addressed separately within the Transparency Directive Committee although with regular feedback on progress to the Working Group. Many participants raised the relationship with the content of the Working Group on Relative Effectiveness. The chairperson of this group therefore has ensured coordination with the other Working Group from the start of the process. 29/9/2006 First Pharmaceutical Forum 4/8 Conclusions 1. The Pharmaceutical Forum endorses the progress made in the Working Group on Pricing to find common ground between ensuring control of pharmaceutical expenditure for Member States, ensuring a timely and equitable access to pharmaceuticals for patients all over Europe and ensuring a reward for innovation within a competitive and dynamic market that also encourages Research & Development. 2. The Pharmaceutical Forum welcomes the active participation of all key stakeholders, patients, competent authorities, industry, physicians, pharmacists, wholesalers and social insurers. The Forum acknowledges that progress will require involvement and responsibilities of all participants. 3. The Pharmaceutical Forum takes note of the key findings of the first discussions within the Working Group on Pricing and Reimbursement: a. Regarding control of expenditure: Iin order to contain rapidly growing pharmaceutical expenditure, Member States make increasing use of a variety of mechanisms, aiming to control levels of price/reimbursement, to rationalise utilisation. To date there has been limited opportunity to evaluate positive and negative impacts of these different mechanisms, notably on containment of expenditure, affordability, access for patients and incentives for industry to bring further innovation. b. Regarding access to medicines: Not all patients within Europe have equal access to medicines. Different economic strengths of EU Member States may lead to different levels of affordability of medicines for both, patients and public authorities. Certain regulatory measures, market sizes and/or business considerations may lead to differences with regard to timing of availability of medicines. c. Regarding market and trade: Systems for distributing medicines are organised differently by each of the Member States, in function of local needs and environment. However, in order to ensure access of patients and citizens to all medicines there are specific public service obligations for the supply chain. Parallel imports are not part of organised systems of distribution but they can increase price competition and can offer an opportunity for cost-containment in several EU Member States. In other EU Member States, export of these medicines leads to pressure to accept higher prices and possible stock-ruptures. Such parallel trade might shift reward for innovation from industry towards trading parties. d. Regarding transparency of data: There is a concern on transparency, consistency and interchangeability of information and data, regarding pricing, price components and related issues, exchanged between different Member States and stakeholders. Although several good initiatives are ongoing in this field, there is need to further coordinate development and exchange of this type of information. 4. According to the mandate of this Working Group, and in line with national competencies of the Member States, the Pharmaceutical Forum encourages the Working Group on Pricing to further progress by: 29/9/2006 First Pharmaceutical Forum 5/8 a. Clarifying views on the value of innovation, taking account of national health systems in order to establish a sound basis for further discussion between different stakeholders. b. Increasing mutual knowledge on pricing and reimbursement systems and on different cost containment mechanisms by further exchanging experiences between Member States and stakeholders. While doing this, taking into account work already undertaken in different other initiatives. c. Identifying, assessing and recommending ways to ensure incentives for competition (including on price) and valuable innovation, in particular in line with the relevant G- 10 recommendations on pricing (Recommendations 3, 4, 5 & 6). d. Identifying, assessing and recommending ways to ensure a timely, equitable and affordable access to medicines for all patients in Europe both within industry business strategies and within the various cost-containment mechanisms applied within Member States. e. Identifying, assessing and recommending ways to minimize risks and adverse consequences for patients, Member States and industry as a result of trade between Member States. f. Following up on different projects and initiatives within Europe, aiming to increase transparency, consistency and interchangeability of information regarding prices, price components and related issues, e.g. within the Transparency Directive Committee. Where appropriate, giving inputs to increase coordination between these efforts. g. The Pharmaceutical Forum requests the working group to report back to its next meeting in 2007. 29/9/2006 First Pharmaceutical Forum 6/8 Relative Effectiveness Mission Statement To support Member States apply relative effectiveness systems in order to allow containment of pharmaceutical costs as well as a fair reward for innovation. Relative Effectiveness systems are relatively new for many Member States and rather complex. Nevertheless the outcome of relative effectiveness is promising as they will help allow identify the most valuable medicines, both in terms of clinical efficiency as of cost-effectiveness, and will help set a fair price for these medicines. The Working Group will bring experiences of different Member States and of industry together in order to further develop this promising field. Progress This Working Group was established in February 2006. As a consequence of the wide variety of national relative effectiveness schemes, it was decided to circulate a questionnaire to all participants to get an overview of different relative effectiveness practices in Member States. This served as basis for discussions on definitions and further objectives. This was supplemented by a further questionnaire focusing on the availability and use of different sources for information and data. The chairpersons of this group ensure coordination with the Working Group on Pricing and Reimbursement on the related issues. Conclusions 1. The Pharmaceutical Forum welcomes the work carried out by the Relative Effectiveness Working Group towards facilitating exchange of information among Member States to improve the quality of relative effectiveness assessments for all stakeholders and to improve the cooperation between Member States. 2. It particularly welcomes the report produced by the Working Group on Relative Effectiveness Assessments in the EU which gives more insight into the goals and timing of the assessments in the different Member States as well as the organisation, the transparency, the data used and other methodological aspects of the assessment. 3. It also endorses the proposal for the future work plan which has three objectives: - to develop mechanisms in order to increase the quality and quantity of the available data to carry out an assessment and to consider ways to manage uncertainty. The lack of reliable data (notably to support the initial pricing and/or reimbursement decision) is one of the key challenges to be addressed, and EU cooperation in this field will help to improve the quality of data for Member States and to achieve efficient use of limited resources. The Working Group will also consider possible ways to share information on assessments made and decisions taken following those assessments, for example by establishing a database/website. In doing so, the different national legislative backgrounds for these assessments and decisions must be taken into account. - to improve the degree of consensus at European level between Member States on the nature of the data required to carry out cost-effectiveness, relative effectiveness and relative efficacy assessments and on the procedure and the time schedule to provide these data. 29/9/2006 First Pharmaceutical Forum 7/8 - to develop a proposal to analyse current assessment processes and to identify good practices. This work could be used to address challenges in the assessment processes in Member States. The Pharmaceutical Forum requests the Working Group to report back on the implementation of this work plan prior to its next meeting in 2007. 29/9/2006 First Pharmaceutical Forum 8/8

26/6/2007 Second Pharmaceutical Forum 1/17 Pharmaceutical Forum Second Progress Report, 26 June 2007 Introduction This is the second Progress Report of the Pharmaceutical Forum. It describes the progress made so far, sets out key deliverables for the Forum and implementation plans as requested by the Pharmaceutical Forum in 2006. Following the political directions given by the first Forum on 29 September 2006, the working groups on information to patients, relative effectiveness assessments and pricing & reimbursement have developed proposals to address the challenges facing Europe as set out in the G10 Medicines recommendations. In addition to this report, deliverables by the working groups are included in the annex to demonstrate the concrete work undertaken. This report is divided into three sections which focus on each of the working groups providing a brief summary of the progress made so far, concrete results and implementation proposals as well as issues for the Forum to consider and discuss. The implementation of the work should be developed into concrete work packages following the political direction given by the Pharmaceutical Forum at its meeting on 26 June 2007. The proposals and work packages which are described in this report aim to provide a framework for discussion for the 2007 Pharmaceutical Forum. Following discussions on the key issues related to the work of the working groups, the Pharmaceutical Forum process should move forward with the implementation of the work through different means and mechanisms in 2008. The implementation plans will be taken forward by all stakeholders to ensure their success in practice. Members of the Pharmaceutical Forum are asked to consider and adopt the draft conclusions of each of the three working groups. Collectively these conclusions will provide the mandate for implementation of proposals. 26/6/2007 Second Pharmaceutical Forum 2/17 Relative Effectiveness Progress The 2006 Pharmaceutical Forum adopted the conclusions of the relative effectiveness working group and in particular, it endorsed the draft work plan with three key objectives: 1.) To develop mechanisms in order to increase the quality and quantity of the available data to carry out an assessment and to consider ways to manage uncertainty. The working group was also asked to consider possible ways to share information on assessments made and decisions taken following those assessments, for example by establishing a database/website. 2.) To improve the degree of consensus at European level between Member States on the nature of the data required to carry out cost-effectiveness, relative effectiveness and relative efficacy assessments and on the procedure and the time schedule to provide these data and; 3.) To develop a proposal to analyse current assessment processes and to identify good practices. This work could be used to address challenges faced by both payers and industry in the assessment processes in Member States. In addition, the Pharmaceutical Forum suggested that the working group would consider, in consultation with industry, how to test methodologies for example by choosing one or more candidate products to go through an assessment. Concretely, the working group has prepared a working document which aims to provide an overview on the critical issues in relation to the data needed to perform a relative effectiveness assessment and methodologies used to undertake such assessments. Although it remains in draft form at this stage, the working document (titled "Report on Data and Methodology in relation to Relative Effectiveness") already shows that Member States encounter similar significant difficulties when undertaking assessments, particularly at early stages such as soon after marketing authorisations are granted. In addition, the pharmaceutical industry encounters difficulties in this context. The draft report makes clear the potential for improving both the principles and the practicality of generating, sharing and using data for relative effectiveness assessments at the national level. The working group has agreed that it will focus on relative effectiveness assessments at this stage. However, issues related to cost-effectiveness would be considered later if necessary. The working group agreed on a set of working definitions which could be also used in the Pharmaceutical Forum meeting to ensure that the terminology is consistent among the members. These working definitions are set out below for ease of reference1. 1 Efficacy is the extent to which an intervention does more good than harm under strictly controlled circumstances. Effectiveness is the extent to which an intervention does more good than harm when provided under the usual circumstances of health care practice. Relative effectiveness can be defined as the extent to which an intervention does more good than harm compared to one or more intervention alternatives for achieving the desired results when provided under the usual circumstances of practice. Relative effectiveness assessments are carried out to investigate to which extent a medicinal product does more good than harm compared to one or more other medicinal products or other alternative health interventions for achieving the desired results when provided under the usual circumstances of health care practice. The process of getting best possible information from relevant relative effectiveness data is referred to as the assessment. The working group has also agreed that the quality of life dimension should be part of assessments of relative effectiveness. 26/6/2007 Second Pharmaceutical Forum 3/17 The working group has proposed ways forward in the following areas: • Working towards a European consensus on general principles and good practices for relative effectiveness assessment, with a toolbox providing support on areas such as methodologies or mechanisms to interpret data, coordination of requests to companies for further work, and exchanging experience and skills; • Improving the data available (including appropriate comparators where available) and their accessibility during product development, at the time of marketing authorisation and afterwards. Recommendations include early dialogue during product development between national authorities and companies to improve the generation of appropriate data so far as possible; agreement on sharing all relevant data with relative effectiveness assessment authorities; ways of generating additional data to assist in relative effectiveness assessment; and exploring the possibility of collaboration among Member States as well as stakeholders for studies or trials of products2; • Strengthening networks among relative effectiveness assessment authorities and relevant stakeholders across Europe and considering mechanisms to help share data, provide support and develop common principles at European level3. Conclusions 1. The Pharmaceutical Forum welcomes the progress made in the working group and its overall approach, and agrees with developing ways to support Member States on relative effectiveness by improving consensus on general principles and good practices when performing relative effectiveness assessments. This will also contribute to strengthening of the competitiveness of the European based pharmaceutical industry. 2. Any relative effectiveness assessment will only be as good as the data on which it is based and its methodology. Relative effectiveness assessments and consequent reimbursement decisions should thus be updated as new data becomes available. The Pharmaceutical Forum agrees that in principle all data that are available at the time of the marketing authorisation should be made available to the agencies in Member States responsible for relative effectiveness assessments in as transparent and complete manner as possible. The Pharmaceutical Forum encourages the relevant authorities and companies to explore ways to communicate and collaborate prior to the market authorisation decision as well as after it in maximising availability and best use of data relevant to relative effectiveness assessment. Cost effectiveness measures the effect of an intervention in relation to the resources it consumes (“Is it worth it?”). Relative efficacy is when an intervention (a product) is compared to other existing interventions in a strictly controlled setting of a clinical trial Reimbursement in the context of this report includes all mechanisms used at national level to apply the principle of solidarity to pharmaceutical products, as for example, pricing decisions, purchasing decisions by authorities, or any other mechanisms used by Member States. 2 ESIP has expressed a reserve. 3 AIM and ESIP have expressed a reserve. 26/6/2007 Second Pharmaceutical Forum 4/17 3. The Pharmaceutical Forum requests that further consensus on principles for relative effectiveness assessment be developed by exploring good practices in the Member States and by developing a toolbox and principles to provide support on areas such as robust methodologies or mechanisms to best use data, coordination of requests to industry, establishing training or other measures4. 4. The Pharmaceutical Forum welcomes the proposals for identifying specific products or groups of products to provide real-life examples against which these principles, methodologies or mechanisms can be tested without aiming to centralise relative effectiveness assessment at the EU level. 5. The Pharmaceutical Forum requests the working group also to explore different ways of encouraging the production of additional relevant data, such as: • Identifying data sets (including the possibility to have appropriate comparators) that can be helpful for relative effectiveness assessments; • Working towards consensus on good practices for concept design and analysis on what kind of new study types/study designs would be needed to improve the information available about products in real-life use; • Elaborating on methods for the transferability of data on relative effectiveness assessments between Member States • Providing Member States with options for encouraging the production of more relevant data or alternative routes for producing additional data; • Considering (with the involvement of the European Medicines Agency) how EPARs and NPARs could make a better contribution to relative effectiveness assessments; • Recognising the value of innovation building on the work of the working group on pricing. 6. The Pharmaceutical Forum supports the aim of sharing data on relative effectiveness assessment at European level and developing sustainable collaboration and networks between the competent authorities of the Member States and other stakeholders, and requests specific proposals for ways of achieving this. 4 ESIP has expressed a reserve. 26/6/2007 Second Pharmaceutical Forum 5/17 Pricing and Reimbursement Progress The working group on pricing has met four times since the first meeting of the Pharmaceutical Forum. These sessions involved all stakeholders and Member States. Additional debates took place within smaller groups and within the Transparency Committee (Member States only) and within a taskforce on innovation. Progress was made in three work streams that were called for by the Pharmaceutical Forum: a. “Clarifying views on the value of innovation, taking account of national health systems in order to establish a sound basis for further discussion between different stakeholders.” The taskforce on innovation has developed an exhaustive list of valuable benefits than can be expected from innovative new medicines. This list was incorporated in a questionnaire to the relevant authorities in all Member States. Fourteen have replied on how they value these different benefits. This has allowed identification of a broad commonality in views as well as some differences between the different authorities. Additional perspectives were provided by the patient’s representatives. b. “Increasing mutual knowledge on pricing and reimbursement systems and on different cost containment mechanisms by further exchanging experiences between Member States and stakeholders. While doing this, taking into account work already undertaken in different other initiatives. “ Contracted experts have built an overview of the application of different pricing and reimbursement practices in the individual EU Member States. In addition, they have collected detailed information on the concrete application of 6 selected practices (reference pricing, cost-sharing, payback, price-control, prescription information and generic substitution). 24 Member States (+ Norway), industry and several stakeholders have provided inputs and the results have been discussed repeatedly in the working group. In parallel, a so-called “toolbox” was developed with guiding principles, which aim to balance the overall impact of national pricing and reimbursement policies between (1) accessibility of patients to medicines, (2) containment of the healthcare budget and (3) reward for industry and incentives to come up with further innovations. This effort was built on the collection and exchange of knowledge and experiences of individual pricing and reimbursement practices. A paper with the developed principles is attached at Annex A. c. “Following up on different projects and initiatives within Europe, aiming to increase transparency, consistency and interchangeability of information regarding prices, price components and related issues, e.g. within the Transparency Directive Committee. Where appropriate, giving inputs to increase coordination between these efforts.” This work stream has been taken forward within the Transparency Committee (with the Member States only). Experts have developed and managed a pilot project on price transparency. 21 countries provided price levels of 15 best-selling and/or recent medicines in a standard format. A first discussion on the preliminary results has revealed initial findings e.g., in terms of price-differences of a similar product between Member States, in terms of availability of medicines on individual EU markets and in terms of costs of distributing medicines to the market. The findings led to interest in organizing a more regular price comparison exercise, focusing on the medicines of interest to Member 26/6/2007 Second Pharmaceutical Forum 6/17 States. In addition, information has been exchanged between 17 Member States on their public websites with national price information. The Pharmaceutical Forum 2006 had also called for progress in three other work streams. The topics on access to medicines and on implementation of the G-10 Recommendations have been discussed occasionally. These two work streams, and a potential third work stream on trade, need to be elaborated further after June 2007. Conclusions 1. The Pharmaceutical Forum endorses the progress made in the Working Group on Pricing to find common ground between participants. It welcomes the shared understanding of the need to ensure (1) timely and equitable access to pharmaceuticals for patients all over Europe, (2) control of pharmaceutical expenditure for Member States, and (3) reward for valuable innovation within a competitive and dynamic market that also encourages Research & Development. 2. The Pharmaceutical Forum welcomes the constructive participation of all key stakeholders, patients, competent authorities, industry, physicians, pharmacists, wholesalers and social insurers. The Forum acknowledges that progress will require further involvement and commitment of all participants. 3. The Pharmaceutical Forum welcomes the key findings of the work within or through the Working Group on Pricing, in particular: a. The report “Guiding principles for good practices implementing a pricing and reimbursement policy”, a first outline on how to ensure a positive and balanced impact of pricing practices in terms of (1) access to medicines, (2) reward for innovation and (3) containment of costs . b. A toolbox with, the first draft of templates summarizing experiences of 6 selected pricing and reimbursement practices, including a description, a listing of potential benefits and risks and references to sources of evidence. c. The report “Characterisation of the value of innovative medicines”, a survey of Member States' competent authorities on what they consider to be valuable dimensions of innovation and indicating significant commonalities in their views. 4. The Pharmaceutical Forum also notes the work in the Transparency Committee on (1) a pilot exercise on exchange of price information between Member States, including the collection and comparison of levels of prices and price-components for 15 best-selling and/or recent medicines and on (2) the exchange of public websites with national price information between Member State authorities. 5. According to the mandate of this Working Group, and in line with national competencies of the Member States, the Pharmaceutical Forum encourages the Working Group on Pricing to make further progress by: a. Fine-tuning and developing more convergence on the principles in the report “Guiding principles for good practices implementing a pricing and reimbursement policy”. In particular, developing solutions for the access-problems and trade- problems described, in collaboration with the concerned Member States and stakeholders. 26/6/2007 Second Pharmaceutical Forum 7/17 b. Further developing the templates summarizing experiences with selected pricing and reimbursement practices. E.g. by updating the existing templates or by creating templates on other practices of interest to the Member States. c. Communicate and discuss the common views from Member States on what is considered valuable innovation, in particular with parties involved in Health and R&D policies and in Health Technology Assessments, including the Working Group on Relative Effectiveness. d. The Pharmaceutical Forum requests the working group to report back to its next meeting in 2008. 6. The Member States in the Pharmaceutical Forum also encourage the Transparency Committee to elaborate further the exercise on exchange of price information, in order to collect and compare price levels of individual medicines in EU Member States where considered particularly useful. 26/6/2007 Second Pharmaceutical Forum 8/17 Information to patients on diseases and treatment options5 Progress Following the mandate provided by the Pharmaceutical Forum in 2006, the working group focused on the following areas of work; 1. Development of information to patients on diseases and treatment options Core Quality Principles The working group developed a set of core quality principles on information to patients on diseases and treatment options. These principles were designed to provide a basis for the development of quality health information on diseases and related issues. The working group agreed on the usefulness of establishing core quality principles which should be applied to all such information at the EU level and developed the list as set out in paragraph 6. of the Conclusions. The Steering Committee agreed that the working definitions of objective and unbiased information should be the following: Information is: Objective when it is based on facts and not influenced by prejudices or personal perceptions; Unbiased when it is impartial, non-directive and balanced. These two definitions do not relate to the source of information which is an issue set out under the transparency principle. These definitions concern the substance and the presentation of the information. The core quality principles are attached at Annex B.. Besides the core quality principles on information to patients on diseases and treatment options, the working group also put together a ‘toolbox’ of good practice and tools to help patients to evaluate health information. Finally, the core quality principles were subject to an open consultation6. Model information package Related to, and in parallel with, the development of the core quality principles, the working group developed a specific example of an information package which was designed to contain the essential information on a condition and its treatment options. The objective of this exercise was to examine the value of developing health information at a European level in a partnership7 with all stakeholders of the Forum. An information package was to test how to develop an example of the key elements that could form the core of this type information and adapted as appropriate to national level. It is 5 AIM and ESIP cannot support parts of the progress report concerning information to patients on diseases and treatment options. Their concerns are set out in a joint position statement available at this website [to be added when the Progress Report is published]. 6 The quality principles and the diabetes information package were subject to a public consultation which ended on 4 May 2007. A summary of the results is currently being undertaken and will be circulated to the Pharmaceutical Forum members. 7 France has expressed a reserve on the term "partnership". 26/6/2007 Second Pharmaceutical Forum 9/17 intended to supplement, and not replace, existing authorised information and the advice of healthcare professionals. The package was also subject to the public consultation. The responses to the consultation broadly supported this proposal but made a number of critical suggestions on the content, the methodology and the need to adapt this kind of information to national situations. All the responses to the consultation can be found at: http://ec.europa.eu/health/ph_overview/other_policies/pharmaceutical/results_consultation_en .htm The working group agreed that there were a number of important lessons to be learnt from this process. The most effective way for taking this model information package on diabetes forward would be to develop a more detailed core set of validated information and a comprehensive methodology for developing an appropriate collaboration involving stakeholders for the future. This could then provide the basis for such information to be adapted by national authorities and stakeholders for different uses such as information to patients, carers, health professionals etc. The working group also agreed that it was not the appropriate platform to further develop the draft model. This would need to be done by a small working group of experts in diabetes reflecting the composition of the working group with a strong patient involvement. Furthermore, there was also a preliminary discussion on the following mechanisms as possible future options for adapting and validating an agreed common core set of information for European and national level; 1) Ex anteriori validation mechanism which could provide a system for national authorities to assess and validate information to patients on diseases and treatment options information prior to its provision to the general public; 2) Co-regulation which includes a review process which would be built on a posteriori controls including sanctions. This mechanism could be based on an obligation for those providing information to allow the information to be reviewed by national authorities and relevant stakeholders; and 3) Self-regulation according to an agreed code of practice. The exact scope, and any possible combination, of these mechanisms would need to be agreed by national authorities. Other areas of co-operation Furthermore, the working group addressed the issue of strengthening European co-operation on information to patients on diseases and treatment options information for example by setting up mechanisms and tools such a European network and database which would allow improved co-operation and sharing of best practices between the competent authorities and other relevant stakeholders. 2. Examining ways to improve access to information to patients on diseases and treatment options in health care settings Two workshops on access to information in pharmacies and hospitals were organised. In addition, a summary of research was undertaken on information needs in different patient groups. Further work is needed to build upon the outcomes from the two workshops. Patients and health care professionals identified barriers such as health literacy and time constraints to accessing/providing information to meet a patient’s specific needs. 26/6/2007 Second Pharmaceutical Forum 10/17 These reports have been put on the Pharmaceutical Forum website of the European Commission to inform the wider public health community on the work in progress. Conclusions 1) The Pharmaceutical Forum welcomes the work undertaken so far to develop a set of core principles on good quality information and the progress made so far on an example information package on diabetes. 2) In addition, the Pharmaceutical Forum welcomes the exploratory work undertaken by the workshops on access to information in pharmacies and hospitals and the summary of research on patient needs and existing information tools. 3) The Pharmaceutical Forum would welcome a proposal to organise a platform to bring together relevant stakeholders to explore ways to exchange good practices and on ways to overcome barriers to accessing information identified in this work and to make proposals to the European Commission. 4) The Pharmaceutical Forum particularly welcomes the fact that the results of the work described above were developed between Member States and stakeholders. 5) Moreover, the Pharmaceutical Forum notes the results of the public consultation and it considers the view of the wider public, and patients in particular, as an essential element in defining the future orientations of this work. 6) The Pharmaceutical Forum welcomes the agreement reached on the core quality principles on information to patients on diseases and treatment options; − objective and unbiased − patient-oriented − evidence-based − up to date − reliable − understandable − accessible − transparent − relevant and appropriate − consistent with statutory information In addition, the Pharmaceutical Forum supports the proposal to develop a methodology for the use of the principles. 7) The Pharmaceutical Forum recommends their use by all providers in the development of all information to patients on diseases and treatment options information in the European Union. 8) The Pharmaceutical Forum requests the working group to consider further the example for an information package which should contain the key elements for a European level core information which could provide a basis for a wide range of 26/6/2007 Second Pharmaceutical Forum 11/17 information material, and the methodology for producing it. It should be adapted to take into account national situations and specific patient needs and different mechanisms may be required to meet individual user needs8. 9) The Pharmaceutical Forum recognises the value of exploring the possibility for setting up, testing and evaluating a European level mechanism to validate information to patients on diseases and treatment options. For this purpose, the Pharmaceutical Forum requests the European Commission to consider a feasibility study which could look at all aspects of this proposal including9; • financial and resource implications • adapting existing information • implications of subsidiarity • the link between stakeholders involved in a process with the responsibility for its outcome • the selection of stakeholders to be involved, and • the supervision of the process 10) The Pharmaceutical Forum welcomes the publication of ‘draft report on current practice with regard to provision of information to patients on medicinal products’, as required under Article 88a of Directive 2001/83/EC to which the working group had submitted a contribution. 11) The Pharmaceutical Forum considers that above actions should be included in an overall strategy for information to patients on diseases and treatment options without prejudice to the outcome of the report on current practice with regard to the provision of information to patients on medicinal products, as required under Article 88a of Directive 2001/83/EC10. 8 France has expressed a reserve. 9 France has expressed a reserve. 10 France has expressed a reserve. 26/6/2007 Second Pharmaceutical Forum 12/17 Annex A. Guiding principles for good practices implementing a pricing and reimbursement policy The decisions on cost of healthcare and pharmaceuticals are a national responsibility, it has appeared in the working group that with decisions on pricing and reimbursement of pharmaceuticals, Member States aim to achieve 3 overall objectives of (1) optimal use of resources to maintain sustainable financing of healthcare, (2) access to medicines for patients and (3) reward for valuable innovation. Each Member State has its specific approach for guaranteeing these 3 overall objectives. Member States shall ensure that any national measure to control the prices of medicinal products or to restrict the range of medicinal products covered by their national health insurance systems complies with the requirements of Directive 89/105/EEC and the Treaty. This EU legal framework requests in particular that pricing and reimbursement decisions are made in a transparent manner. The following toolbox principles will allow good implementation of pricing and reimbursement practices and are meant to offer guidance and facilitate the sharing of information and assessments. They are not binding rules. Access for patients Ensure timely access to valuable innovation. The Transparency Directive defines deadlines that have to be respected in taking pricing and reimbursement decisions. In standard cases, a request for a pricing and reimbursement decision should come with proof of benefit upfront, based on good clinical trials delivered by the applicant, whenever possible in a comparative set-up with a standard treatment. In some cases, when a full assessment is to be made for a new breakthrough medicine with a value not yet certain or difficult to prove, these deadlines might be a constraint in spite of good clinical trials. In these cases more evidence needs to be gathered after a medicine has been put on the market. In such cases, and in particular where it concerns life-threatening situations for which no alternative treatment exists, national authorities and companies could take a first pricing and reimbursement decision with conditional on gathering more information in order to review this decision. Such decisions allow patients to gain early access to potentially valuable medicines and innovative companies to get an earlier reward for investment in R&D. In the meantime necessary data can be collected within well-designed outcome research studies. These pricing and reimbursement decisions should come with a mutual commitment to a risk-sharing contract between companies and authorities. This commitment has to come upfront given that it is difficult to withdraw a medicine from reimbursement. Such a contract lays out the expected benefits of a new medicine, the criteria to assess these benefits, the data needed and methods/capabilities to do these assessments as well as the overall timeframes. On the financial side, the contract can define prices, reimbursement levels and restrictions of utilisation during the temporary period, as well as the financial consequences once new proof of benefit is available (for example leading to price or reimbursement changes –upwards or downwards-, changes in utilisation, premiums or payback). 26/6/2007 Second Pharmaceutical Forum 13/17 Provide affordable medicines. Medicines should be equally accessible at an affordable cost to all concerned patients. Generic medicines provide an opportunity to obtain similar treatments at lower costs for patients and payers, while liberating budgets for financing new innovative medicines. Promoting generic medicines requires a good combination of demand-side as well as supply-side mechanisms. This includes a flexible and adaptive pricing and reimbursement system, an appropriate level of price-sensitivity in patients (and payers where insurers/sickness funds are involved) and a sufficient level of competition among the different actors in the supply system (manufacturers, wholesalers and pharmacists, taking account of their public health role). It has also become clear that affordability has a European dimension. A similar price-level leads to a different level of affordability depending on the economic situation of each Member State. Attention could be given to measures that allow companies to offer medicines at affordable prices in each EU market. Limiting price-control only to nationally used volumes, as Recommendation 6 of the G-10 Medicines report stipulates, would allow differential pricing taking account of national socio-economic indicators like GDP-levels11. Affordability could also be ensured through upfront agreements on maximal expenditure. This could allow authorities across the EU to accept similar prices for a limited number of innovative medicines while maintaining the total expenditure at a nationally affordable level, although this cannot be seen as a large-scale solution. Ensure equal availability of medicines. Several medicines are not available in some markets, in particular small or low-price markets where the potential profits may not seem to justify the investment to organise local supply. Manufacturers should commit to register and supply all EU markets at reasonable prices, including the small and low-price markets. Wholesalers should commit to supply all these EU markets at reasonable prices. Where this is not possible, purchasing and supply managed (partially or totally) by national authorities, potentially in collaboration with other Member States, are to be fully accepted as an alternative. Overall, sufficient attention should be given to patient’s concerns in the development of a pricing and reimbursement policy, in particular to the existing inequities among Member States in availability and affordability. Optimal use of resources Limit price control to where it is needed to contain the public budget. Member State authorities usually fix prices and reimbursement levels to ensure access to medicines at affordable cost for utilisation within their territory. Member States are not interested in fixing prices of products that are only transiting through their territory to be utilised within other Member States. They should, therefore, abstain from fixing prices for products that will not be used within their territory and that will not impact on their national budgets (as outlined by Recommendation 6 of the G-10 Medicines report)12. Control of supply and utilisation, including a system of traceability, might be helpful. 11 France has expressed a reserve on reference to G10. 12 France has expressed a reserve on reference to G10. 26/6/2007 Second Pharmaceutical Forum 14/17 Price control is not necessary for non-reimbursed medicines. For these products, price- competition can steer the price-evolution sufficiently well. Therefore, Member States should abstain from price-control. Monitoring systems might be helpful to get an overview of market- and price-evolutions and to mitigate any potential risk of significant price increases. Set-up a consistent package of supply and demand-side measures. To manage expenditure on pharmaceuticals, authorities need to manage prices, reimbursement levels and proper use. Supply side measures, addressing prices and reimbursement levels, are, therefore, to be managed in coordination and alignment with demand side measures, determining the volume. On the demand side, the individual behaviour of doctors, pharmacists and patients will determine the total use of and expenditure on medicines. Interests of all these actors, therefore, need to be aligned with the national objectives. One or several of these actors should be motivated to push forward utilisation of medicine in a cost effective way, either through a (financial) incentive, or through a controlled obligation. Practices (1) on prescription guidance for doctors, (2) on substitution by pharmacists and (3) on cost-sharing and price-sensitivity of patients, should therefore be aligned. In addition, upfront agreements on overall maximal expenditure, in the form of payback or price-volume agreements, allow effectively increased predictability of overall expenditure. Create the right environment for price competition. Direct or indirect control of prices, reimbursement and expenditure are clearly relevant in a market with low price-sensitivity and high market power of manufacturers, in particular for medicines under patent protection. In situations where competition between different products is possible, e.g. when generics enter the market, open price competition may lead to good containment and significant reduction in prices and costs for patients and payers in a less cumbersome way. On the other hand, maintaining fixed pricing or reimbursement levels, in a situation where competition is possible, could prevent price-reductions. To ensure savings, authorities need to provide for a flexible, adaptive pricing system, an appropriate level of price-sensitivity in patients (and/or payers) and a sufficient level of competition among the different actors in the supply system (manufacturers, wholesalers and pharmacists, taking account of their public health role). Particular attention is to be paid where generic prices are always defined as a fixed percentage of the originator price, regardless of the number of price-decreases of this originator. Such systems may lead generics being out-competed through consecutive price-reductions of the originator. Cost containment mechanisms can create sufficient headroom that is needed for rewarding valuable innovation. This could also benefit from a holistic and long-term perspective, aiming for sustainable financing of healthcare, beyond pharmaceuticals. Reward for Innovation Set expectations. Limited resources force authorities to make choices on what new products to reward and pay for. Through its pricing and reimbursement decisions, each Member States tends to grant incentives (e.g. a high price and reimbursement level, or good access to the market) for those new products that it really appreciates as bringing valuable improvements compared to the standard therapy. In this way, Member States indicate what they expect from pharmaceutical R&D to deliver. It is, therefore, important to reflect what are and will be the desired additional benefits and to allocate resources accordingly. (A separate paper has been prepared by the Working Group. This paper reflects the outcome of a survey of Member States on what they consider to be valuable innovation. 26/6/2007 Second Pharmaceutical Forum 15/17 Recognise innovation. The degree of added value delivered by new medicines is often incremental and, therefore, harder to recognise. Companies should, therefore, be prepared to clearly prove this added value versus existing therapies and authorities should be prepared to recognise proven incremental benefits that are estimated valuable and reward them appropriately (i.e. with incremental price-premiums or with measures allowing a higher utilisation). Pricing and reimbursement mechanisms, as well as utilisation guidelines, should be in line with this and ensure a scaled recognition and reward. It should thus not be expected that incremental benefits would be rewarded with break-though premiums. Where added value versus existing therapies cannot be proven and recognised, timing of market entry of a new medicine should be taken into account as well as its effects on competition. Products coming to market soon after the first-in-class originator are the result of a parallel R&D process and should be rewarded in parallel to the first-in-class originator. Products entering the market significantly later should not get a similar reward. Be consistent when giving reward. Criteria for pricing and reimbursement need to be transparent, as requested by the Transparency Directive, and consistent over time. This gives the right signals to companies on what innovations are expected and valued. Research and development of a medicine is a risky and multi-year process, in particular for small and mid- size biopharmaceutical companies. The national pricing and reimbursement decisions and related decisions on the timing and utilisation are the only indicators that show whether it will be worthwhile starting this risky process. In addition, overall cost-containment mechanisms, like price-cuts or payback, could be aligned with these initial decisions; they could, for example, foresee exemptions for those innovations that are considered very valuable and have been granted a consequent price and reimbursement level. Working Group on Pricing, 14/05/2007 26/6/2007 Second Pharmaceutical Forum 16/17 Annex B. Core quality principles for patient information on diseases and treatment options High quality information must meet the criteria set out in these principles and should also have a clear process for compliance/certification. Information provided by a Member State and/or the European Commission should be done without restricting or replacing other sources. Objective and unbiased Information is objective when it is based on facts and not influenced by prejudices or personal perceptions. Information is unbiased when it is impartial, non-directive and balanced. These two definitions do not relate to the source of information which is a separate issue (see the ‘Transparent’ principle). Patient oriented Information provided should be patient-centred taking into account patients’ needs and expectations in order to empower patients. Patients should be involved in the production and dissemination of information on diseases and treatment options wherever possible. Evidence-based The evidence base for any information resource needs to be clearly stated, including making clear the level of evidence. Information should be verifiable, based on comparisons and backed up by scientific peer review where possible. Up-to-date Information should be kept up-to-date and the date of publication should be included. Reliable Information needs to be factually correct and not misleading. Information should be scientifically valid and reflect latest knowledge. 26/6/2007 Second Pharmaceutical Forum 17/17 Understandable Information provided should be comprehensible for a patient/citizen. Accessible Information should be easily accessible via different mechanisms for example, through written documents, websites of certified official bodies etc. Information should also be accessible to people with disabilities. Transparent Informed choice requires transparency. That entails transparency of what is known as well as what is not known. Funding, sources of information, evidence for that source and transparency when there is known controversy about a particular treatment, for example, all need to be made clear. Relevant Information should include issues of relevance and importance to patients’ decision-making e.g. including adverse effects. Impact on quality of life and the consequences of the disease on contribution of the patient to society/the work place are important elements of information on disease. Consistent with Statutory Information Information not regulated by statute should, nevertheless, be consistent with the legal requirements of European law (e.g. must not be designed to promote a prescription only medicine, reflecting the prohibition of direct to consumer advertising of prescription only medicines, must not be misleading etc.) and should refer, where appropriate, to statutory information approved through the process of regulation.

High Level Pharmaceutical Forum 2005 – 2008 Final Report Final Conclusions and Recommendations of the Pharmaceutical Forum 2 High Level Pharmaceutical Forum 2005-2008 Introduction to the process Three years have now passed since Vice-President Verheugen and former Commissioner Kyprianou jointly set up the Pharmaceutical Forum in 2005, in order to find relevant solutions to public health considerations regarding pharmaceuticals, while ensuring the competitiveness of the industry and the sustainability of the national health-care systems. Background In its Conclusions on Medical Products and Public Health of 2000, the Council of Ministers underlined the importance of identifying innovative medicines with significant added therapeutic value to attain both industrial and public health sector goals. In this spirit, a High Level Group on Innovation and Provision of Medicines (called “G10 Medicines”) was set up by the Commission to take a fresh look at the problems facing the pharmaceutical sector. The G10 Group presented its report in May 2002 in which it set out 14 wide-ranging recommendations. In 2003, the European Commission published the Communication1 “a stronger European-based pharmaceutical industry for the benefit of the patient – a call for action” in response to the G10 Group’s Recommendations. In order to tackle some of these recommendations, the Commission created the Pharmaceutical Forum in 2005 to take the process forward around three key themes: information to patients on pharmaceuticals; pricing policy; and relative effectiveness. Mandate The process was set up to bring the European Commission, Member States, representatives of the European Parliament and a wide range of stakeholders together to take forward, collectively, the challenges relating to the: information to patients on pharmaceuticals; pricing and reimbursement policy; and relative effectiveness assessment. These three themes were identified from a total of 14 recommendations from the so-called G10 Group in its report of May 2002. The other recommendations have been or are being addressed by the Commission, in particular as part of the review of pharmaceutical legislation, research programmes and support to patient groups. Deliverables Concrete recommendations and tools have been produced during the work of the Pharmaceutical Forum in these three challenging issues. Apart from the recommendations presented in this report, it has to be acknowledged that a major deliverable has been the process itself. Bringing the Member States, EFTA, the Commission, representatives of the European Parliament, the industry and major stakeholders 1 Communication from the Commission to the Council, the European Parliament, the economic and social Committee and the Committee of the regions “a stronger European-based pharmaceutical industry for the benefit of the patient – a call for action”, (COM (2003) 383). Final Conclusions and Recommendations of the Pharmaceutical Forum 3 from the public health sector - various parties having potentially divergent interests was as such a challenge. The second deliverable is of course the adoption of conclusions backed by recommendations for direct implementation and/or further improvement resulting from the discussions in the working groups. The last deliverable is that discussions over the last three years have provided direction for future work under the mandate of the new European Parliament and the new Commission. In the meantime, 2009 will be a year of implementation and reflection. Membership The Pharmaceutical Forum was composed of the European Commission, the 27 Member States, three representatives from the European Parliament nominated in their personal capacities, EFTA representatives and key stakeholders from the public and private sectors: - European Patients Forum - EPF - Standing Committee of European Doctors - CPME - Pharmaceutical Group of the European Union - PGEU - Association Internationale de la Mutualité - AIM - European Social Insurance Platform - ESIP - European Federation of Pharmaceutical Industries & Associations - EFPIA - European Generic medicines Association - EGA - European Self-Medication Industry - AESGP - European Association for Bioindustries - EuropaBio - European Association of Full-Line Wholesalers - GIRP A number of other stakeholders were also invited as observers for certain specific discussions. The secretariat of the Pharmaceutical Forum was provided by the European Commission's services in Directorates General Enterprise & Industry and Health & Consumers. Timetable The launch of the Pharmaceutical Forum initiative by the European Commission was officially announced to the Members on 19 October 2005, following discussions in the Health Council on 3 June 2005. Regular meetings of the three working groups and the Steering Committee took place from January 2006 to July 2008. The High Level Pharmaceutical Forum met on 29 September 2006, 26 June 2007 and 2 October 2008. The Pharmaceutical Forum initiative was officially concluded on 2 October 2008. Working methods The Pharmaceutical Forum was a high-level political platform for discussion supported by a Steering Committee and three expert working groups. Final Conclusions and Recommendations of the Pharmaceutical Forum 4 High Level Pharmaceutical Forum The Forum was the overall political driver of the process. The main role of the Forum was to provide strategic direction and political momentum for the initiative. It was also designed as a platform for discussion on competitiveness and related public health issues. The Forum was chaired jointly by Vice-President Verheugen and former Commissioner Kyprianou, followed by Commissioner Vassiliou. Members were Ministers from each Member State, EFTA, three representatives from the European Parliament and senior representatives of stakeholder members of the Pharmaceutical Forum. Steering Committee The Steering Committee gave the strategic guidance needed between the High Level Forum meetings and provided operational guidance to the Working Groups. It was also responsible for ensuring the flow of information between the Pharmaceutical Forum and the Working Groups. The Steering Committee consisted of seven Member States (selected from the EU Presidencies during the Forum process), representation of the European Parliament, and a senior representative from ten key stakeholder organisations. The Committee was chaired jointly by Directorate Generals Health & Consumers and Enterprise & Industry. Working Groups Three expert Working Groups supported the work of the Forum and the Steering Committee. The task of the Working Groups was to provide the ideas to make progress on information to patients, pricing policies and relative effectiveness assessments. The Working Groups were composed of representatives of the Member States, EFTA and stakeholders. Working Groups were chaired jointly by Directorate Generals Enterprise & Industry and by Health & Consumers. Working Group on Information to Patients Working Group on Pricing and Reimbursement Working Group on Relative Effectiveness Final Conclusions and Recommendations of the Pharmaceutical Forum 5 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2nd October 2008, the High Level Pharmaceutical Forum agreed on the following final Conclusions2 and Recommendations3. The High Level Pharmaceutical Forum: 1. Was launched with the overall aim of exchanging best practice and examining efficiency gains within a European high level platform, as a way of contributing to ensuring patient access to medicines within a sustainable healthcare budget, and recalls its initial mandate to discuss the competitiveness of the European pharmaceutical industry and related public health considerations, with a specific focus on information to patients on disease and treatment options, relative effectiveness assessments and pricing and reimbursement of medicinal products. 2. Acknowledges that the three-year process has strengthened the understanding of the positions and concerns of all parties and demonstrated the added value of working together in a consensus -based manner, leading to the adoption of strategic recommendations and priorities for future joint work. 3. Welcomes the political momentum gained in the field of public health and competitiveness of the industry and, more precisely in the three themes of the mandate, which was built on mutual understanding among the interested parties and common diagnosis for the core issues. The continuous exchange of experiences established new networks among experts and enhanced the knowledge within national authorities and relevant stakeholders. The added value of this cooperation has lead to the adoption of strategic recommendations and priorities for future joint-actions to be initiated within the three key themes. 4. Endorses the recommendations made in the specific themes of information to patients, relative effectiveness and pricing and reimbursement. 5. Emphasises the fundamental role and responsibility of each Member of the Forum in actively taking forward the agreed recommendations and reporting on their efforts. 6. Invites the Commission to facilitate the reporting from the Members and to engage in a reflection process in 2009 to identify the remaining challenges in these fields. 2 In line with the competences as enshrined in the EC Treaty, the final Conclusions and Recommendations of the Pharmaceutical Foru m are of a non-binding nature. Their implementations should reflect the overall objectives of the Pharmaceutical Forum and, therefore, contribute to the good usage of pharmaceuticals and efficiency of national healthcare systems. 3 The recommendations provide guidance to address challenges as identified in the final Conclusions from the High Level Pharmaceutical Forum. The recommendations are the result of discussions, brainstorming and exchanges of practices in the different working groups set up under the Forum. The recommendations provide concrete implementing actions, addressed to the European Commission, interested stakeholders and the Member States themselves. All the recommendations are subject to the European and national legal provisions. Final Conclusions and Recommendations of the Pharmaceutical Forum 6 Information to Patients The High Level Pharmaceutical Forum: 7. Is aware that patients and citizens increasingly expect quality information, particularly when related to their health, and recognises the urgent challenge to invest in high quality and accessible information on diseases and treatment options considering the shared responsibility of all engaged parties and the importance of empowered patients and citizens in general. 8. Recognises the role of national authorities to make the best information available and stresses the added value of common principles, European methodologies and specific requirements for information development. The Forum welcomes in this respect the recommendations put forward, notably the quality principles for health information, the core elements for information material, and the enhanced access to information in healthcare settings for the dissemination of information to patients. 9. Recognises the benefit of mobilising the knowledge and resources from different partners towards the generation of information and strongly calls all actors engaged in the field of information to patients to take into account the outcomes of the Pharmaceutical Forum for use in developing approaches and actions. Notes the role of existing partnerships and other collaborative approaches, bearing in mind that healthcare professionals and competent authorities remain primary sources of information on medicinal products and takes note of the Council Conclusion of 10 June 2008.4 10. Invites sound cooperation fostered by the wealth of national initiatives and recommends the Commission and the Members to consider all aspects related to the launch of a European information library of existing high quality information to patients. The Forum invites the Commission and the Member States to consider developing formal strategies to improve health information to ensure coherent approaches both at national and at European level. 11. Stresses the need to enhance health literacy as a policy at EU and Member State levels. Recommends that future EU policy on information to patients on diseases and treatments should move towards new approaches in a coordinated manner, built on dialogue with stakeholders, promoting health literacy and health information in the broadest sense. Recommendation 1: Enhance quality of information 1.1 The Forum recognises that the mandate of the Pharmaceutical Forum is part of a broader health information context, as identified by a number of important elements which Member States and the Commission should commit themselves to taking into consideration when developing work in this field. 4 Council Conclusions on the Communication from the Commission to the European Parliament and the Council concerning the report on current practices with regard to provisions of information to patients on medicinal products, in accordance with Article 88a of Directive 2001/83, as amended by Directive 2004/27/EC on the Community code relating to medicinal products for human use. Final Conclusions and Recommendations of the Pharmaceutical Forum 7 1.2 All the relevant players, including national competent authorities, the Commission, public health stakeholders and industry5, should ensure high quality information and thereafter should commit themselves to implementing and using the core quality principles and their methodology of use for the development of information, and to identifying poor quality information. 1.3 The Forum recognises the added value for patients and citizens of providing information on medical conditions jointly with information on treatment options. All the relevant players should ensure that the identified key elements for information to patients on medical conditions and treatment options are taken into consideration when information to patients is produced, assessed and improved. 1.4 The Commission should consider using the EU Health Portal to raise the visibility of good information sources and ensure that all principles developed by the Forum are applied. Member States and stakeholders, with the assistance of the Commission, should commit themselves to continuing to share information about new initiatives regarding information that are in line with the principles. 1.5 The Commission together with the Member States and the relevant stakeholders should consider developing a common approach to quality assurance of information. 1.6 The ban on advertising of prescription medicines to the general public should continue. Recommendation 2: Increase accessibility and dissemination of Information 2.1 Member States, stakeholders and the Commission should accelerate their engagement toward generation of information to citizens in effective communication formats (electronic and non-electronic means), taking account of local traditions, healthcare systems and languages. To initiate the process, Member States, stakeholders and the Commission are invited to implementing the specific recommendations identified to increase accessibility and dissemination of health information in the various healthcare settings. 2.2 The Commission should commit itself to making visible the best practices identified in the Member States and to promoting cooperation between the Member States and the relevant stakeholders to further exchange experiences. 2.3 The European Medicines Agency should continue, and be financially enabled to continue, its efforts in improving the database on medicinal products authorised in the EU as foreseen in Article 57, 1(l) of Regulation (EC) No 726/2004 and its cooperation with Member States and stakeholders with regard to information on medicinal products. 5 AIM expresses some reserve concerning the involvement of industry in providing information to patients Final Conclusions and Recommendations of the Pharmaceutical Forum 8 Recommendation 3: Generation of information by making the best use of all actors 3.1 Member States, the Commission and other stakeholders should take note of existing partnerships and collaborations between the various parties that mobilise knowledge and resources for producing and disseminating information to patients. 3.2 Member States, the Commission and other stakeholders should exchange information about the different approaches existing across Europe in the choice of partners, structures and responsibilities. They should also consider whether further collaborations could be created. 3.3 Where such partnerships and collaborations are set up, Member States and stakeholders should commit themselves to respecting the minimum ethical requirements of i) transparency, ii) disclosure of financial and other support and iii) definition of responsibilities as identified in the Forum process. 3.4 The Commission should raise the visibility of existing partnerships and collaborations, for instance by using the EU Health Portal6, which respect the ethical guidance and produce information in line with the core quality principles. Recommendation 4: Continued momentum on Information to patients 4.1 The members of the Pharmaceutical Forum are invited to disseminate the outcomes of the Forum to all interested parties and citizens, e.g. through workshops. 4.2 Member States and the relevant stakeholders are expected to ensure that the recommendations are followed up at national level. Member States and the Commission in cooperation with the relevant stakeholders should within the next two years undertake a first review of what exists, and what has been created and/or improved following the recommendations from the Pharmaceutical Forum in the field of information to patients. 4.3 Further cooperation and sharing of experiences at EU level is needed, and thus the Commission should set up a process building on the Information to Patients working group to evaluate the direct outcomes and follow-up of the Pharmaceutical Forum. Relative Effectiveness The High Level Pharmaceutical Forum: 12. Recalls that the evaluation and the decision making process leading to decisions on the pricing and reimbursement of pharmaceutical products lie with the national competent authorities. 13. Acknowledges the distinction between the scientific assessment of the relative effectiveness of medicinal products and health-economic assessments of their costs and benefits. Endorses the aim of relative effectiveness assessment to compare 6 The health portal is accessible at http://ec.europa.eu/health-eu/index_en.htm Final Conclusions and Recommendations of the Pharmaceutical Forum 9 healthcare interventions in daily practice and classifying them according to their added therapeutic value. 14. Acknowledges, in this respect the importance for Member States of exchanging information on their respective relative effectiveness assessment criteria, systems and activities in order to i) consolidate the scientific evidence on relative effectiveness by collecting data, processes and conclusions reached at national level, for purposes of comparison, where appropriate, ii) facilitate the work of the pricing and reimbursement authorities by providing them with consolidated scientific evidence, and iii) inform health-care professionals and patients on the most effective medicines. 15. Endorses the working definitions on efficacy, relative efficacy, effectiveness and relative effectiveness which will serve as a common understanding for future exchange of information between all parties involved and calls on Member States to take these definitions into account when developing and implementing systems of relative effectiveness assessment. 16. Endorses the good practice principles7 for relative effectiveness assessment that will set the scene for the scope of future work and invites Member States to take them into account in developing and implementing systems of relative effectiveness assessment. 17. Welcomes the check-list8 on the use of the agreed principles, which could be used as a basis for a future toolbox for all interested parties involved. 18. Welcomes the significant added value of the first set of information gathered in Member States on data availability and needs and on the methodologies used to conduct relative effectiveness assessments for medicinal products sampled. Welcomes the conclusions and recommendations9 reached, as regards i) the need to improve data availability on relative effectiveness throughout the product life cycle10, notably post-market data and ii) the need to address barriers of all kinds, including legal ones, that can prevent Member States and stakeholders from exchanging data. 19. Acknowledges the fact that more substantial work remains to be done as regards: i) the development of methods for the transferability of such data and ii) the need to consider how information in the European Public Assessment Report and the National Public Assessment Report, as foreseen in Article 13(3) of Regulation (EC) No 726/2004 and Article 28 of Directive 2001/83/EC, can further contribute to relative effectiveness assessment. 20. Welcomes, in this respect the important added value of the mapping exercise of existing networks involved with relative effectiveness assessment at European level which could take these recommendations forward. Notes that the mapping exercise concludes that this objective would be achieved more effectively by an existing network rather than by setting up a new one. 7 See annex 8 See annex 9 See annex 10 AIM and ESIP recall that the major conclusion of the exercise on the availability of data was that there are not enough data to assess relative effectiveness at the time this first needs to be done and even later on. Exploring ways to generate the data needed to make relative effectiveness assessments on a sounder scientific basis should be done. Final Conclusions and Recommendations of the Pharmaceutical Forum 10 21. Considers that the Commission, in consultation with the Members of the Forum, should look together with the relevant networks at how they could take forward the work that needs doing, distinguishing as appropriate, between policy-related and scientific actions. Recommendation 5: Implement agreed good practice principles for Relative Effectiveness assessments 5.1 Member States and stakeholders - the pharmaceutical industry, social insurers, health care professionals and patients' organisations- are encouraged to adopt the agreed working definitions11 on efficacy, relative efficacy, effectiveness and relative effectiveness and to use them in the scientific literature and reports of all kinds. The use of these common definitions will ensure a common understanding of the work done at national level and will facilitate the exchange of information between all parties involved. 5.2 Member States and stakeholders are encouraged to implement the agreed best practice principles12 for relative effectiveness assessment and to regularly communicate and exchange information on their adoption, where appropriate. Such implementation should also ensure medicines receive fast access to market and appropriate reward13. Recommendation 6: Promote the exchange of information on relative effectiveness assessments in order to improve the data availability and transferability 6.1 Member States and stakeholders are encouraged to regularly exchange information in order to achieve the objectives set out in the conclusions, namely: i) to consolidate the scientific evidence on relative effectiveness by collecting data, processes and conclusions reached at national level, for purposes of comparison, where appropriate, ii) to facilitate the work of the pricing and reimbursement authorities by providing them with this consolidated scientific evidence, focusing on their priority areas and iii) to inform health-care professionals and patients on the most effective drugs. This exchange should also aim to identify any barriers, whether scientific, technical or legal, that prevents all the parties involved from circulating the information easily. 6.2 In particular this exchange of scientific evidence should focus on the need to: i) improve the understanding of the scientific evidence generated that can be used for relative effectiveness by sharing best-practice in terms of data requirements and processes; ii) increase the understanding among those involved in relative effectiveness assessments of the possibilities and limitations in the generation of data that can be used for relative effectiveness assessments during and after the granting of marketing authorisation; iii) explore better avenues for dialogue between assessing bodies and/or decision-makers and the marketing authorisation holder to address point i); 11 See annex 12 See annex 13 AIM and ESIP highlight that this last sentence was suggested by some members of the Steering Committee and not agreed upon in the working group. Further the issues of market access and reward for innovation were topics of the working group on pricing not relative effectiveness and should therefore not be included in the recommendations of the working group on relative effectiveness. Final Conclusions and Recommendations of the Pharmaceutical Forum 11 iv) strengthen the methodological quality and rigour of relative effectiveness assessments and identify any scope for common approaches in certain areas of assessment, as appropriate; v) inform health-care professionals and patients on the most effective medicines 6.3 National authorities and companies should also consider ways of having early dialogue during product development to improve the generation of appropriate data as far as possible. 6.4 Member States, with the involvement of the European Medicines Agency, should continue their efforts to consider how European Public Assessment Report and the National Public Assessment Report can further contribute to relative effectiveness assessments. 6.5 In an effort to streamline the exchange of such information and to ensure effective EU-wide coverage of relative effectiveness assessments, Member States and the Commission should identify how existing networks could be involved and any support that might be needed. Member States and the Commission should also address the issue of the involvement of stakeholders, while observing the above agreed principles. Pricing and Reimbursement The High Level Pharmaceutical Forum: 22. Welcomes the development of a shared understanding that pricing and reimbursement policies need to balance (1) timely and equitable access to pharmaceuticals for patients all in the EU, (2) control of pharmaceutical expenditure for Member States, and (3) reward for valuable innovation within a competitive and dynamic market that also encourages Research & Development. 23. Welcomes the identification, analyses and development of options addressing more specifically access issues like orphan medicines and small national markets. The Pharmaceutical Forum considers that patients in the EU should have equitable access to medicines. It therefore invites all Member States, all stakeholders and the European Commission to effectively ensure an equitable access by taking up the suggested options forward. 24. Recognizes the development of common knowledge on what kind of innovation is expected and valued as well as on how value assessments can translate into pricing and reimbursement decisions. The Pharmaceutical Forum considers that clear and common expectations, together with consistent pricing and reimbursement decisions, can motivate the development of highly needed medicines. It therefore invites all Member States, stakeholders and the European Commission to collaborate towards these two goals. 25. Recognizes the development of several knowledge initiatives related to pricing and reimbursement and to the control of pharmaceutical expenditure. The Pharmaceutical Forum considers it necessary that pricing and reimbursement policies and practices are based on good knowledge, including data, facts and experiences exchanged between different Member States and stakeholders. It therefore invites all Final Conclusions and Recommendations of the Pharmaceutical Forum 12 Member States, stakeholders and the European Commission to further develop a joint knowledge basis. Recommendation 7: Access to medicines for EU citizens 7.1 Member State authorities and stakeholders of the Pharmaceutical Forum should strengthen their efforts in ensuring timely access to valuable innovations and in ensuring access to medicines for all citizens. Member States should do so following the requirements laid down in the Transparency Directive (89/105/EEC). 7.2 Member State authorities and stakeholders of the Pharmaceutical Forum should strengthen their efforts in ensuring sustainable availability and delivery of medicines to all EU Member States, in particular to small national markets. They are therefore called upon to take up the appropriate ideas developed in the Working Group Pricing and in other relevant fora. This should be done in parallel and in collaboration with regulatory efforts, taking into account the work of the Heads of Medicines Agencies14. 7.3 Member State authorities, stakeholders and the Commission should strengthen their efforts to ensure access to orphan medicines in all EU Member States. They are therefore called upon to take up the appropriate ideas developed in the Working Group Pricing regarding i) early dialogue on research and development, ii) exchange of knowledge on the scientific assessment of the clinical added value, iii) specific pricing & reimbursement mechanisms and iv) increased awareness on orphan diseases. Recommendation 8: Expect, Identify and Reward Valuable Innovation 8.1 Member States are called upon to set clear and common expectations on what innovation they consider valuable and would reward. This will give companies a clear direction on healthcare priorities and indications on the evidence needed by authorities, while bringing authorities clarity on the mid- to long-term budget needs. Companies are called upon to deliver the innovative medicines that society needs. Cooperation with patient organisations should also be encouraged. 8.2 National pricing and reimbursement policies should reflect and recognize these expectations and give a consistent reward to benefits considered valuable. 8.3 National systems on pricing and reimbursement should therefore be well aligned with systems that assess the value of medicines. Recommendation 9: Optimal use of resources 9.1 Optimal use of national budgets should take into account patients’ needs. 9.2 National pricing and reimbursement policies should ensure an efficient use of price control, a consistent package of supply- and demand-side measures and the right environment 14 See the Report of the task force of the Heads of Medicines Agencies MG, “Availability of Human Medicinal Products – 2007” http://www.hma.eu/uploads/media/Availability_medicines_HMAMG_TF_Report.pdf Final Conclusions and Recommendations of the Pharmaceutical Forum 13 for price competition. Member States should secure the principle that a Member State authority to regulate prices in the EU should extend only to those medicines purchased by, or reimbursed by, the State. Full competition should be allowed for medicines not reimbursed by State systems or medicines sold into private markets. 9.3 National pricing and reimbursement practices should take account of experiences in other Member States. The mutual exchange of knowledge and experiences should be continued and fostered. 9.4 Further knowledge and experience should be gathered and exchanged regarding tendering, conditional pricing / risk sharing and utilisation of generic medicines. Recommendation 10: Continued momentum on Pricing and Reimbursement 10.1 Member States, the Commission and relevant stakeholders are called upon to take into account the above recommendations in policy developments. Member States and the Commission, in cooperation with relevant stakeholders, should within the next 2 years undertake a first review of progress following the recommendations from the Pharmaceutical Forum in the field of pricing and reimbursement. 10.2 Further cooperation and exchange of experiences at EU level is needed. The Commission, in cooperation with Member States, is called upon to build on and bridge the work of the Pricing and Reimbursement Working Group and the Relative Effectiveness Working Group in order to evaluate the direct outcomes and follow up of the Pharmaceutical Forum. Final Conclusions and Recommendations of the Pharmaceutical Forum 14 Annex: Pharmaceutical Forum Reference Documents The reference documents are the result of discussions, brainstorming and exchanges of practices in the different working groups set up under the Forum. 1. Information to Patients - Overview of practices on access of health information in health care settings - Recommendations to enhance access to information using health care settings - Core quality criteria and a Methodology for use of the core quality criteria - Diabetes information example package - Summary of research: equipping patients to distinguish good quality health information - Key elements for information to patients - Overview and explanatory document on different partnerships providing information to patients - Ethical guidance with regard to partnerships - Wider Health Information – looking at the future 2. Relative Effectiveness Assessments - Core principles on relative effectiveness assessments - Study on the availability of date to conduct relative effectiveness assessments - Overview of exiting networks and recommendations for the development of networking and collaboration on relative effectiveness assessments 3. Pricing and Reimbursement - Guiding principles for good practices implementing a pricing and reimbursement policy - Ensuring access to medicines in small national markets in Europe - Improving access to orphan medicines for all affected EU citizens - Characterisation of the value of innovative medicines - From assessing innovative value of pharmaceuticals to pricing and reimbursement decisions - Risk sharing practices and conditional pricing of pharmaceutical - The Toolbox exercise Final Conclusions and Recommendations of the Pharmaceutical Forum 15 Reference Documents To lend support to the high level discussions that resulted in the strategic recommendations, the members of the Forum exchanged considerable national experience and conducted various analyses of existing practices. This pool of knowledge resulted in numerous reference documents for the High Level Pharmaceutical Forum in the field of Information to Patients, Pricing and Reimbursement and Relative Effectiveness. The reference documents were developed on the basis of information provided by the members of the Forum, although none of them should be considered as exhaustive. All the elements developed by the Forum should be given due consideration by all authorities, stakeholders and individuals engaged in the fields of Information to Patients, Pricing and Reimbursement and Relative Effectiveness. The competitiveness of the pharmaceutical industry and related public health issues should also be improved, with better use made of the principles, methodologies, recommendations and other reference documents created within the Pharmaceutical Forum. All the documents will be available on the European Commission website15. In addition, the core documents will be published for the members of the High Level Group with the Conclusions of the Pharmaceutical Forum. List of Reference Documents - Reference Documents on Information to Patients (page16) - Reference Documents on Relative Effectiveness Assessments (page 54) - Reference Documents on Pricing and Reimbursement (page 82) 15 The webpage containing the outcomes of the Pharmaceutical Forum is accessible at http://ec.europa.eu/pharmaforum Final Conclusions and Recommendations of the Pharmaceutical Forum 16 Reference Documents on Information to Patients The Information to Patients Working Group has developed and agreed on a number of documents which should be further disseminated. The documents will be clearly referenced and made available on the European Commission website16. 1. Recommendations to enhance access to information on diseases and treatment options in healthcare settings and examples of good and innovative practices (page 18) The recommendations will help all relevant actors to enhance access and dissemination of healthcare information in the three healthcare settings: general practices, community pharmacies and hospitals. As a complement, a set of examples of good and innovative practices in several Member States have been collected and are made available on the Commission website to provide reference to existing practices. 2. Core Quality Principles on information to patients and detailed practical methodology of use (page 23 and page 25) Core quality principles on information to patients were identified as a basis for developing quality health information on diseases and related issues to patients. The quality principles were submitted to public consultation, the results of which are published on the Commission website. A methodology of use of the core quality principles will make them easier to implement. 3. The key elements for core information on disease and treatment and the diabetes package example (page32) The key elements for core information on diseases and treatment options intends to list in detail what ideally should constitute health information for patients and, more generally, citizens. A specific example of an information package on diabetes was designed as the basis for identification of the key elements of core information. Both the diabetes example package and the results of the public consultation are available on the Commission website. 4. Summary of research on patients tools to distinguish good health information quality. The summary research, based on published studies, covers two aspects. Firstly, the summary provides some examples of patients needs in different population groups and propose in an information "tool-box" some actions to tackle the problems. Secondly, the summary sets out some tools to help consumers find relevant information on the internet, including the so called D.A.R.T.S17 tools. This summary is only published on the European Commission website. 16 The webpage containing the outcomes of the Pharmaceutical Forum is accessible at http://ec.europa.eu/pharmaforum 17 D.A.R.T.S refers to Date, Author, References, Type and Sponsor. Final Conclusions and Recommendations of the Pharmaceutical Forum 17 5. Introduction to Public Private Partnerships and other Collaborative Approaches Delivering Information to Patients on Diseases and Treatment Options in Europe illustrated by an overview of existing initiatives (page 38) This document provides a summary of existing collaborations and partnerships in Europe delivering information to patients. It highlights the existing possibilities for setting up national initiatives with diverse stakeholders, and gives an idea of the multiple models already in existence. An overview table providing key information on some of the existing initiatives is annexed to the document. 6. Ethical guidance as to collaborations and public private partnership among partnering organisations (page 47) The ethical guidance aims at helping create and improve collaborations and partnerships, to ensure that relations between the various categories of partners are responsible and meaningful. 7. Wider Health Aspects (page 51) Discussions within the Pharmaceutical Forum on information to patients are recognised as being part of a wider health information context that can be further expanded in the future. This document sets out a number of issues in this wider context, linking information, for example, to patients and health literacy. Final Conclusions and Recommendations of the Pharmaceutical Forum 18 Recommendations to enhance access to information on diseases and treatment options in healthcare settings 1. Introduction The main objective of this paper is to set out recommendations to Member States, Stakeholders and the European Commission which could assist in enhancing the access to information to patients on diseases and treatment options in healthcare settings, taking into account the healthcare systems in the Member States and the national organization for elaborating and disseminating information to patients. This document focuses on access and dissemination of healthcare information in the three healthcare settings of general practices, community pharmacies and hospitals, as identified by the High Level Pharmaceutical Forum. Other settings where information to patients on diseases and treatment options are or could be accessible are therefore not within the remit of this paper, but could be considered in a future exercise. The recommendations in this document are based on the fact that information to patients needs to be addressed in the wider context of healthcare systems and policies. They are also based on the assumption that high quality information to patients on diseases and treatment options is validated against the quality criteria approved by the Forum18 and should be made available in all Member States. The recommendations target Member States, stakeholders such as healthcare professionals and healthcare institutions and the European Commission. Overall, this document is intended to contribute towards better informed patients by recognizing that patient access to information on diseases and treatment options and its discussion with healthcare professionals enable patients to: § Enhance their ability to make informed decisions about optimal disease management and prevention in full partnership with health care professionals; § Optimise health outcomes through improved treatment concordance19 based on the belief that the more patients are informed, the better they understand their treatment and in particular how medicines must be taken; § Make more effective and rational use of the therapies that are available; § Increase their awareness of benefits and risks of medicines and the importance of reporting and managing possible side effects and adverse reactions; § Improve patients’ quality of life by adopting preventive measures, seeking earlier diagnosis, recovering faster from illness, avoiding hospitalisation and invasive surgery where possible, and enabling patients to continue their normal daily routines. It is important to note that patient access to information on diseases and treatment options in itself should not be seen as the end point but rather part of a process. This information process must not be dissociated from an underlying interactive communication process between the patient and his/her healthcare professional(s). Additionally, it should not be dissociated from an underlying learning process on how to best respond to patients’ and carers’ information 18 Objective and Unbiased; Patient Oriented; Evidence-Based; Up-to-Date; Reliable; Understandable; Accessible; Transparent; Relevant; Consistent with Statutory Information. 19 Concordance describes an agreement between a patient and a healthcare professional about whether, when, and how medicines are to be taken. Concordance therefore refers to the creation of an agreement that respects the beliefs and wishes of the patient, and not to compliance – the following of instructions. Final Conclusions and Recommendations of the Pharmaceutical Forum 19 needs, taking due account of their individual expertise, beliefs, concerns and available resources. In certain situations, such as with severe diseases or elderly people, the assistance of health professionals and social workers should be considered in order to guarantee the adoptive skills of the patient at the time of information exchange. In view of the above-mentioned principles, a strategy towards better informed and thus better educated patients, which can ensure patient safety, and lead to the most cost-effective use of medicines and treatment options while ensuring optimal therapeutic benefits should include: § Developing health literacy20; § Facilitating access to high-quality and validated information within different healthcare settings and through signposting practices (e.g. to patients and consumers organisations, community groups, independent and certified websites and call centres); § Raising awareness of what patients should expect from healthcare professionals and what questions they should ask or seek answers to within the consultation process with healthcare professionals; § Promoting the information flow between the different health settings and teamwork in order to provide consistent messages; § Promoting the human contact between patients and health professionals where verbal information, complemented with tailored written and nonverbal information can be provided. 2. Barriers identified in healthcare settings In order to propose a set of relevant recommendations, an analysis of barriers to access information in healthcare settings was undertaken21. The key barriers identified as common to the three healthcare settings are as follows: Barriers involving the Healthcare setting Barriers involving the Healthcare Professional Barriers involving the Patient Ø Inappropriate or insufficient communication between healthcare settings Ø Duplication and lack of consistency of messages passed on to the patient and to different healthcare professionals Ø Inaccessibility to patient health records Ø Reliance on general standards without auditing their appropriateness and implementation to specific situations Ø Communication skills Ø Time available Ø Lack of patient- friendly information available to healthcare professionals Ø Patronising or judgemental attitudes towards the patient or carer Ø Working pressure/ productivity demands Ø Health literacy Ø Time available Ø State of mind Ø Confidentiality Lack of information/too much information22 20 Health literacy is the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. 21 This refers to the different examples from pharmacies, hospitals and general practices as published on the European Commission website. Final Conclusions and Recommendations of the Pharmaceutical Forum 20 Ø Level of privacy 3. General recommendations The Pharmaceutical Forum recommends Member States, relevant Stakeholders and the European Commission: § To recognise the added value of providing information to patients on diseases and treatment options in friendly and patient-centred healthcare settings, such as general practices, pharmacies and hospitals; § To encourage investment in organisations’ capacity-building initiatives to improve Health Literacy; § To promote the integration of information to patients aspects in health professionals' education and the development of continuous training in communication skills; § To support the development of collaborative care approaches23 within different institutions and among health professionals; § To facilitate the deployment of relevant tools, such as integrated ICT systems and electronic health records. 3.1 Key areas for action for Member States § Undertake regular and exhaustive reviews of what exists at national level, to make sure to target initiatives on the real demands of patients. § Consider development and use of healthcare performance indicators (hcpi) and development of tools to measure the quality of information provision and its effectiveness.24 § Select priorities areas to target, using where relevant information gained from hcpi. § Consider national annual campaigns for the provision of key information, e.g. vaccine immunisation, nutrition, sun protection. § Support development of national health information policies and programmes with an active participation of organisations representing citizens and patients as well as different health professionals and healthcare settings. § Develop collaborative care approaches within different institutions and among health professionals by considering joint educational initiatives. § Promote the education and training of health professionals in communication skills; § Establish effective electronic tools, such as databases of updated information, and communication tools, such as integrated ICT systems and electronic health records. § Invest in organisations’ capacity-building initiatives towards improving Health Literacy. 3.2 Key areas for action for relevant Stakeholders § Map education needs and communicate them to the relevant competent authorities. § Promote implementation of best practices in the provision of information to patients in healthcare settings. § Encourage multidisciplinary and collaborative care among health professionals. § Stimulate the use of modern technology by health professionals and patients. § Collaborate in initiatives to tackle Health Illiteracy. 22 AIM and ESIP considers that lack of access to patients own records is a barrier to access information. 23 Collaborative care is an integrated approach to care management. This type of approach is an ongoing collaboration among a variety of health service providers, patients, their families and caregivers, and the community, with patients as both the focal point and full partner in the overall effort. 24 AIM and ESIP does not agree to include the use of hcpi in this document. Final Conclusions and Recommendations of the Pharmaceutical Forum 21 3.3 Key areas for action for the European Commission § Encourage investment in organisations’ capacity-building initiatives towards improving Health Literacy in the Member States. § Facilitate the exchange of knowledge, evidence and good practice in the provision of information in different healthcare settings. 4. Practical solutions as already existing in some Member States, and exemplified in the input from stakeholders and Member States Considering that a number of good and innovative25 initiatives responding to some of the challenges identified above already exist in the Members States, a number of practical solutions of interest have been extracted from the document "Overview of practices on access to and dissemination of health information in health care settings”. The selected examples26 are not exhaustive and further examples of initiatives can be found in this overview. The sources and nature of the information should be considered together with the ways of dissemination. Member States Stakeholders involved in healthcare settings Ø Joint education programmes Ø Databases Ø Public portals, such as national web-portals on hospitals Ø “Information prescriptions” Ø National campaign with information packages to Healthcare professionals Ø “Questions about your medicines” campaigns Ø … Ø Patient information leaflets, regularly updated, available in hardcopy and possibly in electronic format ready to print with disease and health-related information (1) Ø Electronic templates with core information which can then be tailored to the individual patient by the health professional and printed out(2) Ø More privacy through the creation of more isolated counselling areas, and more emphasis on information counselling(3) Ø Call centres(4) Ø Windows displays and posters(5) Ø Technological tools(6) - On-site TV channel with video content27; - Audio solutions and web-pages - Touch screens/waiting areas with computer access, health contents and printer Ø … Examples: (1) Development of patient leaflets in Danish pharmacies, and patient handbook for safer hospital stay under the chapter on Hospitals in the overview. (2) Finnish pharmacy information system. (3) Counselling session in Swedish pharmacies, internal health communicators in Swedish hospitals, and group sessions and personalised treatment calendars in Spanish hospitals. 25 France and AIM do not agree on the wording "good and innovative" in this sentence. 26 France states that it is necessary to conduct an impact study before advocating an extension of the examples given in the box. 27 AIM could have concerns with this example depending on the source. Final Conclusions and Recommendations of the Pharmaceutical Forum 22 (4) Swedish pharmacy call centre and Finnish and Icelandic GPs call services, for instance, to get "educated guessed" from local health services. (5) Posters in connection with campaigns, e.g. French pharmacies, in GPs' waiting (rooms see Spanish example). (6) Hospital webpages in France and Belgium, TVs in waiting area GP Ireland and Austria, self-service waiting area in Portuguese pharmacies with displays, computer access and printers, use of SMS in a Portuguese hospital, "TV health channel" in France with practical information for people going to hospitals. 5. Future challenges28 The implementation of some of the recommendations to enhance access to information on diseases and treatment options in healthcare settings identified above for stakeholders, Member States and the European Commission will need commitment from all the different players. The Pharmaceutical Forum therefore suggests that the Commission considerers the establishment of a group dedicated to Information to Patients under the coordination of the Commission, where Member States, Stakeholders and the Commission could engage in future steps. In a first instance, such group could focus on exchanging experiences and practices in relation to building capacity for patients’/citizens health literacy to optimise their communication/understanding capacities in healthcare settings. It should also look at encouraging the development of health professionals’ communication skills towards the patients. This could possibly lead to an EU-funded project. 28 AIM considers that point 5 goes beyond access to information in healthcare settings. Final Conclusions and Recommendations of the Pharmaceutical Forum 23 Core quality principles for patient information on diseases and treatment options High quality information must meet the criteria set out in these principles and should also have a clear process for compliance/certification. Information provided by a Member State and/or the European Commission should be done without restricting or replacing other sources. Objective and unbiased Information is objective when it is based on facts and not influenced by prejudices or personal perceptions. Information is unbiased when it is impartial, non-directive and balanced. These two definitions do not relate to the source of information which is a separate issue (see the ‘Transparent’ principle). Patient-oriented Information provided should be patient-centred taking into account patients’ needs and expectations in order to empower patients. Patients should be involved in the production and dissemination of information on diseases and treatment options wherever possible. Evidence-based The evidence base for any information resource needs to be clearly stated, including making clear the level of evidence. Information should be verifiable, based on comparisons and backed up by scientific peer review where possible. Up-to-date Information should be kept up-to-date and the date of publication should be included. Reliable Information needs to be factually correct and not misleading. Information should be scientifically valid and reflect latest knowledge. Understandable Information provided should be comprehensible for a patient/citizen. Accessible Information should be easily accessible via different mechanisms for example, through written documents, websites of certified official bodies etc. Information should also be accessible to people with disabilities. Transparent Informed choice requires transparency. That entails transparency of what is known as well as what is not known. Funding, sources of information, evidence for that source and transparency when there is known controversy about a particular treatment, for example, all need to be made clear. Relevant Information should include issues of relevance and importance to patients’ decision-making e.g. including adverse effects. Impact on quality of life and the consequences of the disease on Final Conclusions and Recommendations of the Pharmaceutical Forum 24 contribution of the patient to society/the work place are important elements of information on disease. Consistent with Statutory Information Information not regulated by statute should, nevertheless, be consistent with the legal requirements of European law (e.g. must not be designed to promote a prescription only medicine, reflecting the prohibition of direct to consumer advertising of prescription only medicines, must not be misleading etc.) and should refer, where appropriate, to statutory information approved through the process of regulation. Final Conclusions and Recommendations of the Pharmaceutical Forum 25 Methodology of use of the core quality principles on information to patients On 26 June 2007 the Pharmaceutical Forum agreed on a set of core quality principles on information to patients on diseases and treatment options: - objective and unbiased - patient-oriented - evidence-based - up to date - reliable - understandable - accessible - transparent - relevant and appropriate - consistent with statutory information On the request of the Pharmaceutical Forum, a methodology of use has been developed to facilitate the implementation of the core quality principles on information to patients on diseases and treatment options. The overarching goal of developing a methodology of use of the core quality principles on information to patients is to set out quality requirements for information material on diseases and treatments to prevent any promotional orientation of the information and ensuring the confidence of patients on the high quality of the information. Thereafter, the main purpose of the methodology in its application is to assist Member States and Stakeholders to develop good quality information and to help patients29 distinguish high quality information from poor quality information. The methodology of use should not undermine national control system that exists but rather contribute to support evaluations by national competent authority. The clear and reproducible criteria for each of the quality principles should be fulfilled to ensure the distinction between promotional data and good quality information. This general methodology applies to all kind of information and has the two overall practical objectives of: • Establishing a guiding framework ensuring the respect and use of the quality principles for providers of information; • Support the Member States and/ or other organisations, as well as patients and healthcare professionals when assessing the quality of information. It has been developed in the format of a checklist under which all the essential points of the list should be fulfilled. 29 AIM and ESIP considers that this methodology is intended for information providers and would be very difficult to be used by patients and citizens. Final Conclusions and Recommendations of the Pharmaceutical Forum 26 Checklist ensuring the application of Core Quality Principles for Information to Patient30 1. Objective and Unbiased Information is objective when it is based on facts and not influenced by prejudices or personal perceptions. Information is unbiased when it is impartial, non-directive and balanced. These two definitions do not relate to the source of information which is a separate issue (see the ‘Transparent’ principle). • Information should be comprehensive, complete, impartial, non-directive and balanced.31 • Information should rely on exhaustive sources of information covering the total of evidence which should be made public32. • A publication should be peer-reviewed and approved by an independent editorial board with proven scientific expertise, with representatives from professional organisations and/or patient and consumer groups.33 • A publication should respond to the need of patients and have its aims stated at the beginning of the publication. • It should be indicated when there are only symptomatic treatments available. • It should be indicated when products are being studied in clinical trials or made available under compassionate use programmes34. Patients should be referred to EUDRACT, the EMEA database, for further information on clinical trials. • It should always be indicated which choices of treatment exist, even if a full account of alternatives has not been presented in the publication35. • It should be indicated how the treatment fits into therapeutic strategies • Information on how each treatment is administered, how it acts on the body and what are the consequences for every day life should be included as well as the benefits and risks. • Information on pharmaceutical treatments should contribute to the good use of medicines 30 The quality principles and their corresponding texts in italic as listed below were endorsed by the Pharmaceutical Forum on 26 June 2007, see http://ec.europa.eu/enterprise/phabiocom/docs/pf_20070626_progr_report.pdf . 31 AIM suggest further criteria: The wording and language should be neutral and non-directive and does not see words that appeal to the emotions, fear, creating a need, unrealistic hope or promises so that decisions are made in accordance with the patients’ own values. 32 AIM and ESIP suggests further wording: (including results of positive and negative studies). AIM added that: Information on (on-going) clinical trials should be made available through the EMEA database on clinical trials (EUDRA CT). 33 ESIP does not agree to characterise the participants. 34 ESIP and AIM do not agree to the reference to compassionate use programmes as these are not validated information. 35 AIM and ESIP suggests to replace this criteria by: For diseases, validated treatments should be equally well described (benefits, harms, risks…) along with information on prevention. Final Conclusions and Recommendations of the Pharmaceutical Forum 27 • The denomination of the pharmaceutical treatments should include the class names and the names of the active ingredients. References to brand names depend on EU and national legislation.36 2. Patient-Oriented and Understandable Information provided should be patient-centred taking into account patients’ needs and expectations in order to empower patients. Patients should be involved in the production and dissemination of information on diseases and treatment options wherever possible. Information provided should be comprehensible for a patient/citizen. • The language should be clear, easy to read and appropriate for patients. • If technical terms are used, there should be an explanation or a glossary at the end of the publication. • There should be some kind of notice that the publication is designed to support, not replace, the relationship between patient and health professionals. • There should be an opportunity for feed-back, asking questions or reporting any problems with the publication. • Patient groups should be involved in information production from the onset or consulted prior to publication whenever possible to ensure the relevance of the information and to test the readability and if the message is understandable to the general public. • The publication should commence with an overview indicating what it is about, what it covers and who it is meant for. • The language and layout of the publication should make the information reader - friendly and facilitate the search for specific information. 36 France, AIM and ESIP do not agree to include a reference to brand names. Final Conclusions and Recommendations of the Pharmaceutical Forum 28 3. Evidence-Based The evidence base for any information resource needs to be clearly stated, including making clear the level of evidence. Information should be verifiable, based on comparisons and backed up by scientific peer review where possible37. • The content is based on rigorous and systematic evidence • The information is developed following a systematic method which aims to minimise bias and maintain neutrality. • Evidence-based communication techniques should be used to meet the goals of informing, supporting and empowering patients and consumers. • A main statement, “fact” or recommendation38 should be accompanied by a level of evidence.39 • Information on evidence should be understandable to the general public and not being directive. • The lack of evidence, contradictory evidence, or uncertainty as well as potential benefits and risks should be clearly stated. 4. Up to Date Information should be kept up-to-date and the date of publication should be included. • The date of publication or last revision and the dates of the main sources of evidence used and reported in the publication should be stated. • The date of the next planned update should be also stated when possible. • Information should be kept up-to date to remain evidence-based. 37 France does not agree to the wording "where possible because it is in contradiction with point 2 and point 5. 38 AIM and ESIP do not agree with the inclusion of "recommendation” in this criteria as information should maintain neutrality. 39 AIM and ESIP wants to add "According to the methodology of evidence-based-medicines". Final Conclusions and Recommendations of the Pharmaceutical Forum 29 5. Reliable Information needs to be factually correct and not misleading. Information should be scientifically valid and reflect latest knowledge. • Information needs referencing to make it clear where the evidence for the information has come from. - A main statement, “fact” or recommendation40 should be accompanied by a reference to the source of the publication. It should not be used out of its context. - A source of evidence should be listed in a bibliography or reference list at the end of the publication. • Method and quality review by an independent editorial board on the accuracy of the content and the structure of the publication should be put in place. • A quality assurance system for the research and selection of information and for the editorial review should be respected. 6. Accessible Information should be easily accessible via different mechanisms for example, through written documents, websites of certified official bodies etc. Information should also be accessible to people with disabilities. • Information material41 should be easily accessible to patients and citizens • Sufficient supply and dissemination of material should be ensured (e.g. through pharmacies, general practices and hospitals)42. • Opportunities to make information accessible to people with disabilities should be put in place. • Additional official43 and/or non-commercial sources of high-quality information and contact for support should be listed at the end of the publication under headings such as “Useful addresses” and “Further reading”. • The reader should be encouraged to ask for further clarification or to discuss the content of the publication with a health professional. 40 AIM and ESIP do not agree with the inclusion of "recommendation" as information should maintain neutrality. 41 AIM wants to have "independent, validated, high quality information material" added to this criteria. 42 ESIP does not agree with this criteria. 43 AIM wants to have "validated additional official" added to this criteria. Final Conclusions and Recommendations of the Pharmaceutical Forum 30 7. Transparent Informed choice requires transparency. That entails transparency of what is known as well as what is not known. Funding, sources of information, evidence for that source and transparency when there is known controversy about a particular treatment, for example, all need to be made clear. • Existing controversy about particular elements in the information should be indicated. • The publication should disclose information or a reference on where to find information44 on the following elements: - Name, mission, structure and financial background of the organisation publishing the material - Sources of funding for the material and possible conflicts of interest of the sponsor - Names, qualifications and possible conflicts of interest of all authors. - Names, qualifications and possible conflicts of interest of the editorial board review and disclosure of the process and quality assurance. - Method, process and respected quality principles for the submitted information • Origin of the information should be indicated. 8. Relevant Information should include issues of relevance and importance to patients’ decision-making e.g. including adverse effects. Impact on quality of life and the consequences of the disease on contribution of the patient to society/the work place are important elements of information on disease. • The information provided on a certain disease should be relevant to the patient’s needs and circumstances, especially healthy lifestyle, prevention, treatment options, benefits and risks.45. • Information should be neutral and non-directive. • The publication should not make recommendations that are unrealistic or contain assumptions or language that may be considered inappropriate or offensive. • The inclusion of comparative information on the different treatment options should be evidence-based and relevant to patients. 44 ESIP is of the opinion that to achieve full "transparency" the information should be included directly in the publication so the reader should not have to look for it. 45 AIM wants to include reference to comparative information. Final Conclusions and Recommendations of the Pharmaceutical Forum 31 • The reader should be made aware that more specific and tailored information to his/her individual situation could be obtained by consulting a health professional. 9. Consistent with Statutory Information Information not regulated by statute should, nevertheless, be consistent with the legal requirements of European law (e.g. must not be designed to promote a prescription only medicine, reflecting the prohibition of direct to consumer advertising of prescription only medicines, must not be misleading etc.) and should refer, where appropriate, to statutory information approved through the process of regulation. • The information material shall be compliant with national and European legislation. • The information delivered shall be compliant with the legal requirements of information on medicinal products. As for information on medicinal products, information should be in conformity with approved summaries of product characteristics and patient information leaflets and it should not contradict or go beyond the key elements specified in them. • Copyright laws must be observed. As for the special requirements internet information calls for, we refer to the report on the implementation of an Austrian health portal, which provides an extensive and feasible methodology for this purpose.46 46 France does not agree to have a reference to the Austrian report in this document. France finds that the quality criteria and other specific criteria for information disseminated by internet have to be added as such in this methodology of use of the core quality principle and there should not be a reference to this Austrian report that has still to be discussed. Final Conclusions and Recommendations of the Pharmaceutical Forum 32 Key elements of information to patients on diseases and treatment options 1. Context This guidance template has been prepared in the framework of the EU High Level Pharmaceutical Forum Working Group on Information to Patients47. At the request of the Pharmaceutical Forum, the working group identified what could be the key elements for European level core information that could provide a basis for a wide range of information material. The development of a list of key elements of information to patients on diseases and treatment options builds on the public consultation by the European Commission on a first model information package on diabetes48. The public consultation revealed a universal acknowledgement of the value of framing what would be a comprehensive information package in different disease areas that covers all issues relevant to patients. A member of the Pharmaceutical Forum, the European Patients Forum, undertook a consultative work with its membership in relation to a framework of the key elements that would constitute a comprehensive information package for patients in different disease areas. This was developed using ‘case study’ examples from different disease areas at European and national level. For the examples selected, an all-embracing approach had been adopted to information including a variety of health-related quality of life, prevention, lifestyle, treatment, therapies, disease management, social and peer support, patient education and reimbursement options.49 2. Objectives The document key elements of information to patients on diseases and treatment options intends to list in detail what should constitute ideally the key elements of health information developed for patients and citizens. The list should constitute a reference template for drafting and development of information material and could also be used as a basis for assessing, benchmarking, improving and completing existing materials. This proposal attempts to reflect implicitly the ‘quality principles’50 in relation to information to patients that were adopted at the High Level Pharmaceutical Forum meeting in June 2007. It is important to reiterate, however, that the delivery of information to patients should be adapted to different situations. Information needs to be disease-specific, very often age and 47 http://ec.europa.eu/enterprise/phabiocom/comp_pf_en.htm 48 A public consultation on the diabetes information package pilot project developed by the Pharmaceutical Forum Information to Patient Working Group took place in spring 2007, http://ec.europa.eu/enterprise/phabiocom/comp_pf_consult_2007.htm 49 Consultation of the European Patients Forum to its membership November and December 2006 http://www.eu- patient.eu/news/attached_documents/EPF_reference_doc_itp.pdf 50 Core Quality Principles for Patient Information on Diseases and Treatment Options, Progress Report, 2nd Pharmaceutical Forum , 26 June 2007 , Annex B, http://ec.europa.eu/enterprise/phabiocom/docs/pf_20070626_progr_report.pdf Final Conclusions and Recommendations of the Pharmaceutical Forum 33 gender group-specific and, most importantly, accessible to the individual patient, in his or her cultural context. 3. Instructions for use Any information provider, even when providing information on a specific issue only, such as prevention, should understand that patients have various information needs. This ideal template aims to cover all the information needs that the provider should consider. The first column describes the key elements of information and is illustrated with guiding topics on what the key information might cover. While aiming to be comprehensive, the template cannot cover all disease-specific issues and does not necessarily show the order in which information should be presented. 4. Key Elements of Information to patients on diseases and treatment options The document key elements of information to patients on diseases and treatment options intends to list in details what should constitute ideally the key aspects of health information developed towards patients and citizens. It comprises a list of what constitute the key elements for information illustrated with the main topics they should cover. The content in the list of the key elements and their specifications is not exhaustive and should be adapted according to the diseases and the targeted group of the publication and the material itself. Final Conclusions and Recommendations of the Pharmaceutical Forum 34 Introduction to the Information material Background information § Objective of the publication § Context of the publication § Purpose of the information § Target audience Disease Repartition of the disease § Prevalence - Different age groups - Gender differences § Incidence - Different age groups - Gender differences Diagnosis § Early signs § Tests § Accuracy Pathology § Disease mechanism Causes § Inherited/Genetic disease § Environment § Lifestyle § Other Symptoms § Description of the symptoms § Causes of symptoms § Occurrence of symptoms § Exacerbations Development of the disease § Natural course/lifecycle of the disease § Severity § Disease at different stages of life - Foetus, childhood - Adolescence - Adulthood - Pregnancy - Old age - End of life § Changes of cure or regression Co-morbidities Misconceptions Uncertainties Essentials on what we do not know Final Conclusions and Recommendations of the Pharmaceutical Forum 35 Living with the disease Coping with the disease • Quality of Life (health related QoL) • In different settings - everyday life - day-care - education - home - work - travelling • At different ages/ stages in the life continuum • Disease and gender • Psychological factors - Self-esteem - Relationships: love & sex, work mates, friends, family - Communicating about the disease (to others) • Disability-adjusted life years (DALY) Compliance/concordance/adherence51 • Issues on managing chronic disease • Taking part in decisions about treatment • Following the treatment regime - Motivation - Reporting exacerbations - Changes in the treatment • Benefits and risks of adherence, compliance/non-compliance Availability Information on whether the medicines are placed on the market; availability of other treatments Price/Reimbursement52 • Reimbursement status • Price status Prospects for future development53 • Prevention • Treatments • Opportunities to be involved as a patient54 Navigating care and support services / Patient resources • Government • Private • Health insurance • Healthcare settings - general practice - hospital 51 AIM suggests moving the elements to the part of patient empowerment. 52 AIM suggests including global cost of the treatment, global costs for patients to live with the disease. 53 ESIP questions this point and makes it clear that they disagree with any invitations to patients to join clinical trials. 54 France and AIM do not agree with this point. Final Conclusions and Recommendations of the Pharmaceutical Forum 36 - pharmacy - others • Patient organisation - membership - services (help lines, education, rehabilitation, peer support) Information for carers • Support • Coping Prevention (as defined by WHO) • Primary prevention • Secondary prevention Lifestyle and environment Medications 1. What can be treated 2. State of the art of treatment options55 • Class name and name of active ingredient (INN) (brand name if possible under national/EU legislation)56 Treatment goal and medicine mechanisms (how they act) • Indications • Contraindication • Effectiveness • Safety - Benefits - Risks • Side-effects • Dosage and interval • Interactions with other medicines and treatments • Evidence-based comparison of medications 3. Future treatment prospects57 Other treatments58 What non pharmaceutical treatments options are existing Rehabilitation Follow-up in the convalescence period • Clinical examinations • Tests • Lifestyle 55 Sweden wants to include environment aspects under that topic. 56 France, ESIP, AIM and Austria do not agree to the reference to brand name. 57 AIM does not support this as they consider that it could probably be used for the promotion of not validated information 58 AIM wants to include comparative information on treatment options. Final Conclusions and Recommendations of the Pharmaceutical Forum 37 Where to find more information References Background information on the publication Author/s Publisher/s Contact information Funding of the publication Date of publication 59 AIM wants to add "official treatment guidelines" Treatment guidelines59 Other non-commercial sources of information • National Competent Authorities • Patients organisation • Health professionals • Health insurance organisations • Other initiatives Final Conclusions and Recommendations of the Pharmaceutical Forum 38 Introduction to Public-Private Partnerships and other Collaborative Approaches Delivering Information to Patients on Diseases and Treatment Options in Europe The purpose of this document is to provide an idea of different models of existing collaborations and partnerships in Europe delivering information to patients on medical conditions and treatment options, considering the possible partners, structures, process, outcomes and funding. Its main objective is to clarify the existing possibilities in setting up initiatives with parties from different sectors and how each partner can contribute to the realisation of the projects. The report does not intend to evaluate the success of any initiative or to assess the information provided to the public. All the projects mentioned in this document were submitted by members of the Pharmaceutical Forum while conducting an analysis of practical implementation of partnerships/collaboration for information package at national level. An overview table mapping out the main characteristics (structure and membership; roles and responsibilities of the partners; budget and sources of financing; outcome; impact) of partnerships/collaborations submitted by the Members of the Pharmaceutical Forum is annexed to this report. For the purpose of this report, the concepts of partnerships and collaborations are understood in the broadest sense. There is indeed not one single approach in building partnerships with the objective of developing and providing information on diseases and treatment options to citizens and patients. The pre-condition for including partnerships or collaborations in this report was the decision of different actors to gather expertise and resources in a single project aiming at informing patients. The experience has shown how diverse and complementary existing approaches can be. Considering the different possibilities from the structures and outcomes of the partnerships, a number of examples were selected in the overview table to illustrate the diversity. The initiatives listed should constitute experiences of interest when developing future cooperation between different partners. Who are the partners? There are many kinds of partnerships in the Member States. The general principle is that parties launch joint projects when there is interest in sharing experiences, resources and knowledge. The variety of approaches presented to the working group has shown that initiatives can involve multiple possibilities of public-private collaborations and public-public collaborations. Examples of private-private collaborations also exist in some Member States. For the Medicine Information Project, a public-private partnership in the UK, NHS Direct online, is the provider of information on conditions and treatment options. In addition, there is the Medicine Guide, independently authored by health experts and subsidised by individual companies, which is directly interlinked with NHS Direct online. Interested parties such as industry, patient organisations, the UK Department of Health and healthcare professionals jointly supervise this initiative. The Medicine and Reason project in Austria is another example of a public-private partnership where the Minister of Health is not involved directly but where the association of Austrian social security institutions, an independent Final Conclusions and Recommendations of the Pharmaceutical Forum 39 administration, is working with the Medical Chamber, the Chamber of Pharmacists, the Chamber of Commerce and the Austrian pharmaceutical industry association. Public-public partnerships also exist in Europe. For instance, individual Swedish county councils launched Health Care Direct, a website and phone advice service on health services disease information and treatments in Sweden. Actors representing different activities and different interests share expertises and resources for specific initiatives resulting in further information to patients on diseases, treatments and health topics. How are partners involved in the projects? The roles and responsibilities of the partners are very diverse. In some initiatives, partners are involved only as resource providers, i.e. providing funding or knowledge. Orphanet, for example, is a government service headed by INSERM, the French Institute for Health and Medical Research. For some of its ad hoc projects, such as the provision of information on orphan drugs and on clinical trials, the private sector is involved by providing financial support. Partners might also contribute by providing initial information, to be used as a basis for the end product. This is the case, for example, with FASS.se, where the pharmaceutical industry provides information on pharmaceutical products – package leaflets, SPC, etc. to the national medical product register. In other projects, partners provide factual content on health/disease topics. In other initiatives, parties are involved at a later stage in the production of information. In a number of cases, independent experts are in charge of the drafting of information and stakeholders, including patient organisations, healthcare professionals and sometimes industry, are involved through being consulted on the text. This is the case with "Informed Health Online" (Gesundheitsinformation.de) in Germany, for instance. Finally, all partners can also be at the core of projects, being deeply involved throughout all stages of the development of the projects. This kind of involvement can be organised in different ways, e.g. within the board of trustees (Informed Health Online), or within a Steering Committee (Informatum in Denmark and Medicine and Reason). What are the possible outcomes of partnerships? Most of the initiatives on information to patients on diseases and treatment options that were mentioned to the Pharmaceutical Forum focus on electronic information. A number of websites created by partnerships which disseminate information on diseases and/or pharmaceutical treatments already exist in the UK, Germany, Sweden and Denmark. Other possible non-electronic outcomes of collaborations are flyers, drug guides, guidelines, fact sheets, newsletters and phone advice. Final Conclusions and Recommendations of the Pharmaceutical Forum 40 What about validation? From these examples, it seems that a common trend exist regarding the validation process of information. In general, initiatives have clearly defined validation systems in place. As part of the process, there are usually two key safeguard mechanisms. Firstly, the draft material is presented to independent expert groups for a first review. Afterwards, as a final condition before publishing, the text is usually sent for validation by a review group, usually composed by stakeholders. The liability of the sources of information is of major importance. How are the outcomes disseminated? It should be mentioned that initiatives resulting from collaborations between different parties are sometimes directly linked to or even integrated within public authorities’ websites. This is the case in the UK, with NHS Direct Online, and in Germany with the website of the German Institute for Quality and Efficiency in Healthcare. Other initiatives are separately promoted, such as FASS.se or Orphanet. Dissemination of the outcomes can also be carried out by specific members of the partnership. For Medicine and Reason, flyers are distributed by three of their funding members (the Main Association of Austrian Social Security Institutions via its Health Care Institutions, the Medical Chamber and the Chamber of Pharmacists) in healthcare settings, while, in parallel, all members have included the project on their websites. Impact 60 Considering the different aims of the initiatives, the impacts of the collaborations mentioned to the Information to Patient Working Group are variable. Some initiatives can reach many citizens, illustrating the increasing need for information by patients. The Swedish FASS.se has 4 million visitors a month, of which 40% are patients or citizens. Orphanet has 20 000 daily users from 150 countries of which 33% are patients. In addition to the extensive use of certain initiatives, the degree of satisfaction among users is also found to be high. 88% of users of the Medicines Information Project found the information to be of use, and 85% found the information to be trustworthy. Financing Funding of the projects can be either public or private. In the Medicine and Reason project, for example, the costs are shared equally by all four members (Austrian pharmaceutical industry association and the Chamber of Commerce are regarded as one member). The financing systems of initiatives also vary. Indeed, the running of the initiatives can depend on annual contributions (Informed Health Online/Gesundheitsinformation.de), sponsorship of ad hoc projects (Orphanet), or even fees from pharmaceutical companies per product mentioned (FASS.se). 60 The figures used in the report were provided by members of the Pharmaceutical Forum and are only indicative. Final Conclusions and Recommendations of the Pharmaceutical Forum 41 Overview of Existing Collaborations / Public Private Partnerships in the field of Information to Patients61 62 Name – Member State Structure and membership (link to legal basis and mandate if publicly available) Role and responsibilities of the partners Budget and sources of financing Outcomes Impact • Number of users/Frequency of use • Level of trust/number of complaints • Other Medicines Information Project UK Partnership including government, MHRA, NHS, pharmaceutical industry, patients, HC professionals Details on the website Supervisory remit for the project, giving it overall direction and setting priorities • Funding for development of the NHS Direct Online content about medical conditions and treatment options, provided by NHS Direct Online. • Funding for individual Medicine Guides provided by the pharmaceutical industry • The funding model is based on a fee per product and contribution to development and management costs based on companies’ turnover. Medicine guide: guide about individual medicines with links to/from information about condition and treatment options published on NHS Direct Online • website • Approaching 500000 pages download per month • Survey about the information: 88% usefulness, 85% trust • Direct electronic interaction with NHS direct and the Health encyclopaedia Medicine and Reason Austria Partnership between main association of Austrian social security institutions, industry/Chamber of Commerce, medical chamber, pharmacist chamber. (Guideline for procedure, external quality assurance of abidance by this procedure) • Members of the Steering Committee and of all other boards (expert group, implementation, evaluation) • After a first draft being developed by experts, stakeholders are consulted through roundtables € 73 000 p.a. 25% paid by each partner Flyers on disease and treatments for patients disseminated free of charge to Healthcare settings and in addition accessible on internet, and guidelines for general practitioners • 9 guidelines and flyers available (Jan. 2008) • website • last printed edition: 260 000 flyers and 18 000 guidelines • support for general practitioners and patients • provision of state-of-the-art and evidence based therapies at an economically reasonable price • interdisciplinary approach 61 This overview is not exhaustive or exclusive. 62 AIM and ESIP stresses that this overview should not aim to provide the basis for a recommendation for the establishment of collaborations or public private partnerships. Final Conclusions and Recommendations of the Pharmaceutical Forum 42 FASS.se Sweden Pharmaceutical industry association involved in certain collaborations contributing to the website - Swedish Association of Local Authorities and Regions: Supply and development of information to the Swedish health care - Medical Products Agency, the Pharmaceutical Benefits Board and the National Corporation of Pharmacies : National Medical Products Register - Uppsala University: interactions and descriptive texts on certain topics - National Poisons Information Centre: overdose treatment - Swedish Environmental Research Institute: Validation of environmental classification - Stockholm county: Development of environmental classification • Product information supplied by pharmaceutical companies. • Other information by independent authors. Individual pharmaceutical companies Website: • Patient FASS text on authorized medicines in Sweden • 300 diseases and their treatments, 40 topics covering general aspects of use • information about patient organisations • R &D information for more than 60 diseases • Access to ongoing and completed clinical trials • Environmental classification • Pregnancy and lactation classification Accessibility for disabled people: Braille, text to voice, large font printouts and automatic translation of medical terms in SmPC and similar documents My Fass: to store patients medications. Rapid alert function available to disseminate information on product information updates. Medicines compendium: Patient-FASS is biannual publication Website • 4 million visitors/mth with 40% visitors from general public/patients. • Information distributed electronically to various information systems within the Swedish health care, pharmacies, etc. • Off-line to PDA • Access from mobile phones • Information structured for electronic transmission and supports medical decision systems • Main provider of information on medicines in Sweden • Cross- reference to several public sites Patient-FASS: 35 000 copies Sjukvårdsrådgivningen (Health Care Direct) Sweden Partnership between county councils Managed by a management board and editorial board. 85 employees working on the text. Financed by the county councils with an annual budget of € 28 500 000 • Website with 1350 topics about diseases and drugs • Phone advice • 80 000 website visitors/mth • 3.5 millions phone advices Final Conclusions and Recommendations of the Pharmaceutical Forum 43 Medical Products Agency Sweden Partnership with the health care, industry, and user organisations Medical Products Agency: responsible for the production of information Other partners: advice and authorship Website for the public on drugs and diseases 5200 website visitors / month Partnership with the Swedish Medical Association Medical Products Agency: production joint authorship Included in the ordinary budget of MPA Drug guide: 460-page book for the public on drugs and diseases 15 000 copies sold Informed Health Online Gesundheitsinformation.de Germany German Institute for Quality and Efficiency in Health Care cooperates with stakeholders in the final stage of the development of the information. Legal basis: Section 139a and 139b of Social Security Code Book V (SGB V) • Board of trustees (health professionals, patients, community and industry) • Researchers in charge of the first drafts which scope and messages will be submitted for approval. Consultations are organised with Health Ministry and board of trustees; Test readers as a final stage Non-government Foundation established by legislation, which is financed by statutory health insurance contributions and funding from the Ministry Website on diseases and treatments • Over 1 000 topics by 2012 • German and English • website • Multiple international cooperation, including adoption of the patient information by NHS Direct and HAS Infomatum Denmark Partnership including government, pharmaceutical industry and organisations: Ministry of Health and Prevention, Industry Association for Generic Medicines, Medical Association, Association of the Pharmaceutical Industry, Medicines Agency, Pharmacy Association, Regions and Association of Parallel Importers Information on the website: http://www.infomatum.dk/ • Steering committee is responsible for 1. Impartial and knowledge based presentations on medicines and the most suitable use in patient treatment and 2. chooses members for the board of directors/executive committee • Executive committee selects a steering group with representative of all the partners • Owned by DADL (Danish Medical Association) and DLI (Danish Medicinal Products Information) which have an annual turnover of DKK 45 million • The publishing establishment is financed by the pharmaceutical firms which are members of the industrial organisations represented in the steering group Guidelines for practitioners of medicines Objectives: - To improve the existing level of knowledge on medicines and strengthen the decision-making in connection with choice of treatment - To ensuring that patients get a treatment of high technical skill • Website • Book • Offline PDA Final Conclusions and Recommendations of the Pharmaceutical Forum 44 Directorate of Health Iceland Government agency headed by the Medical Director of Health. One function is to advise the Minister of Health and Government bodies, health professionals and the public on matters concerning health and health care services. Information about the structure on the website. • A clinical guidelines unit cooperates with other clinical guidelines providers, nationally and abroad, among them the Landspitali University Hospital. The unit makes use of foreign clinical guidelines and adapts them to Icelandic circumstances. • The DH unit of professionals chooses material for website information for the public on health and diseases. Funded by the State Website: • Clinical guidelines for professionals (the most frequently visited pages on the DH website). • Information for the public on health and diseases with links to validated websites in English and in Icelandic. Website: • 46 000 page impressions/month • 7000 visitors/ month Orphanet • Consortium of 37 national partners • Independent national Orphanet teams with scientific advisory board and consortium agreement. • Central coordination by the French team. • Ad hoc cooperation with private and/or public organisations • French team in charge of information on diseases written by experts and peer-reviewed; and of coordination with national teams to collect data on services at national level. • The scientific advisory boards advise the local teams and validates the national information. • Partners involvement depending on the project - Financial support - Data sharing from industry, clinicians and patients organisations. • Core budget: Minister of Health of France, INSERM (National Institute of Health and Medical research) and European Commission • Sponsor financing specific projects: Industry organisation, patient organisation and insurances. • Information mostly electronic: 1. Orpha.net: Website - Database of information on rare diseases (5806 diseases) with direct link to a health encyclopaedia - Database of information on orphan drugs (45 orphan drugs in Europe, 530 European designations, 591 clinical trials) - Specific information per diseases with reference to: specialised clinics, diagnostics test, research activities including clinical trials and patients organisations 2. OrphaNews: Newsletter bi- monthly • Languages: English, French, Spanish, German, Portuguese and Italian • 20 000 daily users from 150 countries. Users: 33% patients and they entourage, 33% Doctors, 18% other health professionals • 96% satisfaction of Orphanet users Final Conclusions and Recommendations of the Pharmaceutical Forum 45 List of websites: 1. Medicines Information Project: http://medguides.medicines.org.uk 2. Medicine and Reason: http://www.sozialversicherung.at 3. Fass.se: http://www.fass.se 4. Sjukvårdsrådgivningen: http://www.sjukvardsradgivningen.se 5. Medical Products Agency (Läkemedelsverket): http://www.lakemedelsverket.se 6. Informed Health Online: http://www.informedhealthonline.com/Gesundheitsinformation.de 7. Infomatum: http://www.medicin.dk 8. Directorate of Health / Iceland : http://www.landlaeknir.is 9. Orphanet : http://www.orpha.net/ Final Conclusions and Recommendations of the Pharmaceutical Forum 47 Ethical guidance as to collaborations and public-private partnerships among partnering organisations for generating and delivering information to patients on diseases and treatment options.63 Preliminary Remarks 1. To support creation and improvement of existing public-private-partnerships or other collaborative approaches for generating and delivering information to patients on diseases and treatment options, the Information to Patients Working Group of the High Level Pharmaceutical Forum has mandated a number of its members to draft a methodology within work area 3 “Practical Implementation of the Partnership for Information Package at the National Level”. 2. As a first step, it was proposed to work on ethical guidance necessary for the realisation of new collaborations or to consolidate existing partnerships among partners of any nature. Indeed, ethical guidance should be considered as a tool and thus, respected by all the partners in order to ensure that relationships between partners in a collaborative initiative take place in an ethical and transparent manner for the success of the initiatives. 3. Certain Member States or organisations have already their own ethical guidance applicable for such collaborations/partnerships. The ethical principles and rules listed in this document should not been seen as "reinventing the wheel", or as an exhaustive list, but rather as general guidance providing the main ethical elements for collaborations and partnerships generating and delivering information to patients on diseases and treatment options. 4. In this document, organisations and partners cover all possible organisations interested in being involved in collaborations and partnerships for generating and delivering information to patients on diseases and treatment options. 5. Any collaboration or partnership should respect in full the existing EU ban on direct- to-consumer advertising of prescription-only medicines. Introduction The purpose of this ethical guidance is to ensure that partnership models and other collaborative approaches for generating and delivering information to patients on diseases and treatment options between any categories of partners take place in a responsible and meaningful manner. This kind of collaboration for the common good should reduce the duplication of effort by allowing to combine diverse strengths and resources and promoting greater effectiveness in tackling priorities. Furthermore, the relations and the outcomes of collaborations should also be conducted in such a manner that the parties’ independence from one another is not jeopardised or questioned from either legal or ethical standpoints. 63 AIM and ESIP would like to recall their serious reservations about the establishment of public-private partnerships in the context of information to patients as expressed to the members of the Forum on 20 June 2007. Final Conclusions and Recommendations of the Pharmaceutical Forum 48 Considering the essential role of ethical aspects in any collaboration, an approach relying on three principles is proposed for the application of the ethical guidance for collaborations or partnerships in the field of information to patients. A - Ethical Principles The following three ethical principles64 should serve as a reference for all collaborations in this context: 1. Transparency 2. Disclosure of financial and other support 3. Definition of responsibilities B - Ethical rules Ethical rules have been developed to provide a common understanding of the implementation and application of ethical principles in any collaborative approach or partnership. Rule 1: Transparency 1.1 Collaboration between partnering organisations should be set down in written agreements. 1.2 The written agreements should state the name of the initiative, the list of the partnering organisations, a description of the initiative and its objectives, the financial plan including the total amount of the initiative, the repartition and origins of direct and indirect funding, and the time frame of the initiative, and it should clearly state the roles, the rights and the obligations of each party. Information regarding the finances and funding of the partners and their interests in the field of activity of the partnership should also be stated. 1.3 Written agreements between organisations, contracts and any other internal documents should be publicly disclosed and be kept available to third parties via their home pages on the Internet and/or on request. 1.4 Openness relates to all agreements, whether ongoing, concluded or regarding future initiatives. Rule 2: Disclosure of financial and other supports 2.1 Financial or other support should only be given to the specified collaborative initiatives or activities developed under written agreement as mentioned in point 1.2. None of the partners should supply financial funds or other supports which are not transparent, unrestricted or compromise the independence of other partners. 2.2 Any financial support should be evident from the written agreement made between the parties with precisions on the amounts and sources. Additional financial or other support required for a collaboration should be submitted to all the partnering 64 AIM and ESIP wants a fourth ethical principle – "None of the partners should have commercial interest in the field of activity of the partnership." Final Conclusions and Recommendations of the Pharmaceutical Forum 49 organisations signatory to the original written agreement and added to the public information domain (1.3). Rule 3: Definition of responsibilities65 3.1 The basis for collaboration is that it should be in the interest of all parties66, with equitable and genuine mutual benefits to each organisation and with a balanced level of responsibilities. Collaboration should be jointly planned and implemented in a manner agreed by the parties. Responsibilities and mandates of all the partners should be formally written, adopted by all the partners and made publicly available. This should always take place openly and in a manner transparent to the public. Furthermore, it should always be clearly evident from any informational material that this is a collaborative initiative, with reference to further information as mentioned in point 1.2, so that the recipient understands who or which parties are behind the material. 3.2 Each partner should ensure mutual respect for each other's role. Reciprocity in the relationship should be non-commercial in the interest of all and none of the partners should seek to influence the initiative in a manner favourable to their own interests. 3.3 The respect of the ethical guidance, of the planning and the right implementation of the initiative is a common responsibility of all partners. C – Respect of the ethical guidance67 68 Enforcement of national and EU legislation is always the responsibility of the national competent authorities. Additional control mechanisms could be set up with regards to ensuring the application of the written agreement establishing the collaborative approach or partnership.69 In particular, it is suggested that self-regulatory mechanisms should be setup within the public-private-partnership or collaborations to ensure the respect and the right application of the ethical guidance by all partners. Prior to the launch of the project, structures, control procedures and appropriate penalties should be fixed and agreed by all the partners to ensure the identification and the condemnation of any violation of the ethical guidance. In the case of violation of the ethical requirements, the public-private-partnership will be responsible, through its self-regulatory mechanisms, for the enforcement of sanctions. A co-regulatory body (including competent authority and stakeholders) can be responsible for the enforcement of sanctions in the case of complaints against a decision of the public-private-partnership and for severe violations of the ethical requirements, or this can be handled through legal actions by the respective judicial authorities.70 65 France wants to add a reference to the liability of the information source and the need for conformity with Article 88 of Directive 2001/81/EC as amended by Directive 2004/27/EC. 66 AIM and ESIP want to include "non-commercial" interest. 67 France does not agree with this paragraph. France thinks that this paragraph reflects the view of the Commission, as expressed in the recent public consultation on the key ideas of a legal proposal on information to patients launched the 5 February 2008. France considers necessary to wait for the result of this consultation before concluding on this proposition. 68 Germany agrees in principle with the common approach in this chapter as long as the concept ‘private public partnership’ is not considered as a legal binding instrument. In so far Germany support the corresponding reservation of France in footnote 5 69 ESIP claims that if the partnership is founded under private lay these mechanisms will have only limited effect. 70 AIM, ESIP and Austria do not support the suggestions of auto-control mechanisms and co-regulatory bodies as they are very sceptic about their efficacy. Final Conclusions and Recommendations of the Pharmaceutical Forum 50 Non compliance with EU legislation and national legal obligations is subject to sanctions enforced by the relevant national competent authorities. Final Conclusions and Recommendations of the Pharmaceutical Forum 51 Wider Health Information – Topics for the future The discussions within the Pharmaceutical Forum on information to patients about treatment and treatment options resulted in recognition of the importance of wider health information considerations, linking information to patients and health literacy issues. The members pinpointed 6 topics that could be expanded on in the future: 1. The importance of having a sound evidence base 2. Further work on information communication technology 3. Issues relating to "Health Literacy" 4. Issues relating to education and communication skills of patients and professionals 5. Continuous support for health mainstreaming (Health in all policies) and information to patients 6. Keeping the momentum of the work done under the Pharmaceutical Forum The selected items are not intended to be exhaustive or exclusive. 1. The importance of having a sound evidence base There is a need for a comprehensive overview and good mapping exercises of the ‘state of the art’ on Information to Patients across the EU Member States, including innovation and good practice. Further research and analysis on identified gaps and opportunities in relation to Information to Patients might be explored, for example, through the Framework Programme on Research and Development. The possible focus of such research could include socio-economic/health equity issues, harnessing the potential of ICT, health literacy, communication skills, etc. 2. Further work on information communication technology There is an intrinsic link between information communication technology and information to patients. Several initiatives are already in progress as part of DG INFSO's work and through the e-health stakeholders group. However, further initiatives could be explored in the future, as outlined below: ü An ‘Information to Patients’ Virtual Network could be set up and linked with the EU Health Portal. This virtual network could include links to existing ITP material that meets the quality criteria, pilot projects and innovations at national level. ü There could be investment in the development of a web-based application, such as ‘My health space’ and a European Virtual Library could be created. The latter could be housed within the EU Health Portal. ü The EUDRAPHARM database could be strengthened with opportunities for direct access by patients and health-care providers. ü Ways of identifying good websites could be explored. Final Conclusions and Recommendations of the Pharmaceutical Forum 52 3. Issues relating to "Health Literacy" The importance of increasing "Health Literacy"71 amongst citizens is widely recognised and could be embedded as a policy and programme priority at EU and Member States level. To expand on the issue of health literacy, further research on the subject is necessary. Ideas put forward in this respect cover targeted research that explores and evaluates: o the concept of health literacy and its role in healthcare and health outcomes, o patients’ challenges in navigating the health care system, which will enrich the understanding of health literacy, o the cost of health illiteracy, and o links and data collection on health literacy and inequality across Europe. Research that identifies good practice and dissemination strategies could also be part of the research agenda in this respect. At EU level, the EU Health Literacy Project72 is ongoing. This work could become more comprehensive, and include all Member States and patient organisations at EU and/or national level. Patient groups could explore how ‘patients rights’ instruments can be used effectively to promote health literacy, particularly among disadvantaged and marginalised groups. 4. Issues relating to education and communication skills of patients and professionals (Productive dialogue) The importance of healthcare professionals in relation to information to patients has been highlighted throughout the Forum process. As regards to the role of healthcare professionals, possible initiatives could include the following: ü An EU capacity-building programme that could address education and training for health care professionals in communication skills and shared decision-making and draws on current good practice in this area. ‘Patient experts’ could be involved in this work. ü Patient organisations could carry out quality health literacy programmes with patients. This should include the active participation of different healthcare professionals. ü Under the issue of education, patients’ own stories and anecdotes regarding their patients’ journey should be recognised as a key resource. 71. Health literacy can be defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. 72 Through the Public Health Programme, the Commission is financing a project that will provide a comprehensive snapshot of the present situation in the Member States. The project aims at developing an European Health Literacy Survey. It is lead by the German Landesinstitut für den Öffentlichen Gesundheitsdienst and has been selected for funding in 2007. Final Conclusions and Recommendations of the Pharmaceutical Forum 53 5. Continuous support for health mainstreaming (Health in all policies) and information to patients “Health in all policies”, including European policies in the fields of education, social affairs, information society, etc., will often have an ‘information to patients’ component. Working to ensure a continuous focus on this issue is an important task. One idea might be to strengthen the communication on ‘Health in all Policies’ developments to patients and the public in general and work towards strengthening the health component of the Structural Funds. 6. Keeping the momentum of the work done under the Pharmaceutical Forum As identified in the recommendations of the Forum, the momentum of information to patients should be maintained. Structures to both implement and monitor the efforts made could be set up at EU and national level. Information on developments at national level should be shared among the members of the Forum. How to set up the structures necessary to facilitate the further sharing of experiences needs to be developed. Final Conclusions and Recommendations of the Pharmaceutical Forum 54 Reference Documents relative effectiveness The Relative Effectiveness Working Group developed and agreed on a number of documents which should be further disseminated. The documents will be clearly referenced and made available on the European Commission website73. 1. Core principles on relative effectiveness (page 55 ) The core principles on relative effectiveness assessments set out certain general principles of public administration that could be relevant for developing national systems and help to encourage of exchange of information, methodologies and experiences between the relevant national authorities. 2. Availability of data to conduct relative effectiveness assessments (page 65 ) The document provides a survey of the current processes on data availability during relative effectiveness assessments at national level. It highlights a number of key findings and best practices. Lastly the document contains some possible recommendations for the future. 3. Development of networking and collaboration (page 75 ) Practically all Member States communicate through bilateral or multilateral forms of collaboration on the issue of relative effectiveness assessments. This document identifies the most relevant networks and puts forward certain recommendations for networking at the European level on this topic. 73 The webpage containing the outcomes of the Pharmaceutical Forum is accessible at http://ec.europa.eu/pharmaforum Final Conclusions and Recommendations of the Pharmaceutical Forum 55 Core principles on relative effectiveness 1. Executive summary 1.1. Context and objectives In 2002, the G10 High-Level Group on innovation and provision of medicines recommended that the Commission (Recommendation No 7) should "organise a European reflection to explore how Member States can improve ways of sharing information and data requirements to achieve greater certainty and reliability for all stakeholders, even if the decisions they take may differ. The objective is to foster the development of health technology assessment (HTA), including clinical and cost effectiveness, in the Member States and the EU; to improve the value of HTA, to share national experiences and data while recognising that relative evaluations should remain a responsibility of Member States". The Pharmaceutical Forum was set up in 2005 to address this and other issues raised by the G10, in particular on information to patients and pricing and reimbursement of drugs. The objective of the relative effectiveness working group is to help Member States to apply relative effectiveness systems in an effort to manage pharmaceutical costs and provide fair reward for innovation. Relative effectiveness assessment systems are relatively new for many Member States and can be rather complex. The Working Group has combined the experience of various Member States and other stakeholders in order to support further development in this important field. The decision to develop core principles in particular to support relative effectiveness assessment was taken by the Pharmaceutical Forum on 26 June 2007. Its progress reports quotes: "The Pharmaceutical Forum requests that further consensus on principles for relative effectiveness assessment be developed by exploring good practices in the Member States and by developing a toolbox and principles to provide support on areas such as robust methodologies or mechanisms to best use data, coordination of requests to industry, establishing training or other measures." The action plan implementing this recommendation assigns the working group the objective of working towards a European consensus on general principles and good practices when performing relative effectiveness assessments. A set of European principles will be drawn up in order to establish good practices for relative effectiveness assessments. As a practical approach, the working group will consider developing a toolbox to provide support on how best to use data in relative effectiveness assessments." 1.2. Deliverables of the working group There are two key deliverables: The first deliverable is a set of “good practice” principles that Member States can draw on as they develop their own systems for relative effectiveness assessment. The attached principles draw on the real-life experience of Member States and stakeholders in relative effectiveness assessment or related fields of activity. It was not intended that the principles should specify individual points of good practice in detail, but rather that they should provide a “good practice” framework on which Final Conclusions and Recommendations of the Pharmaceutical Forum 56 Member States can draw to inform and support their own endeavours in this field. The principles were discussed and amended at a full meeting of the Working Group, and adopted as a consensus position. The second deliverable is a checklist developed to support Member States in the practical application of the agreed principles. The attached checklist is based on the real-life experience of Member States. The purpose of the checklist is to operationalise the principles and to support Member States in their implementation of the principles. 1.3. Implementing actions The good practice principles agreed by the working group can deliver a number of benefits. Firstly, the principles can provide Member States with a resource to draw on when developing their own assessment systems. The draft checklist will be a help in this respect. Secondly, a common agreed framework on good practice principles will allow the Member States to share relevant data and experience in this area. Thirdly, dialogue between Member States and key stakeholders will be improved when the terminology and definitions are based on common agreements. Follow-up actions: – It will be useful to have feedback from Member States on how the principles and the checklist are used. – Such feedback might be channelled through the network set up under Work Package 3. – It has not been possible to create a “toolbox” in the current situation where Member States are at various stages in their development of relative effectiveness assessment. This toolbox could be developed as part of a further network. Final Conclusions and Recommendations of the Pharmaceutical Forum 57 2. Good practice principles for relative effectiveness assessment The aim of relative effectiveness (here-after RE) assessment is to compare healthcare interventions in practice in order to classify them according to their practical therapeutic value74. Differences between the objectives and priorities of different national healthcare systems may create differences in the way in which healthcare interventions will be valued relative to one another. In the EU context, this means that a relative effectiveness assessment is most likely to be meaningful at the national (local healthcare) level. However there is considerable 75 value of stimulating exchange of information, methodologies and experiences between the relevant national authorities. The first step in assessing relative effectiveness is an assessment of relative efficacy. Working definitions of these terms have been developed in the course of the full Working Group’s deliberations (see here-after). While the rules and processes within a given healthcare system should be established by discussion among the local stakeholders concerned, some classical principles of public administration are likely to be generally relevant. The working group suggest the following principles for the Pharmaceutical Forum to endorse, for non-binding use as appropriate in Member States. 1. Individual Member States may use RE assessments for different purposes. Decisions on the detailed operation of RE assessments, including methods and relevant stakeholders76, are most appropriately made at a national level. 2. RE assessment processes, selection of products to be assessed, working methodologies and quality assurance processes should be transparent to all parties and evidence-based. 3 Relevant stakeholders should be able to contribute to the development of assessment methodologies. The purpose of RE assessment and the organisation(s) responsible for its conduct should be clearly identified. 4. RE assessment processes should remain separate from product market authorisation procedures (though this does not mean that they are necessarily performed by different organisations). 5. RE assessment processes should be time-framed, and should minimise or avoid causing unnecessary procedural delays consistent with any associated Transparency Directive requirements where applicable. 6. RE assessments should be capable of addressing transparently uncertainty in the evidence base, and the methodological challenge of translating evidence on relative efficacy and other appropriate available data into conclusions on relative effectiveness. 7. The sources of evidence which are to form the relevant RE input should be specifically discussed among the identified key stakeholders, who should each be able to submit evidence or argumentation for appraisal. 74 EFPIA quotes: "The aim of RE assessment is to compare healthcare interventions in practice in order to determine their practical therapeutic value". 75 EFPIA suggests deleting the adjective "considerable". 76 Relevant stakeholders include patients and health professional organisations, the pharmaceutical industry and social insurers. Final Conclusions and Recommendations of the Pharmaceutical Forum 58 8. RE assessment should include comparison with the most appropriate healthcare interventions. Such comparison should build on the results of active controlled clinical trials, where available. 9. When concluded, outcomes should be communicated in a clear and timely manner to all interested parties. Communication by means of publishing the supporting evaluation on a publicly accessible website is strongly encouraged. 10. RE assessments should be capable of subsequent revision and updating as the evidence base develops. 11. RE assessments should aim to identify areas in which the evidence base on an intervention could most usefully be developed in the future. Working Definitions Efficacy: is the extent to which an intervention does more good than harm under ideal circumstances. Relative efficacy: can be defined as the extent to which an intervention does more good than harm, under ideal circumstances, compared to one or more alternative interventions. Effectiveness is the extent to which an intervention does more good than harm when provided under the usual circumstances of health care practice. Relative effectiveness can be defined as the extent to which an intervention does more good than harm compared to one or more intervention alternatives for achieving the desired results when provided under the usual circumstances of health care practice. Final Conclusions and Recommendations of the Pharmaceutical Forum 59 3. Checklist for use of the principles 3.1. Introduction This checklist has been developed as a technical tool for authorities and stakeholders to use, as appropriate, when developing and conducting RE assessments. It should be revised and updated to reflect developments. The purpose of the checklist is to provide Member States with a framework for evaluating their relative effectiveness assessment as well as their national relative effectiveness assessment systems, and especially how they fit in with the core principles agreed by the Member States. The checklist can be used in different ways to improve relative effectiveness assessment: § National bodies responsible for relative effectiveness assessments can simply fill in the checklist as a form of self-evaluation. § National bodies can collect views from the relevant stakeholders. § The checklist can also be used by national bodies for cross-national comparisons of national relative assessment systems and individual assessments. The checklist consists of 22 key items. Items 1-14 relate to national RE assessment systems and items 15-22 to the assessment of specific pharmaceuticals. The scores from different items can be added together to give the total score, which can be seen as providing a general indication of quality. The Appraisal of Guidelines for Research and Evaluation (AGREE) was used to draw up the checklist (AGREE Collaboration 2001, www.agreecollaboration.org). Response scale Each item is rated on a 4-point scale ranging from 4 “Strongly Agree” to 1 “Strongly disagree” with two mid-points: 3 Agree and 2 Disagree. - If the person conducting the evaluation is confident that the criterion has been fully met, then he or she should answer “Strongly Agree”. - If he or she is confident that the criterion has not been met at all or if there is no information available, then the answer should be “Strongly Disagree”. - If he or she is unsure that the criterion has been met, for example, because the information is unclear or because only some aspects meet the criterion, then the answer should be “Agree” or “Disagree”, depending on the extent to which he or she thinks the issue has been addressed. 3. 2. Content of the checklist NATIONAL RELATIVE EFFECTIVENESS ASSESSMENT SYSTEMS Purpose and responsibilities 1. The purpose of RE assessments is specifically described. Strongly Agree Strongly Disagree Comments: 2. The organisation(s) responsible for its conduct is clearly identified. Strongly Agree Strongly Disagree Comments: Transparency 3. RE assessment processes are transparent to all parties. Strongly Agree Strongly Disagree Comments: 4. RE selection of products to be assessed are transparent to all parties. Strongly Agree Strongly Disagree Comments: 5. RE working methodologies are transparent to all parties. Strongly Agree Strongly Disagree Final Conclusions and Recommendations of the Pharmaceutical Forum 61 Comments: 6. RE quality assurance processes are transparent to all parties. Strongly Agree Strongly Disagree Comments: Evidence-base 7. RE assessments are evidence-based. Strongly Agree Strongly Disagree Comments: Stakeholders 8. The relevant stakeholders are able to contribute to the development of assessment methodologies. Strongly Agree Strongly Disagree Comments: 9. The sources of evidence that form the relevant RE input have been specifically discussed between the key stakeholders. Strongly Agree Strongly Disagree Comments: 10. The key stakeholders are able to submit evidence or arguments for appraisals. Strongly Agree Strongly Disagree Final Conclusions and Recommendations of the Pharmaceutical Forum 62 Comments: Processes 11. RE assessment processes are separate from product market authorisation procedures. Strongly Agree Strongly Disagree Comments: 12. RE assessment processes are time-framed. Strongly Agree Strongly Disagree Comments: 13. RE assessment processes minimise or avoid causing any unnecessary procedural delays and are consistent with any associated Transparency Directive requirements (timing, appeals, etc.), where applicable. Strongly Agree Strongly Disagree Comments: 14. The national assessment body has established contacts with other national or international agencies to exchange views, methodologies and information. Strongly Agree Strongly Disagree Comments: Final Conclusions and Recommendations of the Pharmaceutical Forum 63 RELATIVE EFFECTIVENESS ASSESSMENTS OF SPECIFIC PHARMACEUTICALS Quality of assessment 15. The RE assessment is capable of addressing uncertainty in the evidence base transparently. Strongly Agree Strongly Disagree Comments: 16. The RE assessment is capable of addressing uncertainty in the methodological challenges transparently. Strongly Agree Strongly Disagree Comments: 17. The RE assessment includes comparison with the most appropriate healthcare interventions. Such comparison should build on the results of active controlled clinical trials, where available. Strongly Agree Strongly Disagree Comments: Communication 18. Outcomes of the RE assessment are communicated clearly and in good time to all interested parties. Communication by means of publishing the supporting evaluation on a publicly accessible website is strongly encouraged. Strongly Agree Strongly Disagree Comments: Final Conclusions and Recommendations of the Pharmaceutical Forum 64 19. Outcomes of the RE assessment are published on a publicly accessible website. Strongly Agree Strongly Disagree Comments: Other aspects 20. RE assessment is capable of subsequent revision and updating as the evidence base develops. Strongly Agree Strongly Disagree Comments: 21. RE assessment identifies areas in which the evidence base on an intervention could most usefully be developed in the future. Strongly Agree Strongly Disagree Comments: 22. RE assessment includes input from other national or international agencies on the same or closely related projects. Strongly Agree Strongly Disagree Comments: Final Conclusions and Recommendations of the Pharmaceutical Forum 65 Data availability to conduct on relative effectiveness assessments 1. Executive summary 1.1. Context and objectives In 2002, the G10 High-Level Group on innovation and provision of medicines recommended that the Commission (Recommendation No 7) should "organise a European reflection to explore how Member States can improve ways of sharing information and data requirements to achieve greater certainty and reliability for all stakeholders, even if the decisions they take may differ. The objective is to foster the development of health technology assessment (HTA), including clinical and cost effectiveness, in the Member States and the EU; to improve the value of HTA, to share national experiences and data while recognising that relative evaluations should remain a responsibility of Member States". The Pharmaceutical Forum was set up in 2005 to address this and other issues raised by the G10, in particular on information to patients and pricing and reimbursement of drugs. The objective of the relative effectiveness working group is to help Member States to apply relative effectiveness systems in an effort to manage pharmaceutical costs and provide a fair reward for innovation. Relative effectiveness assessment systems are relatively new for many Member States and can be rather complex. Nevertheless, relative effectiveness is promising as it helps to identify the most valuable medicines, in terms of both clinical efficiency and cost-effectiveness. The Working Group has combined the experience of different Member States and other stakeholders in order to support further development in this important field. The decision to develop core principles in particular to support relative effectiveness assessment was taken by the Pharmaceutical Forum on 26 June 2007. It quotes in its progress report: "The Pharmaceutical Forum encourages the relevant authorities and companies to explore ways to communicate and collaborate prior to the market authorisation decision as well as after it in maximising availability and best use of data relevant to relative effectiveness assessment." In particular, "The Pharmaceutical Forum requests the working group also to explore different ways of encouraging the production of additional relevant data, such as: • Identifying data sets (including the possibility to have appropriate comparators) that can be helpful for relative effectiveness assessments; • Working towards consensus on good practices for concept design and analysis on what kind of new study types/study designs would be needed to improve the information available about products in real-life use; • Elaborating on methods for the transferability of data on relative effectiveness assessments between Member States; • Providing Member States with options for encouraging the production of more relevant data or alternative routes for producing additional data; • Considering (with the involvement of the European Medicines Agency) how EPARs and NPARs could make a better contribution to relative effectiveness assessments; • Recognising the value of innovation building on the work of the working group on pricing.” Final Conclusions and Recommendations of the Pharmaceutical Forum 66 The action plan implementing this recommendation of the progress report assigns the working group the objective to developing: - agreed terms of reference for real-life example test cases - a toolbox on ways to improve the use of relative effectiveness data. This would also make it possible to develop methods for the transferability of data on relative effectiveness assessments between Member States. The aim is to show how relative effectiveness assessments are carried out in the Member States by using specific products or groups of products and looking at what data are used in decision-making on relative effectiveness assessment, focusing on two main phases of a product’s life: 1.) Before market authorisation (MA) (“MA data”) 2.) After market authorisation has been granted and the decision on price and reimbursement is taken (“Access to market data”) Moreover, the issue of updating relative effectiveness on the basis of data from the use of products in practice will need to be considered. The ways the assessment outcomes are used in healthcare settings (for example, in relation to decisions made by hospitals to take medicines in their treatment protocols and in clinical decision-making) could also be looked at. In addition to the evaluation of the availability and use of data based on real-life examples, the work package will also address horizontal issues such as early dialogue between national authorities and companies. In particular, the possibility of reporting on new products in the pipeline by way of a “horizon scanning” mechanism would be looked at in this context. Secondly, collaboration between national authorities and other stakeholders involved in creating relative effectiveness assessment data will be addressed throughout the work package. This will illustrate the current practices on collaboration and identify areas for improvement to generate, share and use data at all stages, i.e. before and after market authorisation. Thirdly, new methodologies and scientific principles from other related areas such as health technology assessment could be included in the search for existing tools and methods that can be incorporated into relative effectiveness assessments. This could result in a toolbox to provide support for robust methodologies and mechanisms. To ensure the objectivity of the work, the issue of which organisations could carry out the work should be considered. Existing forms of collaboration between organisations with analytical capacities to address key aspects could be used. In particular, the working group should consider whether an existing European network on assessing technologies in relation to the scientific aspects of relative effectiveness assessment could be asked to carry out this work. The Commission will draw up terms of reference for discussion by the working group in order to provide a platform for this area of work. After approval by the working group, both the Member States and the industry will be invited to provide potential products as show cases. Final Conclusions and Recommendations of the Pharmaceutical Forum 67 Finally, an additional area in work package 2 will look at how to make better use of EPARs and NPARS for relative effectiveness assessments. 1.2. Deliverables of the working group The main deliverable is a survey on data availability and current evaluation and reimbursement processes in national relative effectiveness assessment systems. Details are given in Section 2. 1.3. Issues that are in the mandate but have not been addressed by the working group so far: The following aspects of the 2nd progress report have not yet been addressed: • Working towards consensus on good practices for concept design and analysis on what kind of new study types/study designs would be needed to improve the information available about products in real-life use; • Developing methods for the transferability of data on relative effectiveness assessments between Member States; • Providing Member States with options for encouraging the production of more relevant data or alternative routes for producing additional data; • Considering (with the involvement of the European Medicines Agency) how EPARs and NPARs could make a better contribution to relative effectiveness assessments; • Recognising the value of innovation, building on the work of the working group on pricing. Final Conclusions and Recommendations of the Pharmaceutical Forum 68 2. Survey conducted by Austria 2.1. Objectives The primary aim was to explore the availability of data for the assessment of relative effectiveness, while the secondary aim was to learn more about the relative effectiveness evaluation processes and the overall reimbursement decision processes that these evaluations are embedded in. 2.2. Methods The relevant bodies that conduct the clinical evaluations for the purpose of reimbursement decisions were identified in all 27 Member States (here-after MS). The parties responsible for these evaluations were contacted and interviewed. For this purpose, five sample medicinal products77 were chosen by the working group (here-after WG). After the interviews the protocols were sent back to the interviewees for reconfirmation (this process was still ongoing at the time of the the printing of this document).78 The final report will be made available once interview protocols are reconfirmed. The Efficacy and Effectiveness definitions from Work Package1 were used.79 2.3. Findings – based on the results of the interviews 2.3.1. No clear cut between efficacy and effectiveness concepts and uses Four important points regarding the original definitions of efficacy and effectiveness emerge from the interviews: (1) The data on effectiveness showed there is no clear consensus as to whether clinical trials yield efficacy or effectiveness information. All data on drugs yield information that is somewhere on an efficacy/effectiveness spectrum (see graph in Annex A). As a general rule, conventional clinical trials tend more to the efficacy side of the spectrum. The term effectiveness is used differently, in a way that is not captured by the WG definition. While some interviewees use it to describe what is actually happening in real life (and as such always theoretical to a certain extent), others use it exclusively to describe clinical trials that are as far as possible to the effectiveness side of the spectrum. This, in their opinion, gives the best estimate of what happens in real life. There is no clear consensus on this among MS. 77 Omalizumab (Xolair), Clopidogrel (Plavix), Sildenafil (Revatio), Trastuzumab (Herceptin), Desloratadin (Aerius) 78 At the time of the adoption of the final Conclusions of the Pharmaceutical Forum, 22 interviews had been conducted. Of these, 2 were incomplete and 4 only answered in writing; thus yielding 16 (or 20) complete interviews. Of the other 5, 4 were scheduled but have not yet been conducted and 1 were still unclear. Also, the 3 EFTA Members of the Working Group volunteered to be interviewed, but this had been postponed due to time constraints. 79 Efficacy is the extent to which an intervention does more good than harm under ideal circumstances. Relative efficacy can be defined as the extent to which an intervention does more good than harm, under ideal circumstances, compared to one or more alternative interventions. Effectiveness is the extent to which an intervention does more good than harm when provided under the usual circumstances of healthcare practice. Relative effectiveness can be defined as the extent to which an intervention does more good than harm compared to one or more alternative interventions for achieving the desired results when provided under the usual circumstances of healthcare practice. Final Conclusions and Recommendations of the Pharmaceutical Forum 69 (2) If there is relative efficacy and relative effectiveness, their non–relative equivalents must also exist. The term relative only makes sense in the setting of clinical trials. When evidence is created in clinical trials a new drug can either be compared to a placebo (this is non-relative efficacy), to any drug (suboptimal) or to the best possible alternative drug (optimal).80 However, it needs to be borne in mind that different MS may have different views on what is the “best alternative therapy”. When “more or better relative effectiveness data” are demanded the word relative refers to trials that have the best possible alternative drug as a comparator. If this is not the case comparisons are indirect and have to be made either through value judgment or by modelling. These indirect comparisons are not preferred by many MS. (3) At the time of a primary reimbursement decision there are often no effectiveness data available, beyond what can be assumed from phase III clinical trials. In contrast, the same data on efficacy are available in all MS. Because of different reimbursement application times the number of studies or volume of efficacy data available may vary. In practice, these differences tend to be small. (4) In general, information on effectiveness can be based on effectiveness data alone or on a combination of efficacy data and some form of extrapolation of the same efficacy data (e.g. modelling). The interviews revealed four possible approaches. It has to be highlighted that not all approaches are endorsed by all MS. Some MS insist on clinical trials as the only reliable source for information. In particular, approaches 3 and 4 below (i.e. modelling and the use of other sources of data) are not accepted by all MS. As a general rule, the level of acceptance decreases from top to bottom in the following list. (1) Better clinical trials (large pragmatic trials/effectiveness trials) yield data that tend more to the effectiveness side of the spectrum, and can be conducted. (2) Efficacy is evaluated in lieu of effectiveness81 or effectiveness is extrapolated from efficacy data without modelling. The latter process normally includes a high degree of value judgment, as explained further below.82 (3) Relative effectiveness is produced through modelling as an integral part of cost-effectiveness studies. MS that accept economic modelling (e.g. cost-effectiveness studies) generally have economic studies that are custom-made for them.83 (4) Other types of data (real-life/post-marketing information, such as observational studies, registries and medical claims data) can be used to assess relative effectiveness. 80 When two drugs are compared to a placebo only, and not to each other, it remains unclear how they compare to each other. This is because differences between the two drugs can always be due to differences in the underlying study populations, and not to the drugs themselves. It is thus mostly preferable to compare drugs directly with one another. In theory, comparisons against placebos should be very rare, as using placebo-controlled trials conflicts with the Declaration of Helsinki wherever effective treatment is available. However, in reality placebo-controlled trials are often accepted by market authorisation agencies. This is further complicated by the fact that some regulatory agencies, most prominently the FDA, actually endorse or even ask for placebo-controlled trials in some circumstances. 81 This approach is based on the idea that in the absence of effectiveness data, efficacy data are the best estimator of effectiveness. 82 In these cases the exact same data are assessed that have been assessed for market authorisation. It is clear that different outcomes can only be obtained if the value judgments differ. However, this makes sense, as the basis for a reimbursement decision is different from a market authorisation decision. This argument is not shared by Spain. 83 However, when effectiveness is modelled, the accuracy of the results also improves, as the quality of the underlying clinical trials improves. Thus, clinical trials that tend more to the effectiveness side of the spectrum yield better information on relative effectiveness for all MS, whether they endorse modelling or otherwise. Final Conclusions and Recommendations of the Pharmaceutical Forum 70 There was an overwhelming response in the interviews that there is very often a lack of studies with the relevant comparator. The main outcome measures are often also wrong, inclusion criteria unrealistic and the observed time period is too short to yield relevant data on effectiveness. The main reason is that these studies are generally still conducted for the purpose of obtaining market authorisation, and not for reimbursement decisions. It should be noted that these studies are generally conducted after detailed discussions with regulatory authorities, including formal procedures for scientific advice from the EMEA. 2.3.2. Importance of effectiveness assessments within the overall process of pricing and reimbursement decisions Relative effectiveness assessments are an important but not the only factor in a reimbursement decision. To understand the differences in relative effectiveness assessments in the EU it has to be understood how reimbursement decisions are taken in general. Health policy decisions cannot be taken in the absence of value judgments.84 Also, these interviews show that, in almost all MS, reimbursement decision processes are two-step procedures: Step one is the analysis of evidence as a scientific basis for the decision and step two is the actual decision-making, which always includes some degree of value judgment.85 While the degree of clarity regarding this distinction is quite varied and tends to be on the low side, in principle all MS reimbursement decisions include some degree of value judgement and are not based on analytical evidence alone. In the first step, evidence is assessed as systematically and as objectively as possible. In the second step, the available evidence is critically appraised, which includes a certain degree of value judgment. Depending on the MS, more or less value judgment might be involved. Mostly, analysis of evidence is in the form of a written report while the value judgment part is made by a committee, which takes a vote on the basis of that report. This vote might be either a final decision or a preliminary recommendation that needs further approval. Step 1: Analysis of evidence (assessment report/dossier) An assessment of relative effectiveness is an important part of such reports in most MS. As a prerequisite to understanding this point, it should be noted that in many MS the process under scrutiny by the WG is not actually called relative effectiveness officially, but something like clinical evaluation, therapeutic (value) evaluation or medical evaluation. Irrespective of the name, this process evaluates the theoretical benefits and harms of drugs without economic considerations. In reality, assessment reports for reimbursement consist in almost all MS of at least the following two parts:86 1) Clinical evaluation 2) Economic evaluation 84 See Reflections On Science, Judgment, And Value In Evidence-Based Decision Making: A Conversation With David Eddy. Health Affairs - Web exclusive. DOI 10.1377/hlthaff.26.4.w500 85 This should not be confused with formal decision-taking, which is mostly done in a third step by a minister of health or a social insurance executive. If this step is included it is often quite formal. However, in theses cases the second step is then not decision- taking in the legal sense but a decision to give a recommendation, which nevertheless involves a high degree of value judgment. 86 In some MS these reports also contain other parts, typically some sort of public health or societal perspective or other. Final Conclusions and Recommendations of the Pharmaceutical Forum 71 The issue is that in some Member States (e.g. France and Italy) what is understood as relative effectiveness is only 1) while in other MS (e.g. UK, Ireland and Sweden – list not exhaustive) relative effectiveness consists of 1) and parts of 2). Relative effectiveness is estimated (i.e. modelled) in some MS as part of cost-effectiveness studies.87 In some Member States, both steps are performed separately, and may be done by different organisations, whereas in others this is part of a single process. It is logical that for MS doing the latter it is harder to disentangle the economic evaluation from the clinical therapeutic evaluation.88 For some MS it is possible but it would be difficult. And in some MS (e.g. France) the clinical evaluation is already quite clearly separated from the economic evaluation. This is the exception rather than the rule, however. Step 2: Value judgment (committee/board) These decision or recommendation committees responsible for the final decision on pricing and reimbursement can be formed very differently in the MS. Some rely on internal members; others staff them with external members. Sometimes there are purely medical experts with or without economists on these committees, but in some MS there are also other members, including lay people, patients, stakeholders (e.g. industry), social insurance personnel, political representatives and even priests and philosophers. Clarification: The above gives rise to a number of issues. Firstly, these reports/assessments of evidence are often not stand-alone documents. In practice, their conclusions are in part dictated by the committee votes. Thus, it can be difficult to separate the analysis of evidence from the value judgment part. These votes are also often taken in combination for both the clinical and the economic evaluation. Thus, in some MS it is difficult in practice to isolate the evaluation of clinical effectiveness as a distinct outcome from the overall evaluation, which includes economic considerations. Some MS do however make a clear distinction between relative effectiveness and economic evaluation. That said, while the overall evaluation processes, and the value judgments in particular, can differ somewhat among MS, the data available on efficacy are almost always the same and even the final decision to put on a reimbursement list tends to be relatively standard throughout the EU. The following factors might cause local variations: – As noted earlier, in MS where cost-effectiveness studies are accepted these tend to be custom-made for the respective MS and their healthcare systems. Thus, both the result and the subsequent decisions can differ. – The level of control that reimbursement decision-taking bodies have over prescription practice varies enormously throughout the EU.89 As this tends to be taken into account 87 True data on effectiveness are very hard to find but effectiveness information is needed for realistic cost calculations. Thus, effectiveness information is often modelled as an integral part of cost-effectiveness studies. It is a common misunderstanding that cost-effectiveness studies are mainly about costs. In general, cost-effectiveness studies consist of two parts, one that models effectiveness and a second part that calculates the costs. 88 However, this should not be confused with price negotiations, which are in principle separate from economic evaluations (see specific findings in point 4) 89 The level of control ranges from almost no control to very tight control over physician prescription habits. An alternative approach to prescription control is a price-volume agreement. Final Conclusions and Recommendations of the Pharmaceutical Forum 72 for decision-taking (mostly at value judgment level), identical data can lead to different results in different MS. – Some Member States advance the argument that they use budget impact analysis to justify negative reimbursement decisions. However, some MS explicitly refrain from the concept of budget impact for their reimbursement decisions. 2.3.3. Interpretation of information flows from market authorisation agencies to reimbursement decision bodies Depending on the legal situation regarding the exchange of information between MAA and reimbursement agencies, the information on efficacy is in varying degrees of detail. This is particularly important for MS that rely more on the assessment of efficacy than on modelling through cost-effectiveness studies. In some MS it is one agency that makes both assessments. In those MS there is a free flow of information. In others these are distinct agencies but exchange of confidential information is at least possible or even mandated by law. In a final category, the transfer of confidential market authorisation information to the reimbursement decision body is deemed illegal. This might be due to differences in national law, mostly due to diverging interpretation of European Law in this context. Clarification might be useful even if, for some MS, the issue of exchanging confidential information is not of primary importance.90 2.3.4. Insights on economic evaluations91 As noted above, some MS do not accept cost-effectiveness studies92 or only attach minor importance to them, while in other MS cost-effectiveness studies or other economic evaluation methods are a core feature of both: relative effectiveness evaluations and the overall reimbursement decisions. In MS where cost-effectiveness studies are not accepted or are of minor importance, economic evaluations are based either on price comparisons or on budget impact analysis alone. Economic evaluations need to be differentiated from price negotiations. While price negotiations feed back into the results of cost-effectiveness studies and budget impact analysis and vice versa, the price of a product is only one of many important variables in an economic analysis. 90 This difference is also rooted in the wide variation in the level of trust that reimbursement decision bodies have in the decisions of the market authorisation agencies. 91 It was agreed to ask interviewees to provide voluntary information on economic assessments so as to improve the link between the work of the Relative Effectiveness working group and the Pricing and Reimbursement working group. 92 Cost-effectiveness studies are the best known but not the only economic evaluations that are based on modelling. The most prominent other types of studies in this field are cost-benefit analyses. Final Conclusions and Recommendations of the Pharmaceutical Forum 73 2.4. Conclusions and possible recommendations It can be seen quite clearly from the interviews that with such a complex issue and such diversity of decision-making processes, there cannot be one single solution. Thus, it was proposed in the interviews that some MS might work together in groups in an effort to advance the issue and improve collaboration. Identifying clusters of interested member states that share common elements in their processes will enhance EU-level cooperation. The first conclusion from the interviews is that data are mainly on efficacy and not enough data are available on effectiveness and relative effectiveness. Thus, all MS, irrespective of whether they accept modelling or not, would benefit from clinical trials that tend more to the effectiveness side of the spectrum. However, it must always be discussed whether effectiveness trials – which also lack in internal validity – can reasonably be expected in the drug development programme.93 While prolonging observation times might come at too high a price (longer waiting time for new drugs), using the right comparator, relevant outcome measures and realistic inclusion criteria is something that would lead to better decisions. If studies were to be designed along these lines they would yield data that tend more to the effectiveness side than to the efficacy side. However, to achieve this, it would need to be made mandatory for companies. Whether this is realistic is debatable.94 One way to improve the quality of data for decisions on RE is for the competent authorities and other players to give advice to companies during the development process. In the meantime, the second conclusion is that the most divisive approach is the cost- effectiveness one. Indeed, the specificities make it difficult to benchmark with other approaches. That does not mean that they should not form part of clinical evaluation. In theory, non-acceptance of cost-effectiveness is not per se a denial of modelling. It is theoretically possible to model relative effectiveness outside of cost-effectiveness studies. But while there is some initiative on this at EMEA level, this is still a very uncommon approach and further research is needed. Cooperation might be easier for MS that endorse the cost-effectiveness approach. It has been mentioned that improved methodology and high quality guidelines that are approved by all stakeholders would enhance the quality and thus usefulness of these studies. The third conclusion is that it might be scientifically relevant for interested MS to share and exchange information on relative effectiveness assessments and economic evaluations at EU level. Clinical evaluations would also not need to be conducted in multiplication throughout the EU. The legal situation regarding the exchange of information should be clarified.95 To enhance trust, it needs to be made clear that the actual decision rests with the MS. One way of reinforcing this trust is by ensuring that, despite similar outcomes of relative effectiveness assessments, different MS will still be able to come to different reimbursement decisions based on either differences in value judgment or for budgetary or other reasons, such as differences in the objectives and priorities of the different national healthcare systems. 93 For EFPIA, "it is often more appropriate to conduct these studies post-approval to confirm effectiveness in real-life situations". This statement is not shared by other members. 94 Spain does not agree with this. 95 Spain does not agree with this. Final Conclusions and Recommendations of the Pharmaceutical Forum 74 The fourth conclusion is that a clear distinction between the assessment of all available evidence and value judgments that lead to a decision would improve the transparency of the decision-making process.. However, transparency should not be understood as being in conflict with value judgments, which are necessary for these decisions. The fifth conclusion is that clarification is needed of the EU legal situation on the issue of transferring market authorisation data and information to the reimbursement decision agency. 2.6. Annex A:96 96 Spain commented on this graph: this table should be discussed further. “No comparator” should not be part of absolute efficacy, and “medical claims data and post-marketing study with no comparator” should not be part of absolute effectiveness, among others. Final Conclusions and Recommendations of the Pharmaceutical Forum 75 Development of networking and collaboration 1. Executive summary 1.1. Context and objectives In 2002, the G10 High-Level Group on innovation and provision of medicines recommended that the Commission (Recommendation No 7) should "organise a European reflection to explore how Member States can improve ways of sharing information and data requirements to achieve greater certainty and reliability for all stakeholders, even if the decisions they take may differ. The objective is to foster the development of health technology assessment (here-after HTA), including clinical and cost effectiveness, in the Member States and the EU; to improve the value of HTA, to share national experiences and data while recognising that relative evaluations should remain a responsibility of Member States". The Pharmaceutical Forum was set up in 2005 to address this and other issues raised by the G10, notably on information to patients and pricing and reimbursement of drugs. The objective of the relative effectiveness (here-after RE) working group is to help Member States to apply relative effectiveness assessments in an effort to manage pharmaceutical costs and provide a fair reward for innovation. Relative effectiveness assessments are relatively new for many Member States and can be rather complex. Nevertheless, relative effectiveness assessment is promising as it helps to identify the most valuable medicines, be it in terms of clinical efficiency or cost-effectiveness. The Working Group has combined the experience of different Member States and other stakeholders in order to support further development in this important field. The decision to develop ideas and thinking in relation to networks to support relative effectiveness assessment was taken by the Pharmaceutical Forum of 26 June 2007. The Forum’s progress report quotes: "Strengthening networks among relative effectiveness assessment authorities and relevant stakeholders across Europe and considering mechanisms to help share data, provide support and develop common principles at European level" In particular, "The Pharmaceutical Forum supports the aim of sharing data on relative effectiveness assessment at European level and developing sustainable collaboration and networks between the competent authorities of the Member States and other stakeholders, and requests specific proposals for ways of achieving this." Collaboration between national authorities and other stakeholders involved in creating relative effectiveness assessment data will be addressed throughout the work package. This will highlight current collaboration practices and identify areas for improvement to generate, share and use data at all stages, i.e. before and after the market authorisation process. Relative effectiveness assessments are ultimately performed in order to improve the quality of care by promoting rational use of medicines. All EU Member States are currently carrying out relative effectiveness assessments and each Member State carries out its own assessments. Final Conclusions and Recommendations of the Pharmaceutical Forum 76 The key objectives of the work package are to consider and make a recommendation as to whether a new European network is needed in the area of relative effectiveness assessment. Regardless of this recommendation, a number of proposals and learning points for existing and planned networks to consider will be developed. 1.2. Deliverables of the working group There are two key deliverables: The first deliverable is a survey of current networks on relative effectiveness assessment, with contributions from the contact persons and members. Details are given in Section 2.1. The second deliverable is a set of recommendations on requirements for existing and future networks: The details are given in Section 3.2 1.3. Implementing actions Ensure proper progress of a network to improve the consistency of relative effectiveness at European level, with special focus on principles and data availability. 2. Deliverables in detail Summary of the questionnaire conducted by Sweden Practically all Member States communicate through bilateral or multilateral collaboration. The most relevant of these forms of collaboration or networks for the purpose of relative effectiveness are: AGREE collaboration, EUNetHTA, Guidelines International Network (G-I-N), Medical Evaluation Committee (MEDEV), Networking of the Competent Authorities for Pricing and Reimbursement of Pharmaceuticals (“Slovenian Presidency initiative”), Nordic collaboration on medicines, Nordic PharmacoEpidemiological Network (NorPEN), PPRI, European Patients' Forum, Transparency committee, UK-Germany-France – collaboration, Working Group on Relative Effectiveness Assessment. It is important to know more about the networks so as to have a full picture of activities at European level and also because these networks evolve and take on different tasks at different times. Table 1 contains a brief description of the different networks. Final Conclusions and Recommendations of the Pharmaceutical Forum 77 Table 1. Network Purpose AGREE collaboration Improving the quality and effectiveness of clinical practice guidelines by establishing a shared framework for their development, reporting and assessment EUNetHTA Establishing an effective and sustainable European Network for Health Technology Assessment that informs policy decisions Guidelines International Network (G-I-N) Promoting systematic development of clinical practice guidelines Medical Evaluation Committee (MEDEV) Exchanging experience in the evaluation of drugs Networking of the Competent Authorities for Pricing and Reimbursement of Pharmaceuticals (“Slovenian Presidency initiative”) Identifying and discussing high-level issues in the field of pricing and reimbursement of pharmaceuticals Nordic collaboration on medicines Exchanging experience in the evaluation of reimbursed drugs Nordic PharmacoEpidemiological Network (NorPEN), Pharmacoepidemiology PPRI Information-sharing initiative on burning issues of pharmaceutical policies from a public health perspective European Patients' Forum Collaboration of patients’ associations Transparency committee EU institution dealing with the transparency directive UK-Germany-France – collaboration Exchanging experience in the evaluation of drugs Working Group on Relative Effectiveness Assessment Working group under the Pharmaceutical Forum (will end in 2008) For this reason, the Secretariat and Sweden contacted these networks with a brief survey. The aim was to map existing networks and also, if possible, to learn something from their experience. The survey was web-based and contained two parts. Part a) was completed by a single representative of the network and described briefly the purpose and organisation of the network. Part b) was evaluative and was supposed to be completed by as many individual members of the networks as possible. It consisted of a few questions such as “How useful do you think the network has been for you?”. Unfortunately, there were rather few respondents to part b) of the questionnaire (30). This limits the extrapolation of the findings, but a few trends can be outlined nevertheless. • Most networks that were studied are new. In fact, only one was more than three years old. • Generally, the respondents were satisfied with the network that they participated in. • Only two problems were mentioned more than once by respondents: Final Conclusions and Recommendations of the Pharmaceutical Forum 78 o Limited resources – e.g. participants’ time and funding. o A lack of structured communication tools and/or a database for communication exchange and a “blackboard” or web-based system rather than just e-mail. Only one network uses a “wiki” tool. • Contrary to expectations, language problems were not mentioned at all. The choice of the language was not investigated. • There is mostly informal participation from patient organisations and generally no participation from industry, which has (rarely/not) been invited to participate. • Seven of the eight networks that responded had activities related to relative effectiveness assessment. • About half of the networks have specific funding and about half have an administration in place for the network. • Participants often quoted their increased access to reliable contacts in other organisations as the most pertinent added value of participating in networks. • Other benefits that were mentioned included exchange of information, harmonisation of methodology and identifying and solving common problems. Relative effectiveness assessments are often carried out using data that have been developed for use in the market authorisation process for a pharmaceutical. Nonetheless, the national regulatory agencies and the EMEA are currently not involved to any great extent in the networks and forms of collaborations discussed here. To conclude, the key objectives for a network (or networks) to meet the demands set out by the Forum include: a) regular exchange of information on methodologies used; b) regular exchange of available data; c) regular exchange on the conclusions reached regarding the relative effectiveness of the drugs assessed; d) implementing work areas 1 and 2; e) having appropriate stakeholder participation; f) reviewing implementation of best practice principles across Member States. These requirements point to two distinct levels, or work streams, for networks: one directed towards political considerations and policy-making, and the other technical, involving, for example, exchanging assessments. Not all members in the WG put the same emphasis on which is the more important for networking at European level. The WG and the Forum should also consider the mandate of the network and the possibilities for influencing the network. Final Conclusions and Recommendations of the Pharmaceutical Forum 79 Taking this into account, the discussion on 12 June 2008 centred on which of the existing networks could best address these objectives. In this respect, two networks were short-listed for discussion: the SL network and MEDEV. As can be seen from Table 1 above, the other networks are dealing with tasks well outside the field of relative effectiveness or have limited geographical coverage. As so discussed on 12 June 2008, neither of these groups involves industry. The proposal to make these groups the basis of a future network needs to be reconciled with the stated goal of wider stakeholder participation. The Slovenian network focuses mainly on policy issues relating to pricing and reimbursement, with the option of including RE. It has a clear mandate from the Competent Authorities of the Member States. At this point, meetings are envisioned to take place about twice a year and involve high-level officials from the Competent Authorities. This network does not formally involve industry or other stakeholders. MEDEV deals explicitly with the RE of pharmaceuticals and is engaged in the exchange of assessments (among other things). Membership and communication is informal. This network does not involve the R&D-based industry. The membership issue was also discussed. There seems to be a general understanding that only the competent authorities of the MS can be part of certain processes in the networks, but stakeholder involvement is in principle desirable and beneficial. It should therefore be encouraged. 3. Recommendation for networking at European level 3.1. Background As noted earlier, there are two distinct levels of cooperation in networks: one directed towards policy/strategy and the other technical/scientific, involving, for example, exchanging assessments. Not all members in the WG put the same emphasis on which is the more important for networking at European level. The traditional tasks of networks that would apply at both levels include promoting exchanges of ideas, giving access to contacts in other organisations and building trust. Apart from these “generic” benefits, other specific tasks that, in the opinion of the WG, should be pursued within networks include: • Policy/strategy network o learning from the success or failure of other organisations’ policies and strategies, o joint problem solving, o harmonisation of methodology, policy or strategy, if appropriate, o being a speaking partner for stakeholders. • Technical/scientific network o sharing and exchanging assessments of RE with the dual purpose of improving the quality of the individual assessments and learning from each other, Final Conclusions and Recommendations of the Pharmaceutical Forum 80 o maintaining a clearinghouse for RE assessments (similar to what exists, for example, for guidelines and HTA reports). For this to work, language issues and funding need to be resolved, o exchanging information (and possibly coordination to avoid duplication?) on post-launch studies of RE. 3.2. Recommendations (1) The Working Group has identified two networks that could potentially function as networks between the Competent Authorities: the Slovenian Network (the network of competent authorities on pricing and reimbursement) and MEDEV97. (2) It is not necessary for just one network to be identified. The WG believes that the Slovenian initiative network has in some ways an appropriate membership basis in the Competent Authorities and already focuses on policy/strategy issues. However, at this point the network puts too little emphasis on RE assessments. MEDEV, on the other hand, is ideally suited as a network for technical/scientific issues but is perhaps too informal. (3) The WG suggests that no new networks should be initiated by the Forum at this point in time. Rather than creating a new network, it makes more sense to invest more in the networks that have already been established. (4) The existing networks seem to suffer from a lack of resources. This concerns funding, but probably more importantly than that, participants’ ability to allocate time to the activities of the network. A second area where investment would be beneficial is in efficient communication tools. (5) There is a need to consider the issue of participation/cooperative arrangements with stakeholders and regulatory agency (a) It is strongly recommended to include both regulatory agencies and EMEA, in some form, in networks that deal with issues related to relative effectiveness. (b) Appropriate participation of the relevant stakeholders in the network/s is encouraged.98 (6) The sharing of relevant data and experience between Competent Authorities and dialogue between the Competent Authorities and key stakeholders can be improved when terminology and definitions are based on common agreements. The WG therefore suggests that networks, where applicable, should adopt the definitions and common agreed framework on good practice principles set out by this WG and the WG on Pricing. 97 The Steering Committee acknowledged on 2 July 2008 the fact that the EUnetHTA could also be a relevant candidate for taking forward the scientific recommendations 98 EPF made the following statement: "The membership of networks will be agreed with the consultation of different stakeholders based on the purpose and functions of the network and efforts will be made to ensure the inclusiveness of the relevant stakeholders.” As mentioned in the draft final report, relevant stakeholders for the purposes of the work of this working group are: the pharmaceutical industry, social insurers, healthcare professionals (and scientific societies) and patient organisations (point requested by AIM) Final Conclusions and Recommendations of the Pharmaceutical Forum 81 (7) There is a need to consider in the post Forum phase the legal obstacles to deeper collaboration in some Member States, in particular relating to exchange of information. Member States are encouraged to look at how and if this problem can be solved. Final Conclusions and Recommendations of the Pharmaceutical Forum 82 Reference Documents pricing and reimbursement The Pricing and Reimbursement Working Group has developed and agreed on a number of documents which should be further disseminated. The documents were finalized and adopted within the Working Group, usually following a preparation by a taskforce of participants from the group. The documents will be clearly referenced and made available on the European Commission website99. 1. Guiding principles for good practices implementing a pricing and reimbursement policy (page 84) With decisions on pricing and reimbursement of pharmaceuticals, Member States aim to achieve 3 overall objectives of (1) finding the optimal use of resources to maintain a sustainable financing of healthcare, (2) ensuring access to medicines for patients and (3) rewarding valuable innovation. Each Member State has its specific approach for balancing these 3 overall objectives. The guiding principles and ideas in the document aim to help Member States obtain such a balance, through implementation of national pricing and reimbursement practices. 2. Ensuring availability to medicines in small national markets in Europe (page 88) The issue of sustainable availability and delivery of medicines is in particular important for the smaller national markets, where some important medicines are not available. The production and supply of medicines is usually undertaken by economic operators (manufacturers, wholesalers and pharmacists) that are driven by economic incentives. This paper aims to understand these economic factors, and bring forward some potential solutions to ensure availability of supply. It should be noted that a parallel and separate effort is ongoing from a regulatory perspective, driven by the Heads of Medicines Agencies. 3. Improving access to orphan medicines for all affected EU citizens (page 93) Orphan medicines amplify the common tensions in the field of pricing and reimbursement: assessing and rewarding innovation is difficult, budget optimisation is challenged and access for patients is limited in several countries. In spite of many policy initiatives increasing the number of newly developed orphan medicines, many of these are not available for all EU citizens. This paper aims to identify the main bottlenecks not only related to (1) development, but also to (2) assessment, to (3) pricing and reimbursement practices by companies and by national authorities and to (4) awareness raising. Consequently this paper puts forward some ideas that should be seriously explored in order to ensure timely and equitable access for all EU citizens to orphan medicines. 99 The webpage containing the outcomes of the Pharmaceutical Forum is accessible at http://ec.europa.eu/pharmaforum Final Conclusions and Recommendations of the Pharmaceutical Forum 83 4. Characterisation of the value of innovative medicines (page 100) This report is a bottom-up exercise, based on discussions and collection of views from the relevant Member State authorities on how to recognise, assess and reward valuable innovative medicines. However, it does not aim to identify and implement an EU-wide definition of “valuable innovation”. This exercise identifies some common ground between individual Member States, in addition to setting out more different and optional views on what constitutes valuable innovation. This exercise covers valuable innovation in 3 main areas: (1) therapeutic/clinical benefits regarding the disease, (2) quality-of-life benefits for the patient and (3) broader socio-economic benefits. 5. From assessing innovative value of pharmaceuticals to pricing and reimbursement decisions (page 104) This paper aims to clarify how some European Member States use assessments of innovative medicines in their pricing and reimbursement decisions. Such decisions drive the expenditure for the authorities as well as the revenue for companies, the basic incentive for further research and development. Hence this paper aims to understand the mechanics behind the incentive for companies to risk investing in R&D. This information is valuable (1) for countries that in their pricing/reimbursement decisions refer to prices in Member States that assesses innovative medicines, to ensure an understanding of the rationale behind the reference price. Moreover, (2) it will benefit Member States that search for experiences and good practices to develop their own value- based pricing systems and (3) for pharmaceutical companies that need to know what revenue can be expected for the value of their medicines. 6. The Toolbox exercise (page 110) Member States increasingly look to the same range of practices to balance budgets with access and reward for innovation. Nevertheless there is need for more evidence of the benefits and risks of different practices. This increases the interest of the Member State participants in sharing their experiences and evidence on different practices. The aim of the toolbox exercise is therefore, for six selected practices, to collect expertise from Member States and stakeholders and to provide answers to questions like: real benefit(s), potential risks and interferences with other practices, driving factors of such risks or successes, practical set-up. 7. Risk-Sharing practices and Conditional Pricing of pharmaceuticals (page 125) An increasing number of Member States have set-up risk sharing practices and conditional pricing and reimbursement practices. These practices allow competent authorities and pharmaceutical companies to build clinical experience on medicines which might normally not be eligible for reimbursement. Such practices allow at the same time budget-control and the identification and reward of valuable innovative medicines. Furthermore, they provide access for patients to highly innovative treatments. This paper describes how these practices are set-up in different Member States and draw some common findings. Final Conclusions and Recommendations of the Pharmaceutical Forum 84 Guiding principles for good practices implementing a pricing and reimbursement policy The decisions on cost of healthcare and pharmaceuticals are a national responsibility, It has appeared in the Working Group that with decisions on pricing and reimbursement of pharmaceuticals, Member States aim to achieve 3 overall objectives of (1) optimal use of resources to maintain sustainable financing of healthcare, (2) access to medicines for patients and (3) reward for valuable innovation. Each Member State has its specific approach for guaranteeing these 3 overall objectives. Member States shall ensure that any national measure to control the prices of medicinal products or to restrict the range of medicinal products covered by their national health insurance systems complies with the requirements of Directive 89/105/EEC and the Treaty. This EU legal framework requests in particular that pricing and reimbursement decisions are made in a transparent manner. The following toolbox principles will allow good implementation of pricing and reimbursement practices and are meant to offer guidance and facilitate the sharing of information and assessments. They are not binding rules. Access for patients Ensure timely access to valuable innovation. The Transparency Directive defines deadlines that have to be respected in taking pricing and reimbursement decisions. In standard cases, a request for a pricing and reimbursement decision should come with proof of benefit upfront, based on good clinical trials delivered by the applicant, whenever possible in a comparative set-up with a standard treatment. In some cases, when a full assessment is to be made for a new breakthrough medicine with a value not yet certain or difficult to prove, these deadlines might be a constraint in spite of good clinical trials. In these cases more evidence needs to be gathered after a medicine has been put on the market. In such cases, and in particular where it concerns life-threatening situations for which no alternative treatment exists, national authorities and companies could take a first pricing and reimbursement decision with conditional on gathering more information in order to review this decision. Such decisions allow patients to gain early access to potentially valuable medicines and innovative companies to get an earlier reward for investment in R&D. In the meantime necessary data can be collected within well-designed outcome research studies. These pricing and reimbursement decisions should come with a mutual commitment to a risk-sharing contract between companies and authorities. This commitment has to come upfront given that it is difficult to withdraw a medicine from reimbursement. Such a contract lays out the expected benefits of a new medicine, the criteria to assess these benefits, the data needed and methods/capabilities to do these assessments as well as the overall timeframes. On the financial side, the contract can define prices, reimbursement levels and restrictions of utilisation during the temporary period, as well as the financial consequences once new proof of benefit is available (for example leading to price or reimbursement changes –upwards or downwards-, changes in utilisation, premiums or payback). Provide affordable medicines. Medicines should be equally accessible at an affordable cost to all concerned patients. Generic medicines provide an opportunity to obtain similar treatments at lower costs for patients and payers, while liberating budgets for financing new innovative medicines. Promoting generic medicines requires a good combination of demand-side as well Final Conclusions and Recommendations of the Pharmaceutical Forum 85 as supply-side mechanisms. This includes a flexible and adaptive pricing and reimbursement system, an appropriate level of price-sensitivity in patients (and payers where insurers/sickness funds are involved) and a sufficient level of competition among the different actors in the supply system (manufacturers, wholesalers and pharmacists, taking account of their public health role). It has also become clear that affordability has a European dimension. A similar price-level leads to a different level of affordability depending on the economic situation of each Member State. Attention could be given to measures that allow companies to offer medicines at affordable prices in each EU market. Limiting price-control only to nationally used volumes, as Recommendation 6 of the G-10 Medicines report stipulates, would allow differential pricing taking account of national socio-economic indicators like GDP-levels. Affordability could also be ensured through upfront agreements on maximal expenditure. This could allow authorities across the EU to accept similar prices for a limited number of innovative medicines while maintaining the total expenditure at a nationally affordable level, although this cannot be seen as a large-scale solution. Ensure equal availability of medicines. Several medicines are not available in some markets, in particular small or low-price markets where the potential profits may not seem to justify the investment to organise local supply. Manufacturers should commit to register and supply all EU markets at reasonable prices, including the small and low-price markets. Wholesalers should commit to supply all these EU markets at reasonable prices. Where this is not possible, purchasing and supply managed (partially or totally) by national authorities, potentially in collaboration with other Member States, are to be fully accepted as an alternative. Overall, sufficient attention should be given to patient’s concerns in the development of a pricing and reimbursement policy, in particular to the existing inequities among Member States in availability and affordability. Optimal use of resources Limit price control to where it is needed to contain the public budget. Member State authorities usually fix prices and reimbursement levels to ensure access to medicines at affordable cost for utilisation within their territory. Member States are not interested in fixing prices of products that are only transiting through their territory to be utilised within other Member States. They should, therefore, abstain from fixing prices for products that will not be used within their territory and that will not impact on their national budgets (as outlined by Recommendation 6 of the G-10 Medicines report). Control of supply and utilisation, including a system of traceability, might be helpful. Price control is not necessary for non-reimbursed medicines. For these products, price- competition can steer the price-evolution sufficiently well. Therefore, Member States should abstain from price-control. Monitoring systems might be helpful to get an overview of market- and price-evolutions and to mitigate any potential risk of significant price increases. Set-up a consistent package of supply and demand-side measures. To manage expenditure on pharmaceuticals, authorities need to manage prices, reimbursement levels and proper use. Supply side measures, addressing prices and reimbursement levels, are, therefore, to be managed in coordination and alignment with demand side measures, determining the volume. On the demand side, the individual behaviour of doctors, pharmacists and patients will determine the total use of and expenditure on medicines. Interests of all these actors, therefore, need to be aligned with the national objectives. One or several of these actors should be motivated to push forward utilisation of medicine in a cost effective way, either Final Conclusions and Recommendations of the Pharmaceutical Forum 86 through a (financial) incentive, or through a controlled obligation. Practices (1) on prescription guidance for doctors, (2) on substitution by pharmacists and (3) on cost-sharing and price-sensitivity of patients, should therefore be aligned. In addition, upfront agreements on overall maximal expenditure, in the form of payback or price-volume agreements, allow effectively increased predictability of overall expenditure. Create the right environment for price competition. Direct or indirect control of prices, reimbursement and expenditure are clearly relevant in a market with low price-sensitivity and high market power of manufacturers, in particular for medicines under patent protection. In situations where competition between different products is possible, e.g. when generics enter the market, open price competition may lead to good containment and significant reduction in prices and costs in a less cumbersome way. On the other hand, maintaining fixed pricing or reimbursement levels, in a situation where competition is possible, could prevent price- reductions. To ensure savings, authorities need to provide for a flexible, adaptive pricing system, an appropriate level of price-sensitivity in patients (and/or payers) and a sufficient level of competition among the different actors in the supply system (manufacturers, wholesalers and pharmacists, taking account of their public health role). Particular attention is to be paid where generic prices are always defined as a fixed percentage of the originator price, regardless of the number of price-decreases of this originator. Such systems may lead generics being out-competed through consecutive price-reductions of the originator. Cost containment mechanisms can create sufficient headroom that is needed for rewarding valuable innovation. This could also benefit from a holistic and long-term perspective, aiming for sustainable financing of healthcare, beyond pharmaceuticals. Reward for Innovation Set expectations. Limited resources force authorities to make choices on what new products to reward and pay for. Through its pricing and reimbursement decisions, each Member States tends to grant incentives (e.g. a high price and reimbursement level, or good access to the market) for those new products that it really appreciates as bringing valuable improvements compared to the standard therapy. In this way, Member States indicate what they expect from pharmaceutical R&D to deliver. It is, therefore, important to reflect what are and will be the desired additional benefits and to allocate resources accordingly. (A separate paper has been prepared for a separate discussion on what Member States consider valuable innovation. See annex) Recognise innovation. The degree of added value delivered by new medicines is often incremental and, therefore, harder to recognise. Companies should, therefore, be prepared to clearly prove this added value versus existing therapies and authorities should be prepared to recognise proven incremental benefits that are estimated valuable and reward them appropriately (i.e. with incremental price-premiums or with measures allowing a higher utilisation). Pricing and reimbursement mechanisms, as well as utilisation guidelines, should be in line with this and ensure a scaled recognition and reward. It should thus not be expected that incremental benefits would be rewarded with break-though premiums. Where added value versus existing therapies cannot be proven and recognised, timing of market entry of a new medicine should be taken into account as well as its effects on competition. Products coming to market soon after the first-in-class originator are the result of a parallel R&D process and should be rewarded in parallel to the first-in-class originator. Products entering the market significantly later should not get a similar reward. Final Conclusions and Recommendations of the Pharmaceutical Forum 87 Be consistent when giving reward. Criteria for pricing and reimbursement need to be transparent, as requested by the Transparency Directive, and consistent over time. This gives the right signals to companies on what innovations are expected and valued. Research and development of a medicine is a risky and multi-year process, in particular for small and mid- size biopharmaceutical companies. The national pricing and reimbursement decisions and related decisions on the timing and utilisation are the only indicators that show whether it will be worthwhile starting this risky process. In addition, overall cost-containment mechanisms, like price-cuts or payback, could be aligned with these initial decisions; they could, for example, foresee exemptions for those innovations that are considered very valuable and have been granted a consequent price and reimbursement level. Final Conclusions and Recommendations of the Pharmaceutical Forum 88 Ensuring availability of medicines in small national markets Promoting the sustainable availability and delivery of medicines to all European markets is one of the objectives of the Pharmaceutical Forum. This is in particular important for the smaller national markets, where some important medicines are not available. This issue has been put forward by the participants of the Working Group Pricing of the Pharmaceutical Forum since the first session. It is in particular a worthwhile exercise for this Working Group to address the unavailability of many medicines to small national markets, as the underlying reason for this unavailability seems also to be of an economic nature. The creation and supply of medicines is usually undertaken by economic operators (manufacturers, wholesalers and pharmacists) that are driven by economic incentives. Any solution for the problem will therefore have to strike a balance between economic reward, access and cost-control. It needs to be noted that a parallel and separate effort is ongoing from a regulatory perspective, driven by the Heads of Medicines Agencies. In their 2007 report they conclude that "Medicinal products are not made available in the markets of all Member States. Member States with small markets face significant problems of medicine availability, especially with products of low volume, low price and specialised products intended to treat severe and/or rare diseases." The European Commission has therefore been asked to see how they can improve the regulatory framework. Both efforts should move forward in parallel, with regular mutual consultation. Introduction While ensuring quality, safety and efficacy of the medicines in the European markets, regulatory procedures can pose some difficulties to the availability of medicines. In addition, there are several other thresholds, of more economic nature, that limit availability as economic operators need to overcome them before making a medicine available on a national market. This paper therefore aims to provide an economic overview of these main thresholds as well as some understanding on the reward for economic operators that motivates them to overcome these thresholds. In addition the paper tries to explain how these economic requirements and rewards are influenced by the (small) size of the market. This knowledge forms the basis for some options for ways forward in the last section. Of course, every country is different, and should take up those options best targeted at the situation of its own market. This paper only aims to provide a general understanding and a menu of options that could potentially improve availability. Thus, economic operators may find more options that allow them to supply medicinal products to all markets in a profitable way. At the same time, one should keep in mind that medicines can not be treated as other commodities by regulators and administrators because of their public health implications. This exact concern and responsibility should help ensure the supply of medicines on the markets of all Member States. Although this paper includes some thoughts on the models and processes of making pricing and reimbursement decisions, it does not aim to express an opinion on the actual or appropriate levels of pricing and reimbursement. These levels are anyhow driven by a multitude of factors, and vary from country to country. Price increases or price reductions are not expected to really address the issue of availability. E.g., Iceland is a small national market Final Conclusions and Recommendations of the Pharmaceutical Forum 89 that, in spite of having amongst the highest prices in Europe100, is facing significant availability problems. On the other hand, price cuts would probably reduce necessary incentives for economic operators to supply medicines on a smaller market. The economics of making medicines available Once the development of a medicine is completed successfully, additional steps are required to make it available on a national market. Within the current frameworks, these steps are usually undertaken by economic operators: manufacturers, marketing authorisation holders, agents, wholesalers and pharmacists. These economic operators will only do so if they can make profit out of it, meaning that costs incurred to overcome the thresholds are lower than expected revenues for doing so. The key activities to be undertaken are: 1. Administration: Market authorisation is a first necessary step to place a medicine on a market. This requires the preparation of a specific file, the hand-over and the administrative follow-up with the authorities. Although Marketing Authorisation files for new, innovative medicines are handled increasingly on a European level by EMEA and the European Commission, for many older medicines the files are usually handled on a national basis. In a next step, pricing decisions (where relevant) are taken. This can only take place on a national level. Also reimbursement negotiations are handled on a national basis with the local authorities. Many authorities require a fee for handling these files. This administrative preparation and follow-up of files, together with the related fees, bring an upfront investment for a manufacturer before a medicine is allowed into a specific market. At the same time, delays in decisions making can bring a significant loss of revenue for manufacturers and delay in access for the patient. Consequently, once put on the market, there is need for additional administration like sales, marketing, pharmacovigilance and other activities to maintain the marketing authorisation for each medicine put on the market. In many countries Marketing Authorisation Holders pay a maintenance fee to the authorities, to perform ongoing tasks like pharmacovigilance. In principle, administrative work related to putting a medicine on the market is not determined by the size of the local market. For some smaller national markets these administrative tasks are performed by exclusive representatives of one or more manufacturers in the national market. 2. Manufacturing, packaging and labelling need to follow the EU legislation and the requirements of each national market, e.g. requirements related to the local language(s). Manufacturing and packaging are planned and executed in continental or global facilities, producing so-called batches (fixed quantities of medicines) specified for a local market and its requirements. Planning and producing consignments of packs for small national markets will be less regular and requires sufficient organisational flexibility. At the same time consignments for small national markets typically have lower quantities and are therefore more expensive per unit produced. This organisation is further complicated by the fact that small national markets need to be continuously supplied, as any other market. 100 Eurostat 2007 Final Conclusions and Recommendations of the Pharmaceutical Forum 90 3. Transport and wholesaling steps bring the prepared medicines from various manufacturing sites to multiple local retail points. Many Member States therefore place public service obligations on wholesalers which require them to deliver all medicines available in the market within certain time limits to all pharmacies. These full-line wholesalers therefore need to build and maintain sufficient stocks and efficient ordering systems, besides their transport capacity. This is in particular complicated for medicines with a low frequency of ordering. For some sophisticated products, manufacturers organize direct supply to the hospital (e.g. oncology). For some of the more distant small national markets like Malta, Cyprus or Iceland, transport costs can be significant. Maintaining stocks of medicines as products with an expiry date, is more complicated and expensive when demand is limited, like in small national markets. In some smaller Member States there are no full-line wholesalers. Often transport and distribution steps are there organised by an agent, who organises through a wholesaler the exclusive supply of those medicines produced by the manufacturer(s) he represents. These agents, if they are not considered wholesalers, would not be submitted to public service obligations according to the EU legislation. As compensation, wholesaling parties/agents earn a margin per unit of medicine delivered. This margin is usually a fraction (percentage) of the ex-factory price of the supplied medicines. To be profitable it is therefore important that wholesalers deliver a broad portfolio of products, so that margins of different products add up to earn sufficient margins in order to cover all costs. The creation of such portfolio also allows cross- subsidisation, so that less-expensive medicines can be supplied, which stand-alone would not offer enough margins to wholesalers to cover costs of supply. This is the basic business model of full-line wholesalers. The smaller the market, and thus the volume of each medicine needed, the broader the portfolios of individual wholesalers need to be. In this way, a wholesaler can supply sufficient high-margin products to be profitable and deliver also all low-margin products. If medicines are to be made available on a local market, it is important that all actors can undertake their activities in a profitable way i.e. manufacturers (authorization, registration, price administration, manufacturing and packaging) wholesalers (transport, storage, wholesale/distribution) and finally also pharmacists (retailing). As mentioned in the different paragraphs above, the specificities of small markets make it harder for each of them to be profitable. Final Conclusions and Recommendations of the Pharmaceutical Forum 91 Potential ways to facilitate availability Looking at these different steps, some ideas could be elaborated in order to improve the availability of medicines, in particular in small national markets: 1. Administration a. The taskforce preparing this paper has discussed several regulatory ideas to reduce the administrative burden to obtain marketing authorisations. These ideas were similar to those expressed by the Heads of medicines Agencies task force on availability, discussed in the Pharmaceutical Committee. b. Marketing authorisation holders should supply, as far as possible, each product in each national market where it is authorised. Alternatively, if a marketing authorisation holder chooses not to have a product supplied in a given Member State, there should be ways to get the product on the market where it is needed. c. Within small national markets, companies should register trademarks, pack-sizes and forms that are similar to the ones within some larger EU markets. d. Authorities in small national markets should ensure a pricing and reimbursement system that facilitates the placing on the market of new medicines and ensures their availability. 2. Manufacturing, packaging and labelling a. The taskforce preparing this paper has discussed several regulatory ideas to solve the problem of availability, in particular those related to the language requirements. These ideas were similar to those expressed by the Heads of Medicines Agencies task force on availability, discussed in the Pharmaceutical Committee. Some of these ideas will also be discussed in the context of the upcoming pharmaceutical package of the Commission (expected in October 2008). b. Companies can produce multi-lingual single packs for multiple (small) national markets. This would allow cheaper and more frequent production of consignments for the small national markets. This is allowed by Community law under Article 63 of Directive EC/2001/83 and e.g. in place in Belgium where packs are adapted to language requirements in Dutch, French and German. 3. Transport and wholesaling a. Ensure the presence of an optimal number of full-line wholesalers to ensure good and continuous supply. Ideally, there should be sufficient full-line wholesalers so that supply problems within one wholesaling actor do not immediately lead to problems for the entire market. However, the presence of too many full-line wholesalers might lead to suboptimal supply of the market. The regulation of margins can be a tool to this end. b. Apply public service obligations on all wholesaling actors, and encourage that as many as possible act as full-line wholesalers and continuously supply all medicines to the entire local market. c. Public wholesaling. Public authorities can organise wholesaling themselves. This is e.g. sometimes done in the context of tendering or purchase of hospital medicines. To ensure that all products are delivered on the market, public wholesaling should be complementary and not competitive to private full-line wholesaling. Public wholesaling should therefore primarily focus on those Final Conclusions and Recommendations of the Pharmaceutical Forum 92 products that are not efficiently delivered through private wholesaling (e.g. where stock-ruptures exist). Public or short-line wholesaling of the most profitable products has an impact on the availability of the full range of products, as these most profitable products offer the main incentive for private full-line wholesalers. Public wholesaling should not pre-empt the need for public service obligations.. Of course, the use of these mechanisms needs to comply fully with the relevant competition legislation. Potentially authorities of smaller Member State could join efforts. Of course, each country situation is different and the reasons for (un)availability vary. Some initiatives are already in place in some countries. It is therefore up to each country to take up the most adequate of the options outlined above, in order to improve availability in their local market. Further collaboration between the concerned authorities and stakeholders should be organised. There is a need for a holistic approach, considering regulatory as well as economic aspects, considering needs and roles of authorities as well as of economic operators and considering the different activities needed to get medicines into the market. The European regulatory aspects will also be addressed by the European Commission, in joint partnership with the Member States. Final Conclusions and Recommendations of the Pharmaceutical Forum 93 Improving access to orphan medicines for all affected EU citizens The overall objective of this document is to promote the sustainable development of valuable orphan medicines and to improve sustainable access to these medicines for all affected citizens in the EU. It is in particular a valuable exercise for the Working Group on Pricing of the Pharmaceutical Forum to address the area of orphan medicines, as these medicines amplify strongly the common tensions we have found in the field of pricing and reimbursement: assessing and rewarding innovation is difficult, budget optimisation is challenged and access for patients is limited in several countries. Introduction Orphan diseases are life-threatening or chronically debilitating diseases that affect less than 5 out of 10.000 citizens. Although each of the orphan diseases only concerns a limited number of patients, rare diseases are socially and ethically relevant. In the EU, about 6% of the population is expected to be affected by one of 5,000-8,000 orphan diseases at one point in their life-time101. The low number of potential patients per disease may limit the economic attractiveness of undertaking research and development of medicines to treat orphan diseases. To promote such research and development, the European Union has adopted the European Regulation on Orphan Medicinal Products in 2000 (Regulation (EC) No 141/2000).This Regulation defines an orphan drug as a medicines (a) for a life-threatening or chronically debilitating condition, (b) that affects not more than 5/10,000 persons or for which a low return on investment is expected without additional incentive and (c) for which no satisfactory alternative treatment method exists or for which this new medicine brings significant benefits to patients compared to the existing treatment. This Regulation has brought some efficient incentives for R&D, in particular the provision of a 10-year market-exclusivity which has led to a significant increase of research and development in the field of rare diseases. By February 2008, 541 molecules got an orphan designation. 45 of them have gone through the entire development-process and have effectively led to a new treatment for which a marketing authorisation was granted (see annex). As such, a medicinal therapy has been developed for many diseases which previously could not be treated. For the coming 5 years a steady inflow of about 10 to 12 new orphan medicines per year is expected. By end 2012, it is anticipated that around 100 orphan medicines will be authorised in the EU. The adoption of recent European legislations like the Paediatric Regulation (Regulation (EC) No 1901/2006) or the Regulation on Advanced Therapies (Regulation (EC) No 1394/2007), has provided an additional stimulus for many orphan medicines. Many measures that were taken by individual Member States on the national level have largely contributed to this success. In spite of this, newly developed orphan medicines are not available for all citizens in the EU in a timely and equitable manner. Effective market access and utilisation vary strongly between and within Member States. Different studies, like e.g. the Alcimed study102 or the 101 These figures come from different institutions’ official documents, such as the Background Paper on Orphan Diseases for the “WHO Report on Priority Medicines for Europe and the World” - 7 October 2004; the European Commission Consultation “Rare Diseases: Europe’s challenges” - November 2007; documents from the National Institutes for Health – Office of Rare Diseases, as well as documents from patients organisations: NORD, the National Organization for Rare Disorders in the USA, and EURORDIS, the European Organisation for Rare Diseases in the EU, in particular the document “Rare Diseases: understanding this Public Health Priority. 102 Commissioned and published by the Commission on 16/11/2004 on http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/archives_en.htm Final Conclusions and Recommendations of the Pharmaceutical Forum 94 Eurordis survey103 series, confirm this variation in access. European reference networks between centers of expertise are a way to reduce this variation in access. This paper aims to identify the main bottlenecks orphan medicines meet on their way to all affected EU citizens. These bottlenecks relate no longer just (1) to development, but also (2) to assessment, (3) to pricing and reimbursement practices by companies and by national authorities and (4) to awareness building. Consequently this paper puts some ideas forward that should be seriously explored in order to ensure timely and equitable access for all EU citizens to more orphan medicines. Specific bottlenecks linked to rarity In spite of increased incentives and in spite of increased flexibility in marketing authorisation procedures, the development of a medicine for an orphan indication remains a risky enterprise. The low number of potential patients, the absence of patient registers and the lack of national centres of expertise complicates research and development while it makes the future return on such R&D investments uncertain. Besides the usual R&D difficulties, researching and developing orphan medicines need to deal with the identification of rare patients, the heterogeneity of the diseases, a limited basic knowledge on the diseases, the application of often novel technologies and specific logistics and infrastructure requirements to run the clinical studies (e.g. flying patients in worldwide to one expert centre). Also manufacturing processes need to be developed at the same high standard-levels of safety, quality and efficacy as for other medicines. The low number of potential patients limits the future sales volume while often high levels of pricing and reimbursement make negotiation processes difficult. Overall, this may make the expected future revenue and return on investment uncertain and unattractive, while it potentially jeopardises the important societal benefits that orphan medicines could offer. The Orphan Medicinal Products Regulation is aiming exactly to address these bottlenecks in development. Assessing the clinical added value of innovative medicines has proven to be a difficult task. Capacities and knowledge to do so are still under development. Orphan medicines add to this complexity due to the rarity of patients, the severity and the heterogeneity of the diseases addressed and the scarcity of clinical experts. Scientific data that are presented to Marketing Authorisation authorities are often limited as clinical trials can only include a low number of patients. The severity of the disease, combined with the lack of satisfactory alternatives, regularly leads to early Market Authorisations, before running phase III- trials which bring more data on a higher number of patients. Often ongoing clinical data-registration (phase IV) needs to be organised in the post-marketing phase as required by regulatory authorities. Data for value assessments (post marketing authorisation) are therefore limited, in particular for the initial assessments. In addition the know-how to make these value assessments of orphan medicines is strongly fragmented over national procedures within the individual Member States and their regions, in spite of some first efforts to collaborate. The disconnection of these national and regional processes from the knowledge and experience gathered upfront in the centralised processes (like for Orphan Designation, for Marketing Authorisation or for Paediatric Use) add to this fragmentation. Pricing and reimbursement decision-making is an area of increasing sensitivity within almost all of the European Member States. The uncertainty about the value, the lack of information, the usual high-prices, the high risk for development, the low and uncertain volumes, the occasional extensions of indications and the often life-long need for treatment add to this sensitivity when discussing pricing and reimbursement of orphan medicines. 103 Available through www.eurordis.org Final Conclusions and Recommendations of the Pharmaceutical Forum 95 Decision-making is further complicated by the frequent use of these treatments in hospitals. As explained above, only a limited set of data on clinical added value is available to justify the initial requests for high prices, while data on drug-specific costs for R&D are usually not available, as is the case for most medicines. When prices are negotiated, initial negotiations between companies and authorities should not only include agreements on price and reimbursement levels but also on monitoring utilisation (based on medical best practices), in order to control budgets in spite of high prices. Negotiations can be further complicated in case of further extension of indications. In many Member States, the national budgets for orphan medicines are still relatively limited, but seem to grow fast. These budgets may lead to different levels of affordability depending on the economic situation of a Member State. To manage budgets and make the right choices, an increasing number of Member States complement the price negotiations with practices to monitor and manage utilisation like e.g. prescription limitations, pre-utilisation approvals or exclusive use in designated expert centres. In contrast to other disease areas, health professionals have limited awareness and skills with diagnosing and treating orphan diseases. The low incidence of these diseases allows only a limited number of health professionals, usually in specialized centers, to build expertise with diagnosing and providing medical care to people affected by a rare disease. Nevertheless, an early diagnosis of these diseases, which often have a genetic origin, is one of the best guarantees for an efficient treatment from a therapeutic and cost perspective. In addition, treatments are often not curative but usually offer from limited to extensive symptomatic support. The novelty of the treatment options offered by innovative orphan medicines further limits awareness and skill levels of health professionals. Some Member States therefore organise the monitored utilisation of orphan medicines through dedicated centres of expertise, to which all patients with a specific orphan disease are referred. Alternatively Member States ask these centres of expertise to issue good practice guidelines to advise all potential concerned physicians and experts. Potential ways forward In addition to ongoing activities promoting the development and access to medicines in the European Union, the Working Group Pricing believes that some specific activities can be explored to promote further development and access to orphan medicines. These include: o Establish early dialogue between companies and pricing and reimbursement authorities, including clinical value assessment authorities regarding orphan medicines in the pipeline and the future needs for these medicines. This dialogue will allow in an early stage to clarify the need for a new orphan medicine under development and give an idea of the number and profile of patients in need. It would offer an early occasion to discuss what clinical data would be required for later clinical value assessments and pricing and reimbursement decisions. This will give the sponsoring company more certainty on its potential future return and will give authorities more knowledge and trust in the value of medicines it will be requested to assess and fund. Also, this will significantly facilitate long-term planning both for companies, for funding authorities and for society. Such dialogue could even help identify areas where further research and development for orphan medicines are needed, taking account of public health priorities. Early dialogue would also bring an opportunity to get more transparency on costs, including the role of publicly funded studies, and on pricing. Such dialogue might require an upfront coordination between Member States and European authorities, in full respect of different competences, in order to jointly pass common messages to the individual companies. This coordination and dialogue can be continued after regulatory approval and after initial Final Conclusions and Recommendations of the Pharmaceutical Forum 96 pricing and reimbursement decisions, where additional studies are requested regarding the utilisation of medicines. Where appropriate this can include the set-up and use of disease registries104. o Exchange of knowledge amongst Member States and European authorities on the scientific assessment of the clinical added value of orphan medicines. Such exchange could improve the flow of knowledge from EU-level authorities (e.g., EMEA committees) to the Member State's pricing and reimbursement authorities, in particular with knowledge gathered during marketing authorisation procedures (quality, safety, efficacy), revision of the orphan designation at the time of marketing authorisation (significant benefit) and potentially the evaluation of paediatric use (paediatric investigation plans). Bundling the fragmented know-how to assess the clinical value of orphan medicines would allow the timely production of well-informed opinions, based on more data, shared information, experiences and in-depth discussion. Such opinions will form a good input and may reduce the information deficit for the national pricing and reimbursement decisions. Clinical/therapeutic aspects, rather than economic and quality-of-life aspects, should be the first focus in common approaches, as variation between Member State practices is lowest in this area. Based on exchange of knowledge, these collaborations could lead to non-binding common clinical added value assessment reports with improved information that facilitate the national pricing and reimbursement decisions, without pre-empting respective roles of the authorities. Of course the applicable rules regarding confidentiality should be considered when exchanging such information. o Promotion of the initial uptake of orphan medicines through conditional pricing and reimbursement decisions. Such conditional decisions could allow fast access for patients to medicines, while the related conditions can, case by case, control the utilisation, specify the expected annual budgets, fix the timings for review and clarify the expected results of further studies and future pricing and reimbursement adjustments. To fully profit from conditional agreements, costs, risks and benefits must be clearly aligned and clarified upfront, in order to avoid later legal and ethical conflicts. At extension of indications a review of the conditions should be organised taking account of the additional development costs and the additional number of patients benefitting from the medicine. The related conditions usually ask for monitored utilisation allowing collection of additional data e.g., in the context of a post-marketing trial or a registry. A high quality of monitoring and data-analysis is needed in these trials. The earlier Member States adopt the utilisation of orphan medicines in such controlled settings, the earlier a substantial set of data on the impact of orphan medicines can be developed. This in return will provide a basis for the future review of pricing and reimbursement decisions. To ensure that patients in all EU and EFTA Member States can benefit early on from orphan medicines other ideas should be explored, like simultaneous applications for pricing and reimbursement to all Member States authorities, early start of national pricing and reimbursement procedures, parallel decision making with common information bases and coordinated follow-up of use and outcomes in clinical practice. Some of these ideas are already in place in some Member States, and these experiences should be shared amongst Member States. 105 o Building EU-level awareness and expertise on orphan diseases. Controlled utilisation can very well be linked to the creation of standardised patient registers106 at international level and networks of centres of expertise. Registers would also allow upfront estimates of 104 Disease registry is a specially designed database with voluntary, observational clinical data collected from physicians and intended to explore and define the natural course and clinical characteristics of disease, as well as to track and characterize response to treatment. 105 For more specificities regarding conditional pricing and reimbursement we refer to the paper "Risk-Sharing practices and Conditional Pricing of pharmaceuticals - How to deal with uncertainty", as well as to the "Guiding Principles Paper", adopted by the Working Group Pricing. 106 Patient register is a database (list) containing baseline information on the existence of patients with (a) certain disease(s), but without any longitudinal follow-up. Final Conclusions and Recommendations of the Pharmaceutical Forum 97 numbers and profiles of patients for study and budget purposes. Another key benefit of such registers is the upfront knowledge of where rare disease patients live so that they can be quickly enrolled in trials for new potential medicines, to the benefit of both the patient and the sponsoring company. At the same time, the set-up of disease registries will facilitate the generation of additional data on the benefits of the medicine in real life settings. These data, in their turn, will form the basis for later reviews of pricing and reimbursement decisions. All registers and registries are to be managed in compliance with data protection rules and other relevant national requirements. To fully leverage collected knowledge, the efforts need to be well coordinated within and between Member States. Within Member States, coordination should be a key element in national plans for rare diseases and orphan medicines. Between Member States, national and regional centres of expertise need to be connected in a cross-border European Reference Network for Rare Diseases. The Orphanet initiative could be a helpful reference for cross-border work in this area107. This will improve access to orphan medicines, increase quality of care, and allow to compile and compare data of all Member States. 107 www.orpha.net Final Conclusions and Recommendations of the Pharmaceutical Forum 98 List of Orphan Drugs with European Market Authorisation - 16 June 2008 Product Name MA Holder Date of MA Indication Replagal Shire 4-may-01 Fabry Disease Fabrazyme Genzyme 4-may-01 Fabry Disease Glivec Novartis 27-aug-01 Chronic Myeloid Leukaemia Trisenox Cephalon 5-march-02 Acute Promyelocytic leukaemia Tracleer Actelion 15-may-02 PAH Somavert Pfizer 13-nov-02 Acromegaly Zavesca Actelion 20-nov-02 Gaucher Disease Carbaglu Orphan Europe 24-jan-03 NAGS Deficiency Aldurazyme Genzyme 10-june-03 MPS I Busilvex Orfagen / Pierre Fabré 9-july-03 Conditioning prior to transplant Ventavis Schering 16-sept-03 PAH Onsenal Pfizer 17-oct-03 Familial Adenomatous Polyposis PhotoBarr Axcan 25-march-04 Dyplasia in Barrett's Esophagus Litak Lipomed 14-apr-04 Indolent Non Hodgkins Lymphoma Lysodren HRA Pharma 28-apr-04 Adrenal Cortical Carcinoma Pedea Orphan Europe 28-july-04 Patent ductus Arteriosus Wilzin Orphan Europe 13-oct-04 Wilson's disease Xagrid Shire 16-nov-04 Essential Thromobythaemia Orfadin Swedish Orphan 21-feb-05 Tyrosinaemia Prialt Eisai Ltd. 21-feb-05 Chronic pain Xyrem UCB 13-oct-05 Narcolepsy Revatio Pfizer 28-oct-05 PAH Naglazyme BioMarin Europe 24-jan-06 MPS VI Myozyme Genzyme 29-march-06 Pompe Disease Evoltra BioEnvision (Genzyme) 29-may-06 Acute Lymphoblastic Leukaemia Final Conclusions and Recommendations of the Pharmaceutical Forum 99 Nexavar Bayer 19-july-06 Advanced Renal Cell Cancer Sutent Pfizer 19-july-06 GIST Savene TopoTarget 28-july-06 Anthracycline Extravasation Thelin Encysive (UK) Ltd. 18-aug-06 PAH Exjade Novartis 28-aug-06 Iron overload req chelation Sprycel BMS Pharma EEIG 20-nov-06 Chronic Myeloid Leukaemia Diacomit Laboratoires Biocodex 4-jan-07 Myoclonic Epilepsy Elaprase Shire 8-jan-07 MPS II Inovelon Eisai Ltd. 16-jan-07 Lennox Gastaut syndrome Cystadane Orphan Europe 15-feb-07 Homocystinuria Revlimid Celgene 14-jun-07 Multiple Myeloma Soliris Alexion Europe 20-jun-07 Haemolysis in Paroxysmal Nocturnal Haemoglobinuria (PNH) Siklos Addmedica SAS 29-jun-07 Vaso-occlusive crisis Increlex Tercica Europe 3-aug-07 Growth failure Atriance Glaxo 22-aug-07 T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic leukaemia (T- LBL) Gliolan Medac 7-sept-07 Visualisation of malignant tissue during surgery for malignant glioma Yondelis Pharma Mar 17-sept-07 Advanced soft tissue sarcoma Torisel Wyeth 19-nov-07 1st Line Renal Cell Carcinoma Tasigna Novartis 20-nov-07 Philadelphia chromosome positive chronic myelogenous leukaemia Thalidomide Pharmion Pharmion Ltd 16-apr-08 Untreated multiple myeloma Volibris GlaxoSmithKline 21-apr-08 PAH Firazyr Jerini AG 11-july-08 Acute attacks of hereditary angioedema * estimated cumulative number of patients treated since launch in EU-27 (non-repetitive treatment). ** reimbursed in 15 countries Final Conclusions and Recommendations of the Pharmaceutical Forum 100 Characterisation of the Value of Innovative Medicines Introduction At the High-Level Meeting on 29 September 2006, the Pharmaceutical Forum asked the Working Group on Pricing to “further progress by …clarifying views on the value of innovation, taking account of national health systems in order to establish a sound basis for further discussion between different stakeholders…”. This mandate has been assigned to an ad hoc taskforce with the Members of the Working Group on Pricing and involving the chairman of the Working Group on Relative Effectiveness. This report does not aim to identify and implement an EU-wide definition of what is valuable innovation. It is rather a bottom-up exercise, based on the collection and discussion of views of the relevant Member State authorities on how to recognise, assess and reward valuable innovative medicines. Thus, the main objective is rather to identify the common ground between the individual Member States, as well as the different, more optional views on what can be valuable innovation. Still, the decisions on healthcare and pharmaceuticals remain a national responsibility. Focus of this exercise It quickly became clear that the taskforce did not need to focus on innovation in se, but rather on the additional benefit(s) that an innovative medicine brings for the user-side, i.e. mainly for the patient and for society. These users do compare these additional benefits to validated existing treatment options. In this paper, the term “innovation” is therefore different from its strict legal and/or technical definition (‘novelty’ as often identified by a patent). Such potential benefits can be structured in 3 main areas: 1. “Therapeutic/Clinical” benefits refer to those new medicinal products, which are able to treat or to prevent, in all patients or in specific patient groups, diseases lacking (adequate) treatments or diseases already treated with pre-existing medicinal products but with clinical or safety advantages. 2. “Quality of Life” benefits refer to those new medicinal products, which, compared to the existing ones, are able, in all patients or in specific patient groups, to provide quality of life gains. 3. ”Socio-economic” benefits refer to those new medicinal products, which, compared to the existing ones, are (also) able to offer benefit on a higher-level for society (e.g. related to public health or public budgets). It is clear that the benefit brought by one medicine can cover more than one area. Furthermore, there is often interdependence between these three areas of benefit, one benefit influencing another. This is to be taken into account during assessments in order to avoid double-counting. Process undertaken During a first brainstorming session in summer 2006, the taskforce has tried to specify further each of these areas by listing a large number of potential benefits that could be expected from new innovative medicines. This list was meant in the first place to be exhaustive and to cover all the different benefits that could be considered by each of the Member States’ competent authorities. Recognition of the benefits on this list can, therefore not be seen as mandatory, Final Conclusions and Recommendations of the Pharmaceutical Forum 101 but rather as a menu of options, from which individual Member States can choose the benefits they consider relevant. The questionnaire was also sent to a number of patients’ organisations. Table 1: potential benefits from innovative medicines Therapeutic/Clinical Quality of Life Socio-economic Higher probability of full recovery Higher physical self- sustainibility/self-management at home Avoiding Pandemics (vaccination, …) Faster partial or total recovery Higher psychological self- sustainibilty Dealing with resistance (HIV, antibiotics, …) Slower progression of diseases Higher social self-sustainability Reduced total cost of medication Increased ability to cope with disease symptoms (e.g. analgesic) Higher convenience/comfort for the patient and his environment Reduced total cost of treatment Higher probability of preventing the (re-) emergence of a disease Reduced Non-healthcare spending Survival rate, life expectancy Reduced cost of sick-leave Less or less severe side effects Higher productivity of the citizen Less or less severe interactions with other medicines Higher tolerability Broader/easier dosing, improving compliance Easier administration schedule, improving compliance To collect the views of the individual Member States, the list was transformed into a questionnaire (see annex 1), adding some questions on each of the potential benefits. Firstly, whether this new benefit, when delivered through a new innovative medicine, is usually considered of value as a desired improvement. And if so, in what disease/therapeutic situation this new benefit is in particular valuable. In addition, the questionnaire tried to understand how competent authorities identify/measure these benefits as well as how they reward/incentivise a company for delivering such a benefit. The questionnaire was completed and sent out at the end of 2006 and by the beginning of 2007 fourteen answers were collected from respectively Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Latvia, Malta, Netherlands, Norway, Slovenia, Sweden and the U.K. Findings The collected results have allowed compilation of the findings in each of the 3 areas of benefits. This report provides only the summary. More detailed views can be consulted in the Member States’ individual replies. However, it is worthwhile first to mention some overall findings. Final Conclusions and Recommendations of the Pharmaceutical Forum 102 General findings: - Most competent authorities consider benefits in each of the 3 areas mentioned. Although therapeutic/clinical benefits are mentioned as being the most important, there is a general openness to consider benefits in quality of life and/or socio-economic benefits. - Although these benefits in se can be valuable, the value of a new medicine each time needs to be considered case-by-case, i.e. what new additional benefits the medicine brings compared to existing treatments. The type of disease and general status of the patient also play a key role in defining the value of the benefit delivered by a new medicine. - The responses indicate that Member States know what benefits they are looking for, but that companies have difficulties in proving these benefits, and authorities have difficulties in identifying and measuring these benefits, to give them a value and reward. - The list of benefits sent out is rather complete. Most respondents have replied on each of them, and only one reply suggested an additional benefit. - Most respondents indicated that they work with these benefits, though they usually have no fully structured overview in place to identify and assess new medicines, as proposed in this exercise. - Many Member States have an evaluation procedure that starts with determining the intrinsic value of innovation, based on therapeutic/clinical benefits and benefits of quality of life. Pharmaco-economic evaluations then follow in a second step. - Replies from the patients’ organisations added the importance of the empowered patient and the importance of a societal perspective including analyses of therapeutic benefits, quality-of-life benefits and savings. Findings on therapeutic/clinical benefits: - Therapeutic and clinical benefits are the main benefits authorities are looking for, in particular benefits related to recovery, survival, disease progress and management of symptoms. Benefits related to side-effect and interactions of a medicine are considered as a second important category. Benefits related to improved compliance are only considered when this translates into an overall clinical benefit. - Ideally, these benefits can be identified and captured within one over-arching parameter. QALY (quality adjusted life years) was mentioned as well as a combination of morbidity, mortality and quality of life (QoL). In most situations, however, this is not possible due to difficulties with the design, running and interpretation of clinical studies, which serve as the main source of proof of the benefit. However, these clinical studies are primarily designed to obtain marketing authorisations, not for assessments of benefits. - Largest rewards are given to medicines that bring benefits in the fields of recovery, survival rate, disease progress and management of symptoms. Findings on benefits for quality of life (QoL): - Benefits on QoL are considered in most countries, in particular benefits related to (physical) self-sustainability. Of course, such benefits are often related to clinical/therapeutic benefits. - Benefits related to convenience and comfort of the patient are considered less important, although these dimensions are indicated to be of high importance by the patient and his community/family. - Many tools exist to measure benefits in terms of QoL, though only few of them allow an objective and validated assessment. This leads to difficulties in recognising and proving these benefits. Final Conclusions and Recommendations of the Pharmaceutical Forum 103 - As a consequence, reward and incentives related to benefits in QoL are rather limited. Although, some competent authorities mention that the individual patients might be willing to add more reward to these kinds of benefits through a higher personal co- payment. Findings on socio-economic benefits: - Socio-economic benefits are considered in all countries. There is a high overall interest in ‘socio-’ benefits related to public health, like the management of pandemics and/or the resistance to certain antibiotics. Most countries also consider economic benefits, often savings, in particular when these relate directly to the cost of the medication or of the treatment. However, these last benefits are often only assessed in order to define an appropriate price and reimbursement level, once therapeutic/clinical benefits and/or benefits in quality of life are recognised. - Measuring ‘socio-‘ benefits is often based on epidemiological data, which are not always easily available. Measuring economic benefits is more straightforward and often directly translated into Euros, though several issues exist with the methodologies. - Authorities give larger incentives to benefits that address ‘socio-‘ public health concerns. The rewards given to medicines with an economic benefit are often directly related to the economic benefits. Final Conclusions and Recommendations of the Pharmaceutical Forum 104 From assessing innovative value of pharmaceuticals to pricing and reimbursement decisions Objective This paper aims to clarify how some different European Member States use assessments of innovative medicines into their pricing and reimbursement decisions. An increasing number of Member States develop their capacities to assess innovative medicines in order to understand the costs and benefits they bring. As a previous exercise of the Working Group Pricing has demonstrated, the benefits that are considered as added value vary between Member States, although there is a common expectation of therapeutic and clinical progress. As a consequence, assessment methods are still very different among Member States. In several EU Member States, the outcome of these assessments will be used as one element for economic pricing and reimbursement decisions and negotiations undertaken by the competent national authorities. These decisions will therefore drive at the same time expenditure for the authorities and revenue for companies. It is this revenue that makes for a company the return on investment in research and development. Hence this paper aims to understand the mechanics that drive the incentive for companies to take the risk of investing in R&D. This information is valuable (1) for countries that in their pricing/reimbursement decisions refer to prices in Member States that assesses innovative medicines, to ensure an understanding of the rationale behind the reference price. Moreover, (2) it will benefit Member States that search for experiences and good practices to develop their own value- based pricing systems and (3) for pharmaceutical companies that need to know what revenue can be expected for the value of their medicines. Methodology It is the Member States' authority to manage the national pharmaceutical budgets and hence to take the economic decisions that drive the expenditure for each medicine. To do so, Member States increasingly perform assessments of the value of new medicines. In this paper we therefore start to describe the systems of 6 EU Member States: France, the Netherlands, Belgium, U.K., Sweden and Germany. This paper is a dynamic document and aims to add descriptions of several other Member States. A previous literature review has provided information for each of this 6 Member States. This information was complemented with the knowledge of the representatives of these Member States in the Working Group. In a first step, this paper aims to briefly explain what kind of value assessment these Member States are performing. It is not at all the objective of this paper to go in depth on the data and methods of these assessments. Sufficient alternative fora exist to do so. It is rather the objective to understand what is the outcome-format of these assessments that will form partial basis of the economic decisions that will follow. In a second step, this paper examines 4 pharmaco-economic decisions: (1) price level, (2) reimbursement level, (3) utilisation rules and (4) timing of uptake. While the price level drives the cost per medicinal unit, the utilisation rules impact the volume of medicinal units. Reimbursement levels will define who will bear the cost, the government or the patient. Final Conclusions and Recommendations of the Pharmaceutical Forum 105 Reimbursement decisions, also indirectly drive the volume, as they define levels of patient co- payment. With an end of exclusivity that is usually fixed by patent expiry, the speed of uptake will define the overall duration of expenditure/revenue. a. France 1. Assessments There is a focused assessment of clinical and therapeutic benefits of new medicines. The assessment is performed by the transparency committee (“Commission de transparence” - CT) part of the Haute Authorité de Santé (HAS) and includes 2 elements. First, the Actual Benefits (Service Médical Rendu, SMR) is assessed based on the severity of the disorder, the clinical effectiveness of the medicine and the impact on public health. This can lead to an SMR that is Major, Important, Moderate, Low or Insufficient. Second, the comparison to existing treatment options and identification of added value will drive the Improvement of Actual Benefit (Amélioration de Service Médical Rendu, ASMR). This can lead to an ASMR that is Major (I), Important (II), Moderate (III), Minor (IV) or None (V). 2. Pharmaco-economic decision making Prices are set by the Economic Committee for Health Products in function of the ASMR. An ASMR-level I-IV can get higher prices than comparators; an ASMR-level I-III can get a price consistent with prices used in other European countries. Products with ASMR-level V will have to offer lower prices than comparators, in order to obtain reimbursement and provide a decrease in expenses for social security funds. Products with an SMR Insufficient do not receive reimbursement. The level of reimbursement and of co-payment is decided by the National Health Insurance and takes account of the SMR. Utilisation is influenced by HAS, which together with the assessments provide recommendations on therapeutic strategies. HAS can also define restrictions of use for a new medicine. Timing: products with ASMR level I-III are eligible for faster access procedures with notification and less negotiation. Fast track procedures, early assessments and conditional decisions are foreseen for products with an expected good ASMR. b. Netherlands 1. Assessments Therapeutic value, together with efficiency and importance to public health are the main focuses of the assessments. The assessments are performed by the Health Insurance Board (CVZ) and include some steps. In a first step the Healthcare Insurance Board will assess whether a new product can be included in the therapeutic reference price system (Annex 1A). The following criteria are used in this assessment: same indication, same route of administration, same targeted age groups and ‘absence of clinically relevant differences’. In case these criteria are met for the new product (in practice this means that the new product is therapeutically comparable to products included in the reference price system) the product will be included in that reference system and included in a group of therapeutically comparable products. All products in that group are subject to same reimbursement limit. Final Conclusions and Recommendations of the Pharmaceutical Forum 106 In case the new product cannot be included in the reference price system (e.g. because of clinically relevant differences) the product may be included in Annex 1B. Overall, a new product is only included in Annex 1B - if the new product cannot be included in Annex 1A - if the product shows added therapeutic value over the golden standard - the product is cost-effective. The criteria to assess the therapeutic value are efficacy/effectiveness, side effects, applicability, convenience, experience and quality of life. Efficacy/effectiveness and side effects are the most important criteria. Both class 1A and class 1B products can also be classified as class 2 in case of high product costs and/or a significant chance of inappropriate use. 2. Pharmcao-economic decision making Class 1B products get a price-premium above the prices of comparators Maximum wholesale prices are usually set in function of the prices in Belgium, France, UK and Germany. For class 1A products, the level of reimbursement is set within a reference price system, in function of average prices of similar products in the reference cluster. For class 1B products, no reference reimbursement level is applicable and there is no direct reimbursement limit. The price that is proposed by the manufacturer will be accepted, as long as the product is cost- effective. Utilisation of Class 2 products can be restricted by conditional reimbursement, e.g. by limiting the indication or by reference to the treatment protocol. Insurers are also allowed to put conditions on the type of prescriber and/or to ask for prior authorisations. Timing: Fast track decision making procedures are possible for medicines that have been licensed under the EMEA 'accelerated assessment procedures'. c. Belgium 1. Assessments Therapeutic value is the primary focus of the assessment, with pharmaco-economics for some products. Assessments are undertaken by the Commission de Remboursement des Médicaments / Commissie Tegemoetkoming Geneesmiddelen (CRM/CTG). In first instance CRM/CTG assesses therapeutic value at hand of efficacy, safety, comfort/convenience of use, applicability and where possible effectiveness in practice. Where significant added therapeutic value is identified, the product is classified as class 1, other products are classified as class 2. For class 1 products, additional pharmaco-economic studies are requested from the companies. 2. Pharmaco-economic decision making Maximum prices for class 2 products are set in function of prices abroad and prices of comparator products. Class 1 products can get a price-premium above comparator products. The pharmaco-economic studies are required to justify the size of this premium. An Incremental Cost Effectiveness ratio (ICER) is calculated to do so. The level of reimbursement is not driven by the assessed value of innovative medicines, but by the type of disease and role of the medicine. Final Conclusions and Recommendations of the Pharmaceutical Forum 107 Utilisation of the medicine is restricted to the indications set in the SPC and to the subgroups of patients that were in the scope of the assessments. As from end 2007, separate assessments are set up to provide guidelines for health professionals. Timing: As from end 2007 early assessments are possible for medicines expected to be class 1, e.g. orphan medicines. These assessments can take place as soon as CHMP (Committee for Medical Products for Human Use) in EMEA has brought its positive advice. d. Sweden 1. Assessments Assessments focus on the cost/effectiveness analysis in societal perspective. As such the proposed price of the new medicine is an element in the assessment. The Pharmaceuticals Benefit Board (LFN) is in charge of the assessments. The cost/effectiveness assessment108 considers direct costs (pharmaceutical, medical, and non-medical) as well as indirect costs (mainly the impact on the patient's productivity). The effect on health is the key benefit considered and includes clinical/therapeutic progress as well as quality of life elements and compliance. The assessment is executed in comparison to the most appropriate alternative treatment. The outcome is preferably expressed in Quality-Adjusted Life Years (QALYs) which include cost, effectiveness and quality of life. 2. Pharmaco-economic decision making Prices are freely proposed by the applicant. As such, the price is an input factor in the assessment of the cost-effectiveness ratio. A too high price will make the cost-effectiveness of the medicine unacceptable. Granting reimbursement takes account of the cost-effectiveness assessment, as well as of 2 other principles: human value and need and solidarity. Levels of reimbursement are progressive (from 0 to 100%) depending on previous consumptions. The outcome of the cost/effectiveness assessment may lead to restrictions in use of medicines and may lead to conditional utilisation. Timing: cost/effectiveness assessments do not relate to the timing of uptake. e. United Kingdom 1. Assessments Assessments focus on the cost-utility of health related benefit (£/QALYs). As such the proposed price of the new medicine is an element in the assessment. Assessments are not automatic for all products and are carried out by the National Institute for Health and Clinical Excellence (NICE). Appraisals are performed following early identification of potential topics through horizon scanning and referred by Ministers following advice from expert panels ran by NICE and including input from clinicians and other specialists. 108 NOTE: In general, it can be said that in a cost-effectiveness analysis the costs are compared with outcomes measured in natural units (for example, life-years gained, episode-free day, etc). In cost-utility analysis the costs are compared with “utility based" units (units that relate to a person's level of wellbeing) and quality adjusted life year (QALY) is the most common unit. Cost-benefit analysis used monetary values in cost and outcomes. Sometimes the use of the term “cost-benefit” is not used in this strict academic meaning, but more general referring to an economic evaluation (to compare cost –input- with benefits –outcomes-) Final Conclusions and Recommendations of the Pharmaceutical Forum 108 Cost-utility assessments are based on clinical/therapeutic benefit and on quality of life. The assessment includes a comparison of the new therapy against standard existing practice.. NICE takes QALYs into account as a key factor, but not as the only factor, when making its appraisal guidance. 2. Pharmaco-economic decision making Prices are freely set by the applicant, once a marketing authorisation has been granted. As such, the price is a major input factor in the assessment of the cost-utility ratio. A too high price will make the cost-effectiveness of the medicine unacceptable. Assessments do not influence reimbursement. In principle there is an automatic reimbursement after the marketing authorisation. Unless a medicines is put on the black list (not reimbursed) or on the grey list (reimbursed only for specific indications). Doctors do not need to await NICE guidance before prescribing a drug. Guidance has been issued to the NHS saying that other sources of information must be looked at prior to the publication of NICE guidance. A positive NICE appraisal is supported by a statutory funding direction, which ensures funding by the National Health Service (NHS). Clinicians have freedom to prescribe as they see appropriate but should be able to demonstrate that they have taken NICE guidance into account. Timing: highly innovative products are assessed in faster procedures, so-called Single Technology Assessments. f. Germany The system described below is currently being set-up, following a legislation adopted in 2007. To date the assessments are based on benefit analyses, while the new system is planned to be based on cost-benefit analysis. 1. Assessments Assessments focus on cost-benefit analysis. As such the proposed price of the new medicine is an element in the assessment. Assessments are not automatic for all products, but are performed on request of the Federal Joint Committee for Medical Affairs (G-BA). The Institute for Quality and Efficiency in Health Care (IQWiG) is doing the assessments. The cost/benefit assessment considers direct costs to the social security system or broader (including the pharmaceutical price). Benefit assessments include clinical/therapeutic benefit and quality of life. The assessment are comparative to appropriate alternative treatments. IQWiG provides as output not only a Cost/Benefit assessment but also guidances for clinical use. 2. Pharmaco-economic decision making Prices are freely set by the applicant, after marketing authorisation. As such, the price is a major input factor in the assessment of the cost/benefit ratio and in the drafting of the guidances for clinical use. A too high price will make the cost/benefit ratio of the medicine unacceptable. Most medicines are added to a cluster of alternative treatments. The reimbursement is then set at a similar reference price for the entire cluster. Only if significant added value is identified, medicines are not added to a cluster and are fully reimbursed. For these medicines the Cost/Benefit assessment can be used by the Federal Association of Sickness Funds to limit the amount of reimbursement. Final Conclusions and Recommendations of the Pharmaceutical Forum 109 The IQWiG guidance reports for clinical use can be used by G-BA to set mandatory utilisation restrictions for prescribers. Timing: The cost/benefits assessments do not relate to the timing of uptake (though, it needs to be noted that individual sickness funds can and do negotiate rebates and/or risk-sharing deals to facilitate the use of new medicines.) Preliminary findings Although based on the inputs of only a limited number of Member States, we can come to some first preliminary findings: o There seem to be 2 general approaches to assessments and related economic decisions. a. In some countries (SE, UK, GE) prices are freely set upfront by the applying companies. The set price is then one of the input factors for the assessments that follow. These assessments compare the benefits (clinical/therapeutic, but also quality of life) with the costs of using the medicine (broader then just the cost of the medicine). b. In other countries the process starts with an upfront assessment (FR, BE, NL), which in first place focuses on therapeutic/clinical benefits. This assessment is then basis for fixing prices, or like in NL for fixing maximum-levels of prices. o In both approaches, authorities can use references to comparator products when defining prices and reimbursement levels of medicines without proven added therapeutic/clinical benefits. Where significant added therapeutic/value is proven, a price premium versus comparator products can be allowed and reimbursed. The assessments are usually used to define the size of this price premium. o To optimize use of resource, assessments are regularly used to avoid over-utilisation and give (mandatory) guidance for the prescribers and/or restrict the use. o Many countries facilitate uptake of those medicines that bring significant added value, by speeding up the procedures (in so-called fast-tracks). The assessments often are the basis for deciding whether a medicine is (expected to) bring(ing) significant added value, and can therefore apply for fast-track procedures. Though, sometimes the central opinion of CHMP (EMEA) can trigger fast-track procedures as well. Final Conclusions and Recommendations of the Pharmaceutical Forum 110 Building a toolbox of good practices to control budget, ensure access and rewards innovation The Pharmaceutical Forum meeting on 29 September 2006 called on the Working Group on Pricing to “leverage our collective knowledge to build a toolbox of concrete options and measures based on Member States' experiences”. Although each Member State setting is different, all Member States aim to offer sustainable healthcare, which is of good quality, affordable and available to all its citizens. To do this, Member States apply a set of cost containment instruments, influencing access to medicines and influencing reward for innovation. Member States, therefore, face a similar challenge to find a balance between three objectives, i.e. (1) containment of costs, (2) reward for innovation and (3) access to medicines. Member States increasingly look to the same range of practices to address these challenges. Nevertheless, in the course of the previous work of the Working Group on Pricing, it has become clear that there is need for more evidence of the benefits and risks of different practices. This increases the interest of the Member State participants in sharing their experiences and evidence on different practices. This toolbox exercise should therefore offer a view on what each practice brings for each of the three dimensions in the balance. As such, Member State authorities will have a good view on which practices to chose and implement in order to achieve their national pharmaceutical policies. It is clear that final decisions on pricing and reimbursement of medicines are a national competence, following the subsidiarity principle. This toolbox is therefore to be seen as an exercise to facilitate Member States’ choices and it is in no way binding for national authorities. The aim of the toolbox exercise presented here, is to collect and provide the answers for those questions a Member State reflects on when considering a new practice: real benefit(s) that can be expected, potential risks and interferences with other practices, driving factors of such risks or successes, etc ; the set-up of a practice. In addition, actual materials that have proven useful in a Member State while setting up a practice, can be exchanged through the toolbox (e.g., algorithms used, examples of materials used in campaigns, etc) The toolbox exercise will work in this direction through three different levels: 1. It is important to keep some principles in mind by which to implement the practices to ensure positive impact on each of the 3 desired objectives. In other words, these principles will allow good implementation of a practice. A list of principles is to be developed based on past and ongoing discussions in the Working Group. 2. A summary of each individual practice in terms of benefits and risks for each of the 3 objectives, i.e. access for patients, cost-containment and reward for innovation. This will be presented in the form of a concrete template per practice, based on evidence where possible. 3. If level 1 and 2 prove useful, an on-going process would then be developed to collect and exchange Member States’ experiences of different practices and policies. A concrete approach is to be developed and implemented. In terms of timing, the summaries of practices and the good principles are the first steps to take, leading to concrete outputs for the High-Level Forum meeting in June 2007. Element 3 is to be elaborated by the next Forum session. Final Conclusions and Recommendations of the Pharmaceutical Forum 111 Summaries of practices Different practices in the field of pricing and reimbursement usually aim to impact on one of the three objectives, i.e. (1) containment of costs (i.e. managing limited financial resources), (2) access to medicines for patients (in hospital and ambulatory settings) and/or (3) reward for innovation (i.e. promoting those medicines bringing new added benefits). However, many practices will have an impact, intended or not, on more than one of these elements. These summaries will bring, per practice, a short and broad overview of the benefits and risks for each of these objectives, both in terms of qualitative and quantitative effects. Most pricing and reimbursement practices use a limited set of levers to influence expenditure on pharmaceuticals, being (1) fixing a price level, (2) fixing a reimbursement level, (3) managing the volume/utilisation through guidelines and obligations, (4) managing time aspects of introducing innovators and generics and (5) using a-posteriori measures to correct overall spending. The summaries will help clarify how each practice uses these levers. The summaries come in the form of factual and dynamic templates that are subject to debate and continuous updating. However, they express the best understanding, both common or conflicting, of the participants of the Working Group on Pricing. The arguments taken up in these templates are to be as much evidence based as possible. The templates will therefore include as sections: • A descriptive part in order to ensure a common understanding of the practice covered. The description includes all modalities, i.e. those elements and levers that need to be organised to set-up a practice. The description also mentions the most common variants of the practice, by indicating which modalities can be set up in different ways. Variants of one practice, should as far as possible be covered within one template. Where needed, i.e. when a variant leads to completely different benefits and risks, separate templates can be prepared for the most common variants. • An impact part, including a benefit and risk matrix, per practice, which covers arguments of possible advantages (“benefits”) and possible disadvantages (“risks”). Each benefit and risk will be related to one of the 3 objectives of concern: cost containment, reward for innovation and access to medicines, covering availability as well as affordability. It is usually understood that these 3 objectives are linked to the perspectives of respectively the budget-holders (government, insurer), industry and patients. Whenever an argument of benefit or risk is added to one of the 3 objectives, coming from other than the usual perspective, this other perspective should be indicated. Arguments should be based as much as possible on analyses and facts and refer/link to these. • Sources of evidence are to be mentioned on the bottom of the template, whenever there is a reference footnote coming with an argument. It might be possible for this to be replaced by click-through links in electronic versions of the template. The toolbox aims to elaborate such summary-templates on all practices of interest to the members of the Working Group, in particular less common ones, on which it is harder to get some first evidence. A list of practices to elaborate, should therefore be developed within the Working Group. Participants should complete this list and thus prioritise those practices on which they want to gather more knowledge. In parallel, we need to gain first experience with these templates before the June 2007 Forum. Some first templates have therefore been developed, focusing on those 6 practices, for which evidence from literature and Member State experience has been collected within the study of Final Conclusions and Recommendations of the Pharmaceutical Forum 112 the Andalusian School of Public Health. These 6 examples are added in the annex and will be presented to the June Forum. Final Conclusions and Recommendations of the Pharmaceutical Forum 113 Practice: Reference Pricing Description: A financing mechanism that establishes a maximum level of reimbursement for a group of drugs assumed to be bio and/or therapeutically equivalent. The share of the price above the reference price is borne by the consumer. (To be distinguished from referring national prices to cross-border prices of the same products) Modalities: • Grouping of medicines (clusters): variant 1 – narrow clusters (ATC level 5); variant 2 –broad clusters (ATC level 4) of originators; variant 3 – broad clusters (ATC level 4) of originators + generics • Fixing common reimbursement-value: variant 1’ – in function of cheapest product; variant 2’ – in function of average Application in EU: BE, DE, DK, EE, EL, ES, HU, IT, LT, LV, NL, PL, PT, RO, SI, SK Impact on: Benefits Risks Cost containment • Medicinal cost reductions up to 50%109 • Net healthcare-savings up to 18%110 • Allows promotion of generics111 • Creates cost-awareness in patients and doctors • Might create a shift to other expensive medicines (out of controlled clusters)112 • Fixed reimbursement-values can hamper further price- competitions and reductions Reward for innovation • Potential to incentivize valuable innovative products through exemptions • Potential to create headroom for innovation • Incremental value not always recognised (in case of variant 2 and 3), though exemptions possible Access to medicines • If one co-payment free medicine is foreseen per cluster, affordable access is ensured • Transparent presentation of alternatives to patients, pharmacists and doctors • In case not all medicines align prices to Reference Price, for some individual patients extra information might be needed to avoid confusion when shifting treatments113. • In this case, price-sensitive (poorer) patients are most affected 109 Augurzky et al 2006 (14%) 110 Savings reported: CY: -20% in 1 year (-11mEUR); HU: -5% in 6 months; IT: basis for price cut in 2004 with 500-600M EUR saving (around 5%); LV: -0.6mEUR in 6 months; DK: 100mDKK (around 1,5 %) 111 PT, Aaserud et al 2006 112 Atun et al 2006 113 Atun et al 2006 Final Conclusions and Recommendations of the Pharmaceutical Forum 114 Reference List Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006;(2):CD005979. Atun R et Gurol-Urganci I. Impact of Regulation on the Uptake and Diffusion of Pharmaceutical Innovations : Systematic Review. Discussion Paper 7. Tanaka Business School. Imperial College London Augurzky B, G÷hlmann S, Gress S, Wasem J. The Effects of Reference Pricing on Ex-factory Prices of Rx Drugs in Germany - A Panel Data Approach. SSRN eLibrary 2006. Final Conclusions and Recommendations of the Pharmaceutical Forum 115 Practice: Cost Sharing Description: A provision of health insurance or third-party payment that requires the individual who is covered to pay part of the cost of the service or product received. Cost- sharing may be in the form of deductibles, co-insurance or co-payments (OECD definition. These modalities are explained below). Cost-sharing might reduce a third-party’s pharmaceutical budget by reducing consumption and by shifting the cost to the consumer. Modalities: § Type of fee: Variant 1 - Co-payment: the user pays a fixed amount for a given service. It is also known as a user fee. Variant 2 - Co-insurance: the user pays a percentage/proportion of the cost of the service, which can be fixed or decrease with the amount. Variant 3 -Deductible or excess: the user must pay a fixed amount for a service before any payment of benefits can take place. Variant 4 - Residual payment: the user has to pay a proportion or the full amount of the cost of a service beyond a certain ceiling. (Reference pricing actually can be considered a form of that type of cost-sharing) § Cost sharing schemes might apply personal exemptions or reductions in the amount to be paid. It might also exclude certain products and indications § Expenditure caps on cumulative payments might be implemented § Positive or negative list can be considered extreme forms of cost-sharing (0 and 100% cost sharing, respectively): Application in EU: AT, BE, CY, DE, DK, EE, EL, ES, FI, FR, HU, IE, IT, LT, LV, NL, PL, PT, SE, SK, UK Impact on: Benefits Risks Cost containment • Creates cost-consciousness in patients114 (This is not a final impact, but a change in consumer attitudes, that might lead to reduced consumption It acts as a price (barrier) for consumer, hence reducing consumption compared to free access) • Reduces public expenditure by reducing consumption and shifting part of the cost to the consumer115 • The effect on overall expenditure is uncertain, and depends on whether and how the reduced drug consumption is substituted by other treatments and on the administrative costs of collecting the fees. • Supplementary voluntary insurance can nullify the cost- awareness and the effect of cost sharing organised by the government Reward for innovation • It is usually assumed to be neutral regarding innovation. • Cost-sharing might maintain use of older alternatives, even if better innovative solutions are available and hence negatively affect the reward of innovation (in case of 114 FI , LV , SE , Rubin et al 1995 115 Lexchin et al 2004 Final Conclusions and Recommendations of the Pharmaceutical Forum 116 variant 2) Access to medicines • Can be used to encourage rational use of medicine • Cost-sharing can reduce access irrespective of effectiveness and needs, and can disproportionably affect the sicker and the poorer116. This can be addressed with correcting measures, e.g. by considering the patient’s income and made pharmaceutical expenses. Reference List Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005; 11(11):730-740. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 2004; 34(1):101-122. Willard G. Manning, Joseph P. Newhouse, Naihua Duan, Emmett B. Keeler, Bernadette Benjamin, Arleen Leibowitz, M. Susan Marquis, Jack Zwanziger (1988). Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. RAND Corporation, Santa Monica, CA. Rubin RJ, Mendelson DN. A framework for cost sharing policy analysis. In: Mattison N, editor. Sharing the costs of health: a multi-country perspective. Basel: 1995: 2-1-2-164. 116 FI , LV , Gibson et al 2005, Manning et al 1988 Final Conclusions and Recommendations of the Pharmaceutical Forum 117 Practice: Payback Description: A financial mechanism that requires manufacturers to reimburse a part of their revenue to a payer/Member State authority if sales exceed a previously determined or agreed target-budget (To be distinguished from rebates and discounts that apply to the global sales of the manufacturer to a given payer). Modalities: • Scope of medicines covered: variant 1 – overall pharma budget; variant 2 – per therapeutic area; variant 3 – per molecule/ single product • Maximum budget allowed • Fraction of overspending to be recovered (same as for previous bullet) • Recovery over different manufacturers: variant 1’ – in function of sales; variant 2’ – in function of sales growth Application in EU: BE, FR, HU, IT, PT Impact on: Benefits Risks Cost containment • Ensures real spending fits to budget117 thus reducing uncertainty and sharing the financial risk with the manufacturers • Recoup of 100-500 mil€/y in larger EU MS’s118 • Allows low-price countries to accept high prices while controlling spending119 (for a limited nr of products only) • Reduced transparency of real prices, limiting possibilities of cross-border comparisons • In practice, real recuperation of funds from companies might be limited to a certain level • Margin for implementing other cost-containment measures might be limited (like e.g. promotion of price competition) Reward for innovation • Expenses on new medicines are fast-growing, and risk therefore to contribute disproportionately (need for exemptions for valuable innovations)120(in particular in variant 1&2) Access to medicines • Agreements might influence access to market of specific products • Agreements might influence access to market of specific products 117 PT, HU 118 FR: 400mEUR (’05) 2%, 160mEUR (’06e) 0,8 %; IT 800mEUR cut (‘06e) 7%; PT: 10mEUR (’06) 0,3% 119 HU 120 FR: exemption for innovatives, PT: recups go to R&D fund Final Conclusions and Recommendations of the Pharmaceutical Forum 118 Practice: Prescription Information Description: Any kind of information or recommendations made available to prescribers, by public or other funding authorities, in order to improve their prescribing behaviour. They are usually based on evidence and/or consensus on efficacy, safety, effectiveness and efficiency (cost-effectiveness) of using medicines. These instruments target the prescriber/doctor, the key agent in the demand and utilization of medicines, as it is the one that is in the best situation for combining the information on the needs of the patient and the benefits, risks and cost of a certain treatment. Modalities: § Target: Individual or all § Objectives: Treatment guidelines/instructions that cover a holistic view on the patient, his disease, possible therapies and their overall cost-effectiveness § Format: Guidelines, Drugs bulletins, education sessions, conferences….. § Type of information: Descriptive / Normative § Follow up: Monitoring or feedback Application in EU: AT, BE, DE, DK, EE, ES, FI, FR, HU, IT, LT, LV, MT, NL, PT, RO, SI, SE, SK, UK Impact on: Benefits Risks Cost containment • Prescription information tools are often not primarily aimed at cost-containment, but at rational use121. They might however incorporate cost-effectiveness criteria and avoid/reduce overspending.122 They might therefore contain costs123 while avoiding or minimising negative effects on the quality of prescription and on health. • Most common purpose of rational use of medicines instruments’ is to spend better from clinical point of view. Nevertheless, it can not be excluded that compliance with guidelines might lead to increase of the drug budget, in particular in case of under-use. • If not supported by monitoring or/and appropriate (financial) incentives have no or very limited impact on actual prescription124 • The cost of changing prescription patterns might be significant • Multitude of guidelines can create confusion amongst prescribers Reward for innovation • Prescription information tools allow promotion of valuable, cost-effective • - 121 BE, DK 122 Soumerai et al 1989 123 LV,MT 124 FI Final Conclusions and Recommendations of the Pharmaceutical Forum 119 innovations and include the recognition of incremental innovation Access to medicines • Prescription information tools can improve access through a rational, cost- effective use of medicines and avoiding over- consumption • Prescription information tools can steer prescriber to behaviour which is not optimal for the patient • Need to avoid overloading and confusing guidelines because of risk of confusion with prescribers. Reference List Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q 1989; 67(2):268-317. Final Conclusions and Recommendations of the Pharmaceutical Forum 120 Practice: Price Control Description: Price control is a form of market regulation that limits the capacity of the supplier to freely set the price of a product. Price control usually takes the form of a maximum price for an individual medicine, which means that supplier is not allowed to set the market price above the former. Price control is aimed at balancing suppliers market power derived from patents and other market exclusivity conditions and to the lack of price-sensitivity of the demand to prices. Modalities: • Scope: Might be applied only to manufacturer’s price, or to wholesaler’s margins and/or pharmacist’s margins as well • Timing: Might be applied to the initial marketing price and/or to posterior price increases • Basis for setting (maximum) price: Variant 1- Therapeutic value/Clinical performance; Variant 2 - Economic evaluation (cost-effectiveness ratios); Variant 3 - Cost of existing treatments for the same condition or disease; Variant 4 - Cost-plus calculations (cost of production plus a certain profit margin); Variant 5 – International prices of the product; Variant 6 - Innovative character of the product Application in EU: AT; BE, CY, DEE, EL, ES, IT, FI, FR, HU, IE, IT, LT, LV, NL, PL, PT, SI, SE, SK Impact on: Benefits Risks Cost containment • Allows controlling or reducing pharmaceutical expenditure, in case of products under market exclusivity, not affected by competition125 • Without price-sensitivity of patients and with large market power of manufacturers, price controls still allow authorities to control expenditure. • Price control might discourage some products to enter the market and induce a shift to treatments which are more expensive for the public system and/or for the consumer. • As expenditure = price x quantity, price control might fail if the amount of units sold grows out of control126. Therefore there is a parallel need for measures controlling utilisation. (quantity) Reward for innovation • A well designed price control system allows a fair and effective incentive for true innovation, e.g. if clinical or economic evaluation is used to set the • As new products are likely to have the highest prices, price control might discriminate against innovation and lead to reduced revenue (through, 125 Jacobzone et 2000 126 Maynard et 2003 Final Conclusions and Recommendations of the Pharmaceutical Forum 121 price and allows a fair premium to innovations127 delays in market access128, lower prices and restrictions of utilisation) Access to medicines • Lower prices lead to better affordability and, hence, access to medicines129 • Access to improperly (too low) priced medicines might worsen because manufacturers might not have the necessary incentives to develop, manufacture and market them130. • Defining prices of generics as fraction of originators, allows originators to out- compete and make disappear generics through multiple price-decreases. Can be avoided in a reference pricing system • Delays on pricing and reimbursement decisions can hinder/delay product availability Reference List Calfee JE. Pharmaceutical price controls and patient welfare. Ann Intern Med 2001; 134(11):1060-1064. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s. Health Econ 2005; 14(3):269-292. Hassett KA. Pharmaceutical Price Controls in OECD Countries. AEI publication 2004. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. 2000. Labour Market And Social Policy - Occasional Papers No. 40. Kessler DP. The Effects of Pharmaceutical Price Controls on the Cost and Quality of Medical Care:A Review of the Empirical Literature. 2004. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff 2003; 22(3):31-41. 127 Dickson et al 2003, Office of Fair Trade 2007 128 Danzon et at 2005 129 Kessler 2004, Santerre 2004 130 Calfee 2001, Hassett 2006 Final Conclusions and Recommendations of the Pharmaceutical Forum 122 Dickson M, Hurst J and Jacobzone S. OECD HEALTH WORKING PAPERS. Survey of Pharmacoeconomic Assessment Activity in Eleven Countries. 2003 Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. An OFT market study. 2007 Santerre REJA. A Cost-Benefit Analysis of Drug Price Controls in the U.S. 2004. AEI- Brooking Joint Center for Regulatory Studies. Final Conclusions and Recommendations of the Pharmaceutical Forum 123 Practice: (Generics) Substitution (by pharmacists) Description: Practice of substituting a prescribed pharmaceutical, whether marketed under a trade name or generic name (branded or unbranded generic), by a pharmaceutical, often a cheaper one, containing the same active ingredient(s). (PPRI Glossary) (The product delivered must also have the same administration route, dosage, etc. and have a proven bioequivalence/interchangeability/therapeutic equivalence with the product prescribed) . Modalities: § Mandatory or voluntary substitution by pharmacist § Substitution might require the consent of the prescriber or the consumer § Substitution might be supported by financial incentives Application in EU: CY, DE, DK, ES, FI, FR, HU, IT, LV, MT, NL, PL, PT, SI, SE, SK Impact on: Benefits Risks Cost containment • It reduces cost to the insurer and/or the consumer while maintaining a standard quality131. • Improving current measures can generate additional savings of 27- 48% depending of Member State132 • The shifts to a different brand might generate extra doctor visits in order to adjust the prescription • Cost savings might be suboptimal if regulations and incentives towards pharmacists are not coherent. • Risk of missing price decreases, if not sufficient generic alternatives enter the market to create a price- competition. Reward for innovation • By reducing expenditure in older, out-of patent drugs, generics policies allow countries to spend more on innovative drugs133. Access to medicines • Reduced cost and hence, increased affordability for patients (not in case of fixed co-pay)134. In the case of budget constraints, it also allows an increase in provision of other medicines and treatments • Frequent changes in brand and shape of preferred medicine might generate confusion and other inconveniences to (mainly older) patients if insufficient information is provided • Lack of perceived credibility of generics in what concerns the generics quality, efficacy and safety135 if patients, 131 FI , ES , Andersson et al 2005, Engstrom et al 2006 132 Simoens et al, 2006, pp11, 84-91 133 LV 134 FI 135 PT, SI Final Conclusions and Recommendations of the Pharmaceutical Forum 124 doctors and pharmacists are not sufficiently informed. Reference List Andersson K, Bergstrom G, Petzold M, Lonnroth K, Carlsten A. Effects of generic substitution on the development of pharmaceutical expenditures during the period January 1998 to May 2005. Value in Health 2005; 8(6):186. Engstrom A, Jacob J, Lundin D. Sharp drop in prices after the introduction of generic substitution. 2006. Simoens and Decoster, Sustaining Generic Medicines Markets in Europe, Research Center for Pharmaceutical Care and Pharmacoeconomics, April 2006, Final Conclusions and Recommendations of the Pharmaceutical Forum 125 Risk-Sharing practices and Conditional Pricing of pharmaceuticals How to deal with uncertainty – Some EU Member State practices Introduction Over the last years, an increasing number of member States have set-up risk sharing practices and conditional pricing and reimbursement practices. These practices allow competent authorities and pharmaceutical companies to build clinical experience with medicines which might normally not be eligible for reimbursement. Such practices allow budget-control and the identification and reward of valuable innovative medicines. At the same time, they provide access for patients to highly innovative treatments. This balanced objective is completely in line with the overall objectives of the Pharmaceutical Forum, and therefore part of our scope. This paper will first describe how these practices are set-up in different Member States and eventually try to deduct some common findings. The Netherlands – Conditional reimbursement in hospitals Background The costs of expensive new medicines in hospitals, in particular in the field of oncology, are growing rapidly and may be an increasing burden to the individual hospital's budget. As such, the availability of these medicines might be inequal depending on the hospital and the resources available in the hospital, although this has not been demonstrated in practice. In addition, it often concerns innovative medicines of which the added value may not be fully proven in real practice. To address these concerns, the Dutch authorities have created a separate fund for the use of such medicines in hospitals within a research setting. The fund foresees additional funding during the 3 first years of use of an expensive innovative medicine. Funding goes up to 80% of expensive medicines, and even up to 100% for orphan medicines. It is essential that involved parties, such as hospitals, ensure proof of value of the medicine by the end of this period, in order to ensure further funding of the medicine. Mechanism The NZa (the Dutch Healthcare Authority), upon advise of the HCIB (Healthcare Insurance Council), decides whether a new expensive medicine is eligible for this temporary additional funding. The medicine therefore needs to (1) bring added value, to (2) exceed a certain threshold of cost-prognosis and to (3) come with a list of open unanswered research questions. While taking up the use of these medicines, representative bodies of hospitals or other relevant parties have to organise for outcome-research. By doing so, these parties must ensure the generation of additional data regarding therapeutic value and cost-effectiveness in clinical practice. The generated data should bring answers to the open questions regarding cost- effectiveness, in a re-appraisal procedure. The maximum time to come with this evidence is 3 years. Final Conclusions and Recommendations of the Pharmaceutical Forum 126 Outcome In case the new data prove an acceptable cost/effectiveness ratio, the NZa provides further indefinite additional funding. In case the new data do not prove the desired cost/effectiveness, NZa will stop the additional funding. Experience The mechanism has been set-up in 2006. To date 23 medicines are subject of this practice. It considers 6 orphan drugs and main indications relate to oncology, auto-immune diseases and macular degeneration. The first 3-year appraisals will only take place at end 2008. In the meantime, the practice has allowed to combine a high need with a high cost, an uncertain value, and to offer quick access to some medicines of which therapeutic and economic value is still uncertain. Some discussion points have been raised regarding the roles of the involved parties, in particular who will conduct the outcome research and who will pay for it. Discussions also concerned the infrastructures and how to weigh the different decision making criteria (therapeutic value, cost-effectiveness and impact for public health). Further info: CIRCA-Library: Working Group on Pricing/Working Group on Pricing 2007/9th Working Group Pricing 12.12.2007/Inputs Risk Sharing/Presentation NL Belgium – Conditional reimbursement Background Since 2002, the new Belgian pricing and reimbursement system requires the Commission Remboursement de Medicaments / Commissie Tegemoetkoming Geneesmiddelen (CRM/CTG) to distinguish a separate class of medicines with claimed added value, because they offer specific benefits compared to existing therapies, and therefore eligible to obtain a price-premium (Class I). It soon became clear that this distinction often needs to be made based on unknown hypothetical factors. Belgium has therefore established a conditional reimbursement procedure, leading to a second mandatory evaluation after 18-36 months. Mechanism Eligible medicines need to be classified as Class I by CRM/CTG. This classification is based on the profile of the medicine regarding efficacy, safety, comfort/convenience of use, applicability and, where possible, effectiveness in practice. At the moment that CRM/CTG classifies medicines as Class I, it also specifies a list of the hypothetical 'unknown' factors it had to take into account. These factors most frequently relate to (1) effectiveness in clinical practice, (2) pharmaco-economics in clinical practice, (3) size of the target group, (4) sales volumes and (5) reimbursement status in other EU Member States. Additional elements can relate to recent CRM-guidelines, scientific studies, yearly cost evolution in the therapeutic class, prescribed daily dose, applicability or consensus reports. A draft guideline is being developed on pharmaco-economic submissions. The CRM/CTG also pre-defines a timing, somewhere between 18 and 36 months, after which the sponsoring company is expected to deliver the additional data that will allow to clarify the 'unknown' hypothetical factors taken into account at the moment of the initial price decisions. Final Conclusions and Recommendations of the Pharmaceutical Forum 127 Outcome In case the new data confirm the hypotheses taken into account, the existing pricing and reimbursement decisions continue to apply. If this is not the case, the CRM/CTG can decide on several types of changes like limiting the target patient groups for which the medicine can be used or restricting the group of potential prescribers for this medicine. In the worst case the re-appraisal can lead to a withdrawal of the medicine from the reimbursement list. Experience In reality missing evidence almost always relates to effectiveness in clinical practice and cost- effectiveness. By first half 2007, 18 products were re-appraised of which only 1 was withdrawn from reimbursement. For some the reimbursement conditions were adapted. These first experiences have also made clear the importance of good upfront communication on the expected deliverables, preferably through a formal meeting between CRM/CTG and applicant. Other helpful factors are quality control procedures and the support of the headquarters for this additional work undertaken by a Belgian affiliate of a pharmaceutical company. Further info: CIRCA-Library: Working Group on Pricing/Working Group on Pricing 2007/9th Working Group Pricing 12.12.2007/Inputs Risk Sharing/Input BE U.K. – Performance Cost-Sharing Background Following NICE’s conclusion that Velcade (bortezomib) is not considered cost-effective as treatment for relapsed multiple myeloma without possibility of bone transplantation, Johnson & Johnson (J&J) put forward its ‘risk-sharing’ scheme to make the product available. The scheme was agreed with the Department of Health and NICE recommended that Velcade could be prescribed on the NHS under the conditions outlined in the scheme. This scheme was developed in collaboration with haematologists and pharmacists and was launched in 2007 and runs until reviewed by NICE. During this period the clinical experience will generate further data on the cost-effectiveness of the treatment. Mechanism Patients are eligible if they suffer from progressive multiple myeloma, with a first relapse, after trying out 1 prior therapy and when bone transplant is not an option. For these patients the scheme is immediately available and NHS foresees initial funding. NICE has drafted guidance for medical doctors that clearly defines when patients are eligible for treatment with Velcade. Doctors are allowed to start the treatment with Velcade. After 4 cycles the impact of the treatment is measured by a serum protein test. If serum proteins are reduced by 50% or more, the treatment is considered to be effective. For patients without sufficient serum proteins, an alternative urine test is performed. Outcome If the serum protein test is showing effectiveness after 4 cycles of treatment with Velcade, treatment can be continued through further cycles. The entire treatment is funded by NHS. Final Conclusions and Recommendations of the Pharmaceutical Forum 128 When the serum protein test does not show sufficient effectiveness, the treatment with Velcade is stopped and the sponsoring company (J&J) will refund the cost of the first 4 cycles. Further info: www.velcade.co.uk CIRCA-Library: Working Group on Pricing/Working Group on Pricing 2007/9th Working Group Pricing 12.12.2007/Inputs Risk Sharing/Input UK Velcade U.K. – Research on cost-effectiveness Background This practice was taken up as NICE did not consider Beta-Interferons, nor Glatiramer, to be cost-effective for treatment of multiple sclerosis. Nevertheless NICE recommended the DH explore ways of more cost-effective use. An acceptable cost-effectiveness level of 36,000£/QALY was defined and a prospective study was launched in 2002 to assess the cost- effectiveness of 4 products. The study runs until 2012, with a mid-term review early 2008. The study envisaged to include 7,500-9,000 patients. Mechanism Patients are eligible for inclusion in the study if they suffer from relapsing, remitting MS or a secondary progressive form of MS with relapses and if they match the criteria drawn up in 2001 by the Association of British Neurologists (ABN). Patients can only be included in specialist centres with the appropriate infrastructure. NHS foresees funding for all recruited patients. Eligible patients are enrolled in the study and each of them was attributed in cohorts to one of the 4 medicines. Target outcomes for the patients have been agreed upfront and match to the expected cost/QALY outcome. Patients' enrolment implies agreement to regular monitoring from which the impact on QALY is measured. Consequently, for each of the 4 medicines, the QALY-impact can be measured and a cost/QALY ratio is calculated. The practicalities for monitoring, assessment, outcome statistics, price adjustments and practical implementation have been written upfront. Outcome If the calculated Cost/QALY of a medicine is found to be above the pre-established acceptable level, the price of the medicine is reduced. If the Cost/QALY is below this level, the price of the medicine can be increased. Monitoring and price adjustments are expected to continue over a 10-year period. Experience A first evaluation is expected early 2008. Preliminary experiences have highlighted the complexities, mainly scientific and methodological. It is also clear that the definition of clear markers to determine patients' responses is a prerequisite. Further info: http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/ DH_4004332 Final Conclusions and Recommendations of the Pharmaceutical Forum 129 CIRCA-Library: Working Group on Pricing/Working Group on Pricing 2007/9th Working Group Pricing 12.12.2007/Inputs Risk Sharing/Input UK multiple Sclerosis First common findings It seems that the adoption of a risk-sharing or conditional pricing practice is case-specific and triggered by the combined presence of 2 factors. The concerned medicine (1) brings a potential significant clinical/therapeutic benefit, usually for a severe disease and at the same time (2) raises serious doubts about its (cost-)effectiveness. These medicines are then often used within a setting that allows for a controlled utilisation. This can be through a study-setting (like MS-UK), through a limited number of expert centers (e.g., NL) and through the use of clear parameters to monitor each patients (e.g., Velcade and MS-UK). Key objective is to build further knowledge on the cost-effectiveness or other elements that are still unclear but needed for decision making on pricing and/or reimbursement. Several elements need to be pre-agreed before starting the practice. In particular the outcomes that can be expected and how these will be measured. E.g., the interpretations of a clear labo-parameter in the case of Velcade, the calculation and comparison of a Cost/QALY ratio for MS and/or a pre-defined list of expected data in order to answer some open questions on unknown hypotheses in BE and NL. Also the timings need to be clearly pre-agreed. The impact of Velcade is measured after 4 cycles. Timings for the company to come up with study results and deliver the required data, are set upfront in BE, NL and UK. Finally, also the consequences need to be clear upfront. This is in particular important, as funding authorities often fear to be limited in possibilities to adapt or stop funding in a later phase. Velcade is continued or stopped and funded by NHS or by the sponsoring company. A medicine is further funded or not by the NHz in NL. Pricing, reimbursement and utilisation decisions can be adapted in BE and in the UK. Final Conclusions and Recommendations of the Pharmaceutical Forum 130

IP/08/1451 Brüssel, 2. Oktober 2008 Arzneimittelforum erfolgreich beendet Der Abschlussbericht des Arzneimittelforums wurde heute in Brüssel vorgelegt. Er beinhaltet Grundsätze und Empfehlungen zur Bewältigung von drei wesentlichen Herausforderungen im Arzneimittelbereich: Wie können Informationen über Krankheiten und Behandlungsmethoden verbessert werden? Wie können Arzneimittel miteinander verglichen und die wirksamsten Medikamente ermittelt werden? Wie kann man angesichts begrenzter Gesundheitsbudgets erreichen, dass Innovationen zugänglich sind und sich bezahlt machen? Günter Verheugen, Vizepräsident der Europäischen Kommission, und EU-Kommissarin Androulla Vassiliou hatten gemeinsam den Vorsitz des Arzneimittelforums inne. Mit dieser Sitzung lief ein dreijähriges Mandat aus. Bei dem Forum kamen Delegierte der Mitgliedstaaten u. a. mit Patientenorganisationen, Angehörigen der Gesundheitsberufe, Vertretern der Industrie und der Versicherungswirtschaft zusammen. Der Abschlussbericht befasst sich mit Grundsätzen und Empfehlungen, die auf eine verstärkte Zusammenarbeit in drei Schlüsselbereichen abzielen. Der für das Ressort Unternehmens- und Industriepolitik zuständige Kommissionsvizepräsident Verheugen erklärte: „Die Empfehlungen des Forums können große Einsparungen bringen und sicherstellen, dass sich pharmazeutische Innovation stärker bezahlt macht. Ich fordere die Industrie und die nationalen Behörden auf, sich dafür zu engagieren, dass diese Empfehlungen zum Wohle der Patienten und zur Entlastung der Gesundheitsbudgets umgesetzt werden.“ Die für Gesundheitspolitik zuständige EU-Kommissarin Vassiliou ergänzte: „Die Patienten haben Anspruch auf eine rasche und überall gleiche Versorgung mit den besten auf dem Markt verfügbaren Medikamenten. Die EU-weite Zusammenarbeit auf dem Gebiet der relativen Wirksamkeit von Arzneimitteln wird uns diesem Ziel näher bringen. Auch ich begrüße die konkreten Empfehlungen zur Information der Patienten über Krankheiten und Behandlungsmethoden. Sie sind ein wesentlicher Beitrag zur Gesundheitspolitik der EU.“ Information der Patienten über Krankheiten und Behandlungsmethoden Auf dem Forum wurden u. a. folgende Empfehlungen angenommen, durch die der Zugang zu Informationen und ihre Qualität verbessert werden sollen: - Qualität der Informationen verbessern: Durch maßgebliche Qualitätsgrundsätze werden bessere Informationen für die Patienten entwickelt, indem ein klar festgelegter Rahmen vorgegeben und Qualitätsmängel aufgezeigt werden. Das Forum ruft alle Akteure des Gesundheitsbereichs auf, die vereinbarten Grundsätze zu berücksichtigen. Das Werbeverbot für verschreibungspflichtige Medikamente sollte beibehalten werden. 2 - Zugänglichkeit erhöhen: Dem Bürger sollten vermehrt Informationen in Form von effizienten Kommunikationsformaten (elektronische und nicht elektronische Mittel) an die Hand gegeben werden. Dabei sollte auf lokale Gepflogenheiten und die jeweiligen Gesundheitssysteme und Sprachen Rücksicht genommen werden. - Informationen unter optimaler Einbindung aller Akteure erstellen: Das Forum empfiehlt den Mitgliedstaaten, der Kommission und den Akteuren des Gesundheitsbereichs, neue Formen der Zusammenarbeit auf dem Gebiet der Patienteninformation anzudenken. Dabei sollte ein Mindestmaß an ethischen Anforderungen respektiert werden: Transparenz, Offenlegung von finanzieller Unterstützung und sonstigen Förderungen sowie Festlegung der Verantwortlichkeiten. Relative Wirksamkeit Die Mitgliedstaaten, Beitragszahler und Patienten stehen alle vor der Herausforderung, die Kosten des Gesundheitswesens und dabei die Arzneimittelkosten einzudämmen und zugleich die Innovation angemessen zu fördern. Daher müssen sie erkennen, wie wichtig es ist, festzustellen, welche Arzneimittel am wirksamsten sind. Die Gruppe erzielte zu folgenden Themen eine Einigung: - Arbeitsdefinitionen und Grundsätze für bewährte Verfahren zur Beurteilung der relativen Wirksamkeit, auf denen eine freiwillige Zusammenarbeit auf EU- Ebene aufbauen könnte. Eine Checkliste zur Anwendung dieser Grundsätze auf nationaler Ebene könnte als Basis zur Selbstbeurteilung dienen; - Bestandsaufnahme zu den derzeitigen Methoden; - gemeinsame Analyse vorhandener technischer und rechtlicher Hindernisse für die Datenproduktion. Preisgestaltung und Kostenerstattung In der Regel sind endgültige Entscheidungen zur Preisgestaltung und Kostenerstattung erforderlich, bevor der Patient Zugang zu neuen Gesundheitskonzepten erhält und sich für die Unternehmen die Forschungsarbeit bezahlt macht. Obwohl Entscheidungen zur Preisgestaltung und Kostenerstattung von den einzelnen Mitgliedstaaten getroffen werden, sind sie doch alle daran interessiert, mit begrenzten Mitteln für ein ausgeglichenes Verhältnis zu sorgen. Die konkreten Empfehlungen beziehen sich auf folgende Bereiche: - optimale Nutzung der Ressourcen: Ein Grundstock an Know-how soll dazu beitragen, beschränkte Ressourcen optimal einzusetzen. Die Gruppe erörterte auch spezifische Mechanismen (Risikoteilung, an Bedingungen geknüpfte Preisgestaltung, Ausschreibungen) und verabschiedete Leitprinzipien, die nationale Behörden dabei unterstützen sollen, Ausgaben, Versorgung und Innovation in Einklang zu bringen. - Versorgung mit Arzneimitteln: Bei den Arbeiten lag der Schwerpunkt auf besonderen Versorgungsproblemen in Zusammenhang mit kleinen Märkten und Arzneimitteln für seltene Leiden. - Gegenwert für Innovation: Der erwartete Innovationswert von innovativen Arzneimitteln und potenzielle einschlägige Mechanismen wurden analysiert, damit die Erfordernisse im Gesundheitsbereich und langfristige FuE- Investitionen besser aufeinander abgestimmt werden können. 3 Folgemaßnahmen Die Mitgliedstaaten und die übrigen Forumsteilnehmer werden gebeten, die Empfehlungen des Forums umzusetzen. Die Kommission wird sich für die Verbesserung der Instrumente einsetzen, mit denen die Zusammenarbeit ausgebaut werden soll. Hintergrundinformationen zur Arbeit des Arzneimittelforums sind unter folgender Adresse abrufbar: http://ec.europa.eu/pharmaforum

1 PharmaReport Russland 8/2014 Russlands Regierung greift verstärkt in den Pharmamarkt ein. Kurzfristig verabschiedete Verordnungen und Gesetze stellen deutsche Arzneimittel- exporteure vor enorme Hürden. PharmaReport Russland – ein Service der Exportinitiative Gesundheitswirtschaft – gibt Ihnen einen umfassenden Überblick über die Gesetzesänderungen und – initiativen der letzten Monate. Die Exportinitiative Gesundheitswirtschaft will Deutschlands Stellung als eines der führenden Exportländer gesundheitswirtschaftlicher Produkte und Dienstleistungen stärken. Die Initiative wurde vom Bundesministerium für Wirtschaft und Energie (BMWi) ins Leben gerufen. Im Mai 2014 wurde in der medizinischen und pharmazeutischen Gesellschaft die Diskussion der Nachbesserungen zum Föderalen Gesetz Nr. 61-FZ1 "Über den Verkehr mit Arzneimitteln" fort- gesetzt. Die Diskussion dauert de facto bereits mehr als anderthalb Jahre an. Nach Auffassung der Experten werden durch das Gesetz Nr. 61-FZ und die dazu vorgeschlagenen Nachbesserungen die systemimmanenten Probleme nicht beseitigt: die unbegründete Aufnahme klinischer Untersuchungen in das Zulassungsverfahren von Arzneimittelpräparaten; die überflüssige Forderung nach Durchführung lokaler klinischer Untersuchungen auch dann, wenn bereits nach GCP-Standards durchgeführte internationale klinische Untersuchungen vorliegen; das Format der Akten für die Registrierung, das nicht mit den internationalen Anforderungen abgestimmt ist(CTD – Common Technical Documentation) sowie die für verschiedene Arten von Arzneimittelpräparaten fehlenden Verfahrensweisen zur Erstellung von Gutachten. Mit dem Gesetzentwurf wird u.a. vorgeschlagen, den Begriff Biopräparate einzuführen und den Verkehr mit diesen zu regeln, allerdings wurden hier internationale Erfahrungen einmal mehr verzerrt. Durch das Procedere zur Feststellung der gegenseitigen Austauschbarkeit von Arzneimittelpräparaten in der gegenwärtigen Fassung der Nachbesserungen wird de facto das Verfahren der staatlichen Registrierung abgelöst. Wird die gegenseitige Austauschbarkeit für ein Arzneimittelpräparat nicht bestätigt, so wird es seine staatliche Registrierung einbüßen. Das heißt, de facto wird hier eine vollständige Revision der staatlichen Registrierung von Arzneimittelpräparaten mit dem Ziel der Bestätigung der gegenseitigen Austauschbarkeit auf der Grundlage umstrittener Kriterien vorgeschlagen. 1 FZ (russ. ФЗ) = Föderales Gesetz PharmaReport Russland 8/2014 2 I. Wesentliche Rechtsvorschriften 1. Weisung Nr. 155 des Ministeriums für Wirtschaftsentwicklung der Russischen Föderation vom 25.03.2014 (eingetragen beim Justizministerium der RF am 06.05.2014) "Zu den Bedingungen für die Zulassung von ausländischen Waren im Rahmen der Beschaffung von Waren, Arbeiten und Leistungen zur Deckung staatlichen und kommunalen Bedarfs" http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=162956 Definiert wurden die Bedingungen für die Zulassung einer Reihe von Waren russischer, weißrussi- scher und/oder kasachischer Herkunft zur Beschaffung. Zum Verzeichnis der Waren, denen hier Vorzugsbedingungen eingeräumt werden, gehören insbesondere: pharmazeutische Präparate, medizinische chemische Produkte und pflanzliche Arzneimittelprodukte, medizinische Erzeugnisse einschließlich chirurgischer Ausrüstungen und orthopädische Apparate. Insbesondere wurde festgelegt, dass bei der Beschaffung von Waren für den staatlichen und kommunalen Bedarf auf dem Wege von Ausschreibungen, Bieterverfahren oder Angebotsanfragen an Ausschreibungsteilnehmer, deren Teilnahmeanträge oder endgültigen Angebote auch Angebote zur Lieferung von Waren russischer, weißrussischer und/oder kasachischer Herkunft beinhalten, hinsichtlich des Vertragswertes Preisnachlässe von 15 % eingeräumt werden. In dem Papier heißt es, dass als Herkunftsland der Waren das Land gilt, in dem die Waren vollständig hergestellt oder einer hinlänglichen Be- bzw. Verarbeitung entsprechend den in den Gesetzen der Zollunion festgelegten Kriterien unterzogen wurden. Dabei können unter dem Herkunftsland der Waren auch eine Gruppe von Ländern oder Zollunionen von Ländern oder eine Region oder ein Landesteil verstanden werden, sofern zwecks Bestimmung des Herkunftslandes der Waren eine derartige Abgrenzung notwendig ist. II. Initiativen 1. In Russland werden Fragen von Steuervergünstigungen für medizinische Erzeugnisse geregelt Im Informationsportal zur Ausarbeitung von Rechtsvorschriften durch föderale Organe der Exekutive wurde der Verordnungsentwurf "Zur Bestätigung der Verzeichnisse von medizinischen Waren, deren Vertrieb in der Russischen Föderation und deren Einfuhr in die Russische Föderation und in andere Gebiete, die der russischen Rechtsprechung unterliegen, die nicht besteuert werden, sowie von Rohstoffen und Zuliefererzeugnissen für deren Herstellung, die ebenfalls nicht besteuert werden" platziert. Mit dem Dokument werden bestätigt: – das Verzeichnis medizinischer Waren, deren Vertrieb in der RF und deren Einfuhr in die RF und in andere Gebiete, die der russischen Rechtsprechung unterliegen, von der Mehrwertsteuer befreit sind; – das Verzeichnis von Rohstoffen und Zuliefererzeugnissen für die Herstellung medizinischer Waren, deren Einfuhr in die RF und in andere Gebiete, die der russischen Rechtsprechung unter- liegen, von der Mehrwertsteuer befreit sind; PharmaReport Russland 8/2014 3 Die Ausarbeitung dieser Verordnung der Regierung der Russischen Föderation zielt auf die Rege- lung von Steuervergünstigungen für medizinische Erzeugnisse ab. 2. Dmitri Medwedew hat eine Reihe von Anweisungen zu Fragen der Entwicklung der pharmazeutischen und medizinischen Industrie erteilt Anhand der Tagungsergebnisse des Rates für Wirtschaftsmodernisierung und Innovationsentwicklung beim russischen Präsidenten hat Dmitri Medwedew eine Reihe von Anwei- sungen erteilt. So wurden das Gesundheitsministerium und das Industrie- und Handelsministerium Russlands angewiesen, bis zum 10. September 2014 zusätzliche Maßnahmen für den Abschlusses staatlicher Verträge über die Lieferung von Waren, die Ausführung von Arbeiten und die Erbringung von Leistungen zur Deckung des föderalen Bedarfs für einen Zeitraum, der über die Geltungsdauer der bestätigten Haushaltslimits hinausgeht, einzuleiten. Das Gesundheitsministerium, das Industrie- und Handelsministerium, das Ministerium für Wirtschaftsentwicklung sowie das Finanzministerium Russlands haben zusammen mit den Entwicklungsinstituten nach der dafür festgelegten Verfahrensweise der Regierung der RF bis zum 7. Oktober 2014 Vorschläge zur Finanzierung von Maßnahmen vorzulegen, die auf die weitere Entwicklung der Nuklearmedizin, technologischer Verfahren der Biomedizin (Entwicklung und Herstellung von Zell- und Gewebeprodukten, Genomtechnologien) sowie auf die Förderung der Entwicklung einer innovativen Infrastruktur, darunter auch auf der Grundlage innovativer biomedizinischer Pilot-Cluster, gerichtet sind, und zwar aus dem föderalen Haushalt für den Zeitraum 2015 – 2017 im Rahmen des Unterprogramms "Entwicklung und Einführung innovativer Methoden der Diagnostik, Prophylaxe und Therapie sowie der Grundlagen der personalisierten Medizin" des staatlichen Programms der Russischen Föderation "Entwicklung des Gesundheitswesens" und des staatlichen Programms der Russischen Föderation "Entwicklung der pharmazeutischen und medizinischen Industrie" für den Zeitraum 2013 – 2020. Das Gesundheitsministerium und das Industrie- und Handelsministerium Russlands wurde zusam- men mit den involvierten föderalen Organen der Exekutive angewiesen, bis zum 8. Oktober 2014 einen Komplex von Maßnahmen zum Schutz der russischen Verbraucher vor qualitativ minderwer- tigen, nachgeahmten und gefälschten medizinischen Produkten zu erarbeiten. Dem russischen Gesundheitsministerium soll zusammen mit den involvierten föderalen Organen der Exekutive, bis zum 23. Juli die Erstellung eines einheitlichen Verzeichnisses von Arzneimittelpräparaten prüfen. Mit Hilfe der Präparate aus diesem Verzeichnis sollen die Bürger im Rahmen des staatlichen Programms der kostenlosen medizinischen Hilfe versorgt werden. Überdies obliegt der Kommission die Prüfung der Verfahrensweise für die Erstellung eines solchen Verzeichnisses. Das Gesundheitsministerium und das Industrie- und Handelsministerium Russlands haben bis zum 23. Juli die Einführung moderner Labordiagnostik bei der Durchführung vorklinischer Untersuchungen von Arzneimitteln abzuklären und der Regierung der Russischen Föderation dazu abgestimmte Vorschläge zu unterbreiten. Das Industrie- und Handelsministerium, das Gesundheitsministerium, das Ministerium für Wirt- schaftsentwicklung und das Finanzministerium Russlands haben bis zum 3. September 2014 der Regierung der RF nach der dafür festgelegten Verfahrensweise Vorschläge zur Aufnahme von PharmaReport Russland 8/2014 4 Maßnahmen, die auf die Entwicklung und Organisation der Produktion pharmazeutischer Substan- zen gerichtet sind, in das föderale Zielprogramm "Entwicklung der pharmazeutischen und medizini- schen Industrie der Russischen Föderation im Zeitraum bis 2020 und in der weiteren Zukunft" sowie Vorschläge zur Aufnahme von Maßnahmen zur Entwicklung und Lokalisierung von Kompo- nenten medizinischer Erzeugnisse in das staatliche Programm der Russischen Föderation "Ent- wicklung der elektronischen und funkelektronischen Industrie im Zeitraum 2013 – 2025" zu unter- breiten. Das Industrie- und Handelsministerium, das Ministerium für Wirtschaftsentwicklung, das Finanz- ministerium und das Gesundheitsministeriums Russlands haben bis zum 6. Oktober 2014 der Regierung der RF einen Entwurf für eine Rechtsvorschrift zur Verlängerung staatlicher Verträge für die Entwicklung von Arzneimitteln vorzulegen, und zwar unter Berücksichtigung der Genehmigungsfristen für die Durchführung klinischer Untersuchungen von Arzneimittelpräparaten. Das Industrie- und Handelsministerium, das Gesundheitsministerium, das Finanzministerium, das Ministerium für Wirtschaftsentwicklung, der Föderale Steuerdienst (FNS) und der Föderale Zoll- dienst (FTS) Russlands haben bis zum 21. August 2014 der Regierung der Russischen Föderation Vorschläge zur Befreiung von der Zahlung bzw. zur Rückerstattung der Mehrwertsteuer bei der Einfuhr von Rohstoffen und Zuliefererzeugnissen für die Herstellung medizinischer Erzeugnisse in die Russische Föderation zu unterbreiten. Das Ministerium für Wirtschaftsentwicklung sowie das Industrie- und Handelsministerium Russlands haben bis zum 29. September zusammen mit den involvierten föderalen Organen der Exekutive einen Entwurf für eine behördliche Rechtsvorschrift für den Zeitraum bis 2018 zu den Bedingungen der Zulassung von Arzneimittelpräparaten ausländischer Herkunft im Rahmen der Erteilung von Aufträgen zur Deckung des staatlichen und kommunalen Bedarfs einschließlich einer differenzierten Skala von Begünstigungen in Abhängigkeit vom Grad der Verarbeitung der Produkte im Gebiet der Russischen Föderation vorzulegen. Ein Zwischenbericht über den Verlauf der Realisierung der Anweisung ist der Regierung der Russischen Föderation bis zum 22. Juli 2014 vorzulegen. Das Ministerium für Wirtschaftsentwicklung, das Industrie- und Handelsministerium, das Finanz- ministerium und das Gesundheitsministerium Russlands werden zusammen mit der OAO "ÈKSAR" [OAO = offene Aktiengesellschaft] und anderen interessierten Organisationen/Firmen angewiesen, bis zum 03. Juli 2014 der Regierung der RF Vorschläge zur Unterstützung russischer Firmen, die Arzneimittel und medizinische Erzeugnisse exportieren, vorzulegen, und zwar unter anderem durch Anwendung einer erweiterten Versicherungsdeckung, durch Einführung von steuerlichen Anreizen, durch Mechanismen zur Subventionierung des Zinssatzes für Exportkredite sowie durch Information über die Spezifik der nationalen Regulierung der Länder, die russische Produkte importieren. Das Bildungs- und Wissenschaftsministerium, das Industrie- und Handelsministerium, das Gesund- heitsministerium und der Föderale Zolldienst Russlands werden zusammen mit den involvierten föderalen Organen der Exekutive angewiesen, bis zum 18. August 2014 Vorschläge zur Verein- fachung der Verfahrensweise für die Einfuhr von Reagenzien für wissenschaftliche Forschungen zu unterbreiten und der Regierung der Russischen Föderation ggf. auch einen Entwurf für eine ent- sprechende Rechtsvorschrift vorzulegen. PharmaReport Russland 8/2014 5 3. Gesetz "Über die Grundlagen des Gesundheitsschutzes der Bürger in der RF" könnte um neuen Artikel ergänzt werden Das russische Gesundheitsministerium hat einen Entwurf für ein föderales Gesetz "Über die Vornahme von Änderungen im Föderalen Gesetz "Über die Grundlagen des Gesundheitsschutzes der Bürger in der Russischen Föderation" ausgearbeitet, nach dem das Föderale Gesetz Nr. 323-FZ vom 21. November 2011 "Über die Grundlagen des Gesundheitsschutzes der Bürger in der Russi- schen Föderation" um einen neuen Artikel ergänzt wird: "Innovative medizinische Hilfe". Die Ein- führung des Artikels erlaubt es, neue Methoden der Prophylaxe, Diagnostik, Therapie von Erkrankungen und Rehabilitation von Patienten zu entwickeln und anschließend im Rahmen von Translationsuntersuchungen und medizinischer Hilfe, die nicht zum Basisprogramm der gesetzlichen Krankenversicherung gehören, anzuwenden und einzuführen. Wie in den Erläuterungen zum Gesetzentwurf ausgeführt wird, ist die Teilnahme von Patienten an den im Rahmen der innovativen medizinischen Tätigkeit durchgeführten Maßnahmen freiwillig. Verboten ist die Durchführung klinischer Untersuchungen neuer oder wesentlich verbesserter Methoden der Prophylaxe, Diagnostik, Therapie von Erkrankungen und Rehabilitation von Patienten unter Beteiligung folgender Gruppen von Patienten: Waisenkinder und Kinder, die nicht unter der Obhut ihrer Eltern stehen; Frauen während der Schwangerschaft und in der Stillzeit; Armeeangehörige; Mitarbeiter der Rechtsschutzorgane; Personen, die eine Freiheitsstrafe verbüßen oder sich in Untersuchungshaft befinden. Der Gesetzentwurf wurde bis zum 23.05.2014 öffentlich diskutiert. 4. Gesetzentwurf zur stärkeren Haftung für die Fälschung von Arzneimitteln hat sämtliche Mitzeichnungskommissionen der involvierten Behörden durchlaufen Der Gesetzentwurf zur stärkeren Haftung für die Fälschung von Arzneimitteln hat sämtliche Mitzeichnungskommissionen der involvierten Behörden durchlaufen und wurde nicht nur vom Obersten Gericht gebilligt, sondern auch vom Ausschuss der Staatsduma für Gesundheitsschutz. Entsprechend den Neuerungen wird vorgeschlagen, die Herstellung gefälschter Arzneimittel mit Freiheitsentzug von 5 bis zu 8 Jahren zu ahnden. Falls ein Medikament zum Tod eines Menschen geführt hat, kann eine Freiheitsstrafe von 8 bis 12 Jahren verhängt werden. Die verwaltungsrechtli- che Haftung für den Vertrieb gefälschter Präparate kann sich auf 1 bis 5 Mio. Rubel belaufen. 5. Regierungsverordnungsentwurf für die Erstellung von Arzneimittelverzeichnissen Vom Gesundheitsministerium wurde ein Regierungsverordnungsentwurf vorbereitet, in dem Regeln für die Erstellung einschränkender Verzeichnisse von Arzneimitteln definiert werden, die vom Staat im Rahmen des Programms staatlicher Garantien der kostenlosen medizinischen Hilfe gewährt werden. Erstmals wurde zur Erstellung der Verzeichnisse ein System von Bewertungskennziffern entwickelt, das die Objektivität getroffener Entscheidungen auf der Grundlage einer Qualitätsbewertung und der Beweiskraft klinischer Untersuchungen von Arzneimittelpräparaten wesentlich erhöhen soll. Experten sind mit dem vorgeschlagenen System von Bewertungskenn- ziffern nicht einverstanden, sie betrachten es als ineffizient. PharmaReport Russland 8/2014 6 В мае 2014 года продолжилось обсуждение в медицинском и фармацевтическом сообществе поправок в 61-ФЗ «Об обращении лекарственных средств». Обсуждение фактически длится уже больше полутора лет. Эксперты считают, что 61-ФЗ и предлагаемые в него поправки не устраняют системных проблем, а именно, необоснованное включение клинических исследований в процедуру госрегисрации ЛП; наличие избыточного требования о необходимости проведения локальных клинических исследований (КИ) при наличии международных КИ, проведенных в соответствии с GCP-стандартами; формат регистрационного досье не гармонизирован с международными требованиями (CTD, Common Technical Documentation); отсутствие порядков проведения экспертиз для разных видов ЛП. Законопроектом предлагается ввести понятие и урегулировать обращение биопрепаратов, однако в очередной раз международный опыт оказался искажен. Процедура установления взаимозаменяемости ЛП в текущей редакции поправок фактически подменяет собой процедуру государственной регистрации. При неподтверждении взаимозаменяемости лекарственный препарат будет лишаться госрегистрации, несмотря на его правомерное нахождение в гражданском обороте. То есть, фактически предлагается полная ревизия госреестра ЛП с целью подтверждения взаимозаменяемости на основании сомнительных критериев. I. Ключевые нормативно-правовые акты других ведомств 1.Приказ Минэкономразвития Российской Федерации №155 от 25.03.2014 г. (зарегистрирован в Минюсте РФ 6.05.2014г.) «Об условиях допуска товаров, происходящих из иностранных государств, для целей осуществления закупок товаров, работ, услуг для обеспечения государственных и муниципальных нужд» http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=162956 Определены условия допуска для целей осуществления закупок ряда товаров российского, белорусского и (или) казахстанского происхождения. В перечень товаров, в отношении которых вводятся преференции, включены, в частности: препараты фармацевтические, продукты медицинские химические и продукты лекарственные растительные, изделия медицинские, включая хирургическое оборудование, ортопедические приспособления. Установлено, в частности, что при осуществлении закупок товаров для обеспечения государственных и муниципальных нужд путем проведения конкурса, аукциона или запроса предложений участникам закупки, заявки на участие или окончательные предложения которых содержат предложения о поставке товаров российского, белорусского и (или) казахстанского происхождения, предоставляются преференции в отношении цены контракта в размере 15%. В документе указывается, что страной происхождения товаров считается страна, в которой товары были полностью произведены или подвергнуты достаточной обработке (переработке) в соответствии с критериями, установленными таможенным законодательством Таможенного союза. При этом под страной происхождения товаров может пониматься группа стран либо таможенные союзы стран, либо регион или часть страны, если имеется необходимость их выделения для целей определения страны происхождения товаров. PharmaReport Russland 8/2014 7 II.Инициативы 1. В России будут урегулированы вопросы льготного налогообложения медизделий На портале для размещения информации о разработке федеральными органами исполнительной власти проектов нормативных правовых актов размещен проект постановления Правительства Российской Федерации «Об утверждении перечней медицинских товаров, реализация в Российской Федерации и ввоз которых на территорию Российской Федерации и иные территории, находящиеся под ее юрисдикцией, сырья и комплектующих изделий для их производства, не подлежащих налогообложению». Документом утверждаются: - перечень медицинских товаров, реализация которых в РФ и ввоз которых на территорию РФ и иные территории, находящиеся под ее юрисдикцией, не подлежит обложению налогом на добавленную стоимость; - перечень сырья и комплектующих изделий для производства медицинских товаров, ввоз которых на территорию РФ и иные территории, находящиеся под ее юрисдикцией, не подлежит обложению налогом на добавленную стоимость. Разработка постановления Правительства Российской Федерации направлена на урегулирование вопросов льготного налогообложения медицинских изделий. 2. Дмитрий Медведев дал ряд поручений по вопросам развития фарм и медпромышленности По итогам заседания президиума Совета при Президенте России по модернизации экономики и инновационному развитию Дмитрий Медведев дал ряд поручений. Так, Минздраву и Минпромторгу России поручено до 10 сентября 2014 г. принять дополнительные меры по использованию механизма заключения государственных контрактов на поставку товаров, выполнение работ, оказание услуг для обеспечения федеральных нужд на срок, превышающий срок действия утверждѐнных лимитов бюджетных обязательств. Минздраву, Минпромторгу, Минэкономразвития и Минфину России совместно с институтами развития представить до 7 октября 2014 г. в установленном порядке в Правительство РФ предложения по финансированию из федерального бюджета в период 2015–2017 годов в рамках подпрограммы «Развитие и внедрение инновационных методов диагностики, профилактики и лечения, а также основ персонализированной медицины» государственной программы Российской Федерации «Развитие здравоохранения» и государственной программы Российской Федерации «Развитие фармацевтической и медицинской промышленности» на 2013–2020 годы мероприятий, направленных на поддержку развития технологий ядерной медицины, технологий биомедицины (разработку и производство клеточных и тканевых продуктов, геномных технологий), а также на поддержку развития инновационной инфраструктуры, в том числе на базе пилотных инновационных биомедицинских кластеров. Минздраву и Минпромторгу России совместно с заинтересованными федеральными органами http://regulation.gov.ru/get.php?view_id=3&doc_id=38154 http://government.ru/news/12433#sov PharmaReport Russland 8/2014 8 исполнительной власти поручено до 8 октября 2014 г. разработать комплекс мер по защите российского потребителя от недоброкачественной, контрафактной и фальсифицированной медицинской продукции, предусмотрев законодательное закрепление подтверждения соответствия зарубежных площадок, производящих лекарственные средства для Российской Федерации, требованиям, установленным для производителя. Минздраву России совместно с заинтересованными федеральными органами исполнительной власти до 23 июля надлежит рассмотреть возможность создания единого перечня лекарственных препаратов, обеспечение которыми осуществляется в рамках программы государственных гарантий бесплатного оказания гражданам медицинской помощи, а также порядка формирования данного перечня. Минздраву и Минпромторгу России до 23 июля необходимо проработать вопрос о внедрении современных технологий лабораторной диагностики при проведении доклинических исследований лекарственных средств и внести согласованные предложения в Правительство Российской Федерации. Минпромторгу, Минздраву, Минэкономразвития и Минфину России до 3 сентября 2014 г. нужно представить в установленном порядке в Правительство РФ предложения по включению в федеральную целевую программу «Развитие фармацевтической и медицинской промышленности Российской Федерации на период до 2020года и дальнейшую перспективу» мероприятий, направленных на разработку и организацию производства фармацевтических субстанций, а также предложения по включению в государственную программу Российской Федерации «Развитие электронной и радиоэлектронной промышленности на 2013–2025годы» мероприятий, направленных на разработку и локализацию компонентов медицинских изделий. Минпромторгу, Минэкономразвития, Минфину и Минздраву России представить до 6 октября 2014 г. нужно внести в установленном порядке в Правительство РФ проект нормативного правового акта о порядке пролонгации государственных контрактов на разработку лекарственных средств, в том числе с учѐтом сроков получения разрешений на проведение клинических исследований лекарственного препарата. Минпромторгу, Минздраву, Минфину, Минэкономразвития, ФНС и ФТС России до 21 августа 2014 г. нужно представить в установленном порядке в Правительство Российской Федерации предложения об освобождении от уплаты и возмещении налога на добавленную стоимость при ввозе на территорию Российской Федерации сырья и комплектующих для производства медицинских изделий. Минэкономразвития и Минпромторгу России до 29 сентября необходимо разработать совместно с заинтересованными федеральными органами исполнительной власти проект ведомственного нормативного правового акта на период до 2018 года об условиях допуска лекарственных препаратов, происходящих из иностранных государств, для целей размещения заказов для государственных и муниципальных нужд, включая дифференцированную шкалу преференций в зависимости от степени переработки продукции на территории Российской Федерации. Промежуточный доклад о ходе реализации поручения необходимо представить в Правительство Российской Федерации до 22 июля 2014 года. Минэкономразвития, Минпромторгу, Минфину и Минздраву России совместно с ОАО «ЭКСАР» и другими заинтересованными организациями поручено до 3 июля 2014 г. представить в установленном порядке в Правительство РФ предложения по поддержке, в том числе за счѐт PharmaReport Russland 8/2014 9 применения расширенного страхового покрытия, внедрения стимулирующих налоговых режимов, реализации механизмов субсидирования процентной ставки по экспортным кредитам, информирования о специфике национального регулирования стран – импортеров российской продукции российских компаний, осуществляющих экспорт лекарственных средств и медицинских изделий. Минобрнауки, Минпромторгу, Минздраву и ФТС России совместно с заинтересованными федеральными органами исполнительной власти поручено представить до 18 августа 2014 года предложения об упрощении порядка ввоза реактивов для научных исследований, а также при необходимости внести в Правительство Российской Федерации проект соответствующего нормативного акта. 3. Закон «Об основах охраны здоровья граждан в РФ» может быть дополнен новой статьей Минздрав России разработал проект федерального закона «О внесении изменений в Федеральный закон «Об основах охраны здоровья граждан в Российской Федерации», в соответствии с которым Федеральный закон от 21 ноября 2011 года № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации» дополняется новой статьей: «Инновационная медицинская помощь». Введение в Федеральный закон «Об основах охраны здоровья граждан в Российской Федерации» статьи «Инновационная медицинская деятельность» позволит упорядочить систему разработки, последующего применения в рамках трансляционных исследований и медицинской помощи, не включенной в базовую программу обязательного медицинского страхования, а также внедрения новых методов профилактики, диагностики, лечения заболеваний и реабилитации пациентов. Как говорится в пояснительной записке к законопроекту, участие пациентов в мероприятиях, осуществляемых в рамках инновационной медицинской деятельности, является добровольным. Запрещается проведение клинических исследований новых или значительно улучшенных методов профилактики, диагностики, лечения заболеваний и реабилитации пациентов с участием в качестве пациентов: детей-сирот и детей, оставшихся без попечения родителей; женщин в период беременности и в период грудного вскармливания; военнослужащих; сотрудников правоохранительных органов; лиц, отбывающих наказание в местах лишения свободы, а также лиц, находящихся под стражей в следственных изоляторах. Общественное обсуждение законопроекта проводилось до 23.05.2014 г. 4.Законопроект об усиление ответственности за подделку лекарств прошел все согласительные комиссии профильных ведомств Законопроект об усиление ответственности за подделку лекарственных средств прошел все согласительные комиссии профильных ведомств и одобрен не только Верховным судом, но и комитетом Госдумы по охране здоровья. Согласно нововведениям предлагается наказывать за производство поддельных лекарств сроком от 5 до 8 лет лишения свободы. В случае, если лекарство привело к гибели человека, то срок заключения может составить от 8 до 12 лет. Административная ответственность при реализации фальсифицированных препаратов может обойтись от 1 млн до 5 млн рублей. http://regulation.gov.ru/project/14823.html?point=view_project&stage=2&stage_id=9759 10 PharmaReport Russland 6/2014 Bei Fragen zu diesem Newsletter werden Sie sich bitte an die Exportinitiative Gesundheitswirtschaft: pharma@health-made-in-germany.com 030.20 00 99 – 0 Weiterführende Informationen zum umfassenden Unterstützungsangebot finden Sie auf www.exportinitiative-gesundheitswirtschaft.de Die in diesem Newsletter enthaltenen Informationen wurden durch PharmCis recherchiert. 5. Проект постановления об формировании перечней лекарственных средств Минздравом подготовлен проект постановления Правительства, определяющий правила формирования ограничительных перечней лекарственных средств, которые гарантируются государством в рамках программы государственных гарантий бесплатного оказания медицинской помощи. Впервые для формирования перечней разработана система оценочных показателей, которая должна существенно повысить объективность принимаемых решений на основе интегральной количественной оценки качества и доказательности клинических исследований лекарственных препаратов в соответствии с уровнем убедительности данных и убедительности доказательств, количественной оценки эффективности и безопасности терапии и количественной оценки экономической эффективности препарата. Эксперты не согласны с предложенной системой оценочных показателей, считают ее неэффективной.

1 Pharmaceutical Forum 1st Meeting of the Steering Committee 6 December 2005, Brussels Draft note of the Meeting Chairpersons: Georgette Lalis, Director, Directorate-General for Enterprise and Industry and Fernand Sauer, Director, Directorate-General for Health and Consumer Affairs. 1. Introduction 1. The chairpersons welcomed the members to the first meeting of the Steering Committee. In the introduction they described the background and main reasons for establishing the Steering Committee, the work programme and the ministerial level Pharmaceutical Forum. 2. The key objective of the Committee is to provide operational direction for the work programme and to prepare the annual Pharmaceutical Forum. The role of the Commission was to act as a facilitator of the work programme. To support this function the Commission will chair the working groups as well as the Steering Committee. Vice-President Verheugen and Commissioner Kyprianou will co-chair the Pharmaceutical Forum. 2. Role of the Pharmaceutical Forum (Paper SC 1/6) 3. The key role of the Pharmaceutical Forum will be to provide a high level platform for discussion of the work programme. In addition, it was agreed that further topics could be added to the agenda of the Forum to reflect current political priorities. The Commission suggested that possible subjects could include the Priority Medicines initiative, the establishment of the Innovative Medicines platform under the 7th Framework Programme on Research and Development of the Commission as well as other technological developments such as genomics. The Steering Committee supported this proposal and agreed to provide suggestions for appropriate subjects. Conclusions: The draft agenda of the first meeting of the Pharmaceutical Forum was agreed. 2 Suggestions for further topics to be added on the agenda of the first Pharmaceutical Forum should be sent to the Secretariat preferably by the end of January 2006. 3. Mandate for the Steering Committee (Paper SC 1/2) 4. With regard to the number of meetings of the Steering Committee it was agreed that the Committee should, in principle, meet three times a year. In order to ensure effective flow of information and communication, an electronic information tool, the CIRCA-site managed by the Secretariat, will be used to give all members access to documentation produced by the Forum and its Committee and to any other relevant information. 5. The number of meetings will be as limited as possible and the Committee will be supported by using other means of communication (e.g. e-mailing, audio-conferences, etc.). The following principles for the meetings of the Steering Committee were proposed as follows; Meeting 1: Agreeing the work programme for the year Meeting 2: Preparing the annual Pharmaceutical Forum Meeting 3: Discussing and following the progress of the working groups 6. More meetings will be organized as needed (for instance if problems arise in the working groups). Conclusions: a) The mandate for the Steering Committee was agreed. b) The Commission will establish a specific site at the CIRCA site to ensure access to relevant documentation on the Pharmaceutical Forum. Instructions to access the CIRCA site are annexed in this note. 4. Working Groups 7. The primary focus of the working groups will be the implementation of the outstanding G10-Recommendations. These will be the starting point for discussion in all the working groups. The groups will therefore need to know what has already been done in G10 but should have significant autonomy if quick progress is to be made. The working groups will provide regular progress reports to the Steering Committee. As there may be an overlap of activities between the working groups, a mutual exchange of information between them will be also important. 8. In order to ensure a solid basis for future work in the working groups, it is necessary to compile information on the key EU level projects and initiatives linked to the subjects. Conclusions: a) The Commission will circulate a summary of the implementation of the G10 Medicines Recommendations. 3 b) The Commission will circulate a summary of existing European projects regarding the key topics to be covered by the Working Groups. 5. Information to patients 9. The first working group to be launched early in 2006 will be on information to patients on pharmaceuticals. This working group was chosen as the first one because the revision of the EU pharmaceutical legislation contains an obligation on the Commission to report on the state of information to patients to the European Parliament and the Council of Ministers in 2007. The Commission wishes to benefit from the work of the working group to meet this obligation. 10. The Commission emphasized that the working group should aim to establish a broad outline of a Public Private Partnership to take forward work in this area. The first task of the working group will be to discuss and define the type and scope of Partnership to be created with a view to making a recommendation on its establishment to the Forum. Following the first meeting of the Forum, the group will need to develop concrete proposals for developing information tools. 11. Although the mandate of the working group focuses on the importance of electronic information, the working group should also take into account the important role of health professionals in providing information to patients as well as the provision of non-electronic forms of information. In addition, best practices and initiatives on information to patients from various Member States should also be considered in the context of developing comprehensive, reliable, objective and up to date information on pharmaceuticals to patients. Conclusions: The mission statement of the working group was agreed subject to some minor amendments to take account of the comments above. Revised mission statement attached. The members of the Steering Committee were invited to send proposals for alternative wording to the Secretariat. 6. Relative effectiveness 12. The EU Member States have a wide range of different practices and experiences of relative effectiveness. The Commission emphasized that the working group on relative effectiveness should focus on finding an appropriate mechanism to pool best practice and share expertise in this field. This is particularly important issue for smaller Member States which do not always have sufficient resources in making relative effectiveness assessments at the national level. 13. The link between relative effectiveness and rewarding innovation was also discussed. Specifically, the issue of incremental innovation was highlighted as an area which should be taken into account when considering use of relative effectiveness. 4 14. The Commission informed the Committee that the delegate from the Italian Ministry of Health, has been invited to co-chair the working group. He has considerable experience in this field and, as chair of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health, he has led work in this area at a European level already. Conclusions: The Mission Statement was agreed subject to the following rephrasing of the first line: “To supply Member States with appropriate instruments to apply Relative Effectiveness systems, in order to allow containment of pharmaceutical costs as well as a fair reward for innovation.” Revised mission statement attached. 7. Pricing 15. The key objective of this working group is to increase access to medicines and transparency of pricing and reimbursement procedures. Access to medicines and other treatments for all patients throughout the EU is a key issue. From the national authority perspective, the importance of exchanging information and understanding ongoing pricing and reimbursement practices in other Member States as well as of an EU discussion on (common) pricing and reimbursement mechanisms was also highlighted as important areas of future work. Finally, the special role of SME’s was mentioned as a point of attention for this working group. 16. In order to map the current situation as regards national pricing practices, an independent study will be financed by DG Enterprise & Industry. The working group will be provided with the information from the study. 17. The implementation of the Transparency Directive would not, in principle, be covered by this group as it is the focus of a separate enforcement exercise. Conclusions: The mission statement was agreed. 8. Working methods 18. The proposed working method paper was agreed without amendments. 9. Final remarks The chairman concluded by explaining that this was his last meeting on pharmaceuticals as the Director of Public Health and Risk Assessment before his retirement. He thanked the Committee members for excellent collaboration over the years in the field of pharmaceuticals. 10. Next steps 5 a.) The Commission will explore the possibility of organising the Pharmaceutical Forum in conjunction with the Health Council on 1 June 2006 to allow as many Ministers as possible to participate. b.) The next meeting of the Steering Committee will be in March 2006 (exact date to be confirmed). c.) The Commission reminded members of the Steering Committee that they are invited to provide the names and contact details of the experts to the working groups. d.) The secretariat will circulate the draft note of the meeting. SANCO C5 & ENTR F5 DG SANCO C5 and DG ENTREPRISE F5 6 Annex 1. List of participants Member States: Austria United Kingdom Portugal France FinlandSloveniGermany Representatives European Parliament and EFPIA AESGP ESIP GIRP PGEU CPME EPF EGA EuropaBio AIM Georgette LALIS, DG Enterprise & Industry Fernand SAUER, DG SANCO Christian SIEBERT, DG Enterprise & Industry Bernard MERKEL, DG SANCO And other Commission officials. Pharmaceutical Forum 1st Meeting of the Steering Committee 6 December 2005, Brussels 1. Introduction 2. Role of the Pharmaceutical Forum (Paper SC 1/6) 3. Mandate for the Steering Committee (Paper SC 1/2) 4. Working Groups 5. Information to patients 6. Relative effectiveness 7. Pricing 8. Working methods 9. Final remarks

Pharmaceutical Forum 2nd Meeting of the Steering Committee 30 March 2006, Brussels Draft note of the Meeting Chairpersons: Georgette Lalis, Director, Directorate-General for Enterprise and Industry and Bernard Merkel, Head of Unit, Directorate-General for Health and Consumer Affairs. 1. Introduction 1. The chairperson welcomed the members to the second meeting of the Steering Committee. She explained that the new SANCO Director, Mr Rys, will become the new co- chair as soon as he takes up his post in June. 2. The minutes of the first meeting of 6 December 2005 were adopted, subject to an amendment noting that the draft mandate of the Pharmaceutical Forum was included in the original invitation letter to participants of 19 October 2005. The revised minutes will be added to the CIRCA site. 2. Updates of the Working Groups 3. All three Working Groups have been kicked off and they have met since the first Steering Committee. The chairmen of the Working Groups were asked to present the progress made in the groups. 3. Relative Effectiveness Working Group 4. The Italian representative gave a presentation on the progress made in the working group. The main aim is to increase mutual understanding on the key issues related to relative effectiveness assessments. 5. In order to develop a basis for discussion, and to take stock on the current state of play of relative effectiveness in the Member States, the working group had developed a questionnaire on the key issues. It covers a wide range of issues such as definition and 1 methodologies of relative effectiveness assessments and organizational aspects of carrying out assessments. In addition, it aims to collect data on different information sources. 6. Following the Italian representative’s presentation, a discussion took place. The issue of what is meant by relative effectiveness was raised as a key to ensuring understanding of the problems. It was also clarified that the focus of the relative effectiveness working group is on post-market evaluation. He also stressed that it is important the working group concentrates on setting out the overall picture on the main issues in order to be able to identify good practices and possible ways to develop this area. Conclusions: All Member States have been asked to respond to the questionnaire. The analysis of the replies will set out the general picture on how relative effectiveness assessments are carried out. It will also form the basis for further work. The Steering Committee agreed on the approach taken by the working group. It will provide a further update of progress and proposals for deliverables for the Forum to the next Steering Committee. 4. Information to Patients Working Group 7. The chair of the Working Group gave an update on progress. The group met on 27 January 2006 and on 21 March to discuss the work programme. The broad objectives of the group are to consider how to improve medicine, disease-related and other treatment options information to patients and to propose ways to improve accessibility to information. In order to take work forward, the working group had agreed on establishing smaller drafting groups. 8. In practice the work is divided into three pillars. The chairman described the activities to be undertaken under pillar I on non-statutory information. The pillar, led by the UK with support from Italy, would focus on developing a model disease information package using diabetes and coronary heart disease as examples. The time schedule for this work is 6 months and thus, should deliver a proposal for the Forum. 9. The chairman set out the activities of pillars II and III. Pillar II, led by the EMEA, is on statutory information and will focus on developing existing proposals from the EMEA/CHMP Working Group with Patient Organisations on harmonised action at the EU- level to improve information on medicines. . 10. Pillar III, led jointly by Austria and the PGEU, will focus on access to information in specific health care settings such as pharmacies and hospitals. The time schedule for this work is 12 months and thus, the deliverable for the Forum is likely to be principles for action. 11. Following the updates members of the Committee made a number of comments with regard to the patients’ needs on information, sources of information and the roles of health professionals in providing information. 12. The next meeting of the full working group is planned for 23 June 2006. 2 Conclusions: The chairmen of the subgroups will define how to best take work forward under the action pillars in order to develop proposals for the Forum. The report of the Pillar II sub-group could provide the basis for the Working Group’s contribution to the preparations of the report to the Council and the Parliament on information provision. 5. Pricing 13. The chairperson of the working group on pricing, explained progress made in the working group. Two meetings took place (10/2 and 24/3). The first meeting of the working group had focused on the overall objective, i.e. finding common ground between (1) control of budget for Member States, (2) reward of innovation for industry and (3) access to medicines for patients. 14. After the first meeting a list of potential key issues and topics to be addressed by the Working Group had been identified by the members of the group. For the second meeting, the Secretariat had prepared a map of key issues. These key issues are now grouped under four main work streams to focus progress: 1) Budget Control 2) Access to Medicines 3) Market and Trade 4) Transparency of Data 15. Independent academic experts will be preparing overviews on the first 3 workstreams, as basis for discussion in further meetings. The 4th workstream will be addressed in a separate setting (to be defined). 16. The Steering Committee agreed on the need for reliable and verifiable data. As this requires an extensive and technical process, this workstream should indeed be addressed in a separate setting, while the Working Group progresses on the other workstreams in parallel. The next meeting is planned on 19-20/6. 17. The Steering emphasized the need for a good coordination between the work of this Working Group and of the Working Group on Relative Effectiveness. It was encouraged that chairmen of both Working Groups meet regularly and that progress of both Working Groups will be discussed in parallel in this meetings of the Steering Committee. 18. Several participants of the Steering Committee emphasized the need to ensure that the Working Group will concentrate on ways to foster European R&D and to implement the outstanding recommendations of the G-10 report (Recommendation 3 and 6). A number of concrete helpful ideas were given and it was agreed to keep these elements on the agenda. It was also mentioned that although deliverables are expected to be mainly limited to raising awareness on the key issues, it would not be feasible to have those for the first Forum in September 2006. 3 Conclusions: The Steering Committee agreed on the approach taken by the Working Group. A further update of progress and proposals for deliverables for the Forum will be communicated in the next meeting of the Steering Committee. 6. Pharmaceutical Forum 19. The Forum will be on the morning on 29 September 2006 in Brussels chaired jointly by Vice President Verheugen and Commissioner Kyprianou. The programme of the Forum will be built on the discussions based on the progress reports and recommendations from the working groups. 20. During the first meeting of the Steering Committee consideration was given to including a special political topic in the Forum’s agenda. This issue was discussed again and a number of subjects were considered. There was broad agreement that any special topic should have a broad theme encompassing competitiveness, research and patients. The scope for including a special topic will need to be considered further given the tight time constraints and the need to discuss progress in the working groups. 7. Next steps a.) The next meeting of the Steering Committee will be in summer [3 July] to agree the progress report and the deliverables to the Forum. b) Finland and Germany would be asked to provide an update to the next meeting on priorities for their Presidencies. c.) The Secretariat will circulate the draft note of the meeting and inform on the date of the next meeting. SANCO C5 & ENTR F5 4 Annex 1. List of participants Member States Austria United Kingdom Portugal France Finland Slovenia Germany Representatives European Parliament and EFPIA ESIP GIRP PGEU AESGP CPME EPF EGA EuropaBio AIM Georgette LALIS, DG Enterprise & Industry Christian SIEBERT, DG Enterprise & Industry Bernard MERKEL, DG SANCO And other Commission officials 5 Pharmaceutical Forum 2nd Meeting of the Steering Committee 30 March 2006, Brussels 1. Introduction 2. Updates of the Working Groups 3. Relative Effectiveness Working Group 4. Information to Patients Working Group 5. Pricing 6. Pharmaceutical Forum

1 PharmaReport Russland 9/2014 Russlands Regierung greift verstärkt in den Pharmamarkt ein. Kurzfristig verabschiedete Verordnungen und Gesetze stellen deutsche Arzneimittel- exporteure vor enorme Hürden. PharmaReport Russland – ein Service der Exportinitiative Gesundheitswirtschaft – gibt Ihnen einen umfassenden Überblick über die Gesetzesänderungen und – initiativen der letzten Monate. Die Exportinitiative Gesundheitswirtschaft will Deutschlands Stellung als eines der führenden Exportländer gesundheitswirtschaftlicher Produkte und Dienstleistungen stärken. Die Initiative wurde vom Bundesministerium für Wirtschaft und Energie (BMWi) ins Leben gerufen. Vorgeschlagen wird eine Ergänzung zum Gesetz Nr. 44-FZ um eine Richtlinie, die es einem Lieferanten erlaubt, dem Organisator einer Ausschreibung oder eines Bieterverfahrens und dem staatlichen Auftraggeber eine "kombinierte" Sicherheit seiner Verpflichtungen bereitzustellen, und zwar gleichzeitig mittels einer Bankbürgschaft und in Form von Geldmitteln. Festgelegt wird, dass bei der Beschaffung von Waren zur Deckung des staatlichen und kommunalen Bedarfs per Ausschreibung, Bieterverfahren oder durch Angebotsanfragen Ausschreibungsteilnehmern, deren Teilnahmeanträge oder endgültige Angebote solche zur Lieferung von Waren russischer, weißrussischer und/oder kasachischer Herkunft enthalten, Preisnachlässe von 15 % des Vertragswertes eingeräumt werden. Ausgegangen wird von der Herausbildung eines gemeinsamen Marktes für Arzneimittel im Rahmen der Eurasischen Wirtschaftsunion. Der gemeinsame Markt für Arzneimittel im Rahmen der Union tritt ab 1. Januar 2016 in Funktion, und zwar in Übereinstimmung mit den internationalen Verträgen im Rahmen der Union, in denen einheitliche Prinzipien und Regeln für den Arzneimittelkreislauf festgelegt sind und die von den Mitgliedsstaaten bis spätestens zum 1. Januar 2015 abgeschlossen werden sollen. Für eine ganze Reihe von Waren werden ab 1. September 2014 neue Einfuhr-Zollsätze festgelegt. Die Änderungen wurden entsprechend der Verpflichtungen der Russischen Föderation im Rahmen der WTO verabschiedet. PharmaReport Russland 9/2014 2 STAATLICHE BESCHAFFUNGEN I. Entwürfe Entwurf des Föderalen Gesetzes Nr. 472415-6 "Zur Vornahme von Änderungen im Artikel 101 des Föderalen Gesetzes 'Über die Grundlagen des Gesundheitsschutzes der Bürger in der Russischen Föderation'" Die Nachbesserungen, die von der Staatsduma am 21. Mai 2014 in erster Lesung verabschiedet wurden, betreffen die Verschiebung der Termine des Inkrafttretens einzelner Bestimmungen des Föderalen Gesetzes bezüglich der Behandlung seltener Erkrankungen. Entsprechend Artikel 15 Absatz 1 Punkt 2 des Föderalen Gesetzes Nr. 323-FZ "Über die Grundlagen des Gesundheitsschutzes der Bürger der Russischen Föderation" wird ab 1. Januar 2015 die Organisation der Versorgung einer Reihe von Personen mit Arzneimittelpräparaten durch die Verwaltungsorgane der Subjekte der Russischen Föderation durchgeführt. Dabei wirkt sich die Dezentralisierung staatlicher Beschaffungen von Arzneimittelpräparaten für die Behandlung von Erkrankungen von sozialer Relevanz im Planungszeitraum negativ auf die Verpflichtungen der Russischen Föderation zur Versorgung mit Arzneimittelpräparaten aus und führt zu einer ineffektiven Verwendung von Haushaltsmitteln, erklären die Autoren des Entwurfs, eine Gruppe Abgeordneter. Der Gesetzentwurf verschiebt den Termin des Inkrafttretens des Artikels 101 des Föderalen Gesetzes Nr. 323-FZ vom 1. Januar 2015 auf den 1. Januar 2018. Entwurf des Föderalen Gesetzes Nr. 522847-6 "Zur Vornahme von Änderungen in einigen Rechtsvorschriften der Russischen Föderation (bezüglich Bankbürgschaften)" In der Staatsduma wurden Nachbesserungen eingebracht, die auf die Beseitigung einer ganzen Reihe von Unzulänglichkeiten in der Anwendungspraxis von Bankbürgschaften gerichtet sind (als ein Verfahren zur Sicherung der Erfüllung von Verpflichtungen im Bereich der Beschaffung von Waren, Arbeiten und Leistungen). Die Änderungen betreffen insbesondere die Beziehungen, die mit elektronischen Bankbürgschaften zusammenhängen. Außerdem ist vorgesehen, dass der Zugang zu Informationen, die im Register der Bankbürgschaften enthalten sind, eingeschränkt werden muss. Ebenso wird vorgeschlagen, den Umfang der Angaben im Register der Bankbürgschaften zu präzisieren. Zur Erhöhung der Effektivität der Absicherung der Erfüllung von Verpflichtungen im Bereich staatlicher Beschaffungen wird in dem Gesetzentwurf vorgeschlagen, das Gesetz Nr. 44-FZ um eine Vorschrift zu ergänzen, die es dem Lieferanten erlaubt, dem Organisator einer Ausschreibung oder eines Bieterverfahrens und dem staatlichen Auftraggeber eine "kombinierte" Sicherheit seiner Verpflichtungen bereitzustellen, und zwar gleichzeitig mittels einer Bankbürgschaft und in Form von Geldmitteln. Vorgesehen ist die Möglichkeit einer Sicherung der Vertragserfüllung sowohl durch eine von einer einzelnen Bank ausgestellten Bankbürgschaft als auch durch mehrere Bankbürgschaften, die von mehreren Banken ausgestellt wurden. http://asozd2.duma.gov.ru/main.nsf/(Spravka)?OpenAgent&RN=472415-6&02 http://asozd2.duma.gov.ru/main.nsf/%28SpravkaNew%29?OpenAgent&RN=522847-6&02 PharmaReport Russland 9/2014 3 Eine wichtige Novellierung des Gesetzentwurfs besteht in der Vorschrift zur Bestätigung einheitlicher Formen von Bankbürgschaften. Das hilft, die Arbeit mit Bankbürgschaften zu standardisieren und beseitigt Risiken des staatlichen Auftraggebers, wie es in der Begründung zum Gesetzentwurf heißt. Entwurf der Verordnung der Regierung der RF "Zur Bestätigung der Verfahrensweise der Erstellung von Verzeichnissen für Arzneimittelpräparate, die von der Gesetzgebung der Russischen Föderation vorgesehen sind" Der Entwurf wurde am 1. Juni dem Ministerkabinett zugeleitet und das aktualisierte Verzeichnis soll lt. Gesundheitsministerium bereits am 15. Juli der Regierung überstellt werden. Das Dokument wurde vom Gesundheitsministerium mit dem Ziel erarbeitet, das Verfahren der Erstellung der Verzeichnisse für Arzneimittel, die über staatliche Bieterverfahren beschafft werden, zu vereinfachen und transparenter zu machen. Die Regeln werden die Verfahrensweise der Erstellung folgender Verzeichnisse festlegen: Verzeichnis lebensnotwendiger Arzneimittelpräparate und der Arzneimittelpräparate von höchster Relevanz; Mindestsortiment an Arzneimittelpräparaten für medizinische Anwendungen, die für die medizinische Behandlung erforderlich sind; Verzeichnis von Arzneimittelpräparaten, die aus Mitteln des föderalen Haushalts beschafft werden, vorgesehen zur Versorgung von Personen mit folgenden Erkrankungen: Hämophilie, Mukoviszidose, hypophysärer Zwergwuchs, Morbus Gaucher, bösartige Neubildungen in lymphatischen, blutbildenden und damit verwandten Geweben, multiple Sklerose sowie für Personen nach Organ- und/oder Gewebetransplantationen; Verzeichnis von Arzneimittelpräparaten für medizinische Anwendungen, darunter solcher, die durch Entscheidungen ärztlicher Kommissionen medizinischer Einrichtungen verordnet werden und deren Bereitstellung entsprechend den Standards medizinischer Behandlungen auf Rezept des Arztes (Arzthelfers) bei Gewährung staatlicher Sozialhilfe im Form eines Paketes sozialer Leistungen erfolgt. Entwurf der Verordnung der Regierung der RF "Zur Bestätigung der Verfahrensweise der Erstellung, Genehmigung und Einführung von Terminplänen für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs sowie der Anforderungen an die Form der Terminpläne für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs" Festgelegt wird die Verfahrensweise der Erstellung, Genehmigung und Einführung von Terminplänen für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs entsprechend Artikel 21 Abs. 4 des Föderalen Gesetzes "Über das Vertragssystem im Bereich der Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen und kommunalen Bedarfs". Aufgeführt werden Anforderungen an die Form von Terminplänen für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs. Definiert werden auch die Besonderheiten bei der Beschaffung von Arzneimittelpräparaten. http://www.pharmvestnik.ru/res/dokumenty/proekt-postanovleniya-04-06.docx http://regulation.gov.ru/project/15104.html?point=view_project&stage=2&stage_id=9995 PharmaReport Russland 9/2014 4 Entwurf der Verordnung der Regierung der RF "Zur Bestätigung der Verfahrensweise der Erstellung, Genehmigung und Einführung von Plänen für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs sowie der Anforderungen an die Form der Pläne zur Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs" Festgelegt wird die Verfahrensweise der Erstellung, Genehmigung und Einführung von Plänen für die Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs entsprechend Artikel 17 Abs. 5 des Föderalen Gesetzes "Über das Vertragssystem im Bereich der Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen und kommunalen Bedarfs". Definiert werden die Anforderungen an die Form der Pläne zur Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des föderalen Bedarfs. Es wird festgelegt, dass die Informationen über die Beschaffung von Arzneimittelpräparaten, deren Realisierung gemäß Artikel 83 Abs. 2 Punkt 7 des Föderalen Gesetzes über das Vertragssystem geplant ist, im Beschaffungsplan durch eine Zeile in Höhe des Jahresgesamtumfangs der finanziellen Absicherung dieser Beschaffungen aufzuführen sind. II. Verabschiedete Dokumente Föderales Gesetz Nr. 140-FZ vom 04.06.2014 "Zur Vornahme von Änderungen im Föderalen Gesetz 'Über das Vertragssystem im Bereich der Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des staatlichen und kommunalen Bedarfs'" Konkretisiert wird der in dem genannten Föderalen Gesetz verwendete Begriffsapparat, insbesondere wird eine Definition des Jahresgesamtumfangs von Beschaffungen vorgenommen. Ebenso werden die Verfahrensweisen der Anwendung von Methoden zur Begründung der Vertragspreise und der Realisierung von Beschaffungen bei Subjekten des Kleinunternehmertums sowie bei sozial orientierten nichtkommerziellen Organisationen präzisiert. Festgelegt werden die Besonderheiten bei der Durchführung von Beschaffungen zur Absicherung der Tätigkeit von Auftraggebern auf dem Territorium ausländischer Staaten. Vereinfacht wird die Durchführung von Beschaffungen bei einem einzigen Lieferanten (Auftragnehmer, Ausführenden). Insbesondere ist die Möglichkeit vorgesehen, kleinere Beschaffungen (bis 2 Mio. Rubel oder 5 % des Jahresgesamtumfangs, jedoch höchstens 50 Mio. Rubel) bei einem einzigen Lieferanten durchzuführen. In einzelnen Fällen muss nicht mehr dokumentiert begründet werden, warum es unmöglich oder unzweckmäßig ist, außer der Realisierung der Beschaffung bei einem einzigen Lieferanten (Auftragnehmer, Ausführenden) noch weitere Verfahren zur Bestimmung eines Lieferanten sowie des Vertragswertes und anderer wesentlicher Vertragsbedingungen heranzuziehen. Darüber hinaus wird das Verzeichnis der Fälle, in denen Beschaffungen bei einem einzigen Lieferanten (Auftragnehmer, Ausführenden) realisiert werden können, erweitert. So sind Beschaffungen bei einem einzigen Lieferanten bei Abschlüssen mit Organisationen möglich, die http://regulation.gov.ru/project/15103.html?point=view_project&stage=2&stage_id=9994 http://news.kremlin.ru/media/events/files/41d4e3bd45cab9529b60.pdf PharmaReport Russland 9/2014 5 Bildungstätigkeit ausüben und entsprechend der Gesetzgebung zur Bildung als föderale oder regionale innovative Plattformen anerkannt sind, ebenso bei Verträgen über die Lieferung von Ausrüstungen und Software, die für die Überleitung von wissenschaftlich-technischen Ergebnissen und von Ergebnissen geistiger Tätigkeit erforderlich sind, mit dem Eigentümer der ausschließlichen Rechte an diesen Ausrüstungen und dieser Software; aus Mitteln, die für die Entwicklung der innovativen Infrastruktur im Bildungssystem zugewiesen wurden. Erweitert wird auch der Umfang der Fälle, in denen der Auftraggeber das Recht hat, Gutachten zu gelieferten Waren (ausgeführten Arbeiten, erbrachten Leistungen) nicht nur unter Heranziehung entsprechender Experten durchzuführen, sondern auch mit eigenen Kräften. Weisung Nr. 155 des Ministeriums für wirtschaftliche Entwicklung vom 25.03.2014 "Über die Bedingungen der Zulassung von Waren ausländischer Herkunft zur Realisierung der Beschaffung von Waren, Arbeiten und Leistungen zur Deckung des staatlichen und kommunalen Bedarfs" (eingetragen beim Justizministerium Russlands am 06.05.2014 unter der Nr. 32183 ) Das Dokument legt die Verfahrensweise fest, nach der ausländische Waren, insbesondere Arzneimittel und medizinische Erzeugnisse, an staatlichen und kommunalen Ausschreibungen teilnehmen können. Es wurde festgelegt, dass bei der Beschaffung von Waren zur Deckung des staatlichen und kommunalen Bedarfs über Ausschreibungen, Bieterverfahren oder Angebotsanfragen für Teilnehmer an der Beschaffung, deren Teilnahmeanträge oder endgültige Angebote solche zur Lieferung von Waren russischer, weißrussischer und/oder kasachischer Herkunft enthalten, Preisnachlässe in Höhe von 15 % des Vertragswertes eingeräumt werden. Schreiben Nr. IA/19950/14 des Föderalen Antimonopoldienstes (FAD) Russlands vom 19.05.2014 "Über die Austauschbarkeit von Arzneimittelpräparaten für die künstliche Ernährung" Die erarbeiteten Kriterien ermöglichen die Anerkennung einer gegenseitigen Austauschbarkeit von Arzneimittelpräparaten im Zuge von staatlichen Beschaffungen. Der FAD Russlands führte unter Hinzuziehung von Experten Arbeiten zur Festlegung von Kriterien bezüglich der gegenseitigen Austauschbarkeit von Arzneimittelpräparaten für die künstliche Ernährung durch. Auf dem Markt für Arzneimittelpräparate für die künstliche Ernährung besteht die Notwendigkeit einer Klarstellung der Besonderheiten bei der Beschaffung von Mehrkomponenten- Präparaten für die staatlichen Auftraggeber, da bei diesen Arzneimittelpräparaten internationale Freinamen entweder fehlen, oder durch Gruppenbezeichnungen ersetzt wurden. Um Einschränkungen und die Abschaffung von Konkurrenz auf dem Markt von Arzneimittelpräparaten für die künstliche Ernährung nicht zuzulassen, wurde eine einheitliche Praxis der Anwendung der Antimonopol-Gesetzgebung bei der Bearbeitung von Beschwerden festgelegt und Ersuchen von Wirtschaftseinheiten und Verwaltungsorganen an den FAD Russlands werden zur Anwendung der http://www.garant.ru/hotlaw/federal/542467/ http://www.fas.gov.ru/clarifications/clarifications_30457.html http://www.fas.gov.ru/clarifications/clarifications_30457.html PharmaReport Russland 9/2014 6 Kriterien gegenseitiger Austauschbarkeit von Arzneimittelpräparaten für die künstliche Ernährung weitergeleitet. RECHTLICHE REGULIERUNGEN IM RAHMEN DER ZOLLUNION (ZU), DES EINHEITLICHEN WIRTSCHAFTSRAUMES (EWR) UND DER WTO I. Verabschiedete Dokumente Vorgeschlagen wird die Bildung eines gemeinsamen Marktes für Arzneimittel im Rahmen der Eurasischen Wirtschaftsunion. Vertrag über die Eurasische Wirtschaftsunion (Unterzeichnet in Astana am 29.05.2014) Mit diesem Vertrag begründen die Republik Belarus, die Republik Kasachstan und die Russische Föderation die Eurasische Wirtschaftsunion (im folgenden: Union), in deren Rahmen ein freier Verkehr von Waren, Dienstleistungen, Kapital und Arbeitskräften gewährleistet ist, dazu die Durchführung einer koordinierten, abgestimmten oder einheitlichen Politik in den Bereichen der Wirtschaft. Ein spezieller Abschnitt des Vertrages behandelt die Regulierung des Verkehrs mit Arzneimitteln und medizinischen Erzeugnissen. Folgende Prinzipien der Bildung eines gemeinsamen Marktes für Arzneimittel wurden festgelegt: 1) Abstimmung und Vereinheitlichung der Anforderungen an die Gesetzgebung der Mitgliedsstaaten auf dem Gebiet des Verkehrs mit Arzneimitteln; 2) Erreichung einheitlicher verbindlicher Anforderungen an Qualität, Effektivität und Sicherheit von Arzneimitteln, die auf dem Territorium der Union im Umlauf sind; 3) Verabschiedung einheitlicher Regeln auf dem Gebiet des Verkehrs mit Arzneimitteln; 4) Erarbeitung und Anwendung gleicher oder vergleichbarer Verfahren für Untersuchungen und Kontrollen bei der Bewertung von Qualität, Effektivität und Sicherheit von Arzneimitteln; 5) Abstimmung der Gesetzgebung der Mitgliedsstaaten bei der Kontrolle (Überwachung) auf dem Gebiet des Verkehrs mit Arzneimitteln; 6) Aufbau von Genehmigungs-, Kontroll- und Überwachungsinstanzen auf dem Gebiet des Verkehrs mit Arzneimitteln durch entsprechende bevollmächtigte Organe der Mitgliedsstaaten. Der gemeinsame Markt für Arzneimittel im Rahmen der Union tritt am 1. Januar 2016 in Funktion, entsprechend einem internationalen Vertrag im Rahmen der Union, der einheitliche Prinzipien und Regeln für den Verkehr mit Arzneimitteln festlegt und durch die Mitgliedsstaaten bis spätestens 1. Januar 2015 abgeschlossen werden soll. http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=163855 PharmaReport Russland 9/2014 7 Beschluss Nr. 77 des Kollegiums der Eurasischen Wirtschaftskommission vom 26.05.2014 "Zur Vornahme von Änderungen in der Einheitlichen Waren-Nomenklatur der außenwirtschaftlichen Tätigkeit der Zollunion, zu einem Einheitlichen Zolltarif der Zollunion bezüglich einzelner Arten von Waren entsprechend der Verpflichtungen der Russischen Föderation im Rahmen der WTO und zur Verabschiedung des Entwurfs des Beschlusses durch den Rat der Eurasischen Wirtschaftskommission" Ab 1. September 2014 werden für eine ganze Reihe von Waren neue Einfuhrzölle festgesetzt. Die Änderungen wurden entsprechend den Verpflichtungen der Russischen Föderation im Rahmen der WTO verabschiedet. Außerdem enthält die neue Fassung Erläuterungen zum Einheitlichen Zolltarif der Zollunion. Die Änderungen betreffen unter anderem eine Reihe von Arzneimittelformen, Seife mit Arzneimittel-Inhaltsstoffen und Impfstoffe für die Veterinärmedizin. STEUERRECHT I. Entwürfe Die Sätze der staatlichen Gebühren für die Vornahme von Änderungen an Dokumenten, die Bestandteile des Zulassungsdossiers für ein zugelassenes Arzneimittelpräparat für Anwendungen in der Veterinärmedizin sind, sollen in Abhängigkeit von der Erforderlichkeit der Durchführung entsprechender Gutachten zum Präparat präzisiert werden. Entwurf des Föderalen Gesetzes Nr. 480685-6 "Zur Vornahme von Änderungen im Artikel 333-32.1 Abs. 2 des Steuergesetzbuches der Russischen Föderation (hinsichtlich der Präzisierung der Sätze der staatlichen Gebühren für die Vornahme von Änderungen an Dokumenten, die Bestandteile des Zulassungsdossiers für ein zugelassenes Arzneimittelpräparat für Anwendungen in der Veterinärmedizin sind)" Am 21. Mai 2014 verabschiedete die Staatsduma in erster Lesung Nachbesserungen, nach denen für die Vornahme von Änderungen in Dokumenten, die Bestandteile des Zulassungsdossiers für ein zugelassenes Arzneimittelpräparat für Anwendungen in der Veterinärmedizin sind, welche die Durchführung eines Gutachtens zu dem Arzneimittelpräparat für Anwendungen in der Veterinärmedizin erfordern, die staatliche Gebühr in der bisherigen Höhe beibehalten wird (50 000 Rubel). Die genannte Höhe der staatlichen Gebühr wurde zum gegenwärtigen Zeitpunkt für die Vornahme von Änderungen an der Gebrauchsinformation des Arzneimittelpräparates für Anwendungen in der Veterinärmedizin festgesetzt. Außerdem wird vorgeschlagen, die staatliche Gebühr für die Aufnahme von Änderungen an Dokumenten, die Bestandteile des Zulassungsdossiers für ein Arzneimittelpräparat für Anwendungen in der Veterinärmedizin sind, welche keine Durchführung eines Gutachtens zu dem Arzneimittel für Anwendungen in der Veterinärmedizin erfordern, in Höhe von 2600 Rubel festzulegen. http://www.eurasiancommission.org/ru/Lists/EECDocs/635367930364053138.pdf http://www.eurasiancommission.org/ru/Lists/EECDocs/635367930364053138.pdf http://asozd2.duma.gov.ru/main.nsf/(Spravka)?OpenAgent&RN=480685-6&02 PharmaReport Russland 9/2014 8 Предлагается дополнить Закон № 44-ФЗ нормой, дозволяющей поставщику предоставлять организатору конкурса или аукциона и государственному заказчику «смешанное» обеспечение своих обязательств - банковскую гарантию и денежные средства одновременно. Установлено, что при осуществлении закупок товаров для обеспечения государственных и муниципальных нужд путем проведения конкурса, аукциона или запроса предложений участникам закупки, заявки на участие или окончательные предложения которых содержат предложения о поставке товаров российского, белорусского и (или) казахстанского происхождения, предоставляются преференции в отношении цены контракта в размере 15%. Предполагается формирование общего рынка лекарственных средств в рамках Евразийского экономического союза. Функционирование общего рынка лекарственных средств в рамках Союза осуществляется начиная с 1 января 2016 года в соответствии с международным договором в рамках Союза, определяющим единые принципы и правила обращения лекарственных средств, который должен быть заключен государствами-членами не позднее 1 января 2015 года. С 1 сентября 2014 года в отношении целого ряда товаров устанавливаются новые ставки ввозных таможенных пошлин. Изменения приняты в соответствии с обязательствами Российской Федерации в рамках ВТО. ГОСУДАРСТВЕННЫЕ ЗАКУПКИ I. Проекты Проект федерального закона № 472415-6 «О внесении изменений в статью 101 Федерального закона «Об основах охраны здоровья граждан в Российской Федерации» Поправки, которые приняты Госдумой в первом чтении 21 мая 2014 года, касаются переноса сроков вступления в силу отдельных положений Федерального закона в части лечения редких заболеваний. Согласно пункту 2 части 1 статьи 15 Федерального закона «Об основах охраны здоровья граждан в Российской Федерации» № 323-ФЗ с 1 января 2015 года организация обеспечения ряда лиц лекарственными препаратами будет осуществляться органами государственной власти субъектов Российской Федерации. Вместе с тем децентрализация в планируемый период государственных закупок лекарственных препаратов для лечения социально-значимых заболеваний негативно отразится на обязательствах Российской Федерации по обеспечению граждан лекарственными препаратами и приведет к неэффективному использованию бюджетных средств, говорят авторы проекта – группа депутатов. Законопроект переносит http://asozd2.duma.gov.ru/main.nsf/(Spravka)?OpenAgent&RN=472415-6&02 PharmaReport Russland 9/2014 9 срок вступления в силу статьи 101 Федерального закона № 323-ФЗ с 1 января 2015 г. на 1 января 2018 г. Проект федерального закона № 522847-6 «О внесении изменений в отдельные законодательные акты Российской Федерации (в части банковских гарантий)» В Госдуму внесены поправки, которые направлены на устранение ряда недостатков практики применения банковских гарантий (один из способов обеспечения исполнения обязательств в сфере закупок товаров (работ, услуг)). Изменения касаются, в частности, отношений, связанных с электронной банковской гарантией. Кроме того, предусмотрено, что доступ к сведениям, содержащимся в реестре банковских гарантий, должен быть ограничен. Также предлагается уточнить состав сведений, включаемых в реестр банковских гарантий. Для повышения эффективности обеспечения исполнения обязательств в сфере государственных закупок законопроектом предлагается дополнить Закон № 44-ФЗ нормой, дозволяющей поставщику предоставлять организатору конкурса или аукциона и государственному заказчику «смешанное» обеспечение своих обязательств - банковскую гарантию и денежные средства одновременно. Предусматривается возможность обеспечения исполнения контракта как банковской гарантией, выданной одним банком, так и банковскими гарантиями, выданными несколькими банками. Важной новеллой законопроекта является норма об утверждении типовых форм банковских гарантий. Это поможет стандартизировать работу с банковскими гарантиями и устранит риски госзаказчика, отмечается в пояснительной записке к проекту. Проект Постановления Правительства РФ «Об утверждении порядка формирования перечней лекарственных препаратов, предусмотренных законодательством Российской Федерации» Субъекты обращения лекарственных средств, медицинские, научные медицинские и (или) фармацевтические организации или общественные объединения в сферах здравоохранения, обращения лекарственных средств, защиты прав граждан в сфере охраны здоровья могут направить в Минздрав РФ свои предложения по формированию перечней не позднее 31 марта текущего года включительно в бумажном и электронном виде, в порядке, предлагаемым данным проектом. Проект был направлен в кабинет министров 1 июня. Документ разработан Минздравом с целью упростить и прояснить процедуру формирования списков лекарственных средств, закупаемых на государственных аукционах. http://asozd2.duma.gov.ru/main.nsf/%28SpravkaNew%29?OpenAgent&RN=522847-6&02 http://www.pharmvestnik.ru/res/dokumenty/proekt-postanovleniya-04-06.docx PharmaReport Russland 9/2014 10 Правила будут определять порядок формирования следующих перечней: Перечня жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП); Минимального ассортимента лекарственных препаратов для медицинского применения, необходимых для оказания медицинской помощи; Перечня закупаемых за счет средств федерального бюджета лекарственных препаратов, предназначенных для обеспечения лиц, больных гемофилией, муковисцидозом, гипофизарным нанизмом, болезнью Гоше, злокачественными новообразованиями лимфоидной, кроветворной и родственных им тканей, рассеянным склерозом, лиц после трансплантации органов и (или) тканей; Перечня лекарственных препаратов для медицинского применения, в том числе лекарственных препаратов для медицинского применения, назначаемых по решению врачебных комиссий медицинских организаций, обеспечение которыми осуществляется в соответствии со стандартами медицинской помощи по рецептам врача (фельдшера) при оказании государственной социальной помощи в виде набора социальных услуг. Проект Постановления Правительства РФ «Об утверждении порядка формирования, утверждения и ведения планов-графиков закупок товаров, работ, услуг для обеспечения федеральных нужд, а также требований к форме плана-графика закупок товаров, работ, услуг для обеспечения федеральных нужд» Устанавливается порядок формирования, утверждения и ведения планов-графиков закупок товаров, работ, услуг для обеспечения федеральных нужд в соответствии с частью 4 статьи 21 Федерального закона «О контрактной системе в сфере закупок товаров, работ и услуг для обеспечения государственных и муниципальных нужд». Приводятся требования к форме плана-графика закупок товаров, работ, услуг для обеспечения федеральных нужд. Определены особенности, касающиеся закупок лекарственных препаратов. http://regulation.gov.ru/project/15104.html?point=view_project&stage=2&stage_id=9995 PharmaReport Russland 9/2014 11 Проект Постановления Правительства РФ «Об утверждении порядка формирования, утверждения и ведения планов закупок товаров, работ, услуг для обеспечения федеральных нужд, а также требований к форме плана закупок товаров, работ, услуг для обеспечения федеральных нужд» Устанавливает порядок формирования, утверждения и ведения планов закупок товаров, работ, услуг для обеспечения федеральных нужд в соответствии с частью 5 статьи 17 Федерального закона «О контрактной системе в сфере закупок товаров, работ и услуг для обеспечения государственных и муниципальных нужд». Определены требования к форме плана закупок товаров, работ, услуг для обеспечения федеральных нужд. Оговаривается, что информация о закупках лекарственных препаратов, которые планируется осуществлять в соответствии с пунктом 7 части 2 статьи 83 Федерального закона о контрактной системе, указывается в плане закупок одной строкой в размере совокупного годового объема финансового обеспечения на такие закупки. Федеральный закон от 04.06.2014 № 140-ФЗ «О внесении изменений в Федеральный закон «О контрактной системе в сфере закупок товаров, работ, услуг для обеспечения государственных и муниципальных нужд» Конкретизируется используемый в названном Федеральном законе понятийный аппарат, в частности, дается определение совокупного годового объема закупок, а также уточняются порядки применения методов обоснования цены контракта и осуществления закупок у субъектов малого предпринимательства, социально ориентированных некоммерческих организаций. Определяются особенности проведения закупок для обеспечения деятельности заказчиков на территории иностранного государства. Упрощается осуществление закупок у единственного поставщика (подрядчика, исполнителя). В частности, предусматривается возможность осуществления малых закупок у единственного поставщика в объеме до 2 млн рублей либо 5% совокупного годового объема, но не более 50 млн рублей. В отдельных случаях исключается документальное обоснование невозможности или нецелесообразности использования иных способов определения поставщика (кроме осуществления закупки у единственного поставщика (подрядчика, исполнителя), а также цены и иных существенных условий контракта. Кроме того, расширяется перечень случаев осуществления закупки у единственного поставщика (подрядчика, исполнителя). В частности, закупка у единственного поставщика возможна в случае заключения организациями, осуществляющими образовательную деятельность и признанными в соответствии с законодательством об образовании федеральными или региональными инновационными площадками, контрактов на поставки оборудования, программного обеспечения, необходимых для внедрения научно-технических результатов и результатов интеллектуальной деятельности, с обладателем исключительных http://regulation.gov.ru/project/15103.html?point=view_project&stage=2&stage_id=9994 http://news.kremlin.ru/media/events/files/41d4e3bd45cab9529b60.pdf PharmaReport Russland 9/2014 12 прав на такие оборудование и программное обеспечение за счет средств, выделенных на развитие инновационной инфраструктуры в системе образования. Расширяются случаи, когда заказчики вправе проводить экспертизу поставленных товаров (выполненных работ, оказанных услуг) не только с привлечением соответствующих экспертов, но и своими силами. Приказ Минэкономразвития России от 25.03.2014 № 155 «Об условиях допуска товаров, происходящих из иностранных государств, для целей осуществления закупок товаров, работ, услуг для обеспечения государственных и муниципальных нужд» (зарегистрировано в Минюсте России 06.05.2014 № 32183) Документ определяет порядок предоставления доступа иностранных товаров, в частности, лекарственных средств и медицинских изделий, к участию в государственных и муниципальных закупках. Установлено, что при осуществлении закупок товаров для обеспечения государственных и муниципальных нужд путем проведения конкурса, аукциона или запроса предложений участникам закупки, заявки на участие или окончательные предложения которых содержат предложения о поставке товаров российского, белорусского и (или) казахстанского происхождения, предоставляются преференции в отношении цены контракта в размере 15%. Письмо ФАС России от 19.05.2014 № ИА/19950/14 «О взаимозаменяемости лекарственных препаратов для парентерального питания» Разработанные критерии позволят признавать лекарственные препараты для парентерального питания взаимозаменяемыми для целей государственных закупок ФАС России с привлечением экспертов провела работу по определению критериев взаимозаменяемости лекарственных препаратов для парентерального питания. На рынке лекарственных препаратов для парентерального питания существует необходимость разъяснений государственным заказчикам особенностей закупок многокомпонентных лекарственных препаратов, поскольку у таких лекарственных препаратов международное непатентованное наименование либо отсутствует, либо заменено на группировочное наименование. С целью недопущения ограничения и устранения конкуренции на рынке лекарственных препаратов для парентерального питания, закрепления единой практики применения антимонопольного законодательства при рассмотрении жалоб и обращений хозяйствующих субъектов и органов власти ФАС России направляет для применения критерии взаимозаменяемости лекарственных препаратов для парентерального питания. http://www.garant.ru/hotlaw/federal/542467/ http://www.fas.gov.ru/clarifications/clarifications_30457.html PharmaReport Russland 9/2014 13 I.Принятые документы Предполагается формирование общего рынка лекарственных средств в рамках Евразийского экономического союза. Договор о Евразийском экономическом союзе (Подписан в г. Астане 29.05.2014) Договором Республика Беларусь, Республика Казахстан и Российская Федерация учреждают Евразийский экономический союз (далее – Союз), в рамках которого обеспечивается свобода движения товаров, услуг, капитала и рабочей силы, проведение скоординированной, согласованной или единой политики в отраслях экономики. Отдельный раздел Договора посвящен регулированию обращения лекарственных средств и медицинских изделий. Определены принципы формирования общего рынка лекарственных средств: 1) гармонизация и унификация требований законодательства государств-членов в сфере обращения лекарственных средств; 2) обеспечение единства обязательных требований к качеству, эффективности и безопасности лекарственных средств, находящихся в обращении на территории Союза; 3) принятие единых правил в сфере обращения лекарственных средств; 4) разработка и применение одинаковых или сопоставимых методов исследования и контроля при оценке качества, эффективности и безопасности лекарственных средств; 5) гармонизация законодательства государств-членов в области контроля (надзора) в сфере обращения лекарственных средств; 6) реализация разрешительных и контрольно-надзорных функций в сфере обращения лекарственных средств соответствующими уполномоченными органами государств-членов. Функционирование общего рынка лекарственных средств в рамках Союза осуществляется начиная с 1 января 2016 года в соответствии с международным договором в рамках Союза, определяющим единые принципы и правила обращения лекарственных средств, который должен быть заключен государствами-членами не позднее 1 января 2015 года. http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=163855 PharmaReport Russland 9/2014 14 Решение Коллегии Евразийской экономической комиссии от 26.05.2014 № 77 «О внесении изменений в единую Товарную номенклатуру внешнеэкономической деятельности Таможенного союза и Единый таможенный тариф Таможенного союза в отношении отдельных видов товаров в соответствии с обязательствами Российской Федерации в рамках ВТО и об одобрении проекта решения Совета Евразийской экономической комиссии» С 1 сентября 2014 года в отношении целого ряда товаров устанавливаются новые ставки ввозных таможенных пошлин. Изменения приняты в соответствии с обязательствами Российской Федерации в рамках ВТО. Кроме того, в новой редакции изложены примечания к Единому таможенному тарифу Таможенного союза. Касается, в том числе, ряда лекарственных форм, мыла, содержащего лекарственные средства, ветеринарных вакцин. НАЛОГОВОЕ ПРАВО I. Проекты Предполагается уточнить размер государственной пошлины за внесение изменений в документы, содержащиеся в регистрационном досье на зарегистрированный лекарственный препарат для ветеринарного применения, в зависимости от необходимости проведения соответствующей экспертизы препарата. Проект федерального закона № 480685-6 «О внесении изменений в статью 333-32.1 части второй Налогового кодекса Российской Федерации (в части уточнения размеров государственной пошлины за внесение изменений в документы, содержащиеся в регистрационном досье на зарегистрированный лекарственный препарат для ветеринарного применения) http://www.eurasiancommission.org/ru/Lists/EECDocs/635367930364053138.pdf http://asozd2.duma.gov.ru/main.nsf/(Spravka)?OpenAgent&RN=480685-6&02 15 PharmaReport Russland 9/2014 Bei Fragen zu diesem Newsletter werden Sie sich bitte an die Exportinitiative Gesundheitswirtschaft: pharma@health-made-in-germany.com 030.20 00 99 – 0 Weiterführende Informationen zum umfassenden Unterstützungsangebot finden Sie auf www.exportinitiative-gesundheitswirtschaft.de Die in diesem Newsletter enthaltenen Informationen wurden durch Thümmel, Schütze & Partner übermittelt. 21 мая 2014 года Госдума приняла в первом чтении поправки, согласно которым, за внесение в документы, содержащиеся в регистрационном досье на зарегистрированный лекарственный препарат для ветеринарного применения, изменений, требующих проведения экспертизы лекарственного средства для ветеринарного применения, размер государственной пошлины сохраняется в прежнем размере (50 000 рублей). В настоящее время указанный размер государственной пошлины установлен за внесение изменений в инструкцию по применению лекарственного препарата для ветеринарного применения. Кроме того, предлагается установить государственную пошлину за внесение в документы, содержащиеся в регистрационном досье на лекарственный препарат для ветеринарного применения, изменений, не требующих проведения экспертизы лекарственного средства для ветеринарного применения, в размере 2 600 рублей.

Pharmaceutical Forum 3rd Meeting of the Steering Committee 3 July 2006, Brussels Draft note of the Meeting Chairpersons: Georgette Lalis, Director, Directorate-General for Enterprise and Industry and Andrzej Rys, Director, Directorate-General for Health and Consumer Affairs. Participants: See the list of participants in the Annex 1. Introduction 1. Ms Lalis welcomed the members to the third meeting of the Steering Committee and introduced Mr Rys, her new colleague, as the co-chair of the meeting. 2. The agenda was adopted without amendment. The minutes of the first meeting of 30 March 2006 were adopted subject to an inclusion of a reference to the availability and use of CIRCA. 2. Information Finnish Presidency 3. Finland provided an overview of the health priorities for the Finnish Presidency. It was explained that the Finnish Minister of Health had already sent a letter to her fellow health ministers setting out the horizontal and strategic priorities for Finland. The main theme will be health in all policies. Finally Finland informed the Committee that the Finnish Health Minister will be in the European Parliament on 13 September to answer questions on these priorities. 4. The main objective for the Health Council will be to achieve political agreement on the Advanced Therapies Regulation. There will also be an information point on the Pharmaceutical Forum in the Health Council on 30 November. 5. Finland also informed the meeting that Ms Haatainen, Finnish Minister of Health, will host a lunch directly after the Forum meeting to all members of the Forum in the Council. German Presidency 6. Germany then provided an overview of the future German Presidency (presentation available in CIRCA). The main health priority areas will be: strengthening the EU-based pharmaceutical industry; HIV/AIDS; prevention; health insurance and E-Health. There will be a number of health-related events during the Presidency including an expert level meeting on pharmaceutical innovation in June 2007. Planning for this meeting is still at an early stage but it is likely to include a number of workshops on specific therapeutic areas supported by plenary lectures on key contextual issues. 3. Work Programme 7. The Commission introduced the draft conclusions that had been circulated ahead of the meeting. The draft conclusions would form the basis of a progress report that would be considered by the Forum. It was stated that, due to the fact that the working groups had only recently had a chance to review the conclusions, the conclusions were still subject to comments by the working group members. The aim would be to reach agreement on the text by written procedure but a further meeting of the Committee could be organised in early September if required. Information to patients 8. The Commission then gave an update on the work of the Information to Patients Working Group. Under all three action pillars work has been taken forward in specific drafting or subgroups. Under Pillar I a drafting group has made a proposal on an information template on diabetes and on principles of quality information. Further work will be required, however, on implementation aspects and, in particular, as regards validation of information. There is also a need to consider feasibility and user testing following the Forum. 9. Under Pillar II on statutory information on medicines the EMEA has prepared a document setting out proposals for harmonising action on information at a European level based on the outcome of the discussions in the EMEA/CHMP Working Group with Patients and Consumers’ Organisations. The document will be considered as part of the preparation of the Commission’s report on the state of information provision on medicines in Europe due to be presented to the Council of Ministers and the European Parliament in 2007. 10. Under pillar III a subgroup has focused on access to information in health care settings and has prepared a draft work plan to develop proposals. 11. The discussion focused on the draft conclusions on information to patients. A number of issues were raised and amendments were suggested to the conclusions. In particular, discussion concentrated on finding a right balance between a focus on information on diseases and medicines. Relative Effectiveness 12. Italian representative then introduced the work of the Working Group on Relative Effectiveness. In its two meetings the group has agreed on a report about the different relative effectiveness practices in Member States, based on input from all members of the working group. This has served as a basis for discussion on definitions and further objectives for the group. 13. The Steering Committee discussed the scope of the work of the group and the level of cooperation between Member States. 14. The lack of reliable data is one of the key challenges to be addressed, and EU cooperation in this field will help to improve the quality of data for Member States and to achieve efficient use of limited resources. The working group will aim at consensus at European level between Member States on the nature of the data required. 15. The Working Group will also consider possible ways to share information on assessments made and decisions taken following those assessments and to identify good practices. It was stressed by some members of the Steering Committee that Member States have the responsibility and competence concerning relative effectiveness and the decisions made on the basis of those assessments. Against this background, the Steering Committee suggested some minor amendments for the draft conclusions for the Pharmaceutical Forum. Pricing and Reimbursement 16. The Commission then introduced the work undertaken so far by the Working Group on Pricing and Reimbursement. The Steering Committee welcomed the progress made and broadly supported the conclusions subject to account being taken of some comments. 17. It was emphasized that there is a need to ensure a balanced text expressing responsibilities and commitment from all parties, i.e. Member States, industry and other stakeholders. Some members suggested including more concrete positions and expectations, though it was agreed to keep the text as balanced as possible. 18. Finally, some stakeholder representatives expressed the need to reflect the discussions regarding transparency of price data. A new paragraph will be included accordingly. 19. The Commission concluded the discussion by suggesting that a revised set of conclusions would be circulated taking into account the points made in discussion, for final comments by 7 July. 20. It was agreed that the conclusions would be included in a Progress Report for the Forum which will include additional factual text taken from established documents such as the original invitation and the mission statements. 4. Pharmaceutical Forum Preparations 21. The Commission introduced the draft programme (previously circulated) for the Forum. The Forum will take place in the morning (10:00 – 13:00) of 29 September 2006 in the Commission’s Berlaymont building. Invitations to all members of the Forum had been sent out on 7 June. 22. The programme anticipates an introduction from the Commission followed by statements by the Finnish and German Presidencies. The rest of the programme has been designed to ensure that all members could have an opportunity to speak subject to the number of participants and time available. This approach was agreed.